-- MySQL dump 10.13  Distrib 5.5.34, for debian-linux-gnu (x86_64)
--
-- Host: localhost    Database: dikbEvidence
-- ------------------------------------------------------
-- Server version	5.5.34-0ubuntu0.12.04.1

/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8 */;
/*!40103 SET @OLD_TIME_ZONE=@@TIME_ZONE */;
/*!40103 SET TIME_ZONE='+00:00' */;
/*!40014 SET @OLD_UNIQUE_CHECKS=@@UNIQUE_CHECKS, UNIQUE_CHECKS=0 */;
/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;
/*!40111 SET @OLD_SQL_NOTES=@@SQL_NOTES, SQL_NOTES=0 */;

--
-- Table structure for table `Assertions`
--

DROP TABLE IF EXISTS `Assertions`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `Assertions` (
  `id` int(11) NOT NULL,
  `_name` varchar(100) DEFAULT NULL,
  `object` varchar(100) DEFAULT NULL,
  `slot` varchar(100) DEFAULT NULL,
  `value` varchar(100) DEFAULT NULL,
  `ready_for_classification` varchar(100) DEFAULT NULL,
  `assert_by_default` varchar(100) DEFAULT NULL,
  `evidence_rating` varchar(100) DEFAULT NULL,
  `cont_val` varchar(100) DEFAULT NULL,
  `numeric_val` varchar(100) DEFAULT NULL,
  `assert_class` varchar(100) DEFAULT NULL,
  `evidence_for` int(11) DEFAULT NULL,
  `evidence_against` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `Assertions`
--

LOCK TABLES `Assertions` WRITE;
/*!40000 ALTER TABLE `Assertions` DISABLE KEYS */;
INSERT INTO `Assertions` VALUES (1,'R-citalopram_substrate_of_cyp2d6','R-citalopram','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1,NULL),(2,'eszopiclone_inhibits_CYP2E1','eszopiclone','inhibits','CYP2E1','1','0','retract!',NULL,NULL,'Assertion',NULL,2),(3,'bupropion_has_metabolite_erythrohydrobupropion','bupropion','has_metabolite','erythrohydrobupropion','1','0','assume!',NULL,NULL,'Assertion',3,NULL),(4,'tolbutamide_maximum_therapeutic_dose_continuous_value','tolbutamide','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'3.0','ContValAssertion',4,NULL),(5,'R-didemethylcitalopram_inhibits_cyp1a2','R-didemethylcitalopram','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,5),(6,'clozapine_is_not_substrate_of_cyp3a4','clozapine','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,6),(7,'ziprasidone_substrate_of_cyp2c19','ziprasidone','substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,7),(8,'atorvastatin_bioavailability_continuous_value','atorvastatin','bioavailability','continuous_value','1','0','assume!','low',NULL,'Assertion_m_discrete',8,NULL),(9,'desacetyldiltiazem_substrate_of_cyp2d6','desacetyldiltiazem','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',9,NULL),(10,'ketoconazole_primary_total_clearance_mechanism_Metabolic_Clearance','ketoconazole','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',10,NULL),(11,'nefazodone_inhibits_cyp1a2','nefazodone','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,11),(12,'midodrine_has_metabolite_desglymidodrine','midodrine','has_metabolite','desglymidodrine','1','0','assume!',NULL,NULL,'Assertion',12,NULL),(13,'topiramate_inhibits_cyp2b6','topiramate','inhibits','cyp2b6','1','0','retract!',NULL,NULL,'Assertion',NULL,13),(14,'aripiprazole_is_not_substrate_of_cyp2b6','aripiprazole','is_not_substrate_of','cyp2b6','1','0','assume!',NULL,NULL,'Assertion',14,NULL),(15,'citalopram_primary_total_clearance_mechanism_Metabolic_Clearance','citalopram','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',15,NULL),(16,'cinacalcet_does_not_inhibit_cyp3a4','cinacalcet','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',16,NULL),(17,'citalopram_is_not_substrate_of_cyp3a4','citalopram','is_not_substrate_of','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',17,18),(18,'simvastatin_has_metabolite_beta-hydroxy-simvastatin','simvastatin','has_metabolite','beta-hydroxy-simvastatin','1','0','assume!',NULL,NULL,'Assertion',19,NULL),(19,'atorvastatin_is_not_substrate_of_cyp3a5','atorvastatin','is_not_substrate_of','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,20),(20,'atorvastatin_is_not_substrate_of_cyp3a4','atorvastatin','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,21),(21,'simvastatin_primary_total_clearance_enzyme_cyp3a4','simvastatin','primary_total_clearance_enzyme','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',22,NULL),(22,'mirtazapine_inhibits_cyp2c9','mirtazapine','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,23),(23,'midodrine_minimum_therapeutic_dose_continuous_value','midodrine','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.03','ContValAssertion',24,NULL),(24,'topiramate_inhibits_cyp2e1','topiramate','inhibits','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,25),(25,'fluvastatin_maximum_therapeutic_dose_continuous_value','fluvastatin','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.8','ContValAssertion',26,NULL),(26,'cyp3a4_controls_formation_of_desmethylcitalopram','cyp3a4','controls_formation_of','desmethylcitalopram','1','0','assume!',NULL,NULL,'Assertion',27,NULL),(27,'dextromethorphan_primary_total_clearance_enzyme_cyp2d6','dextromethorphan','primary_total_clearance_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',28,NULL),(28,'cyp3a4_controls_formation_of_1,3-dimethyluric-acid','cyp3a4','controls_formation_of','1,3-dimethyluric-acid','1','0','assume!',NULL,NULL,'Assertion',29,NULL),(29,'fluconazole_inhibits_cyp2c9','fluconazole','inhibits','cyp2c9','1','1','assume!',NULL,NULL,'Assertion',30,NULL),(30,'diltiazem_increases_auc_triazolam','diltiazem','increases_auc','triazolam','1','0','assume!','high','2.835','ContValAssertion',31,NULL),(31,'aripiprazole_does_not_inhibit_cyp2c19','aripiprazole','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',32,NULL),(32,'fluoxetine_primary_total_clearance_mechanism_Metabolic_Clearance','fluoxetine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',33,NULL),(33,'ketoconazole_increases_auc_simvastatin','ketoconazole','increases_auc','simvastatin','1','0','assume!','high','12.55','ContValAssertion',34,NULL),(34,'clarithromycin_substrate_of_cyp2c9','clarithromycin','substrate_of','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,35),(35,'haloperidol_has_metabolite_4-(4-chlorophenyl)-4-hydroxypiperidine','haloperidol','has_metabolite','4-(4-chlorophenyl)-4-hydroxypiperidine','1','0','can\'t decide',NULL,NULL,'Assertion',36,NULL),(36,'simvastatin_substrate_of_cyp3a4','simvastatin','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',37,NULL),(37,'paliperidone_does_not_inhibit_cyp3a5','paliperidone','does_not_inhibit','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',38,NULL),(38,'fluoxetine_has_metabolite_norfluoxetine','fluoxetine','has_metabolite','norfluoxetine','1','0','assume!',NULL,NULL,'Assertion',39,NULL),(39,'nefazodone_substrate_of_cyp2d6','nefazodone','substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,40),(40,'iloperidone_is_not_substrate_of_cyp2c19','iloperidone','is_not_substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',41,NULL),(41,'clarithromycin_inhibition_constant_cyp3a4','clarithromycin','inhibition_constant','cyp3a4','1','0','assume!',NULL,'0.00168','Assertion_inhibition_constant',42,NULL),(42,'desvenlafaxine_substrate_of_cyp2d6','desvenlafaxine','substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,43),(43,'cimetidine_increases_auc_erythrohydrobupropion','cimetidine','increases_auc','erythrohydrobupropion','1','0','can\'t decide','medium','1.16','ContValAssertion',44,NULL),(44,'venlafaxine_does_not_inhibit_cyp3a4','venlafaxine','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',45,NULL),(45,'clarithromycin_increases_auc_triazolam','clarithromycin','increases_auc','triazolam','1','0','assume!','high','5.255','ContValAssertion',46,NULL),(46,'atorvastatin_has_metabolite_para-hydroxy-atorvastatin','atorvastatin','has_metabolite','para-hydroxy-atorvastatin','1','0','assume!',NULL,NULL,'Assertion',47,NULL),(47,'atorvastatin_substrate_of_cyp3a5','atorvastatin','substrate_of','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',48,NULL),(48,'atorvastatin_substrate_of_cyp3a4','atorvastatin','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',49,NULL),(49,'O-desmethylvenlafaxine_maximum_concentration_continuous_value','O-desmethylvenlafaxine','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.000686','Assertion_maximum_concentration',50,NULL),(50,'cimetidine_does_not_inhibit_cyp3a5','cimetidine','does_not_inhibit','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,51),(51,'duloxetine_does_not_inhibit_cyp3a4','duloxetine','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',52,NULL),(52,'duloxetine_does_not_inhibit_cyp3a5','duloxetine','does_not_inhibit','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',53,NULL),(53,'celecoxib_is_not_substrate_of_cyp2c9','celecoxib','is_not_substrate_of','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,54),(54,'quetiapine_inhibits_cyp3a4','quetiapine','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,55),(55,'atazanavir_does_not_inhibit_cyp2a6','atazanavir','does_not_inhibit','cyp2a6','1','0','assume!',NULL,NULL,'Assertion',56,NULL),(56,'S-demethylcitalopram_inhibits_cyp2c9','S-demethylcitalopram','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,57),(57,'itraconazole_increases_auc_fluvastatin','itraconazole','increases_auc','fluvastatin','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,58),(58,'fluvastatin_substrate_of_cyp2c8','fluvastatin','substrate_of','cyp2c8','1','0','assume!',NULL,NULL,'Assertion',59,NULL),(59,'fluvastatin_substrate_of_cyp2c9','fluvastatin','substrate_of','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',60,NULL),(60,'cyp2d6_controls_formation_of_desmethylclozapine','cyp2d6','controls_formation_of','desmethylclozapine','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(61,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6','dextromethorphan','in_vitro_probe_substrate_of_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',61,NULL),(62,'voriconazole-N-oxide_does_not_inhibit_cyp2c9','voriconazole-N-oxide','does_not_inhibit','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,62),(63,'zafirlukast_inhibits_cyp3a4','zafirlukast','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',63,NULL),(64,'ritonavir_inhibits_cyp3a5','ritonavir','inhibits','cyp3a5','1','1','assume!',NULL,NULL,'Assertion',64,NULL),(65,'ritonavir_inhibits_cyp3a4','ritonavir','inhibits','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',65,NULL),(66,'mirtazapine_bioavailability_continuous_value','mirtazapine','bioavailability','continuous_value','1','0','assume!','medium-high',NULL,'Assertion_m_discrete',66,NULL),(67,'quetiapine_does_not_inhibit_cyp3a4','quetiapine','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',67,NULL),(68,'R-citalopram_inhibits_cyp2e1','R-citalopram','inhibits','cyp2e1','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(69,'valproate_primary_total_clearance_mechanism_Metabolic_Clearance','valproate','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',68,NULL),(70,'ketoconazole_increases_auc_midazolam','ketoconazole','increases_auc','midazolam','1','0','assume!','high','15.9','ContValAssertion',69,NULL),(71,'celecoxib_does_not_inhibit_cyp3a4','celecoxib','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',70,NULL),(72,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4','ketoconazole','in_vitro_selective_inhibitor_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',71,NULL),(73,'aripiprazole_substrate_of_cyp1a2','aripiprazole','substrate_of','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,72),(74,'aripiprazole_substrate_of_cyp1a1','aripiprazole','substrate_of','cyp1a1','1','0','retract!',NULL,NULL,'Assertion',NULL,73),(75,'quetiapine_does_not_inhibit_cyp2c19','quetiapine','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',74,NULL),(76,'cyp2c8_controls_formation_of_N-dealkylperphenazine','cyp2c8','controls_formation_of','N-dealkylperphenazine','1','0','can\'t decide',NULL,NULL,'Assertion',75,NULL),(77,'beta-hydroxy-simvastatin_primary_total_clearance_enzyme_cyp3a4','beta-hydroxy-simvastatin','primary_total_clearance_enzyme','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',76,NULL),(78,'aripiprazole_inhibits_cyp2d6','aripiprazole','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,77),(79,'rosiglitazone_inhibits_cyp1a2','rosiglitazone','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,78),(80,'rosiglitazone_inhibits_cyp1a1','rosiglitazone','inhibits','cyp1a1','1','0','retract!',NULL,NULL,'Assertion',NULL,79),(81,'zafirlukast_does_not_inhibit_cyp3a4','zafirlukast','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,80),(82,'atorvastatin_substrate_of_cyp2b6','atorvastatin','substrate_of','cyp2b6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,81),(83,'duloxetine_inhibits_cyp2c19','duloxetine','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,82),(84,'voriconazole_is_not_substrate_of_cyp2c19','voriconazole','is_not_substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,83),(85,'escitalopram_has_metabolite_S-demethylcitalopram','escitalopram','has_metabolite','S-demethylcitalopram','1','0','assume!',NULL,NULL,'Assertion',84,NULL),(86,'paliperidone_inhibits_cyp3a4','paliperidone','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,85),(87,'paclitaxel_has_metabolite_6alpha-hydroxy-paclitaxel','paclitaxel','has_metabolite','6alpha-hydroxy-paclitaxel','1','0','can\'t decide',NULL,NULL,'Assertion',86,NULL),(88,'perphenazine_does_not_inhibit_cyp2c19','perphenazine','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',87,NULL),(89,'N-desalkylquetiapine_substrate_of_cyp3a4','N-desalkylquetiapine','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',88,NULL),(90,'verapamil_inhibits_cyp3a4','verapamil','inhibits','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',89,NULL),(91,'fluvoxamine_increases_auc_tolbutamide','fluvoxamine','increases_auc','tolbutamide','1','1','assume!','medium','1.5','ContValAssertion',90,NULL),(92,'verapamil_inhibits_cyp3a5','verapamil','inhibits','cyp3a5','1','1','assume!',NULL,NULL,'Assertion',91,NULL),(93,'ziprasidone_substrate_of_cyp1a2','ziprasidone','substrate_of','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',92,93),(94,'atorvastatin_substrate_of_cyp2c19','atorvastatin','substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,94),(95,'ranolazine_does_not_inhibit_cyp2d6','ranolazine','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,95),(96,'ketoconazole_increases_auc_desvenlafaxine','ketoconazole','increases_auc','desvenlafaxine','1','0','can\'t decide','medium','1.43','ContValAssertion',96,NULL),(97,'alprazolam_substrate_of_cyp3a4','alprazolam','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',97,NULL),(98,'alprazolam_substrate_of_cyp3a5','alprazolam','substrate_of','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',98,NULL),(99,'R-demethylcitalopram_substrate_of_cyp2c19','R-demethylcitalopram','substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(100,'atorvastatin_does_not_inhibit_cyp3a4','atorvastatin','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,99),(101,'S-demethylcitalopram_maximum_concentration_continuous_value','S-demethylcitalopram','maximum_concentration','continuous_value','1','0','assume!',NULL,'1.437e-05','Assertion_maximum_concentration',100,NULL),(102,'cyp3a4_polymorphic_enzyme_False','cyp3a4','polymorphic_enzyme','False','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(103,'clarithromycin_increases_auc_atorvastatin','clarithromycin','increases_auc','atorvastatin','1','0','assume!','high','5.381','ContValAssertion',101,NULL),(104,'lansoprazole_maximum_concentration_continuous_value','lansoprazole','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.004','Assertion_maximum_concentration',102,NULL),(105,'atazanavir_inhibits_cyp2a6','atazanavir','inhibits','cyp2a6','1','0','retract!',NULL,NULL,'Assertion',NULL,103),(106,'threohydrobupropion_primary_total_clearance_mechanism_Renal_Excretion','threohydrobupropion','primary_total_clearance_mechanism','Renal_Excretion','1','0','assume!',NULL,NULL,'Assertion',104,NULL),(107,'valproate_increases_auc_bupropion','valproate','increases_auc','bupropion','1','1','assume!',NULL,NULL,'ContValAssertion',NULL,105),(108,'paliperidone_does_not_inhibit_cyp2e1','paliperidone','does_not_inhibit','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',106,NULL),(109,'quetiapine_is_not_substrate_of_cyp1a2','quetiapine','is_not_substrate_of','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',107,NULL),(110,'nefazodone_increases_auc_alprazolam','nefazodone','increases_auc','alprazolam','1','0','assume!','high','2.0','ContValAssertion',108,NULL),(111,'erythromycin_inhibits_cyp3a4','erythromycin','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',109,NULL),(112,'montelukast_inhibits_cyp2c19','montelukast','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,110),(113,'alprazolam_has_metabolite_4-hydroxyalprazolam','alprazolam','has_metabolite','4-hydroxyalprazolam','1','0','assume!',NULL,NULL,'Assertion',111,NULL),(114,'iloperidone_is_not_substrate_of_cyp2d6','iloperidone','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,112),(115,'eszopiclone_does_not_inhibit_CYP1A2','eszopiclone','does_not_inhibit','CYP1A2','1','0','assume!',NULL,NULL,'Assertion',113,NULL),(116,'itraconazole_increases_auc_3alpha-hydroxypravastatin','itraconazole','increases_auc','3alpha-hydroxypravastatin','1','0','assume!','medium','1.941','ContValAssertion',114,NULL),(117,'clozapine_is_not_substrate_of_cyp2d6','clozapine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,115),(118,'lovastatin_inhibition_constant_cyp2c8','lovastatin','inhibition_constant','cyp2c8','1','0','assume!',NULL,'0.003','Assertion_inhibition_constant',116,NULL),(119,'mirtazapine_does_not_inhibit_cyp2c9','mirtazapine','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',117,NULL),(120,'mirtazapine_does_not_inhibit_cyp2e1','mirtazapine','does_not_inhibit','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',118,NULL),(121,'R-citalopram_does_not_inhibit_cyp2c19','R-citalopram','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',119,NULL),(122,'beta-hydroxy-simvastatin_does_not_permanently_deactivate_catalytic_function_cyp2c8','beta-hydroxy-simvastatin','does_not_permanently_deactivate_catalytic_function','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(123,'omeprazole_inhibits_cyp2d6','omeprazole','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,120),(124,'indinavir_does_not_inhibit_cyp2b6','indinavir','does_not_inhibit','cyp2b6','1','0','assume!',NULL,NULL,'Assertion',121,NULL),(125,'pantoprazole_is_not_substrate_of_cyp3a4','pantoprazole','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,122),(126,'zafirlukast_maximum_concentration_continuous_value','zafirlukast','maximum_concentration','continuous_value','1','0','assume!',NULL,'3.26e-05','Assertion_maximum_concentration',123,NULL),(127,'duloxetine_substrate_of_cyp2d6','duloxetine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',124,NULL),(128,'clozapine-N-oxide_is_not_substrate_of_cyp2d6','clozapine-N-oxide','is_not_substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',125,NULL),(129,'fluconazole_increases_auc_triazolam','fluconazole','increases_auc','triazolam','1','0','assume!','high','2.46','ContValAssertion',126,NULL),(130,'indinavir_does_not_inhibit_cyp2e1','indinavir','does_not_inhibit','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',127,NULL),(131,'clarithromycin_maximum_concentration_continuous_value','clarithromycin','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.00251','Assertion_maximum_concentration',128,NULL),(132,'beta-hydroxy-lovastatin_is_not_substrate_of_cyp3a4','beta-hydroxy-lovastatin','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,129),(133,'beta-hydroxy-simvastatin_does_not_inhibit_cyp3a4','beta-hydroxy-simvastatin','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',130,NULL),(134,'itraconazole_sole_PK_effect_alter_metabolic_clearance_atorvastatin','itraconazole','sole_PK_effect_alter_metabolic_clearance','atorvastatin','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(135,'nicardipine_maximum_therapeutic_dose_continuous_value','nicardipine','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.12','ContValAssertion',131,NULL),(136,'demethylcitalopram_is_not_substrate_of_cyp3a4','demethylcitalopram','is_not_substrate_of','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',132,NULL),(137,'alprazolam_is_not_substrate_of_cyp1a2','alprazolam','is_not_substrate_of','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',133,NULL),(138,'lansoprazole_increases_auc_lansoprazole','lansoprazole','increases_auc','lansoprazole','1','1','assume!','medium','1.71','ContValAssertion',134,NULL),(139,'nefazodone_substrate_of_cyp3a4','nefazodone','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',135,NULL),(140,'lansoprazole_primary_total_clearance_mechanism_Metabolic_Clearance','lansoprazole','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',136,NULL),(141,'paroxetine_primary_total_clearance_mechanism_Metabolic_Clearance','paroxetine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',137,NULL),(142,'9-hydroxyrisperidone_inhibition_constant_cyp2d6','9-hydroxyrisperidone','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.007','Assertion_inhibition_constant',138,NULL),(143,'midazolam_has_metabolite_4-hydroxymidazolam','midazolam','has_metabolite','4-hydroxymidazolam','1','0','can\'t decide',NULL,NULL,'Assertion',139,NULL),(144,'perphenazine_inhibition_constant_cyp1a2','perphenazine','inhibition_constant','cyp1a2','1','0','assume!',NULL,'0.026','Assertion_inhibition_constant',140,NULL),(145,'S-demethylcitalopram_inhibits_cyp1a2','S-demethylcitalopram','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,141),(146,'olanzapine_primary_total_clearance_mechanism_Renal_Excretion','olanzapine','primary_total_clearance_mechanism','Renal_Excretion','1','0','retract!',NULL,NULL,'Assertion',NULL,142),(147,'paroxetine_increases_auc_risperidone','paroxetine','increases_auc','risperidone','1','0','can\'t decide','high','4.0','ContValAssertion',143,NULL),(148,'R-citalopram_substrate_of_cyp2c19','R-citalopram','substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',144,NULL),(149,'cyp3a4_controls_formation_of_1\'-hydroxymidazolam','cyp3a4','controls_formation_of','1\'-hydroxymidazolam','1','0','can\'t decide',NULL,NULL,'Assertion',145,NULL),(150,'S-didemethylcitalopram_inhibits_cyp3a4','S-didemethylcitalopram','inhibits','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(151,'pantoprazole_bioavailability_continuous_value','pantoprazole','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',146,NULL),(152,'modafinil_substrate_of_cyp3a4','modafinil','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',147,NULL),(153,'chlorpromazine_maximum_concentration_continuous_value','chlorpromazine','maximum_concentration','continuous_value','1','0','assume!',NULL,'3.79e-05','Assertion_maximum_concentration',148,NULL),(154,'ziprasidone_inhibition_constant_cyp2d6','ziprasidone','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.005','Assertion_inhibition_constant',149,NULL),(155,'lovastatin_substrate_of_cyp3a4','lovastatin','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',150,NULL),(156,'cinacalcet_inhibits_cyp2c19','cinacalcet','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,151),(157,'erythromycin_in_vitro_selective_inhibitor_of_enzyme_cyp3a4','erythromycin','in_vitro_selective_inhibitor_of_enzyme','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(158,'atomoxetine_primary_total_clearance_mechanism_Metabolic_Clearance','atomoxetine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',152,NULL),(159,'trimethoprim_does_not_inhibit_cyp2c8','trimethoprim','does_not_inhibit','cyp2c8','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,153),(160,'R-demethylcitalopram_inhibits_cyp2c19','R-demethylcitalopram','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,154),(161,'fluvastatin_is_not_substrate_of_cyp2c8','fluvastatin','is_not_substrate_of','cyp2c8','1','0','retract!',NULL,NULL,'Assertion',NULL,155),(162,'escitalopram_inhibits_cyp2c19','escitalopram','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,156),(163,'thioridazine_does_not_inhibit_cyp2c19','thioridazine','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',157,NULL),(164,'metronidazole_maximum_therapeutic_dose_continuous_value','metronidazole','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'4.0','ContValAssertion',158,NULL),(165,'ritonavir_does_not_inhibit_cyp3a4','ritonavir','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,159),(166,'ritonavir_does_not_inhibit_cyp3a5','ritonavir','does_not_inhibit','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,160),(167,'N-desalkylquetiapine_inhibits_cyp3a4','N-desalkylquetiapine','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,161),(168,'modafinil-sulfone_does_not_inhibit_cyp2c19','modafinil-sulfone','does_not_inhibit','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,162),(169,'eszopiclone_inhibits_CYP2A6','eszopiclone','inhibits','CYP2A6','1','0','retract!',NULL,NULL,'Assertion',NULL,163),(170,'ziprasidone_inhibits_cyp1a2','ziprasidone','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,164),(171,'citalopram_inhibits_cyp2c9','citalopram','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,165),(172,'chlorpromazine_does_not_inhibit_cyp2c19','chlorpromazine','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',166,NULL),(173,'duloxetine_does_not_inhibit_cyp2c9','duloxetine','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',167,NULL),(174,'quetiapine_substrate_of_cyp1a2','quetiapine','substrate_of','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,168),(175,'cyp2e1_controls_formation_of_1,3-dimethyluric-acid','cyp2e1','controls_formation_of','1,3-dimethyluric-acid','1','0','assume!',NULL,NULL,'Assertion',169,NULL),(176,'itraconazole_increases_auc_beta-hydroxy-lovastatin','itraconazole','increases_auc','beta-hydroxy-lovastatin','1','0','assume!','high','8.559','ContValAssertion',170,NULL),(177,'fluoxetine_inhibits_cyp2d6','fluoxetine','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',171,NULL),(178,'celecoxib_inhibits_cyp3a4','celecoxib','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,172),(179,'cinacalcet_has_metabolite_hydrocinnamic-acid','cinacalcet','has_metabolite','hydrocinnamic-acid','1','0','assume!',NULL,NULL,'Assertion',173,NULL),(180,'lansoprazole_does_not_inhibit_cyp2d6','lansoprazole','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',174,NULL),(181,'eszopiclone_substrate_of_cyp3a4','eszopiclone','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',175,NULL),(182,'atomoxetine_does_not_inhibit_cyp1a2','atomoxetine','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',176,NULL),(183,'rosiglitazone_does_not_inhibit_cyp2c9','rosiglitazone','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',177,NULL),(184,'paliperidone_inhibits_cyp1a2','paliperidone','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,178),(185,'ranolazine_minimum_therapeutic_dose_continuous_value','ranolazine','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'1.0','ContValAssertion',179,NULL),(186,'midodrine_maximum_therapeutic_dose_continuous_value','midodrine','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.04','ContValAssertion',180,NULL),(187,'escitalopram_substrate_of_cyp3a4','escitalopram','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',181,NULL),(188,'duloxetine_inhibits_cyp3a5','duloxetine','inhibits','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,182),(189,'duloxetine_inhibits_cyp3a4','duloxetine','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,183),(190,'bupropion_substrate_of_cyp2b6','bupropion','substrate_of','cyp2b6','1','0','can\'t decide',NULL,NULL,'Assertion',184,NULL),(191,'voriconazole_has_metabolite_voriconazole-N-oxide','voriconazole','has_metabolite','voriconazole-N-oxide','1','0','assume!',NULL,NULL,'Assertion',185,NULL),(192,'montelukast_does_not_inhibit_cyp3a4','montelukast','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',186,NULL),(193,'fluconazole_increases_auc_rosuvastatin','fluconazole','increases_auc','rosuvastatin','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,187),(194,'cinacalcet_substrate_of_cyp1a2','cinacalcet','substrate_of','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',188,NULL),(195,'aripiprazole_is_not_substrate_of_cyp3a4','aripiprazole','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,189),(196,'eszopiclone_has_metabolite_S-N-desmethylzopiclone','eszopiclone','has_metabolite','S-N-desmethylzopiclone','1','0','assume!',NULL,NULL,'Assertion',190,NULL),(197,'trimethoprim_minimum_therapeutic_dose_continuous_value','trimethoprim','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.2','ContValAssertion',191,NULL),(198,'S-didemethylcitalopram_does_not_inhibit_cyp1a2','S-didemethylcitalopram','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',192,NULL),(199,'montelukast_does_not_inhibit_cyp2c19','montelukast','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',193,NULL),(200,'ziprasidone_is_not_substrate_of_cyp3a4','ziprasidone','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,194),(201,'fluconazole_inhibits_cyp3a4','fluconazole','inhibits','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',195,NULL),(202,'verapamil_does_not_inhibit_cyp1a2','verapamil','does_not_inhibit','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,196),(203,'eszopiclone_does_not_inhibit_CYP3A4','eszopiclone','does_not_inhibit','CYP3A4','1','0','assume!',NULL,NULL,'Assertion',197,NULL),(204,'escitalopram_primary_total_clearance_mechanism_Metabolic_Clearance','escitalopram','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',198,NULL),(205,'venlafaxine_primary_total_clearance_mechanism_Metabolic_Clearance','venlafaxine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',199,NULL),(206,'diltiazem_increases_auc_beta-hydroxy-lovastatin','diltiazem','increases_auc','beta-hydroxy-lovastatin','1','0','assume!','high','3.57','ContValAssertion',200,NULL),(207,'escitalopram_does_not_inhibit_cyp2e1','escitalopram','does_not_inhibit','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',201,NULL),(208,'atazanavir_does_not_inhibit_cyp2e1','atazanavir','does_not_inhibit','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',202,NULL),(209,'aripiprazole_substrate_of_cyp2c8','aripiprazole','substrate_of','cyp2c8','1','0','retract!',NULL,NULL,'Assertion',NULL,203),(210,'cyp1a2_controls_formation_of_threohydrobupropion','cyp1a2','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,204),(211,'zafirlukast_inhibits_cyp2c9','zafirlukast','inhibits','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',205,NULL),(212,'ketoconazole_increases_auc_O-desmethylvenlafaxine','ketoconazole','increases_auc','O-desmethylvenlafaxine','1','0','can\'t decide','medium','1.23','ContValAssertion',206,NULL),(213,'paliperidone_does_not_inhibit_cyp3a4','paliperidone','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',207,NULL),(214,'trimethoprim_maximum_therapeutic_dose_continuous_value','trimethoprim','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.2','ContValAssertion',208,NULL),(215,'propafenone_does_not_inhibit_cyp1a2','propafenone','does_not_inhibit','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,209),(216,'erythromycin_increases_auc_risperidone','erythromycin','increases_auc','risperidone','1','0','can\'t decide',NULL,NULL,'ContValAssertion',NULL,210),(217,'omeprazole_primary_total_clearance_enzyme_cyp2c19','omeprazole','primary_total_clearance_enzyme','cyp2c19','1','1','assume!',NULL,NULL,'Assertion',211,NULL),(218,'R-demethylcitalopram_inhibits_cyp3a4','R-demethylcitalopram','inhibits','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(219,'clarithromycin_fraction_absorbed_continuous_value','clarithromycin','fraction_absorbed','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',212,NULL),(220,'theophylline_has_metabolite_1-methylxanthine','theophylline','has_metabolite','1-methylxanthine','1','0','assume!',NULL,NULL,'Assertion',213,NULL),(221,'fluvoxamine_inhibits_cyp2c19','fluvoxamine','inhibits','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',214,NULL),(222,'fluoxetine_permanently_deactivates_catalytic_function_cyp2d6','fluoxetine','permanently_deactivates_catalytic_function','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,215),(223,'S-demethylcitalopram_substrate_of_cyp2c19','S-demethylcitalopram','substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(224,'asenapine_maximum_concentration_continuous_value','asenapine','maximum_concentration','continuous_value','1','0','assume!',NULL,'4.0e-06','Assertion_maximum_concentration',216,NULL),(225,'cyp3a4_controls_formation_of_ziprasidone-sulphoxide','cyp3a4','controls_formation_of','ziprasidone-sulphoxide','1','0','can\'t decide',NULL,NULL,'Assertion',217,NULL),(226,'S-demethylcitalopram_does_not_inhibit_cyp2c19','S-demethylcitalopram','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',218,NULL),(227,'pantoprazole_does_not_inhibit_cyp2d6','pantoprazole','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',219,NULL),(228,'beta-hydroxy-lovastatin_primary_total_clearance_enzyme_cyp3a4','beta-hydroxy-lovastatin','primary_total_clearance_enzyme','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',220,NULL),(229,'rabeprazole_is_not_substrate_of_cyp2c19','rabeprazole','is_not_substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,221),(230,'modafinil_does_not_inhibit_cyp2c19','modafinil','does_not_inhibit','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,222),(231,'duloxetine_does_not_inhibit_cyp2c19','duloxetine','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',223,NULL),(232,'lansoprazole_is_not_substrate_of_cyp3a5','lansoprazole','is_not_substrate_of','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,224),(233,'escitalopram_is_not_substrate_of_cyp2c19','escitalopram','is_not_substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,225),(234,'S-warfarin_in_vitro_probe_substrate_of_enzyme_cyp2c9','S-warfarin','in_vitro_probe_substrate_of_enzyme','cyp2c9','1','1','assume!',NULL,NULL,'Assertion',226,NULL),(235,'paliperidone_inhibits_cyp2c9','paliperidone','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,227),(236,'paliperidone_inhibits_cyp2c8','paliperidone','inhibits','cyp2c8','1','0','retract!',NULL,NULL,'Assertion',NULL,228),(237,'sertraline_increases_auc_desmethylclozapine','sertraline','increases_auc','desmethylclozapine','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,229),(238,'asenapine_primary_total_clearance_mechanism_Metabolic_Clearance','asenapine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',230,NULL),(239,'celecoxib_substrate_of_cyp2c9','celecoxib','substrate_of','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',231,NULL),(240,'clarithromycin_increases_auc_midazolam','clarithromycin','increases_auc','midazolam','1','0','assume!','high','8.45','ContValAssertion',232,NULL),(241,'atazanavir_inhibits_cyp3a5','atazanavir','inhibits','cyp3a5','1','1','assume!',NULL,NULL,'Assertion',233,NULL),(242,'atazanavir_inhibits_cyp3a4','atazanavir','inhibits','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',234,NULL),(243,'R-citalopram_is_not_substrate_of_cyp2c19','R-citalopram','is_not_substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,235),(244,'cyp2c9_controls_formation_of_N-desmethylrosuvastatin','cyp2c9','controls_formation_of','N-desmethylrosuvastatin','1','0','assume!',NULL,NULL,'Assertion',236,NULL),(245,'demethylcitalopram_substrate_of_cyp3a4','demethylcitalopram','substrate_of','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,237),(246,'risperidone_inhibits_cyp2c19','risperidone','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,238),(247,'perphenazine_inhibits_cyp2c19','perphenazine','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,239),(248,'ziprasidone_does_not_inhibit_cyp3a4','ziprasidone','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',240,NULL),(249,'eszopiclone_inhibits_CYP3A4','eszopiclone','inhibits','CYP3A4','1','0','retract!',NULL,NULL,'Assertion',NULL,241),(250,'itraconazole_sole_PK_effect_alter_metabolic_clearance_simvastatin','itraconazole','sole_PK_effect_alter_metabolic_clearance','simvastatin','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(251,'voriconazole-N-oxide_inhibits_cyp3a4','voriconazole-N-oxide','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',242,NULL),(252,'itraconazole_increases_auc_midazolam','itraconazole','increases_auc','midazolam','1','0','assume!','high','10.8','ContValAssertion',243,NULL),(253,'atazanavir_inhibits_cyp2e1','atazanavir','inhibits','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,244),(254,'pantoprazole_substrate_of_cyp2c19','pantoprazole','substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',245,NULL),(255,'N-desalkylquetiapine_inhibits_cyp2d6','N-desalkylquetiapine','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,246),(256,'simvastatin_inhibition_constant_cyp2c8','simvastatin','inhibition_constant','cyp2c8','1','0','assume!',NULL,'0.003','Assertion_inhibition_constant',247,NULL),(257,'simvastatin_is_not_substrate_of_cyp3a4','simvastatin','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,248),(258,'S-demethylcitalopram_substrate_of_cyp3a4','S-demethylcitalopram','substrate_of','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(259,'diltiazem_permanently_deactivates_catalytic_function_cyp3a4','diltiazem','permanently_deactivates_catalytic_function','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',249,NULL),(260,'atomoxetine_has_metabolite_N-desmethylatomoxetine','atomoxetine','has_metabolite','N-desmethylatomoxetine','1','0','assume!',NULL,NULL,'Assertion',250,NULL),(261,'montelukast_does_not_inhibit_cyp2a6','montelukast','does_not_inhibit','cyp2a6','1','0','assume!',NULL,NULL,'Assertion',251,NULL),(262,'clozapine_substrate_of_cyp2d6','clozapine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',252,NULL),(263,'leflunomide_has_metabolite_teriflunomide','leflunomide','has_metabolite','teriflunomide','1','0','assume!',NULL,NULL,'Assertion',253,NULL),(264,'cyp1a2_controls_formation_of_3-methylxanthine','cyp1a2','controls_formation_of','3-methylxanthine','1','0','assume!',NULL,NULL,'Assertion',254,NULL),(265,'dehydro-aripiprazole_substrate_of_cyp3a4','dehydro-aripiprazole','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',255,NULL),(266,'alprazolam_substrate_of_cyp1a2','alprazolam','substrate_of','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,256),(267,'threohydrobupropion_maximum_concentration_continuous_value','threohydrobupropion','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.0005098','Assertion_maximum_concentration',257,NULL),(268,'iloperidone_is_not_substrate_of_cyp2e1','iloperidone','is_not_substrate_of','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',258,NULL),(269,'fluvoxamine_primary_total_clearance_mechanism_Metabolic_Clearance','fluvoxamine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',259,NULL),(270,'cinacalcet_inhibits_cyp3a5','cinacalcet','inhibits','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,260),(271,'cinacalcet_inhibits_cyp3a4','cinacalcet','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,261),(272,'sertraline_is_not_substrate_of_cyp2c19','sertraline','is_not_substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,262),(273,'duloxetine_is_not_substrate_of_cyp2d6','duloxetine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,263),(274,'atazanavir_does_not_inhibit_cyp2d6','atazanavir','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',264,NULL),(275,'voriconazole_maximum_concentration_continuous_value','voriconazole','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.000466','Assertion_maximum_concentration',265,NULL),(276,'beta-hydroxy-simvastatin_inhibits_cyp3a4','beta-hydroxy-simvastatin','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,266),(277,'cyp3a5_controls_formation_of_4-hydroxyalprazolam','cyp3a5','controls_formation_of','4-hydroxyalprazolam','1','0','can\'t decide',NULL,NULL,'Assertion',267,NULL),(278,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2','phenacetin','in_vitro_probe_substrate_of_enzyme','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',268,NULL),(279,'indomethacin_primary_total_clearance_mechanism_Metabolic_Clearance','indomethacin','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',269,NULL),(280,'R-citalopram_inhibits_cyp1a2','R-citalopram','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,270),(281,'itraconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4','itraconazole','in_vitro_selective_inhibitor_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',271,NULL),(282,'itraconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a5','itraconazole','in_vitro_selective_inhibitor_of_enzyme','cyp3a5','1','1','none_assigned',NULL,NULL,'Assertion',272,NULL),(283,'theophylline_primary_total_clearance_enzyme_cyp1a2','theophylline','primary_total_clearance_enzyme','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',273,NULL),(284,'omeprazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c19','omeprazole','in_vitro_selective_inhibitor_of_enzyme','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',274,NULL),(285,'quetiapine_primary_total_clearance_mechanism_Metabolic_Clearance','quetiapine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',275,NULL),(286,'cimetidine_does_not_inhibit_cyp1a2','cimetidine','does_not_inhibit','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,276),(287,'modafinil_inhibits_cyp2c19','modafinil','inhibits','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',277,NULL),(288,'N-desalkylquetiapine_is_not_substrate_of_cyp3a4','N-desalkylquetiapine','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,278),(289,'clozapine_has_metabolite_clozapine-N-oxide','clozapine','has_metabolite','clozapine-N-oxide','1','0','assume!',NULL,NULL,'Assertion',279,NULL),(290,'nicardipine_bioavailability_continuous_value','nicardipine','bioavailability','continuous_value','1','0','assume!','medium',NULL,'Assertion_m_discrete',280,NULL),(291,'aripiprazole_substrate_of_cyp2e1','aripiprazole','substrate_of','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,281),(292,'cimetidine_does_not_inhibit_cyp3a4','cimetidine','does_not_inhibit','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,282),(293,'thiothixene_inhibition_constant_cyp2d6','thiothixene','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.029','Assertion_inhibition_constant',283,NULL),(294,'dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6','dextromethorphan','in_viVo_probe_substrate_of_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',284,NULL),(295,'itraconazole_increases_auc_lovastatin','itraconazole','increases_auc','lovastatin','1','0','assume!','high','14.8','ContValAssertion',285,NULL),(296,'iloperidone_inhibits_cyp2d6','iloperidone','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',286,NULL),(297,'perphenazine_substrate_of_cyp1a2','perphenazine','substrate_of','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',287,NULL),(298,'voriconazole_substrate_of_cyp3a4','voriconazole','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',288,NULL),(299,'citalopram_is_not_substrate_of_cyp2c19','citalopram','is_not_substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,289),(300,'asenapine_substrate_of_cyp2d6','asenapine','substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,290),(301,'cyp3a4_controls_formation_of_ortho-hydroxy-atorvastatin','cyp3a4','controls_formation_of','ortho-hydroxy-atorvastatin','1','0','can\'t decide',NULL,NULL,'Assertion',291,NULL),(302,'mirtazapine_substrate_of_cyp1a2','mirtazapine','substrate_of','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',292,NULL),(303,'fluoxetine_increases_auc_alprazolam','fluoxetine','increases_auc','alprazolam','1','0','can\'t decide','medium','1.318','ContValAssertion',293,294),(304,'cyp2d6_controls_formation_of_4-hydroxyatomoxetine','cyp2d6','controls_formation_of','4-hydroxyatomoxetine','1','0','assume!',NULL,NULL,'Assertion',295,NULL),(305,'thioridazine_has_metabolite_thioridazine-5-sulfoxide','thioridazine','has_metabolite','thioridazine-5-sulfoxide','1','0','assume!',NULL,NULL,'Assertion',296,NULL),(306,'venlafaxine_inhibits_cyp2c9','venlafaxine','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,297),(307,'propoxyphene_maximum_therapeutic_dose_continuous_value','propoxyphene','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.6','ContValAssertion',298,NULL),(308,'theophylline_has_metabolite_1,3-dimethyluric-acid','theophylline','has_metabolite','1,3-dimethyluric-acid','1','0','assume!',NULL,NULL,'Assertion',299,NULL),(309,'S-warfarin_primary_total_clearance_enzyme_cyp2c9','S-warfarin','primary_total_clearance_enzyme','cyp2c9','1','1','assume!',NULL,NULL,'Assertion',300,NULL),(310,'demethylcitalopram_inhibits_cyp2c9','demethylcitalopram','inhibits','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(311,'theophylline_in_vitro_probe_substrate_of_enzyme_cyp1a2','theophylline','in_vitro_probe_substrate_of_enzyme','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',301,NULL),(312,'alprazolam_maximum_concentration_continuous_value','alprazolam','maximum_concentration','continuous_value','1','0','assume!',NULL,'3.7e-05','Assertion_maximum_concentration',302,NULL),(313,'ciprofloxacin_inhibits_cyp1a2','ciprofloxacin','inhibits','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',303,NULL),(314,'venlafaxine_increases_auc_risperidone','venlafaxine','increases_auc','risperidone','1','1','assume!','medium','1.32','ContValAssertion',304,NULL),(315,'atorvastatin_is_not_substrate_of_cyp2c9','atorvastatin','is_not_substrate_of','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',305,NULL),(316,'fluvoxamine_inhibition_constant_cyp1a2','fluvoxamine','inhibition_constant','cyp1a2','1','0','assume!',NULL,'2.072e-05','Assertion_inhibition_constant',306,NULL),(317,'valproate_maximum_therapeutic_dose_continuous_value','valproate','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'4.2','ContValAssertion',307,NULL),(318,'propafenone_inhibits_cyp1a2','propafenone','inhibits','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',308,NULL),(319,'R-citalopram_primary_total_clearance_mechanism_Renal_Excretion','R-citalopram','primary_total_clearance_mechanism','Renal_Excretion','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(320,'ritonavir_inhibits_cyp2d6','ritonavir','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',309,NULL),(321,'eszopiclone_does_not_inhibit_CYP2C19','eszopiclone','does_not_inhibit','CYP2C19','1','0','assume!',NULL,NULL,'Assertion',310,NULL),(322,'fluphenazine_inhibition_constant_cyp1a2','fluphenazine','inhibition_constant','cyp1a2','1','0','assume!',NULL,'0.018','Assertion_inhibition_constant',311,NULL),(323,'citalopram_inhibits_cyp1a2','citalopram','inhibits','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(324,'celecoxib_inhibits_cyp2c9','celecoxib','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,312),(325,'cyp2c8_controls_formation_of_threohydrobupropion','cyp2c8','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,313),(326,'quetiapine_is_not_substrate_of_cyp2e1','quetiapine','is_not_substrate_of','cyp2e1','1','0','can\'t decide',NULL,NULL,'Assertion',314,NULL),(327,'cyp1a2_controls_formation_of_O-desmethylvenlafaxine','cyp1a2','controls_formation_of','O-desmethylvenlafaxine','1','0','retract!',NULL,NULL,'Assertion',NULL,315),(328,'nefazodone_in_viVo_selective_inhibitor_of_enzyme_cyp3a4','nefazodone','in_viVo_selective_inhibitor_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',316,NULL),(329,'R-didemethylcitalopram_inhibits_cyp2d6','R-didemethylcitalopram','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,317),(330,'iloperidone_is_not_substrate_of_cyp3a4','iloperidone','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,318),(331,'quetiapine_substrate_of_cyp2c9','quetiapine','substrate_of','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,319),(332,'venlafaxine_increases_auc_alprazolam','venlafaxine','increases_auc','alprazolam','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,320),(333,'clarithromycin_in_viVo_selective_inhibitor_of_enzyme_cyp3a4','clarithromycin','in_viVo_selective_inhibitor_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',321,NULL),(334,'nefazodone_does_not_inhibit_cyp1a2','nefazodone','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',322,NULL),(335,'escitalopram_inhibits_cyp2c9','escitalopram','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,323),(336,'triazolam_primary_total_clearance_enzyme_cyp3a4','triazolam','primary_total_clearance_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',324,NULL),(337,'S-didemethylcitalopram_inhibits_cyp2d6','S-didemethylcitalopram','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,325),(338,'mirtazapine_is_not_substrate_of_cyp2c19','mirtazapine','is_not_substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',326,NULL),(339,'voriconazole_does_not_inhibit_cyp2c9','voriconazole','does_not_inhibit','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,327),(340,'risperidone_does_not_inhibit_cyp2c19','risperidone','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',328,NULL),(341,'thiothixene_does_not_inhibit_cyp2c19','thiothixene','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',329,NULL),(342,'R-warfarin_in_vitro_probe_substrate_of_enzyme_cyp3a4','R-warfarin','in_vitro_probe_substrate_of_enzyme','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(343,'cyp2d6_controls_formation_of_hydroxybupropion','cyp2d6','controls_formation_of','hydroxybupropion','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,330),(344,'itraconazole_increases_auc_atorvastatin','itraconazole','increases_auc','atorvastatin','1','0','assume!','high','2.5','ContValAssertion',331,NULL),(345,'eszopiclone_inhibits_CYP2D6','eszopiclone','inhibits','CYP2D6','1','0','retract!',NULL,NULL,'Assertion',NULL,332),(346,'erythromycin_in_vitro_probe_substrate_of_enzyme_cyp3a4','erythromycin','in_vitro_probe_substrate_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',333,NULL),(347,'R-didemethylcitalopram_does_not_inhibit_cyp1a2','R-didemethylcitalopram','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',334,NULL),(348,'lovastatin_bioavailability_continuous_value','lovastatin','bioavailability','continuous_value','1','0','assume!','low',NULL,'Assertion_m_discrete',335,NULL),(349,'topiramate_does_not_inhibit_cyp2e1','topiramate','does_not_inhibit','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',336,NULL),(350,'perphenazine_is_not_substrate_of_cyp3a4','perphenazine','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,337),(351,'venlafaxine_does_not_inhibit_cyp2c9','venlafaxine','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',338,NULL),(352,'ticlopidine_inhibition_constant_cyp2b6','ticlopidine','inhibition_constant','cyp2b6','1','1','assume!',NULL,'5.278e-05','Assertion_inhibition_constant',339,NULL),(353,'cimetidine_increases_auc_citalopram','cimetidine','increases_auc','citalopram','1','0','can\'t decide','medium','1.43','ContValAssertion',340,NULL),(354,'nefazodone_increases_auc_triazolam','nefazodone','increases_auc','triazolam','1','0','assume!','high','4.0','ContValAssertion',341,NULL),(355,'cyp2b6_controls_formation_of_threohydrobupropion','cyp2b6','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,342),(356,'amiodarone_does_not_inhibit_cyp3a4','amiodarone','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,343),(357,'topiramate_inhibits_cyp2c9','topiramate','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,344),(358,'aripiprazole_is_not_substrate_of_cyp2c9','aripiprazole','is_not_substrate_of','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',345,NULL),(359,'citalopram_inhibits_cyp2d6','citalopram','inhibits','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(360,'diltiazem_primary_metabolic_clearance_enzyme_cyp2d6','diltiazem','primary_metabolic_clearance_enzyme','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,346),(361,'verapamil_does_not_inhibit_cyp3a4','verapamil','does_not_inhibit','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,347),(362,'cyp1a2_controls_formation_of_hydroxybupropion','cyp1a2','controls_formation_of','hydroxybupropion','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,348),(363,'paroxetine_permanently_deactivates_catalytic_function_cyp2d6','paroxetine','permanently_deactivates_catalytic_function','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',349,NULL),(364,'cyp3a4_controls_formation_of_4-(4-chlorophenyl)-4-hydroxypiperidine','cyp3a4','controls_formation_of','4-(4-chlorophenyl)-4-hydroxypiperidine','1','0','assume!',NULL,NULL,'Assertion',350,NULL),(365,'fluoxetine_does_not_inhibit_cyp2d6','fluoxetine','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,351),(366,'fluvastatin_is_not_substrate_of_cyp3a4','fluvastatin','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,352),(367,'clozapine_substrate_of_cyp3a4','clozapine','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',353,NULL),(368,'atorvastatin_minimum_therapeutic_dose_continuous_value','atorvastatin','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.01','ContValAssertion',354,NULL),(369,'ranolazine_inhibits_cyp2d6','ranolazine','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',355,NULL),(370,'aripiprazole_substrate_of_cyp2a6','aripiprazole','substrate_of','cyp2a6','1','0','retract!',NULL,NULL,'Assertion',NULL,356),(371,'diltiazem_inhibits_cyp3a4','diltiazem','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',357,NULL),(372,'voriconazole-N-oxide_does_not_inhibit_cyp3a4','voriconazole-N-oxide','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,358),(373,'desacetyldiltiazem_primary_total_clearance_enzyme_cyp2d6','desacetyldiltiazem','primary_total_clearance_enzyme','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',359,NULL),(374,'celecoxib_does_not_inhibit_cyp2d6','celecoxib','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,360),(375,'zafirlukast_is_not_substrate_of_cyp2c9','zafirlukast','is_not_substrate_of','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,361),(376,'S-demethylcitalopram_substrate_of_cyp2d6','S-demethylcitalopram','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',362,NULL),(377,'atorvastatin_is_not_substrate_of_cyp1a1','atorvastatin','is_not_substrate_of','cyp1a1','1','0','can\'t decide',NULL,NULL,'Assertion',363,NULL),(378,'clarithromycin_is_not_substrate_of_cyp3a4','clarithromycin','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,364),(379,'triazolam_increases_auc_nefazodone','triazolam','increases_auc','nefazodone','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,365),(380,'diltiazem_increases_auc_pravastatin','diltiazem','increases_auc','pravastatin','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,366),(381,'mirtazapine_is_not_substrate_of_cyp2a6','mirtazapine','is_not_substrate_of','cyp2a6','1','0','can\'t decide',NULL,NULL,'Assertion',367,NULL),(382,'fluvoxamine_in_vitro_selective_inhibitor_of_enzyme_cyp1a2','fluvoxamine','in_vitro_selective_inhibitor_of_enzyme','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(383,'voriconazole_substrate_of_cyp2c19','voriconazole','substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',368,NULL),(384,'cyp2c9_controls_formation_of_4-(4-chlorophenyl)-4-hydroxypiperidine','cyp2c9','controls_formation_of','4-(4-chlorophenyl)-4-hydroxypiperidine','1','0','retract!',NULL,NULL,'Assertion',NULL,369),(385,'diltiazem_is_not_substrate_of_cyp3a5','diltiazem','is_not_substrate_of','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,370),(386,'diltiazem_is_not_substrate_of_cyp3a4','diltiazem','is_not_substrate_of','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,371),(387,'N-desalkylquetiapine_does_not_inhibit_cyp1a2','N-desalkylquetiapine','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',372,NULL),(388,'celecoxib_inhibits_cyp2d6','celecoxib','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',373,NULL),(389,'cyp2e1_controls_formation_of_threohydrobupropion','cyp2e1','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,374),(390,'quetiapine_is_not_substrate_of_cyp2c19','quetiapine','is_not_substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',375,NULL),(391,'citalopram_inhibits_cyp2c19','citalopram','inhibits','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(392,'pantoprazole_primary_total_clearance_mechanism_Renal_Excretion','pantoprazole','primary_total_clearance_mechanism','Renal_Excretion','1','0','retract!',NULL,NULL,'Assertion',NULL,376),(393,'R-citalopram_inhibits_cyp2d6','R-citalopram','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,377),(394,'montelukast_inhibits_cyp3a4','montelukast','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,378),(395,'thioridazine_has_metabolite_sulforidazine','thioridazine','has_metabolite','sulforidazine','1','0','assume!',NULL,NULL,'Assertion',379,NULL),(396,'valproate_increases_auc_hydroxybupropion','valproate','increases_auc','hydroxybupropion','1','1','assume!','medium','1.94','ContValAssertion',380,NULL),(397,'clozapine_inhibits_cyp2c19','clozapine','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,381),(398,'atazanavir_does_not_inhibit_cyp2b6','atazanavir','does_not_inhibit','cyp2b6','1','0','assume!',NULL,NULL,'Assertion',382,NULL),(399,'7-ethoxyresorufin_in_vitro_probe_substrate_of_enzyme_cyp1a2','7-ethoxyresorufin','in_vitro_probe_substrate_of_enzyme','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',383,NULL),(400,'venlafaxine_does_not_inhibit_cyp2d6','venlafaxine','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,384),(401,'ciprofloxacin_does_not_inhibit_cyp1a2','ciprofloxacin','does_not_inhibit','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,385),(402,'chlorpromazine_bioavailability_continuous_value','chlorpromazine','bioavailability','continuous_value','1','0','assume!','low',NULL,'Assertion_m_discrete',386,NULL),(403,'amiodarone_inhibits_cyp2c9','amiodarone','inhibits','cyp2c9','1','1','assume!',NULL,NULL,'Assertion',387,NULL),(404,'amiodarone_inhibits_cyp2d6','amiodarone','inhibits','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',388,NULL),(405,'cyp2e1_controls_formation_of_N-dealkylperphenazine','cyp2e1','controls_formation_of','N-dealkylperphenazine','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,389),(406,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4','ketoconazole','in_viVo_selective_inhibitor_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',390,NULL),(407,'escitalopram_substrate_of_cyp2d6','escitalopram','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',391,NULL),(408,'atorvastatin_substrate_of_cyp2e1','atorvastatin','substrate_of','cyp2e1','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,392),(409,'cimetidine_increases_auc_escitalopram','cimetidine','increases_auc','escitalopram','1','1','assume!','medium','1.72','ContValAssertion',393,NULL),(410,'cyp2d6_controls_formation_of_4-(4-chlorophenyl)-4-hydroxypiperidine','cyp2d6','controls_formation_of','4-(4-chlorophenyl)-4-hydroxypiperidine','1','0','retract!',NULL,NULL,'Assertion',NULL,394),(411,'rosuvastatin_is_not_substrate_of_cyp3a4','rosuvastatin','is_not_substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',395,NULL),(412,'celecoxib_inhibits_cyp2c19','celecoxib','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,396),(413,'ziprasidone_substrate_of_cyp2c9','ziprasidone','substrate_of','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,397),(414,'tamoxifen_has_metabolite_4-hydroxytamoxifin','tamoxifen','has_metabolite','4-hydroxytamoxifin','1','0','assume!',NULL,NULL,'Assertion',398,NULL),(415,'amiodarone_does_not_inhibit_cyp1a2','amiodarone','does_not_inhibit','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,399),(416,'diltiazem_inhibition_constant_cyp3a4','diltiazem','inhibition_constant','cyp3a4','1','0','assume!',NULL,'0.00022','Assertion_inhibition_constant',400,NULL),(417,'clarithromycin_has_metabolite_14-hydroxyclarithromycin','clarithromycin','has_metabolite','14-hydroxyclarithromycin','1','0','assume!',NULL,NULL,'Assertion',401,NULL),(418,'quinidine_does_not_inhibit_cyp2d6','quinidine','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,402),(419,'tamoxifen_is_not_substrate_of_cyp2d6','tamoxifen','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,403),(420,'fluconazole_bioavailability_continuous_value','fluconazole','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',404,NULL),(421,'fluphenazine_inhibition_constant_cyp2d6','fluphenazine','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.004','Assertion_inhibition_constant',405,NULL),(422,'beta-hydroxy-simvastatin_substrate_of_cyp3a4','beta-hydroxy-simvastatin','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',406,NULL),(423,'beta-hydroxy-lovastatin_maximum_concentration_continuous_value','beta-hydroxy-lovastatin','maximum_concentration','continuous_value','1','0','assume!',NULL,'1.19e-05','Assertion_maximum_concentration',407,NULL),(424,'cyp2c19_polymorphic_enzyme_True','cyp2c19','polymorphic_enzyme','True','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(425,'cimetidine_increases_auc_theophylline','cimetidine','increases_auc','theophylline','1','1','assume!','medium','1.458','ContValAssertion',408,NULL),(426,'chlorzoxazone_in_vitro_probe_substrate_of_enzyme_cyp2e1','chlorzoxazone','in_vitro_probe_substrate_of_enzyme','cyp2e1','1','1','assume!',NULL,NULL,'Assertion',409,NULL),(427,'propoxyphene_has_metabolite_norpropoxyphene','propoxyphene','has_metabolite','norpropoxyphene','1','0','assume!',NULL,NULL,'Assertion',410,NULL),(428,'paliperidone_inhibits_cyp2d6','paliperidone','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,411),(429,'metronidazole_minimum_therapeutic_dose_continuous_value','metronidazole','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.75','ContValAssertion',412,NULL),(430,'sertraline_inhibits_cyp2d6','sertraline','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',413,NULL),(431,'atazanavir_does_not_inhibit_cyp3a4','atazanavir','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,414),(432,'atazanavir_does_not_inhibit_cyp3a5','atazanavir','does_not_inhibit','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,415),(433,'cyp2d6_polymorphic_enzyme_True','cyp2d6','polymorphic_enzyme','True','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(434,'fluconazole_increases_auc_midazolam','fluconazole','increases_auc','midazolam','1','0','assume!','high','3.726','ContValAssertion',416,NULL),(435,'haloperidol_does_not_inhibit_cyp2c19','haloperidol','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',417,NULL),(436,'lansoprazole_inhibits_cyp2d6','lansoprazole','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,418),(437,'testosterone_in_vitro_probe_substrate_of_enzyme_cyp3a4','testosterone','in_vitro_probe_substrate_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',419,NULL),(438,'itraconazole_sole_PK_effect_alter_metabolic_clearance_beta-hydroxy-lovastatin','itraconazole','sole_PK_effect_alter_metabolic_clearance','beta-hydroxy-lovastatin','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(439,'didemethylcitalopram_inhibits_cyp3a4','didemethylcitalopram','inhibits','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(440,'duloxetine_increases_auc_theophylline','duloxetine','increases_auc','theophylline','1','1','assume!','medium','1.13','ContValAssertion',420,NULL),(441,'zolpidem_is_not_substrate_of_cyp3a4','zolpidem','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,421),(442,'paliperidone_inhibition_constant_cyp2d6','paliperidone','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.007','Assertion_inhibition_constant',422,NULL),(443,'omeprazole_increases_auc_escitalopram','omeprazole','increases_auc','escitalopram','1','1','assume!','medium','1.51','ContValAssertion',423,NULL),(444,'R-didemethylcitalopram_does_not_inhibit_cyp2d6','R-didemethylcitalopram','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',424,NULL),(445,'ziprasidone_is_not_substrate_of_cyp2c19','ziprasidone','is_not_substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',425,NULL),(446,'olanzapine_inhibition_constant_cyp2c9','olanzapine','inhibition_constant','cyp2c9','1','0','assume!',NULL,'0.223','Assertion_inhibition_constant',426,NULL),(447,'cyp4a11_controls_formation_of_threohydrobupropion','cyp4a11','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,427),(448,'clozapine_inhibition_constant_cyp2d6','clozapine','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.013','Assertion_inhibition_constant',428,NULL),(449,'dehydro-aripiprazole_inhibits_cyp1a2','dehydro-aripiprazole','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,429),(450,'hydroxybupropion_primary_total_clearance_mechanism_Renal_Excretion','hydroxybupropion','primary_total_clearance_mechanism','Renal_Excretion','1','0','assume!',NULL,NULL,'Assertion',430,NULL),(451,'venlafaxine_increases_auc_haloperidol','venlafaxine','increases_auc','haloperidol','1','0','can\'t decide','medium','1.7','ContValAssertion',431,NULL),(452,'paliperidone_inhibits_cyp2c19','paliperidone','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,432),(453,'clopidogrel_inhibition_constant_cyp2b6','clopidogrel','inhibition_constant','cyp2b6','1','1','assume!',NULL,'0.0001609','Assertion_inhibition_constant',433,NULL),(454,'voriconazole_inhibits_cyp2c9','voriconazole','inhibits','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',434,NULL),(455,'diltiazem_maximum_concentration_continuous_value','diltiazem','maximum_concentration','continuous_value','1','0','assume!',NULL,'6.067e-05','Assertion_maximum_concentration',435,NULL),(456,'demethylcitalopram_inhibits_cyp2c19','demethylcitalopram','inhibits','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(457,'S-demethylcitalopram_inhibits_cyp2c19','S-demethylcitalopram','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,436),(458,'nefazodone_substrate_of_cyp2c19','nefazodone','substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,437),(459,'eszopiclone_does_not_inhibit_CYP2A6','eszopiclone','does_not_inhibit','CYP2A6','1','0','assume!',NULL,NULL,'Assertion',438,NULL),(460,'cyp3a4_controls_formation_of_4-hydroxymidazolam','cyp3a4','controls_formation_of','4-hydroxymidazolam','1','0','can\'t decide',NULL,NULL,'Assertion',439,NULL),(461,'teriflunomide_does_not_inhibit_cyp2c9','teriflunomide','does_not_inhibit','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,440),(462,'molindone_primary_total_clearance_mechanism_Metabolic_Clearance','molindone','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',441,NULL),(463,'demethylcitalopram_is_not_substrate_of_cyp2c19','demethylcitalopram','is_not_substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',442,NULL),(464,'rosuvastatin_maximum_concentration_continuous_value','rosuvastatin','maximum_concentration','continuous_value','1','0','assume!',NULL,'1.88e-05','Assertion_maximum_concentration',443,NULL),(465,'escitalopram_substrate_of_cyp2c19','escitalopram','substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',444,NULL),(466,'perphenazine_maximum_concentration_continuous_value','perphenazine','maximum_concentration','continuous_value','1','0','assume!',NULL,'9.84e-07','Assertion_maximum_concentration',445,NULL),(467,'escitalopram_bioavailability_continuous_value','escitalopram','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',446,NULL),(468,'mephenytoin_in_viVo_probe_substrate_of_enzyme_cyp2c19','mephenytoin','in_viVo_probe_substrate_of_enzyme','cyp2c19','1','1','assume!',NULL,NULL,'Assertion',447,NULL),(469,'rabeprazole_substrate_of_cyp3a4','rabeprazole','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',448,NULL),(470,'venlafaxine_inhibits_cyp1a2','venlafaxine','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,449),(471,'S-demethylcitalopram_is_not_substrate_of_cyp2d6','S-demethylcitalopram','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,450),(472,'ketoconazole_increases_auc_zolpidem','ketoconazole','increases_auc','zolpidem','1','1','assume!','medium','1.83','ContValAssertion',451,NULL),(473,'montelukast_does_not_inhibit_cyp2d6','montelukast','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',452,NULL),(474,'demethylcitalopram_inhibits_cyp1a2','demethylcitalopram','inhibits','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(475,'venlafaxine_fraction_absorbed_continuous_value','venlafaxine','fraction_absorbed','continuous_value','1','0','can\'t decide','high',NULL,'Assertion_m_discrete',453,NULL),(476,'simvastatin_does_not_permanently_deactivate_catalytic_function_cyp2c8','simvastatin','does_not_permanently_deactivate_catalytic_function','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(477,'topiramate_minimum_therapeutic_dose_continuous_value','topiramate','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.025','ContValAssertion',454,NULL),(478,'voriconazole_does_not_inhibit_cyp2c19','voriconazole','does_not_inhibit','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,455),(479,'rosiglitazone_inhibits_cyp2c19','rosiglitazone','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,456),(480,'risperidone_substrate_of_cyp2d6','risperidone','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',457,NULL),(481,'aripiprazole_substrate_of_cyp2b6','aripiprazole','substrate_of','cyp2b6','1','0','retract!',NULL,NULL,'Assertion',NULL,458),(482,'voriconazole_minimum_therapeutic_dose_continuous_value','voriconazole','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.2','ContValAssertion',459,NULL),(483,'R-demethylcitalopram_substrate_of_cyp2d6','R-demethylcitalopram','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',460,NULL),(484,'aripiprazole_does_not_inhibit_cyp2d6','aripiprazole','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',461,NULL),(485,'indinavir_inhibits_cyp3a5','indinavir','inhibits','cyp3a5','1','1','assume!',NULL,NULL,'Assertion',462,NULL),(486,'indinavir_inhibits_cyp3a4','indinavir','inhibits','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',463,NULL),(487,'cyp2c19_controls_formation_of_N-desmethylatomoxetine','cyp2c19','controls_formation_of','N-desmethylatomoxetine','1','0','assume!',NULL,NULL,'Assertion',464,NULL),(488,'paliperidone_does_not_inhibit_cyp1a2','paliperidone','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',465,NULL),(489,'ziprasidone_inhibits_cyp2c9','ziprasidone','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,466),(490,'cyp3a5_controls_formation_of_4-hydroxymidazolam','cyp3a5','controls_formation_of','4-hydroxymidazolam','1','0','can\'t decide',NULL,NULL,'Assertion',467,NULL),(491,'midazolam_is_not_substrate_of_cyp3a5','midazolam','is_not_substrate_of','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,468),(492,'venlafaxine_has_metabolite_N-desmethylvenlafaxine','venlafaxine','has_metabolite','N-desmethylvenlafaxine','1','0','assume!',NULL,NULL,'Assertion',469,NULL),(493,'fluoxetine_increases_auc_propafenone','fluoxetine','increases_auc','propafenone','1','1','assume!','medium','1.5','ContValAssertion',470,NULL),(494,'sertraline_substrate_of_cyp2c19','sertraline','substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',471,NULL),(495,'risperidone_bioavailability_continuous_value','risperidone','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',472,NULL),(496,'erythromycin_does_not_permanently_deactivate_catalytic_function_cyp3a4','erythromycin','does_not_permanently_deactivate_catalytic_function','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(497,'modafinil_has_metabolite_modafinil-sulfone','modafinil','has_metabolite','modafinil-sulfone','1','0','assume!',NULL,NULL,'Assertion',473,NULL),(498,'S-demethylcitalopram_is_not_substrate_of_cyp2c19','S-demethylcitalopram','is_not_substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(499,'atomoxetine_primary_total_clearance_enzyme_cyp2d6','atomoxetine','primary_total_clearance_enzyme','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',474,NULL),(500,'rosiglitazone_does_not_inhibit_cyp3a4','rosiglitazone','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',475,NULL),(501,'paliperidone_does_not_inhibit_cyp2c9','paliperidone','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',476,NULL),(502,'aripiprazole_inhibits_cyp1a2','aripiprazole','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,477),(503,'fluconazole_increases_auc_zolpidem','fluconazole','increases_auc','zolpidem','1','1','assume!',NULL,NULL,'ContValAssertion',NULL,478),(504,'atazanavir_inhibits_cyp2c19','atazanavir','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,479),(505,'ranolazine_maximum_therapeutic_dose_continuous_value','ranolazine','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'2.0','ContValAssertion',480,NULL),(506,'cyp1a2_controls_formation_of_4-(4-chlorophenyl)-4-hydroxypiperidine','cyp1a2','controls_formation_of','4-(4-chlorophenyl)-4-hydroxypiperidine','1','0','retract!',NULL,NULL,'Assertion',NULL,481),(507,'paliperidone_does_not_inhibit_cyp2c8','paliperidone','does_not_inhibit','cyp2c8','1','0','assume!',NULL,NULL,'Assertion',482,NULL),(508,'cyp3a4_controls_formation_of_N-desmethylvenlafaxine','cyp3a4','controls_formation_of','N-desmethylvenlafaxine','1','0','assume!',NULL,NULL,'Assertion',483,NULL),(509,'mirtazapine_fraction_absorbed_continuous_value','mirtazapine','fraction_absorbed','continuous_value','1','0','can\'t decide','high',NULL,'Assertion_m_discrete',484,NULL),(510,'didemethylcitalopram_inhibits_cyp2d6','didemethylcitalopram','inhibits','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(511,'voriconazole-N-oxide_inhibits_cyp2c19','voriconazole-N-oxide','inhibits','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',485,NULL),(512,'zafirlukast_maximum_therapeutic_dose_continuous_value','zafirlukast','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.04','ContValAssertion',486,NULL),(513,'nefazodone_substrate_of_cyp2c8','nefazodone','substrate_of','cyp2c8','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,487),(514,'fluconazole_maximum_concentration_continuous_value','fluconazole','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.007','Assertion_maximum_concentration',488,NULL),(515,'duloxetine_primary_total_clearance_mechanism_Metabolic_Clearance','duloxetine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',489,NULL),(516,'topiramate_inhibits_cyp1a2','topiramate','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,490),(517,'quetiapine_inhibits_cyp2c9','quetiapine','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,491),(518,'erythrohydrobupropion_maximum_concentration_continuous_value','erythrohydrobupropion','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.0001457','Assertion_maximum_concentration',492,NULL),(519,'norfloxacin_inhibits_cyp1a2','norfloxacin','inhibits','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',493,NULL),(520,'mirtazapine_is_not_substrate_of_cyp2e1','mirtazapine','is_not_substrate_of','cyp2e1','1','0','can\'t decide',NULL,NULL,'Assertion',494,NULL),(521,'trimethoprim_inhibits_cyp2c8','trimethoprim','inhibits','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',495,NULL),(522,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6','quinidine','in_vitro_selective_inhibitor_of_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',496,NULL),(523,'aripiprazole_does_not_inhibit_cyp1a2','aripiprazole','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',497,NULL),(524,'topiramate_inhibits_cyp2d6','topiramate','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,498),(525,'alprazolam_increases_auc_nefazodone','alprazolam','increases_auc','nefazodone','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,499),(526,'paliperidone_inhibits_cyp3a5','paliperidone','inhibits','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,500),(527,'S-didemethylcitalopram_does_not_inhibit_cyp2d6','S-didemethylcitalopram','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',501,NULL),(528,'asenapine_is_not_substrate_of_cyp2d6','asenapine','is_not_substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',502,NULL),(529,'cimetidine_increases_auc_threohydrobupropion','cimetidine','increases_auc','threohydrobupropion','1','0','can\'t decide','medium','1.16','ContValAssertion',503,NULL),(530,'citalopram_inhibits_cyp2e1','citalopram','inhibits','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,504),(531,'aripiprazole_is_not_substrate_of_cyp2d6','aripiprazole','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,505),(532,'iloperidone_substrate_of_cyp2d6','iloperidone','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',506,NULL),(533,'pantoprazole_substrate_of_cyp3a4','pantoprazole','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',507,NULL),(534,'aripiprazole_inhibits_cyp2c19','aripiprazole','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,508),(535,'atorvastatin_has_metabolite_ortho-hydroxy-atorvastatin','atorvastatin','has_metabolite','ortho-hydroxy-atorvastatin','1','0','assume!',NULL,NULL,'Assertion',509,NULL),(536,'N-demethyldesacetyl-diltiazem_primary_total_clearance_enzyme_cyp2d6','N-demethyldesacetyl-diltiazem','primary_total_clearance_enzyme','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',510,NULL),(537,'rosiglitazone_does_not_inhibit_cyp3a5','rosiglitazone','does_not_inhibit','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',511,NULL),(538,'rosiglitazone_does_not_inhibit_cyp2b6','rosiglitazone','does_not_inhibit','cyp2b6','1','0','assume!',NULL,NULL,'Assertion',512,NULL),(539,'tamoxifen_primary_total_clearance_mechanism_Metabolic_Clearance','tamoxifen','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',513,NULL),(540,'lovastatin_does_not_permanently_deactivate_catalytic_function_cyp2c8','lovastatin','does_not_permanently_deactivate_catalytic_function','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(541,'ranolazine_maximum_concentration_continuous_value','ranolazine','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.00026','Assertion_maximum_concentration',514,NULL),(542,'montelukast_inhibition_constant_cyp2c8','montelukast','inhibition_constant','cyp2c8','1','1','assume!',NULL,'0.0006448','Assertion_inhibition_constant',515,NULL),(543,'erythromycin_increases_auc_triazolam','erythromycin','increases_auc','triazolam','1','0','assume!','high','2.06','ContValAssertion',516,NULL),(544,'citalopram_has_metabolite_didemethylcitalopram','citalopram','has_metabolite','didemethylcitalopram','1','0','assume!',NULL,NULL,'Assertion',517,NULL),(545,'venlafaxine_is_not_substrate_of_cyp2d6','venlafaxine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,518),(546,'venlafaxine_substrate_of_cyp2d6','venlafaxine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',519,NULL),(547,'voriconazole_substrate_of_cyp2c9','voriconazole','substrate_of','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',520,NULL),(548,'R-demethylcitalopram_is_not_substrate_of_cyp2c19','R-demethylcitalopram','is_not_substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(549,'mirtazapine_inhibits_cyp2d6','mirtazapine','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,521),(550,'bupropion_primary_total_clearance_mechanism_Renal_Excretion','bupropion','primary_total_clearance_mechanism','Renal_Excretion','1','0','retract!',NULL,NULL,'Assertion',NULL,522),(551,'rosiglitazone_inhibits_cyp3a5','rosiglitazone','inhibits','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,523),(552,'aripiprazole_substrate_of_cyp3a4','aripiprazole','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',524,NULL),(553,'ziprasidone_is_not_substrate_of_cyp2d6','ziprasidone','is_not_substrate_of','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',525,NULL),(554,'gemfibrozil_does_not_inhibit_cyp2c8','gemfibrozil','does_not_inhibit','cyp2c8','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,526),(555,'furafylline_in_vitro_selective_inhibitor_of_enzyme_cyp1a2','furafylline','in_vitro_selective_inhibitor_of_enzyme','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',527,NULL),(556,'alprazolam_primary_total_clearance_mechanism_Metabolic_Clearance','alprazolam','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',528,NULL),(557,'fluconazole_increases_auc_fluvastatin','fluconazole','increases_auc','fluvastatin','1','0','assume!','medium','1.837','ContValAssertion',529,NULL),(558,'cyp3a5_controls_formation_of_1\'-hydroxymidazolam','cyp3a5','controls_formation_of','1\'-hydroxymidazolam','1','0','can\'t decide',NULL,NULL,'Assertion',530,NULL),(559,'paroxetine_increases_auc_mirtazapine','paroxetine','increases_auc','mirtazapine','1','1','assume!','medium','1.17','ContValAssertion',531,NULL),(560,'fluconazole_inhibition_constant_cyp3a4','fluconazole','inhibition_constant','cyp3a4','1','0','assume!',NULL,'0.000389','Assertion_inhibition_constant',532,NULL),(561,'coumarin_in_vitro_probe_substrate_of_enzyme_cyp2a6','coumarin','in_vitro_probe_substrate_of_enzyme','cyp2a6','1','1','assume!',NULL,NULL,'Assertion',533,NULL),(562,'cyp3a4_controls_formation_of_N-desmethyltamoxifen','cyp3a4','controls_formation_of','N-desmethyltamoxifen','1','0','assume!',NULL,NULL,'Assertion',534,NULL),(563,'quetiapine_inhibits_cyp1a2','quetiapine','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,535),(564,'quetiapine_is_not_substrate_of_cyp3a4','quetiapine','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,536),(565,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4','midazolam','in_vitro_probe_substrate_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',537,NULL),(566,'beta-hydroxy-lovastatin_inhibition_constant_cyp2c8','beta-hydroxy-lovastatin','inhibition_constant','cyp2c8','1','0','assume!',NULL,'0.021','Assertion_inhibition_constant',538,NULL),(567,'ranolazine_primary_total_clearance_enzyme_cyp3a4','ranolazine','primary_total_clearance_enzyme','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',539,NULL),(568,'cimetidine_increases_auc_ziprasidone','cimetidine','increases_auc','ziprasidone','1','0','assume!','medium','1.069','ContValAssertion',540,NULL),(569,'perphenazine_inhibition_constant_cyp2d6','perphenazine','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.00032','Assertion_inhibition_constant',541,NULL),(570,'citalopram_has_metabolite_demethylcitalopram','citalopram','has_metabolite','demethylcitalopram','1','0','assume!',NULL,NULL,'Assertion',542,NULL),(571,'fluvoxamine_increases_auc_lansoprazole','fluvoxamine','increases_auc','lansoprazole','1','1','assume!','high','9.03','ContValAssertion',543,NULL),(572,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4','itraconazole','in_viVo_selective_inhibitor_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',544,NULL),(573,'clarithromycin_substrate_of_cyp3a4','clarithromycin','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',545,NULL),(574,'cinacalcet_is_not_substrate_of_cyp3a4','cinacalcet','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,546),(575,'sparteine_in_viVo_probe_substrate_of_enzyme_cyp2d6','sparteine','in_viVo_probe_substrate_of_enzyme','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(576,'S-demethylcitalopram_does_not_inhibit_cyp2c9','S-demethylcitalopram','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',547,NULL),(577,'perphenazine_substrate_of_cyp2d6','perphenazine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',548,NULL),(578,'cyp2c9_controls_formation_of_O-desmethylvenlafaxine','cyp2c9','controls_formation_of','O-desmethylvenlafaxine','1','0','retract!',NULL,NULL,'Assertion',NULL,549),(579,'clopidogrel_increases_auc_bupropion','clopidogrel','increases_auc','bupropion','1','1','assume!','medium','1.6','ContValAssertion',550,NULL),(580,'tamoxifen_substrate_of_cyp2d6','tamoxifen','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',551,NULL),(581,'fluvoxamine_bioavailability_continuous_value','fluvoxamine','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',552,NULL),(582,'omeprazole_does_not_inhibit_cyp2d6','omeprazole','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',553,NULL),(583,'nefazodone_does_not_inhibit_cyp3a4','nefazodone','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,554),(584,'haloperidol_inhibits_cyp2c19','haloperidol','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,555),(585,'bupropion_has_metabolite_hydroxybupropion','bupropion','has_metabolite','hydroxybupropion','1','0','assume!',NULL,NULL,'Assertion',556,NULL),(586,'nefazodone_does_not_inhibit_cyp3a5','nefazodone','does_not_inhibit','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,557),(587,'olanzapine_primary_total_clearance_mechanism_Metabolic_Clearance','olanzapine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','none_assigned',NULL,NULL,'Assertion',558,NULL),(588,'mirtazapine_substrate_of_cyp2b6','mirtazapine','substrate_of','cyp2b6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,559),(589,'celecoxib_minimum_therapeutic_dose_continuous_value','celecoxib','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.2','ContValAssertion',560,NULL),(590,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6','paroxetine','in_viVo_selective_inhibitor_of_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',561,NULL),(591,'zolpidem_substrate_of_cyp3a5','zolpidem','substrate_of','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',562,NULL),(592,'zolpidem_substrate_of_cyp3a4','zolpidem','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',563,NULL),(593,'mexiletine_does_not_inhibit_cyp1a2','mexiletine','does_not_inhibit','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,564),(594,'ketoconazole_maximum_concentration_continuous_value','ketoconazole','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.002','Assertion_maximum_concentration',565,NULL),(595,'voriconazole_inhibits_cyp3a4','voriconazole','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',566,NULL),(596,'atazanavir_inhibits_cyp2d6','atazanavir','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,567),(597,'aripiprazole_substrate_of_cyp2c19','aripiprazole','substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,568),(598,'voriconazole_primary_total_clearance_enzyme_cyp2c19','voriconazole','primary_total_clearance_enzyme','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',569,NULL),(599,'voriconazole_maximum_therapeutic_dose_continuous_value','voriconazole','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.6','ContValAssertion',570,NULL),(600,'ketoconazole_increases_auc_venlafaxine','ketoconazole','increases_auc','venlafaxine','1','0','can\'t decide','medium','1.21','ContValAssertion',571,NULL),(601,'zaleplon_is_not_substrate_of_cyp3a4','zaleplon','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,572),(602,'fluoxetine_increases_auc_desipramine','fluoxetine','increases_auc','desipramine','1','0','assume!','high','4.8','ContValAssertion',573,NULL),(603,'duloxetine_inhibits_cyp2c9','duloxetine','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,574),(604,'tamoxifen_is_not_substrate_of_cyp3a5','tamoxifen','is_not_substrate_of','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,575),(605,'risperidone_maximum_concentration_continuous_value','risperidone','maximum_concentration','continuous_value','1','0','assume!',NULL,'7.9e-05','Assertion_maximum_concentration',576,NULL),(606,'ritonavir_does_not_inhibit_cyp2d6','ritonavir','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,577),(607,'S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c19','S-mephenytoin','in_vitro_probe_substrate_of_enzyme','cyp2c19','1','1','assume!',NULL,NULL,'Assertion',578,NULL),(608,'ketoconazole_increases_auc_triazolam','ketoconazole','increases_auc','triazolam','1','0','assume!','high','22.4','ContValAssertion',579,NULL),(609,'caffeine_primary_total_clearance_enzyme_cyp1a2','caffeine','primary_total_clearance_enzyme','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',580,NULL),(610,'cinacalcet_does_not_inhibit_cyp3a5','cinacalcet','does_not_inhibit','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',581,NULL),(611,'N-demethyldesacetyl-diltiazem_substrate_of_cyp2d6','N-demethyldesacetyl-diltiazem','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',582,NULL),(612,'aripiprazole_does_not_inhibit_cyp3a4','aripiprazole','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',583,NULL),(613,'norfluoxetine_inhibition_constant_cyp3a4','norfluoxetine','inhibition_constant','cyp3a4','1','0','assume!',NULL,'0.0004252','Assertion_inhibition_constant',584,NULL),(614,'ziprasidone_primary_total_clearance_mechanism_Metabolic_Clearance','ziprasidone','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',585,NULL),(615,'paroxetine_increases_auc_paliperidone','paroxetine','increases_auc','paliperidone','1','1','assume!','medium','1.16','ContValAssertion',586,NULL),(616,'venlafaxine_increases_auc_9-hydroxyrisperidone','venlafaxine','increases_auc','9-hydroxyrisperidone','1','1','assume!',NULL,NULL,'ContValAssertion',NULL,587),(617,'ziprasidone_has_metabolite_benzisothiazole-sulphoxide','ziprasidone','has_metabolite','benzisothiazole-sulphoxide','1','0','assume!',NULL,NULL,'Assertion',588,NULL),(618,'atorvastatin_substrate_of_cyp2d6','atorvastatin','substrate_of','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,589),(619,'nefazodone_increases_auc_midazolam','nefazodone','increases_auc','midazolam','1','0','assume!','high','4.56','ContValAssertion',590,NULL),(620,'cyp2j2_controls_formation_of_threohydrobupropion','cyp2j2','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,591),(621,'rosiglitazone_inhibits_cyp2a6','rosiglitazone','inhibits','cyp2a6','1','0','retract!',NULL,NULL,'Assertion',NULL,592),(622,'pantoprazole_minimum_therapeutic_dose_continuous_value','pantoprazole','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.02','ContValAssertion',593,NULL),(623,'cyp3a4_controls_formation_of_alpha-hydroxyalprazolam','cyp3a4','controls_formation_of','alpha-hydroxyalprazolam','1','0','can\'t decide',NULL,NULL,'Assertion',594,NULL),(624,'bupropion_maximum_concentration_continuous_value','bupropion','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.000144','Assertion_maximum_concentration',595,NULL),(625,'risperidone_inhibition_constant_cyp2d6','risperidone','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.003','Assertion_inhibition_constant',596,NULL),(626,'voriconazole-N-oxide_does_not_inhibit_cyp2c19','voriconazole-N-oxide','does_not_inhibit','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,597),(627,'atomoxetine_inhibits_cyp1a2','atomoxetine','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,598),(628,'paliperidone_bioavailability_continuous_value','paliperidone','bioavailability','continuous_value','1','0','assume!','medium',NULL,'Assertion_m_discrete',599,NULL),(629,'atorvastatin_maximum_concentration_continuous_value','atorvastatin','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.000252','Assertion_maximum_concentration',600,NULL),(630,'ketoconazole_inhibits_cyp3a4','ketoconazole','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',601,NULL),(631,'alprazolam_bioavailability_continuous_value','alprazolam','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',602,NULL),(632,'aripiprazole_substrate_of_cyp2d6','aripiprazole','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',603,NULL),(633,'cyp2c9_controls_formation_of_hydroxybupropion','cyp2c9','controls_formation_of','hydroxybupropion','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,604),(634,'fluvastatin_primary_total_clearance_mechanism_Metabolic_Clearance','fluvastatin','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',605,NULL),(635,'thioridazine_has_metabolite_mesoridazine','thioridazine','has_metabolite','mesoridazine','1','0','assume!',NULL,NULL,'Assertion',606,NULL),(636,'pioglitazone_inhibition_constant_cyp2c8','pioglitazone','inhibition_constant','cyp2c8','1','1','assume!',NULL,'0.0006059','Assertion_inhibition_constant',607,NULL),(637,'aripiprazole_bioavailability_continuous_value','aripiprazole','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',608,NULL),(638,'fluconazole_inhibits_cyp3a5','fluconazole','inhibits','cyp3a5','1','1','assume!',NULL,NULL,'Assertion',609,NULL),(639,'cyp3a4_controls_formation_of_para-hydroxy-atorvastatin','cyp3a4','controls_formation_of','para-hydroxy-atorvastatin','1','0','can\'t decide',NULL,NULL,'Assertion',610,NULL),(640,'zafirlukast_substrate_of_cyp2c9','zafirlukast','substrate_of','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',611,NULL),(641,'ketoconazole_increases_auc_citalopram','ketoconazole','increases_auc','citalopram','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,612),(642,'lovastatin_primary_total_clearance_mechanism_Metabolic_Clearance','lovastatin','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',613,NULL),(643,'erythromycin_inhibition_constant_cyp3a4','erythromycin','inhibition_constant','cyp3a4','1','0','assume!',NULL,'0.006','Assertion_inhibition_constant',614,NULL),(644,'atorvastatin_primary_total_clearance_mechanism_Metabolic_Clearance','atorvastatin','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',615,NULL),(645,'pravastatin_primary_total_clearance_mechanism_Renal_Excretion','pravastatin','primary_total_clearance_mechanism','Renal_Excretion','1','0','assume!',NULL,NULL,'Assertion',616,NULL),(646,'atorvastatin_substrate_of_cyp1a1','atorvastatin','substrate_of','cyp1a1','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,617),(647,'theophylline_maximum_therapeutic_dose_continuous_value','theophylline','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'1.05','ContValAssertion',618,NULL),(648,'iloperidone_substrate_of_cyp2a6','iloperidone','substrate_of','cyp2a6','1','0','retract!',NULL,NULL,'Assertion',NULL,619),(649,'atorvastatin_is_not_substrate_of_cyp2d6','atorvastatin','is_not_substrate_of','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',620,NULL),(650,'iloperidone_is_not_substrate_of_cyp2b6','iloperidone','is_not_substrate_of','cyp2b6','1','0','assume!',NULL,NULL,'Assertion',621,NULL),(651,'quetiapine_inhibits_cyp2d6','quetiapine','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,622),(652,'rosuvastatin_has_metabolite_N-desmethylrosuvastatin','rosuvastatin','has_metabolite','N-desmethylrosuvastatin','1','0','assume!',NULL,NULL,'Assertion',623,NULL),(653,'atorvastatin_does_not_permanently_deactivate_catalytic_function_cyp2c8','atorvastatin','does_not_permanently_deactivate_catalytic_function','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(654,'trazodone_substrate_of_cyp3a4','trazodone','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',624,NULL),(655,'metronidazole_maximum_concentration_continuous_value','metronidazole','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.004','Assertion_maximum_concentration',625,NULL),(656,'cyp2c9_controls_formation_of_threohydrobupropion','cyp2c9','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,626),(657,'quetiapine_substrate_of_cyp2e1','quetiapine','substrate_of','cyp2e1','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,627),(658,'debrisoquine_in_viVo_probe_substrate_of_enzyme_cyp2d6','debrisoquine','in_viVo_probe_substrate_of_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(659,'iloperidone_does_not_inhibit_cyp2d6','iloperidone','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,628),(660,'haloperidol_is_not_substrate_of_cyp3a4','haloperidol','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,629),(661,'tamoxifen_is_not_substrate_of_cyp3a4','tamoxifen','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,630),(662,'cinacalcet_does_not_inhibit_cyp2c9','cinacalcet','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',631,NULL),(663,'verapamil_does_not_inhibit_cyp3a5','verapamil','does_not_inhibit','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,632),(664,'clarithromycin_bioavailability_continuous_value','clarithromycin','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',633,NULL),(665,'aripiprazole_is_not_substrate_of_cyp1a1','aripiprazole','is_not_substrate_of','cyp1a1','1','0','assume!',NULL,NULL,'Assertion',634,NULL),(666,'rosuvastatin_bioavailability_continuous_value','rosuvastatin','bioavailability','continuous_value','1','0','assume!','low',NULL,'Assertion_m_discrete',635,NULL),(667,'ziprasidone_inhibits_cyp2d6','ziprasidone','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,636),(668,'montelukast_does_not_inhibit_cyp1a2','montelukast','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',637,NULL),(669,'desvenlafaxine_is_not_substrate_of_cyp2d6','desvenlafaxine','is_not_substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',638,NULL),(670,'risperidone_substrate_of_cyp3a4','risperidone','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',639,NULL),(671,'trazodone_primary_total_clearance_mechanism_Renal_Excretion','trazodone','primary_total_clearance_mechanism','Renal_Excretion','1','0','retract!',NULL,NULL,'Assertion',NULL,640),(672,'quetiapine_does_not_inhibit_cyp2c9','quetiapine','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',641,NULL),(673,'escitalopram_does_not_inhibit_cyp1a2','escitalopram','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',642,NULL),(674,'fluvastatin_bioavailability_continuous_value','fluvastatin','bioavailability','continuous_value','1','0','assume!','medium',NULL,'Assertion_m_discrete',643,NULL),(675,'ranolazine_does_not_inhibit_cyp3a4','ranolazine','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,644),(676,'haloperidol_inhibition_constant_cyp2d6','haloperidol','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.003','Assertion_inhibition_constant',645,NULL),(677,'clozapine_inhibition_constant_cyp2c19','clozapine','inhibition_constant','cyp2c19','1','0','assume!',NULL,'0.023','Assertion_inhibition_constant',646,NULL),(678,'indomethacin_bioavailability_continuous_value','indomethacin','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',647,NULL),(679,'clarithromycin_is_not_substrate_of_cyp2c9','clarithromycin','is_not_substrate_of','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',648,NULL),(680,'verapamil_inhibits_cyp1a2','verapamil','inhibits','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',649,NULL),(681,'simvastatin_primary_total_clearance_mechanism_Metabolic_Clearance','simvastatin','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',650,NULL),(682,'R-demethylcitalopram_substrate_of_cyp3a4','R-demethylcitalopram','substrate_of','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(683,'lovastatin_is_not_substrate_of_cyp3a4','lovastatin','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,651),(684,'clarithromycin_is_not_substrate_of_cyp2d6','clarithromycin','is_not_substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',652,NULL),(685,'rosiglitazone_does_not_inhibit_cyp2c19','rosiglitazone','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',653,NULL),(686,'cimetidine_increases_auc_quetiapine','cimetidine','increases_auc','quetiapine','1','1','assume!','medium','1.24','ContValAssertion',654,NULL),(687,'ziprasidone_does_not_inhibit_cyp1a2','ziprasidone','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',655,NULL),(688,'modafinil-sulfone_inhibits_cyp2c19','modafinil-sulfone','inhibits','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',656,NULL),(689,'diltiazem_increases_auc_simvastatin','diltiazem','increases_auc','simvastatin','1','0','assume!','high','4.817','ContValAssertion',657,NULL),(690,'mirtazapine_does_not_inhibit_cyp2c19','mirtazapine','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',658,NULL),(691,'haloperidol_substrate_of_cyp3a4','haloperidol','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',659,NULL),(692,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8','paclitaxel','in_vitro_probe_substrate_of_enzyme','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',660,NULL),(693,'escitalopram_is_not_substrate_of_cyp2d6','escitalopram','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,661),(694,'zaleplon_bioavailability_continuous_value','zaleplon','bioavailability','continuous_value','1','0','assume!','medium',NULL,'Assertion_m_discrete',662,NULL),(695,'amiodarone_inhibits_cyp3a4','amiodarone','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',663,NULL),(696,'indinavir_inhibits_cyp2b6','indinavir','inhibits','cyp2b6','1','0','retract!',NULL,NULL,'Assertion',NULL,664),(697,'N-desalkylquetiapine_does_not_inhibit_cyp2c9','N-desalkylquetiapine','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',665,NULL),(698,'ziprasidone_maximum_concentration_continuous_value','ziprasidone','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.0001394','Assertion_maximum_concentration',666,NULL),(699,'R-demethylcitalopram_inhibits_cyp1a2','R-demethylcitalopram','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,667),(700,'duloxetine_substrate_of_cyp1a2','duloxetine','substrate_of','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',668,NULL),(701,'duloxetine_does_not_inhibit_cyp2d6','duloxetine','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,669),(702,'clozapine_does_not_inhibit_cyp2c19','clozapine','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',670,NULL),(703,'cimetidine_increases_auc_mirtazapine','cimetidine','increases_auc','mirtazapine','1','1','assume!','medium','1.54','ContValAssertion',671,NULL),(704,'indinavir_inhibits_cyp2e1','indinavir','inhibits','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,672),(705,'perphenazine_has_metabolite_7-hydroxyperphenazine','perphenazine','has_metabolite','7-hydroxyperphenazine','1','0','assume!',NULL,NULL,'Assertion',673,NULL),(706,'beta-hydroxy-simvastatin_has_metabolite_6\'-hydroxymethyl-simvastatin','beta-hydroxy-simvastatin','has_metabolite','6\'-hydroxymethyl-simvastatin','1','0','assume!',NULL,NULL,'Assertion',674,NULL),(707,'cyp3a4_controls_formation_of_4-hydroxyalprazolam','cyp3a4','controls_formation_of','4-hydroxyalprazolam','1','0','can\'t decide',NULL,NULL,'Assertion',675,NULL),(708,'fluvoxamine_increases_auc_duloxetine','fluvoxamine','increases_auc','duloxetine','1','1','assume!','high','4.6','ContValAssertion',676,NULL),(709,'citalopram_increases_auc_selegiline','citalopram','increases_auc','selegiline','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,677),(710,'cyp2c19_controls_formation_of_hydroxybupropion','cyp2c19','controls_formation_of','hydroxybupropion','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,678),(711,'pantoprazole_primary_total_clearance_enzyme_cyp2c19','pantoprazole','primary_total_clearance_enzyme','cyp2c19','1','1','assume!',NULL,NULL,'Assertion',679,NULL),(712,'fluvastatin_substrate_of_cyp3a4','fluvastatin','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',680,NULL),(713,'clarithromycin_inhibits_cyp3a4','clarithromycin','inhibits','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',681,NULL),(714,'clarithromycin_inhibits_cyp3a5','clarithromycin','inhibits','cyp3a5','1','1','assume!',NULL,NULL,'Assertion',682,NULL),(715,'rosiglitazone_does_not_inhibit_cyp2e1','rosiglitazone','does_not_inhibit','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',683,NULL),(716,'ketoconazole_does_not_inhibit_cyp3a4','ketoconazole','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,684),(717,'paroxetine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6','paroxetine','in_vitro_selective_inhibitor_of_enzyme','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(718,'topiramate_does_not_inhibit_cyp2d6','topiramate','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',685,NULL),(719,'zaleplon_substrate_of_cyp3a4','zaleplon','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',686,NULL),(720,'terbinafine_increases_auc_venlafaxine','terbinafine','increases_auc','venlafaxine','1','1','assume!','high','4.9','ContValAssertion',687,NULL),(721,'reduced-haloperidol_substrate_of_cyp3a4','reduced-haloperidol','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',688,NULL),(722,'theophylline_has_metabolite_3-methylxanthine','theophylline','has_metabolite','3-methylxanthine','1','0','assume!',NULL,NULL,'Assertion',689,NULL),(723,'paliperidone_inhibits_cyp2a6','paliperidone','inhibits','cyp2a6','1','0','retract!',NULL,NULL,'Assertion',NULL,690),(724,'nefazodone_is_not_substrate_of_cyp2d6','nefazodone','is_not_substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',691,NULL),(725,'fluoxetine_inhibition_constant_cyp3a4','fluoxetine','inhibition_constant','cyp3a4','1','0','assume!',NULL,'0.004','Assertion_inhibition_constant',692,NULL),(726,'mirtazapine_is_not_substrate_of_cyp2b6','mirtazapine','is_not_substrate_of','cyp2b6','1','0','can\'t decide',NULL,NULL,'Assertion',693,NULL),(727,'venlafaxine_does_not_inhibit_cyp1a2','venlafaxine','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',694,NULL),(728,'terbinafine_increases_auc_paroxetine','terbinafine','increases_auc','paroxetine','1','1','assume!','high','3.03','ContValAssertion',695,NULL),(729,'clozapine_primary_total_clearance_mechanism_Metabolic_Clearance','clozapine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',696,NULL),(730,'montelukast_inhibits_cyp2d6','montelukast','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,697),(731,'ziprasidone_has_metabolite_S-methyl-dihydroziprasidone','ziprasidone','has_metabolite','S-methyl-dihydroziprasidone','1','0','assume!',NULL,NULL,'Assertion',698,NULL),(732,'indinavir_increases_auc_venlafaxine','indinavir','increases_auc','venlafaxine','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,699),(733,'venlafaxine_is_not_substrate_of_cyp3a4','venlafaxine','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,700),(734,'atazanavir_does_not_inhibit_cyp2c9','atazanavir','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',701,NULL),(735,'venlafaxine_has_metabolite_O-desmethylvenlafaxine','venlafaxine','has_metabolite','O-desmethylvenlafaxine','1','0','assume!',NULL,NULL,'Assertion',702,NULL),(736,'sertraline_increases_auc_desipramine','sertraline','increases_auc','desipramine','1','0','assume!','medium','1.54','ContValAssertion',703,NULL),(737,'zaleplon_substrate_of_cyp2d6','zaleplon','substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,704),(738,'pantoprazole_maximum_therapeutic_dose_continuous_value','pantoprazole','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.24','ContValAssertion',705,NULL),(739,'cyp2d6_controls_formation_of_O-desmethylvenlafaxine','cyp2d6','controls_formation_of','O-desmethylvenlafaxine','1','0','assume!',NULL,NULL,'Assertion',706,NULL),(740,'fluvoxamine_increases_auc_mexiletine','fluvoxamine','increases_auc','mexiletine','1','1','assume!','medium','1.55','ContValAssertion',707,NULL),(741,'R-demethylcitalopram_maximum_concentration_continuous_value','R-demethylcitalopram','maximum_concentration','continuous_value','1','0','assume!',NULL,'1.946e-05','Assertion_maximum_concentration',708,NULL),(742,'fluvoxamine_does_not_inhibit_cyp1a2','fluvoxamine','does_not_inhibit','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,709),(743,'norfloxacin_does_not_inhibit_cyp1a2','norfloxacin','does_not_inhibit','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,710),(744,'bufuralol_in_vitro_probe_substrate_of_enzyme_cyp2d6','bufuralol','in_vitro_probe_substrate_of_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',711,NULL),(745,'pravastatin_does_not_inhibit_cyp2c8','pravastatin','does_not_inhibit','cyp2c8','1','0','assume!',NULL,NULL,'Assertion',712,NULL),(746,'aripiprazole_has_metabolite_dehydro-aripiprazole','aripiprazole','has_metabolite','dehydro-aripiprazole','1','0','assume!',NULL,NULL,'Assertion',713,NULL),(747,'montelukast_inhibits_cyp2a6','montelukast','inhibits','cyp2a6','1','0','retract!',NULL,NULL,'Assertion',NULL,714),(748,'lansoprazole_primary_total_clearance_enzyme_cyp2c19','lansoprazole','primary_total_clearance_enzyme','cyp2c19','1','1','assume!',NULL,NULL,'Assertion',715,NULL),(749,'olanzapine_inhibition_constant_cyp3a4','olanzapine','inhibition_constant','cyp3a4','1','0','assume!',NULL,'0.153','Assertion_inhibition_constant',716,NULL),(750,'eszopiclone_substrate_of_cyp2e1','eszopiclone','substrate_of','cyp2e1','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(751,'indinavir_does_not_inhibit_cyp2c9','indinavir','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',717,NULL),(752,'fluvoxamine_increases_auc_omeprazole','fluvoxamine','increases_auc','omeprazole','1','1','assume!','medium','1.74','ContValAssertion',718,NULL),(753,'iloperidone_substrate_of_cyp3a4','iloperidone','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',719,NULL),(754,'nicardipine_minimum_therapeutic_dose_continuous_value','nicardipine','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.06','ContValAssertion',720,NULL),(755,'aripiprazole_does_not_inhibit_cyp2c9','aripiprazole','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',721,NULL),(756,'pantoprazole_is_not_substrate_of_cyp2c19','pantoprazole','is_not_substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,722),(757,'atazanavir_does_not_inhibit_cyp2c19','atazanavir','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',723,NULL),(758,'escitalopram_does_not_inhibit_cyp2c19','escitalopram','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',724,NULL),(759,'R-citalopram_is_not_substrate_of_cyp2d6','R-citalopram','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,725),(760,'rosuvastatin_primary_total_clearance_mechanism_Biliary_Excretion','rosuvastatin','primary_total_clearance_mechanism','Biliary_Excretion','1','0','assume!',NULL,NULL,'Assertion',726,NULL),(761,'perphenazine_substrate_of_cyp2c19','perphenazine','substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',727,NULL),(762,'lansoprazole_bioavailability_continuous_value','lansoprazole','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',728,NULL),(763,'mirtazapine_is_not_substrate_of_cyp3a4','mirtazapine','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,729),(764,'duloxetine_inhibits_cyp2d6','duloxetine','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',730,NULL),(765,'escitalopram_is_not_substrate_of_cyp3a4','escitalopram','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,731),(766,'risperidone_has_metabolite_9-hydroxyrisperidone','risperidone','has_metabolite','9-hydroxyrisperidone','1','0','assume!',NULL,NULL,'Assertion',732,NULL),(767,'rosiglitazone_inhibition_constant_cyp2c8','rosiglitazone','inhibition_constant','cyp2c8','1','1','assume!',NULL,'0.002','Assertion_inhibition_constant',733,NULL),(768,'paliperidone_inhibits_cyp2e1','paliperidone','inhibits','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,734),(769,'erythromycin_increases_auc_midazolam','erythromycin','increases_auc','midazolam','1','0','assume!','high','4.417','ContValAssertion',735,NULL),(770,'atorvastatin_inhibition_constant_cyp2c8','atorvastatin','inhibition_constant','cyp2c8','1','0','assume!',NULL,'0.019','Assertion_inhibition_constant',736,NULL),(771,'desacetyldiltiazem_is_not_substrate_of_cyp2d6','desacetyldiltiazem','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,737),(772,'cyp4f1_controls_formation_of_threohydrobupropion','cyp4f1','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,738),(773,'clozapine_is_not_substrate_of_cyp1a2','clozapine','is_not_substrate_of','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,739),(774,'S-didemethylcitalopram_inhibits_cyp1a2','S-didemethylcitalopram','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,740),(775,'itraconazole_does_not_inhibit_cyp3a4','itraconazole','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,741),(776,'cyp3a4_controls_formation_of_N-dealkylperphenazine','cyp3a4','controls_formation_of','N-dealkylperphenazine','1','0','assume!',NULL,NULL,'Assertion',742,NULL),(777,'N-desalkylquetiapine_inhibits_cyp2c9','N-desalkylquetiapine','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,743),(778,'R-didemethylcitalopram_inhibits_cyp3a4','R-didemethylcitalopram','inhibits','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(779,'mirtazapine_substrate_of_cyp2c19','mirtazapine','substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,744),(780,'fluvoxamine_substrate_of_cyp2d6','fluvoxamine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',745,NULL),(781,'clozapine_inhibition_constant_cyp3a4','clozapine','inhibition_constant','cyp3a4','1','0','assume!',NULL,'0.032','Assertion_inhibition_constant',746,NULL),(782,'rosuvastatin_substrate_of_cyp3a4','rosuvastatin','substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,747),(783,'ziprasidone_inhibits_cyp2c19','ziprasidone','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,748),(784,'N-desalkylquetiapine_does_not_inhibit_cyp2c19','N-desalkylquetiapine','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',749,NULL),(785,'clozapine_inhibition_constant_cyp2c9','clozapine','inhibition_constant','cyp2c9','1','0','assume!',NULL,'0.01','Assertion_inhibition_constant',750,NULL),(786,'iloperidone_is_not_substrate_of_cyp2a6','iloperidone','is_not_substrate_of','cyp2a6','1','0','assume!',NULL,NULL,'Assertion',751,NULL),(787,'atazanavir_inhibits_cyp2c9','atazanavir','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,752),(788,'celecoxib_maximum_concentration_continuous_value','celecoxib','maximum_concentration','continuous_value','1','0','assume!',NULL,'7.05e-05','Assertion_maximum_concentration',753,NULL),(789,'fluphenazine_does_not_inhibit_cyp2c19','fluphenazine','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',754,NULL),(790,'escitalopram_primary_total_clearance_mechanism_Renal_Excretion','escitalopram','primary_total_clearance_mechanism','Renal_Excretion','1','0','none_assigned',NULL,NULL,'Assertion',NULL,755),(791,'N-desalkylquetiapine_inhibits_cyp2c19','N-desalkylquetiapine','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,756),(792,'ziprasidone_inhibits_cyp3a4','ziprasidone','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,757),(793,'voriconazole_does_not_inhibit_cyp3a4','voriconazole','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,758),(794,'theophylline_minimum_therapeutic_dose_continuous_value','theophylline','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.84','ContValAssertion',759,NULL),(795,'trazodone_is_not_substrate_of_cyp3a4','trazodone','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,760),(796,'tamoxifen_substrate_of_cyp3a5','tamoxifen','substrate_of','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',761,NULL),(797,'trazodone_has_metabolite_M-chlorophenylpiperazine','trazodone','has_metabolite','M-chlorophenylpiperazine','1','0','assume!',NULL,NULL,'Assertion',762,NULL),(798,'escitalopram_does_not_inhibit_cyp2d6','escitalopram','does_not_inhibit','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',763,764),(799,'R-demethylcitalopram_inhibits_cyp2c9','R-demethylcitalopram','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,765),(800,'erythromycin_increases_auc_atorvastatin','erythromycin','increases_auc','atorvastatin','1','0','assume!','medium','1.325','ContValAssertion',766,NULL),(801,'fluvastatin_does_not_permanently_deactivate_catalytic_function_cyp2c8','fluvastatin','does_not_permanently_deactivate_catalytic_function','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(802,'fluoxetine_substrate_of_cyp2d6','fluoxetine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',767,NULL),(803,'montelukast_does_not_inhibit_cyp2c8','montelukast','does_not_inhibit','cyp2c8','1','0','assume!',NULL,NULL,'Assertion',768,NULL),(804,'didemethylcitalopram_inhibits_cyp1a2','didemethylcitalopram','inhibits','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(805,'midazolam_substrate_of_cyp3a5','midazolam','substrate_of','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',769,NULL),(806,'fluvastatin_maximum_concentration_continuous_value','fluvastatin','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.00043','Assertion_maximum_concentration',770,NULL),(807,'reduced-haloperidol_is_not_substrate_of_cyp3a4','reduced-haloperidol','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,771),(808,'cinacalcet_inhibits_cyp1a2','cinacalcet','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,772),(809,'iloperidone_is_not_substrate_of_cyp2c9','iloperidone','is_not_substrate_of','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',773,NULL),(810,'iloperidone_is_not_substrate_of_cyp2c8','iloperidone','is_not_substrate_of','cyp2c8','1','0','assume!',NULL,NULL,'Assertion',774,NULL),(811,'fluvoxamine_does_not_inhibit_cyp2c19','fluvoxamine','does_not_inhibit','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,775),(812,'cyp2d6_controls_formation_of_clozapine-N-oxide','cyp2d6','controls_formation_of','clozapine-N-oxide','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(813,'zolpidem_maximum_concentration_continuous_value','zolpidem','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.000106','Assertion_maximum_concentration',776,NULL),(814,'R-demethylcitalopram_does_not_inhibit_cyp2c19','R-demethylcitalopram','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',777,NULL),(815,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9','tolbutamide','in_vitro_probe_substrate_of_enzyme','cyp2c9','1','1','assume!',NULL,NULL,'Assertion',778,NULL),(816,'rosuvastatin_primary_metabolic_clearance_enzyme_cyp2c9','rosuvastatin','primary_metabolic_clearance_enzyme','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',779,NULL),(817,'nefazodone_is_not_substrate_of_cyp2c19','nefazodone','is_not_substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',780,NULL),(818,'rosiglitazone_inhibits_cyp2b6','rosiglitazone','inhibits','cyp2b6','1','0','retract!',NULL,NULL,'Assertion',NULL,781),(819,'paroxetine_does_not_inhibit_cyp2d6','paroxetine','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,782),(820,'atomoxetine_does_not_inhibit_cyp2c9','atomoxetine','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',783,NULL),(821,'clarithromycin_increases_auc_lansoprazole','clarithromycin','increases_auc','lansoprazole','1','1','assume!','medium','1.71','ContValAssertion',784,NULL),(822,'fluvoxamine_increases_auc_clozapine','fluvoxamine','increases_auc','clozapine','1','1','assume!','high','2.84','ContValAssertion',785,NULL),(823,'cyp3a5_controls_formation_of_alpha-hydroxyalprazolam','cyp3a5','controls_formation_of','alpha-hydroxyalprazolam','1','0','can\'t decide',NULL,NULL,'Assertion',786,NULL),(824,'olanzapine_inhibition_constant_cyp2c19','olanzapine','inhibition_constant','cyp2c19','1','0','assume!',NULL,'0.287','Assertion_inhibition_constant',787,NULL),(825,'risperidone_increases_auc_erythromycin','risperidone','increases_auc','erythromycin','1','0','can\'t decide',NULL,NULL,'ContValAssertion',NULL,788),(826,'cinacalcet_has_metabolite_hydroxy-hydrocinnamic-acid','cinacalcet','has_metabolite','hydroxy-hydrocinnamic-acid','1','0','assume!',NULL,NULL,'Assertion',789,NULL),(827,'diltiazem_does_not_inhibit_cyp3a4','diltiazem','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,790),(828,'citalopram_inhibits_cyp3a4','citalopram','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,791),(829,'clarithromycin_is_not_substrate_of_cyp1a2','clarithromycin','is_not_substrate_of','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',792,NULL),(830,'sertraline_increases_auc_zolpidem','sertraline','increases_auc','zolpidem','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,793),(831,'quinidine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6','quinidine','in_viVo_selective_inhibitor_of_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',794,NULL),(832,'ziprasidone_does_not_inhibit_cyp2c9','ziprasidone','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',795,NULL),(833,'atomoxetine_has_metabolite_4-hydroxyatomoxetine','atomoxetine','has_metabolite','4-hydroxyatomoxetine','1','0','assume!',NULL,NULL,'Assertion',796,NULL),(834,'lansoprazole_does_not_inhibit_cyp3a4','lansoprazole','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',797,NULL),(835,'escitalopram_inhibits_cyp2d6','escitalopram','inhibits','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',798,799),(836,'indinavir_does_not_inhibit_cyp3a4','indinavir','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,800),(837,'indinavir_does_not_inhibit_cyp3a5','indinavir','does_not_inhibit','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,801),(838,'lansoprazole_substrate_of_cyp2c19','lansoprazole','substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',802,NULL),(839,'quetiapine_does_not_inhibit_cyp1a2','quetiapine','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',803,NULL),(840,'midazolam_has_metabolite_1\'-hydroxymidazolam','midazolam','has_metabolite','1\'-hydroxymidazolam','1','0','can\'t decide',NULL,NULL,'Assertion',804,NULL),(841,'R-demethylcitalopram_does_not_inhibit_cyp2c9','R-demethylcitalopram','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',805,NULL),(842,'debrisoquine_in_vitro_probe_substrate_of_enzyme_cyp2d6','debrisoquine','in_vitro_probe_substrate_of_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',806,NULL),(843,'topiramate_inhibits_cyp2c19','topiramate','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,807),(844,'fluphenazine_maximum_concentration_continuous_value','fluphenazine','maximum_concentration','continuous_value','1','0','assume!',NULL,'2.3e-06','Assertion_maximum_concentration',808,NULL),(845,'rosiglitazone_inhibits_cyp3a4','rosiglitazone','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,809),(846,'midodrine_bioavailability_continuous_value','midodrine','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',810,NULL),(847,'clarithromycin_does_not_permanently_deactivate_catalytic_function_cyp3a4','clarithromycin','does_not_permanently_deactivate_catalytic_function','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(848,'diltiazem_has_metabolite_N-demethyldiltiazem','diltiazem','has_metabolite','N-demethyldiltiazem','1','0','assume!',NULL,NULL,'Assertion',811,NULL),(849,'rosiglitazone_inhibits_cyp2c8','rosiglitazone','inhibits','cyp2c8','1','0','retract!',NULL,NULL,'Assertion',NULL,812),(850,'quetiapine_has_metabolite_quetiapine-sulfoxide','quetiapine','has_metabolite','quetiapine-sulfoxide','1','0','assume!',NULL,NULL,'Assertion',813,NULL),(851,'erythromycin_does_not_inhibit_cyp3a4','erythromycin','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,814),(852,'fluphenazine_inhibits_cyp2c19','fluphenazine','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,815),(853,'topiramate_primary_total_clearance_mechanism_Renal_Excretion','topiramate','primary_total_clearance_mechanism','Renal_Excretion','1','0','assume!',NULL,NULL,'Assertion',816,NULL),(854,'bupropion_inhibits_cyp2d6','bupropion','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',817,NULL),(855,'celecoxib_does_not_inhibit_cyp2c19','celecoxib','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',818,NULL),(856,'cinacalcet_substrate_of_cyp3a4','cinacalcet','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',819,NULL),(857,'quetiapine_substrate_of_cyp2c19','quetiapine','substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,820),(858,'perphenazine_is_not_substrate_of_cyp2c19','perphenazine','is_not_substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,821),(859,'ketoconazole_inhibition_constant_cyp3a4','ketoconazole','inhibition_constant','cyp3a4','1','0','assume!',NULL,'1.966e-06','Assertion_inhibition_constant',822,NULL),(860,'eszopiclone_inhibits_CYP2C9','eszopiclone','inhibits','CYP2C9','1','0','retract!',NULL,NULL,'Assertion',NULL,823),(861,'cinacalcet_does_not_inhibit_cyp1a2','cinacalcet','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',824,NULL),(862,'R-citalopram_inhibits_cyp2c19','R-citalopram','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,825),(863,'iloperidone_substrate_of_cyp1a2','iloperidone','substrate_of','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,826),(864,'R-citalopram_substrate_of_cyp3a4','R-citalopram','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',827,NULL),(865,'aripiprazole_maximum_concentration_continuous_value','aripiprazole','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.000452','Assertion_maximum_concentration',828,NULL),(866,'iloperidone_substrate_of_cyp1a1','iloperidone','substrate_of','cyp1a1','1','0','retract!',NULL,NULL,'Assertion',NULL,829),(867,'venlafaxine_maximum_concentration_continuous_value','venlafaxine','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.000393','Assertion_maximum_concentration',830,NULL),(868,'rosiglitazone_does_not_inhibit_cyp2a6','rosiglitazone','does_not_inhibit','cyp2a6','1','0','assume!',NULL,NULL,'Assertion',831,NULL),(869,'beta-hydroxy-simvastatin_inhibition_constant_cyp2c8','beta-hydroxy-simvastatin','inhibition_constant','cyp2c8','1','0','assume!',NULL,'0.018','Assertion_inhibition_constant',832,NULL),(870,'cinacalcet_does_not_inhibit_cyp2c19','cinacalcet','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',833,NULL),(871,'escitalopram_has_metabolite_S-didemethylcitalopram','escitalopram','has_metabolite','S-didemethylcitalopram','1','0','assume!',NULL,NULL,'Assertion',834,NULL),(872,'N-desalkylquetiapine_does_not_inhibit_cyp2d6','N-desalkylquetiapine','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',835,NULL),(873,'bupropion_is_not_substrate_of_cyp2b6','bupropion','is_not_substrate_of','cyp2b6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,836),(874,'paroxetine_is_not_substrate_of_cyp2d6','paroxetine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,837),(875,'cyp2c19_controls_formation_of_threohydrobupropion','cyp2c19','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,838),(876,'gemfibrozil_inhibits_cyp2c8','gemfibrozil','inhibits','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',839,NULL),(877,'quetiapine_does_not_inhibit_cyp2d6','quetiapine','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',840,NULL),(878,'aripiprazole_is_not_substrate_of_cyp2c19','aripiprazole','is_not_substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',841,NULL),(879,'iloperidone_is_not_substrate_of_cyp1a2','iloperidone','is_not_substrate_of','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',842,NULL),(880,'7-hydroxyperphenazine_maximum_concentration_continuous_value','7-hydroxyperphenazine','maximum_concentration','continuous_value','1','0','assume!',NULL,'5.09e-07','Assertion_maximum_concentration',843,NULL),(881,'voriconazole-N-oxide_inhibits_cyp2c9','voriconazole-N-oxide','inhibits','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',844,NULL),(882,'iloperidone_is_not_substrate_of_cyp1a1','iloperidone','is_not_substrate_of','cyp1a1','1','0','assume!',NULL,NULL,'Assertion',845,NULL),(883,'quinidine_permanently_deactivates_catalytic_function_cyp2d6','quinidine','permanently_deactivates_catalytic_function','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,846),(884,'trazodone_maximum_concentration_continuous_value','trazodone','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.002','Assertion_maximum_concentration',847,NULL),(885,'iloperidone_substrate_of_cyp2c9','iloperidone','substrate_of','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,848),(886,'iloperidone_substrate_of_cyp2c8','iloperidone','substrate_of','cyp2c8','1','0','retract!',NULL,NULL,'Assertion',NULL,849),(887,'topiramate_does_not_inhibit_cyp2a6','topiramate','does_not_inhibit','cyp2a6','1','0','assume!',NULL,NULL,'Assertion',850,NULL),(888,'clozapine-N-oxide_substrate_of_cyp2d6','clozapine-N-oxide','substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,851),(889,'valproate_minimum_therapeutic_dose_continuous_value','valproate','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.5','ContValAssertion',852,NULL),(890,'lansoprazole_substrate_of_cyp3a5','lansoprazole','substrate_of','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',853,NULL),(891,'paliperidone_primary_total_clearance_mechanism_Renal_Excretion','paliperidone','primary_total_clearance_mechanism','Renal_Excretion','1','0','assume!',NULL,NULL,'Assertion',854,NULL),(892,'fluvoxamine_increases_auc_thioridazine','fluvoxamine','increases_auc','thioridazine','1','0','can\'t decide','high','3.0','ContValAssertion',855,NULL),(893,'clarithromycin_increases_auc_trazodone','clarithromycin','increases_auc','trazodone','1','1','assume!','medium','1.99','ContValAssertion',856,NULL),(894,'fluphenazine_bioavailability_continuous_value','fluphenazine','bioavailability','continuous_value','1','0','assume!','low',NULL,'Assertion_m_discrete',857,NULL),(895,'thioridazine_substrate_of_cyp2d6','thioridazine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',858,NULL),(896,'atazanavir_does_not_inhibit_cyp1a2','atazanavir','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',859,NULL),(897,'escitalopram_does_not_inhibit_cyp2c9','escitalopram','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',860,NULL),(898,'cyp2d6_controls_formation_of_N-dealkylperphenazine','cyp2d6','controls_formation_of','N-dealkylperphenazine','1','0','assume!',NULL,NULL,'Assertion',861,NULL),(899,'rosuvastatin_does_not_inhibit_cyp2c8','rosuvastatin','does_not_inhibit','cyp2c8','1','0','assume!',NULL,NULL,'Assertion',862,NULL),(900,'zaleplon_primary_total_clearance_mechanism_Metabolic_Clearance','zaleplon','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',863,NULL),(901,'clozapine_has_metabolite_7-hydroxyclozapine','clozapine','has_metabolite','7-hydroxyclozapine','1','0','assume!',NULL,NULL,'Assertion',864,NULL),(902,'ranolazine_does_not_inhibit_cyp3a5','ranolazine','does_not_inhibit','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,865),(903,'cinacalcet_inhibits_cyp2c9','cinacalcet','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,866),(904,'fluconazole_does_not_inhibit_cyp2c9','fluconazole','does_not_inhibit','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,867),(905,'triazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4','triazolam','in_vitro_probe_substrate_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',868,NULL),(906,'mirtazapine_inhibits_cyp2e1','mirtazapine','inhibits','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,869),(907,'aripiprazole_is_not_substrate_of_cyp2e1','aripiprazole','is_not_substrate_of','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',870,NULL),(908,'erythromycin_increases_auc_rosuvastatin','erythromycin','increases_auc','rosuvastatin','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,871),(909,'itraconazole_increases_auc_rosuvastatin','itraconazole','increases_auc','rosuvastatin','1','0','assume!','medium','1.28','ContValAssertion',872,NULL),(910,'topiramate_does_not_inhibit_cyp2c19','topiramate','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',873,NULL),(911,'cinacalcet_does_not_inhibit_cyp2d6','cinacalcet','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,874),(912,'voriconazole_bioavailability_continuous_value','voriconazole','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',875,NULL),(913,'thioridazine_is_not_substrate_of_cyp2d6','thioridazine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,876),(914,'itraconazole_increases_auc_alprazolam','itraconazole','increases_auc','alprazolam','1','0','assume!','medium','1.615','ContValAssertion',877,NULL),(915,'warfarin_primary_total_clearance_enzyme_cyp2c9','warfarin','primary_total_clearance_enzyme','cyp2c9','1','1','assume!',NULL,NULL,'Assertion',878,NULL),(916,'reduced-haloperidol_has_metabolite_4-(4-chlorophenyl)-4-hydroxypiperidine','reduced-haloperidol','has_metabolite','4-(4-chlorophenyl)-4-hydroxypiperidine','1','0','can\'t decide',NULL,NULL,'Assertion',879,NULL),(917,'terbinafine_does_not_inhibit_cyp2d6','terbinafine','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,880),(918,'aripiprazole_inhibits_cyp3a4','aripiprazole','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,881),(919,'aripiprazole_primary_total_clearance_mechanism_Metabolic_Clearance','aripiprazole','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',882,NULL),(920,'mirtazapine_is_not_substrate_of_cyp3a5','mirtazapine','is_not_substrate_of','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,883),(921,'clozapine_maximum_concentration_continuous_value','clozapine','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.000564','Assertion_maximum_concentration',884,NULL),(922,'clozapine_substrate_of_cyp1a2','clozapine','substrate_of','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',885,NULL),(923,'nefazodone_substrate_of_cyp2c9','nefazodone','substrate_of','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,886),(924,'leflunomide_maximum_therapeutic_dose_continuous_value','leflunomide','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.2','ContValAssertion',887,NULL),(925,'N-desalkylquetiapine_inhibits_cyp1a2','N-desalkylquetiapine','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,888),(926,'nefazodone_is_not_substrate_of_cyp2c9','nefazodone','is_not_substrate_of','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',889,NULL),(927,'nefazodone_is_not_substrate_of_cyp2c8','nefazodone','is_not_substrate_of','cyp2c8','1','0','can\'t decide',NULL,NULL,'Assertion',890,NULL),(928,'clarithromycin_increases_auc_pravastatin','clarithromycin','increases_auc','pravastatin','1','0','assume!','high','2.1','ContValAssertion',891,NULL),(929,'fluvoxamine_inhibits_cyp2c9','fluvoxamine','inhibits','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',892,NULL),(930,'rosiglitazone_does_not_inhibit_cyp1a1','rosiglitazone','does_not_inhibit','cyp1a1','1','0','assume!',NULL,NULL,'Assertion',893,NULL),(931,'zaleplon_is_not_substrate_of_cyp2d6','zaleplon','is_not_substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',894,NULL),(932,'rosiglitazone_inhibits_cyp2e1','rosiglitazone','inhibits','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,895),(933,'paliperidone_does_not_inhibit_cyp2d6','paliperidone','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',896,NULL),(934,'cimetidine_increases_auc_venlafaxine','cimetidine','increases_auc','venlafaxine','1','0','assume!','medium','1.62','ContValAssertion',897,NULL),(935,'fluvastatin_minimum_therapeutic_dose_continuous_value','fluvastatin','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.02','ContValAssertion',898,NULL),(936,'pantoprazole_inhibits_cyp2d6','pantoprazole','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,899),(937,'olanzapine_is_not_substrate_of_cyp2d6','olanzapine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,900),(938,'demethylcitalopram_inhibits_cyp3a4','demethylcitalopram','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,901),(939,'nefazodone_substrate_of_cyp1a2','nefazodone','substrate_of','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,902),(940,'citalopram_does_not_inhibit_cyp3a4','citalopram','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',903,NULL),(941,'cyp1a2_controls_formation_of_N-dealkylperphenazine','cyp1a2','controls_formation_of','N-dealkylperphenazine','1','0','assume!',NULL,NULL,'Assertion',904,NULL),(942,'S-didemethylcitalopram_maximum_concentration_continuous_value','S-didemethylcitalopram','maximum_concentration','continuous_value','1','0','assume!',NULL,'1.897e-06','Assertion_maximum_concentration',905,NULL),(943,'itraconazole_inhibition_constant_cyp3a4','itraconazole','inhibition_constant','cyp3a4','1','0','assume!',NULL,'0.000194','Assertion_inhibition_constant',906,NULL),(944,'aripiprazole_is_not_substrate_of_cyp2c8','aripiprazole','is_not_substrate_of','cyp2c8','1','0','assume!',NULL,NULL,'Assertion',907,NULL),(945,'1-methylxanthine_has_metabolite_1-methyluric-acid','1-methylxanthine','has_metabolite','1-methyluric-acid','1','0','assume!',NULL,NULL,'Assertion',908,NULL),(946,'citalopram_does_not_inhibit_cyp2c9','citalopram','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',909,NULL),(947,'ziprasidone_has_metabolite_ziprasidone-sulphoxide','ziprasidone','has_metabolite','ziprasidone-sulphoxide','1','0','assume!',NULL,NULL,'Assertion',910,NULL),(948,'p-nitrophenol_in_vitro_probe_substrate_of_enzyme_cyp2e1','p-nitrophenol','in_vitro_probe_substrate_of_enzyme','cyp2e1','1','1','assume!',NULL,NULL,'Assertion',911,NULL),(949,'bupropion_primary_total_clearance_mechanism_Metabolic_Clearance','bupropion','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','none_assigned',NULL,NULL,'Assertion',912,NULL),(950,'aripiprazole_increases_auc_escitalopram','aripiprazole','increases_auc','escitalopram','1','1','assume!','medium','1.07','ContValAssertion',913,NULL),(951,'bupropion_does_not_inhibit_cyp2d6','bupropion','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,914),(952,'fluvastatin_is_not_substrate_of_cyp2c9','fluvastatin','is_not_substrate_of','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,915),(953,'risperidone_increases_auc_quetiapine','risperidone','increases_auc','quetiapine','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,916),(954,'cyp1a1_controls_formation_of_threohydrobupropion','cyp1a1','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,917),(955,'lansoprazole_is_not_substrate_of_cyp3a4','lansoprazole','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,918),(956,'thiothixene_inhibits_cyp2c19','thiothixene','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,919),(957,'tamoxifen_substrate_of_cyp3a4','tamoxifen','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',920,NULL),(958,'aripiprazole_is_not_substrate_of_cyp1a2','aripiprazole','is_not_substrate_of','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',921,NULL),(959,'escitalopram_inhibits_cyp1a2','escitalopram','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,922),(960,'cyp2c19_controls_formation_of_N-desmethylsertraline','cyp2c19','controls_formation_of','N-desmethylsertraline','1','0','assume!',NULL,NULL,'Assertion',923,NULL),(961,'nefazodone_inhibits_cyp3a5','nefazodone','inhibits','cyp3a5','1','1','assume!',NULL,NULL,'Assertion',924,NULL),(962,'9-hydroxyrisperidone_primary_total_clearance_mechanism_Renal_Excretion','9-hydroxyrisperidone','primary_total_clearance_mechanism','Renal_Excretion','1','0','assume!',NULL,NULL,'Assertion',925,NULL),(963,'venlafaxine_inhibits_cyp3a4','venlafaxine','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,926),(964,'montelukast_does_not_inhibit_cyp2c9','montelukast','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',927,NULL),(965,'quetiapine_inhibits_cyp2c19','quetiapine','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,928),(966,'citalopram_substrate_of_cyp2c19','citalopram','substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',929,NULL),(967,'celecoxib_maximum_therapeutic_dose_continuous_value','celecoxib','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.8','ContValAssertion',930,NULL),(968,'R-citalopram_inhibits_cyp3a4','R-citalopram','inhibits','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(969,'pravastatin_inhibits_cyp2c8','pravastatin','inhibits','cyp2c8','1','0','retract!',NULL,NULL,'Assertion',NULL,931),(970,'risperidone_is_not_substrate_of_cyp2d6','risperidone','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,932),(971,'clozapine_has_metabolite_desmethylclozapine','clozapine','has_metabolite','desmethylclozapine','1','0','assume!',NULL,NULL,'Assertion',933,NULL),(972,'cinacalcet_primary_total_clearance_mechanism_Metabolic_Clearance','cinacalcet','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',934,NULL),(973,'metronidazole_primary_total_clearance_mechanism_Renal_Excretion','metronidazole','primary_total_clearance_mechanism','Renal_Excretion','1','0','retract!',NULL,NULL,'Assertion',NULL,935),(974,'atorvastatin_substrate_of_cyp2c9','atorvastatin','substrate_of','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,936),(975,'R-citalopram_inhibits_cyp2c9','R-citalopram','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,937),(976,'erythromycin_in_viVo_selective_inhibitor_of_enzyme_cyp3a4','erythromycin','in_viVo_selective_inhibitor_of_enzyme','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(977,'R-citalopram_is_not_substrate_of_cyp3a4','R-citalopram','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,938),(978,'diltiazem_has_metabolite_N-demethyldesacetyl-diltiazem','diltiazem','has_metabolite','N-demethyldesacetyl-diltiazem','1','0','assume!',NULL,NULL,'Assertion',939,NULL),(979,'cyp3a4_controls_formation_of_14-hydroxyclarithromycin','cyp3a4','controls_formation_of','14-hydroxyclarithromycin','1','0','assume!',NULL,NULL,'Assertion',940,NULL),(980,'ziprasidone_is_not_substrate_of_cyp1a2','ziprasidone','is_not_substrate_of','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',941,942),(981,'fluoxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6','fluoxetine','in_viVo_selective_inhibitor_of_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',943,NULL),(982,'voriconazole_primary_total_clearance_mechanism_Metabolic_Clearance','voriconazole','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',944,NULL),(983,'tolbutamide_minimum_therapeutic_dose_continuous_value','tolbutamide','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.25','ContValAssertion',945,NULL),(984,'rosiglitazone_does_not_inhibit_cyp1a2','rosiglitazone','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',946,NULL),(985,'rosiglitazone_inhibits_cyp2d6','rosiglitazone','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,947),(986,'alpha-naphthoflavone_in_vitro_selective_inhibitor_of_enzyme_cyp1a2','alpha-naphthoflavone','in_vitro_selective_inhibitor_of_enzyme','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',948,NULL),(987,'voriconazole_is_not_substrate_of_cyp2c9','voriconazole','is_not_substrate_of','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,949),(988,'iloperidone_substrate_of_cyp2c19','iloperidone','substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,950),(989,'telithromycin_inhibits_cyp3a4','telithromycin','inhibits','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',951,NULL),(990,'rabeprazole_primary_total_clearance_mechanism_Metabolic_Clearance','rabeprazole','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',952,NULL),(991,'voriconazole_is_not_substrate_of_cyp3a4','voriconazole','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,953),(992,'lovastatin_has_metabolite_beta-hydroxy-lovastatin','lovastatin','has_metabolite','beta-hydroxy-lovastatin','1','0','assume!',NULL,NULL,'Assertion',954,NULL),(993,'venlafaxine_primary_total_clearance_enzyme_cyp2d6','venlafaxine','primary_total_clearance_enzyme','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',955,NULL),(994,'ranolazine_is_not_substrate_of_cyp2d6','ranolazine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,956),(995,'demethylcitalopram_does_not_inhibit_cyp3a4','demethylcitalopram','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',957,NULL),(996,'cyp2d6_controls_formation_of_9-hydroxyrisperidone','cyp2d6','controls_formation_of','9-hydroxyrisperidone','1','0','assume!',NULL,NULL,'Assertion',958,NULL),(997,'clarithromycin_substrate_of_cyp2d6','clarithromycin','substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,959),(998,'promethazine_minimum_therapeutic_dose_continuous_value','promethazine','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.0125','ContValAssertion',960,NULL),(999,'mirtazapine_substrate_of_cyp2a6','mirtazapine','substrate_of','cyp2a6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,961),(1000,'eszopiclone_has_metabolite_S-zopiclone-N-oxide','eszopiclone','has_metabolite','S-zopiclone-N-oxide','1','0','assume!',NULL,NULL,'Assertion',962,NULL),(1001,'topiramate_does_not_inhibit_cyp3a5','topiramate','does_not_inhibit','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',963,NULL),(1002,'paroxetine_substrate_of_cyp2d6','paroxetine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',964,NULL),(1003,'fluvoxamine_increases_auc_quinidine','fluvoxamine','increases_auc','quinidine','1','1','assume!','medium','1.42','ContValAssertion',965,NULL),(1004,'atorvastatin_is_not_substrate_of_cyp2c19','atorvastatin','is_not_substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',966,NULL),(1005,'midazolam_primary_total_clearance_enzyme_cyp3a4','midazolam','primary_total_clearance_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',967,NULL),(1006,'quetiapine_has_metabolite_7-hydroxy-N-desalkyl-quetiapine','quetiapine','has_metabolite','7-hydroxy-N-desalkyl-quetiapine','1','0','assume!',NULL,NULL,'Assertion',968,NULL),(1007,'ketoconazole_increases_auc_alprazolam','ketoconazole','increases_auc','alprazolam','1','0','assume!','high','3.983','ContValAssertion',969,NULL),(1008,'lansoprazole_maximum_therapeutic_dose_continuous_value','lansoprazole','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.18','ContValAssertion',970,NULL),(1009,'zafirlukast_does_not_inhibit_cyp2c9','zafirlukast','does_not_inhibit','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,971),(1010,'R-demethylcitalopram_does_not_inhibit_cyp1a2','R-demethylcitalopram','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',972,NULL),(1011,'desipramine_primary_total_clearance_enzyme_cyp2d6','desipramine','primary_total_clearance_enzyme','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',973,NULL),(1012,'citalopram_increases_auc_alprazolam','citalopram','increases_auc','alprazolam','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,974),(1013,'risperidone_primary_metabolic_clearance_enzyme_cyp2d6','risperidone','primary_metabolic_clearance_enzyme','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',975,NULL),(1014,'lansoprazole_is_not_substrate_of_cyp2c19','lansoprazole','is_not_substrate_of','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,976),(1015,'atorvastatin_inhibits_cyp3a4','atorvastatin','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',977,NULL),(1016,'atorvastatin_is_not_substrate_of_cyp2e1','atorvastatin','is_not_substrate_of','cyp2e1','1','0','can\'t decide',NULL,NULL,'Assertion',978,NULL),(1017,'lovastatin_maximum_concentration_continuous_value','lovastatin','maximum_concentration','continuous_value','1','0','assume!',NULL,'7.8e-06','Assertion_maximum_concentration',979,NULL),(1018,'eszopiclone_does_not_inhibit_CYP2E1','eszopiclone','does_not_inhibit','CYP2E1','1','0','assume!',NULL,NULL,'Assertion',980,NULL),(1019,'cinacalcet_substrate_of_cyp2d6','cinacalcet','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',981,NULL),(1020,'ticlopidine_inhibition_constant_cyp2c19','ticlopidine','inhibition_constant','cyp2c19','1','1','assume!',NULL,'0.0003165','Assertion_inhibition_constant',982,NULL),(1021,'montelukast_inhibits_cyp2c8','montelukast','inhibits','cyp2c8','1','0','retract!',NULL,NULL,'Assertion',NULL,983),(1022,'topiramate_does_not_inhibit_cyp3a4','topiramate','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',984,NULL),(1023,'fluoxetine_maximum_concentration_continuous_value','fluoxetine','maximum_concentration','continuous_value','1','0','assume!',NULL,'5.5e-05','Assertion_maximum_concentration',985,NULL),(1024,'paliperidone_does_not_inhibit_cyp2c19','paliperidone','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',986,NULL),(1025,'trazodone_bioavailability_continuous_value','trazodone','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',987,NULL),(1026,'cyp3a5_controls_formation_of_para-hydroxy-atorvastatin','cyp3a5','controls_formation_of','para-hydroxy-atorvastatin','1','0','can\'t decide',NULL,NULL,'Assertion',988,NULL),(1027,'mirtazapine_substrate_of_cyp2e1','mirtazapine','substrate_of','cyp2e1','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,989),(1028,'teriflunomide_inhibits_cyp2c9','teriflunomide','inhibits','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',990,NULL),(1029,'mirtazapine_substrate_of_cyp3a4','mirtazapine','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',991,NULL),(1030,'mirtazapine_substrate_of_cyp3a5','mirtazapine','substrate_of','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',992,NULL),(1031,'sertraline_increases_auc_clozapine-N-oxide','sertraline','increases_auc','clozapine-N-oxide','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,993),(1032,'quinidine_inhibits_cyp2d6','quinidine','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',994,NULL),(1033,'propoxyphene_minimum_therapeutic_dose_continuous_value','propoxyphene','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.065','ContValAssertion',995,NULL),(1034,'itraconazole_sole_PK_effect_alter_metabolic_clearance_beta-hydroxy-simvastatin','itraconazole','sole_PK_effect_alter_metabolic_clearance','beta-hydroxy-simvastatin','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(1035,'mirtazapine_inhibits_cyp2c19','mirtazapine','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,996),(1036,'fluconazole_does_not_inhibit_cyp3a4','fluconazole','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,997),(1037,'celecoxib_primary_total_clearance_mechanism_Metabolic_Clearance','celecoxib','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',998,NULL),(1038,'fluconazole_increases_auc_pravastatin','fluconazole','increases_auc','pravastatin','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,999),(1039,'fluconazole_primary_total_clearance_mechanism_Renal_Excretion','fluconazole','primary_total_clearance_mechanism','Renal_Excretion','1','0','assume!',NULL,NULL,'Assertion',1000,NULL),(1040,'ziprasidone_substrate_of_cyp3a4','ziprasidone','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1001,NULL),(1041,'diltiazem_primary_total_clearance_mechanism_Metabolic_Clearance','diltiazem','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',1002,NULL),(1042,'olanzapine_has_metabolite_10-N-glucuronide','olanzapine','has_metabolite','10-N-glucuronide','1','0','assume!',NULL,NULL,'Assertion',1003,NULL),(1043,'itraconazole_increases_auc_pravastatin','itraconazole','increases_auc','pravastatin','1','0','can\'t decide','medium','1.486','ContValAssertion',1004,1005),(1044,'olanzapine_substrate_of_cyp2d6','olanzapine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1006,NULL),(1045,'topiramate_inhibits_cyp3a4','topiramate','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1007),(1046,'topiramate_inhibits_cyp3a5','topiramate','inhibits','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,1008),(1047,'rosuvastatin_fraction_absorbed_continuous_value','rosuvastatin','fraction_absorbed','continuous_value','1','0','assume!','low',NULL,'Assertion_m_discrete',1009,NULL),(1048,'clarithromycin_substrate_of_cyp1a2','clarithromycin','substrate_of','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,1010),(1049,'N-demethyldesacetyl-diltiazem_is_not_substrate_of_cyp2d6','N-demethyldesacetyl-diltiazem','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1011),(1050,'R-citalopram_does_not_inhibit_cyp2c9','R-citalopram','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',1012,NULL),(1051,'citalopram_substrate_of_cyp3a4','citalopram','substrate_of','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',1013,1014),(1052,'amiodarone_does_not_inhibit_cyp2c9','amiodarone','does_not_inhibit','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,1015),(1053,'erythromycin_increases_auc_beta-hydroxy-simvastatin','erythromycin','increases_auc','beta-hydroxy-simvastatin','1','0','assume!','high','3.9','ContValAssertion',1016,NULL),(1054,'eszopiclone_inhibits_CYP1A2','eszopiclone','inhibits','CYP1A2','1','0','retract!',NULL,NULL,'Assertion',NULL,1017),(1055,'fluvoxamine_inhibits_cyp1a2','fluvoxamine','inhibits','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',1018,NULL),(1056,'rosuvastatin_inhibits_cyp2c8','rosuvastatin','inhibits','cyp2c8','1','0','retract!',NULL,NULL,'Assertion',NULL,1019),(1057,'cinacalcet_inhibits_cyp2d6','cinacalcet','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1020,NULL),(1058,'eszopiclone_is_not_substrate_of_cyp3a4','eszopiclone','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1021),(1059,'modafinil_primary_total_clearance_mechanism_Metabolic_Clearance','modafinil','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',1022,NULL),(1060,'lansoprazole_minimum_therapeutic_dose_continuous_value','lansoprazole','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.015','ContValAssertion',1023,NULL),(1061,'perphenazine_primary_total_clearance_mechanism_Metabolic_Clearance','perphenazine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',1024,NULL),(1062,'cyp2d6_controls_formation_of_threohydrobupropion','cyp2d6','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,1025),(1063,'atomoxetine_bioavailability_continuous_value','atomoxetine','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',1026,NULL),(1064,'ranolazine_primary_total_clearance_mechanism_Metabolic_Clearance','ranolazine','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',1027,NULL),(1065,'troleandomycin_in_vitro_selective_inhibitor_of_enzyme_cyp3a4','troleandomycin','in_vitro_selective_inhibitor_of_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',1028,NULL),(1066,'cyp2d6_controls_formation_of_4-hydroxydebrisoquine','cyp2d6','controls_formation_of','4-hydroxydebrisoquine','1','1','assume!',NULL,NULL,'Assertion',1029,NULL),(1067,'valproate_increases_auc_aripiprazole','valproate','increases_auc','aripiprazole','1','1','assume!',NULL,NULL,'ContValAssertion',NULL,1030),(1068,'mirtazapine_does_not_inhibit_cyp1a2','mirtazapine','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',1031,NULL),(1069,'theophylline_primary_total_clearance_mechanism_Metabolic_Clearance','theophylline','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',1032,NULL),(1070,'cinacalcet_is_not_substrate_of_cyp1a2','cinacalcet','is_not_substrate_of','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,1033),(1071,'cimetidine_inhibits_cyp1a2','cimetidine','inhibits','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',1034,NULL),(1072,'atomoxetine_inhibits_cyp2d6','atomoxetine','inhibits','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1035),(1073,'mirtazapine_is_not_substrate_of_cyp2d6','mirtazapine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1036),(1074,'itraconazole_sole_PK_effect_alter_metabolic_clearance_lovastatin','itraconazole','sole_PK_effect_alter_metabolic_clearance','lovastatin','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(1075,'indinavir_inhibits_cyp2c9','indinavir','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,1037),(1076,'aripiprazole_is_not_substrate_of_cyp2a6','aripiprazole','is_not_substrate_of','cyp2a6','1','0','assume!',NULL,NULL,'Assertion',1038,NULL),(1077,'cyp3a4_controls_formation_of_6\'beta-hydroxy-lovastatin','cyp3a4','controls_formation_of','6\'beta-hydroxy-lovastatin','1','0','assume!',NULL,NULL,'Assertion',1039,NULL),(1078,'erythromycin_increases_auc_alprazolam','erythromycin','increases_auc','alprazolam','1','0','assume!','medium','1.61','ContValAssertion',1040,NULL),(1079,'metoprolol_in_viVo_probe_substrate_of_enzyme_cyp2d6','metoprolol','in_viVo_probe_substrate_of_enzyme','cyp2d6','1','0','none_assigned',NULL,NULL,'Assertion',NULL,NULL),(1080,'ziprasidone_does_not_inhibit_cyp2c19','ziprasidone','does_not_inhibit','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',1041,NULL),(1081,'haloperidol_increases_auc_quetiapine','haloperidol','increases_auc','quetiapine','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,1042),(1082,'tamoxifen_is_not_substrate_of_cyp2c9','tamoxifen','is_not_substrate_of','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,1043),(1083,'fluvoxamine_does_not_inhibit_cyp2c9','fluvoxamine','does_not_inhibit','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,1044),(1084,'dehydro-aripiprazole_is_not_substrate_of_cyp3a4','dehydro-aripiprazole','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1045),(1085,'escitalopram_maximum_concentration_continuous_value','escitalopram','maximum_concentration','continuous_value','1','0','assume!',NULL,'5.002e-05','Assertion_maximum_concentration',1046,NULL),(1086,'atomoxetine_does_not_inhibit_cyp2d6','atomoxetine','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1047,NULL),(1087,'mirtazapine_increases_auc_paroxetine','mirtazapine','increases_auc','paroxetine','1','1','assume!',NULL,NULL,'ContValAssertion',NULL,1048),(1088,'thioridazine_primary_total_clearance_enzyme_cyp2d6','thioridazine','primary_total_clearance_enzyme','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1049,NULL),(1089,'atorvastatin_maximum_therapeutic_dose_continuous_value','atorvastatin','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.08','ContValAssertion',1050,NULL),(1090,'rosiglitazone_does_not_inhibit_cyp2d6','rosiglitazone','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1051,NULL),(1091,'rabeprazole_bioavailability_continuous_value','rabeprazole','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',1052,NULL),(1092,'N-desalkylquetiapine_does_not_inhibit_cyp3a4','N-desalkylquetiapine','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1053,NULL),(1093,'venlafaxine_inhibits_cyp2d6','venlafaxine','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1054,NULL),(1094,'topiramate_does_not_inhibit_cyp2c9','topiramate','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',1055,NULL),(1095,'quetiapine_has_metabolite_N-desalkylquetiapine','quetiapine','has_metabolite','N-desalkylquetiapine','1','0','assume!',NULL,NULL,'Assertion',1056,NULL),(1096,'atomoxetine_inhibits_cyp2c9','atomoxetine','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,1057),(1097,'sertraline_does_not_inhibit_cyp2d6','sertraline','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1058),(1098,'cyp2a13_controls_formation_of_threohydrobupropion','cyp2a13','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,1059),(1099,'beta-hydroxy-lovastatin_does_not_permanently_deactivate_catalytic_function_cyp2c8','beta-hydroxy-lovastatin','does_not_permanently_deactivate_catalytic_function','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(1100,'haloperidol_has_metabolite_reduced-haloperidol','haloperidol','has_metabolite','reduced-haloperidol','1','0','assume!',NULL,NULL,'Assertion',1060,NULL),(1101,'R-citalopram_maximum_concentration_continuous_value','R-citalopram','maximum_concentration','continuous_value','1','0','can\'t decide',NULL,NULL,'Assertion_maximum_concentration',NULL,NULL),(1102,'cimetidine_inhibits_cyp3a5','cimetidine','inhibits','cyp3a5','1','1','assume!',NULL,NULL,'Assertion',1061,NULL),(1103,'cimetidine_inhibits_cyp3a4','cimetidine','inhibits','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',1062,NULL),(1104,'atazanavir_inhibits_cyp1a2','atazanavir','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,1063),(1105,'fluvastatin_inhibition_constant_cyp2c8','fluvastatin','inhibition_constant','cyp2c8','1','0','assume!',NULL,'0.008','Assertion_inhibition_constant',1064,NULL),(1106,'erythromycin_increases_auc_simvastatin','erythromycin','increases_auc','simvastatin','1','0','assume!','high','6.3','ContValAssertion',1065,NULL),(1107,'fluoxetine_increases_auc_olanzapine','fluoxetine','increases_auc','olanzapine','1','1','assume!','medium','1.18','ContValAssertion',1066,NULL),(1108,'lansoprazole_inhibits_cyp3a4','lansoprazole','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1067),(1109,'bupropion_has_metabolite_threohydrobupropion','bupropion','has_metabolite','threohydrobupropion','1','0','assume!',NULL,NULL,'Assertion',1068,NULL),(1110,'beta-hydroxy-simvastatin_has_metabolite_6\'-hydroxy-simvastatin','beta-hydroxy-simvastatin','has_metabolite','6\'-hydroxy-simvastatin','1','0','assume!',NULL,NULL,'Assertion',1069,NULL),(1111,'cyp1b1_controls_formation_of_threohydrobupropion','cyp1b1','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,1070),(1112,'quetiapine_substrate_of_cyp3a4','quetiapine','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1071,NULL),(1113,'fluconazole_does_not_inhibit_cyp3a5','fluconazole','does_not_inhibit','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,1072),(1114,'risperidone_is_not_substrate_of_cyp3a4','risperidone','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1073),(1115,'zolpidem_is_not_substrate_of_cyp3a5','zolpidem','is_not_substrate_of','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,1074),(1116,'ziprasidone_has_metabolite_benzisothiazole-sulphone','ziprasidone','has_metabolite','benzisothiazole-sulphone','1','0','assume!',NULL,NULL,'Assertion',1075,NULL),(1117,'rosiglitazone_does_not_inhibit_cyp2c8','rosiglitazone','does_not_inhibit','cyp2c8','1','0','assume!',NULL,NULL,'Assertion',1076,NULL),(1118,'citalopram_does_not_inhibit_cyp2e1','citalopram','does_not_inhibit','cyp2e1','1','0','assume!',NULL,NULL,'Assertion',1077,NULL),(1119,'telithromycin_does_not_inhibit_cyp3a5','telithromycin','does_not_inhibit','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,1078),(1120,'telithromycin_does_not_inhibit_cyp3a4','telithromycin','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1079),(1121,'topiramate_inhibits_cyp2a6','topiramate','inhibits','cyp2a6','1','0','retract!',NULL,NULL,'Assertion',NULL,1080),(1122,'alprazolam_primary_metabolic_clearance_enzyme_cyp3a4','alprazolam','primary_metabolic_clearance_enzyme','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1081,NULL),(1123,'omeprazole_does_not_inhibit_cyp2c19','omeprazole','does_not_inhibit','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,1082),(1124,'montelukast_inhibits_cyp2c9','montelukast','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,1083),(1125,'topiramate_does_not_inhibit_cyp2b6','topiramate','does_not_inhibit','cyp2b6','1','0','assume!',NULL,NULL,'Assertion',1084,NULL),(1126,'14-hydroxyclarithromycin_maximum_concentration_continuous_value','14-hydroxyclarithromycin','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.00088','Assertion_maximum_concentration',1085,NULL),(1127,'cyp2c8_controls_formation_of_6alpha-hydroxy-paclitaxel','cyp2c8','controls_formation_of','6alpha-hydroxy-paclitaxel','1','0','can\'t decide',NULL,NULL,'Assertion',1086,NULL),(1128,'risperidone_primary_total_clearance_mechanism_Metabolic_Clearance','risperidone','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','assume!',NULL,NULL,'Assertion',1087,NULL),(1129,'rabeprazole_substrate_of_cyp3a5','rabeprazole','substrate_of','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',1088,NULL),(1130,'atorvastatin_is_not_substrate_of_cyp2b6','atorvastatin','is_not_substrate_of','cyp2b6','1','0','can\'t decide',NULL,NULL,'Assertion',1089,NULL),(1131,'topiramate_maximum_therapeutic_dose_continuous_value','topiramate','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.4','ContValAssertion',1090,NULL),(1132,'S-demethylcitalopram_inhibits_cyp3a4','S-demethylcitalopram','inhibits','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(1133,'sertraline_increases_auc_clozapine','sertraline','increases_auc','clozapine','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,1091),(1134,'omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c19','omeprazole','in_vitro_probe_substrate_of_enzyme','cyp2c19','1','1','assume!',NULL,NULL,'Assertion',1092,NULL),(1135,'demethylcitalopram_substrate_of_cyp2d6','demethylcitalopram','substrate_of','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(1136,'ziprasidone_does_not_inhibit_cyp2d6','ziprasidone','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1093,NULL),(1137,'eszopiclone_inhibits_CYP2C19','eszopiclone','inhibits','CYP2C19','1','0','retract!',NULL,NULL,'Assertion',NULL,1094),(1138,'diltiazem_substrate_of_cyp3a5','diltiazem','substrate_of','cyp3a5','1','0','can\'t decide',NULL,NULL,'Assertion',1095,NULL),(1139,'diltiazem_substrate_of_cyp3a4','diltiazem','substrate_of','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',1096,NULL),(1140,'tamoxifen_has_metabolite_N-desmethyltamoxifen','tamoxifen','has_metabolite','N-desmethyltamoxifen','1','0','assume!',NULL,NULL,'Assertion',1097,NULL),(1141,'voriconazole_inhibits_cyp2c19','voriconazole','inhibits','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',1098,NULL),(1142,'midodrine_primary_total_clearance_mechanism_Renal_Excretion','midodrine','primary_total_clearance_mechanism','Renal_Excretion','1','0','retract!',NULL,NULL,'Assertion',NULL,1099),(1143,'mirtazapine_substrate_of_cyp2d6','mirtazapine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1100,NULL),(1144,'iloperidone_substrate_of_cyp2e1','iloperidone','substrate_of','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,1101),(1145,'aripiprazole_inhibits_cyp2c9','aripiprazole','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,1102),(1146,'atorvastatin_primary_total_clearance_enzyme_cyp3a4','atorvastatin','primary_total_clearance_enzyme','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1103,NULL),(1147,'mirtazapine_is_not_substrate_of_cyp1a2','mirtazapine','is_not_substrate_of','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,1104),(1148,'R-didemethylcitalopram_maximum_concentration_continuous_value','R-didemethylcitalopram','maximum_concentration','continuous_value','1','0','assume!',NULL,'3.971e-06','Assertion_maximum_concentration',1105,NULL),(1149,'telithromycin_inhibits_cyp3a5','telithromycin','inhibits','cyp3a5','1','1','assume!',NULL,NULL,'Assertion',1106,NULL),(1150,'promethazine_maximum_therapeutic_dose_continuous_value','promethazine','maximum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.15','ContValAssertion',1107,NULL),(1151,'ranolazine_inhibits_cyp3a5','ranolazine','inhibits','cyp3a5','1','0','assume!',NULL,NULL,'Assertion',1108,NULL),(1152,'ranolazine_inhibits_cyp3a4','ranolazine','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1109,NULL),(1153,'itraconazole_increases_auc_triazolam','itraconazole','increases_auc','triazolam','1','0','assume!','high','27.0','ContValAssertion',1110,NULL),(1154,'perphenazine_is_not_substrate_of_cyp1a2','perphenazine','is_not_substrate_of','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,1111),(1155,'mexiletine_inhibits_cyp1a2','mexiletine','inhibits','cyp1a2','1','1','assume!',NULL,NULL,'Assertion',1112,NULL),(1156,'sertraline_increases_auc_alprazolam','sertraline','increases_auc','alprazolam','1','0','retract!',NULL,NULL,'ContValAssertion',NULL,1113),(1157,'fluvoxamine_increases_auc_theophylline','fluvoxamine','increases_auc','theophylline','1','1','assume!','high','3.33','ContValAssertion',1114,NULL),(1158,'itraconazole_inhibits_cyp3a4','itraconazole','inhibits','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1115,NULL),(1159,'atazanavir_inhibits_cyp2b6','atazanavir','inhibits','cyp2b6','1','0','retract!',NULL,NULL,'Assertion',NULL,1116),(1160,'escitalopram_inhibits_cyp3a4','escitalopram','inhibits','cyp3a4','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(1161,'R-demethylcitalopram_is_not_substrate_of_cyp2d6','R-demethylcitalopram','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1117),(1162,'citalopram_bioavailability_continuous_value','citalopram','bioavailability','continuous_value','1','0','assume!','high',NULL,'Assertion_m_discrete',1118,NULL),(1163,'sildenafil_primary_total_clearance_enzyme_cyp3a4','sildenafil','primary_total_clearance_enzyme','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',1119,NULL),(1164,'paroxetine_increases_auc_desipramine','paroxetine','increases_auc','desipramine','1','0','assume!','high','5.2','ContValAssertion',1120,NULL),(1165,'celecoxib_does_not_inhibit_cyp2c9','celecoxib','does_not_inhibit','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',1121,NULL),(1166,'erythromycin_increases_auc_fluvastatin','erythromycin','increases_auc','fluvastatin','1','0','can\'t decide',NULL,NULL,'ContValAssertion',NULL,1122),(1167,'alprazolam_is_not_substrate_of_cyp3a5','alprazolam','is_not_substrate_of','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,1123),(1168,'nefazodone_is_not_substrate_of_cyp1a2','nefazodone','is_not_substrate_of','cyp1a2','1','0','can\'t decide',NULL,NULL,'Assertion',1124,NULL),(1169,'tamoxifen_substrate_of_cyp2c9','tamoxifen','substrate_of','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',1125,NULL),(1170,'R-citalopram_does_not_inhibit_cyp1a2','R-citalopram','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',1126,NULL),(1171,'diphenhydramine_increases_auc_venlafaxine','diphenhydramine','increases_auc','venlafaxine','1','0','assume!','high','2.42','ContValAssertion',1127,NULL),(1172,'topiramate_does_not_inhibit_cyp1a2','topiramate','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',1128,NULL),(1173,'ziprasidone_is_not_substrate_of_cyp2c9','ziprasidone','is_not_substrate_of','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',1129,NULL),(1174,'cinacalcet_is_not_substrate_of_cyp2d6','cinacalcet','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1130),(1175,'citalopram_substrate_of_cyp2d6','citalopram','substrate_of','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,NULL),(1176,'alprazolam_has_metabolite_alpha-hydroxyalprazolam','alprazolam','has_metabolite','alpha-hydroxyalprazolam','1','0','assume!',NULL,NULL,'Assertion',1131,NULL),(1177,'lovastatin_first_pass_effect_continuous_value','lovastatin','first_pass_effect','continuous_value','1','0','can\'t decide','high',NULL,'Assertion_m_discrete',1132,NULL),(1178,'perphenazine_is_not_substrate_of_cyp2d6','perphenazine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1133),(1179,'hydroxybupropion_maximum_concentration_continuous_value','hydroxybupropion','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.001','Assertion_maximum_concentration',1134,NULL),(1180,'beta-hydroxy-lovastatin_has_metabolite_6\'beta-hydroxy-lovastatin','beta-hydroxy-lovastatin','has_metabolite','6\'beta-hydroxy-lovastatin','1','0','can\'t decide',NULL,NULL,'Assertion',1135,NULL),(1181,'indinavir_does_not_inhibit_cyp1a2','indinavir','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',1136,NULL),(1182,'fluvastatin_primary_total_clearance_enzyme_cyp2c9','fluvastatin','primary_total_clearance_enzyme','cyp2c9','1','0','assume!',NULL,NULL,'Assertion',1137,NULL),(1183,'fluvoxamine_is_not_substrate_of_cyp2d6','fluvoxamine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1138),(1184,'eszopiclone_does_not_inhibit_CYP2C9','eszopiclone','does_not_inhibit','CYP2C9','1','0','assume!',NULL,NULL,'Assertion',1139,NULL),(1185,'duloxetine_is_not_substrate_of_cyp1a2','duloxetine','is_not_substrate_of','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,1140),(1186,'cyp2b6_controls_formation_of_hydroxybupropion','cyp2b6','controls_formation_of','hydroxybupropion','1','0','assume!',NULL,NULL,'Assertion',1141,NULL),(1187,'nefazodone_is_not_substrate_of_cyp3a4','nefazodone','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1142),(1188,'ranolazine_substrate_of_cyp2d6','ranolazine','substrate_of','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1143,NULL),(1189,'clarithromycin_does_not_inhibit_cyp3a4','clarithromycin','does_not_inhibit','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1144),(1190,'sulphaphenazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c9','sulphaphenazole','in_vitro_selective_inhibitor_of_enzyme','cyp2c9','1','1','assume!',NULL,NULL,'Assertion',1145,NULL),(1191,'citalopram_primary_total_clearance_mechanism_Renal_Excretion','citalopram','primary_total_clearance_mechanism','Renal_Excretion','1','0','none_assigned',NULL,NULL,'Assertion',NULL,1146),(1192,'beta-hydroxy-simvastatin_is_not_substrate_of_cyp3a4','beta-hydroxy-simvastatin','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1147),(1193,'omeprazole_inhibits_cyp2c19','omeprazole','inhibits','cyp2c19','1','1','assume!',NULL,NULL,'Assertion',1148,NULL),(1194,'aripiprazole_substrate_of_cyp2c9','aripiprazole','substrate_of','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,1149),(1195,'nefazodone_inhibits_cyp3a4','nefazodone','inhibits','cyp3a4','1','1','assume!',NULL,NULL,'Assertion',1150,NULL),(1196,'modafinil_is_not_substrate_of_cyp3a4','modafinil','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1151),(1197,'erythromycin_increases_auc_quetiapine','erythromycin','increases_auc','quetiapine','1','1','assume!','high','2.29','ContValAssertion',1152,NULL),(1198,'rosiglitazone_inhibits_cyp2c9','rosiglitazone','inhibits','cyp2c9','1','0','retract!',NULL,NULL,'Assertion',NULL,1153),(1199,'cyp2c9_controls_formation_of_N-dealkylperphenazine','cyp2c9','controls_formation_of','N-dealkylperphenazine','1','0','can\'t decide',NULL,NULL,'Assertion',1154,NULL),(1200,'eszopiclone_primary_total_clearance_mechanism_Renal_Excretion','eszopiclone','primary_total_clearance_mechanism','Renal_Excretion','1','0','retract!',NULL,NULL,'Assertion',NULL,1155),(1201,'perphenazine_substrate_of_cyp3a4','perphenazine','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1156,NULL),(1202,'cyp2c19_controls_formation_of_N-dealkylperphenazine','cyp2c19','controls_formation_of','N-dealkylperphenazine','1','0','can\'t decide',NULL,NULL,'Assertion',1157,NULL),(1203,'theophylline_has_metabolite_caffeine','theophylline','has_metabolite','caffeine','1','0','assume!',NULL,NULL,'Assertion',1158,NULL),(1204,'pravastatin_has_metabolite_3alpha-hydroxypravastatin','pravastatin','has_metabolite','3alpha-hydroxypravastatin','1','0','assume!',NULL,NULL,'Assertion',1159,NULL),(1205,'terbinafine_inhibits_cyp2d6','terbinafine','inhibits','cyp2d6','1','1','assume!',NULL,NULL,'Assertion',1160,NULL),(1206,'lansoprazole_substrate_of_cyp3a4','lansoprazole','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1161,NULL),(1207,'dehydro-aripiprazole_does_not_inhibit_cyp1a2','dehydro-aripiprazole','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',1162,NULL),(1208,'leflunomide_minimum_therapeutic_dose_continuous_value','leflunomide','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.01','ContValAssertion',1163,NULL),(1209,'montelukast_inhibits_cyp1a2','montelukast','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,1164),(1210,'sertraline_has_metabolite_N-desmethylsertraline','sertraline','has_metabolite','N-desmethylsertraline','1','0','assume!',NULL,NULL,'Assertion',1165,NULL),(1211,'cyp2c9_polymorphic_enzyme_True','cyp2c9','polymorphic_enzyme','True','1','1','assume!',NULL,NULL,'Assertion',NULL,NULL),(1212,'aripiprazole_increases_auc_venlafaxine','aripiprazole','increases_auc','venlafaxine','1','0','assume!','medium','1.183','ContValAssertion',1166,NULL),(1213,'alprazolam_is_not_substrate_of_cyp3a4','alprazolam','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1167),(1214,'desglymidodrine_primary_total_clearance_mechanism_Renal_Excretion','desglymidodrine','primary_total_clearance_mechanism','Renal_Excretion','1','0','assume!',NULL,NULL,'Assertion',1168,NULL),(1215,'diltiazem_increases_auc_midazolam','diltiazem','increases_auc','midazolam','1','0','assume!','high','3.75','ContValAssertion',1169,NULL),(1216,'escitalopram_inhibits_cyp2e1','escitalopram','inhibits','cyp2e1','1','0','retract!',NULL,NULL,'Assertion',NULL,1170),(1217,'itraconazole_increases_auc_zolpidem','itraconazole','increases_auc','zolpidem','1','1','assume!','medium','1.34','ContValAssertion',1171,1172),(1218,'mirtazapine_does_not_inhibit_cyp2d6','mirtazapine','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1173,NULL),(1219,'pantoprazole_maximum_concentration_continuous_value','pantoprazole','maximum_concentration','continuous_value','1','0','assume!',NULL,'0.00025','Assertion_maximum_concentration',1174,NULL),(1220,'diltiazem_bioavailability_continuous_value','diltiazem','bioavailability','continuous_value','1','0','assume!','medium',NULL,'Assertion_m_discrete',1175,NULL),(1221,'tolbutamide_primary_total_clearance_enzyme_cyp2c9','tolbutamide','primary_total_clearance_enzyme','cyp2c9','1','1','assume!',NULL,NULL,'Assertion',1176,NULL),(1222,'simvastatin_does_not_inhibit_cyp3a4','simvastatin','does_not_inhibit','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1177,NULL),(1223,'paroxetine_inhibits_cyp2d6','paroxetine','inhibits','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1178,NULL),(1224,'mirtazapine_inhibits_cyp1a2','mirtazapine','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,1179),(1225,'venlafaxine_substrate_of_cyp3a4','venlafaxine','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1180,NULL),(1226,'paliperidone_does_not_inhibit_cyp2a6','paliperidone','does_not_inhibit','cyp2a6','1','0','assume!',NULL,NULL,'Assertion',1181,NULL),(1227,'beta-hydroxy-lovastatin_substrate_of_cyp3a4','beta-hydroxy-lovastatin','substrate_of','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1182,NULL),(1228,'rabeprazole_substrate_of_cyp2c19','rabeprazole','substrate_of','cyp2c19','1','0','assume!',NULL,NULL,'Assertion',1183,NULL),(1229,'clarithromycin_does_not_inhibit_cyp3a5','clarithromycin','does_not_inhibit','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,1184),(1230,'thioridazine_inhibition_constant_cyp2d6','thioridazine','inhibition_constant','cyp2d6','1','0','assume!',NULL,'0.0005699','Assertion_inhibition_constant',1185,NULL),(1231,'chlorpromazine_inhibits_cyp2c19','chlorpromazine','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,1186),(1232,'olanzapine_maximum_concentration_continuous_value','olanzapine','maximum_concentration','continuous_value','1','0','assume!',NULL,'1.05e-05','Assertion_maximum_concentration',1187,NULL),(1233,'zafirlukast_minimum_therapeutic_dose_continuous_value','zafirlukast','minimum_therapeutic_dose','continuous_value','1','1','assume!',NULL,'0.04','ContValAssertion',1188,NULL),(1234,'beta-hydroxy-simvastatin_has_metabolite_6\'-exomethylene-simvastatin','beta-hydroxy-simvastatin','has_metabolite','6\'-exomethylene-simvastatin','1','0','assume!',NULL,NULL,'Assertion',1189,NULL),(1235,'fluoxetine_is_not_substrate_of_cyp2d6','fluoxetine','is_not_substrate_of','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1190),(1236,'cyp3a5_controls_formation_of_ortho-hydroxy-atorvastatin','cyp3a5','controls_formation_of','ortho-hydroxy-atorvastatin','1','0','can\'t decide',NULL,NULL,'Assertion',1191,NULL),(1237,'cyp2a6_controls_formation_of_threohydrobupropion','cyp2a6','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,1192),(1238,'cyp3a5_controls_formation_of_threohydrobupropion','cyp3a5','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,1193),(1239,'rosiglitazone_primary_total_clearance_enzyme_cyp2c8','rosiglitazone','primary_total_clearance_enzyme','cyp2c8','1','1','assume!',NULL,NULL,'Assertion',1194,NULL),(1240,'R-warfarin_in_vitro_probe_substrate_of_enzyme_cyp1a2','R-warfarin','in_vitro_probe_substrate_of_enzyme','cyp1a2','1','0','none_assigned',NULL,NULL,'Assertion',NULL,NULL),(1241,'sulfinpyrazone_in_vitro_selective_inhibitor_of_enzyme_cyp2c9','sulfinpyrazone','in_vitro_selective_inhibitor_of_enzyme','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',1195,NULL),(1242,'indinavir_inhibits_cyp1a2','indinavir','inhibits','cyp1a2','1','0','retract!',NULL,NULL,'Assertion',NULL,1196),(1243,'verapamil_increases_auc_risperidone','verapamil','increases_auc','risperidone','1','1','assume!','medium','1.82','ContValAssertion',1197,NULL),(1244,'thioridazine_inhibits_cyp2c19','thioridazine','inhibits','cyp2c19','1','0','retract!',NULL,NULL,'Assertion',NULL,1198),(1245,'eszopiclone_does_not_inhibit_CYP2D6','eszopiclone','does_not_inhibit','CYP2D6','1','0','assume!',NULL,NULL,'Assertion',1199,NULL),(1246,'quetiapine_is_not_substrate_of_cyp2c9','quetiapine','is_not_substrate_of','cyp2c9','1','0','can\'t decide',NULL,NULL,'Assertion',1200,NULL),(1247,'lovastatin_primary_total_clearance_enzyme_cyp3a4','lovastatin','primary_total_clearance_enzyme','cyp3a4','1','0','assume!',NULL,NULL,'Assertion',1201,NULL),(1248,'cyp3a4_controls_formation_of_threohydrobupropion','cyp3a4','controls_formation_of','threohydrobupropion','1','0','retract!',NULL,NULL,'Assertion',NULL,1202),(1249,'demethylcitalopram_substrate_of_cyp2c19','demethylcitalopram','substrate_of','cyp2c19','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,1203),(1250,'amiodarone_inhibits_cyp1a2','amiodarone','inhibits','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',1204,NULL),(1251,'S-demethylcitalopram_does_not_inhibit_cyp1a2','S-demethylcitalopram','does_not_inhibit','cyp1a2','1','0','assume!',NULL,NULL,'Assertion',1205,NULL),(1252,'quetiapine_has_metabolite_7-hydroxy-quetiapine','quetiapine','has_metabolite','7-hydroxy-quetiapine','1','0','assume!',NULL,NULL,'Assertion',1206,NULL),(1253,'R-citalopram_does_not_inhibit_cyp2d6','R-citalopram','does_not_inhibit','cyp2d6','1','0','assume!',NULL,NULL,'Assertion',1207,NULL),(1254,'amiodarone_does_not_inhibit_cyp2d6','amiodarone','does_not_inhibit','cyp2d6','1','0','retract!',NULL,NULL,'Assertion',NULL,1208),(1255,'ziprasidone_substrate_of_cyp2d6','ziprasidone','substrate_of','cyp2d6','1','0','can\'t decide',NULL,NULL,'Assertion',NULL,1209),(1256,'iloperidone_substrate_of_cyp2b6','iloperidone','substrate_of','cyp2b6','1','0','retract!',NULL,NULL,'Assertion',NULL,1210),(1257,'beta-hydroxy-lovastatin_has_metabolite_6\'-exomethylene-lovastatin','beta-hydroxy-lovastatin','has_metabolite','6\'-exomethylene-lovastatin','1','0','can\'t decide',NULL,NULL,'Assertion',1211,NULL),(1258,'rabeprazole_is_not_substrate_of_cyp3a5','rabeprazole','is_not_substrate_of','cyp3a5','1','0','retract!',NULL,NULL,'Assertion',NULL,1212),(1259,'diltiazem_has_metabolite_desacetyldiltiazem','diltiazem','has_metabolite','desacetyldiltiazem','1','0','assume!',NULL,NULL,'Assertion',1213,NULL),(1260,'simvastatin_inhibits_cyp3a4','simvastatin','inhibits','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1214),(1261,'pantoprazole_primary_total_clearance_mechanism_Metabolic_Clearance','pantoprazole','primary_total_clearance_mechanism','Metabolic_Clearance','1','0','none_assigned',NULL,NULL,'Assertion',1215,NULL),(1262,'rabeprazole_is_not_substrate_of_cyp3a4','rabeprazole','is_not_substrate_of','cyp3a4','1','0','retract!',NULL,NULL,'Assertion',NULL,1216),(1263,'alprazolam_increases_auc_selegiline','alprazolam','increases_auc','selegiline','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1217),(1264,'itraconazole_increases_auc_selegiline','itraconazole','increases_auc','selegiline','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1218),(1265,'olanzapine_increases_auc_selegiline','olanzapine','increases_auc','selegiline','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1219),(1266,'prasugrel_increases_auc_bupropion','prasugrel','increases_auc','bupropion','0','0','none_assigned',NULL,NULL,'ContValAssertion',1220,NULL),(1267,'ticlopidine_increases_auc_bupropion','ticlopidine','increases_auc','bupropion','0','0','none_assigned',NULL,NULL,'ContValAssertion',1221,NULL),(1268,'ritonavir_increases_auc_bupropion','ritonavir','increases_auc','bupropion','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1222),(1269,'lithium_increases_auc_mirtazapine','lithium','increases_auc','mirtazapine','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1223),(1270,'cimetidine_increases_auc_nefazodone','cimetidine','increases_auc','nefazodone','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1224),(1271,'desipramine_increases_auc_nefazodone','desipramine','increases_auc','nefazodone','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1225),(1272,'lithium_increases_auc_nefazodone','lithium','increases_auc','nefazodone','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1226),(1273,'paroxetine_increases_auc_duloxetine','paroxetine','increases_auc','duloxetine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1227,NULL),(1274,'desloratadine_increases_auc_fluoxetine','desloratadine','increases_auc','fluoxetine','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1228),(1275,'alosetron_increases_auc_fluoxetine','alosetron','increases_auc','fluoxetine','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1229),(1276,'risperidone_increases_auc_selegiline','risperidone','increases_auc','selegiline','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1230),(1277,'ritonavir_increases_auc_trazodone','ritonavir','increases_auc','trazodone','0','0','none_assigned',NULL,NULL,'ContValAssertion',1231,NULL),(1278,'cimetidine_increases_auc_paroxetine','cimetidine','increases_auc','paroxetine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1232,NULL),(1279,'ketoconazole_increases_auc_amitriptyline','ketoconazole','increases_auc','amitriptyline','0','0','none_assigned',NULL,NULL,'ContValAssertion',1233,NULL),(1280,'fluvoxamine_increases_auc_amitriptyline','fluvoxamine','increases_auc','amitriptyline','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1234),(1281,'cimetidine_increases_auc_amitriptyline','cimetidine','increases_auc','amitriptyline','0','0','none_assigned',NULL,NULL,'ContValAssertion',1235,NULL),(1282,'atomoxetine_increases_auc_desipramine','atomoxetine','increases_auc','desipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1236),(1283,'ketoconazole_increases_auc_desipramine','ketoconazole','increases_auc','desipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1237),(1284,'cimetidine_increases_auc_doxepin','cimetidine','increases_auc','doxepin','0','0','none_assigned',NULL,NULL,'ContValAssertion',1238,NULL),(1285,'cimetidine_increases_auc_imipramine','cimetidine','increases_auc','imipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1239,NULL),(1286,'fluoxetine_increases_auc_imipramine','fluoxetine','increases_auc','imipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1240,NULL),(1287,'ketoconazole_increases_auc_imipramine','ketoconazole','increases_auc','imipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1241,NULL),(1288,'paroxetine_increases_auc_imipramine','paroxetine','increases_auc','imipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1242,NULL),(1289,'verapamil_increases_auc_imipramine','verapamil','increases_auc','imipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1243,NULL),(1290,'diltiazem_increases_auc_imipramine','diltiazem','increases_auc','imipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1244,NULL),(1291,'cimetidine_increases_auc_nortriptyline','cimetidine','increases_auc','nortriptyline','0','0','none_assigned',NULL,NULL,'ContValAssertion',NULL,1245),(1292,'paroxetine_increases_auc_nortriptyline','paroxetine','increases_auc','nortriptyline','0','0','none_assigned',NULL,NULL,'ContValAssertion',1246,NULL),(1293,'cimetidine_increases_auc_sertraline','cimetidine','increases_auc','sertraline','0','0','none_assigned',NULL,NULL,'ContValAssertion',1247,NULL),(1294,'desvenlafaxine_increases_auc_desipramine','desvenlafaxine','increases_auc','desipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1248,NULL),(1295,'citalopram_increases_auc_desipramine','citalopram','increases_auc','desipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1249,NULL),(1296,'venlafaxine_increases_auc_imipramine','venlafaxine','increases_auc','imipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1250,NULL),(1297,'venlafaxine_increases_auc_desipramine','venlafaxine','increases_auc','desipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1251,NULL),(1298,'quinidine_increases_auc_venlafaxine','quinidine','increases_auc','venlafaxine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1252,NULL),(1299,'bupropion_increases_auc_desipramine','bupropion','increases_auc','desipramine','0','0','none_assigned',NULL,NULL,'ContValAssertion',1253,NULL);
/*!40000 ALTER TABLE `Assertions` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `Assumption_map`
--

DROP TABLE IF EXISTS `Assumption_map`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `Assumption_map` (
  `id` int(11) NOT NULL,
  `assump_list_id` int(11) DEFAULT NULL,
  `ev_id` int(11) DEFAULT NULL,
  `assump_assert_name` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `Assumption_map`
--

LOCK TABLES `Assumption_map` WRITE;
/*!40000 ALTER TABLE `Assumption_map` DISABLE KEYS */;
INSERT INTO `Assumption_map` VALUES (1,1,1,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(2,2,5,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(3,3,10,'cyp2d6_polymorphic_enzyme_True'),(4,4,13,'theophylline_primary_total_clearance_enzyme_cyp1a2'),(5,5,28,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(6,5,28,'itraconazole_sole_PK_effect_alter_metabolic_clearance_simvastatin'),(7,6,29,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(8,7,32,'p-nitrophenol_in_vitro_probe_substrate_of_enzyme_cyp2e1'),(9,8,34,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(10,9,37,'warfarin_primary_total_clearance_enzyme_cyp2c9'),(11,10,43,'sulphaphenazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c9'),(12,11,45,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(13,12,47,'clarithromycin_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(14,13,51,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(15,14,53,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(16,15,54,'testosterone_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(17,16,55,'testosterone_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(18,17,56,'cyp2d6_polymorphic_enzyme_True'),(19,18,64,'itraconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a5'),(20,19,66,'itraconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(21,20,78,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(22,21,89,'sildenafil_primary_total_clearance_enzyme_cyp3a4'),(23,22,100,'itraconazole_sole_PK_effect_alter_metabolic_clearance_beta-hydroxy-simvastatin'),(24,22,100,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(25,23,116,'furafylline_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(26,24,124,'troleandomycin_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(27,25,140,'triazolam_primary_total_clearance_enzyme_cyp3a4'),(28,26,141,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(29,27,151,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(30,28,155,'bufuralol_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(31,29,159,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(32,30,160,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(33,31,170,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(34,32,173,'alpha-naphthoflavone_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(35,33,175,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(36,34,178,'bufuralol_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(37,35,180,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(38,36,181,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(39,37,184,'omeprazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c19'),(40,38,191,'bufuralol_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(41,39,193,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(42,40,197,'S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(43,41,200,'S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(44,42,211,'7-ethoxyresorufin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(45,43,213,'S-warfarin_primary_total_clearance_enzyme_cyp2c9'),(46,44,219,'dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(47,45,221,'dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(48,46,226,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(49,47,233,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(50,48,251,'triazolam_primary_total_clearance_enzyme_cyp3a4'),(51,49,252,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(52,50,264,'S-warfarin_primary_total_clearance_enzyme_cyp2c9'),(53,51,275,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(54,52,280,'itraconazole_sole_PK_effect_alter_metabolic_clearance_beta-hydroxy-lovastatin'),(55,52,280,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(56,53,303,'omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(57,54,304,'omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(58,55,312,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(59,56,320,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(60,57,324,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(61,58,325,'alpha-naphthoflavone_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(62,59,329,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(63,60,330,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(64,61,338,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(65,62,342,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(66,63,355,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(67,64,358,'dextromethorphan_primary_total_clearance_enzyme_cyp2d6'),(68,65,359,'furafylline_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(69,66,363,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(70,67,366,'alpha-naphthoflavone_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(71,68,372,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(72,69,383,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(73,70,384,'theophylline_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(74,71,388,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(75,72,390,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(76,73,394,'alpha-naphthoflavone_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(77,74,396,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(78,75,403,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(79,76,405,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(80,77,429,'S-warfarin_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(81,78,431,'cyp2d6_polymorphic_enzyme_True'),(82,79,434,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(83,80,435,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(84,81,436,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(85,82,437,'troleandomycin_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(86,83,443,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(87,84,447,'triazolam_primary_total_clearance_enzyme_cyp3a4'),(88,85,449,'cyp2d6_polymorphic_enzyme_True'),(89,86,453,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(90,87,462,'sulphaphenazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c9'),(91,88,467,'metoprolol_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(92,89,471,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(93,90,475,'omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(94,91,488,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(95,92,491,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(96,93,497,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(97,94,498,'testosterone_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(98,95,499,'testosterone_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(99,96,505,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(100,97,506,'clarithromycin_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(101,98,507,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(102,99,515,'dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(103,100,525,'bufuralol_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(104,101,530,'bufuralol_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(105,102,534,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(106,103,536,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(107,104,545,'S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(108,105,554,'omeprazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c19'),(109,106,558,'clarithromycin_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(110,107,561,'7-ethoxyresorufin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(111,108,562,'caffeine_primary_total_clearance_enzyme_cyp1a2'),(112,109,570,'dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(113,110,571,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(114,111,574,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(115,112,579,'sildenafil_primary_total_clearance_enzyme_cyp3a4'),(116,113,584,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(117,114,590,'cyp2c19_polymorphic_enzyme_True'),(118,115,603,'furafylline_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(119,116,606,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(120,117,614,'R-warfarin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(121,118,630,'fluoxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(122,119,631,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(123,120,637,'cyp2d6_polymorphic_enzyme_True'),(124,121,649,'paroxetine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(125,122,650,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(126,123,652,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(127,124,656,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(128,125,666,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(129,126,668,'erythromycin_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(130,127,674,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(131,128,675,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(132,129,677,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(133,130,682,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(134,131,687,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(135,132,689,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(136,133,690,'cyp2d6_polymorphic_enzyme_True'),(137,134,691,'cyp2d6_polymorphic_enzyme_True'),(138,135,692,'sulfinpyrazone_in_vitro_selective_inhibitor_of_enzyme_cyp2c9'),(139,136,700,'omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(140,137,707,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(141,137,707,'sparteine_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(142,138,709,'itraconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(143,139,710,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(144,140,733,'cyp2d6_polymorphic_enzyme_True'),(145,141,735,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(146,142,749,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(147,143,750,'bufuralol_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(148,144,758,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(149,145,759,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(150,146,777,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(151,147,778,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(152,148,779,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(153,149,806,'dextromethorphan_primary_total_clearance_enzyme_cyp2d6'),(154,150,810,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(155,151,816,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(156,152,817,'S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(157,153,819,'sulphaphenazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c9'),(158,154,824,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(159,155,832,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(160,156,845,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(161,157,861,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(162,158,874,'troleandomycin_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(163,159,875,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(164,160,881,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(165,161,900,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(166,162,903,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(167,163,904,'paroxetine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(168,164,912,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(169,165,916,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(170,166,919,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(171,167,933,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(172,168,934,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(173,169,941,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(174,170,946,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(175,171,949,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(176,172,953,'debrisoquine_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(177,173,954,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(178,174,957,'S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(179,175,959,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(180,176,975,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(181,177,978,'debrisoquine_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(182,178,1006,'S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(183,179,1011,'triazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(184,180,1012,'triazolam_primary_total_clearance_enzyme_cyp3a4'),(185,181,1013,'furafylline_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(186,182,1020,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(187,183,1022,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(188,184,1042,'omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(189,185,1044,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(190,186,1045,'dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(191,187,1048,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(192,188,1051,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(193,189,1054,'S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(194,190,1056,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(195,191,1067,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(196,192,1081,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(197,193,1087,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(198,194,1100,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(199,195,1101,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(200,196,1109,'chlorzoxazone_in_vitro_probe_substrate_of_enzyme_cyp2e1'),(201,197,1133,'fluvoxamine_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(202,198,1140,'warfarin_primary_total_clearance_enzyme_cyp2c9'),(203,199,1148,'bufuralol_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(204,200,1150,'triazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(205,201,1156,'furafylline_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(206,202,1158,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(207,203,1174,'omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(208,204,1177,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(209,205,1182,'testosterone_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(210,206,1188,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(211,207,1195,'tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c9'),(212,208,1199,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(213,209,1212,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(214,210,1217,'cyp2d6_polymorphic_enzyme_True'),(215,211,1221,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(216,212,1241,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(217,213,1258,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(218,214,1263,'S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(219,215,1272,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(220,216,1273,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(221,217,1279,'fluoxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(222,218,1281,'R-warfarin_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(223,219,1284,'furafylline_in_vitro_selective_inhibitor_of_enzyme_cyp1a2'),(224,220,1287,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(225,221,1288,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(226,222,1294,'theophylline_primary_total_clearance_enzyme_cyp1a2'),(227,223,1295,'theophylline_primary_total_clearance_enzyme_cyp1a2'),(228,224,1296,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(229,225,1297,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(230,226,1298,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(231,227,1299,'dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(232,228,1316,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(233,229,1321,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(234,230,1334,'debrisoquine_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(235,231,1348,'debrisoquine_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(236,232,1352,'paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c8'),(237,233,1355,'midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a4'),(238,234,1360,'erythromycin_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(239,235,1361,'ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(240,236,1373,'coumarin_in_vitro_probe_substrate_of_enzyme_cyp2a6'),(241,237,1375,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(242,238,1378,'S-warfarin_primary_total_clearance_enzyme_cyp2c9'),(243,239,1400,'quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d6'),(244,240,1403,'itraconazole_sole_PK_effect_alter_metabolic_clearance_atorvastatin'),(245,240,1403,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(246,241,1416,'theophylline_primary_total_clearance_enzyme_cyp1a2'),(247,242,1417,'caffeine_primary_total_clearance_enzyme_cyp1a2'),(248,243,1458,'paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d6'),(249,244,1470,'triazolam_primary_total_clearance_enzyme_cyp3a4'),(250,245,1476,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(251,246,1487,'theophylline_primary_total_clearance_enzyme_cyp1a2'),(252,247,1505,'midazolam_primary_total_clearance_enzyme_cyp3a4'),(253,248,1506,'dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(254,249,1507,'dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(255,250,1508,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(256,251,1509,'desipramine_primary_total_clearance_enzyme_cyp2d6'),(257,251,1509,'sparteine_in_viVo_probe_substrate_of_enzyme_cyp2d6'),(258,252,1511,'phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a2'),(259,253,1512,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(260,254,1515,'ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a4'),(261,255,1516,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(262,256,1520,'dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d6'),(263,257,1521,'omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(264,258,1534,'omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c19'),(265,259,1537,'itraconazole_sole_PK_effect_alter_metabolic_clearance_lovastatin'),(266,259,1537,'itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4'),(267,260,1551,'midazolam_primary_total_clearance_enzyme_cyp3a4');
/*!40000 ALTER TABLE `Assumption_map` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `Chemical`
--

DROP TABLE IF EXISTS `Chemical`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `Chemical` (
  `id` int(11) NOT NULL,
  `_name` varchar(100) DEFAULT NULL,
  `chemical` tinyint(1) DEFAULT NULL,
  `primary_total_clearance_mechanism` int(11) DEFAULT NULL,
  `primary_metabolic_clearance_enzyme` int(11) DEFAULT NULL,
  `primary_total_clearance_enzyme` int(11) DEFAULT NULL,
  `in_vitro_probe_substrate_of_enzyme` int(11) DEFAULT NULL,
  `in_viVo_probe_substrate_of_enzyme` int(11) DEFAULT NULL,
  `in_vitro_selective_inhibitor_of_enzyme` int(11) DEFAULT NULL,
  `in_viVo_selective_inhibitor_of_enzyme` int(11) DEFAULT NULL,
  `pceut_entity_of_concern` int(11) DEFAULT NULL,
  `maximum_concentration` int(11) DEFAULT NULL,
  `minimum_therapeutic_dose` int(11) DEFAULT NULL,
  `maximum_therapeutic_dose` int(11) DEFAULT NULL,
  `assumed_effective_dose` int(11) DEFAULT NULL,
  `substrate_of` int(11) DEFAULT NULL,
  `is_not_substrate_of` int(11) DEFAULT NULL,
  `inhibits` int(11) DEFAULT NULL,
  `does_not_inhibit` int(11) DEFAULT NULL,
  `has_metabolite` int(11) DEFAULT NULL,
  `permanently_deactivates_catalytic_function` int(11) DEFAULT NULL,
  `does_not_permanently_deactivate_catalytic_function` int(11) DEFAULT NULL,
  `inhibition_constant` int(11) DEFAULT NULL,
  `induces` int(11) DEFAULT NULL,
  `increases_auc` int(11) DEFAULT NULL,
  `sole_PK_effect_alter_metabolic_clearance` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `Chemical`
--

LOCK TABLES `Chemical` WRITE;
/*!40000 ALTER TABLE `Chemical` DISABLE KEYS */;
INSERT INTO `Chemical` VALUES (1,'sparteine',1,75,76,77,78,79,80,81,82,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(2,'7-ethoxyresorufin',1,96,97,98,99,100,101,102,103,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(3,'furafylline',1,493,494,495,496,497,498,499,500,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(4,'bufuralol',1,501,502,503,504,505,506,507,508,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(5,'coumarin',1,1677,1678,1679,1680,1681,1682,1683,1684,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(6,'p-nitrophenol',1,2317,2318,2319,2320,2321,2322,2323,2324,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL);
/*!40000 ALTER TABLE `Chemical` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `DDIObservations`
--

DROP TABLE IF EXISTS `DDIObservations`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `DDIObservations` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `precipitant` varchar(100) DEFAULT NULL,
  `object` varchar(100) DEFAULT NULL,
  `assertionId` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM AUTO_INCREMENT=104 DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `DDIObservations`
--

LOCK TABLES `DDIObservations` WRITE;
/*!40000 ALTER TABLE `DDIObservations` DISABLE KEYS */;
INSERT INTO `DDIObservations` VALUES (1,'diltiazem','triazolam',30),(2,'ketoconazole','simvastatin',33),(3,'cimetidine','erythrohydrobupropion',43),(4,'clarithromycin','triazolam',45),(5,'ketoconazole','midazolam',70),(6,'fluvoxamine','tolbutamide',91),(7,'ketoconazole','desvenlafaxine',96),(8,'clarithromycin','atorvastatin',103),(9,'nefazodone','alprazolam',110),(10,'itraconazole','3alpha-hydroxypravastatin',116),(11,'fluconazole','triazolam',129),(12,'lansoprazole','lansoprazole',138),(13,'paroxetine','risperidone',147),(14,'itraconazole','beta-hydroxy-lovastatin',176),(15,'diltiazem','beta-hydroxy-lovastatin',206),(16,'ketoconazole','O-desmethylvenlafaxine',212),(17,'clarithromycin','midazolam',240),(18,'itraconazole','midazolam',252),(19,'itraconazole','lovastatin',295),(20,'fluoxetine','alprazolam',303),(21,'venlafaxine','risperidone',314),(22,'itraconazole','atorvastatin',344),(23,'cimetidine','citalopram',353),(24,'nefazodone','triazolam',354),(25,'valproate','hydroxybupropion',396),(26,'cimetidine','escitalopram',409),(27,'cimetidine','theophylline',425),(28,'fluconazole','midazolam',434),(29,'duloxetine','theophylline',440),(30,'omeprazole','escitalopram',443),(31,'venlafaxine','haloperidol',451),(32,'ketoconazole','zolpidem',472),(33,'fluoxetine','propafenone',493),(34,'cimetidine','threohydrobupropion',529),(35,'erythromycin','triazolam',543),(36,'fluconazole','fluvastatin',557),(37,'paroxetine','mirtazapine',559),(38,'cimetidine','ziprasidone',568),(39,'fluvoxamine','lansoprazole',571),(40,'clopidogrel','bupropion',579),(41,'ketoconazole','venlafaxine',600),(42,'fluoxetine','desipramine',602),(43,'ketoconazole','triazolam',608),(44,'paroxetine','paliperidone',615),(45,'nefazodone','midazolam',619),(46,'cimetidine','quetiapine',686),(47,'diltiazem','simvastatin',689),(48,'cimetidine','mirtazapine',703),(49,'fluvoxamine','duloxetine',708),(50,'terbinafine','venlafaxine',720),(51,'terbinafine','paroxetine',728),(52,'sertraline','desipramine',736),(53,'fluvoxamine','mexiletine',740),(54,'fluvoxamine','omeprazole',752),(55,'erythromycin','midazolam',769),(56,'erythromycin','atorvastatin',800),(57,'clarithromycin','lansoprazole',821),(58,'fluvoxamine','clozapine',822),(59,'fluvoxamine','thioridazine',892),(60,'clarithromycin','trazodone',893),(61,'itraconazole','rosuvastatin',909),(62,'itraconazole','alprazolam',914),(63,'clarithromycin','pravastatin',928),(64,'cimetidine','venlafaxine',934),(65,'aripiprazole','escitalopram',950),(66,'fluvoxamine','quinidine',1003),(67,'ketoconazole','alprazolam',1007),(68,'itraconazole','pravastatin',1043),(69,'erythromycin','beta-hydroxy-simvastatin',1053),(70,'erythromycin','alprazolam',1078),(71,'erythromycin','simvastatin',1106),(72,'fluoxetine','olanzapine',1107),(73,'itraconazole','triazolam',1153),(74,'fluvoxamine','theophylline',1157),(75,'paroxetine','desipramine',1164),(76,'diphenhydramine','venlafaxine',1171),(77,'erythromycin','quetiapine',1197),(78,'aripiprazole','venlafaxine',1212),(79,'diltiazem','midazolam',1215),(80,'itraconazole','zolpidem',1217),(81,'verapamil','risperidone',1243),(82,'prasugrel','bupropion',1266),(83,'ticlopidine','bupropion',1267),(84,'paroxetine','duloxetine',1273),(85,'ritonavir','trazodone',1277),(86,'cimetidine','paroxetine',1278),(87,'ketoconazole','amitriptyline',1279),(88,'cimetidine','amitriptyline',1281),(89,'cimetidine','doxepin',1284),(90,'cimetidine','imipramine',1285),(91,'fluoxetine','imipramine',1286),(92,'ketoconazole','imipramine',1287),(93,'paroxetine','imipramine',1288),(94,'verapamil','imipramine',1289),(95,'diltiazem','imipramine',1290),(96,'paroxetine','nortriptyline',1292),(97,'cimetidine','sertraline',1293),(98,'desvenlafaxine','desipramine',1294),(99,'citalopram','desipramine',1295),(100,'venlafaxine','imipramine',1296),(101,'venlafaxine','desipramine',1297),(102,'quinidine','venlafaxine',1298),(103,'bupropion','desipramine',1299);
/*!40000 ALTER TABLE `DDIObservations` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `DDIPredictions`
--

DROP TABLE IF EXISTS `DDIPredictions`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `DDIPredictions` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `OBJECT` varchar(100) DEFAULT NULL,
  `PRECIPITANT` varchar(100) DEFAULT NULL,
  `ENZYME` varchar(100) DEFAULT NULL,
  `LEVEL` varchar(10) DEFAULT NULL,
  `TIER` varchar(30) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM AUTO_INCREMENT=721 DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `DDIPredictions`
--

LOCK TABLES `DDIPredictions` WRITE;
/*!40000 ALTER TABLE `DDIPredictions` DISABLE KEYS */;
INSERT INTO `DDIPredictions` VALUES (1,'eszopiclone','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(2,'zaleplon','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(3,'zolpidem','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(4,'eszopiclone','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(5,'zaleplon','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(6,'zolpidem','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(7,'eszopiclone','voriconazole','CYP3A4','PKI-1','fourth-tier'),(8,'zaleplon','voriconazole','CYP3A4','PKI-1','fourth-tier'),(9,'zolpidem','voriconazole','CYP3A4','PKI-1','fourth-tier'),(10,'zolpidem','verapamil','CYP3A5','PKI-1','fourth-tier'),(11,'eszopiclone','verapamil','CYP3A4','PKI-1','fourth-tier'),(12,'zaleplon','verapamil','CYP3A4','PKI-1','fourth-tier'),(13,'zolpidem','verapamil','CYP3A4','PKI-1','fourth-tier'),(14,'zolpidem','telithromycin','CYP3A5','PKI-1','fourth-tier'),(15,'eszopiclone','telithromycin','CYP3A4','PKI-1','fourth-tier'),(16,'zaleplon','telithromycin','CYP3A4','PKI-1','fourth-tier'),(17,'zolpidem','telithromycin','CYP3A4','PKI-1','fourth-tier'),(18,'zolpidem','ritonavir','CYP3A5','PKI-1','fourth-tier'),(19,'eszopiclone','ritonavir','CYP3A4','PKI-1','fourth-tier'),(20,'zaleplon','ritonavir','CYP3A4','PKI-1','fourth-tier'),(21,'zolpidem','ritonavir','CYP3A4','PKI-1','fourth-tier'),(22,'zolpidem','ranolazine','CYP3A5','PKI-1','fourth-tier'),(23,'eszopiclone','ranolazine','CYP3A4','PKI-1','fourth-tier'),(24,'zaleplon','ranolazine','CYP3A4','PKI-1','fourth-tier'),(25,'zolpidem','ranolazine','CYP3A4','PKI-1','fourth-tier'),(26,'zolpidem','nefazodone','CYP3A5','PKI-1','fourth-tier'),(27,'eszopiclone','nefazodone','CYP3A4','PKI-1','fourth-tier'),(28,'zaleplon','nefazodone','CYP3A4','PKI-1','fourth-tier'),(29,'zolpidem','nefazodone','CYP3A4','PKI-1','fourth-tier'),(30,'eszopiclone','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(31,'zaleplon','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(32,'zolpidem','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(33,'eszopiclone','itraconazole','CYP3A4','PKI-1','fourth-tier'),(34,'zaleplon','itraconazole','CYP3A4','PKI-1','fourth-tier'),(35,'zolpidem','itraconazole','CYP3A4','PKI-1','fourth-tier'),(36,'zolpidem','indinavir','CYP3A5','PKI-1','fourth-tier'),(37,'eszopiclone','indinavir','CYP3A4','PKI-1','fourth-tier'),(38,'zaleplon','indinavir','CYP3A4','PKI-1','fourth-tier'),(39,'zolpidem','indinavir','CYP3A4','PKI-1','fourth-tier'),(40,'zolpidem','fluconazole','CYP3A5','PKI-1','fourth-tier'),(41,'eszopiclone','fluconazole','CYP3A4','PKI-1','fourth-tier'),(42,'zaleplon','fluconazole','CYP3A4','PKI-1','fourth-tier'),(43,'zolpidem','fluconazole','CYP3A4','PKI-1','fourth-tier'),(44,'eszopiclone','erythromycin','CYP3A4','PKI-1','fourth-tier'),(45,'zaleplon','erythromycin','CYP3A4','PKI-1','fourth-tier'),(46,'zolpidem','erythromycin','CYP3A4','PKI-1','fourth-tier'),(47,'eszopiclone','diltiazem','CYP3A4','PKI-1','fourth-tier'),(48,'zaleplon','diltiazem','CYP3A4','PKI-1','fourth-tier'),(49,'zolpidem','diltiazem','CYP3A4','PKI-1','fourth-tier'),(50,'zolpidem','clarithromycin','CYP3A5','PKI-1','fourth-tier'),(51,'eszopiclone','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(52,'zaleplon','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(53,'zolpidem','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(54,'zolpidem','cimetidine','CYP3A5','PKI-1','fourth-tier'),(55,'eszopiclone','cimetidine','CYP3A4','PKI-1','fourth-tier'),(56,'zaleplon','cimetidine','CYP3A4','PKI-1','fourth-tier'),(57,'zolpidem','cimetidine','CYP3A4','PKI-1','fourth-tier'),(58,'eszopiclone','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(59,'zaleplon','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(60,'zolpidem','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(61,'zolpidem','atazanavir','CYP3A5','PKI-1','fourth-tier'),(62,'eszopiclone','atazanavir','CYP3A4','PKI-1','fourth-tier'),(63,'zaleplon','atazanavir','CYP3A4','PKI-1','fourth-tier'),(64,'zolpidem','atazanavir','CYP3A4','PKI-1','fourth-tier'),(65,'eszopiclone','amiodarone','CYP3A4','PKI-1','fourth-tier'),(66,'zaleplon','amiodarone','CYP3A4','PKI-1','fourth-tier'),(67,'zolpidem','amiodarone','CYP3A4','PKI-1','fourth-tier'),(68,'r-citalopram','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(69,'escitalopram','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(70,'mirtazapine','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(71,'nefazodone','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(72,'trazodone','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(73,'venlafaxine','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(74,'r-citalopram','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(75,'escitalopram','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(76,'mirtazapine','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(77,'nefazodone','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(78,'trazodone','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(79,'venlafaxine','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(80,'citalopram','voriconazole-n-oxide','CYP2C19','PKI-1','fourth-tier'),(81,'sertraline','voriconazole-n-oxide','CYP2C19','PKI-1','fourth-tier'),(82,'r-citalopram','voriconazole','CYP3A4','PKI-1','fourth-tier'),(83,'escitalopram','voriconazole','CYP3A4','PKI-1','fourth-tier'),(84,'mirtazapine','voriconazole','CYP3A4','PKI-1','fourth-tier'),(85,'nefazodone','voriconazole','CYP3A4','PKI-1','fourth-tier'),(86,'trazodone','voriconazole','CYP3A4','PKI-1','fourth-tier'),(87,'venlafaxine','voriconazole','CYP3A4','PKI-1','fourth-tier'),(88,'citalopram','voriconazole','CYP2C19','PKI-1','fourth-tier'),(89,'sertraline','voriconazole','CYP2C19','PKI-1','fourth-tier'),(90,'mirtazapine','verapamil','CYP3A5','PKI-1','fourth-tier'),(91,'r-citalopram','verapamil','CYP3A4','PKI-1','fourth-tier'),(92,'escitalopram','verapamil','CYP3A4','PKI-1','fourth-tier'),(93,'mirtazapine','verapamil','CYP3A4','PKI-1','fourth-tier'),(94,'nefazodone','verapamil','CYP3A4','PKI-1','fourth-tier'),(95,'trazodone','verapamil','CYP3A4','PKI-1','fourth-tier'),(96,'venlafaxine','verapamil','CYP3A4','PKI-1','fourth-tier'),(97,'duloxetine','verapamil','CYP1A2','PKI-1','fourth-tier'),(98,'mirtazapine','verapamil','CYP1A2','PKI-1','fourth-tier'),(99,'r-citalopram','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(100,'duloxetine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(101,'escitalopram','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(102,'fluoxetine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(103,'fluvoxamine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(104,'mirtazapine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(105,'paroxetine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(106,'r-citalopram','terbinafine','CYP2D6','PKI-1','fourth-tier'),(107,'duloxetine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(108,'escitalopram','terbinafine','CYP2D6','PKI-1','fourth-tier'),(109,'fluoxetine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(110,'fluvoxamine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(111,'mirtazapine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(112,'paroxetine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(113,'venlafaxine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(114,'mirtazapine','telithromycin','CYP3A5','PKI-1','fourth-tier'),(115,'r-citalopram','telithromycin','CYP3A4','PKI-1','fourth-tier'),(116,'escitalopram','telithromycin','CYP3A4','PKI-1','fourth-tier'),(117,'mirtazapine','telithromycin','CYP3A4','PKI-1','fourth-tier'),(118,'nefazodone','telithromycin','CYP3A4','PKI-1','fourth-tier'),(119,'trazodone','telithromycin','CYP3A4','PKI-1','fourth-tier'),(120,'venlafaxine','telithromycin','CYP3A4','PKI-1','fourth-tier'),(121,'r-citalopram','sertraline','CYP2D6','PKI-1','fourth-tier'),(122,'duloxetine','sertraline','CYP2D6','PKI-1','fourth-tier'),(123,'escitalopram','sertraline','CYP2D6','PKI-1','fourth-tier'),(124,'fluoxetine','sertraline','CYP2D6','PKI-1','fourth-tier'),(125,'fluvoxamine','sertraline','CYP2D6','PKI-1','fourth-tier'),(126,'mirtazapine','sertraline','CYP2D6','PKI-1','fourth-tier'),(127,'paroxetine','sertraline','CYP2D6','PKI-1','fourth-tier'),(128,'venlafaxine','sertraline','CYP2D6','PKI-1','fourth-tier'),(129,'mirtazapine','ritonavir','CYP3A5','PKI-1','fourth-tier'),(130,'r-citalopram','ritonavir','CYP3A4','PKI-1','fourth-tier'),(131,'escitalopram','ritonavir','CYP3A4','PKI-1','fourth-tier'),(132,'mirtazapine','ritonavir','CYP3A4','PKI-1','fourth-tier'),(133,'nefazodone','ritonavir','CYP3A4','PKI-1','fourth-tier'),(134,'trazodone','ritonavir','CYP3A4','PKI-1','fourth-tier'),(135,'venlafaxine','ritonavir','CYP3A4','PKI-1','fourth-tier'),(136,'r-citalopram','ritonavir','CYP2D6','PKI-1','fourth-tier'),(137,'duloxetine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(138,'escitalopram','ritonavir','CYP2D6','PKI-1','fourth-tier'),(139,'fluoxetine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(140,'fluvoxamine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(141,'mirtazapine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(142,'paroxetine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(143,'venlafaxine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(144,'mirtazapine','ranolazine','CYP3A5','PKI-1','fourth-tier'),(145,'r-citalopram','ranolazine','CYP3A4','PKI-1','fourth-tier'),(146,'escitalopram','ranolazine','CYP3A4','PKI-1','fourth-tier'),(147,'mirtazapine','ranolazine','CYP3A4','PKI-1','fourth-tier'),(148,'nefazodone','ranolazine','CYP3A4','PKI-1','fourth-tier'),(149,'trazodone','ranolazine','CYP3A4','PKI-1','fourth-tier'),(150,'venlafaxine','ranolazine','CYP3A4','PKI-1','fourth-tier'),(151,'r-citalopram','ranolazine','CYP2D6','PKI-1','fourth-tier'),(152,'duloxetine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(153,'escitalopram','ranolazine','CYP2D6','PKI-1','fourth-tier'),(154,'fluoxetine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(155,'fluvoxamine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(156,'mirtazapine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(157,'paroxetine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(158,'venlafaxine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(159,'r-citalopram','quinidine','CYP2D6','PKI-1','fourth-tier'),(160,'duloxetine','quinidine','CYP2D6','PKI-1','fourth-tier'),(161,'escitalopram','quinidine','CYP2D6','PKI-1','fourth-tier'),(162,'fluoxetine','quinidine','CYP2D6','PKI-1','fourth-tier'),(163,'fluvoxamine','quinidine','CYP2D6','PKI-1','fourth-tier'),(164,'mirtazapine','quinidine','CYP2D6','PKI-1','fourth-tier'),(165,'paroxetine','quinidine','CYP2D6','PKI-1','fourth-tier'),(166,'venlafaxine','quinidine','CYP2D6','PKI-1','fourth-tier'),(167,'duloxetine','propafenone','CYP1A2','PKI-1','fourth-tier'),(168,'mirtazapine','propafenone','CYP1A2','PKI-1','fourth-tier'),(169,'r-citalopram','paroxetine','CYP2D6','PKI-1','fourth-tier'),(170,'duloxetine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(171,'escitalopram','paroxetine','CYP2D6','PKI-1','fourth-tier'),(172,'fluoxetine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(173,'fluvoxamine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(174,'mirtazapine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(175,'venlafaxine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(176,'citalopram','omeprazole','CYP2C19','PKI-1','fourth-tier'),(177,'sertraline','omeprazole','CYP2C19','PKI-1','fourth-tier'),(178,'duloxetine','norfloxacin','CYP1A2','PKI-1','fourth-tier'),(179,'mirtazapine','norfloxacin','CYP1A2','PKI-1','fourth-tier'),(180,'mirtazapine','nefazodone','CYP3A5','PKI-1','fourth-tier'),(181,'r-citalopram','nefazodone','CYP3A4','PKI-1','fourth-tier'),(182,'escitalopram','nefazodone','CYP3A4','PKI-1','fourth-tier'),(183,'mirtazapine','nefazodone','CYP3A4','PKI-1','fourth-tier'),(184,'trazodone','nefazodone','CYP3A4','PKI-1','fourth-tier'),(185,'venlafaxine','nefazodone','CYP3A4','PKI-1','fourth-tier'),(186,'citalopram','modafinil-sulfone','CYP2C19','PKI-1','fourth-tier'),(187,'sertraline','modafinil-sulfone','CYP2C19','PKI-1','fourth-tier'),(188,'citalopram','modafinil','CYP2C19','PKI-1','fourth-tier'),(189,'sertraline','modafinil','CYP2C19','PKI-1','fourth-tier'),(190,'duloxetine','mexiletine','CYP1A2','PKI-1','fourth-tier'),(191,'mirtazapine','mexiletine','CYP1A2','PKI-1','fourth-tier'),(192,'r-citalopram','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(193,'escitalopram','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(194,'mirtazapine','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(195,'nefazodone','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(196,'trazodone','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(197,'venlafaxine','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(198,'r-citalopram','itraconazole','CYP3A4','PKI-1','fourth-tier'),(199,'escitalopram','itraconazole','CYP3A4','PKI-1','fourth-tier'),(200,'mirtazapine','itraconazole','CYP3A4','PKI-1','fourth-tier'),(201,'nefazodone','itraconazole','CYP3A4','PKI-1','fourth-tier'),(202,'trazodone','itraconazole','CYP3A4','PKI-1','fourth-tier'),(203,'venlafaxine','itraconazole','CYP3A4','PKI-1','fourth-tier'),(204,'mirtazapine','indinavir','CYP3A5','PKI-1','fourth-tier'),(205,'r-citalopram','indinavir','CYP3A4','PKI-1','fourth-tier'),(206,'escitalopram','indinavir','CYP3A4','PKI-1','fourth-tier'),(207,'mirtazapine','indinavir','CYP3A4','PKI-1','fourth-tier'),(208,'nefazodone','indinavir','CYP3A4','PKI-1','fourth-tier'),(209,'trazodone','indinavir','CYP3A4','PKI-1','fourth-tier'),(210,'venlafaxine','indinavir','CYP3A4','PKI-1','fourth-tier'),(211,'r-citalopram','iloperidone','CYP2D6','PKI-1','fourth-tier'),(212,'duloxetine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(213,'escitalopram','iloperidone','CYP2D6','PKI-1','fourth-tier'),(214,'fluoxetine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(215,'fluvoxamine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(216,'mirtazapine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(217,'paroxetine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(218,'venlafaxine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(219,'citalopram','fluvoxamine','CYP2C19','PKI-1','fourth-tier'),(220,'sertraline','fluvoxamine','CYP2C19','PKI-1','fourth-tier'),(221,'duloxetine','fluvoxamine','CYP1A2','PKI-1','fourth-tier'),(222,'mirtazapine','fluvoxamine','CYP1A2','PKI-1','fourth-tier'),(223,'r-citalopram','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(224,'duloxetine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(225,'escitalopram','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(226,'fluvoxamine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(227,'mirtazapine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(228,'paroxetine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(229,'venlafaxine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(230,'mirtazapine','fluconazole','CYP3A5','PKI-1','fourth-tier'),(231,'r-citalopram','fluconazole','CYP3A4','PKI-1','fourth-tier'),(232,'escitalopram','fluconazole','CYP3A4','PKI-1','fourth-tier'),(233,'mirtazapine','fluconazole','CYP3A4','PKI-1','fourth-tier'),(234,'nefazodone','fluconazole','CYP3A4','PKI-1','fourth-tier'),(235,'trazodone','fluconazole','CYP3A4','PKI-1','fourth-tier'),(236,'venlafaxine','fluconazole','CYP3A4','PKI-1','fourth-tier'),(237,'r-citalopram','erythromycin','CYP3A4','PKI-1','fourth-tier'),(238,'escitalopram','erythromycin','CYP3A4','PKI-1','fourth-tier'),(239,'mirtazapine','erythromycin','CYP3A4','PKI-1','fourth-tier'),(240,'nefazodone','erythromycin','CYP3A4','PKI-1','fourth-tier'),(241,'trazodone','erythromycin','CYP3A4','PKI-1','fourth-tier'),(242,'venlafaxine','erythromycin','CYP3A4','PKI-1','fourth-tier'),(243,'r-citalopram','duloxetine','CYP2D6','PKI-1','fourth-tier'),(244,'escitalopram','duloxetine','CYP2D6','PKI-1','fourth-tier'),(245,'fluoxetine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(246,'fluvoxamine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(247,'mirtazapine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(248,'paroxetine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(249,'venlafaxine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(250,'r-citalopram','diltiazem','CYP3A4','PKI-1','fourth-tier'),(251,'escitalopram','diltiazem','CYP3A4','PKI-1','fourth-tier'),(252,'mirtazapine','diltiazem','CYP3A4','PKI-1','fourth-tier'),(253,'nefazodone','diltiazem','CYP3A4','PKI-1','fourth-tier'),(254,'trazodone','diltiazem','CYP3A4','PKI-1','fourth-tier'),(255,'venlafaxine','diltiazem','CYP3A4','PKI-1','fourth-tier'),(256,'mirtazapine','clarithromycin','CYP3A5','PKI-1','fourth-tier'),(257,'r-citalopram','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(258,'escitalopram','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(259,'mirtazapine','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(260,'nefazodone','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(261,'trazodone','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(262,'venlafaxine','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(263,'duloxetine','ciprofloxacin','CYP1A2','PKI-1','fourth-tier'),(264,'mirtazapine','ciprofloxacin','CYP1A2','PKI-1','fourth-tier'),(265,'desipramine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(266,'desipramine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(267,'desipramine','sertraline','CYP2D6','PKI-1','fourth-tier'),(268,'desipramine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(269,'desipramine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(270,'desipramine','quinidine','CYP2D6','PKI-1','fourth-tier'),(271,'desipramine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(272,'desipramine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(273,'desipramine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(274,'desipramine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(275,'r-citalopram','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(276,'duloxetine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(277,'escitalopram','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(278,'fluoxetine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(279,'fluvoxamine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(280,'mirtazapine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(281,'paroxetine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(282,'venlafaxine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(283,'desipramine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(284,'mirtazapine','cimetidine','CYP3A5','PKI-1','fourth-tier'),(285,'r-citalopram','cimetidine','CYP3A4','PKI-1','fourth-tier'),(286,'escitalopram','cimetidine','CYP3A4','PKI-1','fourth-tier'),(287,'mirtazapine','cimetidine','CYP3A4','PKI-1','fourth-tier'),(288,'nefazodone','cimetidine','CYP3A4','PKI-1','fourth-tier'),(289,'trazodone','cimetidine','CYP3A4','PKI-1','fourth-tier'),(290,'venlafaxine','cimetidine','CYP3A4','PKI-1','fourth-tier'),(291,'duloxetine','cimetidine','CYP1A2','PKI-1','fourth-tier'),(292,'mirtazapine','cimetidine','CYP1A2','PKI-1','fourth-tier'),(293,'r-citalopram','bupropion','CYP2D6','PKI-1','fourth-tier'),(294,'duloxetine','bupropion','CYP2D6','PKI-1','fourth-tier'),(295,'escitalopram','bupropion','CYP2D6','PKI-1','fourth-tier'),(296,'fluoxetine','bupropion','CYP2D6','PKI-1','fourth-tier'),(297,'fluvoxamine','bupropion','CYP2D6','PKI-1','fourth-tier'),(298,'mirtazapine','bupropion','CYP2D6','PKI-1','fourth-tier'),(299,'paroxetine','bupropion','CYP2D6','PKI-1','fourth-tier'),(300,'venlafaxine','bupropion','CYP2D6','PKI-1','fourth-tier'),(301,'desipramine','bupropion','CYP2D6','PKI-1','fourth-tier'),(302,'r-citalopram','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(303,'escitalopram','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(304,'mirtazapine','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(305,'nefazodone','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(306,'trazodone','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(307,'venlafaxine','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(308,'mirtazapine','atazanavir','CYP3A5','PKI-1','fourth-tier'),(309,'r-citalopram','atazanavir','CYP3A4','PKI-1','fourth-tier'),(310,'escitalopram','atazanavir','CYP3A4','PKI-1','fourth-tier'),(311,'mirtazapine','atazanavir','CYP3A4','PKI-1','fourth-tier'),(312,'nefazodone','atazanavir','CYP3A4','PKI-1','fourth-tier'),(313,'trazodone','atazanavir','CYP3A4','PKI-1','fourth-tier'),(314,'venlafaxine','atazanavir','CYP3A4','PKI-1','fourth-tier'),(315,'r-citalopram','amiodarone','CYP3A4','PKI-1','fourth-tier'),(316,'escitalopram','amiodarone','CYP3A4','PKI-1','fourth-tier'),(317,'mirtazapine','amiodarone','CYP3A4','PKI-1','fourth-tier'),(318,'nefazodone','amiodarone','CYP3A4','PKI-1','fourth-tier'),(319,'trazodone','amiodarone','CYP3A4','PKI-1','fourth-tier'),(320,'venlafaxine','amiodarone','CYP3A4','PKI-1','fourth-tier'),(321,'r-citalopram','amiodarone','CYP2D6','PKI-1','fourth-tier'),(322,'duloxetine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(323,'escitalopram','amiodarone','CYP2D6','PKI-1','fourth-tier'),(324,'fluoxetine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(325,'fluvoxamine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(326,'mirtazapine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(327,'paroxetine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(328,'venlafaxine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(329,'desipramine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(330,'duloxetine','amiodarone','CYP1A2','PKI-1','fourth-tier'),(331,'mirtazapine','amiodarone','CYP1A2','PKI-1','fourth-tier'),(332,'atorvastatin','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(333,'fluvastatin','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(334,'lovastatin','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(335,'simvastatin','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(336,'fluvastatin','zafirlukast','CYP2C9','PKI-1','fourth-tier'),(337,'atorvastatin','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(338,'fluvastatin','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(339,'lovastatin','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(340,'simvastatin','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(341,'fluvastatin','voriconazole-n-oxide','CYP2C9','PKI-1','fourth-tier'),(342,'atorvastatin','voriconazole','CYP3A4','PKI-1','fourth-tier'),(343,'fluvastatin','voriconazole','CYP3A4','PKI-1','fourth-tier'),(344,'lovastatin','voriconazole','CYP3A4','PKI-1','fourth-tier'),(345,'simvastatin','voriconazole','CYP3A4','PKI-1','fourth-tier'),(346,'fluvastatin','voriconazole','CYP2C9','PKI-1','fourth-tier'),(347,'atorvastatin','verapamil','CYP3A4','PKI-1','fourth-tier'),(348,'fluvastatin','verapamil','CYP3A4','PKI-1','fourth-tier'),(349,'lovastatin','verapamil','CYP3A4','PKI-1','fourth-tier'),(350,'simvastatin','verapamil','CYP3A4','PKI-1','fourth-tier'),(351,'fluvastatin','trimethoprim','CYP2C8','PKI-1','fourth-tier'),(352,'fluvastatin','teriflunomide','CYP2C9','PKI-1','fourth-tier'),(353,'atorvastatin','telithromycin','CYP3A4','PKI-1','fourth-tier'),(354,'fluvastatin','telithromycin','CYP3A4','PKI-1','fourth-tier'),(355,'lovastatin','telithromycin','CYP3A4','PKI-1','fourth-tier'),(356,'simvastatin','telithromycin','CYP3A4','PKI-1','fourth-tier'),(357,'atorvastatin','ritonavir','CYP3A4','PKI-1','fourth-tier'),(358,'fluvastatin','ritonavir','CYP3A4','PKI-1','fourth-tier'),(359,'lovastatin','ritonavir','CYP3A4','PKI-1','fourth-tier'),(360,'simvastatin','ritonavir','CYP3A4','PKI-1','fourth-tier'),(361,'atorvastatin','ranolazine','CYP3A4','PKI-1','fourth-tier'),(362,'fluvastatin','ranolazine','CYP3A4','PKI-1','fourth-tier'),(363,'lovastatin','ranolazine','CYP3A4','PKI-1','fourth-tier'),(364,'simvastatin','ranolazine','CYP3A4','PKI-1','fourth-tier'),(365,'atorvastatin','nefazodone','CYP3A4','PKI-1','fourth-tier'),(366,'fluvastatin','nefazodone','CYP3A4','PKI-1','fourth-tier'),(367,'lovastatin','nefazodone','CYP3A4','PKI-1','fourth-tier'),(368,'simvastatin','nefazodone','CYP3A4','PKI-1','fourth-tier'),(369,'atorvastatin','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(370,'fluvastatin','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(371,'lovastatin','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(372,'simvastatin','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(373,'atorvastatin','itraconazole','CYP3A4','PKI-1','fourth-tier'),(374,'fluvastatin','itraconazole','CYP3A4','PKI-1','fourth-tier'),(375,'lovastatin','itraconazole','CYP3A4','PKI-1','fourth-tier'),(376,'simvastatin','itraconazole','CYP3A4','PKI-1','fourth-tier'),(377,'atorvastatin','indinavir','CYP3A4','PKI-1','fourth-tier'),(378,'fluvastatin','indinavir','CYP3A4','PKI-1','fourth-tier'),(379,'lovastatin','indinavir','CYP3A4','PKI-1','fourth-tier'),(380,'simvastatin','indinavir','CYP3A4','PKI-1','fourth-tier'),(381,'fluvastatin','gemfibrozil','CYP2C8','PKI-1','fourth-tier'),(382,'fluvastatin','fluvoxamine','CYP2C9','PKI-1','fourth-tier'),(383,'atorvastatin','fluconazole','CYP3A4','PKI-1','fourth-tier'),(384,'fluvastatin','fluconazole','CYP3A4','PKI-1','fourth-tier'),(385,'lovastatin','fluconazole','CYP3A4','PKI-1','fourth-tier'),(386,'simvastatin','fluconazole','CYP3A4','PKI-1','fourth-tier'),(387,'fluvastatin','fluconazole','CYP2C9','PKI-1','fourth-tier'),(388,'atorvastatin','erythromycin','CYP3A4','PKI-1','fourth-tier'),(389,'fluvastatin','erythromycin','CYP3A4','PKI-1','fourth-tier'),(390,'lovastatin','erythromycin','CYP3A4','PKI-1','fourth-tier'),(391,'simvastatin','erythromycin','CYP3A4','PKI-1','fourth-tier'),(392,'atorvastatin','diltiazem','CYP3A4','PKI-1','fourth-tier'),(393,'fluvastatin','diltiazem','CYP3A4','PKI-1','fourth-tier'),(394,'lovastatin','diltiazem','CYP3A4','PKI-1','fourth-tier'),(395,'simvastatin','diltiazem','CYP3A4','PKI-1','fourth-tier'),(396,'atorvastatin','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(397,'fluvastatin','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(398,'lovastatin','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(399,'simvastatin','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(400,'atorvastatin','cimetidine','CYP3A4','PKI-1','fourth-tier'),(401,'fluvastatin','cimetidine','CYP3A4','PKI-1','fourth-tier'),(402,'lovastatin','cimetidine','CYP3A4','PKI-1','fourth-tier'),(403,'simvastatin','cimetidine','CYP3A4','PKI-1','fourth-tier'),(404,'fluvastatin','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(405,'lovastatin','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(406,'simvastatin','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(407,'atorvastatin','atazanavir','CYP3A4','PKI-1','fourth-tier'),(408,'fluvastatin','atazanavir','CYP3A4','PKI-1','fourth-tier'),(409,'lovastatin','atazanavir','CYP3A4','PKI-1','fourth-tier'),(410,'simvastatin','atazanavir','CYP3A4','PKI-1','fourth-tier'),(411,'atorvastatin','amiodarone','CYP3A4','PKI-1','fourth-tier'),(412,'fluvastatin','amiodarone','CYP3A4','PKI-1','fourth-tier'),(413,'lovastatin','amiodarone','CYP3A4','PKI-1','fourth-tier'),(414,'simvastatin','amiodarone','CYP3A4','PKI-1','fourth-tier'),(415,'fluvastatin','amiodarone','CYP2C9','PKI-1','fourth-tier'),(416,'rosuvastatin','zafirlukast','CYP2C9','PKI-1','fourth-tier'),(417,'rosuvastatin','voriconazole-n-oxide','CYP2C9','PKI-1','fourth-tier'),(418,'rosuvastatin','voriconazole','CYP2C9','PKI-1','fourth-tier'),(419,'rosuvastatin','teriflunomide','CYP2C9','PKI-1','fourth-tier'),(420,'rosuvastatin','fluvoxamine','CYP2C9','PKI-1','fourth-tier'),(421,'rosuvastatin','fluconazole','CYP2C9','PKI-1','fourth-tier'),(422,'rosuvastatin','amiodarone','CYP2C9','PKI-1','fourth-tier'),(423,'aripiprazole','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(424,'clozapine','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(425,'iloperidone','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(426,'risperidone','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(427,'ziprasidone','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(428,'aripiprazole','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(429,'clozapine','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(430,'iloperidone','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(431,'risperidone','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(432,'ziprasidone','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(433,'aripiprazole','voriconazole','CYP3A4','PKI-1','fourth-tier'),(434,'clozapine','voriconazole','CYP3A4','PKI-1','fourth-tier'),(435,'iloperidone','voriconazole','CYP3A4','PKI-1','fourth-tier'),(436,'risperidone','voriconazole','CYP3A4','PKI-1','fourth-tier'),(437,'ziprasidone','voriconazole','CYP3A4','PKI-1','fourth-tier'),(438,'aripiprazole','verapamil','CYP3A4','PKI-1','fourth-tier'),(439,'clozapine','verapamil','CYP3A4','PKI-1','fourth-tier'),(440,'iloperidone','verapamil','CYP3A4','PKI-1','fourth-tier'),(441,'risperidone','verapamil','CYP3A4','PKI-1','fourth-tier'),(442,'ziprasidone','verapamil','CYP3A4','PKI-1','fourth-tier'),(443,'aripiprazole','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(444,'clozapine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(445,'iloperidone','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(446,'olanzapine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(447,'risperidone','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(448,'aripiprazole','terbinafine','CYP2D6','PKI-1','fourth-tier'),(449,'clozapine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(450,'iloperidone','terbinafine','CYP2D6','PKI-1','fourth-tier'),(451,'olanzapine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(452,'risperidone','terbinafine','CYP2D6','PKI-1','fourth-tier'),(453,'aripiprazole','telithromycin','CYP3A4','PKI-1','fourth-tier'),(454,'clozapine','telithromycin','CYP3A4','PKI-1','fourth-tier'),(455,'iloperidone','telithromycin','CYP3A4','PKI-1','fourth-tier'),(456,'risperidone','telithromycin','CYP3A4','PKI-1','fourth-tier'),(457,'ziprasidone','telithromycin','CYP3A4','PKI-1','fourth-tier'),(458,'aripiprazole','sertraline','CYP2D6','PKI-1','fourth-tier'),(459,'clozapine','sertraline','CYP2D6','PKI-1','fourth-tier'),(460,'iloperidone','sertraline','CYP2D6','PKI-1','fourth-tier'),(461,'olanzapine','sertraline','CYP2D6','PKI-1','fourth-tier'),(462,'risperidone','sertraline','CYP2D6','PKI-1','fourth-tier'),(463,'aripiprazole','ritonavir','CYP3A4','PKI-1','fourth-tier'),(464,'clozapine','ritonavir','CYP3A4','PKI-1','fourth-tier'),(465,'iloperidone','ritonavir','CYP3A4','PKI-1','fourth-tier'),(466,'risperidone','ritonavir','CYP3A4','PKI-1','fourth-tier'),(467,'ziprasidone','ritonavir','CYP3A4','PKI-1','fourth-tier'),(468,'aripiprazole','ritonavir','CYP2D6','PKI-1','fourth-tier'),(469,'clozapine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(470,'iloperidone','ritonavir','CYP2D6','PKI-1','fourth-tier'),(471,'olanzapine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(472,'risperidone','ritonavir','CYP2D6','PKI-1','fourth-tier'),(473,'aripiprazole','ranolazine','CYP3A4','PKI-1','fourth-tier'),(474,'clozapine','ranolazine','CYP3A4','PKI-1','fourth-tier'),(475,'iloperidone','ranolazine','CYP3A4','PKI-1','fourth-tier'),(476,'risperidone','ranolazine','CYP3A4','PKI-1','fourth-tier'),(477,'ziprasidone','ranolazine','CYP3A4','PKI-1','fourth-tier'),(478,'aripiprazole','ranolazine','CYP2D6','PKI-1','fourth-tier'),(479,'clozapine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(480,'iloperidone','ranolazine','CYP2D6','PKI-1','fourth-tier'),(481,'olanzapine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(482,'risperidone','ranolazine','CYP2D6','PKI-1','fourth-tier'),(483,'aripiprazole','quinidine','CYP2D6','PKI-1','fourth-tier'),(484,'clozapine','quinidine','CYP2D6','PKI-1','fourth-tier'),(485,'iloperidone','quinidine','CYP2D6','PKI-1','fourth-tier'),(486,'olanzapine','quinidine','CYP2D6','PKI-1','fourth-tier'),(487,'risperidone','quinidine','CYP2D6','PKI-1','fourth-tier'),(488,'aripiprazole','paroxetine','CYP2D6','PKI-1','fourth-tier'),(489,'clozapine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(490,'iloperidone','paroxetine','CYP2D6','PKI-1','fourth-tier'),(491,'olanzapine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(492,'risperidone','paroxetine','CYP2D6','PKI-1','fourth-tier'),(493,'aripiprazole','nefazodone','CYP3A4','PKI-1','fourth-tier'),(494,'clozapine','nefazodone','CYP3A4','PKI-1','fourth-tier'),(495,'iloperidone','nefazodone','CYP3A4','PKI-1','fourth-tier'),(496,'risperidone','nefazodone','CYP3A4','PKI-1','fourth-tier'),(497,'ziprasidone','nefazodone','CYP3A4','PKI-1','fourth-tier'),(498,'aripiprazole','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(499,'clozapine','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(500,'iloperidone','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(501,'risperidone','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(502,'ziprasidone','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(503,'aripiprazole','itraconazole','CYP3A4','PKI-1','fourth-tier'),(504,'clozapine','itraconazole','CYP3A4','PKI-1','fourth-tier'),(505,'iloperidone','itraconazole','CYP3A4','PKI-1','fourth-tier'),(506,'risperidone','itraconazole','CYP3A4','PKI-1','fourth-tier'),(507,'ziprasidone','itraconazole','CYP3A4','PKI-1','fourth-tier'),(508,'aripiprazole','indinavir','CYP3A4','PKI-1','fourth-tier'),(509,'clozapine','indinavir','CYP3A4','PKI-1','fourth-tier'),(510,'iloperidone','indinavir','CYP3A4','PKI-1','fourth-tier'),(511,'risperidone','indinavir','CYP3A4','PKI-1','fourth-tier'),(512,'ziprasidone','indinavir','CYP3A4','PKI-1','fourth-tier'),(513,'aripiprazole','iloperidone','CYP2D6','PKI-1','fourth-tier'),(514,'clozapine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(515,'olanzapine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(516,'risperidone','iloperidone','CYP2D6','PKI-1','fourth-tier'),(517,'aripiprazole','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(518,'clozapine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(519,'iloperidone','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(520,'olanzapine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(521,'risperidone','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(522,'aripiprazole','fluconazole','CYP3A4','PKI-1','fourth-tier'),(523,'clozapine','fluconazole','CYP3A4','PKI-1','fourth-tier'),(524,'iloperidone','fluconazole','CYP3A4','PKI-1','fourth-tier'),(525,'risperidone','fluconazole','CYP3A4','PKI-1','fourth-tier'),(526,'ziprasidone','fluconazole','CYP3A4','PKI-1','fourth-tier'),(527,'aripiprazole','erythromycin','CYP3A4','PKI-1','fourth-tier'),(528,'clozapine','erythromycin','CYP3A4','PKI-1','fourth-tier'),(529,'iloperidone','erythromycin','CYP3A4','PKI-1','fourth-tier'),(530,'risperidone','erythromycin','CYP3A4','PKI-1','fourth-tier'),(531,'ziprasidone','erythromycin','CYP3A4','PKI-1','fourth-tier'),(532,'aripiprazole','duloxetine','CYP2D6','PKI-1','fourth-tier'),(533,'clozapine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(534,'iloperidone','duloxetine','CYP2D6','PKI-1','fourth-tier'),(535,'olanzapine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(536,'risperidone','duloxetine','CYP2D6','PKI-1','fourth-tier'),(537,'aripiprazole','diltiazem','CYP3A4','PKI-1','fourth-tier'),(538,'clozapine','diltiazem','CYP3A4','PKI-1','fourth-tier'),(539,'iloperidone','diltiazem','CYP3A4','PKI-1','fourth-tier'),(540,'risperidone','diltiazem','CYP3A4','PKI-1','fourth-tier'),(541,'ziprasidone','diltiazem','CYP3A4','PKI-1','fourth-tier'),(542,'aripiprazole','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(543,'clozapine','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(544,'iloperidone','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(545,'risperidone','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(546,'ziprasidone','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(547,'aripiprazole','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(548,'clozapine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(549,'iloperidone','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(550,'olanzapine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(551,'risperidone','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(552,'aripiprazole','cimetidine','CYP3A4','PKI-1','fourth-tier'),(553,'clozapine','cimetidine','CYP3A4','PKI-1','fourth-tier'),(554,'iloperidone','cimetidine','CYP3A4','PKI-1','fourth-tier'),(555,'risperidone','cimetidine','CYP3A4','PKI-1','fourth-tier'),(556,'ziprasidone','cimetidine','CYP3A4','PKI-1','fourth-tier'),(557,'aripiprazole','bupropion','CYP2D6','PKI-1','fourth-tier'),(558,'clozapine','bupropion','CYP2D6','PKI-1','fourth-tier'),(559,'iloperidone','bupropion','CYP2D6','PKI-1','fourth-tier'),(560,'olanzapine','bupropion','CYP2D6','PKI-1','fourth-tier'),(561,'risperidone','bupropion','CYP2D6','PKI-1','fourth-tier'),(562,'aripiprazole','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(563,'clozapine','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(564,'iloperidone','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(565,'risperidone','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(566,'ziprasidone','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(567,'aripiprazole','atazanavir','CYP3A4','PKI-1','fourth-tier'),(568,'clozapine','atazanavir','CYP3A4','PKI-1','fourth-tier'),(569,'iloperidone','atazanavir','CYP3A4','PKI-1','fourth-tier'),(570,'risperidone','atazanavir','CYP3A4','PKI-1','fourth-tier'),(571,'ziprasidone','atazanavir','CYP3A4','PKI-1','fourth-tier'),(572,'aripiprazole','amiodarone','CYP3A4','PKI-1','fourth-tier'),(573,'clozapine','amiodarone','CYP3A4','PKI-1','fourth-tier'),(574,'iloperidone','amiodarone','CYP3A4','PKI-1','fourth-tier'),(575,'risperidone','amiodarone','CYP3A4','PKI-1','fourth-tier'),(576,'ziprasidone','amiodarone','CYP3A4','PKI-1','fourth-tier'),(577,'aripiprazole','amiodarone','CYP2D6','PKI-1','fourth-tier'),(578,'clozapine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(579,'iloperidone','amiodarone','CYP2D6','PKI-1','fourth-tier'),(580,'olanzapine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(581,'risperidone','amiodarone','CYP2D6','PKI-1','fourth-tier'),(582,'haloperidol','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(583,'perphenazine','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(584,'reduced-haloperidol','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(585,'haloperidol','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(586,'perphenazine','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(587,'reduced-haloperidol','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(588,'haloperidol','voriconazole','CYP3A4','PKI-1','fourth-tier'),(589,'perphenazine','voriconazole','CYP3A4','PKI-1','fourth-tier'),(590,'reduced-haloperidol','voriconazole','CYP3A4','PKI-1','fourth-tier'),(591,'haloperidol','verapamil','CYP3A4','PKI-1','fourth-tier'),(592,'perphenazine','verapamil','CYP3A4','PKI-1','fourth-tier'),(593,'reduced-haloperidol','verapamil','CYP3A4','PKI-1','fourth-tier'),(594,'perphenazine','verapamil','CYP1A2','PKI-1','fourth-tier'),(595,'perphenazine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(596,'thioridazine','venlafaxine','CYP2D6','PKI-1','fourth-tier'),(597,'perphenazine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(598,'thioridazine','terbinafine','CYP2D6','PKI-1','fourth-tier'),(599,'haloperidol','telithromycin','CYP3A4','PKI-1','fourth-tier'),(600,'perphenazine','telithromycin','CYP3A4','PKI-1','fourth-tier'),(601,'reduced-haloperidol','telithromycin','CYP3A4','PKI-1','fourth-tier'),(602,'perphenazine','sertraline','CYP2D6','PKI-1','fourth-tier'),(603,'thioridazine','sertraline','CYP2D6','PKI-1','fourth-tier'),(604,'haloperidol','ritonavir','CYP3A4','PKI-1','fourth-tier'),(605,'perphenazine','ritonavir','CYP3A4','PKI-1','fourth-tier'),(606,'reduced-haloperidol','ritonavir','CYP3A4','PKI-1','fourth-tier'),(607,'perphenazine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(608,'thioridazine','ritonavir','CYP2D6','PKI-1','fourth-tier'),(609,'haloperidol','ranolazine','CYP3A4','PKI-1','fourth-tier'),(610,'perphenazine','ranolazine','CYP3A4','PKI-1','fourth-tier'),(611,'reduced-haloperidol','ranolazine','CYP3A4','PKI-1','fourth-tier'),(612,'perphenazine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(613,'thioridazine','ranolazine','CYP2D6','PKI-1','fourth-tier'),(614,'perphenazine','quinidine','CYP2D6','PKI-1','fourth-tier'),(615,'thioridazine','quinidine','CYP2D6','PKI-1','fourth-tier'),(616,'perphenazine','propafenone','CYP1A2','PKI-1','fourth-tier'),(617,'perphenazine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(618,'thioridazine','paroxetine','CYP2D6','PKI-1','fourth-tier'),(619,'perphenazine','norfloxacin','CYP1A2','PKI-1','fourth-tier'),(620,'haloperidol','nefazodone','CYP3A4','PKI-1','fourth-tier'),(621,'perphenazine','nefazodone','CYP3A4','PKI-1','fourth-tier'),(622,'reduced-haloperidol','nefazodone','CYP3A4','PKI-1','fourth-tier'),(623,'perphenazine','mexiletine','CYP1A2','PKI-1','fourth-tier'),(624,'haloperidol','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(625,'perphenazine','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(626,'reduced-haloperidol','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(627,'haloperidol','itraconazole','CYP3A4','PKI-1','fourth-tier'),(628,'perphenazine','itraconazole','CYP3A4','PKI-1','fourth-tier'),(629,'reduced-haloperidol','itraconazole','CYP3A4','PKI-1','fourth-tier'),(630,'haloperidol','indinavir','CYP3A4','PKI-1','fourth-tier'),(631,'perphenazine','indinavir','CYP3A4','PKI-1','fourth-tier'),(632,'reduced-haloperidol','indinavir','CYP3A4','PKI-1','fourth-tier'),(633,'perphenazine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(634,'thioridazine','iloperidone','CYP2D6','PKI-1','fourth-tier'),(635,'perphenazine','fluvoxamine','CYP1A2','PKI-1','fourth-tier'),(636,'perphenazine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(637,'thioridazine','fluoxetine','CYP2D6','PKI-1','fourth-tier'),(638,'haloperidol','fluconazole','CYP3A4','PKI-1','fourth-tier'),(639,'perphenazine','fluconazole','CYP3A4','PKI-1','fourth-tier'),(640,'reduced-haloperidol','fluconazole','CYP3A4','PKI-1','fourth-tier'),(641,'haloperidol','erythromycin','CYP3A4','PKI-1','fourth-tier'),(642,'perphenazine','erythromycin','CYP3A4','PKI-1','fourth-tier'),(643,'reduced-haloperidol','erythromycin','CYP3A4','PKI-1','fourth-tier'),(644,'perphenazine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(645,'thioridazine','duloxetine','CYP2D6','PKI-1','fourth-tier'),(646,'haloperidol','diltiazem','CYP3A4','PKI-1','fourth-tier'),(647,'perphenazine','diltiazem','CYP3A4','PKI-1','fourth-tier'),(648,'reduced-haloperidol','diltiazem','CYP3A4','PKI-1','fourth-tier'),(649,'haloperidol','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(650,'perphenazine','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(651,'reduced-haloperidol','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(652,'perphenazine','ciprofloxacin','CYP1A2','PKI-1','fourth-tier'),(653,'perphenazine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(654,'thioridazine','cinacalcet','CYP2D6','PKI-1','fourth-tier'),(655,'haloperidol','cimetidine','CYP3A4','PKI-1','fourth-tier'),(656,'perphenazine','cimetidine','CYP3A4','PKI-1','fourth-tier'),(657,'reduced-haloperidol','cimetidine','CYP3A4','PKI-1','fourth-tier'),(658,'perphenazine','cimetidine','CYP1A2','PKI-1','fourth-tier'),(659,'perphenazine','bupropion','CYP2D6','PKI-1','fourth-tier'),(660,'thioridazine','bupropion','CYP2D6','PKI-1','fourth-tier'),(661,'haloperidol','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(662,'perphenazine','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(663,'reduced-haloperidol','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(664,'haloperidol','atazanavir','CYP3A4','PKI-1','fourth-tier'),(665,'perphenazine','atazanavir','CYP3A4','PKI-1','fourth-tier'),(666,'reduced-haloperidol','atazanavir','CYP3A4','PKI-1','fourth-tier'),(667,'haloperidol','amiodarone','CYP3A4','PKI-1','fourth-tier'),(668,'perphenazine','amiodarone','CYP3A4','PKI-1','fourth-tier'),(669,'reduced-haloperidol','amiodarone','CYP3A4','PKI-1','fourth-tier'),(670,'perphenazine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(671,'thioridazine','amiodarone','CYP2D6','PKI-1','fourth-tier'),(672,'perphenazine','amiodarone','CYP1A2','PKI-1','fourth-tier'),(673,'alprazolam','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(674,'alprazolam','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(675,'alprazolam','voriconazole','CYP3A4','PKI-1','fourth-tier'),(676,'alprazolam','verapamil','CYP3A5','PKI-1','fourth-tier'),(677,'alprazolam','verapamil','CYP3A4','PKI-1','fourth-tier'),(678,'alprazolam','telithromycin','CYP3A5','PKI-1','fourth-tier'),(679,'alprazolam','telithromycin','CYP3A4','PKI-1','fourth-tier'),(680,'alprazolam','ritonavir','CYP3A5','PKI-1','fourth-tier'),(681,'alprazolam','ritonavir','CYP3A4','PKI-1','fourth-tier'),(682,'alprazolam','ranolazine','CYP3A5','PKI-1','fourth-tier'),(683,'alprazolam','ranolazine','CYP3A4','PKI-1','fourth-tier'),(684,'alprazolam','nefazodone','CYP3A5','PKI-1','fourth-tier'),(685,'alprazolam','nefazodone','CYP3A4','PKI-1','fourth-tier'),(686,'alprazolam','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(687,'alprazolam','itraconazole','CYP3A4','PKI-1','fourth-tier'),(688,'alprazolam','indinavir','CYP3A5','PKI-1','fourth-tier'),(689,'alprazolam','indinavir','CYP3A4','PKI-1','fourth-tier'),(690,'alprazolam','fluconazole','CYP3A5','PKI-1','fourth-tier'),(691,'alprazolam','fluconazole','CYP3A4','PKI-1','fourth-tier'),(692,'alprazolam','erythromycin','CYP3A4','PKI-1','fourth-tier'),(693,'triazolam','zafirlukast','CYP3A4','PKI-1','fourth-tier'),(694,'triazolam','voriconazole-n-oxide','CYP3A4','PKI-1','fourth-tier'),(695,'triazolam','voriconazole','CYP3A4','PKI-1','fourth-tier'),(696,'triazolam','verapamil','CYP3A4','PKI-1','fourth-tier'),(697,'triazolam','telithromycin','CYP3A4','PKI-1','fourth-tier'),(698,'triazolam','ritonavir','CYP3A4','PKI-1','fourth-tier'),(699,'triazolam','ranolazine','CYP3A4','PKI-1','fourth-tier'),(700,'triazolam','nefazodone','CYP3A4','PKI-1','fourth-tier'),(701,'triazolam','ketoconazole','CYP3A4','PKI-1','fourth-tier'),(702,'triazolam','itraconazole','CYP3A4','PKI-1','fourth-tier'),(703,'triazolam','indinavir','CYP3A4','PKI-1','fourth-tier'),(704,'triazolam','fluconazole','CYP3A4','PKI-1','fourth-tier'),(705,'triazolam','erythromycin','CYP3A4','PKI-1','fourth-tier'),(706,'alprazolam','diltiazem','CYP3A4','PKI-1','fourth-tier'),(707,'triazolam','diltiazem','CYP3A4','PKI-1','fourth-tier'),(708,'alprazolam','clarithromycin','CYP3A5','PKI-1','fourth-tier'),(709,'alprazolam','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(710,'triazolam','clarithromycin','CYP3A4','PKI-1','fourth-tier'),(711,'alprazolam','cimetidine','CYP3A5','PKI-1','fourth-tier'),(712,'alprazolam','cimetidine','CYP3A4','PKI-1','fourth-tier'),(713,'triazolam','cimetidine','CYP3A4','PKI-1','fourth-tier'),(714,'alprazolam','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(715,'triazolam','atorvastatin','CYP3A4','PKI-1','fourth-tier'),(716,'alprazolam','atazanavir','CYP3A5','PKI-1','fourth-tier'),(717,'alprazolam','atazanavir','CYP3A4','PKI-1','fourth-tier'),(718,'triazolam','atazanavir','CYP3A4','PKI-1','fourth-tier'),(719,'alprazolam','amiodarone','CYP3A4','PKI-1','fourth-tier'),(720,'triazolam','amiodarone','CYP3A4','PKI-1','fourth-tier');
/*!40000 ALTER TABLE `DDIPredictions` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `Drugs`
--

DROP TABLE IF EXISTS `Drugs`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `Drugs` (
  `id` int(11) NOT NULL,
  `_name` varchar(100) DEFAULT NULL,
  `prodrug` tinyint(1) DEFAULT NULL,
  `primary_total_clearance_mechanism` int(11) DEFAULT NULL,
  `primary_metabolic_clearance_enzyme` int(11) DEFAULT NULL,
  `primary_total_clearance_enzyme` int(11) DEFAULT NULL,
  `in_vitro_probe_substrate_of_enzyme` int(11) DEFAULT NULL,
  `in_viVo_probe_substrate_of_enzyme` int(11) DEFAULT NULL,
  `in_vitro_selective_inhibitor_of_enzyme` int(11) DEFAULT NULL,
  `in_viVo_selective_inhibitor_of_enzyme` int(11) DEFAULT NULL,
  `pceut_entity_of_concern` int(11) DEFAULT NULL,
  `active_ingredient_name` varchar(100) DEFAULT NULL,
  `active_ingredient` tinyint(1) DEFAULT NULL,
  `maximum_concentration` int(11) DEFAULT NULL,
  `minimum_therapeutic_dose` int(11) DEFAULT NULL,
  `maximum_therapeutic_dose` int(11) DEFAULT NULL,
  `assumed_effective_dose` int(11) DEFAULT NULL,
  `substrate_of` int(11) DEFAULT NULL,
  `is_not_substrate_of` int(11) DEFAULT NULL,
  `inhibits` int(11) DEFAULT NULL,
  `does_not_inhibit` int(11) DEFAULT NULL,
  `has_metabolite` int(11) DEFAULT NULL,
  `permanently_deactivates_catalytic_function` int(11) DEFAULT NULL,
  `does_not_permanently_deactivate_catalytic_function` int(11) DEFAULT NULL,
  `inhibition_constant` int(11) DEFAULT NULL,
  `induces` int(11) DEFAULT NULL,
  `increases_auc` int(11) DEFAULT NULL,
  `sole_PK_effect_alter_metabolic_clearance` int(11) DEFAULT NULL,
  `bioavailability` int(11) DEFAULT NULL,
  `fraction_absorbed` int(11) DEFAULT NULL,
  `fraction_cleared_by` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `Drugs`
--

LOCK TABLES `Drugs` WRITE;
/*!40000 ALTER TABLE `Drugs` DISABLE KEYS */;
INSERT INTO `Drugs` VALUES (1,'escitalopram',0,1,2,3,4,5,6,7,8,'escitalopram',1,9,NULL,NULL,NULL,10,11,12,13,14,NULL,NULL,NULL,NULL,NULL,NULL,15,NULL,NULL),(2,'sertraline',0,16,17,18,19,20,21,22,23,'sertraline',1,NULL,NULL,NULL,NULL,24,25,26,27,28,NULL,NULL,NULL,NULL,29,NULL,NULL,NULL,NULL),(3,'tamoxifen',0,30,31,32,33,34,35,36,37,'tamoxifen',1,NULL,NULL,NULL,NULL,38,39,NULL,NULL,40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(4,'saquinavir',0,51,52,53,54,55,56,57,58,'saquinavir',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(5,'delavirdine',0,59,60,61,62,63,64,65,66,'delavirdine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(6,'troleandomycin',0,67,68,69,70,71,72,73,74,'troleandomycin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(7,'modafinil',0,83,84,85,86,87,88,89,90,'modafinil',1,NULL,NULL,NULL,NULL,91,92,93,94,95,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(8,'alprazolam',0,137,138,139,140,141,142,143,144,'alprazolam',1,145,NULL,NULL,NULL,146,147,NULL,NULL,148,NULL,NULL,NULL,NULL,149,NULL,150,NULL,NULL),(9,'thiotepa',0,151,152,153,154,155,156,157,158,'thiotepa',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(10,'zaleplon',0,159,160,161,162,163,164,165,166,'zaleplon',1,NULL,NULL,NULL,NULL,167,168,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,169,NULL,NULL),(11,'trimethoprim',0,170,171,172,173,174,175,176,177,'trimethoprim',1,NULL,178,179,NULL,NULL,NULL,180,181,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(12,'midazolam',0,182,183,184,185,186,187,188,189,'midazolam',1,NULL,NULL,NULL,NULL,190,191,NULL,NULL,192,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(13,'pantoprazole',0,209,210,211,212,213,214,215,216,'pantoprazole',1,217,218,219,NULL,220,221,222,223,NULL,NULL,NULL,NULL,NULL,NULL,NULL,224,NULL,NULL),(14,'S-warfarin',0,225,226,227,228,229,230,231,232,'S-warfarin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(15,'rosuvastatin',0,241,242,243,244,245,246,247,248,'rosuvastatin',1,249,NULL,NULL,NULL,250,251,252,253,254,NULL,NULL,NULL,NULL,NULL,NULL,255,256,NULL),(16,'capecitabine',0,257,258,259,260,261,262,263,264,'capecitabine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(17,'quinupristin',0,265,266,267,268,269,270,271,272,'quinupristin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(18,'fluorouracil',0,281,282,283,284,285,286,287,288,'fluorouracil',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(19,'fluoxetine',0,289,290,291,292,293,294,295,296,'fluoxetine',1,297,NULL,NULL,NULL,298,299,300,301,302,303,NULL,304,NULL,305,NULL,NULL,NULL,NULL),(20,'diphenhydramine',0,314,315,316,317,318,319,320,321,'diphenhydramine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,322,NULL,NULL,NULL,NULL),(21,'methoxsalen',0,323,324,325,326,327,328,329,330,'methoxsalen',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(22,'quetiapine',0,331,332,333,334,335,336,337,338,'quetiapine',1,NULL,NULL,NULL,NULL,339,340,341,342,343,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(23,'zafirlukast',0,344,345,346,347,348,349,350,351,'zafirlukast',1,352,353,354,NULL,355,356,357,358,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(24,'mephenytoin',0,359,360,361,362,363,364,365,366,'mephenytoin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(25,'tacrine',0,386,387,388,389,390,391,392,393,'tacrine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(26,'clotrimazole',0,413,414,415,416,417,418,419,420,'clotrimazole',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(27,'norfloxacin',0,421,422,423,424,425,426,427,428,'norfloxacin',1,NULL,NULL,NULL,NULL,NULL,NULL,429,430,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(28,'paclitaxel',0,431,432,433,434,435,436,437,438,'paclitaxel',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,439,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(29,'atomoxetine',0,440,441,442,443,444,445,446,447,'atomoxetine',1,NULL,NULL,NULL,NULL,NULL,NULL,448,449,450,NULL,NULL,NULL,NULL,NULL,NULL,451,NULL,NULL),(30,'cyclosporine',0,452,453,454,455,456,457,458,459,'cyclosporine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(31,'oxcarbazepine',0,468,469,470,471,472,473,474,475,'oxcarbazepine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(32,'voriconazole',0,476,477,478,479,480,481,482,483,'voriconazole',1,484,485,486,NULL,487,488,489,490,491,NULL,NULL,NULL,NULL,NULL,NULL,492,NULL,NULL),(33,'erythromycin',0,509,510,511,512,513,514,515,516,'erythromycin',1,NULL,NULL,NULL,NULL,NULL,NULL,517,518,NULL,NULL,519,520,NULL,521,NULL,NULL,NULL,NULL),(34,'midodrine',1,522,523,524,525,526,527,528,529,'midodrine',1,NULL,530,531,NULL,NULL,NULL,NULL,NULL,532,NULL,NULL,NULL,NULL,NULL,NULL,533,NULL,NULL),(35,'warfarin',0,542,543,544,545,546,547,548,549,'warfarin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(36,'prasugrel',0,550,551,552,553,554,555,556,557,'prasugrel',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(37,'R-citalopram',0,558,559,560,561,562,563,564,565,'R-citalopram',1,566,NULL,NULL,NULL,567,568,569,570,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(38,'dextromethorphan',0,587,588,589,590,591,592,593,594,'dextromethorphan',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(39,'sildenafil',0,608,609,610,611,612,613,614,615,'sildenafil',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(40,'imatinib',0,639,640,641,642,643,644,645,646,'imatinib',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(41,'ibuprofen',0,656,657,658,659,660,661,662,663,'ibuprofen',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(42,'thioridazine',0,664,665,666,667,668,669,670,671,'thioridazine',1,NULL,NULL,NULL,NULL,672,673,674,675,676,NULL,NULL,677,NULL,NULL,NULL,NULL,NULL,NULL),(43,'trifluoperazine',0,678,679,680,681,682,683,684,685,'trifluoperazine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(44,'paliperidone',0,686,687,688,689,690,691,692,693,'paliperidone',1,NULL,NULL,NULL,NULL,NULL,NULL,694,695,NULL,NULL,NULL,696,NULL,NULL,NULL,697,NULL,NULL),(45,'clozapine',0,698,699,700,701,702,703,704,705,'clozapine',1,706,NULL,NULL,NULL,707,708,709,710,711,NULL,NULL,712,NULL,NULL,NULL,NULL,NULL,NULL),(46,'ticlopidine',0,713,714,715,716,717,718,719,720,'ticlopidine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,721,NULL,NULL,NULL,NULL,NULL,NULL),(47,'nilotinib',0,730,731,732,733,734,735,736,737,'nilotinib',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(48,'triazolam',0,738,739,740,741,742,743,744,745,'triazolam',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,746,NULL,NULL,NULL,NULL),(49,'pravastatin',0,747,748,749,750,751,752,753,754,'pravastatin',1,NULL,NULL,NULL,NULL,NULL,NULL,755,756,757,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(50,'caffeine',0,758,759,760,761,762,763,764,765,'caffeine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(51,'asenapine',0,778,779,780,781,782,783,784,785,'asenapine',1,786,NULL,NULL,NULL,787,788,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(52,'omeprazole',0,797,798,799,800,801,802,803,804,'omeprazole',1,NULL,NULL,NULL,NULL,NULL,NULL,805,806,NULL,NULL,NULL,NULL,NULL,807,NULL,NULL,NULL,NULL),(53,'leflunomide',1,808,809,810,811,812,813,814,815,'leflunomide',1,NULL,816,817,NULL,NULL,NULL,NULL,NULL,818,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(54,'itraconazole',0,819,820,821,822,823,824,825,826,'itraconazole',1,NULL,NULL,NULL,NULL,NULL,NULL,827,828,NULL,NULL,NULL,829,NULL,830,831,NULL,NULL,NULL),(55,'trazodone',0,832,833,834,835,836,837,838,839,'trazodone',1,840,NULL,NULL,NULL,841,842,NULL,NULL,843,NULL,NULL,NULL,NULL,NULL,NULL,844,NULL,NULL),(56,'eszopiclone',0,864,865,866,867,868,869,870,871,'eszopiclone',1,NULL,NULL,NULL,NULL,872,873,874,875,876,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(57,'diltiazem',0,893,894,895,896,897,898,899,900,'diltiazem',1,901,NULL,NULL,NULL,902,903,904,905,906,907,NULL,908,NULL,909,NULL,910,NULL,NULL),(58,'R-warfarin',0,919,920,921,922,923,924,925,926,'R-warfarin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(59,'nelfinavir',0,927,928,929,930,931,932,933,934,'nelfinavir',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(60,'terbinafine',0,935,936,937,938,939,940,941,942,'terbinafine',1,NULL,NULL,NULL,NULL,NULL,NULL,943,944,NULL,NULL,NULL,NULL,NULL,945,NULL,NULL,NULL,NULL),(61,'mifepristone',0,946,947,948,949,950,951,952,953,'mifepristone',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(62,'topiramate',0,954,955,956,957,958,959,960,961,'topiramate',1,NULL,962,963,NULL,NULL,NULL,964,965,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(63,'ethanol',0,966,967,968,969,970,971,972,973,'ethanol',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(64,'venlafaxine',0,974,975,976,977,978,979,980,981,'venlafaxine',1,982,NULL,NULL,NULL,983,984,985,986,987,NULL,NULL,NULL,NULL,988,NULL,NULL,989,NULL),(65,'sulfamethoxazole',0,990,991,992,993,994,995,996,997,'sulfamethoxazole',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(66,'miconazole',0,998,999,1000,1001,1002,1003,1004,1005,'miconazole',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(67,'droperidol',0,1006,1007,1008,1009,1010,1011,1012,1013,'droperidol',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(68,'propoxyphene',0,1014,1015,1016,1017,1018,1019,1020,1021,'propoxyphene',1,NULL,1022,1023,NULL,NULL,NULL,NULL,NULL,1024,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(69,'testosterone',0,1033,1034,1035,1036,1037,1038,1039,1040,'testosterone',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(70,'telithromycin',0,1041,1042,1043,1044,1045,1046,1047,1048,'telithromycin',1,NULL,NULL,NULL,NULL,NULL,NULL,1049,1050,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(71,'ziprasidone',0,1051,1052,1053,1054,1055,1056,1057,1058,'ziprasidone',1,1059,NULL,NULL,NULL,1060,1061,1062,1063,1064,NULL,NULL,1065,NULL,NULL,NULL,NULL,NULL,NULL),(72,'posaconazole',0,1066,1067,1068,1069,1070,1071,1072,1073,'posaconazole',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(73,'efavirenz',0,1083,1084,1085,1086,1087,1088,1089,1090,'efavirenz',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(74,'duloxetine',0,1122,1123,1124,1125,1126,1127,1128,1129,'duloxetine',1,NULL,NULL,NULL,NULL,1130,1131,1132,1133,NULL,NULL,NULL,NULL,NULL,1134,NULL,NULL,NULL,NULL),(75,'thiothixene',0,1135,1136,1137,1138,1139,1140,1141,1142,'thiothixene',1,NULL,NULL,NULL,NULL,NULL,NULL,1143,1144,NULL,NULL,NULL,1145,NULL,NULL,NULL,NULL,NULL,NULL),(76,'atazanavir',0,1156,1157,1158,1159,1160,1161,1162,1163,'atazanavir',1,NULL,NULL,NULL,NULL,NULL,NULL,1164,1165,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(77,'basiliximab',0,1166,1167,1168,1169,1170,1171,1172,1173,'basiliximab',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(78,'quinidine',0,1174,1175,1176,1177,1178,1179,1180,1181,'quinidine',1,NULL,NULL,NULL,NULL,NULL,NULL,1182,1183,NULL,1184,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(79,'sulfinpyrazone',0,1185,1186,1187,1188,1189,1190,1191,1192,'sulfinpyrazone',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(80,'montelukast',0,1193,1194,1195,1196,1197,1198,1199,1200,'montelukast',1,NULL,NULL,NULL,NULL,NULL,NULL,1201,1202,NULL,NULL,NULL,1203,NULL,NULL,NULL,NULL,NULL,NULL),(81,'nicardipine',0,1204,1205,1206,1207,1208,1209,1210,1211,'nicardipine',1,NULL,1212,1213,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1214,NULL,NULL),(82,'quinine',0,1215,1216,1217,1218,1219,1220,1221,1222,'quinine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(83,'chlorpheniramine',0,1223,1224,1225,1226,1227,1228,1229,1230,'chlorpheniramine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(84,'phenacetin',0,1231,1232,1233,1234,1235,1236,1237,1238,'phenacetin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(85,'rosiglitazone',0,1239,1240,1241,1242,1243,1244,1245,1246,'rosiglitazone',1,NULL,NULL,NULL,NULL,NULL,NULL,1247,1248,NULL,NULL,NULL,1249,NULL,NULL,NULL,NULL,NULL,NULL),(86,'aprepitant',0,1250,1251,1252,1253,1254,1255,1256,1257,'aprepitant',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(87,'disulfiram',0,1258,1259,1260,1261,1262,1263,1264,1265,'disulfiram',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(88,'rabeprazole',0,1274,1275,1276,1277,1278,1279,1280,1281,'rabeprazole',1,NULL,NULL,NULL,NULL,1282,1283,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1284,NULL,NULL),(89,'clomipramine',0,1285,1286,1287,1288,1289,1290,1291,1292,'clomipramine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(90,'ciprofloxacin',0,1293,1294,1295,1296,1297,1298,1299,1300,'ciprofloxacin',1,NULL,NULL,NULL,NULL,NULL,NULL,1301,1302,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(91,'fluvoxamine',0,1311,1312,1313,1314,1315,1316,1317,1318,'fluvoxamine',1,NULL,NULL,NULL,NULL,1319,1320,1321,1322,NULL,NULL,NULL,1323,NULL,1324,NULL,1325,NULL,NULL),(92,'atorvastatin',0,1334,1335,1336,1337,1338,1339,1340,1341,'atorvastatin',1,1342,1343,1344,NULL,1345,1346,1347,1348,1349,NULL,1350,1351,NULL,NULL,NULL,1352,NULL,NULL),(93,'sulphaphenazole',0,1353,1354,1355,1356,1357,1358,1359,1360,'sulphaphenazole',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(94,'flecainide',0,1361,1362,1363,1364,1365,1366,1367,1368,'flecainide',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(95,'alosetron',0,1369,1370,1371,1372,1373,1374,1375,1376,'alosetron',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(96,'zolpidem',0,1377,1378,1379,1380,1381,1382,1383,1384,'zolpidem',1,1385,NULL,NULL,NULL,1386,1387,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(97,'ketoconazole',0,1388,1389,1390,1391,1392,1393,1394,1395,'ketoconazole',1,1396,NULL,NULL,NULL,NULL,NULL,1397,1398,NULL,NULL,NULL,1399,NULL,1400,NULL,NULL,NULL,NULL),(98,'sulfamethizole',0,1401,1402,1403,1404,1405,1406,1407,1408,'sulfamethizole',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(99,'gemfibrozil',0,1409,1410,1411,1412,1413,1414,1415,1416,'gemfibrozil',1,NULL,NULL,NULL,NULL,NULL,NULL,1417,1418,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(100,'mexiletine',0,1419,1420,1421,1422,1423,1424,1425,1426,'mexiletine',1,NULL,NULL,NULL,NULL,NULL,NULL,1427,1428,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(101,'phenytoin',0,1437,1438,1439,1440,1441,1442,1443,1444,'phenytoin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(102,'chloroquine',0,1445,1446,1447,1448,1449,1450,1451,1452,'chloroquine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(103,'chlorpromazine',0,1453,1454,1455,1456,1457,1458,1459,1460,'chlorpromazine',1,1461,NULL,NULL,NULL,NULL,NULL,1462,1463,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1464,NULL,NULL),(104,'pimozide',0,1465,1466,1467,1468,1469,1470,1471,1472,'pimozide',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(105,'risperidone',0,1481,1482,1483,1484,1485,1486,1487,1488,'risperidone',1,1489,NULL,NULL,NULL,1490,1491,1492,1493,1494,NULL,NULL,1495,NULL,1496,NULL,1497,NULL,NULL),(106,'chloramphenicol',0,1506,1507,1508,1509,1510,1511,1512,1513,'chloramphenicol',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(107,'metronidazole',0,1514,1515,1516,1517,1518,1519,1520,1521,'metronidazole',1,1522,1523,1524,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(108,'desipramine',0,1525,1526,1527,1528,1529,1530,1531,1532,'desipramine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(109,'indinavir',0,1563,1564,1565,1566,1567,1568,1569,1570,'indinavir',1,NULL,NULL,NULL,NULL,NULL,NULL,1571,1572,NULL,NULL,NULL,NULL,NULL,1573,NULL,NULL,NULL,NULL),(110,'felbamate',0,1574,1575,1576,1577,1578,1579,1580,1581,'felbamate',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(111,'fosamprenavir',0,1591,1592,1593,1594,1595,1596,1597,1598,'fosamprenavir',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(112,'fluphenazine',0,1608,1609,1610,1611,1612,1613,1614,1615,'fluphenazine',1,1616,NULL,NULL,NULL,NULL,NULL,1617,1618,NULL,NULL,NULL,1619,NULL,NULL,NULL,1620,NULL,NULL),(113,'ranolazine',0,1621,1622,1623,1624,1625,1626,1627,1628,'ranolazine',1,1629,1630,1631,NULL,1632,1633,1634,1635,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(114,'lapatinib',0,1644,1645,1646,1647,1648,1649,1650,1651,'lapatinib',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(115,'doxorubicin',0,1685,1686,1687,1688,1689,1690,1691,1692,'doxorubicin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(116,'desloratadine',0,1693,1694,1695,1696,1697,1698,1699,1700,'desloratadine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(117,'aripiprazole',0,1709,1710,1711,1712,1713,1714,1715,1716,'aripiprazole',1,1717,NULL,NULL,NULL,1718,1719,1720,1721,1722,NULL,NULL,NULL,NULL,1723,NULL,1724,NULL,NULL),(118,'chlorzoxazone',0,1733,1734,1735,1736,1737,1738,1739,1740,'chlorzoxazone',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(119,'mirtazapine',0,1750,1751,1752,1753,1754,1755,1756,1757,'mirtazapine',1,NULL,NULL,NULL,NULL,1758,1759,1760,1761,NULL,NULL,NULL,NULL,NULL,1762,NULL,1763,1764,NULL),(120,'paroxetine',0,1765,1766,1767,1768,1769,1770,1771,1772,'paroxetine',1,NULL,NULL,NULL,NULL,1773,1774,1775,1776,NULL,1777,NULL,NULL,NULL,1778,NULL,NULL,NULL,NULL),(121,'haloperidol',0,1779,1780,1781,1782,1783,1784,1785,1786,'haloperidol',1,NULL,NULL,NULL,NULL,1787,1788,1789,1790,1791,NULL,NULL,1792,NULL,1793,NULL,NULL,NULL,NULL),(122,'debrisoquine',0,1794,1795,1796,1797,1798,1799,1800,1801,'debrisoquine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(123,'theophylline',0,1802,1803,1804,1805,1806,1807,1808,1809,'theophylline',1,NULL,1810,1811,NULL,NULL,NULL,NULL,NULL,1812,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(124,'fluconazole',0,1813,1814,1815,1816,1817,1818,1819,1820,'fluconazole',1,1821,NULL,NULL,NULL,NULL,NULL,1822,1823,NULL,NULL,NULL,1824,NULL,1825,NULL,1826,NULL,NULL),(125,'dasatinib',0,1837,1838,1839,1840,1841,1842,1843,1844,'dasatinib',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(126,'promethazine',0,1845,1846,1847,1848,1849,1850,1851,1852,'promethazine',1,NULL,1853,1854,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(127,'cimetidine',0,1872,1873,1874,1875,1876,1877,1878,1879,'cimetidine',1,NULL,NULL,NULL,NULL,NULL,NULL,1880,1881,NULL,NULL,NULL,NULL,NULL,1882,NULL,NULL,NULL,NULL),(128,'cinacalcet',0,1895,1896,1897,1898,1899,1900,1901,1902,'cinacalcet',1,NULL,NULL,NULL,NULL,1903,1904,1905,1906,1907,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(129,'nefazodone',0,1908,1909,1910,1911,1912,1913,1914,1915,'nefazodone',1,NULL,NULL,NULL,NULL,1916,1917,1918,1919,NULL,NULL,NULL,NULL,NULL,1920,NULL,NULL,NULL,NULL),(130,'zileuton',0,1921,1922,1923,1924,1925,1926,1927,1928,'zileuton',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(131,'pioglitazone',0,1929,1930,1931,1932,1933,1934,1935,1936,'pioglitazone',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1937,NULL,NULL,NULL,NULL,NULL,NULL),(132,'isoniazid',0,1938,1939,1940,1941,1942,1943,1944,1945,'isoniazid',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(133,'molindone',0,1946,1947,1948,1949,1950,1951,1952,1953,'molindone',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(134,'lansoprazole',0,1954,1955,1956,1957,1958,1959,1960,1961,'lansoprazole',1,1962,1963,1964,NULL,1965,1966,1967,1968,NULL,NULL,NULL,NULL,NULL,1969,NULL,1970,NULL,NULL),(135,'oxycarbazepine',0,1980,1981,1982,1983,1984,1985,1986,1987,'oxycarbazepine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(136,'citalopram',0,1988,1989,1990,1991,1992,1993,1994,1995,'citalopram',1,NULL,NULL,NULL,NULL,1996,1997,1998,1999,2000,NULL,NULL,NULL,NULL,2001,NULL,2002,NULL,NULL),(137,'simvastatin',1,2036,2037,2038,2039,2040,2041,2042,2043,'simvastatin',1,NULL,NULL,NULL,NULL,2044,2045,2046,2047,2048,NULL,2049,2050,NULL,NULL,NULL,NULL,NULL,NULL),(138,'lithium',0,2051,2052,2053,2054,2055,2056,2057,2058,'lithium',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(139,'teniposide',0,2059,2060,2061,2062,2063,2064,2065,2066,'teniposide',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(140,'thiabendazole',0,2067,2068,2069,2070,2071,2072,2073,2074,'thiabendazole',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(141,'ritonavir',0,2075,2076,2077,2078,2079,2080,2081,2082,'ritonavir',1,NULL,NULL,NULL,NULL,NULL,NULL,2083,2084,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(142,'fluvastatin',0,2085,2086,2087,2088,2089,2090,2091,2092,'fluvastatin',1,2093,2094,2095,NULL,2096,2097,NULL,NULL,NULL,NULL,2098,2099,NULL,NULL,NULL,2100,NULL,NULL),(143,'amprenavir',0,2109,2110,2111,2112,2113,2114,2115,2116,'amprenavir',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(144,'verapamil',0,2117,2118,2119,2120,2121,2122,2123,2124,'verapamil',1,NULL,NULL,NULL,NULL,NULL,NULL,2125,2126,NULL,NULL,NULL,NULL,NULL,2127,NULL,NULL,NULL,NULL),(145,'tolbutamide',0,2128,2129,2130,2131,2132,2133,2134,2135,'tolbutamide',1,NULL,2136,2137,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(146,'valproate',0,2146,2147,2148,2149,2150,2151,2152,2153,'valproate',1,NULL,2154,2155,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,2156,NULL,NULL,NULL,NULL),(147,'amiodarone',0,2157,2158,2159,2160,2161,2162,2163,2164,'amiodarone',1,NULL,NULL,NULL,NULL,NULL,NULL,2165,2166,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(148,'hydroxychloroquine',0,2198,2199,2200,2201,2202,2203,2204,2205,'hydroxychloroquine',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(149,'iloperidone',0,2214,2215,2216,2217,2218,2219,2220,2221,'iloperidone',1,NULL,NULL,NULL,NULL,2222,2223,2224,2225,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(150,'cotrimoxazole',0,2226,2227,2228,2229,2230,2231,2232,2233,'cotrimoxazole',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(151,'propafenone',0,2234,2235,2236,2237,2238,2239,2240,2241,'propafenone',1,NULL,NULL,NULL,NULL,NULL,NULL,2242,2243,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(152,'olanzapine',0,2244,2245,2246,2247,2248,2249,2250,2251,'olanzapine',1,2252,NULL,NULL,NULL,2253,2254,NULL,NULL,2255,NULL,NULL,2256,NULL,NULL,NULL,NULL,NULL,NULL),(153,'lovastatin',0,2257,2258,2259,2260,2261,2262,2263,2264,'lovastatin',1,2265,NULL,NULL,NULL,2266,2267,NULL,NULL,2268,NULL,2269,2270,NULL,NULL,NULL,2271,NULL,NULL),(154,'danazol',0,2280,2281,2282,2283,2284,2285,2286,2287,'danazol',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(155,'clarithromycin',0,2288,2289,2290,2291,2292,2293,2294,2295,'clarithromycin',1,2296,NULL,NULL,NULL,2297,2298,2299,2300,2301,NULL,2302,2303,NULL,2304,NULL,2305,2306,NULL),(156,'desvenlafaxine',0,2325,2326,2327,2328,2329,2330,2331,2332,'desvenlafaxine',1,NULL,NULL,NULL,NULL,2333,2334,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(157,'methadone',0,2335,2336,2337,2338,2339,2340,2341,2342,'methadone',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(158,'perphenazine',0,2343,2344,2345,2346,2347,2348,2349,2350,'perphenazine',1,2351,NULL,NULL,NULL,2352,2353,2354,2355,2356,NULL,NULL,2357,NULL,NULL,NULL,NULL,NULL,NULL),(159,'bupropion',0,2358,2359,2360,2361,2362,2363,2364,2365,'bupropion',1,2366,NULL,NULL,NULL,2367,2368,2369,2370,2371,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(160,'indomethacin',0,2372,2373,2374,2375,2376,2377,2378,2379,'indomethacin',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,2380,NULL,NULL),(161,'clopidogrel',0,2381,2382,2383,2384,2385,2386,2387,2388,'clopidogrel',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,2389,NULL,2390,NULL,NULL,NULL,NULL),(162,'celecoxib',0,2391,2392,2393,2394,2395,2396,2397,2398,'celecoxib',1,2399,2400,2401,NULL,2402,2403,2404,2405,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL);
/*!40000 ALTER TABLE `Drugs` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `EMultiSlot`
--

DROP TABLE IF EXISTS `EMultiSlot`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `EMultiSlot` (
  `id` int(11) NOT NULL,
  `range_id` int(11) DEFAULT NULL,
  `type` varchar(100) DEFAULT NULL,
  `value_id` int(11) DEFAULT NULL,
  `d_slot_id` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `EMultiSlot`
--

LOCK TABLES `EMultiSlot` WRITE;
/*!40000 ALTER TABLE `EMultiSlot` DISABLE KEYS */;
INSERT INTO `EMultiSlot` VALUES (1,NULL,'EMultiContValSlot',1,9),(2,NULL,'EMultiSlot',2,10),(3,NULL,'EMultiSlot',NULL,11),(4,NULL,'EMultiSlot',NULL,12),(5,NULL,'EMultiSlot',5,13),(6,NULL,'EMultiSlot',6,14),(7,NULL,'EMultiContValSlot',7,15),(8,NULL,'EMultiSlot',8,24),(9,NULL,'EMultiSlot',NULL,25),(10,NULL,'EMultiSlot',10,26),(11,NULL,'EMultiSlot',NULL,27),(12,NULL,'EMultiSlot',12,28),(13,NULL,'EMultiContValSlot',13,29),(14,NULL,'EMultiSlot',14,38),(15,NULL,'EMultiSlot',NULL,39),(16,NULL,'EMultiSlot',16,40),(17,NULL,'EMultiSlot',17,49),(18,NULL,'EMultiSlot',NULL,50),(19,NULL,'EMultiSlot',19,91),(20,NULL,'EMultiSlot',NULL,92),(21,NULL,'EMultiSlot',21,93),(22,NULL,'EMultiSlot',NULL,94),(23,NULL,'EMultiSlot',23,95),(24,NULL,'EMultiContValSlot',24,136),(25,NULL,'EMultiContValSlot',25,145),(26,NULL,'EMultiSlot',26,146),(27,NULL,'EMultiSlot',27,147),(28,NULL,'EMultiSlot',28,148),(29,NULL,'EMultiContValSlot',NULL,149),(30,NULL,'EMultiContValSlot',30,150),(31,NULL,'EMultiSlot',31,167),(32,NULL,'EMultiSlot',32,168),(33,NULL,'EMultiContValSlot',33,169),(34,NULL,'EMultiContValSlot',34,178),(35,NULL,'EMultiContValSlot',35,179),(36,NULL,'EMultiSlot',36,180),(37,NULL,'EMultiSlot',NULL,181),(38,NULL,'EMultiSlot',NULL,190),(39,NULL,'EMultiSlot',NULL,191),(40,NULL,'EMultiSlot',NULL,192),(41,NULL,'EMultiContValSlot',41,217),(42,NULL,'EMultiContValSlot',42,218),(43,NULL,'EMultiContValSlot',43,219),(44,NULL,'EMultiSlot',44,220),(45,NULL,'EMultiSlot',NULL,221),(46,NULL,'EMultiSlot',NULL,222),(47,NULL,'EMultiSlot',47,223),(48,NULL,'EMultiContValSlot',48,224),(49,NULL,'EMultiContValSlot',49,249),(50,NULL,'EMultiSlot',NULL,250),(51,NULL,'EMultiSlot',51,251),(52,NULL,'EMultiSlot',NULL,252),(53,NULL,'EMultiSlot',53,253),(54,NULL,'EMultiSlot',54,254),(55,NULL,'EMultiContValSlot',55,255),(56,NULL,'EMultiContValSlot',56,256),(57,NULL,'EMultiContValSlot',57,297),(58,NULL,'EMultiSlot',58,298),(59,NULL,'EMultiSlot',NULL,299),(60,NULL,'EMultiSlot',60,300),(61,NULL,'EMultiSlot',NULL,301),(62,NULL,'EMultiSlot',62,302),(63,NULL,'EMultiSlot',NULL,303),(64,NULL,'EMultiContValSlot',64,304),(65,NULL,'EMultiContValSlot',65,305),(66,NULL,'EMultiContValSlot',66,322),(67,NULL,'EMultiSlot',67,339),(68,NULL,'EMultiSlot',NULL,340),(69,NULL,'EMultiSlot',NULL,341),(70,NULL,'EMultiSlot',70,342),(71,NULL,'EMultiSlot',71,343),(72,NULL,'EMultiContValSlot',72,352),(73,NULL,'EMultiContValSlot',73,353),(74,NULL,'EMultiContValSlot',74,354),(75,NULL,'EMultiSlot',75,355),(76,NULL,'EMultiSlot',NULL,356),(77,NULL,'EMultiSlot',77,357),(78,NULL,'EMultiSlot',NULL,358),(79,NULL,'EMultiContValSlot',79,375),(80,NULL,'EMultiSlot',80,384),(81,NULL,'EMultiSlot',NULL,385),(82,NULL,'EMultiSlot',82,410),(83,NULL,'EMultiSlot',NULL,411),(84,NULL,'EMultiSlot',NULL,412),(85,NULL,'EMultiSlot',85,429),(86,NULL,'EMultiSlot',NULL,430),(87,NULL,'EMultiSlot',NULL,439),(88,NULL,'EMultiSlot',NULL,448),(89,NULL,'EMultiSlot',89,449),(90,NULL,'EMultiSlot',90,450),(91,NULL,'EMultiContValSlot',91,451),(92,NULL,'EMultiContValSlot',92,484),(93,NULL,'EMultiContValSlot',93,485),(94,NULL,'EMultiContValSlot',94,486),(95,NULL,'EMultiSlot',95,487),(96,NULL,'EMultiSlot',NULL,488),(97,NULL,'EMultiSlot',97,489),(98,NULL,'EMultiSlot',NULL,490),(99,NULL,'EMultiSlot',99,491),(100,NULL,'EMultiContValSlot',100,492),(101,NULL,'EMultiSlot',101,517),(102,NULL,'EMultiSlot',NULL,518),(103,NULL,'EMultiSlot',103,519),(104,NULL,'EMultiContValSlot',104,520),(105,NULL,'EMultiContValSlot',105,521),(106,NULL,'EMultiContValSlot',106,530),(107,NULL,'EMultiContValSlot',107,531),(108,NULL,'EMultiSlot',108,532),(109,NULL,'EMultiContValSlot',109,533),(110,NULL,'EMultiContValSlot',NULL,566),(111,NULL,'EMultiSlot',111,567),(112,NULL,'EMultiSlot',NULL,568),(113,NULL,'EMultiSlot',NULL,569),(114,NULL,'EMultiSlot',114,570),(115,NULL,'EMultiContValSlot',115,603),(116,NULL,'EMultiSlot',116,604),(117,NULL,'EMultiSlot',NULL,605),(118,NULL,'EMultiSlot',NULL,606),(119,NULL,'EMultiSlot',119,607),(120,NULL,'EMultiSlot',120,632),(121,NULL,'EMultiSlot',NULL,633),(122,NULL,'EMultiSlot',NULL,634),(123,NULL,'EMultiSlot',123,635),(124,NULL,'EMultiSlot',124,636),(125,NULL,'EMultiSlot',125,637),(126,NULL,'EMultiContValSlot',126,638),(127,NULL,'EMultiContValSlot',NULL,655),(128,NULL,'EMultiSlot',128,672),(129,NULL,'EMultiSlot',NULL,673),(130,NULL,'EMultiSlot',NULL,674),(131,NULL,'EMultiSlot',131,675),(132,NULL,'EMultiSlot',132,676),(133,NULL,'EMultiContValSlot',133,677),(134,NULL,'EMultiSlot',NULL,694),(135,NULL,'EMultiSlot',135,695),(136,NULL,'EMultiContValSlot',136,696),(137,NULL,'EMultiContValSlot',137,697),(138,NULL,'EMultiContValSlot',138,706),(139,NULL,'EMultiSlot',139,707),(140,NULL,'EMultiSlot',NULL,708),(141,NULL,'EMultiSlot',NULL,709),(142,NULL,'EMultiSlot',142,710),(143,NULL,'EMultiSlot',143,711),(144,NULL,'EMultiContValSlot',144,712),(145,NULL,'EMultiContValSlot',145,721),(146,NULL,'EMultiContValSlot',NULL,746),(147,NULL,'EMultiSlot',NULL,755),(148,NULL,'EMultiSlot',148,756),(149,NULL,'EMultiSlot',149,757),(150,NULL,'EMultiSlot',150,774),(151,NULL,'EMultiSlot',NULL,775),(152,NULL,'EMultiSlot',NULL,776),(153,NULL,'EMultiSlot',153,777),(154,NULL,'EMultiContValSlot',154,786),(155,NULL,'EMultiSlot',NULL,787),(156,NULL,'EMultiSlot',156,788),(157,NULL,'EMultiSlot',157,805),(158,NULL,'EMultiSlot',158,806),(159,NULL,'EMultiContValSlot',159,807),(160,NULL,'EMultiContValSlot',160,816),(161,NULL,'EMultiContValSlot',161,817),(162,NULL,'EMultiSlot',162,818),(163,NULL,'EMultiSlot',163,827),(164,NULL,'EMultiSlot',NULL,828),(165,NULL,'EMultiContValSlot',165,829),(166,NULL,'EMultiContValSlot',166,830),(167,NULL,'EMultiSlot',167,831),(168,NULL,'EMultiContValSlot',168,840),(169,NULL,'EMultiSlot',169,841),(170,NULL,'EMultiSlot',NULL,842),(171,NULL,'EMultiSlot',171,843),(172,NULL,'EMultiContValSlot',172,844),(173,NULL,'EMultiContValSlot',173,853),(174,NULL,'EMultiSlot',NULL,854),(175,NULL,'EMultiSlot',175,855),(176,NULL,'EMultiSlot',176,872),(177,NULL,'EMultiSlot',NULL,873),(178,NULL,'EMultiSlot',NULL,874),(179,NULL,'EMultiSlot',179,875),(180,NULL,'EMultiSlot',180,876),(181,NULL,'EMultiContValSlot',181,901),(182,NULL,'EMultiSlot',NULL,902),(183,NULL,'EMultiSlot',NULL,903),(184,NULL,'EMultiSlot',184,904),(185,NULL,'EMultiSlot',NULL,905),(186,NULL,'EMultiSlot',186,906),(187,NULL,'EMultiSlot',187,907),(188,NULL,'EMultiContValSlot',188,908),(189,NULL,'EMultiContValSlot',189,909),(190,NULL,'EMultiContValSlot',190,910),(191,NULL,'EMultiSlot',191,943),(192,NULL,'EMultiSlot',NULL,944),(193,NULL,'EMultiContValSlot',193,945),(194,NULL,'EMultiContValSlot',194,962),(195,NULL,'EMultiContValSlot',195,963),(196,NULL,'EMultiSlot',NULL,964),(197,NULL,'EMultiSlot',197,965),(198,NULL,'EMultiContValSlot',198,982),(199,NULL,'EMultiSlot',199,983),(200,NULL,'EMultiSlot',NULL,984),(201,NULL,'EMultiSlot',201,985),(202,NULL,'EMultiSlot',202,986),(203,NULL,'EMultiSlot',203,987),(204,NULL,'EMultiContValSlot',204,988),(205,NULL,'EMultiContValSlot',NULL,989),(206,NULL,'EMultiContValSlot',206,1022),(207,NULL,'EMultiContValSlot',207,1023),(208,NULL,'EMultiSlot',208,1024),(209,NULL,'EMultiSlot',209,1049),(210,NULL,'EMultiSlot',NULL,1050),(211,NULL,'EMultiContValSlot',211,1059),(212,NULL,'EMultiSlot',212,1060),(213,NULL,'EMultiSlot',NULL,1061),(214,NULL,'EMultiSlot',NULL,1062),(215,NULL,'EMultiSlot',215,1063),(216,NULL,'EMultiSlot',216,1064),(217,NULL,'EMultiContValSlot',217,1065),(218,NULL,'EMultiSlot',NULL,1082),(219,NULL,'EMultiSlot',219,1107),(220,NULL,'EMultiSlot',NULL,1108),(221,NULL,'EMultiContValSlot',221,1117),(222,NULL,'EMultiSlot',222,1118),(223,NULL,'EMultiSlot',NULL,1119),(224,NULL,'EMultiSlot',NULL,1120),(225,NULL,'EMultiSlot',225,1121),(226,NULL,'EMultiSlot',226,1130),(227,NULL,'EMultiSlot',NULL,1131),(228,NULL,'EMultiSlot',228,1132),(229,NULL,'EMultiSlot',229,1133),(230,NULL,'EMultiContValSlot',230,1134),(231,NULL,'EMultiSlot',NULL,1143),(232,NULL,'EMultiSlot',232,1144),(233,NULL,'EMultiContValSlot',233,1145),(234,NULL,'EMultiSlot',NULL,1154),(235,NULL,'EMultiSlot',235,1155),(236,NULL,'EMultiSlot',236,1164),(237,NULL,'EMultiSlot',237,1165),(238,NULL,'EMultiSlot',238,1182),(239,NULL,'EMultiSlot',NULL,1183),(240,NULL,'EMultiSlot',NULL,1184),(241,NULL,'EMultiSlot',NULL,1201),(242,NULL,'EMultiSlot',242,1202),(243,NULL,'EMultiContValSlot',243,1203),(244,NULL,'EMultiContValSlot',244,1212),(245,NULL,'EMultiContValSlot',245,1213),(246,NULL,'EMultiContValSlot',246,1214),(247,NULL,'EMultiSlot',NULL,1247),(248,NULL,'EMultiSlot',248,1248),(249,NULL,'EMultiContValSlot',249,1249),(250,NULL,'EMultiSlot',250,1282),(251,NULL,'EMultiSlot',NULL,1283),(252,NULL,'EMultiContValSlot',252,1284),(253,NULL,'EMultiSlot',253,1301),(254,NULL,'EMultiSlot',NULL,1302),(255,NULL,'EMultiSlot',255,1319),(256,NULL,'EMultiSlot',NULL,1320),(257,NULL,'EMultiSlot',257,1321),(258,NULL,'EMultiSlot',NULL,1322),(259,NULL,'EMultiContValSlot',259,1323),(260,NULL,'EMultiContValSlot',260,1324),(261,NULL,'EMultiContValSlot',261,1325),(262,NULL,'EMultiContValSlot',262,1342),(263,NULL,'EMultiContValSlot',263,1343),(264,NULL,'EMultiContValSlot',264,1344),(265,NULL,'EMultiSlot',265,1345),(266,NULL,'EMultiSlot',NULL,1346),(267,NULL,'EMultiSlot',267,1347),(268,NULL,'EMultiSlot',NULL,1348),(269,NULL,'EMultiSlot',269,1349),(270,NULL,'EMultiSlot',270,1350),(271,NULL,'EMultiContValSlot',271,1351),(272,NULL,'EMultiContValSlot',272,1352),(273,NULL,'EMultiContValSlot',273,1385),(274,NULL,'EMultiSlot',274,1386),(275,NULL,'EMultiSlot',NULL,1387),(276,NULL,'EMultiContValSlot',276,1396),(277,NULL,'EMultiSlot',277,1397),(278,NULL,'EMultiSlot',NULL,1398),(279,NULL,'EMultiContValSlot',279,1399),(280,NULL,'EMultiContValSlot',280,1400),(281,NULL,'EMultiSlot',281,1417),(282,NULL,'EMultiSlot',NULL,1418),(283,NULL,'EMultiSlot',283,1427),(284,NULL,'EMultiSlot',NULL,1428),(285,NULL,'EMultiContValSlot',285,1461),(286,NULL,'EMultiSlot',NULL,1462),(287,NULL,'EMultiSlot',287,1463),(288,NULL,'EMultiContValSlot',288,1464),(289,NULL,'EMultiContValSlot',289,1489),(290,NULL,'EMultiSlot',290,1490),(291,NULL,'EMultiSlot',NULL,1491),(292,NULL,'EMultiSlot',NULL,1492),(293,NULL,'EMultiSlot',293,1493),(294,NULL,'EMultiSlot',294,1494),(295,NULL,'EMultiContValSlot',295,1495),(296,NULL,'EMultiContValSlot',NULL,1496),(297,NULL,'EMultiContValSlot',297,1497),(298,NULL,'EMultiContValSlot',298,1522),(299,NULL,'EMultiContValSlot',299,1523),(300,NULL,'EMultiContValSlot',300,1524),(301,NULL,'EMultiContValSlot',301,1541),(302,NULL,'EMultiSlot',302,1542),(303,NULL,'EMultiSlot',NULL,1543),(304,NULL,'EMultiSlot',NULL,1544),(305,NULL,'EMultiSlot',305,1545),(306,NULL,'EMultiContValSlot',306,1546),(307,NULL,'EMultiSlot',307,1571),(308,NULL,'EMultiSlot',308,1572),(309,NULL,'EMultiContValSlot',NULL,1573),(310,NULL,'EMultiContValSlot',310,1590),(311,NULL,'EMultiContValSlot',311,1607),(312,NULL,'EMultiContValSlot',312,1616),(313,NULL,'EMultiSlot',NULL,1617),(314,NULL,'EMultiSlot',314,1618),(315,NULL,'EMultiContValSlot',315,1619),(316,NULL,'EMultiContValSlot',316,1620),(317,NULL,'EMultiContValSlot',317,1629),(318,NULL,'EMultiContValSlot',318,1630),(319,NULL,'EMultiContValSlot',319,1631),(320,NULL,'EMultiSlot',320,1632),(321,NULL,'EMultiSlot',NULL,1633),(322,NULL,'EMultiSlot',322,1634),(323,NULL,'EMultiSlot',NULL,1635),(324,NULL,'EMultiContValSlot',324,1668),(325,NULL,'EMultiContValSlot',325,1717),(326,NULL,'EMultiSlot',326,1718),(327,NULL,'EMultiSlot',327,1719),(328,NULL,'EMultiSlot',NULL,1720),(329,NULL,'EMultiSlot',329,1721),(330,NULL,'EMultiSlot',330,1722),(331,NULL,'EMultiContValSlot',331,1723),(332,NULL,'EMultiContValSlot',332,1724),(333,NULL,'EMultiSlot',333,1749),(334,NULL,'EMultiSlot',334,1758),(335,NULL,'EMultiSlot',NULL,1759),(336,NULL,'EMultiSlot',NULL,1760),(337,NULL,'EMultiSlot',337,1761),(338,NULL,'EMultiContValSlot',NULL,1762),(339,NULL,'EMultiContValSlot',339,1763),(340,NULL,'EMultiContValSlot',NULL,1764),(341,NULL,'EMultiSlot',341,1773),(342,NULL,'EMultiSlot',NULL,1774),(343,NULL,'EMultiSlot',343,1775),(344,NULL,'EMultiSlot',NULL,1776),(345,NULL,'EMultiSlot',NULL,1777),(346,NULL,'EMultiContValSlot',346,1778),(347,NULL,'EMultiSlot',347,1787),(348,NULL,'EMultiSlot',NULL,1788),(349,NULL,'EMultiSlot',NULL,1789),(350,NULL,'EMultiSlot',350,1790),(351,NULL,'EMultiSlot',351,1791),(352,NULL,'EMultiContValSlot',352,1792),(353,NULL,'EMultiContValSlot',NULL,1793),(354,NULL,'EMultiContValSlot',354,1810),(355,NULL,'EMultiContValSlot',355,1811),(356,NULL,'EMultiSlot',356,1812),(357,NULL,'EMultiContValSlot',357,1821),(358,NULL,'EMultiSlot',358,1822),(359,NULL,'EMultiSlot',NULL,1823),(360,NULL,'EMultiContValSlot',360,1824),(361,NULL,'EMultiContValSlot',361,1825),(362,NULL,'EMultiContValSlot',362,1826),(363,NULL,'EMultiSlot',363,1835),(364,NULL,'EMultiSlot',NULL,1836),(365,NULL,'EMultiContValSlot',365,1853),(366,NULL,'EMultiContValSlot',366,1854),(367,NULL,'EMultiContValSlot',367,1863),(368,NULL,'EMultiSlot',368,1880),(369,NULL,'EMultiSlot',NULL,1881),(370,NULL,'EMultiContValSlot',370,1882),(371,NULL,'EMultiSlot',371,1891),(372,NULL,'EMultiSlot',NULL,1892),(373,NULL,'EMultiSlot',NULL,1893),(374,NULL,'EMultiSlot',374,1894),(375,NULL,'EMultiSlot',375,1903),(376,NULL,'EMultiSlot',NULL,1904),(377,NULL,'EMultiSlot',377,1905),(378,NULL,'EMultiSlot',378,1906),(379,NULL,'EMultiSlot',379,1907),(380,NULL,'EMultiSlot',380,1916),(381,NULL,'EMultiSlot',381,1917),(382,NULL,'EMultiSlot',382,1918),(383,NULL,'EMultiSlot',383,1919),(384,NULL,'EMultiContValSlot',384,1920),(385,NULL,'EMultiContValSlot',385,1937),(386,NULL,'EMultiContValSlot',386,1962),(387,NULL,'EMultiContValSlot',387,1963),(388,NULL,'EMultiContValSlot',388,1964),(389,NULL,'EMultiSlot',389,1965),(390,NULL,'EMultiSlot',NULL,1966),(391,NULL,'EMultiSlot',NULL,1967),(392,NULL,'EMultiSlot',392,1968),(393,NULL,'EMultiContValSlot',393,1969),(394,NULL,'EMultiContValSlot',394,1970),(395,NULL,'EMultiContValSlot',395,1979),(396,NULL,'EMultiSlot',396,1996),(397,NULL,'EMultiSlot',NULL,1997),(398,NULL,'EMultiSlot',NULL,1998),(399,NULL,'EMultiSlot',399,1999),(400,NULL,'EMultiSlot',400,2000),(401,NULL,'EMultiContValSlot',NULL,2001),(402,NULL,'EMultiContValSlot',402,2002),(403,NULL,'EMultiContValSlot',403,2011),(404,NULL,'EMultiSlot',404,2044),(405,NULL,'EMultiSlot',NULL,2045),(406,NULL,'EMultiSlot',NULL,2046),(407,NULL,'EMultiSlot',407,2047),(408,NULL,'EMultiSlot',408,2048),(409,NULL,'EMultiSlot',409,2049),(410,NULL,'EMultiContValSlot',410,2050),(411,NULL,'EMultiSlot',411,2083),(412,NULL,'EMultiSlot',NULL,2084),(413,NULL,'EMultiContValSlot',413,2093),(414,NULL,'EMultiContValSlot',414,2094),(415,NULL,'EMultiContValSlot',415,2095),(416,NULL,'EMultiSlot',416,2096),(417,NULL,'EMultiSlot',NULL,2097),(418,NULL,'EMultiSlot',418,2098),(419,NULL,'EMultiContValSlot',419,2099),(420,NULL,'EMultiContValSlot',420,2100),(421,NULL,'EMultiSlot',421,2125),(422,NULL,'EMultiSlot',NULL,2126),(423,NULL,'EMultiContValSlot',423,2127),(424,NULL,'EMultiContValSlot',424,2136),(425,NULL,'EMultiContValSlot',425,2137),(426,NULL,'EMultiContValSlot',426,2154),(427,NULL,'EMultiContValSlot',427,2155),(428,NULL,'EMultiContValSlot',428,2156),(429,NULL,'EMultiSlot',429,2165),(430,NULL,'EMultiSlot',NULL,2166),(431,NULL,'EMultiContValSlot',431,2175),(432,NULL,'EMultiSlot',NULL,2176),(433,NULL,'EMultiSlot',433,2177),(434,NULL,'EMultiSlot',NULL,2194),(435,NULL,'EMultiSlot',NULL,2195),(436,NULL,'EMultiSlot',NULL,2196),(437,NULL,'EMultiSlot',437,2197),(438,NULL,'EMultiSlot',438,2222),(439,NULL,'EMultiSlot',439,2223),(440,NULL,'EMultiSlot',440,2224),(441,NULL,'EMultiSlot',NULL,2225),(442,NULL,'EMultiSlot',442,2242),(443,NULL,'EMultiSlot',NULL,2243),(444,NULL,'EMultiContValSlot',444,2252),(445,NULL,'EMultiSlot',445,2253),(446,NULL,'EMultiSlot',NULL,2254),(447,NULL,'EMultiSlot',447,2255),(448,NULL,'EMultiContValSlot',448,2256),(449,NULL,'EMultiContValSlot',449,2265),(450,NULL,'EMultiSlot',450,2266),(451,NULL,'EMultiSlot',NULL,2267),(452,NULL,'EMultiSlot',452,2268),(453,NULL,'EMultiSlot',453,2269),(454,NULL,'EMultiContValSlot',454,2270),(455,NULL,'EMultiContValSlot',455,2271),(456,NULL,'EMultiContValSlot',456,2296),(457,NULL,'EMultiSlot',457,2297),(458,NULL,'EMultiSlot',458,2298),(459,NULL,'EMultiSlot',459,2299),(460,NULL,'EMultiSlot',NULL,2300),(461,NULL,'EMultiSlot',461,2301),(462,NULL,'EMultiSlot',462,2302),(463,NULL,'EMultiContValSlot',463,2303),(464,NULL,'EMultiContValSlot',464,2304),(465,NULL,'EMultiContValSlot',465,2305),(466,NULL,'EMultiContValSlot',466,2306),(467,NULL,'EMultiSlot',467,2315),(468,NULL,'EMultiSlot',NULL,2316),(469,NULL,'EMultiSlot',NULL,2333),(470,NULL,'EMultiSlot',470,2334),(471,NULL,'EMultiContValSlot',471,2351),(472,NULL,'EMultiSlot',472,2352),(473,NULL,'EMultiSlot',NULL,2353),(474,NULL,'EMultiSlot',NULL,2354),(475,NULL,'EMultiSlot',475,2355),(476,NULL,'EMultiSlot',476,2356),(477,NULL,'EMultiContValSlot',477,2357),(478,NULL,'EMultiContValSlot',478,2366),(479,NULL,'EMultiSlot',NULL,2367),(480,NULL,'EMultiSlot',NULL,2368),(481,NULL,'EMultiSlot',481,2369),(482,NULL,'EMultiSlot',NULL,2370),(483,NULL,'EMultiSlot',483,2371),(484,NULL,'EMultiContValSlot',484,2380),(485,NULL,'EMultiContValSlot',485,2389),(486,NULL,'EMultiContValSlot',486,2390),(487,NULL,'EMultiContValSlot',487,2399),(488,NULL,'EMultiContValSlot',488,2400),(489,NULL,'EMultiContValSlot',489,2401),(490,NULL,'EMultiSlot',490,2402),(491,NULL,'EMultiSlot',NULL,2403),(492,NULL,'EMultiSlot',492,2404),(493,NULL,'EMultiSlot',493,2405);
/*!40000 ALTER TABLE `EMultiSlot` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `ESlot`
--

DROP TABLE IF EXISTS `ESlot`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `ESlot` (
  `id` int(11) NOT NULL,
  `range_id` int(11) DEFAULT NULL,
  `type` varchar(100) DEFAULT NULL,
  `d_slot_id` int(11) DEFAULT NULL,
  `value_string` varchar(100) DEFAULT NULL,
  `value_numeric` float DEFAULT NULL,
  `value_boolean` tinyint(1) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `ESlot`
--

LOCK TABLES `ESlot` WRITE;
/*!40000 ALTER TABLE `ESlot` DISABLE KEYS */;
INSERT INTO `ESlot` VALUES (1,NULL,'ESlot',1,'Metabolic_Clearance',NULL,NULL),(2,NULL,'ESlot',2,'',NULL,NULL),(3,NULL,'ESlot',3,'',NULL,NULL),(4,NULL,'ESlot',4,'',NULL,NULL),(5,NULL,'ESlot',5,'',NULL,NULL),(6,NULL,'ESlot',6,'',NULL,NULL),(7,NULL,'ESlot',7,'',NULL,NULL),(8,NULL,'ESlot',8,'',NULL,NULL),(9,NULL,'ESlot',16,'',NULL,NULL),(10,NULL,'ESlot',17,'',NULL,NULL),(11,NULL,'ESlot',18,'',NULL,NULL),(12,NULL,'ESlot',19,'',NULL,NULL),(13,NULL,'ESlot',20,'',NULL,NULL),(14,NULL,'ESlot',21,'',NULL,NULL),(15,NULL,'ESlot',22,'',NULL,NULL),(16,NULL,'ESlot',23,'',NULL,NULL),(17,NULL,'ESlot',30,'Metabolic_Clearance',NULL,NULL),(18,NULL,'ESlot',31,'',NULL,NULL),(19,NULL,'ESlot',32,'',NULL,NULL),(20,NULL,'ESlot',33,'',NULL,NULL),(21,NULL,'ESlot',34,'',NULL,NULL),(22,NULL,'ESlot',35,'',NULL,NULL),(23,NULL,'ESlot',36,'',NULL,NULL),(24,NULL,'ESlot',37,'',NULL,NULL),(25,NULL,'ESlot',41,'',NULL,NULL),(26,NULL,'ESlot',42,'',NULL,NULL),(27,NULL,'ESlot',43,'',NULL,NULL),(28,NULL,'ESlot',44,'',NULL,NULL),(29,NULL,'ESlot',45,'',NULL,NULL),(30,NULL,'ESlot',46,'',NULL,NULL),(31,NULL,'ESlot',47,'',NULL,NULL),(32,NULL,'ESlot',48,'',NULL,NULL),(33,NULL,'ESlot',51,'',NULL,NULL),(34,NULL,'ESlot',52,'',NULL,NULL),(35,NULL,'ESlot',53,'',NULL,NULL),(36,NULL,'ESlot',54,'',NULL,NULL),(37,NULL,'ESlot',55,'',NULL,NULL),(38,NULL,'ESlot',56,'',NULL,NULL),(39,NULL,'ESlot',57,'',NULL,NULL),(40,NULL,'ESlot',58,'',NULL,NULL),(41,NULL,'ESlot',59,'',NULL,NULL),(42,NULL,'ESlot',60,'',NULL,NULL),(43,NULL,'ESlot',61,'',NULL,NULL),(44,NULL,'ESlot',62,'',NULL,NULL),(45,NULL,'ESlot',63,'',NULL,NULL),(46,NULL,'ESlot',64,'',NULL,NULL),(47,NULL,'ESlot',65,'',NULL,NULL),(48,NULL,'ESlot',66,'',NULL,NULL),(49,NULL,'ESlot',67,'',NULL,NULL),(50,NULL,'ESlot',68,'',NULL,NULL),(51,NULL,'ESlot',69,'',NULL,NULL),(52,NULL,'ESlot',70,'',NULL,NULL),(53,NULL,'ESlot',71,'',NULL,NULL),(54,NULL,'ESlot',72,'cyp3a4',NULL,NULL),(55,NULL,'ESlot',73,'',NULL,NULL),(56,NULL,'ESlot',74,'',NULL,NULL),(57,NULL,'ESlot',75,'',NULL,NULL),(58,NULL,'ESlot',76,'',NULL,NULL),(59,NULL,'ESlot',77,'',NULL,NULL),(60,NULL,'ESlot',78,'',NULL,NULL),(61,NULL,'ESlot',79,'',NULL,NULL),(62,NULL,'ESlot',80,'',NULL,NULL),(63,NULL,'ESlot',81,'',NULL,NULL),(64,NULL,'ESlot',82,'',NULL,NULL),(65,NULL,'ESlot',83,'Metabolic_Clearance',NULL,NULL),(66,NULL,'ESlot',84,'',NULL,NULL),(67,NULL,'ESlot',85,'',NULL,NULL),(68,NULL,'ESlot',86,'',NULL,NULL),(69,NULL,'ESlot',87,'',NULL,NULL),(70,NULL,'ESlot',88,'',NULL,NULL),(71,NULL,'ESlot',89,'',NULL,NULL),(72,NULL,'ESlot',90,'',NULL,NULL),(73,NULL,'ESlot',96,'',NULL,NULL),(74,NULL,'ESlot',97,'',NULL,NULL),(75,NULL,'ESlot',98,'',NULL,NULL),(76,NULL,'ESlot',99,'cyp1a2',NULL,NULL),(77,NULL,'ESlot',100,'',NULL,NULL),(78,NULL,'ESlot',101,'',NULL,NULL),(79,NULL,'ESlot',102,'',NULL,NULL),(80,NULL,'ESlot',103,'',NULL,NULL),(81,NULL,'ESlot',104,'',NULL,NULL),(82,NULL,'ESlot',105,'',NULL,NULL),(83,NULL,'ESlot',106,'',NULL,NULL),(84,NULL,'ESlot',107,'',NULL,NULL),(85,NULL,'ESlot',108,'',NULL,NULL),(86,NULL,'ESlot',109,'',NULL,NULL),(87,NULL,'ESlot',110,'',NULL,NULL),(88,NULL,'ESlot',111,'',NULL,NULL),(89,NULL,'ESlot',112,'Renal_Excretion',NULL,NULL),(90,NULL,'ESlot',113,'',NULL,NULL),(91,NULL,'ESlot',114,'',NULL,NULL),(92,NULL,'ESlot',115,'',NULL,NULL),(93,NULL,'ESlot',116,'',NULL,NULL),(94,NULL,'ESlot',117,'',NULL,NULL),(95,NULL,'ESlot',118,'',NULL,NULL),(96,NULL,'ESlot',119,'',NULL,NULL),(97,NULL,'ESlot',120,'',NULL,NULL),(98,NULL,'ESlot',121,'',NULL,NULL),(99,NULL,'ESlot',122,'',NULL,NULL),(100,NULL,'ESlot',123,'',NULL,NULL),(101,NULL,'ESlot',124,'',NULL,NULL),(102,NULL,'ESlot',125,'',NULL,NULL),(103,NULL,'ESlot',126,'',NULL,NULL),(104,NULL,'ESlot',127,'',NULL,NULL),(105,NULL,'ESlot',128,'Renal_Excretion',NULL,NULL),(106,NULL,'ESlot',129,'',NULL,NULL),(107,NULL,'ESlot',130,'',NULL,NULL),(108,NULL,'ESlot',131,'',NULL,NULL),(109,NULL,'ESlot',132,'',NULL,NULL),(110,NULL,'ESlot',133,'',NULL,NULL),(111,NULL,'ESlot',134,'',NULL,NULL),(112,NULL,'ESlot',135,'',NULL,NULL),(113,NULL,'ESlot',137,'Metabolic_Clearance',NULL,NULL),(114,NULL,'ESlot',138,'cyp3a4',NULL,NULL),(115,NULL,'ESlot',139,'',NULL,NULL),(116,NULL,'ESlot',140,'',NULL,NULL),(117,NULL,'ESlot',141,'',NULL,NULL),(118,NULL,'ESlot',142,'',NULL,NULL),(119,NULL,'ESlot',143,'',NULL,NULL),(120,NULL,'ESlot',144,'',NULL,NULL),(121,NULL,'ESlot',151,'',NULL,NULL),(122,NULL,'ESlot',152,'',NULL,NULL),(123,NULL,'ESlot',153,'',NULL,NULL),(124,NULL,'ESlot',154,'',NULL,NULL),(125,NULL,'ESlot',155,'',NULL,NULL),(126,NULL,'ESlot',156,'',NULL,NULL),(127,NULL,'ESlot',157,'',NULL,NULL),(128,NULL,'ESlot',158,'',NULL,NULL),(129,NULL,'ESlot',159,'Metabolic_Clearance',NULL,NULL),(130,NULL,'ESlot',160,'',NULL,NULL),(131,NULL,'ESlot',161,'',NULL,NULL),(132,NULL,'ESlot',162,'',NULL,NULL),(133,NULL,'ESlot',163,'',NULL,NULL),(134,NULL,'ESlot',164,'',NULL,NULL),(135,NULL,'ESlot',165,'',NULL,NULL),(136,NULL,'ESlot',166,'',NULL,NULL),(137,NULL,'ESlot',170,'',NULL,NULL),(138,NULL,'ESlot',171,'',NULL,NULL),(139,NULL,'ESlot',172,'',NULL,NULL),(140,NULL,'ESlot',173,'',NULL,NULL),(141,NULL,'ESlot',174,'',NULL,NULL),(142,NULL,'ESlot',175,'',NULL,NULL),(143,NULL,'ESlot',176,'',NULL,NULL),(144,NULL,'ESlot',177,'',NULL,NULL),(145,NULL,'ESlot',182,'',NULL,NULL),(146,NULL,'ESlot',183,'',NULL,NULL),(147,NULL,'ESlot',184,'cyp3a4',NULL,NULL),(148,NULL,'ESlot',185,'cyp3a4',NULL,NULL),(149,NULL,'ESlot',186,'',NULL,NULL),(150,NULL,'ESlot',187,'',NULL,NULL),(151,NULL,'ESlot',188,'',NULL,NULL),(152,NULL,'ESlot',189,'',NULL,NULL),(153,NULL,'ESlot',193,'',NULL,NULL),(154,NULL,'ESlot',194,'',NULL,NULL),(155,NULL,'ESlot',195,'',NULL,NULL),(156,NULL,'ESlot',196,'',NULL,NULL),(157,NULL,'ESlot',197,'',NULL,NULL),(158,NULL,'ESlot',198,'',NULL,NULL),(159,NULL,'ESlot',199,'',NULL,NULL),(160,NULL,'ESlot',200,'',NULL,NULL),(161,NULL,'ESlot',201,'',NULL,NULL),(162,NULL,'ESlot',202,'',NULL,NULL),(163,NULL,'ESlot',203,'',NULL,NULL),(164,NULL,'ESlot',204,'',NULL,NULL),(165,NULL,'ESlot',205,'',NULL,NULL),(166,NULL,'ESlot',206,'',NULL,NULL),(167,NULL,'ESlot',207,'',NULL,NULL),(168,NULL,'ESlot',208,'',NULL,NULL),(169,NULL,'ESlot',209,'',NULL,NULL),(170,NULL,'ESlot',210,'',NULL,NULL),(171,NULL,'ESlot',211,'cyp2c19',NULL,NULL),(172,NULL,'ESlot',212,'',NULL,NULL),(173,NULL,'ESlot',213,'',NULL,NULL),(174,NULL,'ESlot',214,'',NULL,NULL),(175,NULL,'ESlot',215,'',NULL,NULL),(176,NULL,'ESlot',216,'',NULL,NULL),(177,NULL,'ESlot',225,'',NULL,NULL),(178,NULL,'ESlot',226,'',NULL,NULL),(179,NULL,'ESlot',227,'cyp2c9',NULL,NULL),(180,NULL,'ESlot',228,'cyp2c9',NULL,NULL),(181,NULL,'ESlot',229,'',NULL,NULL),(182,NULL,'ESlot',230,'',NULL,NULL),(183,NULL,'ESlot',231,'',NULL,NULL),(184,NULL,'ESlot',232,'',NULL,NULL),(185,NULL,'ESlot',233,'',NULL,NULL),(186,NULL,'ESlot',234,'',NULL,NULL),(187,NULL,'ESlot',235,'',NULL,NULL),(188,NULL,'ESlot',236,'',NULL,NULL),(189,NULL,'ESlot',237,'',NULL,NULL),(190,NULL,'ESlot',238,'',NULL,NULL),(191,NULL,'ESlot',239,'',NULL,NULL),(192,NULL,'ESlot',240,'',NULL,NULL),(193,NULL,'ESlot',241,'Biliary_Excretion',NULL,NULL),(194,NULL,'ESlot',242,'cyp2c9',NULL,NULL),(195,NULL,'ESlot',243,'',NULL,NULL),(196,NULL,'ESlot',244,'',NULL,NULL),(197,NULL,'ESlot',245,'',NULL,NULL),(198,NULL,'ESlot',246,'',NULL,NULL),(199,NULL,'ESlot',247,'',NULL,NULL),(200,NULL,'ESlot',248,'',NULL,NULL),(201,NULL,'ESlot',257,'',NULL,NULL),(202,NULL,'ESlot',258,'',NULL,NULL),(203,NULL,'ESlot',259,'',NULL,NULL),(204,NULL,'ESlot',260,'',NULL,NULL),(205,NULL,'ESlot',261,'',NULL,NULL),(206,NULL,'ESlot',262,'',NULL,NULL),(207,NULL,'ESlot',263,'',NULL,NULL),(208,NULL,'ESlot',264,'',NULL,NULL),(209,NULL,'ESlot',265,'',NULL,NULL),(210,NULL,'ESlot',266,'',NULL,NULL),(211,NULL,'ESlot',267,'',NULL,NULL),(212,NULL,'ESlot',268,'',NULL,NULL),(213,NULL,'ESlot',269,'',NULL,NULL),(214,NULL,'ESlot',270,'',NULL,NULL),(215,NULL,'ESlot',271,'',NULL,NULL),(216,NULL,'ESlot',272,'',NULL,NULL),(217,NULL,'ESlot',273,'',NULL,NULL),(218,NULL,'ESlot',274,'',NULL,NULL),(219,NULL,'ESlot',275,'',NULL,NULL),(220,NULL,'ESlot',276,'',NULL,NULL),(221,NULL,'ESlot',277,'',NULL,NULL),(222,NULL,'ESlot',278,'',NULL,NULL),(223,NULL,'ESlot',279,'',NULL,NULL),(224,NULL,'ESlot',280,'',NULL,NULL),(225,NULL,'ESlot',281,'',NULL,NULL),(226,NULL,'ESlot',282,'',NULL,NULL),(227,NULL,'ESlot',283,'',NULL,NULL),(228,NULL,'ESlot',284,'',NULL,NULL),(229,NULL,'ESlot',285,'',NULL,NULL),(230,NULL,'ESlot',286,'',NULL,NULL),(231,NULL,'ESlot',287,'',NULL,NULL),(232,NULL,'ESlot',288,'',NULL,NULL),(233,NULL,'ESlot',289,'Metabolic_Clearance',NULL,NULL),(234,NULL,'ESlot',290,'',NULL,NULL),(235,NULL,'ESlot',291,'',NULL,NULL),(236,NULL,'ESlot',292,'',NULL,NULL),(237,NULL,'ESlot',293,'',NULL,NULL),(238,NULL,'ESlot',294,'',NULL,NULL),(239,NULL,'ESlot',295,'cyp2d6',NULL,NULL),(240,NULL,'ESlot',296,'',NULL,NULL),(241,NULL,'ESlot',306,'',NULL,NULL),(242,NULL,'ESlot',307,'',NULL,NULL),(243,NULL,'ESlot',308,'',NULL,NULL),(244,NULL,'ESlot',309,'',NULL,NULL),(245,NULL,'ESlot',310,'',NULL,NULL),(246,NULL,'ESlot',311,'',NULL,NULL),(247,NULL,'ESlot',312,'',NULL,NULL),(248,NULL,'ESlot',313,'',NULL,NULL),(249,NULL,'ESlot',314,'',NULL,NULL),(250,NULL,'ESlot',315,'',NULL,NULL),(251,NULL,'ESlot',316,'',NULL,NULL),(252,NULL,'ESlot',317,'',NULL,NULL),(253,NULL,'ESlot',318,'',NULL,NULL),(254,NULL,'ESlot',319,'',NULL,NULL),(255,NULL,'ESlot',320,'',NULL,NULL),(256,NULL,'ESlot',321,'',NULL,NULL),(257,NULL,'ESlot',323,'',NULL,NULL),(258,NULL,'ESlot',324,'',NULL,NULL),(259,NULL,'ESlot',325,'',NULL,NULL),(260,NULL,'ESlot',326,'',NULL,NULL),(261,NULL,'ESlot',327,'',NULL,NULL),(262,NULL,'ESlot',328,'',NULL,NULL),(263,NULL,'ESlot',329,'',NULL,NULL),(264,NULL,'ESlot',330,'',NULL,NULL),(265,NULL,'ESlot',331,'Metabolic_Clearance',NULL,NULL),(266,NULL,'ESlot',332,'',NULL,NULL),(267,NULL,'ESlot',333,'',NULL,NULL),(268,NULL,'ESlot',334,'',NULL,NULL),(269,NULL,'ESlot',335,'',NULL,NULL),(270,NULL,'ESlot',336,'',NULL,NULL),(271,NULL,'ESlot',337,'',NULL,NULL),(272,NULL,'ESlot',338,'',NULL,NULL),(273,NULL,'ESlot',344,'',NULL,NULL),(274,NULL,'ESlot',345,'',NULL,NULL),(275,NULL,'ESlot',346,'',NULL,NULL),(276,NULL,'ESlot',347,'',NULL,NULL),(277,NULL,'ESlot',348,'',NULL,NULL),(278,NULL,'ESlot',349,'',NULL,NULL),(279,NULL,'ESlot',350,'',NULL,NULL),(280,NULL,'ESlot',351,'',NULL,NULL),(281,NULL,'ESlot',359,'',NULL,NULL),(282,NULL,'ESlot',360,'',NULL,NULL),(283,NULL,'ESlot',361,'',NULL,NULL),(284,NULL,'ESlot',362,'',NULL,NULL),(285,NULL,'ESlot',363,'cyp2c19',NULL,NULL),(286,NULL,'ESlot',364,'',NULL,NULL),(287,NULL,'ESlot',365,'',NULL,NULL),(288,NULL,'ESlot',366,'',NULL,NULL),(289,NULL,'ESlot',367,'',NULL,NULL),(290,NULL,'ESlot',368,'',NULL,NULL),(291,NULL,'ESlot',369,'',NULL,NULL),(292,NULL,'ESlot',370,'',NULL,NULL),(293,NULL,'ESlot',371,'',NULL,NULL),(294,NULL,'ESlot',372,'',NULL,NULL),(295,NULL,'ESlot',373,'',NULL,NULL),(296,NULL,'ESlot',374,'',NULL,NULL),(297,NULL,'ESlot',376,'',NULL,NULL),(298,NULL,'ESlot',377,'',NULL,NULL),(299,NULL,'ESlot',378,'cyp2d6',NULL,NULL),(300,NULL,'ESlot',379,'',NULL,NULL),(301,NULL,'ESlot',380,'',NULL,NULL),(302,NULL,'ESlot',381,'',NULL,NULL),(303,NULL,'ESlot',382,'',NULL,NULL),(304,NULL,'ESlot',383,'',NULL,NULL),(305,NULL,'ESlot',386,'',NULL,NULL),(306,NULL,'ESlot',387,'',NULL,NULL),(307,NULL,'ESlot',388,'',NULL,NULL),(308,NULL,'ESlot',389,'',NULL,NULL),(309,NULL,'ESlot',390,'',NULL,NULL),(310,NULL,'ESlot',391,'',NULL,NULL),(311,NULL,'ESlot',392,'',NULL,NULL),(312,NULL,'ESlot',393,'',NULL,NULL),(313,NULL,'ESlot',394,'',NULL,NULL),(314,NULL,'ESlot',395,'',NULL,NULL),(315,NULL,'ESlot',396,'',NULL,NULL),(316,NULL,'ESlot',397,'',NULL,NULL),(317,NULL,'ESlot',398,'',NULL,NULL),(318,NULL,'ESlot',399,'',NULL,NULL),(319,NULL,'ESlot',400,'',NULL,NULL),(320,NULL,'ESlot',401,'',NULL,NULL),(321,NULL,'ESlot',402,'',NULL,NULL),(322,NULL,'ESlot',403,'',NULL,NULL),(323,NULL,'ESlot',404,'',NULL,NULL),(324,NULL,'ESlot',405,'',NULL,NULL),(325,NULL,'ESlot',406,'',NULL,NULL),(326,NULL,'ESlot',407,'',NULL,NULL),(327,NULL,'ESlot',408,'',NULL,NULL),(328,NULL,'ESlot',409,'',NULL,NULL),(329,NULL,'ESlot',413,'',NULL,NULL),(330,NULL,'ESlot',414,'',NULL,NULL),(331,NULL,'ESlot',415,'',NULL,NULL),(332,NULL,'ESlot',416,'',NULL,NULL),(333,NULL,'ESlot',417,'',NULL,NULL),(334,NULL,'ESlot',418,'',NULL,NULL),(335,NULL,'ESlot',419,'',NULL,NULL),(336,NULL,'ESlot',420,'',NULL,NULL),(337,NULL,'ESlot',421,'',NULL,NULL),(338,NULL,'ESlot',422,'',NULL,NULL),(339,NULL,'ESlot',423,'',NULL,NULL),(340,NULL,'ESlot',424,'',NULL,NULL),(341,NULL,'ESlot',425,'',NULL,NULL),(342,NULL,'ESlot',426,'',NULL,NULL),(343,NULL,'ESlot',427,'',NULL,NULL),(344,NULL,'ESlot',428,'',NULL,NULL),(345,NULL,'ESlot',431,'',NULL,NULL),(346,NULL,'ESlot',432,'',NULL,NULL),(347,NULL,'ESlot',433,'',NULL,NULL),(348,NULL,'ESlot',434,'cyp2c8',NULL,NULL),(349,NULL,'ESlot',435,'',NULL,NULL),(350,NULL,'ESlot',436,'',NULL,NULL),(351,NULL,'ESlot',437,'',NULL,NULL),(352,NULL,'ESlot',438,'',NULL,NULL),(353,NULL,'ESlot',440,'Metabolic_Clearance',NULL,NULL),(354,NULL,'ESlot',441,'',NULL,NULL),(355,NULL,'ESlot',442,'cyp2d6',NULL,NULL),(356,NULL,'ESlot',443,'',NULL,NULL),(357,NULL,'ESlot',444,'',NULL,NULL),(358,NULL,'ESlot',445,'',NULL,NULL),(359,NULL,'ESlot',446,'',NULL,NULL),(360,NULL,'ESlot',447,'',NULL,NULL),(361,NULL,'ESlot',452,'',NULL,NULL),(362,NULL,'ESlot',453,'',NULL,NULL),(363,NULL,'ESlot',454,'',NULL,NULL),(364,NULL,'ESlot',455,'',NULL,NULL),(365,NULL,'ESlot',456,'',NULL,NULL),(366,NULL,'ESlot',457,'',NULL,NULL),(367,NULL,'ESlot',458,'',NULL,NULL),(368,NULL,'ESlot',459,'',NULL,NULL),(369,NULL,'ESlot',460,'',NULL,NULL),(370,NULL,'ESlot',461,'',NULL,NULL),(371,NULL,'ESlot',462,'',NULL,NULL),(372,NULL,'ESlot',463,'',NULL,NULL),(373,NULL,'ESlot',464,'',NULL,NULL),(374,NULL,'ESlot',465,'',NULL,NULL),(375,NULL,'ESlot',466,'',NULL,NULL),(376,NULL,'ESlot',467,'',NULL,NULL),(377,NULL,'ESlot',468,'',NULL,NULL),(378,NULL,'ESlot',469,'',NULL,NULL),(379,NULL,'ESlot',470,'',NULL,NULL),(380,NULL,'ESlot',471,'',NULL,NULL),(381,NULL,'ESlot',472,'',NULL,NULL),(382,NULL,'ESlot',473,'',NULL,NULL),(383,NULL,'ESlot',474,'',NULL,NULL),(384,NULL,'ESlot',475,'',NULL,NULL),(385,NULL,'ESlot',476,'Metabolic_Clearance',NULL,NULL),(386,NULL,'ESlot',477,'',NULL,NULL),(387,NULL,'ESlot',478,'cyp2c19',NULL,NULL),(388,NULL,'ESlot',479,'',NULL,NULL),(389,NULL,'ESlot',480,'',NULL,NULL),(390,NULL,'ESlot',481,'',NULL,NULL),(391,NULL,'ESlot',482,'',NULL,NULL),(392,NULL,'ESlot',483,'',NULL,NULL),(393,NULL,'ESlot',493,'',NULL,NULL),(394,NULL,'ESlot',494,'',NULL,NULL),(395,NULL,'ESlot',495,'',NULL,NULL),(396,NULL,'ESlot',496,'',NULL,NULL),(397,NULL,'ESlot',497,'',NULL,NULL),(398,NULL,'ESlot',498,'cyp1a2',NULL,NULL),(399,NULL,'ESlot',499,'',NULL,NULL),(400,NULL,'ESlot',500,'',NULL,NULL),(401,NULL,'ESlot',501,'',NULL,NULL),(402,NULL,'ESlot',502,'',NULL,NULL),(403,NULL,'ESlot',503,'',NULL,NULL),(404,NULL,'ESlot',504,'cyp2d6',NULL,NULL),(405,NULL,'ESlot',505,'',NULL,NULL),(406,NULL,'ESlot',506,'',NULL,NULL),(407,NULL,'ESlot',507,'',NULL,NULL),(408,NULL,'ESlot',508,'',NULL,NULL),(409,NULL,'ESlot',509,'',NULL,NULL),(410,NULL,'ESlot',510,'',NULL,NULL),(411,NULL,'ESlot',511,'',NULL,NULL),(412,NULL,'ESlot',512,'cyp3a4',NULL,NULL),(413,NULL,'ESlot',513,'',NULL,NULL),(414,NULL,'ESlot',514,'',NULL,NULL),(415,NULL,'ESlot',515,'',NULL,NULL),(416,NULL,'ESlot',516,'',NULL,NULL),(417,NULL,'ESlot',522,'',NULL,NULL),(418,NULL,'ESlot',523,'',NULL,NULL),(419,NULL,'ESlot',524,'',NULL,NULL),(420,NULL,'ESlot',525,'',NULL,NULL),(421,NULL,'ESlot',526,'',NULL,NULL),(422,NULL,'ESlot',527,'',NULL,NULL),(423,NULL,'ESlot',528,'',NULL,NULL),(424,NULL,'ESlot',529,'',NULL,NULL),(425,NULL,'ESlot',534,'',NULL,NULL),(426,NULL,'ESlot',535,'',NULL,NULL),(427,NULL,'ESlot',536,'',NULL,NULL),(428,NULL,'ESlot',537,'',NULL,NULL),(429,NULL,'ESlot',538,'',NULL,NULL),(430,NULL,'ESlot',539,'',NULL,NULL),(431,NULL,'ESlot',540,'',NULL,NULL),(432,NULL,'ESlot',541,'',NULL,NULL),(433,NULL,'ESlot',542,'',NULL,NULL),(434,NULL,'ESlot',543,'',NULL,NULL),(435,NULL,'ESlot',544,'cyp2c9',NULL,NULL),(436,NULL,'ESlot',545,'',NULL,NULL),(437,NULL,'ESlot',546,'',NULL,NULL),(438,NULL,'ESlot',547,'',NULL,NULL),(439,NULL,'ESlot',548,'',NULL,NULL),(440,NULL,'ESlot',549,'',NULL,NULL),(441,NULL,'ESlot',550,'',NULL,NULL),(442,NULL,'ESlot',551,'',NULL,NULL),(443,NULL,'ESlot',552,'',NULL,NULL),(444,NULL,'ESlot',553,'',NULL,NULL),(445,NULL,'ESlot',554,'',NULL,NULL),(446,NULL,'ESlot',555,'',NULL,NULL),(447,NULL,'ESlot',556,'',NULL,NULL),(448,NULL,'ESlot',557,'',NULL,NULL),(449,NULL,'ESlot',558,'',NULL,NULL),(450,NULL,'ESlot',559,'',NULL,NULL),(451,NULL,'ESlot',560,'',NULL,NULL),(452,NULL,'ESlot',561,'',NULL,NULL),(453,NULL,'ESlot',562,'',NULL,NULL),(454,NULL,'ESlot',563,'',NULL,NULL),(455,NULL,'ESlot',564,'',NULL,NULL),(456,NULL,'ESlot',565,'',NULL,NULL),(457,NULL,'ESlot',571,'',NULL,NULL),(458,NULL,'ESlot',572,'',NULL,NULL),(459,NULL,'ESlot',573,'',NULL,NULL),(460,NULL,'ESlot',574,'',NULL,NULL),(461,NULL,'ESlot',575,'',NULL,NULL),(462,NULL,'ESlot',576,'',NULL,NULL),(463,NULL,'ESlot',577,'',NULL,NULL),(464,NULL,'ESlot',578,'',NULL,NULL),(465,NULL,'ESlot',579,'',NULL,NULL),(466,NULL,'ESlot',580,'',NULL,NULL),(467,NULL,'ESlot',581,'',NULL,NULL),(468,NULL,'ESlot',582,'',NULL,NULL),(469,NULL,'ESlot',583,'',NULL,NULL),(470,NULL,'ESlot',584,'',NULL,NULL),(471,NULL,'ESlot',585,'',NULL,NULL),(472,NULL,'ESlot',586,'',NULL,NULL),(473,NULL,'ESlot',587,'',NULL,NULL),(474,NULL,'ESlot',588,'',NULL,NULL),(475,NULL,'ESlot',589,'cyp2d6',NULL,NULL),(476,NULL,'ESlot',590,'cyp2d6',NULL,NULL),(477,NULL,'ESlot',591,'cyp2d6',NULL,NULL),(478,NULL,'ESlot',592,'',NULL,NULL),(479,NULL,'ESlot',593,'',NULL,NULL),(480,NULL,'ESlot',594,'',NULL,NULL),(481,NULL,'ESlot',595,'',NULL,NULL),(482,NULL,'ESlot',596,'',NULL,NULL),(483,NULL,'ESlot',597,'',NULL,NULL),(484,NULL,'ESlot',598,'',NULL,NULL),(485,NULL,'ESlot',599,'',NULL,NULL),(486,NULL,'ESlot',600,'',NULL,NULL),(487,NULL,'ESlot',601,'',NULL,NULL),(488,NULL,'ESlot',602,'',NULL,NULL),(489,NULL,'ESlot',608,'',NULL,NULL),(490,NULL,'ESlot',609,'',NULL,NULL),(491,NULL,'ESlot',610,'cyp3a4',NULL,NULL),(492,NULL,'ESlot',611,'',NULL,NULL),(493,NULL,'ESlot',612,'',NULL,NULL),(494,NULL,'ESlot',613,'',NULL,NULL),(495,NULL,'ESlot',614,'',NULL,NULL),(496,NULL,'ESlot',615,'',NULL,NULL),(497,NULL,'ESlot',616,'',NULL,NULL),(498,NULL,'ESlot',617,'',NULL,NULL),(499,NULL,'ESlot',618,'',NULL,NULL),(500,NULL,'ESlot',619,'cyp2c19',NULL,NULL),(501,NULL,'ESlot',620,'',NULL,NULL),(502,NULL,'ESlot',621,'',NULL,NULL),(503,NULL,'ESlot',622,'',NULL,NULL),(504,NULL,'ESlot',623,'',NULL,NULL),(505,NULL,'ESlot',624,'',NULL,NULL),(506,NULL,'ESlot',625,'',NULL,NULL),(507,NULL,'ESlot',626,'cyp3a4',NULL,NULL),(508,NULL,'ESlot',627,'',NULL,NULL),(509,NULL,'ESlot',628,'',NULL,NULL),(510,NULL,'ESlot',629,'',NULL,NULL),(511,NULL,'ESlot',630,'',NULL,NULL),(512,NULL,'ESlot',631,'',NULL,NULL),(513,NULL,'ESlot',639,'',NULL,NULL),(514,NULL,'ESlot',640,'',NULL,NULL),(515,NULL,'ESlot',641,'',NULL,NULL),(516,NULL,'ESlot',642,'',NULL,NULL),(517,NULL,'ESlot',643,'',NULL,NULL),(518,NULL,'ESlot',644,'',NULL,NULL),(519,NULL,'ESlot',645,'',NULL,NULL),(520,NULL,'ESlot',646,'',NULL,NULL),(521,NULL,'ESlot',647,'',NULL,NULL),(522,NULL,'ESlot',648,'',NULL,NULL),(523,NULL,'ESlot',649,'',NULL,NULL),(524,NULL,'ESlot',650,'',NULL,NULL),(525,NULL,'ESlot',651,'',NULL,NULL),(526,NULL,'ESlot',652,'',NULL,NULL),(527,NULL,'ESlot',653,'',NULL,NULL),(528,NULL,'ESlot',654,'',NULL,NULL),(529,NULL,'ESlot',656,'',NULL,NULL),(530,NULL,'ESlot',657,'',NULL,NULL),(531,NULL,'ESlot',658,'',NULL,NULL),(532,NULL,'ESlot',659,'',NULL,NULL),(533,NULL,'ESlot',660,'',NULL,NULL),(534,NULL,'ESlot',661,'',NULL,NULL),(535,NULL,'ESlot',662,'',NULL,NULL),(536,NULL,'ESlot',663,'',NULL,NULL),(537,NULL,'ESlot',664,'',NULL,NULL),(538,NULL,'ESlot',665,'',NULL,NULL),(539,NULL,'ESlot',666,'cyp2d6',NULL,NULL),(540,NULL,'ESlot',667,'',NULL,NULL),(541,NULL,'ESlot',668,'',NULL,NULL),(542,NULL,'ESlot',669,'',NULL,NULL),(543,NULL,'ESlot',670,'',NULL,NULL),(544,NULL,'ESlot',671,'',NULL,NULL),(545,NULL,'ESlot',678,'',NULL,NULL),(546,NULL,'ESlot',679,'',NULL,NULL),(547,NULL,'ESlot',680,'',NULL,NULL),(548,NULL,'ESlot',681,'',NULL,NULL),(549,NULL,'ESlot',682,'',NULL,NULL),(550,NULL,'ESlot',683,'',NULL,NULL),(551,NULL,'ESlot',684,'',NULL,NULL),(552,NULL,'ESlot',685,'',NULL,NULL),(553,NULL,'ESlot',686,'Renal_Excretion',NULL,NULL),(554,NULL,'ESlot',687,'',NULL,NULL),(555,NULL,'ESlot',688,'',NULL,NULL),(556,NULL,'ESlot',689,'',NULL,NULL),(557,NULL,'ESlot',690,'',NULL,NULL),(558,NULL,'ESlot',691,'',NULL,NULL),(559,NULL,'ESlot',692,'',NULL,NULL),(560,NULL,'ESlot',693,'',NULL,NULL),(561,NULL,'ESlot',698,'Metabolic_Clearance',NULL,NULL),(562,NULL,'ESlot',699,'',NULL,NULL),(563,NULL,'ESlot',700,'',NULL,NULL),(564,NULL,'ESlot',701,'',NULL,NULL),(565,NULL,'ESlot',702,'',NULL,NULL),(566,NULL,'ESlot',703,'',NULL,NULL),(567,NULL,'ESlot',704,'',NULL,NULL),(568,NULL,'ESlot',705,'',NULL,NULL),(569,NULL,'ESlot',713,'',NULL,NULL),(570,NULL,'ESlot',714,'',NULL,NULL),(571,NULL,'ESlot',715,'',NULL,NULL),(572,NULL,'ESlot',716,'',NULL,NULL),(573,NULL,'ESlot',717,'',NULL,NULL),(574,NULL,'ESlot',718,'',NULL,NULL),(575,NULL,'ESlot',719,'',NULL,NULL),(576,NULL,'ESlot',720,'',NULL,NULL),(577,NULL,'ESlot',722,'',NULL,NULL),(578,NULL,'ESlot',723,'',NULL,NULL),(579,NULL,'ESlot',724,'',NULL,NULL),(580,NULL,'ESlot',725,'',NULL,NULL),(581,NULL,'ESlot',726,'',NULL,NULL),(582,NULL,'ESlot',727,'',NULL,NULL),(583,NULL,'ESlot',728,'',NULL,NULL),(584,NULL,'ESlot',729,'',NULL,NULL),(585,NULL,'ESlot',730,'',NULL,NULL),(586,NULL,'ESlot',731,'',NULL,NULL),(587,NULL,'ESlot',732,'',NULL,NULL),(588,NULL,'ESlot',733,'',NULL,NULL),(589,NULL,'ESlot',734,'',NULL,NULL),(590,NULL,'ESlot',735,'',NULL,NULL),(591,NULL,'ESlot',736,'',NULL,NULL),(592,NULL,'ESlot',737,'',NULL,NULL),(593,NULL,'ESlot',738,'',NULL,NULL),(594,NULL,'ESlot',739,'',NULL,NULL),(595,NULL,'ESlot',740,'cyp3a4',NULL,NULL),(596,NULL,'ESlot',741,'cyp3a4',NULL,NULL),(597,NULL,'ESlot',742,'',NULL,NULL),(598,NULL,'ESlot',743,'',NULL,NULL),(599,NULL,'ESlot',744,'',NULL,NULL),(600,NULL,'ESlot',745,'',NULL,NULL),(601,NULL,'ESlot',747,'Renal_Excretion',NULL,NULL),(602,NULL,'ESlot',748,'',NULL,NULL),(603,NULL,'ESlot',749,'',NULL,NULL),(604,NULL,'ESlot',750,'',NULL,NULL),(605,NULL,'ESlot',751,'',NULL,NULL),(606,NULL,'ESlot',752,'',NULL,NULL),(607,NULL,'ESlot',753,'',NULL,NULL),(608,NULL,'ESlot',754,'',NULL,NULL),(609,NULL,'ESlot',758,'',NULL,NULL),(610,NULL,'ESlot',759,'',NULL,NULL),(611,NULL,'ESlot',760,'cyp1a2',NULL,NULL),(612,NULL,'ESlot',761,'',NULL,NULL),(613,NULL,'ESlot',762,'',NULL,NULL),(614,NULL,'ESlot',763,'',NULL,NULL),(615,NULL,'ESlot',764,'',NULL,NULL),(616,NULL,'ESlot',765,'',NULL,NULL),(617,NULL,'ESlot',766,'',NULL,NULL),(618,NULL,'ESlot',767,'',NULL,NULL),(619,NULL,'ESlot',768,'',NULL,NULL),(620,NULL,'ESlot',769,'',NULL,NULL),(621,NULL,'ESlot',770,'',NULL,NULL),(622,NULL,'ESlot',771,'',NULL,NULL),(623,NULL,'ESlot',772,'',NULL,NULL),(624,NULL,'ESlot',773,'',NULL,NULL),(625,NULL,'ESlot',778,'Metabolic_Clearance',NULL,NULL),(626,NULL,'ESlot',779,'',NULL,NULL),(627,NULL,'ESlot',780,'',NULL,NULL),(628,NULL,'ESlot',781,'',NULL,NULL),(629,NULL,'ESlot',782,'',NULL,NULL),(630,NULL,'ESlot',783,'',NULL,NULL),(631,NULL,'ESlot',784,'',NULL,NULL),(632,NULL,'ESlot',785,'',NULL,NULL),(633,NULL,'ESlot',789,'',NULL,NULL),(634,NULL,'ESlot',790,'',NULL,NULL),(635,NULL,'ESlot',791,'',NULL,NULL),(636,NULL,'ESlot',792,'',NULL,NULL),(637,NULL,'ESlot',793,'',NULL,NULL),(638,NULL,'ESlot',794,'cyp1a2',NULL,NULL),(639,NULL,'ESlot',795,'',NULL,NULL),(640,NULL,'ESlot',796,'',NULL,NULL),(641,NULL,'ESlot',797,'',NULL,NULL),(642,NULL,'ESlot',798,'',NULL,NULL),(643,NULL,'ESlot',799,'cyp2c19',NULL,NULL),(644,NULL,'ESlot',800,'cyp2c19',NULL,NULL),(645,NULL,'ESlot',801,'',NULL,NULL),(646,NULL,'ESlot',802,'',NULL,NULL),(647,NULL,'ESlot',803,'',NULL,NULL),(648,NULL,'ESlot',804,'',NULL,NULL),(649,NULL,'ESlot',808,'',NULL,NULL),(650,NULL,'ESlot',809,'',NULL,NULL),(651,NULL,'ESlot',810,'',NULL,NULL),(652,NULL,'ESlot',811,'',NULL,NULL),(653,NULL,'ESlot',812,'',NULL,NULL),(654,NULL,'ESlot',813,'',NULL,NULL),(655,NULL,'ESlot',814,'',NULL,NULL),(656,NULL,'ESlot',815,'',NULL,NULL),(657,NULL,'ESlot',819,'',NULL,NULL),(658,NULL,'ESlot',820,'',NULL,NULL),(659,NULL,'ESlot',821,'',NULL,NULL),(660,NULL,'ESlot',822,'',NULL,NULL),(661,NULL,'ESlot',823,'',NULL,NULL),(662,NULL,'ESlot',824,'cyp3a4',NULL,NULL),(663,NULL,'ESlot',825,'cyp3a4',NULL,NULL),(664,NULL,'ESlot',826,'',NULL,NULL),(665,NULL,'ESlot',832,'',NULL,NULL),(666,NULL,'ESlot',833,'',NULL,NULL),(667,NULL,'ESlot',834,'',NULL,NULL),(668,NULL,'ESlot',835,'',NULL,NULL),(669,NULL,'ESlot',836,'',NULL,NULL),(670,NULL,'ESlot',837,'',NULL,NULL),(671,NULL,'ESlot',838,'',NULL,NULL),(672,NULL,'ESlot',839,'',NULL,NULL),(673,NULL,'ESlot',845,'',NULL,NULL),(674,NULL,'ESlot',846,'',NULL,NULL),(675,NULL,'ESlot',847,'',NULL,NULL),(676,NULL,'ESlot',848,'',NULL,NULL),(677,NULL,'ESlot',849,'',NULL,NULL),(678,NULL,'ESlot',850,'',NULL,NULL),(679,NULL,'ESlot',851,'',NULL,NULL),(680,NULL,'ESlot',852,'',NULL,NULL),(681,NULL,'ESlot',856,'',NULL,NULL),(682,NULL,'ESlot',857,'',NULL,NULL),(683,NULL,'ESlot',858,'',NULL,NULL),(684,NULL,'ESlot',859,'',NULL,NULL),(685,NULL,'ESlot',860,'',NULL,NULL),(686,NULL,'ESlot',861,'',NULL,NULL),(687,NULL,'ESlot',862,'',NULL,NULL),(688,NULL,'ESlot',863,'',NULL,NULL),(689,NULL,'ESlot',864,'',NULL,NULL),(690,NULL,'ESlot',865,'',NULL,NULL),(691,NULL,'ESlot',866,'',NULL,NULL),(692,NULL,'ESlot',867,'',NULL,NULL),(693,NULL,'ESlot',868,'',NULL,NULL),(694,NULL,'ESlot',869,'',NULL,NULL),(695,NULL,'ESlot',870,'',NULL,NULL),(696,NULL,'ESlot',871,'',NULL,NULL),(697,NULL,'ESlot',877,'',NULL,NULL),(698,NULL,'ESlot',878,'',NULL,NULL),(699,NULL,'ESlot',879,'',NULL,NULL),(700,NULL,'ESlot',880,'',NULL,NULL),(701,NULL,'ESlot',881,'',NULL,NULL),(702,NULL,'ESlot',882,'',NULL,NULL),(703,NULL,'ESlot',883,'',NULL,NULL),(704,NULL,'ESlot',884,'',NULL,NULL),(705,NULL,'ESlot',885,'',NULL,NULL),(706,NULL,'ESlot',886,'',NULL,NULL),(707,NULL,'ESlot',887,'',NULL,NULL),(708,NULL,'ESlot',888,'',NULL,NULL),(709,NULL,'ESlot',889,'',NULL,NULL),(710,NULL,'ESlot',890,'',NULL,NULL),(711,NULL,'ESlot',891,'',NULL,NULL),(712,NULL,'ESlot',892,'',NULL,NULL),(713,NULL,'ESlot',893,'Metabolic_Clearance',NULL,NULL),(714,NULL,'ESlot',894,'',NULL,NULL),(715,NULL,'ESlot',895,'',NULL,NULL),(716,NULL,'ESlot',896,'',NULL,NULL),(717,NULL,'ESlot',897,'',NULL,NULL),(718,NULL,'ESlot',898,'',NULL,NULL),(719,NULL,'ESlot',899,'',NULL,NULL),(720,NULL,'ESlot',900,'',NULL,NULL),(721,NULL,'ESlot',911,'',NULL,NULL),(722,NULL,'ESlot',912,'',NULL,NULL),(723,NULL,'ESlot',913,'',NULL,NULL),(724,NULL,'ESlot',914,'',NULL,NULL),(725,NULL,'ESlot',915,'',NULL,NULL),(726,NULL,'ESlot',916,'',NULL,NULL),(727,NULL,'ESlot',917,'',NULL,NULL),(728,NULL,'ESlot',918,'',NULL,NULL),(729,NULL,'ESlot',919,'',NULL,NULL),(730,NULL,'ESlot',920,'',NULL,NULL),(731,NULL,'ESlot',921,'',NULL,NULL),(732,NULL,'ESlot',922,'',NULL,NULL),(733,NULL,'ESlot',923,'',NULL,NULL),(734,NULL,'ESlot',924,'',NULL,NULL),(735,NULL,'ESlot',925,'',NULL,NULL),(736,NULL,'ESlot',926,'',NULL,NULL),(737,NULL,'ESlot',927,'',NULL,NULL),(738,NULL,'ESlot',928,'',NULL,NULL),(739,NULL,'ESlot',929,'',NULL,NULL),(740,NULL,'ESlot',930,'',NULL,NULL),(741,NULL,'ESlot',931,'',NULL,NULL),(742,NULL,'ESlot',932,'',NULL,NULL),(743,NULL,'ESlot',933,'',NULL,NULL),(744,NULL,'ESlot',934,'',NULL,NULL),(745,NULL,'ESlot',935,'',NULL,NULL),(746,NULL,'ESlot',936,'',NULL,NULL),(747,NULL,'ESlot',937,'',NULL,NULL),(748,NULL,'ESlot',938,'',NULL,NULL),(749,NULL,'ESlot',939,'',NULL,NULL),(750,NULL,'ESlot',940,'',NULL,NULL),(751,NULL,'ESlot',941,'',NULL,NULL),(752,NULL,'ESlot',942,'',NULL,NULL),(753,NULL,'ESlot',946,'',NULL,NULL),(754,NULL,'ESlot',947,'',NULL,NULL),(755,NULL,'ESlot',948,'',NULL,NULL),(756,NULL,'ESlot',949,'',NULL,NULL),(757,NULL,'ESlot',950,'',NULL,NULL),(758,NULL,'ESlot',951,'',NULL,NULL),(759,NULL,'ESlot',952,'',NULL,NULL),(760,NULL,'ESlot',953,'',NULL,NULL),(761,NULL,'ESlot',954,'Renal_Excretion',NULL,NULL),(762,NULL,'ESlot',955,'',NULL,NULL),(763,NULL,'ESlot',956,'',NULL,NULL),(764,NULL,'ESlot',957,'',NULL,NULL),(765,NULL,'ESlot',958,'',NULL,NULL),(766,NULL,'ESlot',959,'',NULL,NULL),(767,NULL,'ESlot',960,'',NULL,NULL),(768,NULL,'ESlot',961,'',NULL,NULL),(769,NULL,'ESlot',966,'',NULL,NULL),(770,NULL,'ESlot',967,'',NULL,NULL),(771,NULL,'ESlot',968,'',NULL,NULL),(772,NULL,'ESlot',969,'',NULL,NULL),(773,NULL,'ESlot',970,'',NULL,NULL),(774,NULL,'ESlot',971,'',NULL,NULL),(775,NULL,'ESlot',972,'',NULL,NULL),(776,NULL,'ESlot',973,'',NULL,NULL),(777,NULL,'ESlot',974,'Metabolic_Clearance',NULL,NULL),(778,NULL,'ESlot',975,'',NULL,NULL),(779,NULL,'ESlot',976,'cyp2d6',NULL,NULL),(780,NULL,'ESlot',977,'',NULL,NULL),(781,NULL,'ESlot',978,'',NULL,NULL),(782,NULL,'ESlot',979,'',NULL,NULL),(783,NULL,'ESlot',980,'',NULL,NULL),(784,NULL,'ESlot',981,'',NULL,NULL),(785,NULL,'ESlot',990,'',NULL,NULL),(786,NULL,'ESlot',991,'',NULL,NULL),(787,NULL,'ESlot',992,'',NULL,NULL),(788,NULL,'ESlot',993,'',NULL,NULL),(789,NULL,'ESlot',994,'',NULL,NULL),(790,NULL,'ESlot',995,'',NULL,NULL),(791,NULL,'ESlot',996,'',NULL,NULL),(792,NULL,'ESlot',997,'',NULL,NULL),(793,NULL,'ESlot',998,'',NULL,NULL),(794,NULL,'ESlot',999,'',NULL,NULL),(795,NULL,'ESlot',1000,'',NULL,NULL),(796,NULL,'ESlot',1001,'',NULL,NULL),(797,NULL,'ESlot',1002,'',NULL,NULL),(798,NULL,'ESlot',1003,'',NULL,NULL),(799,NULL,'ESlot',1004,'',NULL,NULL),(800,NULL,'ESlot',1005,'',NULL,NULL),(801,NULL,'ESlot',1006,'',NULL,NULL),(802,NULL,'ESlot',1007,'',NULL,NULL),(803,NULL,'ESlot',1008,'',NULL,NULL),(804,NULL,'ESlot',1009,'',NULL,NULL),(805,NULL,'ESlot',1010,'',NULL,NULL),(806,NULL,'ESlot',1011,'',NULL,NULL),(807,NULL,'ESlot',1012,'',NULL,NULL),(808,NULL,'ESlot',1013,'',NULL,NULL),(809,NULL,'ESlot',1014,'',NULL,NULL),(810,NULL,'ESlot',1015,'',NULL,NULL),(811,NULL,'ESlot',1016,'',NULL,NULL),(812,NULL,'ESlot',1017,'',NULL,NULL),(813,NULL,'ESlot',1018,'',NULL,NULL),(814,NULL,'ESlot',1019,'',NULL,NULL),(815,NULL,'ESlot',1020,'',NULL,NULL),(816,NULL,'ESlot',1021,'',NULL,NULL),(817,NULL,'ESlot',1025,'',NULL,NULL),(818,NULL,'ESlot',1026,'',NULL,NULL),(819,NULL,'ESlot',1027,'',NULL,NULL),(820,NULL,'ESlot',1028,'',NULL,NULL),(821,NULL,'ESlot',1029,'',NULL,NULL),(822,NULL,'ESlot',1030,'',NULL,NULL),(823,NULL,'ESlot',1031,'',NULL,NULL),(824,NULL,'ESlot',1032,'',NULL,NULL),(825,NULL,'ESlot',1033,'',NULL,NULL),(826,NULL,'ESlot',1034,'',NULL,NULL),(827,NULL,'ESlot',1035,'',NULL,NULL),(828,NULL,'ESlot',1036,'cyp3a4',NULL,NULL),(829,NULL,'ESlot',1037,'',NULL,NULL),(830,NULL,'ESlot',1038,'',NULL,NULL),(831,NULL,'ESlot',1039,'',NULL,NULL),(832,NULL,'ESlot',1040,'',NULL,NULL),(833,NULL,'ESlot',1041,'',NULL,NULL),(834,NULL,'ESlot',1042,'',NULL,NULL),(835,NULL,'ESlot',1043,'',NULL,NULL),(836,NULL,'ESlot',1044,'',NULL,NULL),(837,NULL,'ESlot',1045,'',NULL,NULL),(838,NULL,'ESlot',1046,'',NULL,NULL),(839,NULL,'ESlot',1047,'',NULL,NULL),(840,NULL,'ESlot',1048,'',NULL,NULL),(841,NULL,'ESlot',1051,'Metabolic_Clearance',NULL,NULL),(842,NULL,'ESlot',1052,'',NULL,NULL),(843,NULL,'ESlot',1053,'',NULL,NULL),(844,NULL,'ESlot',1054,'',NULL,NULL),(845,NULL,'ESlot',1055,'',NULL,NULL),(846,NULL,'ESlot',1056,'',NULL,NULL),(847,NULL,'ESlot',1057,'',NULL,NULL),(848,NULL,'ESlot',1058,'',NULL,NULL),(849,NULL,'ESlot',1066,'',NULL,NULL),(850,NULL,'ESlot',1067,'',NULL,NULL),(851,NULL,'ESlot',1068,'',NULL,NULL),(852,NULL,'ESlot',1069,'',NULL,NULL),(853,NULL,'ESlot',1070,'',NULL,NULL),(854,NULL,'ESlot',1071,'',NULL,NULL),(855,NULL,'ESlot',1072,'',NULL,NULL),(856,NULL,'ESlot',1073,'',NULL,NULL),(857,NULL,'ESlot',1074,'',NULL,NULL),(858,NULL,'ESlot',1075,'',NULL,NULL),(859,NULL,'ESlot',1076,'',NULL,NULL),(860,NULL,'ESlot',1077,'',NULL,NULL),(861,NULL,'ESlot',1078,'',NULL,NULL),(862,NULL,'ESlot',1079,'',NULL,NULL),(863,NULL,'ESlot',1080,'',NULL,NULL),(864,NULL,'ESlot',1081,'',NULL,NULL),(865,NULL,'ESlot',1083,'',NULL,NULL),(866,NULL,'ESlot',1084,'',NULL,NULL),(867,NULL,'ESlot',1085,'',NULL,NULL),(868,NULL,'ESlot',1086,'',NULL,NULL),(869,NULL,'ESlot',1087,'',NULL,NULL),(870,NULL,'ESlot',1088,'',NULL,NULL),(871,NULL,'ESlot',1089,'',NULL,NULL),(872,NULL,'ESlot',1090,'',NULL,NULL),(873,NULL,'ESlot',1091,'',NULL,NULL),(874,NULL,'ESlot',1092,'',NULL,NULL),(875,NULL,'ESlot',1093,'',NULL,NULL),(876,NULL,'ESlot',1094,'',NULL,NULL),(877,NULL,'ESlot',1095,'',NULL,NULL),(878,NULL,'ESlot',1096,'',NULL,NULL),(879,NULL,'ESlot',1097,'',NULL,NULL),(880,NULL,'ESlot',1098,'',NULL,NULL),(881,NULL,'ESlot',1099,'',NULL,NULL),(882,NULL,'ESlot',1100,'',NULL,NULL),(883,NULL,'ESlot',1101,'',NULL,NULL),(884,NULL,'ESlot',1102,'',NULL,NULL),(885,NULL,'ESlot',1103,'',NULL,NULL),(886,NULL,'ESlot',1104,'',NULL,NULL),(887,NULL,'ESlot',1105,'',NULL,NULL),(888,NULL,'ESlot',1106,'',NULL,NULL),(889,NULL,'ESlot',1109,'',NULL,NULL),(890,NULL,'ESlot',1110,'',NULL,NULL),(891,NULL,'ESlot',1111,'',NULL,NULL),(892,NULL,'ESlot',1112,'',NULL,NULL),(893,NULL,'ESlot',1113,'',NULL,NULL),(894,NULL,'ESlot',1114,'',NULL,NULL),(895,NULL,'ESlot',1115,'',NULL,NULL),(896,NULL,'ESlot',1116,'',NULL,NULL),(897,NULL,'ESlot',1122,'Metabolic_Clearance',NULL,NULL),(898,NULL,'ESlot',1123,'',NULL,NULL),(899,NULL,'ESlot',1124,'',NULL,NULL),(900,NULL,'ESlot',1125,'',NULL,NULL),(901,NULL,'ESlot',1126,'',NULL,NULL),(902,NULL,'ESlot',1127,'',NULL,NULL),(903,NULL,'ESlot',1128,'',NULL,NULL),(904,NULL,'ESlot',1129,'',NULL,NULL),(905,NULL,'ESlot',1135,'',NULL,NULL),(906,NULL,'ESlot',1136,'',NULL,NULL),(907,NULL,'ESlot',1137,'',NULL,NULL),(908,NULL,'ESlot',1138,'',NULL,NULL),(909,NULL,'ESlot',1139,'',NULL,NULL),(910,NULL,'ESlot',1140,'',NULL,NULL),(911,NULL,'ESlot',1141,'',NULL,NULL),(912,NULL,'ESlot',1142,'',NULL,NULL),(913,NULL,'ESlot',1146,'',NULL,NULL),(914,NULL,'ESlot',1147,'',NULL,NULL),(915,NULL,'ESlot',1148,'',NULL,NULL),(916,NULL,'ESlot',1149,'',NULL,NULL),(917,NULL,'ESlot',1150,'',NULL,NULL),(918,NULL,'ESlot',1151,'',NULL,NULL),(919,NULL,'ESlot',1152,'',NULL,NULL),(920,NULL,'ESlot',1153,'',NULL,NULL),(921,NULL,'ESlot',1156,'',NULL,NULL),(922,NULL,'ESlot',1157,'',NULL,NULL),(923,NULL,'ESlot',1158,'',NULL,NULL),(924,NULL,'ESlot',1159,'',NULL,NULL),(925,NULL,'ESlot',1160,'',NULL,NULL),(926,NULL,'ESlot',1161,'',NULL,NULL),(927,NULL,'ESlot',1162,'',NULL,NULL),(928,NULL,'ESlot',1163,'',NULL,NULL),(929,NULL,'ESlot',1166,'',NULL,NULL),(930,NULL,'ESlot',1167,'',NULL,NULL),(931,NULL,'ESlot',1168,'',NULL,NULL),(932,NULL,'ESlot',1169,'',NULL,NULL),(933,NULL,'ESlot',1170,'',NULL,NULL),(934,NULL,'ESlot',1171,'',NULL,NULL),(935,NULL,'ESlot',1172,'',NULL,NULL),(936,NULL,'ESlot',1173,'',NULL,NULL),(937,NULL,'ESlot',1174,'',NULL,NULL),(938,NULL,'ESlot',1175,'',NULL,NULL),(939,NULL,'ESlot',1176,'',NULL,NULL),(940,NULL,'ESlot',1177,'',NULL,NULL),(941,NULL,'ESlot',1178,'',NULL,NULL),(942,NULL,'ESlot',1179,'cyp2d6',NULL,NULL),(943,NULL,'ESlot',1180,'cyp2d6',NULL,NULL),(944,NULL,'ESlot',1181,'',NULL,NULL),(945,NULL,'ESlot',1185,'',NULL,NULL),(946,NULL,'ESlot',1186,'',NULL,NULL),(947,NULL,'ESlot',1187,'',NULL,NULL),(948,NULL,'ESlot',1188,'',NULL,NULL),(949,NULL,'ESlot',1189,'',NULL,NULL),(950,NULL,'ESlot',1190,'',NULL,NULL),(951,NULL,'ESlot',1191,'',NULL,NULL),(952,NULL,'ESlot',1192,'',NULL,NULL),(953,NULL,'ESlot',1193,'',NULL,NULL),(954,NULL,'ESlot',1194,'',NULL,NULL),(955,NULL,'ESlot',1195,'',NULL,NULL),(956,NULL,'ESlot',1196,'',NULL,NULL),(957,NULL,'ESlot',1197,'',NULL,NULL),(958,NULL,'ESlot',1198,'',NULL,NULL),(959,NULL,'ESlot',1199,'',NULL,NULL),(960,NULL,'ESlot',1200,'',NULL,NULL),(961,NULL,'ESlot',1204,'',NULL,NULL),(962,NULL,'ESlot',1205,'',NULL,NULL),(963,NULL,'ESlot',1206,'',NULL,NULL),(964,NULL,'ESlot',1207,'',NULL,NULL),(965,NULL,'ESlot',1208,'',NULL,NULL),(966,NULL,'ESlot',1209,'',NULL,NULL),(967,NULL,'ESlot',1210,'',NULL,NULL),(968,NULL,'ESlot',1211,'',NULL,NULL),(969,NULL,'ESlot',1215,'',NULL,NULL),(970,NULL,'ESlot',1216,'',NULL,NULL),(971,NULL,'ESlot',1217,'',NULL,NULL),(972,NULL,'ESlot',1218,'',NULL,NULL),(973,NULL,'ESlot',1219,'',NULL,NULL),(974,NULL,'ESlot',1220,'',NULL,NULL),(975,NULL,'ESlot',1221,'',NULL,NULL),(976,NULL,'ESlot',1222,'',NULL,NULL),(977,NULL,'ESlot',1223,'',NULL,NULL),(978,NULL,'ESlot',1224,'',NULL,NULL),(979,NULL,'ESlot',1225,'',NULL,NULL),(980,NULL,'ESlot',1226,'',NULL,NULL),(981,NULL,'ESlot',1227,'',NULL,NULL),(982,NULL,'ESlot',1228,'',NULL,NULL),(983,NULL,'ESlot',1229,'',NULL,NULL),(984,NULL,'ESlot',1230,'',NULL,NULL),(985,NULL,'ESlot',1231,'',NULL,NULL),(986,NULL,'ESlot',1232,'',NULL,NULL),(987,NULL,'ESlot',1233,'',NULL,NULL),(988,NULL,'ESlot',1234,'cyp1a2',NULL,NULL),(989,NULL,'ESlot',1235,'',NULL,NULL),(990,NULL,'ESlot',1236,'',NULL,NULL),(991,NULL,'ESlot',1237,'',NULL,NULL),(992,NULL,'ESlot',1238,'',NULL,NULL),(993,NULL,'ESlot',1239,'',NULL,NULL),(994,NULL,'ESlot',1240,'',NULL,NULL),(995,NULL,'ESlot',1241,'cyp2c8',NULL,NULL),(996,NULL,'ESlot',1242,'',NULL,NULL),(997,NULL,'ESlot',1243,'',NULL,NULL),(998,NULL,'ESlot',1244,'',NULL,NULL),(999,NULL,'ESlot',1245,'',NULL,NULL),(1000,NULL,'ESlot',1246,'',NULL,NULL),(1001,NULL,'ESlot',1250,'',NULL,NULL),(1002,NULL,'ESlot',1251,'',NULL,NULL),(1003,NULL,'ESlot',1252,'',NULL,NULL),(1004,NULL,'ESlot',1253,'',NULL,NULL),(1005,NULL,'ESlot',1254,'',NULL,NULL),(1006,NULL,'ESlot',1255,'',NULL,NULL),(1007,NULL,'ESlot',1256,'',NULL,NULL),(1008,NULL,'ESlot',1257,'',NULL,NULL),(1009,NULL,'ESlot',1258,'',NULL,NULL),(1010,NULL,'ESlot',1259,'',NULL,NULL),(1011,NULL,'ESlot',1260,'',NULL,NULL),(1012,NULL,'ESlot',1261,'',NULL,NULL),(1013,NULL,'ESlot',1262,'',NULL,NULL),(1014,NULL,'ESlot',1263,'',NULL,NULL),(1015,NULL,'ESlot',1264,'',NULL,NULL),(1016,NULL,'ESlot',1265,'',NULL,NULL),(1017,NULL,'ESlot',1266,'',NULL,NULL),(1018,NULL,'ESlot',1267,'',NULL,NULL),(1019,NULL,'ESlot',1268,'',NULL,NULL),(1020,NULL,'ESlot',1269,'',NULL,NULL),(1021,NULL,'ESlot',1270,'',NULL,NULL),(1022,NULL,'ESlot',1271,'',NULL,NULL),(1023,NULL,'ESlot',1272,'',NULL,NULL),(1024,NULL,'ESlot',1273,'',NULL,NULL),(1025,NULL,'ESlot',1274,'Metabolic_Clearance',NULL,NULL),(1026,NULL,'ESlot',1275,'',NULL,NULL),(1027,NULL,'ESlot',1276,'',NULL,NULL),(1028,NULL,'ESlot',1277,'',NULL,NULL),(1029,NULL,'ESlot',1278,'',NULL,NULL),(1030,NULL,'ESlot',1279,'',NULL,NULL),(1031,NULL,'ESlot',1280,'',NULL,NULL),(1032,NULL,'ESlot',1281,'',NULL,NULL),(1033,NULL,'ESlot',1285,'',NULL,NULL),(1034,NULL,'ESlot',1286,'',NULL,NULL),(1035,NULL,'ESlot',1287,'',NULL,NULL),(1036,NULL,'ESlot',1288,'',NULL,NULL),(1037,NULL,'ESlot',1289,'',NULL,NULL),(1038,NULL,'ESlot',1290,'',NULL,NULL),(1039,NULL,'ESlot',1291,'',NULL,NULL),(1040,NULL,'ESlot',1292,'',NULL,NULL),(1041,NULL,'ESlot',1293,'',NULL,NULL),(1042,NULL,'ESlot',1294,'',NULL,NULL),(1043,NULL,'ESlot',1295,'',NULL,NULL),(1044,NULL,'ESlot',1296,'',NULL,NULL),(1045,NULL,'ESlot',1297,'',NULL,NULL),(1046,NULL,'ESlot',1298,'',NULL,NULL),(1047,NULL,'ESlot',1299,'',NULL,NULL),(1048,NULL,'ESlot',1300,'',NULL,NULL),(1049,NULL,'ESlot',1303,'',NULL,NULL),(1050,NULL,'ESlot',1304,'',NULL,NULL),(1051,NULL,'ESlot',1305,'',NULL,NULL),(1052,NULL,'ESlot',1306,'',NULL,NULL),(1053,NULL,'ESlot',1307,'',NULL,NULL),(1054,NULL,'ESlot',1308,'',NULL,NULL),(1055,NULL,'ESlot',1309,'',NULL,NULL),(1056,NULL,'ESlot',1310,'',NULL,NULL),(1057,NULL,'ESlot',1311,'Metabolic_Clearance',NULL,NULL),(1058,NULL,'ESlot',1312,'',NULL,NULL),(1059,NULL,'ESlot',1313,'',NULL,NULL),(1060,NULL,'ESlot',1314,'',NULL,NULL),(1061,NULL,'ESlot',1315,'',NULL,NULL),(1062,NULL,'ESlot',1316,'',NULL,NULL),(1063,NULL,'ESlot',1317,'',NULL,NULL),(1064,NULL,'ESlot',1318,'',NULL,NULL),(1065,NULL,'ESlot',1326,'',NULL,NULL),(1066,NULL,'ESlot',1327,'',NULL,NULL),(1067,NULL,'ESlot',1328,'',NULL,NULL),(1068,NULL,'ESlot',1329,'',NULL,NULL),(1069,NULL,'ESlot',1330,'',NULL,NULL),(1070,NULL,'ESlot',1331,'',NULL,NULL),(1071,NULL,'ESlot',1332,'',NULL,NULL),(1072,NULL,'ESlot',1333,'',NULL,NULL),(1073,NULL,'ESlot',1334,'Metabolic_Clearance',NULL,NULL),(1074,NULL,'ESlot',1335,'',NULL,NULL),(1075,NULL,'ESlot',1336,'cyp3a4',NULL,NULL),(1076,NULL,'ESlot',1337,'',NULL,NULL),(1077,NULL,'ESlot',1338,'',NULL,NULL),(1078,NULL,'ESlot',1339,'',NULL,NULL),(1079,NULL,'ESlot',1340,'',NULL,NULL),(1080,NULL,'ESlot',1341,'',NULL,NULL),(1081,NULL,'ESlot',1353,'',NULL,NULL),(1082,NULL,'ESlot',1354,'',NULL,NULL),(1083,NULL,'ESlot',1355,'',NULL,NULL),(1084,NULL,'ESlot',1356,'',NULL,NULL),(1085,NULL,'ESlot',1357,'',NULL,NULL),(1086,NULL,'ESlot',1358,'cyp2c9',NULL,NULL),(1087,NULL,'ESlot',1359,'',NULL,NULL),(1088,NULL,'ESlot',1360,'',NULL,NULL),(1089,NULL,'ESlot',1361,'',NULL,NULL),(1090,NULL,'ESlot',1362,'',NULL,NULL),(1091,NULL,'ESlot',1363,'',NULL,NULL),(1092,NULL,'ESlot',1364,'',NULL,NULL),(1093,NULL,'ESlot',1365,'',NULL,NULL),(1094,NULL,'ESlot',1366,'',NULL,NULL),(1095,NULL,'ESlot',1367,'',NULL,NULL),(1096,NULL,'ESlot',1368,'',NULL,NULL),(1097,NULL,'ESlot',1369,'',NULL,NULL),(1098,NULL,'ESlot',1370,'',NULL,NULL),(1099,NULL,'ESlot',1371,'',NULL,NULL),(1100,NULL,'ESlot',1372,'',NULL,NULL),(1101,NULL,'ESlot',1373,'',NULL,NULL),(1102,NULL,'ESlot',1374,'',NULL,NULL),(1103,NULL,'ESlot',1375,'',NULL,NULL),(1104,NULL,'ESlot',1376,'',NULL,NULL),(1105,NULL,'ESlot',1377,'',NULL,NULL),(1106,NULL,'ESlot',1378,'',NULL,NULL),(1107,NULL,'ESlot',1379,'',NULL,NULL),(1108,NULL,'ESlot',1380,'',NULL,NULL),(1109,NULL,'ESlot',1381,'',NULL,NULL),(1110,NULL,'ESlot',1382,'',NULL,NULL),(1111,NULL,'ESlot',1383,'',NULL,NULL),(1112,NULL,'ESlot',1384,'',NULL,NULL),(1113,NULL,'ESlot',1388,'Metabolic_Clearance',NULL,NULL),(1114,NULL,'ESlot',1389,'',NULL,NULL),(1115,NULL,'ESlot',1390,'',NULL,NULL),(1116,NULL,'ESlot',1391,'',NULL,NULL),(1117,NULL,'ESlot',1392,'',NULL,NULL),(1118,NULL,'ESlot',1393,'cyp3a4',NULL,NULL),(1119,NULL,'ESlot',1394,'cyp3a4',NULL,NULL),(1120,NULL,'ESlot',1395,'',NULL,NULL),(1121,NULL,'ESlot',1401,'',NULL,NULL),(1122,NULL,'ESlot',1402,'',NULL,NULL),(1123,NULL,'ESlot',1403,'',NULL,NULL),(1124,NULL,'ESlot',1404,'',NULL,NULL),(1125,NULL,'ESlot',1405,'',NULL,NULL),(1126,NULL,'ESlot',1406,'',NULL,NULL),(1127,NULL,'ESlot',1407,'',NULL,NULL),(1128,NULL,'ESlot',1408,'',NULL,NULL),(1129,NULL,'ESlot',1409,'',NULL,NULL),(1130,NULL,'ESlot',1410,'',NULL,NULL),(1131,NULL,'ESlot',1411,'',NULL,NULL),(1132,NULL,'ESlot',1412,'',NULL,NULL),(1133,NULL,'ESlot',1413,'',NULL,NULL),(1134,NULL,'ESlot',1414,'',NULL,NULL),(1135,NULL,'ESlot',1415,'',NULL,NULL),(1136,NULL,'ESlot',1416,'',NULL,NULL),(1137,NULL,'ESlot',1419,'',NULL,NULL),(1138,NULL,'ESlot',1420,'',NULL,NULL),(1139,NULL,'ESlot',1421,'',NULL,NULL),(1140,NULL,'ESlot',1422,'',NULL,NULL),(1141,NULL,'ESlot',1423,'',NULL,NULL),(1142,NULL,'ESlot',1424,'',NULL,NULL),(1143,NULL,'ESlot',1425,'',NULL,NULL),(1144,NULL,'ESlot',1426,'',NULL,NULL),(1145,NULL,'ESlot',1429,'',NULL,NULL),(1146,NULL,'ESlot',1430,'',NULL,NULL),(1147,NULL,'ESlot',1431,'',NULL,NULL),(1148,NULL,'ESlot',1432,'',NULL,NULL),(1149,NULL,'ESlot',1433,'',NULL,NULL),(1150,NULL,'ESlot',1434,'',NULL,NULL),(1151,NULL,'ESlot',1435,'',NULL,NULL),(1152,NULL,'ESlot',1436,'',NULL,NULL),(1153,NULL,'ESlot',1437,'',NULL,NULL),(1154,NULL,'ESlot',1438,'',NULL,NULL),(1155,NULL,'ESlot',1439,'',NULL,NULL),(1156,NULL,'ESlot',1440,'',NULL,NULL),(1157,NULL,'ESlot',1441,'',NULL,NULL),(1158,NULL,'ESlot',1442,'',NULL,NULL),(1159,NULL,'ESlot',1443,'',NULL,NULL),(1160,NULL,'ESlot',1444,'',NULL,NULL),(1161,NULL,'ESlot',1445,'',NULL,NULL),(1162,NULL,'ESlot',1446,'',NULL,NULL),(1163,NULL,'ESlot',1447,'',NULL,NULL),(1164,NULL,'ESlot',1448,'',NULL,NULL),(1165,NULL,'ESlot',1449,'',NULL,NULL),(1166,NULL,'ESlot',1450,'',NULL,NULL),(1167,NULL,'ESlot',1451,'',NULL,NULL),(1168,NULL,'ESlot',1452,'',NULL,NULL),(1169,NULL,'ESlot',1453,'',NULL,NULL),(1170,NULL,'ESlot',1454,'',NULL,NULL),(1171,NULL,'ESlot',1455,'',NULL,NULL),(1172,NULL,'ESlot',1456,'',NULL,NULL),(1173,NULL,'ESlot',1457,'',NULL,NULL),(1174,NULL,'ESlot',1458,'',NULL,NULL),(1175,NULL,'ESlot',1459,'',NULL,NULL),(1176,NULL,'ESlot',1460,'',NULL,NULL),(1177,NULL,'ESlot',1465,'',NULL,NULL),(1178,NULL,'ESlot',1466,'',NULL,NULL),(1179,NULL,'ESlot',1467,'',NULL,NULL),(1180,NULL,'ESlot',1468,'',NULL,NULL),(1181,NULL,'ESlot',1469,'',NULL,NULL),(1182,NULL,'ESlot',1470,'',NULL,NULL),(1183,NULL,'ESlot',1471,'',NULL,NULL),(1184,NULL,'ESlot',1472,'',NULL,NULL),(1185,NULL,'ESlot',1473,'',NULL,NULL),(1186,NULL,'ESlot',1474,'',NULL,NULL),(1187,NULL,'ESlot',1475,'',NULL,NULL),(1188,NULL,'ESlot',1476,'',NULL,NULL),(1189,NULL,'ESlot',1477,'',NULL,NULL),(1190,NULL,'ESlot',1478,'',NULL,NULL),(1191,NULL,'ESlot',1479,'',NULL,NULL),(1192,NULL,'ESlot',1480,'',NULL,NULL),(1193,NULL,'ESlot',1481,'Metabolic_Clearance',NULL,NULL),(1194,NULL,'ESlot',1482,'cyp2d6',NULL,NULL),(1195,NULL,'ESlot',1483,'',NULL,NULL),(1196,NULL,'ESlot',1484,'',NULL,NULL),(1197,NULL,'ESlot',1485,'',NULL,NULL),(1198,NULL,'ESlot',1486,'',NULL,NULL),(1199,NULL,'ESlot',1487,'',NULL,NULL),(1200,NULL,'ESlot',1488,'',NULL,NULL),(1201,NULL,'ESlot',1498,'',NULL,NULL),(1202,NULL,'ESlot',1499,'',NULL,NULL),(1203,NULL,'ESlot',1500,'',NULL,NULL),(1204,NULL,'ESlot',1501,'',NULL,NULL),(1205,NULL,'ESlot',1502,'',NULL,NULL),(1206,NULL,'ESlot',1503,'',NULL,NULL),(1207,NULL,'ESlot',1504,'',NULL,NULL),(1208,NULL,'ESlot',1505,'',NULL,NULL),(1209,NULL,'ESlot',1506,'',NULL,NULL),(1210,NULL,'ESlot',1507,'',NULL,NULL),(1211,NULL,'ESlot',1508,'',NULL,NULL),(1212,NULL,'ESlot',1509,'',NULL,NULL),(1213,NULL,'ESlot',1510,'',NULL,NULL),(1214,NULL,'ESlot',1511,'',NULL,NULL),(1215,NULL,'ESlot',1512,'',NULL,NULL),(1216,NULL,'ESlot',1513,'',NULL,NULL),(1217,NULL,'ESlot',1514,'',NULL,NULL),(1218,NULL,'ESlot',1515,'',NULL,NULL),(1219,NULL,'ESlot',1516,'',NULL,NULL),(1220,NULL,'ESlot',1517,'',NULL,NULL),(1221,NULL,'ESlot',1518,'',NULL,NULL),(1222,NULL,'ESlot',1519,'',NULL,NULL),(1223,NULL,'ESlot',1520,'',NULL,NULL),(1224,NULL,'ESlot',1521,'',NULL,NULL),(1225,NULL,'ESlot',1525,'',NULL,NULL),(1226,NULL,'ESlot',1526,'',NULL,NULL),(1227,NULL,'ESlot',1527,'cyp2d6',NULL,NULL),(1228,NULL,'ESlot',1528,'',NULL,NULL),(1229,NULL,'ESlot',1529,'',NULL,NULL),(1230,NULL,'ESlot',1530,'',NULL,NULL),(1231,NULL,'ESlot',1531,'',NULL,NULL),(1232,NULL,'ESlot',1532,'',NULL,NULL),(1233,NULL,'ESlot',1533,'',NULL,NULL),(1234,NULL,'ESlot',1534,'',NULL,NULL),(1235,NULL,'ESlot',1535,'cyp3a4',NULL,NULL),(1236,NULL,'ESlot',1536,'',NULL,NULL),(1237,NULL,'ESlot',1537,'',NULL,NULL),(1238,NULL,'ESlot',1538,'',NULL,NULL),(1239,NULL,'ESlot',1539,'',NULL,NULL),(1240,NULL,'ESlot',1540,'',NULL,NULL),(1241,NULL,'ESlot',1547,'',NULL,NULL),(1242,NULL,'ESlot',1548,'',NULL,NULL),(1243,NULL,'ESlot',1549,'',NULL,NULL),(1244,NULL,'ESlot',1550,'',NULL,NULL),(1245,NULL,'ESlot',1551,'',NULL,NULL),(1246,NULL,'ESlot',1552,'',NULL,NULL),(1247,NULL,'ESlot',1553,'',NULL,NULL),(1248,NULL,'ESlot',1554,'',NULL,NULL),(1249,NULL,'ESlot',1555,'',NULL,NULL),(1250,NULL,'ESlot',1556,'',NULL,NULL),(1251,NULL,'ESlot',1557,'',NULL,NULL),(1252,NULL,'ESlot',1558,'',NULL,NULL),(1253,NULL,'ESlot',1559,'',NULL,NULL),(1254,NULL,'ESlot',1560,'',NULL,NULL),(1255,NULL,'ESlot',1561,'',NULL,NULL),(1256,NULL,'ESlot',1562,'',NULL,NULL),(1257,NULL,'ESlot',1563,'',NULL,NULL),(1258,NULL,'ESlot',1564,'',NULL,NULL),(1259,NULL,'ESlot',1565,'',NULL,NULL),(1260,NULL,'ESlot',1566,'',NULL,NULL),(1261,NULL,'ESlot',1567,'',NULL,NULL),(1262,NULL,'ESlot',1568,'',NULL,NULL),(1263,NULL,'ESlot',1569,'',NULL,NULL),(1264,NULL,'ESlot',1570,'',NULL,NULL),(1265,NULL,'ESlot',1574,'',NULL,NULL),(1266,NULL,'ESlot',1575,'',NULL,NULL),(1267,NULL,'ESlot',1576,'',NULL,NULL),(1268,NULL,'ESlot',1577,'',NULL,NULL),(1269,NULL,'ESlot',1578,'',NULL,NULL),(1270,NULL,'ESlot',1579,'',NULL,NULL),(1271,NULL,'ESlot',1580,'',NULL,NULL),(1272,NULL,'ESlot',1581,'',NULL,NULL),(1273,NULL,'ESlot',1582,'',NULL,NULL),(1274,NULL,'ESlot',1583,'',NULL,NULL),(1275,NULL,'ESlot',1584,'',NULL,NULL),(1276,NULL,'ESlot',1585,'',NULL,NULL),(1277,NULL,'ESlot',1586,'',NULL,NULL),(1278,NULL,'ESlot',1587,'',NULL,NULL),(1279,NULL,'ESlot',1588,'',NULL,NULL),(1280,NULL,'ESlot',1589,'',NULL,NULL),(1281,NULL,'ESlot',1591,'',NULL,NULL),(1282,NULL,'ESlot',1592,'',NULL,NULL),(1283,NULL,'ESlot',1593,'',NULL,NULL),(1284,NULL,'ESlot',1594,'',NULL,NULL),(1285,NULL,'ESlot',1595,'',NULL,NULL),(1286,NULL,'ESlot',1596,'',NULL,NULL),(1287,NULL,'ESlot',1597,'',NULL,NULL),(1288,NULL,'ESlot',1598,'',NULL,NULL),(1289,NULL,'ESlot',1599,'',NULL,NULL),(1290,NULL,'ESlot',1600,'',NULL,NULL),(1291,NULL,'ESlot',1601,'',NULL,NULL),(1292,NULL,'ESlot',1602,'',NULL,NULL),(1293,NULL,'ESlot',1603,'',NULL,NULL),(1294,NULL,'ESlot',1604,'',NULL,NULL),(1295,NULL,'ESlot',1605,'',NULL,NULL),(1296,NULL,'ESlot',1606,'',NULL,NULL),(1297,NULL,'ESlot',1608,'',NULL,NULL),(1298,NULL,'ESlot',1609,'',NULL,NULL),(1299,NULL,'ESlot',1610,'',NULL,NULL),(1300,NULL,'ESlot',1611,'',NULL,NULL),(1301,NULL,'ESlot',1612,'',NULL,NULL),(1302,NULL,'ESlot',1613,'',NULL,NULL),(1303,NULL,'ESlot',1614,'',NULL,NULL),(1304,NULL,'ESlot',1615,'',NULL,NULL),(1305,NULL,'ESlot',1621,'Metabolic_Clearance',NULL,NULL),(1306,NULL,'ESlot',1622,'',NULL,NULL),(1307,NULL,'ESlot',1623,'cyp3a4',NULL,NULL),(1308,NULL,'ESlot',1624,'',NULL,NULL),(1309,NULL,'ESlot',1625,'',NULL,NULL),(1310,NULL,'ESlot',1626,'',NULL,NULL),(1311,NULL,'ESlot',1627,'',NULL,NULL),(1312,NULL,'ESlot',1628,'',NULL,NULL),(1313,NULL,'ESlot',1636,'',NULL,NULL),(1314,NULL,'ESlot',1637,'',NULL,NULL),(1315,NULL,'ESlot',1638,'',NULL,NULL),(1316,NULL,'ESlot',1639,'',NULL,NULL),(1317,NULL,'ESlot',1640,'',NULL,NULL),(1318,NULL,'ESlot',1641,'',NULL,NULL),(1319,NULL,'ESlot',1642,'',NULL,NULL),(1320,NULL,'ESlot',1643,'',NULL,NULL),(1321,NULL,'ESlot',1644,'',NULL,NULL),(1322,NULL,'ESlot',1645,'',NULL,NULL),(1323,NULL,'ESlot',1646,'',NULL,NULL),(1324,NULL,'ESlot',1647,'',NULL,NULL),(1325,NULL,'ESlot',1648,'',NULL,NULL),(1326,NULL,'ESlot',1649,'',NULL,NULL),(1327,NULL,'ESlot',1650,'',NULL,NULL),(1328,NULL,'ESlot',1651,'',NULL,NULL),(1329,NULL,'ESlot',1652,'',NULL,NULL),(1330,NULL,'ESlot',1653,'',NULL,NULL),(1331,NULL,'ESlot',1654,'',NULL,NULL),(1332,NULL,'ESlot',1655,'',NULL,NULL),(1333,NULL,'ESlot',1656,'',NULL,NULL),(1334,NULL,'ESlot',1657,'',NULL,NULL),(1335,NULL,'ESlot',1658,'',NULL,NULL),(1336,NULL,'ESlot',1659,'',NULL,NULL),(1337,NULL,'ESlot',1660,'Renal_Excretion',NULL,NULL),(1338,NULL,'ESlot',1661,'',NULL,NULL),(1339,NULL,'ESlot',1662,'',NULL,NULL),(1340,NULL,'ESlot',1663,'',NULL,NULL),(1341,NULL,'ESlot',1664,'',NULL,NULL),(1342,NULL,'ESlot',1665,'',NULL,NULL),(1343,NULL,'ESlot',1666,'',NULL,NULL),(1344,NULL,'ESlot',1667,'',NULL,NULL),(1345,NULL,'ESlot',1669,'',NULL,NULL),(1346,NULL,'ESlot',1670,'',NULL,NULL),(1347,NULL,'ESlot',1671,'',NULL,NULL),(1348,NULL,'ESlot',1672,'',NULL,NULL),(1349,NULL,'ESlot',1673,'',NULL,NULL),(1350,NULL,'ESlot',1674,'',NULL,NULL),(1351,NULL,'ESlot',1675,'',NULL,NULL),(1352,NULL,'ESlot',1676,'',NULL,NULL),(1353,NULL,'ESlot',1677,'',NULL,NULL),(1354,NULL,'ESlot',1678,'',NULL,NULL),(1355,NULL,'ESlot',1679,'',NULL,NULL),(1356,NULL,'ESlot',1680,'cyp2a6',NULL,NULL),(1357,NULL,'ESlot',1681,'',NULL,NULL),(1358,NULL,'ESlot',1682,'',NULL,NULL),(1359,NULL,'ESlot',1683,'',NULL,NULL),(1360,NULL,'ESlot',1684,'',NULL,NULL),(1361,NULL,'ESlot',1685,'',NULL,NULL),(1362,NULL,'ESlot',1686,'',NULL,NULL),(1363,NULL,'ESlot',1687,'',NULL,NULL),(1364,NULL,'ESlot',1688,'',NULL,NULL),(1365,NULL,'ESlot',1689,'',NULL,NULL),(1366,NULL,'ESlot',1690,'',NULL,NULL),(1367,NULL,'ESlot',1691,'',NULL,NULL),(1368,NULL,'ESlot',1692,'',NULL,NULL),(1369,NULL,'ESlot',1693,'',NULL,NULL),(1370,NULL,'ESlot',1694,'',NULL,NULL),(1371,NULL,'ESlot',1695,'',NULL,NULL),(1372,NULL,'ESlot',1696,'',NULL,NULL),(1373,NULL,'ESlot',1697,'',NULL,NULL),(1374,NULL,'ESlot',1698,'',NULL,NULL),(1375,NULL,'ESlot',1699,'',NULL,NULL),(1376,NULL,'ESlot',1700,'',NULL,NULL),(1377,NULL,'ESlot',1701,'',NULL,NULL),(1378,NULL,'ESlot',1702,'',NULL,NULL),(1379,NULL,'ESlot',1703,'',NULL,NULL),(1380,NULL,'ESlot',1704,'',NULL,NULL),(1381,NULL,'ESlot',1705,'',NULL,NULL),(1382,NULL,'ESlot',1706,'',NULL,NULL),(1383,NULL,'ESlot',1707,'',NULL,NULL),(1384,NULL,'ESlot',1708,'',NULL,NULL),(1385,NULL,'ESlot',1709,'Metabolic_Clearance',NULL,NULL),(1386,NULL,'ESlot',1710,'',NULL,NULL),(1387,NULL,'ESlot',1711,'',NULL,NULL),(1388,NULL,'ESlot',1712,'',NULL,NULL),(1389,NULL,'ESlot',1713,'',NULL,NULL),(1390,NULL,'ESlot',1714,'',NULL,NULL),(1391,NULL,'ESlot',1715,'',NULL,NULL),(1392,NULL,'ESlot',1716,'',NULL,NULL),(1393,NULL,'ESlot',1725,'',NULL,NULL),(1394,NULL,'ESlot',1726,'',NULL,NULL),(1395,NULL,'ESlot',1727,'',NULL,NULL),(1396,NULL,'ESlot',1728,'',NULL,NULL),(1397,NULL,'ESlot',1729,'',NULL,NULL),(1398,NULL,'ESlot',1730,'',NULL,NULL),(1399,NULL,'ESlot',1731,'',NULL,NULL),(1400,NULL,'ESlot',1732,'',NULL,NULL),(1401,NULL,'ESlot',1733,'',NULL,NULL),(1402,NULL,'ESlot',1734,'',NULL,NULL),(1403,NULL,'ESlot',1735,'',NULL,NULL),(1404,NULL,'ESlot',1736,'cyp2e1',NULL,NULL),(1405,NULL,'ESlot',1737,'',NULL,NULL),(1406,NULL,'ESlot',1738,'',NULL,NULL),(1407,NULL,'ESlot',1739,'',NULL,NULL),(1408,NULL,'ESlot',1740,'',NULL,NULL),(1409,NULL,'ESlot',1741,'',NULL,NULL),(1410,NULL,'ESlot',1742,'',NULL,NULL),(1411,NULL,'ESlot',1743,'',NULL,NULL),(1412,NULL,'ESlot',1744,'',NULL,NULL),(1413,NULL,'ESlot',1745,'',NULL,NULL),(1414,NULL,'ESlot',1746,'',NULL,NULL),(1415,NULL,'ESlot',1747,'',NULL,NULL),(1416,NULL,'ESlot',1748,'',NULL,NULL),(1417,NULL,'ESlot',1750,'',NULL,NULL),(1418,NULL,'ESlot',1751,'',NULL,NULL),(1419,NULL,'ESlot',1752,'',NULL,NULL),(1420,NULL,'ESlot',1753,'',NULL,NULL),(1421,NULL,'ESlot',1754,'',NULL,NULL),(1422,NULL,'ESlot',1755,'',NULL,NULL),(1423,NULL,'ESlot',1756,'',NULL,NULL),(1424,NULL,'ESlot',1757,'',NULL,NULL),(1425,NULL,'ESlot',1765,'Metabolic_Clearance',NULL,NULL),(1426,NULL,'ESlot',1766,'',NULL,NULL),(1427,NULL,'ESlot',1767,'',NULL,NULL),(1428,NULL,'ESlot',1768,'',NULL,NULL),(1429,NULL,'ESlot',1769,'',NULL,NULL),(1430,NULL,'ESlot',1770,'',NULL,NULL),(1431,NULL,'ESlot',1771,'cyp2d6',NULL,NULL),(1432,NULL,'ESlot',1772,'',NULL,NULL),(1433,NULL,'ESlot',1779,'',NULL,NULL),(1434,NULL,'ESlot',1780,'',NULL,NULL),(1435,NULL,'ESlot',1781,'',NULL,NULL),(1436,NULL,'ESlot',1782,'',NULL,NULL),(1437,NULL,'ESlot',1783,'',NULL,NULL),(1438,NULL,'ESlot',1784,'',NULL,NULL),(1439,NULL,'ESlot',1785,'',NULL,NULL),(1440,NULL,'ESlot',1786,'',NULL,NULL),(1441,NULL,'ESlot',1794,'',NULL,NULL),(1442,NULL,'ESlot',1795,'',NULL,NULL),(1443,NULL,'ESlot',1796,'',NULL,NULL),(1444,NULL,'ESlot',1797,'cyp2d6',NULL,NULL),(1445,NULL,'ESlot',1798,'cyp2d6',NULL,NULL),(1446,NULL,'ESlot',1799,'',NULL,NULL),(1447,NULL,'ESlot',1800,'',NULL,NULL),(1448,NULL,'ESlot',1801,'',NULL,NULL),(1449,NULL,'ESlot',1802,'Metabolic_Clearance',NULL,NULL),(1450,NULL,'ESlot',1803,'',NULL,NULL),(1451,NULL,'ESlot',1804,'cyp1a2',NULL,NULL),(1452,NULL,'ESlot',1805,'cyp1a2',NULL,NULL),(1453,NULL,'ESlot',1806,'',NULL,NULL),(1454,NULL,'ESlot',1807,'',NULL,NULL),(1455,NULL,'ESlot',1808,'',NULL,NULL),(1456,NULL,'ESlot',1809,'',NULL,NULL),(1457,NULL,'ESlot',1813,'Renal_Excretion',NULL,NULL),(1458,NULL,'ESlot',1814,'',NULL,NULL),(1459,NULL,'ESlot',1815,'',NULL,NULL),(1460,NULL,'ESlot',1816,'',NULL,NULL),(1461,NULL,'ESlot',1817,'',NULL,NULL),(1462,NULL,'ESlot',1818,'',NULL,NULL),(1463,NULL,'ESlot',1819,'',NULL,NULL),(1464,NULL,'ESlot',1820,'',NULL,NULL),(1465,NULL,'ESlot',1827,'',NULL,NULL),(1466,NULL,'ESlot',1828,'',NULL,NULL),(1467,NULL,'ESlot',1829,'',NULL,NULL),(1468,NULL,'ESlot',1830,'',NULL,NULL),(1469,NULL,'ESlot',1831,'',NULL,NULL),(1470,NULL,'ESlot',1832,'',NULL,NULL),(1471,NULL,'ESlot',1833,'',NULL,NULL),(1472,NULL,'ESlot',1834,'',NULL,NULL),(1473,NULL,'ESlot',1837,'',NULL,NULL),(1474,NULL,'ESlot',1838,'',NULL,NULL),(1475,NULL,'ESlot',1839,'',NULL,NULL),(1476,NULL,'ESlot',1840,'',NULL,NULL),(1477,NULL,'ESlot',1841,'',NULL,NULL),(1478,NULL,'ESlot',1842,'',NULL,NULL),(1479,NULL,'ESlot',1843,'',NULL,NULL),(1480,NULL,'ESlot',1844,'',NULL,NULL),(1481,NULL,'ESlot',1845,'',NULL,NULL),(1482,NULL,'ESlot',1846,'',NULL,NULL),(1483,NULL,'ESlot',1847,'',NULL,NULL),(1484,NULL,'ESlot',1848,'',NULL,NULL),(1485,NULL,'ESlot',1849,'',NULL,NULL),(1486,NULL,'ESlot',1850,'',NULL,NULL),(1487,NULL,'ESlot',1851,'',NULL,NULL),(1488,NULL,'ESlot',1852,'',NULL,NULL),(1489,NULL,'ESlot',1855,'',NULL,NULL),(1490,NULL,'ESlot',1856,'',NULL,NULL),(1491,NULL,'ESlot',1857,'',NULL,NULL),(1492,NULL,'ESlot',1858,'',NULL,NULL),(1493,NULL,'ESlot',1859,'',NULL,NULL),(1494,NULL,'ESlot',1860,'',NULL,NULL),(1495,NULL,'ESlot',1861,'',NULL,NULL),(1496,NULL,'ESlot',1862,'',NULL,NULL),(1497,NULL,'ESlot',1864,'',NULL,NULL),(1498,NULL,'ESlot',1865,'',NULL,NULL),(1499,NULL,'ESlot',1866,'',NULL,NULL),(1500,NULL,'ESlot',1867,'',NULL,NULL),(1501,NULL,'ESlot',1868,'',NULL,NULL),(1502,NULL,'ESlot',1869,'',NULL,NULL),(1503,NULL,'ESlot',1870,'',NULL,NULL),(1504,NULL,'ESlot',1871,'',NULL,NULL),(1505,NULL,'ESlot',1872,'',NULL,NULL),(1506,NULL,'ESlot',1873,'',NULL,NULL),(1507,NULL,'ESlot',1874,'',NULL,NULL),(1508,NULL,'ESlot',1875,'',NULL,NULL),(1509,NULL,'ESlot',1876,'',NULL,NULL),(1510,NULL,'ESlot',1877,'',NULL,NULL),(1511,NULL,'ESlot',1878,'',NULL,NULL),(1512,NULL,'ESlot',1879,'',NULL,NULL),(1513,NULL,'ESlot',1883,'',NULL,NULL),(1514,NULL,'ESlot',1884,'',NULL,NULL),(1515,NULL,'ESlot',1885,'',NULL,NULL),(1516,NULL,'ESlot',1886,'',NULL,NULL),(1517,NULL,'ESlot',1887,'',NULL,NULL),(1518,NULL,'ESlot',1888,'',NULL,NULL),(1519,NULL,'ESlot',1889,'',NULL,NULL),(1520,NULL,'ESlot',1890,'',NULL,NULL),(1521,NULL,'ESlot',1895,'Metabolic_Clearance',NULL,NULL),(1522,NULL,'ESlot',1896,'',NULL,NULL),(1523,NULL,'ESlot',1897,'',NULL,NULL),(1524,NULL,'ESlot',1898,'',NULL,NULL),(1525,NULL,'ESlot',1899,'',NULL,NULL),(1526,NULL,'ESlot',1900,'',NULL,NULL),(1527,NULL,'ESlot',1901,'',NULL,NULL),(1528,NULL,'ESlot',1902,'',NULL,NULL),(1529,NULL,'ESlot',1908,'',NULL,NULL),(1530,NULL,'ESlot',1909,'',NULL,NULL),(1531,NULL,'ESlot',1910,'',NULL,NULL),(1532,NULL,'ESlot',1911,'',NULL,NULL),(1533,NULL,'ESlot',1912,'',NULL,NULL),(1534,NULL,'ESlot',1913,'',NULL,NULL),(1535,NULL,'ESlot',1914,'cyp3a4',NULL,NULL),(1536,NULL,'ESlot',1915,'',NULL,NULL),(1537,NULL,'ESlot',1921,'',NULL,NULL),(1538,NULL,'ESlot',1922,'',NULL,NULL),(1539,NULL,'ESlot',1923,'',NULL,NULL),(1540,NULL,'ESlot',1924,'',NULL,NULL),(1541,NULL,'ESlot',1925,'',NULL,NULL),(1542,NULL,'ESlot',1926,'',NULL,NULL),(1543,NULL,'ESlot',1927,'',NULL,NULL),(1544,NULL,'ESlot',1928,'',NULL,NULL),(1545,NULL,'ESlot',1929,'',NULL,NULL),(1546,NULL,'ESlot',1930,'',NULL,NULL),(1547,NULL,'ESlot',1931,'',NULL,NULL),(1548,NULL,'ESlot',1932,'',NULL,NULL),(1549,NULL,'ESlot',1933,'',NULL,NULL),(1550,NULL,'ESlot',1934,'',NULL,NULL),(1551,NULL,'ESlot',1935,'',NULL,NULL),(1552,NULL,'ESlot',1936,'',NULL,NULL),(1553,NULL,'ESlot',1938,'',NULL,NULL),(1554,NULL,'ESlot',1939,'',NULL,NULL),(1555,NULL,'ESlot',1940,'',NULL,NULL),(1556,NULL,'ESlot',1941,'',NULL,NULL),(1557,NULL,'ESlot',1942,'',NULL,NULL),(1558,NULL,'ESlot',1943,'',NULL,NULL),(1559,NULL,'ESlot',1944,'',NULL,NULL),(1560,NULL,'ESlot',1945,'',NULL,NULL),(1561,NULL,'ESlot',1946,'Metabolic_Clearance',NULL,NULL),(1562,NULL,'ESlot',1947,'',NULL,NULL),(1563,NULL,'ESlot',1948,'',NULL,NULL),(1564,NULL,'ESlot',1949,'',NULL,NULL),(1565,NULL,'ESlot',1950,'',NULL,NULL),(1566,NULL,'ESlot',1951,'',NULL,NULL),(1567,NULL,'ESlot',1952,'',NULL,NULL),(1568,NULL,'ESlot',1953,'',NULL,NULL),(1569,NULL,'ESlot',1954,'Metabolic_Clearance',NULL,NULL),(1570,NULL,'ESlot',1955,'',NULL,NULL),(1571,NULL,'ESlot',1956,'cyp2c19',NULL,NULL),(1572,NULL,'ESlot',1957,'',NULL,NULL),(1573,NULL,'ESlot',1958,'',NULL,NULL),(1574,NULL,'ESlot',1959,'',NULL,NULL),(1575,NULL,'ESlot',1960,'',NULL,NULL),(1576,NULL,'ESlot',1961,'',NULL,NULL),(1577,NULL,'ESlot',1971,'Renal_Excretion',NULL,NULL),(1578,NULL,'ESlot',1972,'',NULL,NULL),(1579,NULL,'ESlot',1973,'',NULL,NULL),(1580,NULL,'ESlot',1974,'',NULL,NULL),(1581,NULL,'ESlot',1975,'',NULL,NULL),(1582,NULL,'ESlot',1976,'',NULL,NULL),(1583,NULL,'ESlot',1977,'',NULL,NULL),(1584,NULL,'ESlot',1978,'',NULL,NULL),(1585,NULL,'ESlot',1980,'',NULL,NULL),(1586,NULL,'ESlot',1981,'',NULL,NULL),(1587,NULL,'ESlot',1982,'',NULL,NULL),(1588,NULL,'ESlot',1983,'',NULL,NULL),(1589,NULL,'ESlot',1984,'',NULL,NULL),(1590,NULL,'ESlot',1985,'',NULL,NULL),(1591,NULL,'ESlot',1986,'',NULL,NULL),(1592,NULL,'ESlot',1987,'',NULL,NULL),(1593,NULL,'ESlot',1988,'Metabolic_Clearance',NULL,NULL),(1594,NULL,'ESlot',1989,'',NULL,NULL),(1595,NULL,'ESlot',1990,'',NULL,NULL),(1596,NULL,'ESlot',1991,'',NULL,NULL),(1597,NULL,'ESlot',1992,'',NULL,NULL),(1598,NULL,'ESlot',1993,'',NULL,NULL),(1599,NULL,'ESlot',1994,'',NULL,NULL),(1600,NULL,'ESlot',1995,'',NULL,NULL),(1601,NULL,'ESlot',2003,'',NULL,NULL),(1602,NULL,'ESlot',2004,'',NULL,NULL),(1603,NULL,'ESlot',2005,'',NULL,NULL),(1604,NULL,'ESlot',2006,'',NULL,NULL),(1605,NULL,'ESlot',2007,'',NULL,NULL),(1606,NULL,'ESlot',2008,'',NULL,NULL),(1607,NULL,'ESlot',2009,'',NULL,NULL),(1608,NULL,'ESlot',2010,'',NULL,NULL),(1609,NULL,'ESlot',2012,'',NULL,NULL),(1610,NULL,'ESlot',2013,'',NULL,NULL),(1611,NULL,'ESlot',2014,'',NULL,NULL),(1612,NULL,'ESlot',2015,'',NULL,NULL),(1613,NULL,'ESlot',2016,'',NULL,NULL),(1614,NULL,'ESlot',2017,'',NULL,NULL),(1615,NULL,'ESlot',2018,'',NULL,NULL),(1616,NULL,'ESlot',2019,'',NULL,NULL),(1617,NULL,'ESlot',2020,'',NULL,NULL),(1618,NULL,'ESlot',2021,'',NULL,NULL),(1619,NULL,'ESlot',2022,'',NULL,NULL),(1620,NULL,'ESlot',2023,'',NULL,NULL),(1621,NULL,'ESlot',2024,'',NULL,NULL),(1622,NULL,'ESlot',2025,'',NULL,NULL),(1623,NULL,'ESlot',2026,'',NULL,NULL),(1624,NULL,'ESlot',2027,'',NULL,NULL),(1625,NULL,'ESlot',2028,'',NULL,NULL),(1626,NULL,'ESlot',2029,'',NULL,NULL),(1627,NULL,'ESlot',2030,'',NULL,NULL),(1628,NULL,'ESlot',2031,'',NULL,NULL),(1629,NULL,'ESlot',2032,'',NULL,NULL),(1630,NULL,'ESlot',2033,'',NULL,NULL),(1631,NULL,'ESlot',2034,'',NULL,NULL),(1632,NULL,'ESlot',2035,'',NULL,NULL),(1633,NULL,'ESlot',2036,'Metabolic_Clearance',NULL,NULL),(1634,NULL,'ESlot',2037,'',NULL,NULL),(1635,NULL,'ESlot',2038,'cyp3a4',NULL,NULL),(1636,NULL,'ESlot',2039,'',NULL,NULL),(1637,NULL,'ESlot',2040,'',NULL,NULL),(1638,NULL,'ESlot',2041,'',NULL,NULL),(1639,NULL,'ESlot',2042,'',NULL,NULL),(1640,NULL,'ESlot',2043,'',NULL,NULL),(1641,NULL,'ESlot',2051,'',NULL,NULL),(1642,NULL,'ESlot',2052,'',NULL,NULL),(1643,NULL,'ESlot',2053,'',NULL,NULL),(1644,NULL,'ESlot',2054,'',NULL,NULL),(1645,NULL,'ESlot',2055,'',NULL,NULL),(1646,NULL,'ESlot',2056,'',NULL,NULL),(1647,NULL,'ESlot',2057,'',NULL,NULL),(1648,NULL,'ESlot',2058,'',NULL,NULL),(1649,NULL,'ESlot',2059,'',NULL,NULL),(1650,NULL,'ESlot',2060,'',NULL,NULL),(1651,NULL,'ESlot',2061,'',NULL,NULL),(1652,NULL,'ESlot',2062,'',NULL,NULL),(1653,NULL,'ESlot',2063,'',NULL,NULL),(1654,NULL,'ESlot',2064,'',NULL,NULL),(1655,NULL,'ESlot',2065,'',NULL,NULL),(1656,NULL,'ESlot',2066,'',NULL,NULL),(1657,NULL,'ESlot',2067,'',NULL,NULL),(1658,NULL,'ESlot',2068,'',NULL,NULL),(1659,NULL,'ESlot',2069,'',NULL,NULL),(1660,NULL,'ESlot',2070,'',NULL,NULL),(1661,NULL,'ESlot',2071,'',NULL,NULL),(1662,NULL,'ESlot',2072,'',NULL,NULL),(1663,NULL,'ESlot',2073,'',NULL,NULL),(1664,NULL,'ESlot',2074,'',NULL,NULL),(1665,NULL,'ESlot',2075,'',NULL,NULL),(1666,NULL,'ESlot',2076,'',NULL,NULL),(1667,NULL,'ESlot',2077,'',NULL,NULL),(1668,NULL,'ESlot',2078,'',NULL,NULL),(1669,NULL,'ESlot',2079,'',NULL,NULL),(1670,NULL,'ESlot',2080,'',NULL,NULL),(1671,NULL,'ESlot',2081,'',NULL,NULL),(1672,NULL,'ESlot',2082,'',NULL,NULL),(1673,NULL,'ESlot',2085,'Metabolic_Clearance',NULL,NULL),(1674,NULL,'ESlot',2086,'',NULL,NULL),(1675,NULL,'ESlot',2087,'cyp2c9',NULL,NULL),(1676,NULL,'ESlot',2088,'',NULL,NULL),(1677,NULL,'ESlot',2089,'',NULL,NULL),(1678,NULL,'ESlot',2090,'',NULL,NULL),(1679,NULL,'ESlot',2091,'',NULL,NULL),(1680,NULL,'ESlot',2092,'',NULL,NULL),(1681,NULL,'ESlot',2101,'',NULL,NULL),(1682,NULL,'ESlot',2102,'',NULL,NULL),(1683,NULL,'ESlot',2103,'',NULL,NULL),(1684,NULL,'ESlot',2104,'',NULL,NULL),(1685,NULL,'ESlot',2105,'',NULL,NULL),(1686,NULL,'ESlot',2106,'',NULL,NULL),(1687,NULL,'ESlot',2107,'',NULL,NULL),(1688,NULL,'ESlot',2108,'',NULL,NULL),(1689,NULL,'ESlot',2109,'',NULL,NULL),(1690,NULL,'ESlot',2110,'',NULL,NULL),(1691,NULL,'ESlot',2111,'',NULL,NULL),(1692,NULL,'ESlot',2112,'',NULL,NULL),(1693,NULL,'ESlot',2113,'',NULL,NULL),(1694,NULL,'ESlot',2114,'',NULL,NULL),(1695,NULL,'ESlot',2115,'',NULL,NULL),(1696,NULL,'ESlot',2116,'',NULL,NULL),(1697,NULL,'ESlot',2117,'',NULL,NULL),(1698,NULL,'ESlot',2118,'',NULL,NULL),(1699,NULL,'ESlot',2119,'',NULL,NULL),(1700,NULL,'ESlot',2120,'',NULL,NULL),(1701,NULL,'ESlot',2121,'',NULL,NULL),(1702,NULL,'ESlot',2122,'',NULL,NULL),(1703,NULL,'ESlot',2123,'',NULL,NULL),(1704,NULL,'ESlot',2124,'',NULL,NULL),(1705,NULL,'ESlot',2128,'',NULL,NULL),(1706,NULL,'ESlot',2129,'',NULL,NULL),(1707,NULL,'ESlot',2130,'cyp2c9',NULL,NULL),(1708,NULL,'ESlot',2131,'cyp2c9',NULL,NULL),(1709,NULL,'ESlot',2132,'',NULL,NULL),(1710,NULL,'ESlot',2133,'',NULL,NULL),(1711,NULL,'ESlot',2134,'',NULL,NULL),(1712,NULL,'ESlot',2135,'',NULL,NULL),(1713,NULL,'ESlot',2138,'',NULL,NULL),(1714,NULL,'ESlot',2139,'',NULL,NULL),(1715,NULL,'ESlot',2140,'',NULL,NULL),(1716,NULL,'ESlot',2141,'',NULL,NULL),(1717,NULL,'ESlot',2142,'',NULL,NULL),(1718,NULL,'ESlot',2143,'',NULL,NULL),(1719,NULL,'ESlot',2144,'',NULL,NULL),(1720,NULL,'ESlot',2145,'',NULL,NULL),(1721,NULL,'ESlot',2146,'Metabolic_Clearance',NULL,NULL),(1722,NULL,'ESlot',2147,'',NULL,NULL),(1723,NULL,'ESlot',2148,'',NULL,NULL),(1724,NULL,'ESlot',2149,'',NULL,NULL),(1725,NULL,'ESlot',2150,'',NULL,NULL),(1726,NULL,'ESlot',2151,'',NULL,NULL),(1727,NULL,'ESlot',2152,'',NULL,NULL),(1728,NULL,'ESlot',2153,'',NULL,NULL),(1729,NULL,'ESlot',2157,'',NULL,NULL),(1730,NULL,'ESlot',2158,'',NULL,NULL),(1731,NULL,'ESlot',2159,'',NULL,NULL),(1732,NULL,'ESlot',2160,'',NULL,NULL),(1733,NULL,'ESlot',2161,'',NULL,NULL),(1734,NULL,'ESlot',2162,'',NULL,NULL),(1735,NULL,'ESlot',2163,'',NULL,NULL),(1736,NULL,'ESlot',2164,'',NULL,NULL),(1737,NULL,'ESlot',2167,'',NULL,NULL),(1738,NULL,'ESlot',2168,'',NULL,NULL),(1739,NULL,'ESlot',2169,'',NULL,NULL),(1740,NULL,'ESlot',2170,'',NULL,NULL),(1741,NULL,'ESlot',2171,'',NULL,NULL),(1742,NULL,'ESlot',2172,'',NULL,NULL),(1743,NULL,'ESlot',2173,'',NULL,NULL),(1744,NULL,'ESlot',2174,'',NULL,NULL),(1745,NULL,'ESlot',2178,'',NULL,NULL),(1746,NULL,'ESlot',2179,'',NULL,NULL),(1747,NULL,'ESlot',2180,'',NULL,NULL),(1748,NULL,'ESlot',2181,'',NULL,NULL),(1749,NULL,'ESlot',2182,'',NULL,NULL),(1750,NULL,'ESlot',2183,'',NULL,NULL),(1751,NULL,'ESlot',2184,'',NULL,NULL),(1752,NULL,'ESlot',2185,'',NULL,NULL),(1753,NULL,'ESlot',2186,'',NULL,NULL),(1754,NULL,'ESlot',2187,'',NULL,NULL),(1755,NULL,'ESlot',2188,'',NULL,NULL),(1756,NULL,'ESlot',2189,'',NULL,NULL),(1757,NULL,'ESlot',2190,'',NULL,NULL),(1758,NULL,'ESlot',2191,'',NULL,NULL),(1759,NULL,'ESlot',2192,'',NULL,NULL),(1760,NULL,'ESlot',2193,'',NULL,NULL),(1761,NULL,'ESlot',2198,'',NULL,NULL),(1762,NULL,'ESlot',2199,'',NULL,NULL),(1763,NULL,'ESlot',2200,'',NULL,NULL),(1764,NULL,'ESlot',2201,'',NULL,NULL),(1765,NULL,'ESlot',2202,'',NULL,NULL),(1766,NULL,'ESlot',2203,'',NULL,NULL),(1767,NULL,'ESlot',2204,'',NULL,NULL),(1768,NULL,'ESlot',2205,'',NULL,NULL),(1769,NULL,'ESlot',2206,'',NULL,NULL),(1770,NULL,'ESlot',2207,'',NULL,NULL),(1771,NULL,'ESlot',2208,'',NULL,NULL),(1772,NULL,'ESlot',2209,'',NULL,NULL),(1773,NULL,'ESlot',2210,'',NULL,NULL),(1774,NULL,'ESlot',2211,'',NULL,NULL),(1775,NULL,'ESlot',2212,'',NULL,NULL),(1776,NULL,'ESlot',2213,'',NULL,NULL),(1777,NULL,'ESlot',2214,'',NULL,NULL),(1778,NULL,'ESlot',2215,'',NULL,NULL),(1779,NULL,'ESlot',2216,'',NULL,NULL),(1780,NULL,'ESlot',2217,'',NULL,NULL),(1781,NULL,'ESlot',2218,'',NULL,NULL),(1782,NULL,'ESlot',2219,'',NULL,NULL),(1783,NULL,'ESlot',2220,'',NULL,NULL),(1784,NULL,'ESlot',2221,'',NULL,NULL),(1785,NULL,'ESlot',2226,'',NULL,NULL),(1786,NULL,'ESlot',2227,'',NULL,NULL),(1787,NULL,'ESlot',2228,'',NULL,NULL),(1788,NULL,'ESlot',2229,'',NULL,NULL),(1789,NULL,'ESlot',2230,'',NULL,NULL),(1790,NULL,'ESlot',2231,'',NULL,NULL),(1791,NULL,'ESlot',2232,'',NULL,NULL),(1792,NULL,'ESlot',2233,'',NULL,NULL),(1793,NULL,'ESlot',2234,'',NULL,NULL),(1794,NULL,'ESlot',2235,'',NULL,NULL),(1795,NULL,'ESlot',2236,'',NULL,NULL),(1796,NULL,'ESlot',2237,'',NULL,NULL),(1797,NULL,'ESlot',2238,'',NULL,NULL),(1798,NULL,'ESlot',2239,'',NULL,NULL),(1799,NULL,'ESlot',2240,'',NULL,NULL),(1800,NULL,'ESlot',2241,'',NULL,NULL),(1801,NULL,'ESlot',2244,'',NULL,NULL),(1802,NULL,'ESlot',2245,'',NULL,NULL),(1803,NULL,'ESlot',2246,'',NULL,NULL),(1804,NULL,'ESlot',2247,'',NULL,NULL),(1805,NULL,'ESlot',2248,'',NULL,NULL),(1806,NULL,'ESlot',2249,'',NULL,NULL),(1807,NULL,'ESlot',2250,'',NULL,NULL),(1808,NULL,'ESlot',2251,'',NULL,NULL),(1809,NULL,'ESlot',2257,'Metabolic_Clearance',NULL,NULL),(1810,NULL,'ESlot',2258,'',NULL,NULL),(1811,NULL,'ESlot',2259,'cyp3a4',NULL,NULL),(1812,NULL,'ESlot',2260,'',NULL,NULL),(1813,NULL,'ESlot',2261,'',NULL,NULL),(1814,NULL,'ESlot',2262,'',NULL,NULL),(1815,NULL,'ESlot',2263,'',NULL,NULL),(1816,NULL,'ESlot',2264,'',NULL,NULL),(1817,NULL,'ESlot',2272,'',NULL,NULL),(1818,NULL,'ESlot',2273,'',NULL,NULL),(1819,NULL,'ESlot',2274,'',NULL,NULL),(1820,NULL,'ESlot',2275,'',NULL,NULL),(1821,NULL,'ESlot',2276,'',NULL,NULL),(1822,NULL,'ESlot',2277,'',NULL,NULL),(1823,NULL,'ESlot',2278,'',NULL,NULL),(1824,NULL,'ESlot',2279,'',NULL,NULL),(1825,NULL,'ESlot',2280,'',NULL,NULL),(1826,NULL,'ESlot',2281,'',NULL,NULL),(1827,NULL,'ESlot',2282,'',NULL,NULL),(1828,NULL,'ESlot',2283,'',NULL,NULL),(1829,NULL,'ESlot',2284,'',NULL,NULL),(1830,NULL,'ESlot',2285,'',NULL,NULL),(1831,NULL,'ESlot',2286,'',NULL,NULL),(1832,NULL,'ESlot',2287,'',NULL,NULL),(1833,NULL,'ESlot',2288,'',NULL,NULL),(1834,NULL,'ESlot',2289,'',NULL,NULL),(1835,NULL,'ESlot',2290,'',NULL,NULL),(1836,NULL,'ESlot',2291,'',NULL,NULL),(1837,NULL,'ESlot',2292,'',NULL,NULL),(1838,NULL,'ESlot',2293,'',NULL,NULL),(1839,NULL,'ESlot',2294,'cyp3a4',NULL,NULL),(1840,NULL,'ESlot',2295,'',NULL,NULL),(1841,NULL,'ESlot',2307,'',NULL,NULL),(1842,NULL,'ESlot',2308,'',NULL,NULL),(1843,NULL,'ESlot',2309,'cyp2d6',NULL,NULL),(1844,NULL,'ESlot',2310,'',NULL,NULL),(1845,NULL,'ESlot',2311,'',NULL,NULL),(1846,NULL,'ESlot',2312,'',NULL,NULL),(1847,NULL,'ESlot',2313,'',NULL,NULL),(1848,NULL,'ESlot',2314,'',NULL,NULL),(1849,NULL,'ESlot',2317,'',NULL,NULL),(1850,NULL,'ESlot',2318,'',NULL,NULL),(1851,NULL,'ESlot',2319,'',NULL,NULL),(1852,NULL,'ESlot',2320,'cyp2e1',NULL,NULL),(1853,NULL,'ESlot',2321,'',NULL,NULL),(1854,NULL,'ESlot',2322,'',NULL,NULL),(1855,NULL,'ESlot',2323,'',NULL,NULL),(1856,NULL,'ESlot',2324,'',NULL,NULL),(1857,NULL,'ESlot',2325,'',NULL,NULL),(1858,NULL,'ESlot',2326,'',NULL,NULL),(1859,NULL,'ESlot',2327,'',NULL,NULL),(1860,NULL,'ESlot',2328,'',NULL,NULL),(1861,NULL,'ESlot',2329,'',NULL,NULL),(1862,NULL,'ESlot',2330,'',NULL,NULL),(1863,NULL,'ESlot',2331,'',NULL,NULL),(1864,NULL,'ESlot',2332,'',NULL,NULL),(1865,NULL,'ESlot',2335,'',NULL,NULL),(1866,NULL,'ESlot',2336,'',NULL,NULL),(1867,NULL,'ESlot',2337,'',NULL,NULL),(1868,NULL,'ESlot',2338,'',NULL,NULL),(1869,NULL,'ESlot',2339,'',NULL,NULL),(1870,NULL,'ESlot',2340,'',NULL,NULL),(1871,NULL,'ESlot',2341,'',NULL,NULL),(1872,NULL,'ESlot',2342,'',NULL,NULL),(1873,NULL,'ESlot',2343,'Metabolic_Clearance',NULL,NULL),(1874,NULL,'ESlot',2344,'',NULL,NULL),(1875,NULL,'ESlot',2345,'',NULL,NULL),(1876,NULL,'ESlot',2346,'',NULL,NULL),(1877,NULL,'ESlot',2347,'',NULL,NULL),(1878,NULL,'ESlot',2348,'',NULL,NULL),(1879,NULL,'ESlot',2349,'',NULL,NULL),(1880,NULL,'ESlot',2350,'',NULL,NULL),(1881,NULL,'ESlot',2358,'',NULL,NULL),(1882,NULL,'ESlot',2359,'',NULL,NULL),(1883,NULL,'ESlot',2360,'',NULL,NULL),(1884,NULL,'ESlot',2361,'',NULL,NULL),(1885,NULL,'ESlot',2362,'',NULL,NULL),(1886,NULL,'ESlot',2363,'',NULL,NULL),(1887,NULL,'ESlot',2364,'',NULL,NULL),(1888,NULL,'ESlot',2365,'',NULL,NULL),(1889,NULL,'ESlot',2372,'Metabolic_Clearance',NULL,NULL),(1890,NULL,'ESlot',2373,'',NULL,NULL),(1891,NULL,'ESlot',2374,'',NULL,NULL),(1892,NULL,'ESlot',2375,'',NULL,NULL),(1893,NULL,'ESlot',2376,'',NULL,NULL),(1894,NULL,'ESlot',2377,'',NULL,NULL),(1895,NULL,'ESlot',2378,'',NULL,NULL),(1896,NULL,'ESlot',2379,'',NULL,NULL),(1897,NULL,'ESlot',2381,'',NULL,NULL),(1898,NULL,'ESlot',2382,'',NULL,NULL),(1899,NULL,'ESlot',2383,'',NULL,NULL),(1900,NULL,'ESlot',2384,'',NULL,NULL),(1901,NULL,'ESlot',2385,'',NULL,NULL),(1902,NULL,'ESlot',2386,'',NULL,NULL),(1903,NULL,'ESlot',2387,'',NULL,NULL),(1904,NULL,'ESlot',2388,'',NULL,NULL),(1905,NULL,'ESlot',2391,'Metabolic_Clearance',NULL,NULL),(1906,NULL,'ESlot',2392,'',NULL,NULL),(1907,NULL,'ESlot',2393,'',NULL,NULL),(1908,NULL,'ESlot',2394,'',NULL,NULL),(1909,NULL,'ESlot',2395,'',NULL,NULL),(1910,NULL,'ESlot',2396,'',NULL,NULL),(1911,NULL,'ESlot',2397,'',NULL,NULL),(1912,NULL,'ESlot',2398,'',NULL,NULL);
/*!40000 ALTER TABLE `ESlot` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `Evidence`
--

DROP TABLE IF EXISTS `Evidence`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `Evidence` (
  `id` int(11) NOT NULL,
  `_name` varchar(100) DEFAULT NULL,
  `doc_pointer` varchar(500) DEFAULT NULL,
  `quote` varchar(4000) DEFAULT NULL,
  `reviewer` varchar(100) DEFAULT NULL,
  `timestamp` varchar(100) DEFAULT NULL,
  `evidence_type` varchar(100) DEFAULT NULL,
  `evidence_class` varchar(100) DEFAULT NULL,
  `value` float DEFAULT NULL,
  `object_dose` float DEFAULT NULL,
  `precip_dose` float DEFAULT NULL,
  `numb_subjects` int(11) DEFAULT NULL,
  `enzyme_system` varchar(100) DEFAULT NULL,
  `dose` float DEFAULT NULL,
  `assump_list_id` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `Evidence`
--

LOCK TABLES `Evidence` WRITE;
/*!40000 ALTER TABLE `Evidence` DISABLE KEYS */;
INSERT INTO `Evidence` VALUES (1,'evidence_1949','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','06/12/2009 19:20:37\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,1),(2,'evidence_1793','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','11/09/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(3,'evidence_1128','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','Metabolism: Bupropion is extensively metabolized in humans. Three metabolites have been shown to be active: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, which are formed via reduction of the carbonyl group. In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high or higher than those of bupropion.','boycer','01/19/2010 10:25:17\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(4,'evidence_1821','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',3,NULL,NULL,NULL,'',NULL,NULL),(5,'evidence_1017','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote:\n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM. ','boycer','06/12/2009 11:40:41\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,2),(6,'evidence_1605','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978','Pharmacokinetic-related Interactions\n\nClozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(7,'evidence_1088','http://www.ncbi.nlm.nih.gov/pubmed/9384460','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: clozapine demethylation and N-oxidation\n\nQuote: \nKetconazole inhibited [clozapine] demethylation by 28+/-20% and 68+/-15% at 0.2 and 2 micM, respectively... CLZ-NO formation was inhibited by ketoconazole by 41+/-14% and 51+/-13% at 0.2 and 2 micM, respectively. \n\n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(8,'evidence_1320','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','06/19/2009 12:33:21\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(9,'evidence_1704','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0','&quot;Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.&quot;','boycer','09/27/2007 10:16:28\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.14,NULL,NULL,NULL,'',NULL,NULL),(10,'evidence_1627','http://www.ncbi.nlm.nih.gov/pubmed/12235455','Route of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: single 120mg oral dose of diltiazem with 24 hours of plasma level monitoring\n\npopulation: 15 individuals; 5 for each genetically based phenotype. Study does not state gender of participants\n\nages: 20-30\n\ndescription: \nThe aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS: Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence resonance energy transfer probes hybridized to polymerase chain reaction-amplified deoxyribonucleic acid. The first 5 individuals identified with genotypes corresponding to a homozygous extensive, heterozygous extensive, or homozygous poor CYP2D6-metabolizing phenotype, respectively, were voluntarily enrolled in the pharmacokinetic study. The participants received diltiazem, 120 mg, as a single oral dose, and plasma samples were collected up to 24 hours after administration. Plasma samples were purified by solid phase extraction. Diltiazem and 7 phase I metabolites were analyzed by liquid chromatography-mass spectrometry. RESULTS: The pharmacokinetics of diltiazem was not significantly different between the subgroups. However, the systemic exposure of the pharmacologically active metabolites desacetyl diltiazem and N-demethyldesacetyl diltiazem was &gt; or = 5 times higher in poor CYP2D6 metabolizers than in extensive CYP2D6 metabolizers (P &lt;.01). CONCLUSIONS: CYP2D6 activity does not have a major impact on the disposition of diltiazem. In contrast, desacetyl diltiazem and N-demethyldesacetyl diltiazem are markedly accumulated in individuals expressing a deficient CYP2D6 phenotype. Because these metabolites exhibit pharmacologic properties of possible importance, individual CYP2D6 activity might be an aspect to consider in the clinical use of diltiazem.','boycer','08/09/2007 07:08:28\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,3),(11,'evidence_1139','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1332','ketoconazole-janssen-2006-daily-med \n\nLabel date: 08/2006\nDate of DIKB entry: 05/21/2007\n\nAmbiguous statement? NO\n\ndescription:\nFollowing absorption from the gastrointestinal tract, NIZORAL (ketoconazole) is converted into several inactive metabolites. The major identified metabolic pathways are oxidation and degradation of the imidazole and piperazine rings, oxidative O-dealkylation and aromatic hydroxylation. About 13% of the dose is excreted in the urine, of which 2 to 4% is unchanged drug. The major route of excretion is through the bile into the intestinal tract. ','boycer','05/21/2007 16:04:57\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(12,'evidence_1232','http://www.ncbi.nlm.nih.gov/pubmed/3428348','Quote: Route of administration: oral\n\nstudy duration: 2 days with patients who had been taking ketconazole for 1 to 6 months\n\npopulation: male:5 female:2\n\nages:20-68 \n\nWe have studied the pharmacokinetics of the anti-mycotic ketoconazole in seven patients who took it for 1-6 months at a dose of 200 mg daily. The mean elimination half-life of the drug was 3.3 h, and although the ketoconazole was given only once daily, a satisfactory clinical response was obtained in all seven individuals. Only a small fraction of the absorbed drug (mean 0.22%) was excreted unchanged in the urine, suggesting almost complete metabolism.','boycer','06/05/2007 07:29:02\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(13,'evidence_1823','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1d149db-ad43-4f3f-aef1-fb0395ba4191','Theophylline\n\nWhen nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.','boycer','01/11/2010 19:09:34\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,4),(14,'evidence_1588','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9550','\nPharmacokinetics\n\n Midodrine hydrochloride is a prodrug, i.e., the therapeutic effect of orally administered midodrine is due to the major metabolite desglymidodrine, formed by deglycination of midodrine. ','boycer','09/24/2009 12:53:54\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(15,'evidence_1474','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(16,'evidence_1508','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(17,'evidence_1897','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','Because citalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment with citalopram, however, it should be used with caution in such patients (see DOSAGE AND ADMINISTRATION).','boycer','05/15/2009 10:48:20\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(18,'evidence_1877','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n....\n\nMidazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(19,'evidence_1556','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nAn in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(20,'evidence_1059','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','\nKetoconazole\n\nCombined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(21,'evidence_1568','http://www.ncbi.nlm.nih.gov/pubmed/10494454','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: citalopram --&gt; desmethylcitalopram\n\nQuote: \nKetoconazole produced concentration-dependent inhibition of DCT formation (Figure 4). The mean (+/-SE) IC50 values for ketoconazole were 0.81 (+/-.24) micM/L at\nCT = 10 micM/L, and 1.54 (+/-.35) micM/L CT = 100 micM/L; these values were not significantly different.\n\n\n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(22,'evidence_1600','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/0a238e82-20d5-45ec-8c13-4725d1065230','The major active metabolites of simvastatin present in human plasma are the &#946;-hydroxyacid of simvastatin and its 6&#8242;-hydroxy, 6&#8242;-hydroxymethyl, and 6&#8242;-exomethylene derivatives. ','boycer','05/29/2007 14:34:53\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(23,'evidence_1288','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\ninhibitor used: itraconazole\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nitraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(24,'evidence_1389','http://www.ncbi.nlm.nih.gov/pubmed/11038166','Enzyme system: recombinant human CYP3A5 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nAccording to the authors, this enzyme system catalyzed the above reactions similar to that of the CYP3A4 recombinant enzyme system whose Km values ranged from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(25,'evidence_1561','http://www.ncbi.nlm.nih.gov/pubmed/11038166','Enzyme system: human liver microsomes\n\nNADPH added: yes\ninhibitor used: itraconazole\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nitraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(26,'evidence_1129','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP3A4 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(27,'evidence_1473','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0','&quot;In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme&quot;','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(28,'evidence_1931','http://www.ncbi.nlm.nih.gov/pubmed/9542477','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 4 days\n\npopulation: 7 male, 3 female\n\nages:19-29\n\ndescription:\nTwo randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p &lt; 0.001).','boycer','12/07/2007 12:37:19\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,5),(29,'evidence_1550','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: tolbutamide\n\nreaction: tolbutamide hydroxylation \n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).\n\n\n','boycer','02/12/2010 17:32:18\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,6),(30,'evidence_1397','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.03,NULL,NULL,NULL,'',NULL,NULL),(31,'evidence_1923','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(32,'evidence_1587','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: p-nitrophenol\n\nreaction: p-nitrophenol hydroxylation to p-nitrocatechol\n\nQuote:\nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. ','boycer','09/22/2009 18:00:34\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,7),(33,'evidence_1304','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.8,NULL,NULL,NULL,'',NULL,NULL),(34,'evidence_1446','http://www.ncbi.nlm.nih.gov/pubmed/10494454','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: citalopram --&gt; desmethylcitalopram\n\nQuote: \nKetoconazole produced concentration-dependent inhibition of DCT formation (Figure 4). The mean (+/-SE) IC50 values for ketoconazole were 0.81 (+/-.24) micM/L at\nCT = 10 micM/L, and 1.54 (+/-.35) micM/L CT = 100 micM/L; these values were not significantly different.\n\n','boycer','02/12/2010 18:35:58\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,8),(35,'evidence_1239','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf',' The FDA recommends this as a preferred CYP2D6 substrate for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','04/29/2009 20:10:28\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(36,'evidence_1412','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/3829d74e-b3ab-46df-a08b-f0327b63304e','\nMetabolism \n\nTheophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. \n\nNOTE: the DIKB reviewers inferred the P-450 3A3 in this context refers to CYP4503A4','boycer','09/24/2009 14:46:57\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(37,'evidence_1381','http://www.ncbi.nlm.nih.gov/pubmed/8801057','\nRoute of administration: fluconazole oral; warfarin - IV\n\nstudy duration: phase 1 - 8 days of .75mg/kg warfarin alone; phase 2 (21 days later) 14 days of .75mg/kg q.d. AND 400mg q.d. of fluconazole\n\npopulation: 6 male\n\nages: 23-29\n\ndescription: \nformation of 6- and 7-OH-(s)-warfarin decreased by 70%; this reaction is considered primarily catalyzed by CYP2C9. There was also a notable increase in AUC of (S)-warfarin (mean AUC_i/AUC=7.633)','boycer','09/27/2007 11:44:51\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,9),(38,'evidence_1793','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP2C9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 13:32:26\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(39,'evidence_1978','http://www.ncbi.nlm.nih.gov/pubmed/8612379','\nRoute of administration: oral\n\nstudy duration: 1 day pretreatment with diltiazem given 3x/day @ 60mg PO. On day two .25mg triazolam was given PO\n\npopulation: 10 subjects, male: 3 female: 7\n\nages: 18-31\n\nAUC_i/AUC 0-time of measurement (17hrs): 36.0/12.7 = 2.835\n\nAUC_i/AUC 0 -inf: 47/13.9 = 3.381\n\n','boycer','07/02/2007 17:38:07\n','EV_PK_DDI_RCT','PKStudy',2.835,0.00025,0.06,10,'',NULL,NULL),(40,'evidence_1033','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(41,'evidence_1147','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1','Metabolism  Fluoxetine is extensively metabolized in the liver to norfluoxetine and a number of other unidentified metabolites. The only identified active metabolite, norfluoxetine, is formed by demethylation of fluoxetine. In animal models, S-norfluoxetine is a potent and selective inhibitor of serotonin uptake and has activity essentially equivalent to R- or S-fluoxetine. R-norfluoxetine is significantly less potent than the parent drug in the inhibition of serotonin uptake. The primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney.','boycer','05/15/2009 11:14:43\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(42,'evidence_1424','http://www.ncbi.nlm.nih.gov/pubmed/16580903','\nRoute of administration: oral\n\nstudy duration: 40mg of simvastatin to establish baseline given two seperate times with a one day gap; after a &gt;1 week washout period participants were given 10 days treatment ketoconazole 40mg 1x/day. 40mg of simvastatin was given during this phase once on day 6 and once on day nine. \n\npopulation: 19 (20 - 1 dropout) 9 male, 10 women\n\nages:30-47\n\nAUC_i/AUC (0 to infinity):12.55\n\ndescription:\nThis study used an open-label, fixed-sequential, 3-way crossover study design. Nineteen subjects received oral doses of 0.075 mg/kg midazolam and 40 mg simvastatin during 3 phases (baseline, after inhibition with 400 mg ketoconazole for 10 days, and after induction with 600 mg rifampin [INN, rifampicin] for 9 days). Serial plasma concentrations of midazolam and simvastatin were obtained. Oral clearances of midazolam and simvastatin were compared. RESULTS: Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P &lt; .001)','boycer','10/30/2007 11:25:31\n','EV_PK_DDI_NR','PKStudy',12.55,0.04,0.4,19,'',NULL,NULL),(43,'evidence_1933','http://www.ncbi.nlm.nih.gov/pubmed/9152603','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: sulphaphenazole\n\nreaction:\nclarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin\nclarithromycin --&gt; 14-N-demethylase-clarithromycin\n\ndescription: \nclarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor','boycer','10/20/2007 08:13:36\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,10),(44,'evidence_1890','http://www.ncbi.nlm.nih.gov/pubmed/9431831','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\n4-(4-chlorophenyl)-4-hydroxypiperidine (CPHP) formation from haloperidol was detected and analyzed using HPLC and UV \n\n','boycer','06/17/2009 08:04:03\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(45,'evidence_1111','http://www.ncbi.nlm.nih.gov/pubmed/9542477','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 4 days\n\npopulation: 7 male, 3 female\n\nages:19-29\n\ndescription:\nTwo randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001).','boycer','05/16/2007 15:02:11\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,11),(46,'evidence_1853','http://www.ncbi.nlm.nih.gov/pubmed/9321523','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 3\',5\'-dihydrodiol, 3\'-hydroxy, and 6\'-exomethylene metabolites using a recombinant CYP3A4 system\n','boycer','05/29/2007 14:58:01\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(47,'evidence_1859','http://www.ncbi.nlm.nih.gov/pubmed/15518608','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days simvastatin only, 8 days simva and clarithromycin\n\ndose: .040g simvastatin 1xday\n      .5g clarithromycin 2xday\n\npopulation: 45 men and women (15 received simvastatin)\n\nages:18-60 \n\n(mean AUC_i)/(mean AUC) = 219/22 \n\ndescription: Clarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC)\n','boycer','05/29/2007 15:23:02\n','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,12),(48,'evidence_1031','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(49,'evidence_1985','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1','Metabolism  Fluoxetine is extensively metabolized in the liver to norfluoxetine and a number of other unidentified metabolites. The only identified active metabolite, norfluoxetine, is formed by demethylation of fluoxetine. In animal models, S-norfluoxetine is a potent and selective inhibitor of serotonin uptake and has activity essentially equivalent to R- or S-fluoxetine. R-norfluoxetine is significantly less potent than the parent drug in the inhibition of serotonin uptake. The primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney.','boycer','05/14/2009 14:27:42\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(50,'evidence_1331','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(51,'evidence_1424','http://www.ncbi.nlm.nih.gov/pubmed/11872324','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: quinidine\n\nreaction: nefazodone --&gt; OH-NEF ; nefazodone --&gt; mCPP\n\nQuote: \nIncubations of human liver microsomes with NEF and the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3). Incubations of human liver microsomes with NEF and the CYP2D6 inhibitor quinidine did not affect the production of OH-NEF and mCPP. Incubations of OH-NEF with the CYP3A4 inhibitor ketoconazole resulted in the inhibition of metabolite formation, and incubations with the CYP2D6 inhibitor quinidine did not, similar to what was found with NEF metabolism (data not presented).\n\n\n\n','boycer','02/12/2010 13:56:37\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,13),(52,'evidence_1535','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(53,'evidence_1943','http://www.ncbi.nlm.nih.gov/pubmed/10950845','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam-->1\'-hydroxy-midazolam\n\nQuote: \n\nestimated k_i from Table 1: 5.49microM/L','boycer','06/05/2007 08:23:06\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.004,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,14),(54,'evidence_1426','http://www.ncbi.nlm.nih.gov/pubmed/16416302','Enzyme system: human recombinant enzymes in e.coli \n\nNADPH added: yes\n\nsubstrate used: testosterone\n\nreaction: testosterone--&gt;6beta-OH-testosterone\n\nclarithromycin inhibited beta-hydroxylation of testosterone Ki = 2.25microM\n','boycer','07/02/2007 12:16:37\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Recom','In_vitro_inhibition_study',0.00168,NULL,NULL,NULL,'Human_Recombinant_Enzymes',NULL,15),(55,'evidence_1525','http://www.ncbi.nlm.nih.gov/pubmed/16416302',': Enzyme system: human microsomes\n\nNADPH added: yes\n\nsubstrate used: testosterone\n\nreaction: testosterone--&gt;6beta-OH-testosterone\n\nclarithromycin inhibited beta-hydroxylation of testosterone Ki = 29.5microM','boycer','07/02/2007 12:21:48\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.0221,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,16),(56,'evidence_1406','http://www.ncbi.nlm.nih.gov/pubmed/19142106','\nRoute of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: 100 mg desvenlafaxine on day 1 followed by 120 hours of PK data sampling; repeated on day 11\n\npopulation: healthy adults, non-smokers (&gt; 1yr), genotyped (7 CYP2D6 extensive metabolizers and 7 poor metabolizers)\n\nages: 18-55\n\ndescription: \nResults: After administration of venlafaxine ER, mean Cmax and AUC of venlafaxine were significantly greater in PMs compared with EMs, whereas mean Cmax and AUC of its metabolite, desvenlafaxine, were significantly lower for PMs than for EMs (P = 0.001, all comparisons). In contrast, mean Cmax and AUC of desvenlafaxine after administration of desvenlafaxine were comparable between EMs and PMs.\n','boycer','09/22/2009 18:18:19\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,17),(57,'evidence_1099','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','\nRoute of administration: oral \n\nstudy duration: single dose of bupropion XR with and w/out cimetidine \n\npopulation: 24 male ages:young adult (inferred from statement) \n\nAUC_i/AUC: 16% increase stated --&gt; 1.16-fold increase \n\nQuote: The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers. Following oral administration of two 150-mg Bupropion Hydrochloride Extended-Release Tablets, USP (SR) with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and its hydroxy metabolite were unaffected. However, there were 16% and 32% increases, respectively, in the AUC and Cmax of the combined moieties of threohydro- and erythrohydro-bupropion.','boycer','05/14/2009 14:50:14\n','Non_traceable_Drug_Label_Statement','PKStudy',1.16,0.3,0.8,24,'',NULL,NULL),(58,'evidence_1022','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','CYP3A4: Venlafaxine did not inhibit CYP3A4 in vitro. This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(59,'evidence_1365','http://www.ncbi.nlm.nih.gov/pubmed/9205822','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nreaction: testosterone 6beta hydroxylation\n\nQuote: \nThe IC50 for venlafaxine\'s inhibition of the reaction was &gt; 1000micM ','boycer','02132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(60,'evidence_1854','http://www.ncbi.nlm.nih.gov/pubmed/9757151','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 1 day petreatment with clarithromycin, single dose of triazolam\n\npopulation: 6 male, 6 female\n\nages:21-39 \n\nAUC_i/AUC: 28.9/5.5ng/Ml*h\n\nIn a randomized, double-blind, 5-trial clinical pharmacokinetic-pharmacodynamic study, 12 volunteers received 0.125 mg triazolam orally, together with placebo, azithromycin, erythromycin, or clarithromycin....The effects of triazolam on dynamic measures were nearly identical when triazolam was given with placebo or azithromycin, but benzodiazepine agonist effects were enhanced during erythromycin and clarithromycin trials.','boycer','06/05/2007 13:57:26\n','EV_PK_DDI_RCT','PKStudy',5.255,0.000125,0.5,12,'',NULL,NULL),(61,'evidence_1266','http://www.ncbi.nlm.nih.gov/pubmed/11038166','Enzyme system: human liver microsomes\n\nNADPH added: yes\nsubstrate used: N/A\n\nreaction:\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nhuman liver microsomes incubated with both atorvastatin acid and atorvastatin lactone generated the para-hydroxy-atorvastatin metabolite','boycer','09/25/2007 07:36:42\n','EV_EX_Met_Enz_ID','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(62,'evidence_1026','http://www.ncbi.nlm.nih.gov/pubmed/16765141','\nRoute of administration: oral \n\nstudy duration: 7 days Dose: 10mg atorvastatin \n\npopulation: 13 (7 male/6 female) in the exposure group; 15 (7 male and 8 female) in the control\n\nages:41-72 in the exposure and 30 - 60 in the control \n\nDescription: para-hydroxy-atorvastatin present in measurable quantities in both exposure and control populations. Interestingly, the control groups (all patients experiencing statin induced myopathy) had significantly higher concentrations of the para-hydroxy-atorvastatin metabolite and atorvastatin lactone in their system','boycer','09/27/2007 09:26:28\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(63,'evidence_1259','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0','&quot;Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.&quot;','boycer','09/27/2007 10:30:52\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(64,'evidence_1435','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\ninhibitor used: itraconazole\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nitraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin','boycer','09/25/2007 07:59:50\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,18),(65,'evidence_1756','http://www.ncbi.nlm.nih.gov/pubmed/11038166','Enzyme system: recombinant human CYP3A5 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nAccording to the authors, this enzyme system catalyzed the above reactions similar to that of the CYP3A4 recombinant enzyme system whose Km values ranged from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin\n\n','boycer','09/25/2007 08:35:33\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(66,'evidence_1169','http://www.ncbi.nlm.nih.gov/pubmed/11038166','Enzyme system: human liver microsomes\n\nNADPH added: yes\ninhibitor used: itraconazole\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nitraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin','boycer','09/25/2007 07:52:24\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,19),(67,'evidence_1636','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP3A4 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin\n\n','boycer','09/25/2007 08:33:11\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(68,'evidence_1246','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0','&quot;In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme&quot;','boycer','09/27/2007 10:18:37\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(69,'evidence_1356','http://www.ncbi.nlm.nih.gov/pubmed/1487561','\n\nroute of administration: oral\n\nstudy duration: &quot;The study was a randomized three-period cross-over design using a pair of Latin squares.  Each sub-ject participated for three 5-day venlafaxine treatment periods separated by a 9-day drug-free interval.  Each treatment period consisted of 25, 75, or 150mg of venlafaxine given as a single dose on day 1, followed by the same dose given every 8 hours (q8h) on days 2 to 4, and ending with a single dose given on day 5, for a total of 2 doses. All doses were administered after food as multiple tablets of 25 mg venlafaxine base. The single doses on days 1 and 5 were administered 30 minutes after the subject had eaten a medium-fat breakfast and were followed by a 4-hour fast.&quot;\n\npopulation: 18, non-smoking, healthy men, NOTE: none were tested for known CYP450 phenotypes \n\nages: 20 - 34\n\nC_max (day 4) @ 450mg/day venlafaxine: 686ng/mL\n\n686ng/mL X 1g/10^9ng X 1000mL/1L = 0.000686g/L\n','boycer','06/19/2009 20:06:32\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000686,NULL,NULL,NULL,'',0.45,NULL),(70,'evidence_1833','http://www.ncbi.nlm.nih.gov/pubmed/1487561','\n\nroute of administration: oral\n\nstudy duration: &quot;The study was a randomized three-period cross-over design using a pair of Latin squares.  Each sub-ject participated for three 5-day venlafaxine treatment periods separated by a 9-day drug-free interval.  Each treatment period consisted of 25, 75, or 150mg of venlafaxine given as a single dose on day 1, followed by the same dose given every 8 hours (q8h) on days 2 to 4, and ending with a single dose given on day 5, for a total of 2 doses. All doses were administered after food as multiple tablets of 25 mg venlafaxine base. The single doses on days 1 and 5 were administered 30 minutes after the subject had eaten a medium-fat breakfast and were followed by a 4-hour fast.&quot;\n\npopulation: 18, non-smoking, healthy men, NOTE: none were tested for known CYP450 phenotypes \n\nages: 20 - 34\n\nC_max (day 4) @ 75mg/day venlafaxine: 148ng/mL\n\n148ng/mL X 1g/10^9ng X 1000mL/1L = 0.000148g/L\n','boycer','06/19/2009 20:48:21\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000148,NULL,NULL,NULL,'',0.075,NULL),(71,'evidence_1668','http://www.ncbi.nlm.nih.gov/pubmed/1487561','\n\nroute of administration: oral\n\nstudy duration: &quot;The study was a randomized three-period cross-over design using a pair of Latin squares.  Each sub-ject participated for three 5-day venlafaxine treatment periods separated by a 9-day drug-free interval.  Each treatment period consisted of 25, 75, or 150mg of venlafaxine given as a single dose on day 1, followed by the same dose given every 8 hours (q8h) on days 2 to 4, and ending with a single dose given on day 5, for a total of 2 doses. All doses were administered after food as multiple tablets of 25 mg venlafaxine base. The single doses on days 1 and 5 were administered 30 minutes after the subject had eaten a medium-fat breakfast and were followed by a 4-hour fast.&quot;\n\npopulation: 18, non-smoking, healthy men, NOTE: none were tested for known CYP450 phenotypes \n\nages: 20 - 34\n\nC_max (day 4) @ 225mg/day venlafaxine: 397ng/mL\n\n397ng/mL X 1g/10^9ng X 1000mL/1L = 0.000397g/L\n','boycer','06/19/2009 20:52:12\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000397,NULL,NULL,NULL,'',0.225,NULL),(72,'evidence_1516','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(73,'evidence_1344','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.11 Drugs Metabolized by CYP3A\n\nResults of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(74,'evidence_1884','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.11 Drugs Metabolized by CYP3A\n\nResults of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(75,'evidence_1105','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','\nMetabolism: Celecoxib metabolism is primarily mediated via CYP2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors.\n\nCYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from 4 published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed celecoxib systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups. ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(76,'evidence_1107','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(77,'evidence_1313','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(78,'evidence_1359','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: tolbutamide --&gt; hydroxytolbutamide\n\nQuote:\n\nCYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7 (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM). ','boycer','06/12/2009 11:30:27\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,20),(79,'evidence_1203','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','\nStatement in the \'Drug Interactions\' section: \n\n&quot;Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.&quot;','boycer','10/22/2007 12:25:44\n','Non_traceable_Drug_Label_Statement','PKStudy',0,0.04,0.1,NULL,'',NULL,NULL),(80,'evidence_1899','http://www.ncbi.nlm.nih.gov/pubmed/9690949','\nRoute of administration: oral\n\nstudy duration: 4 dys pre-treatment with 100mg oral itraconazole or placebo; on day 4 a single 40mg dose of oral fluvastatin was given\n\npopulation: 10 \nmale: 5\nfemale: 5\n\nages: 20-25\n\nNo statistically significant (p &lt; .05) increase in fluvastatin AUC was found\n\n','boycer','10/29/2007 12:12:09\n','EV_PK_DDI_RCT','PKStudy',0,0.04,0.1,10,'',NULL,NULL),(81,'evidence_1339','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','&quot;\nFluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.\n\n      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;','boycer','10/20/2007 09:40:46\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(82,'evidence_1253','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','&quot;\nFluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.\n\n      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;','boycer','10/20/2007 09:37:05\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(83,'evidence_1949','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA guidance considers DMT-O-demethylation to be catalyzed selectively by CYP2D6; see Table 3 of page 32','boycer','04/24/2009 16:19:19\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(84,'evidence_1409','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(85,'evidence_1135','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c','Metabolism\n\nZafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations','boycer','09/24/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(86,'evidence_1909','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 14:07:18\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(87,'evidence_1008','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 14:06:14\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(88,'evidence_1796','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3','Drug Interactions\n\nRitonavir is an inhibitor of cytochrome P450 3A (CYP3A) both in vitro and in vivo. Ritonavir also inhibits CYP2D6 in vitro, but to a lesser extent than CYP3A. Co-administration of ritonavir and drugs primarily metabolized by CYP3A or CYP2D6 may result in increased plasma concentrations of other drugs that could increase or prolong its therapeutic and adverse effects ','boycer','01/11/2010 17:43:46\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(89,'evidence_1614','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3','Table 3 shows that the AUC of sildenafil increased 11-fold in the presence of ritonavir','boycer','01/11/2010 17:52:19\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,21),(90,'evidence_1358','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\n&quot;Mirtazapine has an absolute bioavailability of about 50%. It is eliminated predominantly via urine (75%) with 15% in feces.&quot;\n\nNOTE: no difference in the product label statement for the tablet formulations','boycer','06/15/2009 15:19:37\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.5,NULL,NULL,NULL,'',NULL,NULL),(91,'evidence_1344','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(92,'evidence_1252','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cef3e335-5891-412f-89c4-79fcd2f145b7','\nMetabolism\n\nValproate is metabolized almost entirely by the liver. In adult patients on monotherapy, 30-50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial beta-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15-20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine.','boycer','09/24/2009 15:56:55\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(93,'evidence_1226','http://www.ncbi.nlm.nih.gov/pubmed/8181191','Route of administration: oral\n\nstudy duration: four days pre-treatment with ketoconazole\n\npopulation: male: 2 female: 7\n\nages: 19-26\n\nNOTE: AUC data taken from table 1\n\nInteraction between ketoconazole, itraconazole, and midazolam was investigated in a double-blind, randomized crossover study of three phases at intervals of 4 weeks. Nine volunteers were given either 400 mg ketoconazole, 200 mg itraconazole, or matched placebo orally once daily for 4 days. On day 4, the subjects ingested 7.5 mg midazolam. Plasma samples were collected and psychomotor performance was measured. Both ketoconazole and itraconazole increased the area under the midazolam concentration-time curve from 10 to 15 times (p < 0.001) and mean peak concentrations three to four times (p < 0.001) compared with the placebo phase.','boycer','06/05/2007 07:52:40\n','EV_PK_DDI_RCT','PKStudy',15.9,0.0075,0.4,9,'',NULL,NULL),(94,'evidence_1425','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','Drug interactions:\n\nIn vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(95,'evidence_1113','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','the FDA lists this as a preferred in vitro inhibitor in it most recent guidance document. See Table 2, p. 28','boycer','05/21/2007 10:07:44\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(96,'evidence_1317','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','04/29/2009 19:44:42\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(97,'evidence_1169','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','04/29/2009 19:44:07\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(98,'evidence_1214','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(99,'evidence_1179','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:37:41\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(100,'evidence_1010','http://www.ncbi.nlm.nih.gov/pubmed/9542477','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 4 days\n\npopulation: 7 male, 3 female\n\nages:19-29\n\ndescription:\nTwo randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p &lt; 0.001).','boycer','12/07/2007 12:31:20\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,22),(101,'evidence_1061','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','04/29/2009 19:38:21\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(102,'evidence_1264','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(103,'evidence_1330','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(104,'evidence_1764','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c','Metabolism\n\nZafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(105,'evidence_1203','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2B6 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent\n','boycer','09/25/2007 08:58:04\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(106,'evidence_1763','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.12 Drugs Metabolized by CYP2C19\n\nResults of in vitro studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations. Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed.','boycer','05/05/2009 17:40:26\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(107,'evidence_1515','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nMetabolism\n\nIn vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(108,'evidence_1071','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','Metabolism and Elimination\n\nFollowing oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance.\n\nEscitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT). In humans, unchanged escitalopram is the predominant compound in plasma. At steady state, the concentration of the escitalopram metabolite S-DCT in plasma is approximately one-third that of escitalopram. The level of S-DDCT was not detectable in most subjects. In vitro studies show that escitalopram is at least 7 and 27 times more potent than S-DCT and S-DDCT, respectively, in the inhibition of serotonin reuptake, suggesting that the metabolites of escitalopram do not contribute significantly to the antidepressant actions of escitalopram. S-DCT and S-DDCT also have no or very low affinity for serotonergic (5-HT1-7) or other receptors including alpha- and beta-adrenergic, dopamine (D1-5), histamine (H1-3), muscarinic (M1-5), and benzodiazepine receptors. S-DCT and S-DDCT also do not bind to various ion channels including Na+, K+, Cl-, and Ca++ channels.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(109,'evidence_1805','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(110,'evidence_1470','http://www.ncbi.nlm.nih.gov/pubmed/7923194','\nEnzyme system: recombinant human enzyme in Hep G2 cells\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel\n\nOnly CYP2C8 formed detectable 6alpha-OH-paclitaxel\n\n','boycer','10/29/2007 09:39:45\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(111,'evidence_1074','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(112,'evidence_1071','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','Quetiapine is extensively metabolized by the liver. The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive. In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite and in the metabolism of its active metabolite N-desalkyl quetiapine .','boycer','05/14/2009 14:23:32\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(113,'evidence_1543','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','06/30/2009 14:26:54\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(114,'evidence_1873','http://www.ncbi.nlm.nih.gov/pubmed/11180037','NOTE: The AUC_i/AUC value is for the group that took 150mg of fluvoxamine and is calculated from Table I.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 5 days\r\n\r\npopulation: 14 healthy volunteers, all male\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 21-30\r\n\r\ndescription:\r\nSUBJECTS: The study was carried out as an open, randomized, crossover design. The participants were 14 volunteers; all of the participants were men with a median age of 26 years (range, 21 to 30 years). The subjects had no known heart, liver, or kidney disease according to a clinical examination, clinical chemical and hematologic screening, and electrocardiogram. No participants consumed alcohol or drugs on a regular basis at the time of the study. The volunteers consented to participate in the study on the basis of oral and written information.\r\n\r\nMETHODS: The study was divided into two periods. In period A, all volunteers took 500 mg of tolbutamide (Tolbutamide DAK, Nycomed Denmark, Roskilde, Denmark) as a single oral dose. In period B, the volunteers were randomly assigned to two fluvoxamine groups. One group took 150 mg/d of fluvoxamine (Fevarin 100-mg tablets, Solvay Duphar BV, Weesp, The\r\nNetherlands) for 5 days with a single oral dose of 500 mg of tolbutamide. The other group took a dose of 75 mg of fluvoxamine for 5 days and a single oral dose of 500 mg of tolbutamide. Period A and period B were separated by at least 1 week. Fluvoxamine was given at 20.00 hours.\r\n\r\nRESULTS: Total tolbutamide (TB) clearance (CL_TB) was calculated as follows: CL_TB = Dose/AUC in which AUC is the area under the plasma concentration-time curve calculated by means of the trapezoidal rule with extrapolation from the last measurable concentration to infinity. Complete absorption of tolbutamide from the intestine was assumed.\r\n\r\nThe mean plasma concentration of tolbutamide versus time after a single oral dose of 500 mg of tolbutamide before (period A) and during (period B) concomitant intake of 150 mg/d or 75 mg/d of fluvoxamine is shown in Fig 2. The results of the pharmacokinetic analysis are listed in Table I. Thus the median values of the total clearance of tolbutamide were 845 and 962 mL/h in the group that received 75 mg and the group that received 150 mg, respectively, before the administration of fluvoxamine. During fluvoxamine intake, the clearance values decreased to 688 and 642 mL/h, respectively, and the decrease was statistically significant both in the group that received 75 mg and in the entire group (75 mg and 150 mg) but not in the group that received 150 mg alone. The picture was even more clear for the hydroxylation clearance, for which there was a statistically significant reduction as judged from 95% confidence intervals for the median difference not comprising zero both in the 75-mg and 150-mg fluvoxamine groups. There was a tendency toward a more marked reduction in the latter group, although the difference between the two groups (150 mg versus 75 mg in period B) did not reach a level of statistical significance (Table I).\r\n\r\nSee Table I and the equation CL_TB = Dose/AUC for more information. The AUC_i/AUC for the 150mg dose was 1.50 and for the 75mg dose was 1.22.','boycer','09/22/2010 12:59:40\r\n','EV_PK_DDI_RCT','PKStudy',1.5,0.5,0.15,14,'',NULL,NULL),(115,'evidence_1094','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','06/30/2009 14:28:00\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(116,'evidence_1942','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: furafylline\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide/sulphone\n2) ziprasidone --&gt; oxindole acetic acid\n\nQuote:\nInhibition of metabolite formation by each inhibitor is\nsummarized in Table 2. Ketoconazole (10micM) inhibited\nthe formation of ziprasidone sulphoxide (sulphoxide and\nsulphone) by 79% and oxindole acetic acid N-dealkylated\nproduct) completely. Sulphaphenazole an furafylline did\nnot inhibit the formation of ziprasidone sulphoxide. The formation of oxindole acetic acid was inhibited (~50%) by furafylline. The formation of ziprasidone metabolites was not inhibited by quinidine but rather increased. ','boycer','06/19/2009 17:46:18\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,23),(117,'evidence_1792','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Smoking\n\nBased on in vitro studies utilizing human liver enzymes, ziprasidone is not a substrate for CYP1A2; smoking should therefore not have an effect on the pharmacokinetics of ziprasidone. Consistent with these in vitro results, population pharmacokinetic evaluation has not revealed any significant pharmacokinetic differences between smokers and nonsmokers.','boycer','05/14/2009 13:40:01\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(118,'evidence_1261','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','06/19/2009 12:30:38\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(119,'evidence_1866','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2C19 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent\n','boycer','09/25/2007 08:59:05\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(120,'evidence_1211','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','7.2 Effects of Ranolazine on Other Drugs\n\nIn vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(121,'evidence_1512','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/0f43610c-f290-46ea-d186-4f998ed99fce','route of administration: not mentioned\n\nstudy duration: not mentioned\n\npopulation: not mentioned\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: not mentioned\n\nQuote:\nIn a clinical study, ketoconazole (200 mg BID) increased the area under the concentration vs. time curve (AUC) of PRISTIQ (400 mg single dose) by about 43% and Cmax by about 8%. Concomitant use of PRISTIQ with potent inhibitors of CYP3A4 may result in higher concentrations of PRISTIQ.','boycer','02/16/2012 21:52:08\n','Non_traceable_Drug_Label_Statement','PKStudy',1.43,0.04,0.04,NULL,'',NULL,NULL),(122,'evidence_1341','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of both 1\'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a4 Supersome system','boycer','06/26/2007 07:11:48\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(123,'evidence_1371','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78','\n&quot;Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.&quot;','boycer','06/26/2007 07:39:29\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(124,'evidence_1559','http://www.ncbi.nlm.nih.gov/pubmed/10548453','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (p. 394 `chemical inhibition`\n\ninhibitor used: \n\nreaction: alprazolam --&gt; 4-OH-alprazolam\n          alprazolam --&gt; 1\'-OH-alprazolam\n\nQuote: \n\n&quot;Co-incubation of human liver microsomes with the prototypic 3A4 inhibitor, troleandomycin, ( &gt; 50microM) resulted in no detectable formation of 1\'-OH-alprazolam and 4-OH-alprazolam&quot;','boycer','07/02/2007 10:51:34\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,24),(125,'evidence_1774','http://www.ncbi.nlm.nih.gov/pubmed/16765147','\nRoute of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: single dose with 72 hours of plasma level monitoring\n\npopulation: study does not state gender of participants\n\nages: 22-30\n\ndescription: \nOur objective was to evaluate the effect of the CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. METHODS: Nineteen healthy male volunteers were divided into 3 groups on the basis of the genetic polymorphism of CYP3A5. The groups comprised subjects with CYP3A5*1/*1 (n=5), CYP3A5*1/*3 (n=7), or CYP3A5*3/*3 (n=7). After a single oral 1-mg dose of alprazolam, plasma concentrations of alprazolam were measured up to 72 hours, together with assessment of psychomotor function by use of the Digit Symbol Substitution Test, according to CYP3A5 genotype. RESULTS: The area under the plasma concentration-time curve for alprazolam was significantly greater in subjects with CYP3A5*3/*3 (830.5+/-160.4 ng . h/mL [mean+/-SD]) than in those with CYP3A5*1/*1 (599.9+/-141.0 ng . h/mL) (P=.030). The oral clearance of alprazolam was also significantly different between the CYP3A5*1/*1 group (3.5+/-0.8 L/h) and CYP3A5*3/*3 group (2.5+/-0.5 L/h) (P=.036). Although a trend was noted for the area under the Digit Symbol Substitution Test score change-time curve (area under the effect curve) to be greater in subjects with CYP3A5*3/*3 (177.2+/-84.6) than in those with CYP3A5*1/*1 (107.5+/-44), the difference did not reach statistical significance (P=.148). CONCLUSIONS: The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam.','boycer','06/26/2007 06:27:38\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(126,'evidence_1169','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of both 1\'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a5 Supersome system','boycer','06/26/2007 07:14:26\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(127,'evidence_1298','http://www.ncbi.nlm.nih.gov/pubmed/12911366','\nRoute of administration: oral\n\npolymorphic enzyme: no\n\nstudy duration: this was a matched pair study; 7 patients already take atorvastatin were matched with patients who were not taking atorvastatin or any other known CYP3A4 inhibitor. Of the patients taking atorvastatin, 5 were on 10mg/day, 1 on 20mg/day, and one on 40mg/day. All patient\'s received a .25mg/kg bolus of IV midazolam.\n\npopulation: 14 individuals; 10 male, 4 female\n\nages: generally older ~61 (unfortunately ages given in mean/std dev)\n\nAUC_i/AUC of midazolam: 889.4/629.1=1.41\n\n\n','boycer','12172009','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(128,'evidence_1596','http://www.ncbi.nlm.nih.gov/pubmed/9366029','Route of administration: oral\n\nstudy duration: rac-citalopram given @ 40mg qd X 21days\n\npopulation: 10 adults (6 female and 4 male) all extensive metabolizers according to 2d6 and 2c19 specific assays (sparteine and mephenytoin respectively)\n\nages: 23-32\n\n\nDescription: \nC_max for S-demethylcitalopram : 46.3nMol/L\n\n46.3nMol/L X 1M/10^9nMol X 324.39g/1M = 0.00001437g/L','boycer','06/12/2009 20:11:55\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00001437,NULL,NULL,NULL,'',0.04,NULL),(129,'evidence_1972','http://www.ncbi.nlm.nih.gov/pubmed/11936570','\nRoute of administration: oral\n\nstudy duration: 5 days pre-treatment with atorvastatin then 3 days atorvastatin and clarithromycin\n\npopulation: 36 from which 12 were randomly chosen to receive clarithromycin, 12 to receive azithromycin, and 12 to receive placebo the study \n\nmale: 16 or 17 female: 19 or 20 (data appears incorrect in paper)\n\nages: 24-33\n\nAUC_i/AUC: 151.5/83.3ng/h/ml\n\nThis study investigated the potential for azithromycin and clarithromycin to inhibit the metabolism of atorvastatin. Although there was no interaction between azithromycin and atorvastatin, clarithromycin did have a significant effect on atorvastatin pharmacokinetic parameters. When coadministered, clarithromycin raised subject exposure (AUC24) by 82% and peak plasma concentrations by 56%. These data suggest that while azithromycin appears to be safe to coadminister with atorvastatin, clarithromycin should be avoided in patients taking this and similarly metabolized HMG-CoA inhibitors.','boycer','06/05/2007 08:47:56\n','EV_PK_DDI_RCT','PKStudy',1.819,0.01,0.5,36,'',NULL,NULL),(130,'evidence_1730','http://www.ncbi.nlm.nih.gov/pubmed/15518608','oute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days atorvastatin only, 8 days atorvastatin and clarithromycin\n\ndose: .050g atorvastatin1xday\n.5g clarithromycin 2xday\n\npopulation: 45 men and women (only 15 received atorvastatin)\n\nages:18-60\n\n(mean AUC_i)/(mean AUC) = 113/21\n\ndescription:\nClarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC) and simvastatin acid (12-fold), followed by atorvastatin (greater than fourfold) and then pravastatin (almost twofold).','boycer','06/05/2007 09:07:04\n','EV_PK_DDI_RCT','PKStudy',5.381,0.08,0.5,15,'',NULL,NULL),(131,'evidence_1890','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdfa991c-0ba9-4d12-ba4c-8909504c27d6','\nCLINICAL PHARMACOLOGY\n...\nFollowing oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. Plasma concentrations of metronidazole are proportional to the administered dose. Oral administration of 250 mg, 500 mg, or 2,000 mg produced peak plasma concentrations of 6 mcg/mL, 12 mcg/mL, and 40 mcg/mL, respectively. Studies reveal no significant bioavailability differences between males and females; however, because of weight differences, the resulting plasma levels in males are generally lower.\n\n40mcg/mL X 1g/10^6mcg X 1000mL/L = 0.004g/L','boycer','09/24/2009 10:33:29\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.004,NULL,NULL,NULL,'',2,NULL),(132,'evidence_1858','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(133,'evidence_1637','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','Renal: There is limited information on the pharmacokinetics of bupropion in patients with renal impairment. An inter-study comparison between normal subjects and patients with end-stage renal failure demonstrated that the parent drug Cmax and AUC values were comparable in the 2 groups, whereas the hydroxybupropion and threohydrobupropion metabolites had a 2.3- and 2.8-fold increase, respectively, in AUC for patients with end-stage renal failure. The elimination of the major metabolites of bupropion may be reduced by impaired renal function (see  PRECAUTIONS: Renal Impairment).','boycer','05/14/2009 16:38:11\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(134,'evidence_1918','http://www.ncbi.nlm.nih.gov/pubmed/8830063','\nNOTE: The AUC_i/AUC value given is calculated from Table 1. The precip_dose given is the mean dose (+/- 0.866)\n\nroute of administration: oral\n\nstudy duration: 22 days\n\npopulation: 5 volunteers with major affective disorders (DSM-III-R criteria), (2 male, 3 female)\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: mean age 40.4 +/- 11.5\n\ndescription:\nSUBJECTS: Patients meeting DSM-III-R criteria for major affective disorders were admitted to the 3-West Clinical Research Unit of the Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland. Patients volunteered to participate in the clinical research program and gave oral and written informed consent for clinical trials of CBZ, VPA, and BUP, as well as other medications and associated research procedures. A thorough medical and neurologic history and examination and a pretreatment electroencephalogram were done to rule out the presence of seizure disorders and other medical illnesses. A detailed life course of illness was visually plotted and quantified for each patient as previously described. Psychiatric diagnoses were confirmed by the Schedule for Affective Disorders and Schizophrenia structured diagnostic interview. Thus, these patients were carefully characterized as having primary mood disorders (for the purpose of assessing clinical responses to medications) and lacking concurrent medical disorders that could alter pharmacokinetics. Patients and nursing staff were blind to chronic medications, as well as to the pharmacokinetic study drug being administered, in order to allow a more objective assessment of clinical responses. The blind condition was also maintained with patients and nurses by having blind &quot;CBZ&quot; and &quot;VPA&quot; concentrations drawn throughout the hospitalization, even at times when patients were not receiving either drug.\n\nThe placebo and VPA groups did not differ significantly with respect to mean age (placebo, 38.5 +/- 10.2; VPA, 40.4 +/- 11.5) or gender (placebo, eight men and nine women; VPA, two men and three women). Four patients had both placebo and VPA studies.\n\nMETHODS: Patients had 24-hour pharmacokinetic profiles of BUP and metabolites after single oral doses of BUP, 150 mg, while receiving placebo (N = 17) or during chronic VPA (N = 5) monotherapy. Patients were on VPA for at least 3 weeks in order to allow dosage titration and the attainment of steady state. Patients on VPA received a mean dose of 1,750 +/- 866 mg/day with a mean trough VPA concentration in plasma of 97 +/- 19 micro gram/ml. Single trough VPA concentrations in plasma were determined during the week of the kinetic study for each patient on these agents.\n\nFor each pharmacokinetic study, a single oral dose of BUP, 150 mg, was administered at 9 a.m. in a blind fashion. Patients had nothing by mouth from 11:30 p.m. the night before until 3 hours after receiving the blind BUP dose, at which point they resumed their blinded placebo or VPA and their usual oral intake of food and fluids. Patients were receiving VPA in three or four divided doses each day and missed at most a single morning dose of VPA, so that the concentrations of these agents in plasma were maintained during the kinetic studies.\n\nRESULTS: CBZ but not VPA therapy decreased BUP C_max by 87% (p &lt;0.0001) and 24-hour AUC by 90% (p &lt; 0.0001) (Table 1; Figure 2). These findings were similar in paired analyses of the seven patients who had studies both on placebo and CBZ (CBZ decreased C_max by 81% [p = 0.0005] and AUC by 84% [p = 0.0003]) and the four patients with studies both on placebo and VPA. Five (42%) of 12 patients on CBZ had no detectable BUP concentrations at all times sampled, whereas no patients on placebo or VPA had such null profiles. There was a trend toward an earlier time of BUP C_max (T_max) on VPA (1.1 +/- 0.2 hours) than on placebo (1.7 +/- 0.8 hours, p &lt; 0.10) that was also evident in the four patients with studies both on placebo and VPA (p &lt; 0.07).','boycer','09/22/2010 14:41:01\n','EV_PK_DDI_RCT','PKStudy',0.99,0.15,1.75,5,'',NULL,NULL),(135,'evidence_1594','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(136,'evidence_1880','http://www.ncbi.nlm.nih.gov/pubmed/16390352','Enzyme system: recombinant human enzymes in human lymphoblastoid\nNADPH added: not explicitly mentioned but assumed\n\ninhibitor used: no\n\nQuetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4.','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(137,'evidence_1585','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f','\n&quot;When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for nefazodone.&quot;','boycer','10/16/2007 11:08:32\n','Non_traceable_Drug_Label_Statement','PKStudy',2,0.001,0.2,NULL,'',NULL,NULL),(138,'evidence_1127','http://www.ncbi.nlm.nih.gov/pubmed/8748428','\nRoute of administration: oral\n\nstudy duration: read description below\n\npopulation: 48 male volunteers\n\nages: mean(std dev): 26(6.7)\n\nDay 7 Alprazolam AUC_i/AUC (0-inf): 1.987\nDay 7 4-OH-Alprazolam AUC_i/AUC (0-inf): .71 \n\nDescription:\nThis study was conducted to determine the potential for an interaction between nefazodone, a new antidepressant, and alprazolam after single- and multiple-dose administration in a randomized, double-blind, parallel-group, placebo-controlled study in 48 healthy male volunteers. A group of 12 subjects received either placebo twice daily, 1 mg of alprazolam twice daily, 200 mg of nefazodone twice daily, or the combination of 1 mg of alprazolam and 200 mg of nefazodone twice daily for 7 days. Serial blood samples were collected after dosing on day 1 and day 7 and before the morning dose on days 4, 5, and 6 for the determination of alprazolam and its metabolites alpha-hydroxyalprazolam (AOH) and 4-hydroxyalprazolam (4OH) and nefazodone and its metabolites hydroxynefazodone (HO-nefazodone), m-chlorophenylpiperazine (mCPP), and a triazole dione metabolite (dione) by validated high-performance liquid chromatography methods. Steady-state levels in plasma were reached by day 4 for alprazolam, 4OH, nefazodone, HO-nefazodone, mCPP, and dione. Noncompartmental pharmacokinetic analysis showed that at steady state, alprazolam Cmax and AUCtau values significantly increased approximately twofold and 4OH Cmax and AUCtau values significantly decreased by 40 and 26%, respectively, when nefazodone was coadministered with alprazolam. There was no effect of alprazolam on the single-dose or steady-state pharmacokinetics of nefazodone, HO-nefazodone, or dione after the coadministration of alprazolam and nefazodone.\n','boycer','11/13/2007 08:46:01\n','EV_PK_DDI_RCT','PKStudy',1.987,0.001,0.2,48,'',NULL,NULL),(139,'evidence_1772','http://www.ncbi.nlm.nih.gov/pubmed/14709940','\nRoute of administration: oral\n\nstudy duration: open label cross-over study involving three other antidepressants with at least a 7 day washout period between study arms. In the nefazodone arm, participants received 200mg bid for 3 days then 400mg bid for 5 days.  Participants received 2mg of alprazolam on day 1 and the last day of nefazodone treatment.\n\npopulation: 16 male\nages: 24-40\n\nAUC_i/AUC (0-inf): 1.47 \n\n','boycer','11/13/2007 08:58:59\n','EV_PK_DDI_NR','PKStudy',1.47,0.002,0.4,16,'',NULL,NULL),(140,'evidence_1434','http://www.ncbi.nlm.nih.gov/pubmed/9757151','\nRoute of administration: oral\n\nstudy duration: 1 day pre-treatment with erythromycin 500mg 2x/day\n\npopulation: 12 healthy adults \nmale: 6\nfemale: 6\nages: 21-39 years\n\nAUC_i/AUC: 20.9/5.5\n\nQuote:\nIn a randomized, double-blind, 5-trial clinical pharmacokinetic-pharmacodynamic study, 12 volunteers received 0.125 mg triazolam orally, together with placebo, azithromycin, erythromycin, or clarithromycin. In a fifth trial they received placebo plus placebo...Apparent oral clearance was significantly reduced (P < .05) during erythromycin and clarithromycin trials (146 and 95 mL/min). Peak plasma concentration was correspondingly increased, and elimination half-life was prolonged. The effects of triazolam on dynamic measures were nearly identical when triazolam was given with placebo or azithromycin, but benzodiazepine agonist effects were enhanced during erythromycin and clarithromycin trials.','boycer','06/25/2007 13:47:05\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,25),(141,'evidence_1265','http://www.ncbi.nlm.nih.gov/pubmed/8720318','\nRoute of administration: oral\n\nstudy duration: 4 days pre-treatment with erythromycin 500mg 3x/day; 5th day patients in the treatment arm received a single 15mg oral dose of MDZ\n\npopulation: 12 healthy adults\nmale: 4\nfemale: 8\nages: 24-53 years\n\nAUC_i/AUC: 662.71/173.77 ng*hr/ml = 3.814\n\nNOTE: AUC values  appear to be 0-24 hour \n\nQuote:\n&quot;The pharmacokinetic and pharmacodynamic interaction between azithromycin (CAS 83905-01-5), an azalide antibiotic, and midazolam (CAS 59467-70-8), a short-acting hypnotic agent, was investigated in an open, three-way cross-over study, including erythromycin (CAS 114-07-8) as a positive control. Twelve healthy male and female subjects had standard doses of azithromycin (500 mg o.d. over 3 days), or erythromycin (500 mg t.i.d. over 5 days), or no pretreatment. On the day of the last dose, they ingested 15 mg midazolam. Blood samples were collected and psychometric tests performed. Erythromycin pretreatment (E) significantly changed the pharmacokinetics of midazolam compared to control (C), whereas azithromycin (A) had no such effect. The parameters are summarized as follows: area under the concentration-time curve, AUC (C) 173.8 h.ng.ml-1 vs. (E) 662.7 h.ng.ml-1*+ and (A) 220.0 h.ng.ml-1; concentration maxima (C) 67.2 ng.ml-1 vs. (E) 182.3 ng.ml-1*+ and (A) 86.7 ng.ml-1; elimination half-life (C) 2.21 h vs. (E) 4.85 h* and (A) 2.41 h (* p &lt; 0.05 vs. (C), +p &lt; 0.05 vs. (A)). Pharmacodynamic tests (digit symbol substitution test; critical flicker fusion test; subjective analog scale for rating of alertness; duration of sleep) consistently showed significant differences after erythromycin pretreatment compared to control, but not after azithromycin. Erythromycin, but not azithromycin, causes clinically significant changes in the pharmacokinetics and pharmacodynamics of midazolam.&quot;','boycer','10/16/2007 09:38:08\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,26),(142,'evidence_1467','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(143,'evidence_1159','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78','Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.','boycer','06/26/2007 06:56:12\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(144,'evidence_1485','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 4-OH-alprazolam in a recombinant cyp3a4 Supersome system Km = 81','boycer','11/17/2007 12:09:30\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(145,'evidence_1669','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29-44, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2-3 fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. When fluoxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level. Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to the previous level.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(146,'evidence_1774','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Paroxetine: Co-administration of paroxetine (20 mg/day for 5-8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18-65 resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6 fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. When paroxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level. Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to previous levels.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(147,'evidence_1679','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(148,'evidence_1022','http://www.ncbi.nlm.nih.gov/pubmed/11061579','\nRoute of administration: oral\n\nstudy duration: 13 days\n\npopulation: 18 participants; 5 male, 5 female\n\nages:18-45\n\ndose: 40mg of pravastatin on day one, three days no drug, days 6-10 participants were given 200mg itraconazole 1xday for 5 days, on day 10 a portion of the participants were given a single dose of 40 mg pravastatin. PK parameters were measured followed for another three days\n\n(mean AUC_i)/(mean AUC) = 137.9/267.7 (AUC is 0-infinity)\n\n\ndescription:\nTable 3 shows PK results for pravastatin and 3alpha-hydroxypravastatin\n\nQuote:\n&quot;In this single-site, randomized, three-way crossover, open-labeled study, healthy subjects (n = 18) received single doses of cerivastatin 0.8 mg, atorvastatin 20 mg, or pravastatin 40 mg without and with itraconazole 200 mg. Pharmacokinetic parameters [AUC(0-infinity), AUC(0-tn), peak concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2)] were determined for parent statins and major metabolites. RESULTS: Concomitant cerivastatin/itraconazole treatment produced small elevations in the cerivastatin AUC(0-infinity), Cmax, and t1/2 (27%, 25%, and 19%, respectively; P &lt; .05 versus cerivastatin alone). Itraconazole coadministration produced similar changes in pravastatin pharmacokinetics [AUC elevated 51% (P &lt; .05 versus pravastatin alone), 24% (Cmax), and 23% (t1/2), respectively]. However, itraconazole dramatically increased atorvastatin AUC (150%), Cmax (38%), and t1/2 (30%) (P &lt; .05).&quot;','boycer','10/16/2007 09:11:34\n','EV_PK_DDI_RCT','PKStudy',1.941,0.04,0.2,18,'',NULL,NULL),(149,'evidence_1827','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978','Pharmacokinetic-related Interactions\n\nClozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(150,'evidence_1605','http://www.ncbi.nlm.nih.gov/pubmed/11147928','\nRoute of administration: oral\n\nstudy duration: three weeks\n\npopulation: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks\n\nages: 29 - 55\n\n\nQuote:\n\nThe effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline.','boycer','12172009','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(151,'evidence_1285','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel \n\nK_i = 8.4micM\n\n8.4micM/1L x 1M/1e6micM x 404.55g/1M = .003g/L\n','boycer','10/29/2007 10:46:09\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.003,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,27),(152,'evidence_1097','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: tolbutamide\n\nreaction: tolbutamide hydroxylation \n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).\n\n\n','boycer','02132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(153,'evidence_1622','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: chlorzoxazone\n\nreaction: chlorzoxazone hydroxylation\n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).\n\n\n','boycer','02132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(154,'evidence_1641','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: S-mepheytoin 4\'hydroxylation\n\nQuote: \n\nCYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI\nfluvoxamine (see Table 2).\n\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(155,'evidence_1263','http://www.ncbi.nlm.nih.gov/pubmed/15258107','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: bufuralol\n\nreaction: bufuralol 1\'hydroxylation\n\nIC50 &gt; 200micM (see Table 3)\n\nQuote: \nCYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM.\n\n\n\n','boycer','09/23/2009 11:38:21\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,28),(156,'evidence_1096','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(157,'evidence_1174','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6','\n\nMetabolism\n\nPantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(158,'evidence_1739','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c','\nThe pharmacokinetic parameters of zafirlukast 20 mg administered as a single dose to 36 male volunteers: 326ng/mL\n\n326ng/mL X 1g/10^9ng X 1000mL/1L = 0.0000326g/L','boycer','09/24/2009 15:24:57\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.0000326,NULL,NULL,NULL,'',0.02,NULL),(159,'evidence_1125','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.2 Inhibitors of CYP2D6\n\nConcomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)].','boycer','05/05/2009 17:43:52\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,29),(160,'evidence_1550','http://www.ncbi.nlm.nih.gov/pubmed/12621382','\n\nroute of administration: oral\n\nstudy duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;\n\npopulation: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study\n\ntested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.\n\nages: 21 - 27\n\ndescription:\n&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;\n\n','boycer','06/20/2009 13:36:32\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,30),(161,'evidence_1565','http://www.ncbi.nlm.nih.gov/pubmed/11147928','\nRoute of administration: oral\n\nstudy duration: three weeks\n\npopulation: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks\n\nages: 29 - 55\n\n\nQuote:\n\nThe effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline.','boycer','12172009','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(162,'evidence_1337','http://www.ncbi.nlm.nih.gov/pubmed/8730978','\nRoute of administration: oral\n\nstudy duration: 4 days pretreatment with oral fluconazole 100mg; on day 4 a single oral dose of .25mg triazolam\n\npopulation: 12\nmale: 2\nfemale: 10 (8 used oral contraceptives)\n\nages: 19-31 \n\nAUC_i/AUC (0 to infinity): 30 / 12.2 = 2.46','boycer','10/30/2007 06:43:43\n','EV_PK_DDI_RCT','PKStudy',2.46,0.00025,0.1,12,'',NULL,NULL),(163,'evidence_1871','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(164,'evidence_1935','http://www.ncbi.nlm.nih.gov/pubmed/1531484','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: single dose of clarithromycin\n\npopulation: 26 male\n\nages:28-42\n\nC_max = 1.65mg/L for subjects given breakfast two hours after drug administration and 2.51mg/L for subjects given breakfast 1/2 hour before drug administration. The difference was statistically significant (p &lt;0.05); the highest value was  entered into the system','boycer','07/02/2007 13:09:54\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00251,NULL,NULL,NULL,'',0.5,NULL),(165,'evidence_1374','http://www.ncbi.nlm.nih.gov/pubmed/1474166','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: single dose of clarithromycin\n\npopulation: 12 male\n\nages:18-30\n\nC_max = 2.41mg/L ','boycer','07/02/2007 13:14:38\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00241,NULL,NULL,NULL,'',0.5,NULL),(166,'evidence_1498','http://www.ncbi.nlm.nih.gov/pubmed/8331208','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 250mg  clarithromycin 2x/day for 5 doses \n\npopulation: 6 \'healthy volunteers\'\n\nages:45-64\n\nC_max = 1.52mg/L','boycer','07/02/2007 13:28:54\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000152,NULL,NULL,NULL,'',0.25,NULL),(167,'evidence_1308','http://www.ncbi.nlm.nih.gov/pubmed/8408732','\n\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 250mg  clarithromycin single dose \n\npopulation: 17 male\n\nages:18-40\n\nC_max = .78mg/L','boycer','07/02/2007 13:41:41\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00078,NULL,NULL,NULL,'',0.25,NULL),(168,'evidence_1672','http://www.ncbi.nlm.nih.gov/pubmed/9929499','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: beta-OH-lovastatin--&gt;6\'beta-hydroxy-lovastatin\n\nQuote:\n\nLovastatin was metabolized by human liver microsomes to two major metabolites: 6\'beta-hydroxy [Michaelis-Menten constant (Km): 7.8 +/- 2.7 microM] and 6\'-exomethylene lovastatin (Km,10.3 +/- 2.6 microM). 6\'beta-Hydroxylovastatin formation in the liver was inhibited by the specific CYP3A inhibitors cyclosporine (Ki, 7.6 +/- 2.3 microM), ketoconazole (Ki, 0.25 +/- 0.2 microM), and troleandomycin (Ki, 26.6 +/- 18.5 microM).\n\nNOTE: the authors mention that lovastatin is a lactone that is completely converted to its &quot;open acid&quot; form in vivo - we in the DIKB infer this form to be beta-OH-lovastatin','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(169,'evidence_1151','http://www.ncbi.nlm.nih.gov/pubmed/8689812','\nRoute of administration: oral\n\nstudy duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4\n\npopulation: 12\nmale: 5\nfemale: 7 (2 on contraceptive steroids)\n\nages: 20-29\n\nAUC_i/AUC: 1212/54.8 = 22.117\n\n','boycer','12172009','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(170,'evidence_1457','http://www.ncbi.nlm.nih.gov/pubmed/11075313','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days\n\npopulation: 12 male\n\nages:21-41\n\ndescription:\nPotential for inhibition of CYP3A activity by simvastatin, an HMG-CoA reductase inhibitor, was evaluated in 12 healthy male subjects who received placebo or 80 mg of simvastatin, the maximal recommended dose, once daily for 7 consecutive days. On day 7, an intravenous injection of 3 microCi [14C N-methyl]erythromycin for the erythromycin breath test (EBT) was coadministered with a 2 mg oral solution of midazolam. The values for percent 14C exhaled during the first hour (for EBT) and the pharmacokinetic parameters of midazolam (AUC, Cmax, t1/2) were not affected following multiple once-daily oral doses of simvastatin 80 mg. The 95% confidence interval was 0.97 to 1.18 for EBT and 0.99 to 1.23 for midazolam AUC. In addition, the total urinary recoveries of midazolam and its 1\'-hydroxy metabolites (free plus conjugate) obtained from both treatments were not statistically different (p > 0.200). These data demonstrate that multiple dosing of simvastatin, at the highest recommended clinical dose, does not significantly alter the in vivo hepatic or intestinal CYP3A4/5 activity as measured by the commonly used EBT and oral midazolam probes.','boycer','05/21/2007 11:02:52\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,31),(171,'evidence_1513','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.12,NULL,NULL,NULL,'',NULL,NULL),(172,'evidence_1874','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: recombinant human enzymes (human lymphoblastoid)\n\nNADPH added: yes (a dehydrogenase generating system) \n\ninhibitor used: no\n\nThis study showed NO formation of didesmethylcitalopram (aka didemethylcitalopram) in a recombinant human lymphoblastoid cell system','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(173,'evidence_1506','http://www.ncbi.nlm.nih.gov/pubmed/10548453','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: alpha-napthoflavone\n\nreaction: alprazolam --&gt; 4-OH-alprazolam\nalprazolam --&gt; 1\'-OH-alprazolam\n\nInhibition of CYP1A2 by in vitro selective inhibitor alpha-napthoflavone had no effect on the transformation of alprazolam to its two major metabolites\n\nNOTE: the use of a NADPH generating system is inferred from paragraph 2 of p. 934 &quot;Alprazolam hydrozylase assay&quot; ','boycer','01/14/2008 13:22:18\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,32),(174,'evidence_1788','http://www.ncbi.nlm.nih.gov/pubmed/16778714','NOTE: The AUC_i/AUC is from the heterozygous EMs and calculated from Table 1.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 6 days\r\n\r\npopulation: 18 healthy volunteers (9 male, 9 female), all Japanese\r\n\r\ntested for known CYP450 polymorphisms?\r\nYes -- CYP2C19 genotypes - 6 homozygous EMs, 6 heterozygous EMs, 6 homozygous PMs\r\n\r\nages: mean 25.1 years (+/- 3.8)\r\n\r\ndescription:\r\nEighteen healthy Japanese volunteers (9 men and 9 women) who were H. pylori-negative were enrolled in this study. Their mean age was 25.1 +/- 3.8 years and mean body weight was 56.6 +/- 13.3 kg. Most subjects in this study had participated in our previous studies. The mutated alleles for CYP2C19, CYP2C19*3(*3), and CYP2C19*2(*2) had been identified using polymerase chain reaction-restriction fragment length polymorphism methods of De Morais et al, before this study. The CYP2C19 genotype analyses revealed 5 different patterns as follows: *1/*1 in 6, *1/*2 in 3, *1/*3 in 3, *2/*2 in 5, and *2/*3 in 1. These were divided into 3 groups, homozygous EMs (*1/*1, n=6), heterozygous EMs (*1/*2 and *1/*3, n=6), and PMs (*2/*2 and *2/*3, n=6).\r\nMETHODS: A randomized double-blind placebo-controlled crossover study design in 3 phases was conducted at intervals of 2 weeks. Clarithromycin (400 mg) as a capsule containing the equivalent of 2 tablets, fluvoxamine (25 mg) as a capsule containing the equivalent of a tablet, or matched placebo was given orally twice a\r\nday (9 AM, 9 PM) for 6 days. Six volunteers within each group were allocated to each of the 3 different drug sequences: placebo-clarithromycin-fluvoxamine, fluvoxamine-placebo-clarithromycin, or clarithromycin-fluvoxamine-placebo. On day 6, they took a single oral 60-mg dose of lansoprazole with 400 mg dose of clarithromycin, 25mg dose of fluvoxamine, or placebo after overnight fasting (9 AM). No other medications were taken during the study periods. No meal was allowed until 4 hours after the dosing (1 PM). The use of alcohol, tea, coffee, and cola was forbidden during the test days.\r\nRESULTS: Clarithromycin treatment significantly increased Cmax and AUC_0-24 of lansoprazole in heterozygous EMs (P&lt;0.05) and in PMs (P&lt;0.01), and prolonged elimination half-life by 1.6-fold (P&lt;0.05) in PMs. Calculated from Table 1, the AUC_i/AUC were: 1.62 (homozygous EMs), 1.71 (heterozygous EMs [p&lt;0.05]), and 1.89 (PMs [p&lt;0.01]).','boycer','08/23/2010 13:06:43\r\n','EV_PK_DDI_RCT','PKStudy',1.71,0.06,0.8,18,'',NULL,NULL),(175,'evidence_1544','http://www.ncbi.nlm.nih.gov/pubmed/11872324','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: nefazodone --&gt; OH-NEF and nefazodone --&gt; mCPP\n\nQuote: \nIncubations of human liver microsomes with NEF and\nthe CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3).\n\n\n\n','boycer','02/13/2010 09:12:03\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,33),(176,'evidence_1240','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84','\n12.3 Pharmacokinetics\n\nMetabolism: Lansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by blocking the proton pump [(H+, K+)-ATPase enzyme system] at the secretory surface of the gastric parietal cell. The two active species are not present in the systemic circulation. The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours. Therefore, the plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion.\n\nElimination: Following single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.','boycer','09/24/2009 10:19:47\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(177,'evidence_1902','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/08320ea3-8f93-6f04-5d1c-f69af3eb5a81','\n&quot;Approximately 64% of a 30-mg oral solution dose of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites over a 10-day post-dosing period. About 36% was excreted in the feces (probably via the bile), mostly as metabolites and less than 1% as the parent compound over the 10-day post-dosing period.&quot;','boycer','06/16/2009 16:41:05\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(178,'evidence_1037','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: bufuralol 1\'hydroxylation\n\nK_i = 16micM\n\n16micM/1L x 1M/10^6micM x 426.484g/1M = 0.007g/1L','boycer','06/22/2009 12:16:25\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.007,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,34),(179,'evidence_1067','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 4-OH-midazolam using a recombinant CYP3A4 Supersome system.','boycer','07/02/2007 11:25:14\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(180,'evidence_1062','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: phenacetin-o-deethylation\n\nk_i = 65.1micM\n\n65.1micM/L x 1M/10^6micM x 403.97g/M = 0.026g/L','boycer','04/25/2009 09:42:37\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.026,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,35),(181,'evidence_1317','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote:\n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.\n','boycer','06/12/2009 11:10:32\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,36),(182,'evidence_1632','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d5051fbc-846b-4946-82df-341fb1216341','\n&quot;Metabolism and Elimination  Following a single oral dose of 14C labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized. Approximately 57% and 30% of the dose was recovered in the urine and feces, respectively. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the concentration of olanzapine, and 4&amp;#8242;-N-desmethyl olanzapine, present at steady state at 31% of the concentration of olanzapine. Both metabolites lack pharmacological activity at the concentrations observed&quot;','boycer','06/16/2009 16:59:50\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(183,'evidence_1517','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/08320ea3-8f93-6f04-5d1c-f69af3eb5a81','\n&quot;Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.&quot;','boycer','06/16/2009 16:47:59\n','Non_traceable_Drug_Label_Statement','PKStudy',4,0.008,0.02,NULL,'',NULL,NULL),(184,'evidence_1196','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','06/12/2009 19:19:09\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,37),(185,'evidence_1885','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 1\'-OH-midazolam using a recombinant CYP3A4 Supersome system (Km = 5microM).','boycer','07/02/2007 11:29:26\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(186,'evidence_1896','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6','\nAbsorption\n\nThe absorption of pantoprazole is rapid, with a Cmax of 2.5 mcg/mL that occurs approximately 2.5 hours after administration of a single or multiple oral 40-mg doses of pantoprazole sodium delayed-release tablets. Pantoprazole is well absorbed; it undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%. Pantoprazole absorption is not affected by concomitant administration of antacids. ','boycer','09/24/2009 13:09:27\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.77,NULL,NULL,NULL,'',NULL,NULL),(187,'evidence_1038','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf','\nDrug-Drug Interactions:\n\nBased on in vitro data, modafinil is metabolized partially by the 3A isoform subfamily of hepatic cytochrome P450 (CYP3A4). I','boycer','09/24/2009 12:45:45\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(188,'evidence_1911','http://www.ncbi.nlm.nih.gov/pubmed/8157044','\nRoute of administration: oral\n\nstudy duration: single dose \n\npopulation: 11 male\n\nages:20-30\n\nC_max = 4.31ng/ml\n\n4.31ng/1mL x 1000mL/1L x 1g/10^9ng = 0.00000431g/L','boycer','06/15/2009 14:45:42\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00000431,NULL,NULL,NULL,'',0.025,NULL),(189,'evidence_1956','http://www.ncbi.nlm.nih.gov/pubmed/8157044','\nRoute of administration: oral\n\nstudy duration: single dose \n\npopulation: 11 male\n\nages:20-30\n\nC_max = 11.9ng/ml\n\n11.9ng/1mL x 1000mL/1L x 1g/10^9ng = 0.0000119g/L','boycer','06/15/2009 14:47:15\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000119,NULL,NULL,NULL,'',0.05,NULL),(190,'evidence_1183','http://www.ncbi.nlm.nih.gov/pubmed/8157044','\nRoute of administration: oral\n\nstudy duration: single dose \n\npopulation: 11 male\n\nages:20-30\n\nC_max = 37.9ng/ml\n\n37.9ng/1mL x 1000mL/1L x 1g/10^9ng = 0.0000379g/L','boycer','06/15/2009 14:51:23\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000379,NULL,NULL,NULL,'',0.1,NULL),(191,'evidence_1177','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: bufuralol 1\'hydroxylation\n\nK_i = 11micM\n\n11micM/1L x 1M/10^6micM x 412.936g/1M = 0.005g/1L','boycer','06/22/2009 12:19:29\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.005,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,38),(192,'evidence_1117','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2','&quot;Potent inhibitors of CYP3A4: Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a potent inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin.&quot;\n','boycer','09/28/2007 14:01:54\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(193,'evidence_1476','http://www.ncbi.nlm.nih.gov/pubmed/8689812','\nRoute of administration: oral\n\nstudy duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4\n\npopulation: 12\nmale: 5\nfemale: 7 (2 on contraceptive steroids)\n\nages: 20-29\n\nAUC_i/AUC: 546/15 = &gt;36.4\nNOTE: AUC of lovastatin w/ placebo could not be measured but was known to be &lt; 15ng/ml*h','boycer','10/29/2007 13:18:39\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,39),(194,'evidence_1717','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nAn in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(195,'evidence_1915','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','\nMetabolism and elimination \n...\nAtomoxetine is excreted primarily as 4hydroxyatomoxetine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose). Only a small fraction of the STRATTERA dose is excreted as unchanged atomoxetine (less than 3% of the dose), indicating extensive biotransformation.','boycer','09/24/2009 11:13:31\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(196,'evidence_1913','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP2C8 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(197,'evidence_1575','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: S-mepheytoin 4\'hydroxylation\n\nQuote:\n\nCYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI\nfluvoxamine (see Table 2). ','boycer','06/12/2009 11:34:15\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,40),(198,'evidence_1514','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','&quot;\nFluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.\n\n      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(199,'evidence_1667','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(200,'evidence_1457','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: S-mepheytoin 4\'hydroxylation\n\nQuote: \n\nCYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI\nfluvoxamine (see Table 2).\n\n\n','boycer','06/11/2009 16:10:21\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,41),(201,'evidence_1284','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(202,'evidence_1689','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',4,NULL,NULL,NULL,'',NULL,NULL),(203,'evidence_1661','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(204,'evidence_1242','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3','Drug Interactions\n\nRitonavir is an inhibitor of cytochrome P450 3A (CYP3A) both in vitro and in vivo. Ritonavir also inhibits CYP2D6 in vitro, but to a lesser extent than CYP3A. Co-administration of ritonavir and drugs primarily metabolized by CYP3A or CYP2D6 may result in increased plasma concentrations of other drugs that could increase or prolong its therapeutic and adverse effects ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(205,'evidence_1680','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3','Table 3 shows that the AUC of sildenafil increased 11-fold in the presence of ritonavir','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(206,'evidence_1122','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(207,'evidence_1179','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(208,'evidence_1164','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf','\nDrug Interactions\n...\nIn vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(209,'evidence_1259','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','11/09/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(210,'evidence_1908','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(211,'evidence_1690','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: 7-ethoxyresoruvin O-deethylation\n\nThe IC50 for ziprasidone inhibition of this reaction was greater than 100micM \n\n\n','boycer','06/19/2009 17:06:15\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,42),(212,'evidence_1552','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(213,'evidence_1478','http://www.ncbi.nlm.nih.gov/pubmed/9278211','\n\nroute of administration: oral\n\nstudy duration: a single 25 mg dose of racemic warfarin either alone or on Day 15 of a 21-day oral dosing regimen of 40 mg citalopram daily. Blood samples for pharmacokinetic analysis were obtained over a 168 h period after warfarin dosing.\n\npopulation: 12 healthy males \n\ntested for known CYP450 polymorphisms? no\n\nages: 21 - 32\n\ndescription:\nCitalopram produced no change in the pharmacokinetics of (R)- and (S)-warfarin, indicating that citalopram does not alter the metabolism of warfarin mediated via CYP1A2, CYP3A4 and CYP2C9.\n\n\n','boycer','02/12/2010 14:53:49\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,43),(214,'evidence_1685','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(215,'evidence_1319','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.10 Drugs Metabolized by CYP2C9\n\nDuloxetine does not inhibit the in vitro enzyme activity of CYP2C9. Inhibition of the metabolism of CYP2C9 substrates is therefore not anticipated, although clinical studies have not been performed.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(216,'evidence_1394','http://www.ncbi.nlm.nih.gov/pubmed/16390352','Enzyme system: recombinant human enzymes in human lymphoblastoid\nNADPH added: not explicitly mentioned but assumed\n\ninhibitor used: no\n\nQuetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4.','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(217,'evidence_1472','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/3829d74e-b3ab-46df-a08b-f0327b63304e','\nMetabolism \n\nTheophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. \n\nNOTE: the DIKB reviewers inferred the P-450 3A3 in this context refers to CYP4503A4','boycer','09/24/2009 14:46:11\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(218,'evidence_1669','http://www.ncbi.nlm.nih.gov/pubmed/9690949','\nRoute of administration: oral\n\nstudy duration: 4 dys pre-treatment with 100mg oral itraconazole or placebo; on day 4 a single 40mg dose of oral lovastatin was given\n\npopulation: 10 \nmale: 8\nfemale: 2\n\nages: 19-24\n\nAUC_i/AUC (total): 291/34 = 8.559\n\n','boycer','10/29/2007 12:17:24\n','EV_PK_DDI_RCT','PKStudy',8.559,0.04,0.1,10,'',NULL,NULL),(219,'evidence_1794','http://www.ncbi.nlm.nih.gov/pubmed/11910262','Route of administration: oral\n\nstudy duration: read description below\n\npopulation: (fluoxetine group) 14 healthy volunteers (7 male and 7 female), all extensive metabolizers of dextromethorphan\n\nages: mean(std dev): 26 (unknown)\n\nDescription: \nIn an open label, parallel group study of 45 healthy volunteers, the time course of CYP2D6 inhibition of the above SSRIs was evaluated. Subjects were randomized to receive paroxetine at 20 mg/day for 10 days; sertraline at 50 mg/day for 3 days, followed by sertraline at 100 mg/day for 10 days; or fluoxetine at 20 mg/day for 28 days. CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine. Following SSRI discontinuation, calculation of a CYP2D6 inhibition half-life (t(1/2)inh) revealed the time course of fluoxetine inhibition (t(1/2)inh = 7.0 +/- 1.5 days) to be significantly longer than either paroxetine (t(1/2)inh = 2.9 +/- 1.9) or sertraline (t(1/2)inh = 3.0 +/- 3.0) (p &lt; 0.01), but the latter were not significantly different from each other (p &gt; 0.05). Time for the extrapolated DMR versus time log-linear plots to return to baseline was significantly different between fluoxetine (63.2 +/- 5.6 days) and both paroxetine (20.3 +/- 6.4 days) and sertraline (25.0 +/- 11.0 days) (p &lt; 0.01), making the rank order (from longest to shortest) of time for CYP2D6 inhibition to dissipate: fluoxetine &gt; sertraline &gt;or= paroxetine. Differences between mean baseline DMR values and measured values obtained after drug discontinuation for each drug group became nonsignificant on discontinuation day 5 for both paroxetine and sertraline and on discontinuation day 42 for fluoxetine. ','boycer','05/05/2009 17:04:02\n','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,44),(220,'evidence_1375','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1','Drugs metabolized by CYP2D6  Fluoxetine inhibits the activity of CYP2D6, and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. Therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index (see list below) should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. Thus, his/her dosing requirements resemble those of poor metabolizers. If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for decreased dose of the original medication should be considered. Drugs with a narrow therapeutic index represent the greatest concern (e.g., flecainide, propafenone, vinblastine, and TCAs). Due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued (see CONTRAINDICATIONS and WARNINGS).','boycer','05/15/2009 11:16:23\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(221,'evidence_1166','http://www.ncbi.nlm.nih.gov/pubmed/12173784','\nroute of administration: oral\n\nstudy duration: fluoxetine 80mg qd for eight days\n\npopulation: 32 healthy adults, all extensive CYP2D6 metabolizers based on DM:DX\n\nages: unmentioned\n\nDescription: \nThe urinary concentration ratio of dextromethorphan:dextrorphan (interpreted as an in vivo index of CYP2D6 activity) was determined for each subject before and after the 8 days of receiving SSRIs. Plasma SSRI trough concentrations were measured on days 6-9. The CYP2D6 genotype was determined in a subject with an undetectable paroxetine concentration. Inhibition of CYP2D6 correlated significantly with plasma concentrations of paroxetine and fluoxetine. In contrast, no significant correlations emerged between CYP2D6 inhibition and plasma concentrations of sertraline or fluvoxamine. The subject with an undetectable paroxetine concentration was found to carry at least three functional CYP2D6 genes.','boycer','06/16/2009 17:07:34\n','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,45),(222,'evidence_1649','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','Drug interactions:\n\nIn vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(223,'evidence_1410','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nMetabolism and Excretion\n\nCinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2. After administration of a 75 mg radiolabeled dose to healthy volunteers, cinacalcet was rapidly and extensively metabolized via: 1) oxidative N-dealkylation to hydrocinnamic acid and hydroxy-hydrocinnamic acid, which are further metabolized via &amp;#946;-oxidation and glycine conjugation; the oxidative N-dealkylation process also generates metabolites that contain the naphthalene ring; and 2) oxidation of the naphthalene ring on the parent drug to form dihydrodiols, which are further conjugated with glucuronic acid. The plasma concentrations of the major circulating metabolites including the cinnamic acid derivatives and glucuronidated dihydrodiols markedly exceed parent drug concentrations. The hydrocinnamic acid metabolite was shown to be inactive at concentrations up to 10 M in a cell-based assay measuring calcium-receptor activation. The glucuronide conjugates formed after cinacalcet oxidation were shown to have a potency approximately 0.003 times that of cinacalcet in a cell-based assay measuring a calcimimetic response.','boycer','09/24/2009 12:30:15\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(224,'evidence_1396','http://www.ncbi.nlm.nih.gov/pubmed/15258107','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: bufuralol\n\nreaction: bufuralol 1\'hydroxylation\n\nIC50 &gt; 200micM (see Table 3)\n\nQuote:\nCYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. ','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(225,'evidence_1054','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','\nMetabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','09/23/2009 15:48:01\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(226,'evidence_1963','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','\nDrugs That Inhibit CYP3A4 (Ketoconazole)\n\nCYP3A4 is a major metabolic pathway for elimination of eszopiclone. The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days. Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.','boycer','09/23/2009 16:09:10\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,46),(227,'evidence_1750','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','7.5  Effect of Atomoxetine on P450 Enzymes\n\nAtomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(228,'evidence_1643','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(229,'evidence_1001','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(230,'evidence_1073','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(231,'evidence_1348','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',1,NULL,NULL,NULL,'',NULL,NULL),(232,'evidence_1083','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.04,NULL,NULL,NULL,'',NULL,NULL),(233,'evidence_1302','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','06/12/2009 19:11:52\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,47),(234,'evidence_1935','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.11 Drugs Metabolized by CYP3A\n\nResults of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. ','boycer','05/05/2009 17:39:38\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(235,'evidence_1148','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.11 Drugs Metabolized by CYP3A\n\nResults of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. ','boycer','05/05/2009 17:38:52\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(236,'evidence_1064','http://www.ncbi.nlm.nih.gov/pubmed/10997944','\nEnzyme system: recombinant CYP450 enzymes in baculovirus-infected insect cells\n\nNADPH added: yes\n\nreaction: bupropion --&gt; hydroxybupropion\n\nNOTE: the experiment provides no clear minimum Km CYP2B6 catalysis of the mentioned reaction\n\nQuote:\n&quot;Evaluation of BUP Hydroxylation by Individual cDNA-Expressed Human P450s. Because the biphasic kinetic data observed with low activity HLMs (HLMs 20 and 24) indicated the contribution of more than one enzyme to BUP hydroxylation at higher substrate concentrations, a panel of eight cDNA-expressed enzymes (SUPER- SOMES) was screened for BUP hydroxylase activity at 12 mM to identify enzymes requiring further investigation (Fig. 7). This sub- strate concentration was selected to ensure saturation of any high Km isozyme capable of catalyzing BUP hydroxylation. cDNA-expressed CYP2B6 demonstrated the highest rate of HBUP formation (7.0 pmol/min/pmol of P450). cDNA-expressed CYP2E1 and CYP3A4 catalyzed BUP hydroxylation at the second and third highest rates, although at 3- and 30-fold lower rates than cDNA-expressed CYP2B6 (2.4 and 0.23 pmol/min/pmol of P450, respectively). Of note, CYP2E1 was the only cDNA-expressed enzyme in which cytochrome b5 was coexpressed. Rates of BUP hydroxylation by CYP1A2, CYP2A6, CYP2C9, CYP2C19, and CYP2D6 were greater than 30-fold lower than CYP2B6 (Fig. 7). HBUP formation in control microsomes was negligible.&quot;','boycer','06/20/2009 15:22:12\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(237,'evidence_1292','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nEffects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','09/24/2009 15:10:02\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(238,'evidence_1944','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(239,'evidence_1284','http://www.ncbi.nlm.nih.gov/pubmed/12451430','\nRoute of administration: oral\n\nstudy duration: 200mg of fluconazole or matching placebo once daily for 11 days, 80mg of rosuvastatin on day 8\n\npopulation: 14 healthy male\n\nages: 29-51\n\nAUC_i/AUC (0 to time of C_max): 1.139 BUT not statistically significant\n\ndescription: \nThis was a randomised, double-blind, two-way crossover, placebo-controlled trial. Healthy male volunteers ( n=14) were given fluconazole 200 mg or matching placebo once daily for 11 days; rosuvastatin 80 mg was co-administered on day 8 of dosing. Plasma concentrations of rosuvastatin, N-desmethyl rosuvastatin, and active and total 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors were measured up to 96 h post-dose. RESULTS: Following co-administration with fluconazole, rosuvastatin geometric least-square mean area under the plasma concentration-time curve (AUC(0-t)) and peak plasma concentration (C(max)) were increased by 14% and 9%, respectively, compared with placebo (90% confidence intervals for the treatment ratios: 0.967 to 1.341 and 0.874 to 1.355, respectively). Individual treatment ratios for AUC(0-t) ranged from 0.59 to 2.23, and for C(max) ranged from 0.52 to 2.28. The limited data available for the N-desmethyl metabolite show that geometric mean C(max) was decreased by approximately 25% compared with placebo. Rosuvastatin accounted for essentially all of the circulating active HMG-CoA reductase inhibitors and most (&gt;90%) of the total inhibitors. Fluconazole did not affect the proportion of circulating active or total inhibitors accounted for by circulating rosuvastatin. CONCLUSIONS: Fluconazole produced only small increases in rosuvastatin AUC(0-t) and C(max), which were not considered to be of clinical relevance.','boycer','12/10/2007 14:53:13\n','EV_PK_DDI_RCT','PKStudy',NULL,0.08,0.2,14,'',NULL,NULL),(240,'evidence_1016','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nMetabolism and Excretion\n\nCinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(241,'evidence_1505','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.\n\nKetoconazole and Other CYP3A4 Inhibitors\n\nCoadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.\n\nQuinidine and Other CYP2D6 Inhibitors\n\nCoadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with Major Depressive Disorder, ABILIFY should be administered without dosage adjustment as specified in DOSAGE AND ADMINISTRATION (2.3).\n\nCarbamazepine and Other CYP3A4 Inducers\n\nCoadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(242,'evidence_1980','http://www.ncbi.nlm.nih.gov/pubmed/15770075','Route of administration: oral\n\nstudy duration: Two phases : Phase I - a single dose of aripiprazole; Phase II - 7 days pre-treatment with ITZ, single dose of aripiprazole with ITZ, then ITZ alone or 14 more days; a 35 day washout between Phase I and II\n\npopulation: 24 healthy adult Japanese males\n\nmeean age (SD): 23.2 (2.4)\n\nAUC_i/AUC (336hr): 1075/736 = 1.48\n\nDescription:\nThe objective of the present study was to investigate the influence of itraconazole (hereafter referred to as ITZ) co-administration (CYP3A4 inhibition) on the pharmacokinetics of ARIPIPRAZOLE administered to 24 healthy adult male volunteers in a fasting condition. The influence of CYP3A4 inhibition was also examined by CYP2D6 genotype. All subjects were administered a single oral dose of ARIPIPRAZOLE alone in Period I and a single oral dose of ARIPIPRAZOLE following administration of ITZ at 100 mg/day for 7 consecutive days in Period II. The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined. Co-administration of ITZ increased the Cmax, AUC336 hr, and t1/2,z of ARIPIPRAZOLE and OPC-14857 by 19.4%, 48.0%, and 18.6% and by 18.6%, 38.8%, and 53.4%, respectively. By co-administration of ITZ, the CL/F of ARIPIPRAZOLE in extensive metabolizers was decreased by 26.6%, with an even greater decrease (47.3%) in intermediate metabolizers. For the co-administration period, the CL/F of ARIPIPRAZOLE in intermediate metabolizers was about half of that in extensive metabolizers. For Cmax, there was no significant difference between extensive metabolizers and intermediate metabolizers, and the percent change by co-administration of ITZ was less than 20% in both extensive metabolizers and intermediate metabolizers. For OPC-14857, the t(max) in intermediate metabolizers was longer than that in extensive metabolizers, with the difference being amplified by co-administration of ITZ. The AUC336 hr showed similar increases by co-administration of ITZ in all genotypes. The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ. The influence of CYP3A4 inhibition on the pharmacokinetics of ARIPIPRAZOLE was not considered to be clinically significant. On the other hand, definite differences in pharmacokinetics were observed between CYP2D6 genotypes. ','boycer','01132010','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(243,'evidence_1144','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','\nMetabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. ','boycer','09/23/2009 16:07:07\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(244,'evidence_1396','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.2,NULL,NULL,NULL,'',NULL,NULL),(245,'evidence_1103','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote:\n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM. ','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(246,'evidence_1038','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(247,'evidence_1161','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Metabolism and Elimination\n\n... In vitro studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone. CYP1A2 may contribute to a much lesser extent. Based on in vivo abundance of excretory metabolites, less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(248,'evidence_1764','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19,2D6, and 3A4 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(249,'evidence_1777','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide/sulphone\n2) ziprasidone --&gt; oxindole acetic acid\n\nQuote: \nInhibition of metabolite formation by each inhibitor is\nsummarized in Table 2. Ketoconazole (10micM) inhibited\nthe formation of ziprasidone sulphoxide (sulphoxide and\nsulphone) by 79% and oxindole acetic acid N-dealkylated\nproduct) completely. Sulphaphenazole an furafylline did\nnot inhibit the formation of ziprasidone sulphoxide. The formation of oxindole acetic acid was inhibited (~50%) by furafylline. The formation of ziprasidone metabolites was not inhibited by quinidine but rather increased.\n\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(250,'evidence_1810','http://www.ncbi.nlm.nih.gov/pubmed/10771458','\n\nroute of administration: oral\n\nstudy duration: \n\npopulation: 14 healthy, non-smoking, adults (6 male, 8 female); only 13 completed the study\n\ntested for known CYP450 polymorphisms? \n\nages: 18 - 45\n\ndescription:\n&quot;Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole. Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively. The treatment effect on both of these parameters was statistically significant (P&lt;0.02).&quot;\n','boycer','01132010','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(251,'evidence_1777','http://www.ncbi.nlm.nih.gov/pubmed/8904618','\nRoute of administration: oral\n\nstudy duration: four phase crossover study; each phase consisted of four days pre-treatment with placebo or fluconazole (50,100, or 200mg), on day four 0.25mg of triazolam was administered\n\npopulation: 8 healthy adults \nmale:3\nfemale:5\n\nages: 20-32\n\nAUC_i/AUC (0-inf): \n50mg fluconazole = 1.63\n100mg fluconazole = 2.05\n200mg fluconazole = 4.42\n\ndescription: \n','boycer','10/22/2007 13:08:14\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,48),(252,'evidence_1140','http://www.ncbi.nlm.nih.gov/pubmed/16172184','\nRoute of administration: oral\n\nstudy duration: 4-way crossover; subjects received oral fluconazole (100, 200, or 400mg) or placebo;  2 hours later a single dose of MDZ (1mg IV or oral depending on the study arm) was given followed 30 minutes later by 4mg IV of ondansetron, followed by 15ug/kg of IV alfentanil (one arm) or 40mcg oral alfentanil.\n\npopulation: 6 male, 6 female\n\nages: 19-36\n\nAUC_i/AUC (0-inf; oral dosing; 100mg fluconazole): 46.1/21.3 \n\nAUC_i/AUC (0-inf; oral dosing; 200mg fluconazole): 70.7/21.3 \n\nAUC_i/AUC (0-inf; oral dosing; 400mg fluconazole): 105/21.3 \n','boycer','12/10/2007 15:42:25\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,49),(253,'evidence_1484','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','06/30/2009 13:33:58\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(254,'evidence_1857','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(255,'evidence_1014','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(256,'evidence_1880','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','Metabolism and Elimination\n\nFollowing oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance.','boycer','05/15/2009 09:53:40\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(257,'evidence_1314','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','Pharmacokinetics\n\nVenlafaxine is well absorbed and extensively metabolized in the liver. O-desmethylvenlafaxine (ODV) is the only major active metabolite. On the basis of mass balance studies, at least 92% of a single dose of venlafaxine is absorbed. Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%). Renal elimination of venlafaxine and its metabolites is the primary route of excretion. The relative bioavailability of venlafaxine from a tablet was 100% when compared to an oral solution. Food has no significant effect on the absorption of venlafaxine or on the formation of ODV. ','boycer','05/15/2009 10:31:50\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(258,'evidence_1027','http://www.ncbi.nlm.nih.gov/pubmed/9797793','\nRoute of administration: oral\n\nstudy duration: 14 days pretreatment with diltiazem \n\npopulation: male: 5 female: 5 \n\nages: 27-38 \n\nNOTE: investigators measured the &quot;open acid form&quot; of lovastatin which we take to be equivalent to the  lovastatin lactone\'s immediate child metabolite, beta-hydroxy-lovastatin\n\nQuote:\nThis was a balanced, randomized, open-label, 4-way crossover study in 10 healthy volunteers, with a 2-week washout period between the phases. Study arms were (1) administration of a single dose of 20 mg lovastatin, (2) administration of a single dose of 20 mg pravastatin, (3) administration of a single dose of lovastatin after administration of 120 mg diltiazem twice a day for 2 weeks, and (4) administration of a single dose of pravastatin after administration of 120 mg diltiazem twice a day for 2 weeks. RESULTS: Diltiazem significantly (P &lt; .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life. Diltiazem did not affect the oral AUC, Cmax, or half-life of pravastatin.','boycer','10/15/2007 11:00:05\n','EV_PK_DDI_RCT','PKStudy',3.57,0.12,0.02,10,'',NULL,NULL),(259,'evidence_1770','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(260,'evidence_1642','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(261,'evidence_1746','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','04/29/2009 19:46:49\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(262,'evidence_1811','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(263,'evidence_1366','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c','Metabolism\n\nZafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations','boycer','09/24/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(264,'evidence_1896','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c','\nDrug-Drug Interactions:\n...\nCoadministration of multiple doses of zafirlukast (160 mg/day) to steady-state with a single 25 mg dose of warfarin (a substrate of CYP2C9) resulted in a significant increase in the mean AUC (+63%) and half-life (+36%) of S-warfarin. The mean prothrombin time increased by approximately 35%. The pharmacokinetics of zafirlukast were unaffected by coadministration with warfarin.','boycer','09/24/2009 15:41:53\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,50),(265,'evidence_1012','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','\n Route of administration: oral\n\nstudy duration: not mentioned\n\npopulation: 14 CYP2D6 extensive metabolizers (adults inferred)\n\nages: mean(std dev): not mentioned\n\nQuote:\nKetoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n = 14) and 25 mg in poor metabolizers (PM; n = 6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O&amp;#8209;desvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.\n\nVenlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PMs  2% to 206%), and AUC values for ODV increased by 23% and 141% in EM and PM subjects (range in PMS  38% to 105%) subjects, respectively. Combined AUCs of venlafaxine and ODV increased on average by approximately 23% in EMS and 53% in PMs (range in PMs  4 to 134%).','boycer','06/09/2009 19:55:20\n','Non_traceable_Drug_Label_Statement','PKStudy',1.23,0.05,0.1,14,'',NULL,NULL),(266,'evidence_1075','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(267,'evidence_1298','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.2,NULL,NULL,NULL,'',NULL,NULL),(268,'evidence_1906','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(269,'evidence_1258','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7e117c7e-02fc-4343-92a1-230061dfc5e0','\n&quot;There were no significant interactions between risperidone (1 mg QD) and erythromycin (500 mg QID)&quot;','boycer','06/16/2009 12:57:41\n','Non_traceable_Drug_Label_Statement','PKStudy',0,0.5,0.001,NULL,'',NULL,NULL),(270,'evidence_1887','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA recommends omeprazole as a recommended CYP2C19 substrate for in vivo studies in it most recent guidance document (See Table 2, p. 19)','boycer','09/28/2009 11:18:46\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(271,'evidence_1864','http://www.ncbi.nlm.nih.gov/pubmed/1387301','\nAbstract: \nThe absolute bioavailability of clarithromycin, a new macrolide antimicrobial agent, was assessed in a three-way, randomized, single-dose, crossover study conducted with 22 healthy volunteers, 19 of whom provided analyzable study data. The bioavailability parameters of two 250-mg oral tablet formulations were calculated with reference to an identical dose administered by intravenous infusion of the lactobionate salt. After adjustment for formulation potency, the mean absolute bioavailabilities of the two oral formulations were 52 and 55%, on the basis of the appearance of parent compound in the systemic circulation. Metabolite peak concentration and area under the plasma concentration-time curve data after oral dosing were generally greater than those after intravenous infusion, suggesting that marked first-pass metabolism of clarithromycin occurs after oral administration. Pharmacokinetic analysis of the parent drug and the active 14-hydroxy metabolite data suggests complete (or nearly complete) absorption of the drug after oral administration.\n\nNOTE: last paragraph of p1150 estimates the fraction of dose absorbed to be 89%\n\n','boycer','06/25/2007 12:49:25\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.89,NULL,NULL,NULL,'',NULL,NULL),(272,'evidence_1604','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/3829d74e-b3ab-46df-a08b-f0327b63304e','\nMetabolism Following oral dosing, theophylline does not undergo any measurable first-pass elimination. In adults and children beyond one year of age, approximately 90%of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6%of a theophylline dose is N-methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.\n\nCaffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity. 3-methylxanthine has approximately one tenth the pharmacologic activity of theophylline and serum concentrations in adults with normal renal function are <1 mcg/mL. In patients with end-stage renal disease, 3-methylxanthine may accumulate to concentrations that approximate the unmetabolized theophylline concentration. Caffeine concentrations are usually undetectable in adults regardless of renal function. In neonates, caffeine may accumulate to concentrations that approximate the unmetabolized theophylline concentration and thus, exert a pharmacologic effect.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(273,'evidence_1764','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','Fluvoxamine is listed as a recommended inhibitor of CYP2C19 for in vivo studies in Table 2 (p. 19). Typically, this would qualify it as a in vivo selective inhibitor however, Table 2 also shows fluvoxamine as a recommended inhibitor of CYP1A2.','boycer','05/05/2009 17:27:55\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(274,'evidence_1067','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','(table from section &quot;Drug Interactions&quot;)\n\nBased on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also  WARNINGS for details) and limited in vitro data for the IIIA4 isozyme, it appears that fluvoxamine inhibits the following isozymes that are known to be involved in the metabolism of the listed drugs:\nIA2             IIC9	        IIIA4         IIC19\nWarfarin	Warfarin	Alprazolam   Omeprazole\nTheophylline			\nPropranolol			\nTizanidine			','boycer','05/15/2009 08:52:34\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(275,'evidence_1824','http://www.ncbi.nlm.nih.gov/pubmed/12584155','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nQuote: \nTo determine whether preincubation affects the inhibition of human liver microsomal dextromethorphan demethylation activity by paroxetine, we used a two-step incubation scheme in which all of the enzyme assay components, minus substrate, are preincubated with paroxetine...Time-dependent inhibition was demonstrated with an apparent K(I) of 4.85 microM and an apparent k(INACT) value of 0.17 min(-1). Spectral scanning of CYP2D6 with paroxetine yielded an increase in absorbance at 456 nm suggesting paroxetine inactivation of CYP2D6 via the formation of a metabolite intermediate complex.\n...In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation-dependent increase in inhibitory potency. These data are consistent with mechanism-based inhibition of CYP2D6 by paroxetine but not by quinidine or fluoxetine.','boycer','06/16/2009 13:05:51\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,51),(276,'evidence_1730','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/17209c32-56eb-4f84-954d-aed7b7a1b18d','12.3 Pharmacokinetics\n\nFollowing a single 5-mg dose of SAPHRIS, the mean Cmax was approximately 4 ng/mL and was observed at a mean tmax of 1 hr. \n\n4ng/1mL X 10-9g/1ng X 1000mL/1L = 4 x 10-6g/L','boycer','01/11/2010 18:07:00\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000004,NULL,NULL,NULL,'',0.005,NULL),(277,'evidence_1004','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19,2D6, and 3A4 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','06/19/2009 13:01:42\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(278,'evidence_1638','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: S-mepheytoin 4\'hydroxylation\n\nQuote:\n\nCYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI\nfluvoxamine (see Table 2). ','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(279,'evidence_1406','http://www.ncbi.nlm.nih.gov/pubmed/15258107','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: bufuralol\n\nreaction: bufuralol 1\'hydroxylation\n\nIC50 &gt; 200micM (see Table 3)\n\nQuote:\nCYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. ','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(280,'evidence_1342','http://www.ncbi.nlm.nih.gov/pubmed/8689812','\nRoute of administration: oral\n\nstudy duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4\n\npopulation: 12\nmale: 5\nfemale: 7 (2 on contraceptive steroids)\n\nages: 20-29\n\nAUC_i/AUC: 1212/54.8 = 22.117 ','boycer','12/07/2007 12:28:01\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,52),(281,'evidence_1389','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\n7.5 Drugs metabolized by CYP2C19\n\nIn a clinical study in Japan evaluating rabeprazole in patients categorized by CYP2C19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. This could be due to higher rabeprazole plasma levels in poor metabolizers. Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(282,'evidence_1192','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf','Drug Interactions\n...\nIn vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(283,'evidence_1984','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.12 Drugs Metabolized by CYP2C19\n\nResults of in vitro studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations. Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(284,'evidence_1020','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84','\n12.5 Drug-Drug Interactions\n...\nPREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(285,'evidence_1346','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','7.18 CYP3A4 and -2C19 Inhibitors\n\nIn vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.\n\n','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(286,'evidence_1600','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(287,'evidence_1962','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends S-warfarin to be an acceptable chemical CYP2C9 substrate (S-warfarin 7-hydroxylation) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','09/22/2009 17:30:05\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(288,'evidence_1401','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(289,'evidence_1442','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(290,'evidence_1793','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(291,'evidence_1966','http://www.ncbi.nlm.nih.gov/pubmed/11147928','Route of administration: oral\n\nstudy duration: three weeks\n\npopulation: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks\n\nages: 29 - 55\n\n\nQuote:\n\nThe effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline.','boycer','06/16/2009 12:00:23\n','EV_PK_DDI_NR','PKStudy',0,0.05,0.2,17,'',NULL,NULL),(292,'evidence_1148','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/17209c32-56eb-4f84-954d-aed7b7a1b18d','After administration of a single dose of [14C]-labeled asenapine, about 90% of the dose was recovered; approximately 50% was recovered in urine, and 40% recovered in feces. About 50% of the circulating species in plasma have been identified. The predominant species was asenapine N+-glucuronide; others included N-desmethylasenapine, N-desmethylasenapine N-carbamoyl glucuronide, and unchanged asenapine in smaller amounts. SAPHRIS activity is primarily due to the parent drug.','boycer','01/11/2010 18:20:30\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(293,'evidence_1852','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','\nMetabolism: Celecoxib metabolism is primarily mediated via CYP2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors.\n\nCYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from 4 published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed celecoxib systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups. ','boycer','09/24/2009 10:57:14\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(294,'evidence_1322','http://www.ncbi.nlm.nih.gov/pubmed/16432272','\nRoute of administration: oral\n\nstudy duration: This study looked at the interaction between 3 herbal suplements and midazolam. For inhibition/induction controls, they included two rounds in their study where they looked at the interaction of clarithromycin or rifampin and midazolam. Between every round of their study there were 30 days washout and participants were randomized to treatment order but not treatment. The evidence from the clarithromycin round is used here. All 19 participants were given a single oral dose of 8mg midazolam; 24 hours later they started 500mg bid of clarithromycin for 7 days; on day 7 they were given 500mg bid of clarithromycin. \n\npopulation: 19\nmale: 10\nfemale: 9\n\nages: mean (STD DEV)= 28 +/- 6\n\nAUC_i/AUC (0 - inf): 752 / 89.6 = 8.45','boycer','10/30/2007 07:09:46\n','EV_PK_DDI_NR','PKStudy',8.45,0.008,0.5,19,'',NULL,NULL),(295,'evidence_1195','http://www.ncbi.nlm.nih.gov/pubmed/9728893','\nRoute of administration: oral\n\nstudy duration: This was a non-random, fixed order, study. Participants received a simultaneous dose of .05mg/kg of IV midazolam and 4mg of oral midazolam to collect baseline data. 24 hours later 500mg bid of oral clarithromycin was given to participants for 7 days. On the last day .05mg/kg of IV midazolam and 4mg of oral midazolam  was administered after the last dose of clarithromycine\n\npopulation: 16 : 8 male, 8 female\n\nages: 30-38\n\nAUC_i/AUC (radiolabeled oral): 336/48 = 7\n','boycer','10/30/2007 07:28:31\n','EV_PK_DDI_NR','PKStudy',7,0.004,0.5,16,'',NULL,NULL),(296,'evidence_1591','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','06/30/2009 12:48:44\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(297,'evidence_1835','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','7.1 Potential for REYATAZ to Affect Other Drugs \n\nAtazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.\ntype: Non_traceable_Drug_Label_Statement ','boycer','01/11/2010 15:40:48\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(298,'evidence_1699','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','06/30/2009 12:47:19\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(299,'evidence_1729','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','7.1 Potential for REYATAZ to Affect Other Drugs\n\nAtazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.','boycer','01/11/2010 15:38:56\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(300,'evidence_1800','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(301,'evidence_1478','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3249','&quot;Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of rosuvastatin. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by rosuvastatin.&quot;','boycer','09/28/2007 08:04:34\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(302,'evidence_1824','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: recombinant human enzymes (human lymphoblastoid)\n\nNADPH added: yes (a dehydrogenase generating system) \n\ninhibitor used: no\n\nThis study showed NO formation of didesmethylcitalopram (aka didemethylcitalopram) in a recombinant human lymphoblastoid cell system','boycer','06/12/2009 12:39:36\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(303,'evidence_1818','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','04/25/2009 09:58:43\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,53),(304,'evidence_1084','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','04/25/2009 10:18:23\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,54),(305,'evidence_1476','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(306,'evidence_1590','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','11/09/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(307,'evidence_1948','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','09/24/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(308,'evidence_1578','http://www.ncbi.nlm.nih.gov/pubmed/8181191','Route of administration: oral\n\nstudy duration: four days pre-treatment with itraconazole\n\npopulation: male: 2 female: 7\n\nages: 19-26\n\nNOTE: AUC data taken from table 1 AUC_i/AUC:42/3.9\n\nInteraction between ketoconazole, itraconazole, and midazolam was investigated in a double-blind, randomized crossover study of three phases at intervals of 4 weeks. Nine volunteers were given either 400 mg ketoconazole, 200 mg itraconazole, or matched placebo orally once daily for 4 days. On day 4, the subjects ingested 7.5 mg midazolam. Plasma samples were collected and psychomotor performance was measured. Both ketoconazole and itraconazole increased the area under the midazolam concentration-time curve from 10 to 15 times (p < 0.001) and mean peak concentrations three to four times (p < 0.001) compared with the placebo phase.','boycer','06/05/2007 14:37:35\n','EV_PK_DDI_RCT','PKStudy',10.8,0.0075,0.2,9,'',NULL,NULL),(309,'evidence_1960','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(310,'evidence_1410','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6','\nMetabolism\n\nPantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. ','boycer','09/24/2009 13:17:14\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(311,'evidence_1728','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(312,'evidence_1743','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel\n\nk_i = 7.1micM\n\n','boycer','10/29/2007 10:31:30\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.003,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,55),(313,'evidence_1350','http://www.ncbi.nlm.nih.gov/pubmed/9542477','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 4 days\n\npopulation: 7 male, 3 female\n\nages:19-29\n\ndescription:\nTwo randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001).','boycer','12172009','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(314,'evidence_1908','http://www.ncbi.nlm.nih.gov/pubmed/9321523','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 3\',5\'-dihydrodiol, 3\'-hydroxy, and 6\'-exomethylene metabolites using a recombinant CYP3A4 system\n','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(315,'evidence_1091','http://www.ncbi.nlm.nih.gov/pubmed/15518608','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days simvastatin only, 8 days simva and clarithromycin\n\ndose: .040g simvastatin 1xday\n      .5g clarithromycin 2xday\n\npopulation: 45 men and women (15 received simvastatin)\n\nages:18-60 \n\n(mean AUC_i)/(mean AUC) = 219/22 \n\ndescription: Clarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC)\n','boycer','12172009','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(316,'evidence_1894','http://www.ncbi.nlm.nih.gov/pubmed/10640508','\nEnzyme system: recombinant human enzymes in insect cells\n\nNADPH added: yes \nsubstrate used: N/A\n\nThis study showed the formation of a P-450-Metabolite complex in diltiazem-incubated both human liver microsomes and recombinant human enzymes in insect cells. The extant of metabolite complex formation was estimated to be ~20%','boycer','07/03/2007 09:25:04\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(317,'evidence_1145','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','\nMetabolism and elimination \n...\nThe major oxidative metabolite formed, regardless of CYP2D6 status, is 4hydroxyatomoxetine, which is glucuronidated. 4Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes. NDesmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs).','boycer','09/24/2009 11:29:56\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(318,'evidence_1200','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(319,'evidence_1970','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978','Pharmacokinetic-related Interactions\n\nClozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes.','boycer','05/15/2009 11:01:27\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(320,'evidence_1939','http://www.ncbi.nlm.nih.gov/pubmed/11147928','\nRoute of administration: oral\n\nstudy duration: three weeks\n\npopulation: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks\n\nages: 29 - 55\n\n\nQuote:\n\nThe effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline.','boycer','06/20/2009 14:35:57\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,56),(321,'evidence_1447','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/151ffcf4-e503-4954-af7c-93d0a4f9f80','\nPharmacokinetics:\n\nFollowing oral administration, leflunomide is metabolized to an active metabolite A77 1726 (hereafter referred to as M1) which is responsible for essentially all of its activity in vivo. Plasma levels of leflunomide are occasionally seen, at very low levels. Studies of the pharmacokinetics of leflunomide have primarily examined the plasma concentrations of this active metabolite.\n\nNOTE: A77 1726 is referred to as \'teriflunomide\' in the DIKB based on its common name in various literature sources including Wikipedia (http://en.wikipedia.org/wiki/Teriflunomide)\n\n\n','boycer','09/24/2009 12:09:57\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(322,'evidence_1448','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/3829d74e-b3ab-46df-a08b-f0327b63304e','\nTheophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. ','boycer','09/24/2009 14:48:41\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(323,'evidence_1011','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied.','boycer','04/29/2009 19:27:27\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(324,'evidence_1208','http://www.ncbi.nlm.nih.gov/pubmed/15770075','Route of administration: oral\n\nstudy duration: Two phases : Phase I - a single dose of aripiprazole; Phase II - 7 days pre-treatment with ITZ, single dose of aripiprazole with ITZ, then ITZ alone or 14 more days; a 35 day washout between Phase I and II\n\npopulation: 24 healthy adult Japanese males\n\nmean age (SD): 23.2 (2.4)\n\nAUC_i/AUC (336hr): 365/269 = 1.36\n\nDescription:\nThe objective of the present study was to investigate the influence of itraconazole (hereafter referred to as ITZ) co-administration (CYP3A4 inhibition) on the pharmacokinetics of ARIPIPRAZOLE administered to 24 healthy adult male volunteers in a fasting condition. The influence of CYP3A4 inhibition was also examined by CYP2D6 genotype. All subjects were administered a single oral dose of ARIPIPRAZOLE alone in Period I and a single oral dose of ARIPIPRAZOLE following administration of ITZ at 100 mg/day for 7 consecutive days in Period II. The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined. Co-administration of ITZ increased the Cmax, AUC336 hr, and t1/2,z of ARIPIPRAZOLE and OPC-14857 by 19.4%, 48.0%, and 18.6% and by 18.6%, 38.8%, and 53.4%, respectively. By co-administration of ITZ, the CL/F of ARIPIPRAZOLE in extensive metabolizers was decreased by 26.6%, with an even greater decrease (47.3%) in intermediate metabolizers. For the co-administration period, the CL/F of ARIPIPRAZOLE in intermediate metabolizers was about half of that in extensive metabolizers. For Cmax, there was no significant difference between extensive metabolizers and intermediate metabolizers, and the percent change by co-administration of ITZ was less than 20% in both extensive metabolizers and intermediate metabolizers. For OPC-14857, the t(max) in intermediate metabolizers was longer than that in extensive metabolizers, with the difference being amplified by co-administration of ITZ. The AUC336 hr showed similar increases by co-administration of ITZ in all genotypes. The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ. The influence of CYP3A4 inhibition on the pharmacokinetics of ARIPIPRAZOLE was not considered to be clinically significant. On the other hand, definite differences in pharmacokinetics were observed between CYP2D6 genotypes. ','boycer','05/06/2009 14:22:53\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,57),(325,'evidence_1719','http://www.ncbi.nlm.nih.gov/pubmed/10548453','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: alpha-napthoflavone\n\nreaction: alprazolam --&gt; 4-OH-alprazolam\nalprazolam --&gt; 1\'-OH-alprazolam\n\nInhibition of CYP1A2 by in vitro selective inhibitor alpha-napthoflavone had no effect on the transformation of alprazolam to its two major metabolites\n\nNOTE: the use of a NADPH generating system is inferred from paragraph 2 of p. 934 &quot;Alprazolam hydrozylase assay&quot;\n','boycer','08/14/2007 06:08:03\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,58),(326,'evidence_1972','http://www.ncbi.nlm.nih.gov/pubmed/3932079','\nroute of administration: oral (parent drug)\n\nstudy duration: Plasma profiles were obtained: 1) after a single 100 mg oral dose of [NON-XR] bupropion hydrochloride, 2) following administration of 100 mg 8-hourly for 14 days and 3) again after a single 100 mg dose 14 days later.\n\npopulation: 8 healthy, non-smoking, male subjects\n\ntested for known CYP450 polymorphisms? NO\n\nages: 22 - 42\n\nC_max of THREOHYDROBUPROPION @ 300mg/day of NON-XR bupropion for 14 days: 2.1micM/L (OCCASION 2, Table 2, 494U)\n\n2.1micM/1L X 1M/10^6micM X 242.765g/1M = 0.0005098g/L\n','boycer','06/22/2009 11:09:27\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0005098,NULL,NULL,NULL,'',0.3,NULL),(327,'evidence_1797','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(328,'evidence_1792','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','Metabolism\n\nFluvoxamine maleate is extensively metabolized by the liver; the main metabolic routes are oxidative demethylation and deamination. Nine metabolites were identified following a 5 mg radiolabelled dose of fluvoxamine maleate, constituting approximately 85% of the urinary excretion products of fluvoxamine. The main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products. A third metabolite, fluvoxethanol, formed by oxidative deamination, accounted for about 10%. Fluvoxamine acid and fluvoxethanol were tested in an in vitro assay of serotonin and norepinephrine reuptake inhibition in rats; they were inactive except for a weak effect of the former metabolite on inhibition of serotonin uptake (one to two orders of magnitude less potent than the parent compound). Approximately 2% of fluvoxamine was excreted in urine unchanged. (See PRECAUTIONS: Drug Interactions.)\n\nElimination\n\nFollowing a 14C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours.','boycer','05/14/2009 16:49:09\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(329,'evidence_1770','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nMidazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5.','boycer','09/21/2009 15:22:09\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,59),(330,'evidence_1509','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n....\n\nMidazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5.','boycer','09/21/2009 15:20:18\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,60),(331,'evidence_1656','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nAn in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(332,'evidence_1539','http://www.ncbi.nlm.nih.gov/pubmed/11452243','\n\nroute of administration: oral\n\nstudy duration: single dose of 100 mg sertraline \n\npopulation: 12 healthy Chinese male, non-smokers\n\ntested for known CYP450 polymorphisms? Patients were genotyped for CYP2C19 polymorphisms and also phenotyped using the omeprazole/5-hydroxy-omeprazole metabolic ratio. 6 extensive metabolizers (EM) and 6 poor metabolizers (PM) were chosen using stratified random selection from a pool of 66 EMs and 11 PMs.\n\nages: 19 - 22 years\n\ndescription:\nThe poor metabolizers had a 41% increase in sertraline AUC(0-inf) (983.6  199.3 micg  h/L versus 697.6  133.0 mcg  h/L; P &lt; .05) and a 51% increase in sertraline terminal elimination half-life (t_1/2) (35.5  5.6 hours 2 versus 23.5  4.4 hours; P &lt; .01) compared with extensive metabolizers. The oral clearance (CL_oral) of sertraline in poor metabolizers was significantly lower than that in extensive metabolizers (105.3  19.4 L/h versus 148.4  28.6 L/h; P &lt; .05). The AUC0-144 and Cmax of desmethylsertraline in poor metabolizers were significantly lower than the values in extensive metabolizers (627.6  203.8 g  h/L versus 972.1  270.3 g  h/L; P &lt; .05; 23.6  6.5 nmol/L versus 32.4  8.2 nmol/L; P &lt; .01; respectively). In addition, desmethylsertraline Tmax (time to reach Cmax) in poor metabolizers was markedly higher than that in extensive metabolizers (70.0  24.5 hours versus 26.4  5.4 hours; P &lt; .01). \n\n\n','boycer','12172009','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(333,'evidence_1909','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.2 Inhibitors of CYP2D6\n\nConcomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)].','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(334,'evidence_1371','http://www.ncbi.nlm.nih.gov/pubmed/12621382','\n\nroute of administration: oral\n\nstudy duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;\n\npopulation: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study\n\ntested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.\n\nages: 21 - 27\n\ndescription:\n&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;\n\n','boycer','12172009','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(335,'evidence_1825','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(336,'evidence_1214','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nDuring oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or hematopoietic tissue), the observed pharmacokinetic characteristics were similar to those observed in healthy subjects:\n\nCmax @ 200 mg Oral Q12h(n=9): 3.0mcg/mL\n\nCmax @ 300 mg Oral Q12h(n=9): 4.66mcg/mL\n\n3mcg/mL X 1g/10^6mcg X 1000mL/1L = 0.0003g/L\n\n4.66mcG/mL X 1g/10^6mcg X 1000mL/1L = 0.000466g/L','boycer','09/24/2009 14:55:38\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.0003,NULL,NULL,NULL,'',0.4,NULL),(337,'evidence_1360','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nDuring oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or hematopoietic tissue), the observed pharmacokinetic characteristics were similar to those observed in healthy subjects:\n\nCmax @ 200 mg Oral Q12h(n=9): 3.0mcg/mL\n\nCmax @ 300 mg Oral Q12h(n=9): 4.66mcg/mL\n\n3mcg/mL X 1g/10^6mcg X 1000mL/1L = 0.0003g/L\n\n4.66mcG/mL X 1g/10^6mcg X 1000mL/1L = 0.000466g/L','boycer','09/24/2009 14:57:05\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000466,NULL,NULL,NULL,'',0.6,NULL),(338,'evidence_1906','http://www.ncbi.nlm.nih.gov/pubmed/11075313','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days\n\npopulation: 12 male\n\nages:21-41\n\ndescription:\nPotential for inhibition of CYP3A activity by simvastatin, an HMG-CoA reductase inhibitor, was evaluated in 12 healthy male subjects who received placebo or 80 mg of simvastatin, the maximal recommended dose, once daily for 7 consecutive days. On day 7, an intravenous injection of 3 microCi [14C N-methyl]erythromycin for the erythromycin breath test (EBT) was coadministered with a 2 mg oral solution of midazolam. The values for percent 14C exhaled during the first hour (for EBT) and the pharmacokinetic parameters of midazolam (AUC, Cmax, t1/2) were not affected following multiple once-daily oral doses of simvastatin 80 mg. The 95% confidence interval was 0.97 to 1.18 for EBT and 0.99 to 1.23 for midazolam AUC. In addition, the total urinary recoveries of midazolam and its 1\'-hydroxy metabolites (free plus conjugate) obtained from both treatments were not statistically different (p &gt; 0.200). These data demonstrate that multiple dosing of simvastatin, at the highest recommended clinical dose, does not significantly alter the in vivo hepatic or intestinal CYP3A4/5 activity as measured by the commonly used EBT and oral midazolam probes.','boycer','11/13/2007 13:22:40\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,61),(339,'evidence_1982','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 4-OH-alprazolam in a recombinant cyp3a5 Supersome system; Km = 126','boycer','06/26/2007 07:52:18\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(340,'evidence_1658','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA guidance considers phenacetin-O-deethylation to be catalyzed selectively by CYP1A2; see Table 3 of page 32','boycer','04/24/2009 16:21:57\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(341,'evidence_1357','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/57c11bb8-d133-43e2-a74f-838c31296eb5','CLINICAL PHARMACOLOGY\n...\nIndomethacin exists in the plasma as the parent drug and its desmethyl, desbenzoyl, and desmethyldesbenzoyl metabolites, all in the unconjugated form. About 60 percent of an oral dosage is recovered in urine as drug and metabolites (26 percent as indomethacin and its glucuronide), and 33 percent is recovered in feces (1.5 percent as indomethacin).','boycer','09/24/2009 12:17:39\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(342,'evidence_1922','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote: \n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.\n\n\n','boycer','06/11/2009 14:58:44\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,62),(343,'evidence_1334','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','the FDA lists this as a preferred in vitro inhibitor in it most recent guidance document. See Table 2, p. 28','boycer','05/21/2007 10:05:44\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(344,'evidence_1995','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','the FDA lists this as a preferred in vitro inhibitor in it most recent guidance document. See Table 2, p. 28','boycer','09/25/2007 07:56:10\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(345,'evidence_1105','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a preferred CYP1A2 substrate for in vivo studies in it most recent guidance document. See Table 2, p. 19\n','boycer','05/15/2009 09:01:56\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(346,'evidence_1815','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA lists this as a &quot;strong&quot; CYP2C19 inhibitor in its most recent guidance document. See Tables 2, p19 and 6, p. 23. \n\nNOTE: there is no mention of omeprazole as a recommended or acceptable in vitro inhibitor in Table 2, p28','boycer','06/12/2009 13:29:15\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(347,'evidence_1559','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','Metabolism and Elimination:\n\nFollowing a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.\n\nQuetiapine is extensively metabolized by the liver. The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive. In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite.','boycer','05/15/2009 09:49:13\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(348,'evidence_1256','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(349,'evidence_1729','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf','Drug Interactions\n...\nIn vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity.','boycer','09/24/2009 12:37:09\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(350,'evidence_1128','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','Quetiapine is extensively metabolized by the liver. The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive. In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite and in the metabolism of its active metabolite N-desalkyl quetiapine .','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(351,'evidence_1465','http://www.ncbi.nlm.nih.gov/pubmed/7891353','\nEnzyme system: human liver microsomes\n\nNADPH added: yes \n\nQuote:\nMetabolism of clozapine to stable and protein-reactive metabolites by human liver.     \n\nChromatographic analysis of the microsomal       incubation supernatants showed that clozapine was metabolized to five metabolites: desmethylclozapine,     clozapine N-oxide, 7-hydroxyclozapine and two un-\nidentified metabolites (fig 1). The CYP2D6            genotype did not affect the formation of these metabolites (table 2).','boycer','06/15/2009 16:15:27\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(352,'evidence_1911','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cdd5fd28-bfeb-4872-b642-95cd82732df3','\nPharmacokinetics and Metabolism\n\nNicardipine is completely absorbed following oral doses administered as capsules. Plasma levels are detectable as early as 20 minutes following an oral dose and maximal plasma levels are observed within 30 minutes to two hours (mean Tmax = 1 hour). While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.','boycer','09/24/2009 12:47:50\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.35,NULL,NULL,NULL,'',NULL,NULL),(353,'evidence_1984','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','04/29/2009 19:49:12\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(354,'evidence_1473','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(355,'evidence_1121','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: dextromethorphan-o-demethylation\n\nk_i = 65micM\n\n65micM/L x 1M/10^6micM x 443.627g/1M = 0.029g/L ','boycer','05/06/2009 13:50:03\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.029,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,63),(356,'evidence_1263','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA guidance considers DMT-O-demethylation to be catalyzed selectively by CYP2D6 in vitro (see Table 3 of page 32) and recommends it as an substrate for in vivo DDI PK studies (see Table 2 page 19)','boycer','06/17/2009 09:26:37\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(357,'evidence_1558','http://www.ncbi.nlm.nih.gov/pubmed/9690949','\n\nRoute of administration: oral\n\nstudy duration: 4 dys pre-treatment with 100mg oral itraconazole or placebo; on day 4 a single 40mg dose of oral lovastatin was given\n\npopulation: 10 \nmale: 8\nfemale: 2\n\nages: 19-24\n\nAUC_i/AUC (total): 222 / 15 = 14.8\nNOTE: placebo AUC could not be accurately measured but was known to be lower than 15ng/ml*h\n','boycer','10/29/2007 12:20:41\n','EV_PK_DDI_RCT','PKStudy',14.8,0.04,0.1,10,'',NULL,NULL),(358,'evidence_1671','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Dextromethorphan: A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in Cmax of dextromethorphan.','boycer','01/11/2010 18:24:21\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,64),(359,'evidence_1193','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: furafylline\n\nreaction: perphenazine N-dealkylation\n\nQuote: \nTo identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.\n\n','boycer','06/15/2009 14:26:44\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,65),(360,'evidence_1232','http://www.ncbi.nlm.nih.gov/pubmed/11136295','Enzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:29:22\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(361,'evidence_1237','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nMetabolism\n\nIn vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 ','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(362,'evidence_1888','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(363,'evidence_1912','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/17209c32-56eb-4f84-954d-aed7b7a1b18d','Table 4 shows that paroxetine (20mg 1xd X 9) effected no increase (and in fact a slight decrease) of the AUC of asenapine in vivo','boycer','01/11/2010 19:02:26\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,66),(364,'evidence_1904','http://www.ncbi.nlm.nih.gov/pubmed/11038166','Enzyme system: recombinant human CYP3A4 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin\n','boycer','09/25/2007 08:41:42\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(365,'evidence_1021','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\nMirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.','boycer','06/15/2009 15:23:39\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(366,'evidence_1256','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: alpha-napthoflavone\n\nreaction: mirtazapine 8-hydroxylation (25 and 250 micM) \n\nQuote: \nIncubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-\noxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. \n\nNOTE: lowest MIR concentration tested was 25 micM\n\n','boycer','02/13/2010 07:59:40\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,67),(367,'evidence_1828','http://www.ncbi.nlm.nih.gov/pubmed/12920410','\nroute of administration: oral\n\nstudy duration: at least 27 days\n\npopulation: 11 subjects\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: none given\n\ndescription:\nSUBJECTS: 11 subjects received fluoxetine treatment (n = 4 placebo first, n = 7 alprazolam first).\n\nMETHODS: The study had a within-subject, double-blind, placebo-controlled, parallel design. Subjects attended 4 study sessions; the first 2 study sessions occurred in the absence of SSRI medications, while the final 2 sessions occurred after a minimum of 21 days of administration of SSRI medication (citalopram 20 mg or fluoxetine 20 mg). Study sessions took place at least 3 days apart. At each study session, subjects were randomly assigned to a single oral dose of alprazolam (1 mg) or placebo at 9:00 am in the morning (ie, 1 of each for the 2 sessions before SSRI administration and 1 of each for the final 2 sessions after SSRI administration). During the post-SSRI study sessions, daily SSRI dosing was continued, while blood samples were collected up to 48.0 hours (ie, SSRIs were administered at 24.0 and 48.0 hours after single-dose alprazolam administration). Trough citalopram, fluoxetine, and metabolite serum concentrations were determined on 5 occasions: on days 1 and 7 of SSRI administration, prior to alprazolam/placebo administration at study sessions 3 and 4, and 7 days after discontinuation of study medications. During the study sessions, a small standardized breakfast (bagel and apple juice) was provided 1 hour postalprazolam administration, and a sandwich and apple juice was provided 4 hours postalprazolam administration. From 8 hours postalprazolam administration, food intake was not regulated. Subjects were instructed not to consume grapefruit juice during the study due to the potential for inhibition of the CYP3A4 enzyme.\n\nRESULTS: Coadministration with fluoxetine significantly increased alprazolam AUC for all time intervals: 0-3 hours (P &lt; 0.05), 0-8 hours (P &lt; 0.005), 0-48 hours (P &lt; 0.001), and 0-inf ( P &lt; 0.001) (Table 2 and Fig. 1). The AUC 0-inf increased by 31.8% postfluoxetine. \n','boycer','09/22/2010 15:33:48\n','EV_PK_DDI_RCT','PKStudy',1.318,0.001,0.02,11,'',NULL,NULL),(368,'evidence_1365','http://www.ncbi.nlm.nih.gov/pubmed/14709940','\n\nroute of administration: oral\n\nstudy duration: Fluoxetine was dosed at 40 mg/day for 11 days. On the morning of the 12th day participants received a final dose of antidepressant followed by a 3-mCi dose of radio-labled erythromycin by IV then, 20 minutes later, a 2 mg dose of alprazolam orally. (See NOTE below)\n\npopulation: 16 healthy males, non-smokers, \n\ntested for known CYP450 polymorphisms? Yes; &quot;subjects were phenotyped with dextromethorphan prior to entering the study to exclude CYP2D6-poor metabolizers&quot;\n\nages:18 - 25\n\ndescription:\nCompared to baseline, venlafaxine, sertraline, and fluoxetine caused no apparent inhibition or induction of erythromycin metabolism ( P &gt; 0.05). For nefazodone, a statistically significant inhibition was observed ( P &lt; 0.0005). Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration  versus  time curve (AUC; P &lt; 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P &lt; 0.05) compared with values at  aseline. No significant differences were found in the pharmacokinetics of ALPZ with any of the other antidepressants tested. \n\n\nNOTE: Although erythromycin is known to inhibit CYP3A4 activity, it is the opinion of DIKB reviewer\'s, the dose of erythromycin given in this study was too low to have any relevant inhibitory effect on CYP3A4','boycer','09/22/2009 19:37:07\n','EV_PK_DDI_NR','PKStudy',1,0.002,0.04,16,'',NULL,NULL),(369,'evidence_1752','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','\nMetabolism and elimination \n...\nThe major oxidative metabolite formed, regardless of CYP2D6 status, is 4hydroxyatomoxetine, which is glucuronidated. 4Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes. NDesmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs).\n\n','boycer','09/24/2009 11:34:03\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(370,'evidence_1919','http://www.ncbi.nlm.nih.gov/pubmed/2007317','\n\nroute of administration: oral\n\nstudy duration: single 25mg dose of thioridazine\n\npopulation: 19 healthy male subjects: 6 slow and 13 rapid hydroxylators of debrisoquin\n\nages: 19 - 41\n\nHPLC detected mesoridazine, thioridazine-5-sulfoxide (called thioridazine ring-sulphoxide in the study) and other metabolites\n\n','boycer','06/19/2009 19:21:24\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(371,'evidence_1669','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','CYP2C9: Venlafaxine did not inhibit CYP2C9 in vitro. In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide. ','boycer','05/14/2009 13:49:46\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(372,'evidence_1104','http://www.ncbi.nlm.nih.gov/pubmed/9205822','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nreaction: tolbutamide-4-hydroxylation\n\nQuote: \nThe IC50 for venlafaxine\'s inhibition of the reaction was &gt; 1000micM ','boycer','02/12/2010 14:23:14\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,68),(373,'evidence_1457','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.6,NULL,NULL,NULL,'',NULL,NULL),(374,'evidence_1178','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/3829d74e-b3ab-46df-a08b-f0327b63304e','\nMetabolism Following oral dosing, theophylline does not undergo any measurable first-pass elimination. In adults and children beyond one year of age, approximately 90%of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6%of a theophylline dose is N-methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.\n\nCaffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity. 3-methylxanthine has approximately one tenth the pharmacologic activity of theophylline and serum concentrations in adults with normal renal function are <1 mcg/mL. In patients with end-stage renal disease, 3-methylxanthine may accumulate to concentrations that approximate the unmetabolized theophylline concentration. Caffeine concentrations are usually undetectable in adults regardless of renal function. In neonates, caffeine may accumulate to concentrations that approximate the unmetabolized theophylline concentration and thus, exert a pharmacologic effect.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(375,'evidence_1656','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA recommends warfarin as a preferred CYP2D6 substrate for in vivo studies in it most recent guidance document (See Table 2, p. 19) and expressly mentions that S-warfarin should be target of chemical analysis on 9, 1st paragraph.','boycer','09/24/2009 15:39:40\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(376,'evidence_1007','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA recommends theophylline to be an acceptable chemical CYP1A2 substrate (theophylline N-demethylation) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','06/20/2009 11:58:32\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(377,'evidence_1705','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/a23063c0-099a-4256-b95f-3a857bbf704b','Following oral administration, alprazolam is readily absorbed. Peak concentrations in the plasma occur in one to two hours following administration. Plasma levels are proportionate to the dose given; over the dose range of 0.5 to 3 mg, peak levels of 8 to 37 ng/mL were observed.','boycer','08/10/2007 10:04:22\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000008,NULL,NULL,NULL,'',0.0005,NULL),(378,'evidence_1673','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/a23063c0-099a-4256-b95f-3a857bbf704b','Following oral administration, alprazolam is readily absorbed. Peak concentrations in the plasma occur in one to two hours following administration. Plasma levels are proportionate to the dose given; over the dose range of 0.5 to 3 mg, peak levels of 8 to 37 ng/mL were observed.','boycer','08/10/2007 10:05:57\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000037,NULL,NULL,NULL,'',0.003,NULL),(379,'evidence_1958','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','06/30/2009 12:58:54\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(380,'evidence_1152','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c103da18-a822-4944-1bd7-8ecdb5205d69','Cytochrome P450 (CYP450)\n\nCiprofloxacin is an inhibitor of the hepatic CYP1A2 enzyme pathway. Coadministration of ciprofloxacin and other drugs primarily metabolized by CYP1A2 (e.g. theophylline, methylxanthines, tizanidine) results in increased plasma concentrations of the coadministered drug and could lead to clinically significant pharmacodynamic side effects of the coadministered drug.','boycer','01/11/2010 16:43:17\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(381,'evidence_1143','http://www.ncbi.nlm.nih.gov/pubmed/10073330','\nNOTE: The precip_dose is the dose from days 8-14\n\nroute of administration: oral\n\nstudy duration: 15 days\n\npopulation:24 healthy volunteers (18 male, 6 female)\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 19-45\n\ndescription:\nSUBJECTS: Thirty healthy male (22) and female (8) volunteers participated in the study. Informed consent was obtained for all subjects. Mean (range) age, weight, and height for the subjects were 29.6 years (19-45 years), 78.3 kg (46-102 kg), and 179 cm (158-198 cm), respectively.\n\nTwenty-eight of the 30 enrolled subjects completed the study. Two male subjects withdrew their consent, one on Day 8 during a morning clinic visit and the other on Day 12 before the morning dose of venlafaxine. Pharmacokinetic and pharmacodynamic data were evaluated for only 24 subjects. Four subjects were excluded from the analyses because of protocol violations. Two male subjects did not collect complete 96-hour urine samples, and 2 female subjects consumed\nxanthene-containing foods or beverages during the study.\n\nMETHODS: This was an open-label drug interaction study to evaluate the effects of steady-state venlafaxine on the pharmacokinetic disposition of single oral doses of\nrisperidone. Single 1 mg doses of risperidone (1 mg Risperdal tablet, Janssen Pharmaceutica, Titusville, NJ) were administered on Days 1 and 11 with 180 mL of room-temperature water at approximately 10 a.m. following an overnight fast. Multiple doses of venlafaxine (37.5 mg and 75 mg Effexor tablets, Wyeth-Ayerst Laboratories, Radnor, PA) were administered as follows: 37.5 mg bid from Days 5 through 7 and then 75 mg twice daily from Days 8 through 14. Venlafaxine doses were administered with approximately 240 mL of room- temperature water at 8 a.m. and 8 p.m. with food\n(except during the designated fasting period on Day\n11). Single-dose pharmacokinetic profiles of risperidone and 9-hydroxyrisperidone and the total active moiety were evaluated on Days 1 through 5 (risperidone alone) and on Days 11 through 15 (risperidone plus venlafaxine).\n\nRESULTS: Risperidone mean oral clearance decreased by 38% (885 +/- 707 mL/min vs. 550 +/- 406 mL/min), and volume of distribution decreased by 17% (215 +/- 91 L vs. 178 +/- 66 L), resulting in a 32% increase in mean AUC_(0inf) (35.3 +/- 32.1 ng x h/mL vs. 46.7 +/- 31.1 ng x h/mL) and a 29% increase in mean C_max (5.33 +/- 2.15 ng/mL vs. 6.89 +/- 2.96 ng/mL) with venlafaxine coadministration. Both risperidone AUC_(0inf) and C_max failed to meet bioequivalence criteria (90% CI = 134%-167% and 117%-143%, respectively).','boycer','09/16/2010 15:08:01\n','EV_PK_DDI_NR','PKStudy',1.32,0.001,0.15,24,'',NULL,NULL),(382,'evidence_1424','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2C9 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent ','boycer','01/14/2008 13:46:45\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(383,'evidence_1148','http://www.ncbi.nlm.nih.gov/pubmed/8466541','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nreaction: phenacetin O-dethylation\n\nK_i from Table 1 based on assays with microsomes from three livers: (0.18 + 0,24 + 0.12) / 3 = 0.18micM\n\n0.18micM/L x 1M/10^6micM x 318.335g/M = 0.0000573g/L','boycer','06/17/2009 08:24:10\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.0000573,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,69),(384,'evidence_1951','http://www.ncbi.nlm.nih.gov/pubmed/11719727','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nreaction: theophylline --&gt; 1-methylxanthine\n\nK_i,total (from Table I): 115nMol/L\n\nM.W.: 180.164g/Mol\n\n115nMol/L X 1Mol/10^9nMol X 180.164g/1Mol = 0.00002072g/Mol  \n\n\n','boycer','06/20/2009 12:17:10\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.00002072,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,70),(385,'evidence_1499','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',4.2,NULL,NULL,NULL,'',NULL,NULL),(386,'evidence_1005','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','06/30/2009 14:03:13\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(387,'evidence_1910','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3','Ritonavir also inhibits CYP2D6 to a lesser extent. Co-administration of substrates of CYP2D6 with ritonavir could result in increases (up to 2-fold) in the AUC of the other agent, possibly requiring a proportional dosage reduction. ','boycer','01/11/2010 17:46:31\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(388,'evidence_1116','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3','Table 3 shows that the AUC of desipramine increased 145% in the presence of ritonavir','boycer','01/11/2010 17:54:47\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,71),(389,'evidence_1284','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(390,'evidence_1935','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: phenacetin-o-deethylation\n\nk_i = 40.2micM (Table 2)\n\n40.2micM/L x 1M/10^6micM x 437.523g/1M = 0.018g/L\n','boycer','04/25/2009 09:00:41\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.018,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,72),(391,'evidence_1725','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','Drug interactions:\n\nIn vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(392,'evidence_1267','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(393,'evidence_1579','http://www.ncbi.nlm.nih.gov/pubmed/16390352','Enzyme system: recombinant human enzymes in human lymphoblastoid\nNADPH added: not explicitly mentioned but assumed\n\ninhibitor used: no\n\nQuetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4.','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(394,'evidence_1565','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: alpha-napthoflavone\n\nreaction: venlafaxine --&gt; O-desmethylvenlafaxine\n\nQuote:\nIncubations of 50micM VF with varying concentra-\ntions of SFZ and ANA, inhibitors of CYP2C9 and CYP1A2, respectively, revealed no consistent inhibitory effect on ODV formation','boycer','06/16/2009 14:24:07\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,73),(395,'evidence_1462','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf',' The FDA lists this as a recommended in vivo inhibitor of CYP3A4 in it most recent guidance document. See Appendix A, Table 2, p. 19','boycer','05/21/2007 13:47:44\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(396,'evidence_1700','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: dextromethorphan O-demethylation\n\nQuote: \n\nCYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors. ','boycer','06/12/2009 11:44:35\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,74),(397,'evidence_1712','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Both CYP3A4 and CYP2D6 are responsible for iloperidone metabolism. Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., fluoxetine, paroxetine) can inhibit iloperidone elimination and cause increased blood levels.\n\nKetoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18-45, increased the AUC of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(398,'evidence_1497','http://www.ncbi.nlm.nih.gov/pubmed/16390352','Enzyme system: recombinant human enzymes in human lymphoblastoid\nNADPH added: not explicitly mentioned but assumed\n\ninhibitor used: no\n\nQuetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4.','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(399,'evidence_1371','http://www.ncbi.nlm.nih.gov/pubmed/14709940','\n\nroute of administration: oral\n\nstudy duration: 75 mg/day venlafaxine for 3 days followed by 150 mg/day for 5 days. On the morning of the sixth day participants received a final dose of antidepressant followed by a 3-mCi dose of radio-labled erythromycin by IV then, 20 minutes later, a 2 mg dose of alprazolam orally. (See NOTE below)\n\npopulation: 16 healthy males, non-smokers, \n\ntested for known CYP450 polymorphisms? Yes; &quot;subjects were phenotyped with dextromethorphan prior to entering the study to exclude CYP2D6-poor metabolizers&quot;\n\nages:18 - 25\n\ndescription:\nCompared to baseline, venlafaxine, sertraline, and fluoxetine caused no apparent inhibition or induction of erythromycin metabolism ( P &gt; 0.05). For nefazodone, a statistically significant inhibition was observed ( P &lt; 0.0005). Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration  versus  time curve (AUC; P &lt; 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P &lt; 0.05) compared with values at  aseline. No significant differences were found in the pharmacokinetics of ALPZ with any of the other antidepressants tested. \n\n\nNOTE: Although erythromycin is known to inhibit CYP3A4 activity, it isi the opinion of DIKB reviewer\'s, the dose of erythromycin given in this study was too low to have any relevant inhibitory effect on CYP3A4','boycer','09/22/2009 19:29:34\n','EV_PK_DDI_NR','PKStudy',1,0.002,0.075,16,'',NULL,NULL),(400,'evidence_1153','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf',' The FDA lists this as a recommended in vivo inhibitor of CYP3A4 in it most recent guidance document. See Appendix A, Table 2, p. 19','boycer','05/21/2007 13:48:48\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(401,'evidence_1034','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1d149db-ad43-4f3f-aef1-fb0395ba4191','Theophylline\n\nWhen nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(402,'evidence_1848','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(403,'evidence_1332','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: tolbutamide --&gt; hydroxytolbutamide\n\nQuote: \n\nCYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7  (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM).\n\n\n','boycer','06/11/2009 15:15:34\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,75),(404,'evidence_1520','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA lists this as a recommended in vivo substrate of CYP3A4 in it most recent guidance document. See Appendix A, Table 2, p. 19','boycer','05/21/2007 15:31:44\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(405,'evidence_1888','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: dextromethorphan O-demethylation\n\nQuote: \n\nCYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors. ','boycer','06/12/2009 11:45:39\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,76),(406,'evidence_1666','http://www.ncbi.nlm.nih.gov/pubmed/10997935','Enzyme system: recombinant human enzymes in human lymphoblastoid cells\nNADPH added:yes\n\ninhibitor used: no\n\nTable 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. ','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(407,'evidence_1882','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(408,'evidence_1593','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(409,'evidence_1150','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(410,'evidence_1861','http://www.ncbi.nlm.nih.gov/pubmed/10997944','\nEnzyme system: recombinant CYP450 enzymes in baculovirus-infected insect cells\n\nNADPH added: yes\n\nreaction: bupropion --&gt; hydroxybupropion\n\nQuote: \nEvaluation of BUP Hydroxylation by Individual cDNA-Ex- pressed Human P450s. Because the biphasic kinetic data observed with low activity HLMs (HLMs 20 and 24) indicated the contribution of more than one enzyme to BUP hydroxylation at higher substrate concentrations, a panel of eight cDNA-expressed enzymes (SUPER- SOMES) was screened for BUP hydroxylase activity at 12 mM to identify enzymes requiring further investigation (Fig. 7). This sub- strate concentration was selected to ensure saturation of any high Km isozyme capable of catalyzing BUP hydroxylation. cDNA-expressed CYP2B6 demonstrated the highest rate of HBUP formation (7.0 pmol/min/pmol of P450). cDNA-expressed CYP2E1 and CYP3A4 catalyzed BUP hydroxylation at the second and third highest rates, although at 3- and 30-fold lower rates than cDNA-expressed CYP2B6 (2.4 and 0.23 pmol/min/pmol of P450, respectively). Of note, CYP2E1 was the only cDNA-expressed enzyme in which cytochrome b5 was coexpressed. Rates of BUP hydroxylation by CYP1A2, CYP2A6, CYP2C9, CYP2C19, and CYP2D6 were greater than 30-fold lower than CYP2B6 (Fig. 7). HBUP formation in control microsomes was negligible. \n\n\n','boycer','06/19/2009 17:29:44\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(411,'evidence_1387','http://www.ncbi.nlm.nih.gov/pubmed/11061579','Route of administration: oral\n\nstudy duration: 13 days\n\npopulation: 18 participants; 5 male, 5 female\n\nages:18-45\n\ndose: 20mg of atorvastatin on day one, three days no drug, days 6-10 participants were given 200mg itraconazole 1xday for 5 days, on day 10 a portion of the participants were given a single dose of 20 mg atorvastatin. PK parameters were measured followed for another three days\n\n(mean AUC_i)/(mean AUC) = 246.7/98.7 (AUC is 0-infinity)\n\n\ndescription: \nn this single-site, randomized, three-way crossover, open-labeled study, healthy subjects (n = 18) received single doses of cerivastatin 0.8 mg, atorvastatin 20 mg, or pravastatin 40 mg without and with itraconazole 200 mg. Pharmacokinetic parameters [AUC(0-infinity), AUC(0-tn), peak concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2)] were determined for parent statins and major metabolites. RESULTS: Concomitant cerivastatin/itraconazole treatment produced small elevations in the cerivastatin AUC(0-infinity), Cmax, and t1/2 (27%, 25%, and 19%, respectively; P &lt; .05 versus cerivastatin alone). Itraconazole coadministration produced similar changes in pravastatin pharmacokinetics [AUC elevated 51% (P &lt; .05 versus pravastatin alone), 24% (Cmax), and 23% (t1/2), respectively]. However, itraconazole dramatically increased atorvastatin AUC (150%), Cmax (38%), and t1/2 (30%) (P &lt; .05).','boycer','09/24/2007 10:14:08\n','EV_PK_DDI_RCT','PKStudy',2.5,0.02,0.2,18,'',NULL,NULL),(412,'evidence_1293','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','11/09/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(413,'evidence_1526','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a acceptable chemical CYP3A4 substrate (CYP3A4-->(erythromycin->N-Demethyl-erythromycin)) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','05/21/2007 10:39:17\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(414,'evidence_1190','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote:\n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM. ','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(415,'evidence_1063','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2','&quot;\nLovastatin undergoes extensive first-pass extraction in the liver, its primary site of action, with subsequent excretion of drug equivalents in the bile. As a consequence of extensive hepatic extraction of lovastatin, the availability of drug to the general circulation is low and variable. In a single dose study in four hypercholesterolemic patients, it was estimated that less than 5% of an oral dose of lovastatin reaches the general circulation as active inhibitors. Following administration of lovastatin tablets the coefficient of variation, based on between-subject variability, was approximately 40% for the area under the curve (AUC) of total inhibitory activity in the general circulation.&quot;','boycer','09/28/2007 13:44:46\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.05,NULL,NULL,NULL,'',NULL,NULL),(416,'evidence_1102','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(417,'evidence_1377','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: p-nitrophenol\n\nreaction: p-nitrophenol hydroxylation to p-nitrocatechol\n\nQuote:\nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. ','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(418,'evidence_1162','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: perphenazine N-dealkylation\n\nQuote: \nTo identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(419,'evidence_1423','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant CYP enzymes in baculovirus infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(420,'evidence_1345','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','CYP2C9: Venlafaxine did not inhibit CYP2C9 in vitro. In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide. ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(421,'evidence_1735','http://www.ncbi.nlm.nih.gov/pubmed/9205822','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nreaction: tolbutamide-4-hydroxylation\n\nQuote: \nThe IC50 for venlafaxine\'s inhibition of the reaction was &gt; 1000micM ','boycer','02132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(422,'evidence_1544','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA, in it most recent guidance document, recommends this as a chemical inhibitor of CYP2B6 for in vitro experiments at a K_i of 0.2micM. See Table 2, p. 28\n\n0.2.micM/L X 1M/10^6micM X 263.876g/M = 0.00005278g/L','boycer','06/30/2009 14:20:44\n','Non_Tracable_Statement','In_vitro_inhibition_study',0.00005278,NULL,NULL,NULL,'none_assigned',NULL,NULL),(423,'evidence_1490','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/4259d9b1-de34-43a4-85a8-41dd214e9177 ','Cimetidine - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.','boycer','02/09/2012 10:26:38\n','Non_traceable_Drug_Label_Statement','PKStudy',1.43,0.04,0.4,NULL,'',NULL,NULL),(424,'evidence_1265','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f','&quot;When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. Nefazodone plasma concentrations were unaffected by triazolam. Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests. &quot;','boycer','10/16/2007 11:03:11\n','Non_traceable_Drug_Label_Statement','PKStudy',4,0.00025,0.2,NULL,'',NULL,NULL),(425,'evidence_1234','http://www.ncbi.nlm.nih.gov/pubmed/8830062','\nRoute of administration: oral\n\nstudy duration: 2 days treatment w/ triazolam (TRZ) alone (.25mg 1xday) followed by 7 days treatment with nevazodone alone (200mg, bid); followed by two days dosing with nevazodone + TRZ\n\npopulation: 12 male\n\nages:23-38\n\n&quot;\nMean triazolam peak concentration values increased (p = 0.003) from 2.33 to 3.88 ng/ml when triazolam was administered alone and in combination with nefazodone, respectively. Corresponding mean triazolam area under the curve values increased (p &lt; 0.001) from 8.14 to 31.74 ng.h/ml.&quot;\n','boycer','10/29/2007 11:25:10\n','EV_PK_DDI_RCT','PKStudy',3.899,0.00025,0.2,12,'',NULL,NULL),(426,'evidence_1274','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(427,'evidence_1444','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645','Drug Interactions\n...\nAmiodarone is also known to be an inhibitor of CYP3A4. Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4. While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, the potential for other interactions should be anticipated. This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics. If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured. In view of the long and variable half-life of amiodarone, potential for drug interactions exists, not only with concomitant medication, but also with drugs administered after discontinuation of amiodarone.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(428,'evidence_1270','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(429,'evidence_1065','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: S-warfarin\n\nreaction: S-warfarin 7-hydroxylation\n\nQuote:\nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. ','boycer','09/22/2009 17:58:27\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,77),(430,'evidence_1910','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(431,'evidence_1855','http://www.ncbi.nlm.nih.gov/pubmed/12235455','\nRoute of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: single 120mg oral dose of diltiazem with 24 hours of plasma level monitoring\n\npopulation: 15 individuals; 5 for each genetically based phenotype. Study does not state gender of participants\n\nages: 20-30\n\ndescription:\nThe aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS: Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence resonance energy transfer probes hybridized to polymerase chain reaction-amplified deoxyribonucleic acid. The first 5 individuals identified with genotypes corresponding to a homozygous extensive, heterozygous extensive, or homozygous poor CYP2D6-metabolizing phenotype, respectively, were voluntarily enrolled in the pharmacokinetic study. The participants received diltiazem, 120 mg, as a single oral dose, and plasma samples were collected up to 24 hours after administration. Plasma samples were purified by solid phase extraction. Diltiazem and 7 phase I metabolites were analyzed by liquid chromatography-mass spectrometry. RESULTS: The pharmacokinetics of diltiazem was not significantly different between the subgroups. ...','boycer','08/09/2007 07:14:30\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,78),(432,'evidence_1022','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(433,'evidence_1124','http://www.ncbi.nlm.nih.gov/pubmed/10997944','\nEnzyme system: recombinant CYP450 enzymes in baculovirus-infected insect cells\n\nNADPH added: yes\n\nreaction: bupropion --&gt; hydroxybupropion\n\nQuote: \nEvaluation of BUP Hydroxylation by Individual cDNA-Ex- pressed Human P450s. Because the biphasic kinetic data observed with low activity HLMs (HLMs 20 and 24) indicated the contribution of more than one enzyme to BUP hydroxylation at higher substrate concentrations, a panel of eight cDNA-expressed enzymes (SUPER- SOMES) was screened for BUP hydroxylase activity at 12 mM to identify enzymes requiring further investigation (Fig. 7). This sub- strate concentration was selected to ensure saturation of any high Km isozyme capable of catalyzing BUP hydroxylation. cDNA-expressed CYP2B6 demonstrated the highest rate of HBUP formation (7.0 pmol/min/pmol of P450). cDNA-expressed CYP2E1 and CYP3A4 catalyzed BUP hydroxylation at the second and third highest rates, although at 3- and 30-fold lower rates than cDNA-expressed CYP2B6 (2.4 and 0.23 pmol/min/pmol of P450, respectively). Of note, CYP2E1 was the only cDNA-expressed enzyme in which cytochrome b5 was coexpressed. Rates of BUP hydroxylation by CYP1A2, CYP2A6, CYP2C9, CYP2C19, and CYP2D6 were greater than 30-fold lower than CYP2B6 (Fig. 7). HBUP formation in control microsomes was negligible. \n\n\n','boycer','06/19/2009 17:27:20\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(434,'evidence_1466','http://www.ncbi.nlm.nih.gov/pubmed/12584155','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nQuote:\nTo determine whether preincubation affects the inhibition of human liver microsomal dextromethorphan demethylation activity by paroxetine, we used a two-step incubation scheme in which all of the enzyme assay components, minus substrate, are preincubated with paroxetine...Time-dependent inhibition was demonstrated with an apparent K(I) of 4.85 microM and an apparent k(INACT) value of 0.17 min(-1). Spectral scanning of CYP2D6 with paroxetine yielded an increase in absorbance at 456 nm suggesting paroxetine inactivation of CYP2D6 via the formation of a metabolite intermediate complex.\n...In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation-dependent increase in inhibitory potency. These data are consistent with mechanism-based inhibition of CYP2D6 by paroxetine but not by quinidine or fluoxetine.','boycer','06/16/2009 17:14:06\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,79),(435,'evidence_1164','http://www.ncbi.nlm.nih.gov/pubmed/9431831','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: haloperidol --&gt; 4-(4-chlorophenyl)-4-\nhydroxypiperidine\n\nQuote:\nKetoconazole was a potent inhibitor of CPHP (4-(4-chlorophenyl)-4-hydroxypiperidine) formation with IC50 values of 0,10, 0,23 and 0,14 micM in microsomes HL-1, HL-6 and HL-9 respectively, wheras sulphaphenazole, furafylline and quinidine showed little inhibition (IC50 &gt; 100micM)','boycer','06/17/2009 07:59:15\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,80),(436,'evidence_1081','http://www.ncbi.nlm.nih.gov/pubmed/9825830','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor: ketoconazole\n\nreaction: reduced-haloperidol --&gt; 4-(4-chlorophenyl)-4-hydroxypiperidine\n\nDescription:\nketoconazole was a potent inhibitor of both HAL and 4-(4-chlorophenyl)-4-hydroxypiperidine formation, see p.387 ','boycer','06/22/2009 12:39:41\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,81),(437,'evidence_1768','http://www.ncbi.nlm.nih.gov/pubmed/9825830','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor: troleandomycin\n\nreaction: reduced-haloperidol --&gt; 4-(4-chlorophenyl)-4-hydroxypiperidine\n\nDescription:\nTroleandomycin was a potent inhibitor of both HAL and 4-(4-chlorophenyl)-4-hydroxypiperidine formation, see p.387 ','boycer','06/22/2009 12:42:21\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,82),(438,'evidence_1832','http://www.ncbi.nlm.nih.gov/pubmed/11910262','Route of administration: oral\n\nstudy duration: read description below\n\npopulation: (fluoxetine group) 14 healthy volunteers (7 male and 7 female), all extensive metabolizers of dextromethorphan\n\nages: mean(std dev): 26 (unknown)\n\nDescription: \nIn an open label, parallel group study of 45 healthy volunteers, the time course of CYP2D6 inhibition of the above SSRIs was evaluated. Subjects were randomized to receive paroxetine at 20 mg/day for 10 days; sertraline at 50 mg/day for 3 days, followed by sertraline at 100 mg/day for 10 days; or fluoxetine at 20 mg/day for 28 days. CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine. Following SSRI discontinuation, calculation of a CYP2D6 inhibition half-life (t(1/2)inh) revealed the time course of fluoxetine inhibition (t(1/2)inh = 7.0 +/- 1.5 days) to be significantly longer than either paroxetine (t(1/2)inh = 2.9 +/- 1.9) or sertraline (t(1/2)inh = 3.0 +/- 3.0) (p &lt; 0.01), but the latter were not significantly different from each other (p &gt; 0.05). Time for the extrapolated DMR versus time log-linear plots to return to baseline was significantly different between fluoxetine (63.2 +/- 5.6 days) and both paroxetine (20.3 +/- 6.4 days) and sertraline (25.0 +/- 11.0 days) (p &lt; 0.01), making the rank order (from longest to shortest) of time for CYP2D6 inhibition to dissipate: fluoxetine &gt; sertraline &gt;or= paroxetine. Differences between mean baseline DMR values and measured values obtained after drug discontinuation for each drug group became nonsignificant on discontinuation day 5 for both paroxetine and sertraline and on discontinuation day 42 for fluoxetine. ','boycer','12172009','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(439,'evidence_1900','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1','Drugs metabolized by CYP2D6  Fluoxetine inhibits the activity of CYP2D6, and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. Therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index (see list below) should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. Thus, his/her dosing requirements resemble those of poor metabolizers. If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for decreased dose of the original medication should be considered. Drugs with a narrow therapeutic index represent the greatest concern (e.g., flecainide, propafenone, vinblastine, and TCAs). Due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued (see CONTRAINDICATIONS and WARNINGS).','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(440,'evidence_1219','http://www.ncbi.nlm.nih.gov/pubmed/12173784','\nroute of administration: oral\n\nstudy duration: fluoxetine 80mg qd for eight days\n\npopulation: 32 healthy adults, all extensive CYP2D6 metabolizers based on DM:DX\n\nages: unmentioned\n\nDescription: \nThe urinary concentration ratio of dextromethorphan:dextrorphan (interpreted as an in vivo index of CYP2D6 activity) was determined for each subject before and after the 8 days of receiving SSRIs. Plasma SSRI trough concentrations were measured on days 6-9. The CYP2D6 genotype was determined in a subject with an undetectable paroxetine concentration. Inhibition of CYP2D6 correlated significantly with plasma concentrations of paroxetine and fluoxetine. In contrast, no significant correlations emerged between CYP2D6 inhibition and plasma concentrations of sertraline or fluvoxamine. The subject with an undetectable paroxetine concentration was found to carry at least three functional CYP2D6 genes.','boycer','12172009','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(441,'evidence_1791','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','&quot;\nFluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.\n\n      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(442,'evidence_1019','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978','Pharmacokinetic-related Interactions\n\nClozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes.','boycer','05/15/2009 11:02:18\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(443,'evidence_1299','http://www.ncbi.nlm.nih.gov/pubmed/9384460','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: clozapine demethylation and N-oxidation\n\nQuote: \nKetconazole inhibited [clozapine] demethylation by 28+/-20% and 68+/-15% at 0.2 and 2 micM, respectively... CLZ-NO formation was inhibited by ketoconazole by 41+/-14% and 51+/-13% at 0.2 and 2 micM, respectively. \n\n\n','boycer','02/12/2010 18:20:56\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,83),(444,'evidence_1346','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.01,NULL,NULL,NULL,'',NULL,NULL),(445,'evidence_1690','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','7.2 Effects of Ranolazine on Other Drugs\n\nIn vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. ','boycer','09/25/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(446,'evidence_1646','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','04/29/2009 19:45:20\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(447,'evidence_1612','http://www.ncbi.nlm.nih.gov/pubmed/9146848','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 3 day pretreatment with diltiazem\n\npopulation: 7 male\n\nages: 20-22\n\ndescription: \nWe investigated the interaction between triazolam and diltiazem in a randomized, three-phase crossover study. Seven healthy male volunteers received orally either a single 0.25 mg dose of triazolam, a 0.25 mg dose of triazolam after a 3-day treatment of diltiazem (180 mg day-1), or a placebo. Plasma samples were collected to determine triazolam concentration over a 24 h period. The pharmacodynamic effects of triazolam were investigated using the peak saccadic velocity of eye movements (PSV), electroencephalogram (EEG), and visual analogue scale (VAS) through 8 h. RESULTS: Diltiazem pretreatment significantly increased the area under the triazolam concentration-time curve (8.0 +/- 2.4 to 18.2 +/- 3.1 ng ml-1 h; P < 0.001; mean +/- s.d.). Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01). The PSV, EEG, and VAS of the triazolam plus diltiazem group revealed significant differences from the triazolam alone group or the control placebo group.','boycer','05/29/2007 11:43:17\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,84),(448,'evidence_1199','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(449,'evidence_1911','http://www.ncbi.nlm.nih.gov/pubmed/12235455','\nRoute of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: single 120mg oral dose of diltiazem with 24 hours of plasma level monitoring\n\npopulation: 15 individuals; 5 for each genetically based phenotype. Study does not state gender of participants\n\nages: 20-30\n\ndescription:\nThe aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS: Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence resonance energy transfer probes hybridized to polymerase chain reaction-amplified deoxyribonucleic acid. The first 5 individuals identified with genotypes corresponding to a homozygous extensive, heterozygous extensive, or homozygous poor CYP2D6-metabolizing phenotype, respectively, were voluntarily enrolled in the pharmacokinetic study. The participants received diltiazem, 120 mg, as a single oral dose, and plasma samples were collected up to 24 hours after administration. Plasma samples were purified by solid phase extraction. Diltiazem and 7 phase I metabolites were analyzed by liquid chromatography-mass spectrometry. RESULTS: The pharmacokinetics of diltiazem was not significantly different between the subgroups. However, the systemic exposure of the pharmacologically active metabolites desacetyl diltiazem and N-demethyldesacetyl diltiazem was &gt; or = 5 times higher in poor CYP2D6 metabolizers than in extensive CYP2D6 metabolizers (P &lt;.01). CONCLUSIONS: CYP2D6 activity does not have a major impact on the disposition of diltiazem. In contrast, desacetyl diltiazem and N-demethyldesacetyl diltiazem are markedly accumulated in individuals expressing a deficient CYP2D6 phenotype. Because these metabolites exhibit pharmacologic properties of possible importance, individual CYP2D6 activity might be an aspect to consider in the clinical use of diltiazem.','boycer','08/09/2007 07:18:17\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,85),(450,'evidence_1282','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','\n7. DRUG INTERACTIONS\n...\nIn vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by CYP2D6. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(451,'evidence_1573','http://www.ncbi.nlm.nih.gov/pubmed/12891223','\n\nroute of administration: oral\n\nstudy duration: Controls: a single dose of 50 mg immediate-release metoprolol was given after 7-days of placebo. Exposed: a single dose of 50 mg immediate-release metoprolol was given after 7-days of 400 mg/day of celecoxib.\n\npopulation: 12 male volunteers \n\ntested for known CYP450 polymorphisms? Yes, all participants were genotyped as having heterozygous or homozygous extensive metabolizing CYP2D6 alleles. Participants CYP2C9 was also genotyped but no classification of the alleles appears in the paper. \n\nages: mean age 30.7 +/- 5.3\n\ndescription:\nCelecoxib increased the AUC(0-inf) of metoprolol\nsigni&amp;#64257;cantly in all 12 volunteers, by 64.4% +/-57.0% (P &lt; .001).\n\n\n\n\n','boycer','01132010','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(452,'evidence_1615','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c','\nMetabolism\n\nZafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(453,'evidence_1602','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-desmethylcitalopram (aka demethylcitalopram) --&gt; R- and S- didemethylcitalopram\n\nQuote:\n\nQuinidine (5micM) reduced formation of DDCT from R- or S-DCT to only 70 to 80% of control (Fig. 7), whereas the same concentration of quinidine reduced formation of R- and S-DCT to less than 10% of control values in heterologously expressed CYP2D6.\n\n','boycer','06/12/2009 19:29:37\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,86),(454,'evidence_1534','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP1A1 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent ','boycer','01/14/2008 13:23:51\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(455,'evidence_1461','http://www.ncbi.nlm.nih.gov/pubmed/9152603','\nEnzyme system: human liver microsomes \n\nNADPH added: yes \n\ninhibitor used: ketoconazole \n\nreaction: \nclarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin \n\ndescription: clarithromycin oxidative metabolism was nearly completely wiped out by the addition of this selective inhibitor ','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(456,'evidence_1148','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of both 14-(R)-hydroxylase-clarithromycin and  14-N-demethylase-clarithromycin in a recombinant cyp3a4 Supersome system','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(457,'evidence_1749','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f','&quot;\nWhen a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. *Nefazodone plasma concentrations were unaffected by triazolam.*&quot;','boycer','10/19/2007 16:34:37\n','Non_traceable_Drug_Label_Statement','PKStudy',0,0.2,0.025,NULL,'',NULL,NULL),(458,'evidence_1625','http://www.ncbi.nlm.nih.gov/pubmed/8830062','\nRoute of administration: oral\n\nstudy duration: 2 days treatment w/ triazolam (TRZ) alone (.25mg 1xday) followed by 7 days treatment with nevazodone alone (200mg, bid); followed by two days dosing with nevazodone + TRZ\n\npopulation: 12 male\n\nages:23-38\n\nNOTE: this evidence supports that no interaction occurs  when &lt;= 2 doses of alprazolam are co-administered with nefazodone\n\n&quot;\nNoncompartmental pharmacokinetic analysis showed that there was no effect of triazolam on the pharmacokinetics of nefazodone, HO-nefazodone, or mCPP after the coadministration of triazolam and nefazodone. There was a significant effect of 200 mg of nefazodone twice daily on the pharmacokinetics of triazolam.\n&quot; ','boycer','12/10/2007 16:03:18\n','EV_PK_DDI_RCT','PKStudy',NULL,0.2,0.00025,12,'',NULL,NULL),(459,'evidence_1874','http://www.ncbi.nlm.nih.gov/pubmed/9797793','Route of administration: oral\n\nstudy duration: 14 days pretreatment with diltiazem\n\npopulation: male: female:\n\nages:\n\nThis was a balanced, randomized, open-label, 4-way crossover study in 10 healthy volunteers, with a 2-week washout period between the phases. Study arms were (1) administration of a single dose of 20 mg lovastatin, (2) administration of a single dose of 20 mg pravastatin, (3) administration of a single dose of lovastatin after administration of 120 mg diltiazem twice a day for 2 weeks, and (4) administration of a single dose of pravastatin after administration of 120 mg diltiazem twice a day for 2 weeks. RESULTS: Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life. Diltiazem did not affect the oral AUC, Cmax, or half-life of pravastatin.','boycer','05/29/2007 11:57:17\n','EV_PK_DDI_RCT','PKStudy',0,0.02,0.12,10,'',NULL,NULL),(460,'evidence_1673','http://www.ncbi.nlm.nih.gov/pubmed/10997935','Enzyme system: recombinant human enzymes in human lymphoblastoid cells\nNADPH added:yes\n\ninhibitor used: no\n\nTable 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. ','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(461,'evidence_1647','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nMetabolism\n\nIn vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 ','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(462,'evidence_1796','http://www.ncbi.nlm.nih.gov/pubmed/9431831','\nEnzyme system: human liver microsomes\n NADPH added: yes\n inhibitor used: sulphaphenazole\n reaction: haloperidol --> 4-(4-chlorophenyl)-4-hydroxypiperidine\n Quote: Ketoconazole was a potent inhibitor of CPHP (4-(4-chlorophenyl)-4-hydroxypiperidine) formation with IC50 values of 0,10, 0,23 and 0,14 micM in microsomes HL-1, HL-6 and HL-9 respectively, wheras sulphaphenazole, furafylline and quinidine showed little inhibition (IC50 > 100micM)','boycer','06/11/2009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,87),(463,'evidence_1912','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of N-Desmethyl diltiazem using a recombinant CYP3A5 Supersome system.','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(464,'evidence_1132','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of N-Desmethyl diltiazem   using a recombinant CYP3A4 Supersome system. ','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(465,'evidence_1359','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(466,'evidence_1240','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','\n7. DRUG INTERACTIONS\n...\nIn vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by CYP2D6. ','boycer','09/24/2009 10:54:45\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(467,'evidence_1621','http://www.ncbi.nlm.nih.gov/pubmed/12891223','\n\nroute of administration: oral\n\nstudy duration: Controls: a single dose of 50 mg immediate-release metoprolol was given after 7-days of placebo. Exposed: a single dose of 50 mg immediate-release metoprolol was given after 7-days of 400 mg/day of celecoxib.\n\npopulation: 12 male volunteers \n\ntested for known CYP450 polymorphisms? Yes, all participants were genotyped as having heterozygous or homozygous extensive metabolizing CYP2D6 alleles. Participants CYP2C9 was also genotyped but no classification of the alleles appears in the paper. \n\nages: mean age 30.7 +/- 5.3\n\ndescription:\nCelecoxib increased the AUC(0-inf) of metoprolol\nsigni&amp;#64257;cantly in all 12 volunteers, by 64.4% +/-57.0% (P &lt; .001).\n\n\n\n\n','boycer','09/25/2009 09:49:39\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,88),(468,'evidence_1287','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(469,'evidence_1296','http://www.ncbi.nlm.nih.gov/pubmed/16390352','Enzyme system: recombinant human enzymes in human lymphoblastoid\nNADPH added: not explicitly mentioned but assumed\n\ninhibitor used: no\n\nQuetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4.','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(470,'evidence_1426','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6','Elimination\n\nAfter a single oral or intravenous dose of 14C-labeled pantoprazole to healthy, normal metabolizer volunteers, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion. There was no renal excretion of unchanged pantoprazole. \n','boycer','09/21/2009 15:17:23\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(471,'evidence_1186','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: dextromethorphan O-demethylation\n\nQuote: \n\nCYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors.\n\n','boycer','06/11/2009 16:25:20\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,89),(472,'evidence_1241','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(473,'evidence_1778','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/56b3f4c2-52af-4947-b225-6808ae9f26f5','&quot;Fluvoxamine\n\nThe effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady state concentration was evaluated in 10 male in-patients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased three-fold following co-administration of fluvoxamine. Fluvoxamine and thioridazine should not be co-administered&quot;','boycer','06/15/2009 15:47:28\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(474,'evidence_1806','http://www.ncbi.nlm.nih.gov/pubmed/8830063','\nNOTE: The prceip_dose value is the mean dose (+/- .866).\n\nroute of administration: oral\n\nstudy duration: 22 days\n\npopulation: 5 volunteers with major affective disorders (2 male, 3 female)\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: mean age 40.4 +/- 11.5\n\ndescription:\nSUBJECTS: Patients meeting DSM-III-R criteria for major affective disorders were admitted to the 3-West Clinical Research Unit of the Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland. Patients volunteered to participate in the clinical research program and gave oral and written informed consent for clinical trials of CBZ, VPA, and BUP, as well as other medications and associated research procedures. A thorough medical and neurologic history and examination and a pretreatment electroencephalogram were done to rule out the presence of seizure disorders and other medical illnesses. A detailed life course of illness was visually plotted and quantified for each patient as previously described. Psychiatric diagnoses were confirmed by the Schedule for Affective Disorders and Schizophrenia structured diagnostic interview. Thus, these patients were carefully characterized as having primary mood disorders (for the purpose of assessing clinical responses to medications) and lacking concurrent medical disorders that could alter pharmacokinetics. \n\nPatients and nursing staff were blind to chronic medications, as well as to the pharmacokinetic study drug being administered, in order to allow a more objective assessment of clinical responses. The blind condition was also maintained with patients and nurses by having blind &quot;CBZ&quot; and &quot;VPA&quot; concentrations drawn throughout the hospitalization, even at times when patients were not receiving either drug.\n\nMETHODS: Patients had 24-hour pharmacokinetic profiles of BUP and metabolites after single oral doses of BUP, 150 mg, while receiving placebo (N = 17) or during chronic CBZ (N = 12) or VPA (N = 5) monotherapy. Patients were on CBZ and VPA for at least 3 weeks in order to allow dosage titration and the attainment of steady state, as well as the full induction of hepatic metabolism with CBZ. The placebo, CBZ, and VPA groups did not differ significantly with respect to mean age (placebo, 38.5 +/- 10.2; CBZ, 35.4 +/- 8.7; VPA, 40.4 +/- 11.5) or gender (placebo, eight men and nine women; CBZ, seven men and five women; VPA two men and three women). Seven patients had both placebo and CBZ studies, and four patients had both placebo and VPA studies. Patients on VPA received a mean dose of 1,750 +/- 866 mg/day with a mean trough VPA concentration in plasma of 97 +/- 19 micro gram/ml. Single trough CBZ and VPA concentrations in plasma were determined during the week of the kinetic study for each patient on these agents.\n\nFor each pharmacokinetic study, a single oral dose of BUP, 150 mg, was administered at 9 a.m. in a blind fashion. Patients had nothing by mouth from 11:30 p.m. the night before until 3 hours after receiving the blind BUP dose, at which point they resumed their blinded placebo, CBZ, or VPA and their usual oral intake of food and fluids. Patients were receiving CBZ and VPA in three or four divided doses each day and missed at most a single morning dose of CBZ or VPA, so that the concentrations of these agents in plasma were maintained during the kinetic studies.\n\nRESULTS: VPA increased H-BUP C_max by 56% (p &lt; 0.09) and H-BUP AUC by 94% (p &lt; 0.02).\n','boycer','09/16/2010 14:29:59\n','EV_PK_DDI_RCT','PKStudy',1.94,0.15,1.75,5,'',NULL,NULL),(475,'evidence_1275','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','04/25/2009 10:22:07\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,90),(476,'evidence_1470','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(477,'evidence_1120','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends 7-ethoxyresorufin to be an acceptable chemical CYP1A2 substrate (7-ethoxyresorufin O-deethylation) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','06/19/2009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(478,'evidence_1276','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','Drugs Metabolized by Cytochrome P450 Isoenzymes\n\nCYP2D6: In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6. These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine to that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(479,'evidence_1699','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(480,'evidence_1427','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c103da18-a822-4944-1bd7-8ecdb5205d69','Cytochrome P450 (CYP450)\n\nCiprofloxacin is an inhibitor of the hepatic CYP1A2 enzyme pathway. Coadministration of ciprofloxacin and other drugs primarily metabolized by CYP1A2 (e.g. theophylline, methylxanthines, tizanidine) results in increased plasma concentrations of the coadministered drug and could lead to clinically significant pharmacodynamic side effects of the coadministered drug.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(481,'evidence_1268','http://www.ncbi.nlm.nih.gov/pubmed/8157044','\nRoute of administration: oral\n\nstudy duration: single dose\n\npopulation: 11 male\n\nages:20-30 \n\nThis study provides three values for f% (bioavailability) at different doses of chlorpromazine:\n\n25mg : 8.07\n50mg : 11.6\n100mg : 18.4\n\nThe 25 and 50mg values are not statistically different from one another while the 100mg value is statistically different from the other two. The value entered in for this evidence item is the simple average of the 25 and 50mg dose rounded up to the nearest tenth.','boycer','06/17/2009 08:13:00\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.1,NULL,NULL,NULL,'',NULL,NULL),(482,'evidence_1706','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a CYPC9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','06/30/2009 12:43:42\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(483,'evidence_1262','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645','Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. ','boycer','01/11/2010 16:39:16\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(484,'evidence_1985','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a weak CYP2D6 inhibitor for in vivo studies in it most recent guidance document. See Table 6, p. 23','boycer','06/30/2009 12:45:54\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(485,'evidence_1639','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645','Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. ','boycer','01/11/2010 16:40:43\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(486,'evidence_1360','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes\n\nQuote: \nInitially, we screened the cDNA-expressed CYP isoforms\n1A2, 3A4, 2C8, 2C9, 2C18, 2C19, 2D6 and 2E1 for their\nability to catalyse the N-dealkylation of perphenazine.\nOnly CYP2E1 did not display a measurable activity.','boycer','06/16/2009 13:53:30\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(487,'evidence_1987','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf',' The FDA lists this as a recommended in vivo inhibitor of CYP3A4 in it most recent guidance document. See Appendix A, Table 2, p. 19','boycer','05/21/2007 13:47:09\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(488,'evidence_1556','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','06/12/2009 19:07:47\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,91),(489,'evidence_1079','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2E1 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent\n','boycer','09/25/2007 09:01:13\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(490,'evidence_1695','http://www.ncbi.nlm.nih.gov/pubmed/16120067','route of admininistration: oral\r\n\r\nstudy duration: 5 days\r\n\r\npopulation: 16 healthy subjects (12 male, 4 female) from the UK; 14 Caucasian, 2 of African ancestry\r\n\r\ntested for known CYP450 polymorphisms?\r\nYes -- CYP2D6 and CYP2C19 genotyping -- 1 CYP2D6 poor metabolizer\r\n\r\nages: 18-45\r\n\r\ndescription:\r\nSUBJECTS: 16 healthy subjects (18-45 years; 12 male and four female (14 Caucasian and two black subjects) in the cimetidine study were recruited in the UK. CYP2D6 and CYP2C19 [genotyping] were determined according to standard methods. The results were only used to aid interpretation of the pharmacokinetic results.\r\nSTUDY DESIGN: Sixteen subjects were administered cimetidine (400 mg twice daily) or placebo for 5 days. On the morning of day 4, a single dose of 20 mg escitalopram was administered. The wash-out period was 3 weeks between the treatments.\r\nRESULTS: Cimetidine (400 mg twice daily) caused a significant increase of 72% in the AUC(0-inf) for escitalopram given as a single oral dose.\r\nA single CYP2D6 poor metabolizer was identified in each of the two studies. However, the results from these subjects were within the ranges of those from the other subjects.','boycer','09/15/2010 13:20:38\r\n','EV_PK_DDI_RCT','PKStudy',1.72,0.02,0.8,16,'',NULL,NULL),(491,'evidence_1723','http://www.ncbi.nlm.nih.gov/pubmed/9431831','\nEnzyme system: human liver microsomes\n NADPH added: yes\n inhibitor used: quinidine\n reaction: haloperidol --> 4-(4-chlorophenyl)-4-hydroxypiperidine\n Quote: Ketoconazole was a potent inhibitor of CPHP (4-(4-chlorophenyl)-4-hydroxypiperidine) formation with IC50 values of 0,10, 0,23 and 0,14 micM in microsomes HL-1, HL-6 and HL-9 respectively, wheras sulphaphenazole, furafylline and quinidine showed little inhibition (IC50 > 100micM)','boycer','06/11/2009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,92),(492,'evidence_1519','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3249','\n&quot;Cytochrome P450 3A4: In vitro and in vivo data indicate that rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent. This has been confirmed in studies with known cytochrome P450 3A4 inhibitors (ketoconazole, erythromycin, itraconazole).\n\nKetoconazole: Coadministration of ketoconazole (200 mg twice daily for 7 days) with rosuvastatin (80 mg) resulted in no change in plasma concentrations of rosuvastatin.\n\nErythromycin: Coadministration of erythromycin (500 mg four times daily for 7 days) with rosuvastatin (80 mg) decreased AUC and Cmax of rosuvastatin by 20% and 31%, respectively. These reductions are not considered clinically significant.&quot;','boycer','01/14/2008 13:14:22\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(493,'evidence_1681','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','Drug interactions:\n\nIn vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(494,'evidence_1032','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','06/19/2009 12:32:07\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(495,'evidence_1228','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','09/24/2009 14:11:19\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(496,'evidence_1521','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645','Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(497,'evidence_1357','http://www.ncbi.nlm.nih.gov/pubmed/15743977','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam-->1\'-hydroxy-midazolam\n\nQuote:\nestimated k_i from Table 2: .48 microM/L','boycer','06/25/2007 14:24:40\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.00022,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,93),(498,'evidence_1925','http://www.ncbi.nlm.nih.gov/pubmed/11422004','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nsubstrate used: testosterone\n\nreaction: testosterone--&gt;6beta-OH-testosterone\n\nQuote:\nVerapamil and diltiazem inhibited testosterone 6beta-hydroxylation in a time- and concentration-dependent manner, key features of mechanism-based inactivation. Values for the inactivation parameters kinact and KI were 0.15 +/- 0.04 min-1 (mean +/- s.d.) and 2.9 +/- 0.6 microM, respectively, for verapamil and 0.07 +/- 0.01 min-1 and 3.3 +/- 1.5 microM, respectively, for diltiazem.','boycer','07/02/2007 17:27:00\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.001,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,94),(499,'evidence_1741','http://www.ncbi.nlm.nih.gov/pubmed/10640508','\nEnzyme system: human liver microsome and recombinant human enzymes in insect cells\n\nNADPH added: yes\n\nsubstrate used: testosterone\nreaction: testosterone--&gt;6beta-OH-testosterone\n\nThis study showed significant inhibition of 6beta-OH-testosterone in enzyme systems incubated with diltiazem. IC50 = 5.0microM, Ki = .5microM ','boycer','07/03/2007 09:31:31\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.0002255,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,95),(500,'evidence_1673','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/52c09a36-879b-4b0e-b3a5-f4a4bba9bde5','\nThis drug label states multiple times that clarithromycin has the antimicrobially active metabolite 14-OH-clarithromycin\n\n','boycer','07/02/2007 12:37:05\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(501,'evidence_1015','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 14-OH-clarithromycin using a recombinant CYP3A4 Supersome system','boycer','11/17/2007 12:01:14\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(502,'evidence_1496','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/19a30c59-15da-4324-bc08-d09495dc1074','Quinidine is not metabolized by cytochrome P450IID6, but therapeutic serum levels of quinidine inhibit the action of cytochrome P450IID6, effectively converting extensive metabolizers into poor metabolizers. Caution must be exercised whenever quinidine is prescribed together with drugs metabolized by cytochrome P450IID6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(503,'evidence_1771','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(504,'evidence_1580','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/cf26b007-df4f-4936-b2d3-183969761f69','&quot;The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral routes. In normal volunteers, the bioavailability of orally administered fluconazole is over 90% compared with intravenous administration.&quot;','boycer','09/27/2007 10:42:13\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.9,NULL,NULL,NULL,'',NULL,NULL),(505,'evidence_1529','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes \n\nNADPH added: yes\n\nreaction: dextromethorphan o-demethylation\n\nKi: 9.4micM (table 2)\n\n9.4micM/L x 1M/10^6micM x 437.523g/L = .004g/L','boycer','04/25/2009 08:56:21\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.004,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,96),(506,'evidence_1272','http://www.ncbi.nlm.nih.gov/pubmed/15518608','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days simvastatin only, 8 days simva and clarithromycin\n\ndose: .040g simvastatin 1xday\n.5g clarithromycin 2xday\n\npopulation: 45 men and women\n\nages:18-60\n\n(mean AUC_i)/(mean AUC) = 73/6\n\ndescription: Clarithromycin significantly increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC) and simvastatin acid (12-fold)','boycer','05/29/2007 15:29:12\n','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,97),(507,'evidence_1228','http://www.ncbi.nlm.nih.gov/pubmed/9542477','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 4 days\n\npopulation: 7 male, 3 female\n\nages:19-29\n\ndescription:\nTwo randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001).','boycer','06/25/2007 15:56:14\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,98),(508,'evidence_1409','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01','\nNOTE: This value is for the extended release formulation. Table 1 of the drug label lists PK parameters for lovastatin and &quot;lovastatin acid&quot; (beta-hydroxy-lovastatin) for both the immediate and extended release forms.\n\nLovastatin (immediate release):5.5ng/ml\nLovastatin (extended release):7.8ng/ml\nLovastatin acid (immediate release):5.8ng/ml\nLovastatin acid (extended release):11.9ng/ml ','boycer','09/28/2007 13:37:55\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.0000119,NULL,NULL,NULL,'',0.04,NULL),(509,'evidence_1144','http://www.ncbi.nlm.nih.gov/pubmed/9855322','\nNOTE: The object dose is the dose of aminophylline and is equivalent to 0.2765 g of anhydrous theophylline. The AUC_i/AUC is from table 2.\n\nroute of administration: iv (object), oral (precip)\n\nstudy duration: 9 days\n\npopulation: 7 healthy subjects (all male); 5 smokers, 2 nonsmokers\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 25-44\n\ndescription:\nSUBJECTS: 7 subjects in group 2 (5 smokers, 2 nonsmokers) age ranged from 25-44 (mean 34 +/- 8.3yrs.) and weight from 69.9-81.2 kg (mean 74.0 +/- 4.2 kg). Eighty-four percent of subjects were smokers. Sixty-three percent were Caucasian and 37% were African-American.\n\nMETHODS: A two-way, randomized, crossover study was performed to assess the pharmacokinetics of theophylline administered with placebo or after administration of 9 days of dosing with either olanzapine or cimetidine. Subjects were divided into two groups. Group 1 received theophylline after olanzapine or placebo and group 2 received theophylline after cimetidine or placebo. Cimetidine (Tagamet) 400 mg orally 3 times/day was administered approximately every 8 hours for 9 days (27 total doses). Placebo was administered in the same manner as cimetidine or olanzapine, corresponding to study group. Aminophylline was admininstered as a single intravenous dose of 350 mg over 30 minutes on the last day of each treatment period, 1 hour after the morning dose of olanzapine, cimetidine or placebo. This dose is equivalent to 276.5 mg of anhydrous theophlline.\n\nRESULTS: Administration of aminophylline with cimetidine resulted in a statistically significant increase in theophylline AUC and half-life.','boycer','09/16/2010 13:53:17\n','EV_PK_DDI_Par_Grps','PKStudy',1.458,0.35,1.2,7,'',NULL,NULL),(510,'evidence_1923','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends chlorzoxazone to be an acceptable chemical CYP2E1 substrate (chlorzoxazone 6-hydroxylation) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','02/12/2010 17:51:24\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(511,'evidence_1364','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/773c3627-1635-4415-a89a-aaf74329f9c2','CLINICAL PHARMACOLOGY\n...\nPropoxyphene is metabolized in the liver to yield norpropoxyphene. Propoxyphene has a half&amp;#8209;life of 6 to 12 hours, whereas that of norpropoxyphene is 30 to 36 hours.\n\nNorpropoxyphene has substantially less central&amp;#8209;nervous&amp;#8209;system&amp;#8209;depressant effect than propoxyphene, but a greater local anesthetic effect, which is similar to that of amitriptyline and antiarrhythmic agents, such as lidocaine and quinidine.','boycer','09/24/2009 13:04:47\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(512,'evidence_1274','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(513,'evidence_1931','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.75,NULL,NULL,NULL,'',NULL,NULL),(514,'evidence_1797','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','Sertraline is listed as a moderate inhibitor in Table 6 (p23) but does not show up in Table 2 (a table listing several selective in viVo inhibitors)','boycer','04/29/2009 20:01:03\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(515,'evidence_1210','http://www.ncbi.nlm.nih.gov/pubmed/11910262','Route of administration: oral\n\nstudy duration: read description below\n\npopulation: (sertraline group) 12 healthy volunteers (8 male and 4 female), all extensive metabolizers of dextromethorphan\n\nages: mean(std dev): 27 (unknown)\n\nDescription: \nIn an open label, parallel group study of 45 healthy volunteers, the time course of CYP2D6 inhibition of the above SSRIs was evaluated. Subjects were randomized to receive paroxetine at 20 mg/day for 10 days; sertraline at 50 mg/day for 3 days, followed by sertraline at 100 mg/day for 10 days; or fluoxetine at 20 mg/day for 28 days. CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine. Following SSRI discontinuation, calculation of a CYP2D6 inhibition half-life (t(1/2)inh) revealed the time course of fluoxetine inhibition (t(1/2)inh = 7.0 +/- 1.5 days) to be significantly longer than either paroxetine (t(1/2)inh = 2.9 +/- 1.9) or sertraline (t(1/2)inh = 3.0 +/- 3.0) (p &lt; 0.01), but the latter were not significantly different from each other (p &gt; 0.05). Time for the extrapolated DMR versus time log-linear plots to return to baseline was significantly different between fluoxetine (63.2 +/- 5.6 days) and both paroxetine (20.3 +/- 6.4 days) and sertraline (25.0 +/- 11.0 days) (p &lt; 0.01), making the rank order (from longest to shortest) of time for CYP2D6 inhibition to dissipate: fluoxetine &gt; sertraline &gt;or= paroxetine. Differences between mean baseline DMR values and measured values obtained after drug discontinuation for each drug group became nonsignificant on discontinuation day 5 for both paroxetine and sertraline and on discontinuation day 42 for fluoxetine. ','boycer','05/05/2009 17:06:30\n','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,99),(516,'evidence_1197','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1de3ed9-1cb8-e419-3f25-5b0aeed5779a','Drugs Metabolized by P450 2D6\n\nMany drugs effective in the treatment of major depressive disorder, e.g., the SSRIs, including sertraline, and most tricyclic antidepressant drugs effective in the treatment of major depressive disorder inhibit the biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase), and, thus, may increase the plasma concentrations of coadministered drugs that are metabolized by P450 2D6. The drugs for which this potential interaction is of greatest concern are those metabolized primarily by 2D6 and which have a narrow therapeutic index, e.g., the tricyclic antidepressant drugs effective in the treatment of major depressive disorder and the Type 1C antiarrhythmics propafenone and flecainide. The extent to which this interaction is an important clinical problem depends on the extent of the inhibition of P450 2D6 by the antidepressant and the therapeutic index of the coadministered drug. There is variability among the drugs effective in the treatment of major depressive disorder in the extent of clinically important 2D6 inhibition, and in fact sertraline at lower doses has a less prominent inhibitory effect on 2D6 than some others in the class. Nevertheless, even sertraline has the potential for clinically important 2D6 inhibition. Consequently, concomitant use of a drug metabolized by P450 2D6 with sertraline may require lower doses than usually prescribed for the other drug. Furthermore, whenever sertraline is withdrawn from cotherapy, an increased dose of the coadministered drug may be required (see PRECAUTIONS: Drug Interactions: Tricyclic Antidepressant Drugs Effective in the Treatment of Major Depressive Disorder). ','boycer','05/15/2009 10:42:02\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(517,'evidence_1326','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(518,'evidence_1274','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','7.1 Potential for REYATAZ to Affect Other Drugs\n\nAtazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(519,'evidence_1625','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(520,'evidence_1975','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','7.1 Potential for REYATAZ to Affect Other Drugs \n\nAtazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.\ntype: Non_traceable_Drug_Label_Statement ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(521,'evidence_1244','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/cf26b007-df4f-4936-b2d3-183969761f69','\nRoute of administration: oral/iv\n\nstudy duration: six days of fluconazole with 3 administrations of midazolam; once on day 1, day 3, and day 6.\n\npopulation: 12\n\nages: ?\n\nAUC_i/AUC: 2.59\n\n\nQuote:\nThe effect of fluconazole on the pharmacokinetics and pharmacodynamics of midazolam was examined in a randomized, crossover study in 12 volunteers. In the study, subjects ingested placebo or 400 mg fluconazole on Day 1 followed by 200 mg daily from Day 2 to Day 6. In addition, a 7.5 mg dose of midazolam was orally ingested on the first day, 0.05 mg/kg was administered intravenously on the fourth day, and 7.5 mg orally on the sixth day. Fluconazole reduced the clearance of IV midazolam by 51%. On the first day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 150%, respectively. On the sixth day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 74%, respectively. The psychomotor effects of midazolam were significantly increased after oral administration of midazolam but not significantly affected following intravenous midazolam.','boycer','10/22/2007 12:38:50\n','Non_traceable_Drug_Label_Statement','PKStudy',2.59,0.0075,0.2,12,'',NULL,NULL),(522,'evidence_1153','http://www.ncbi.nlm.nih.gov/pubmed/8623953','\nRoute of administration: oral\n\nstudy duration: randomized cross-over design; participants given placebo or 400mg fluconazole on day 1 and 200mg days 2 to 6. A single dose of 7.5mg oral MDZ was given on day 1 and day 6 while .05mg/kg of IV MDZ was given on day 4. \n\npopulation: 12 healthy volunteers, 7 male, 5 female\n\nages: 19-25\n\n\nDay 1 (AUC is 0-infinity) AUC_i/AUC = 3.513\nDay 6 (AUC is 0-infinity) AUC_i/AUC = 3.6\n\n','boycer','11/13/2007 08:06:22\n','EV_PK_DDI_RCT','PKStudy',3.55,0.0075,0.2,12,'',NULL,NULL),(523,'evidence_1400','http://www.ncbi.nlm.nih.gov/pubmed/9049584','\n\nRoute of administration: oral\n\nstudy duration: a single dose of 400mg oral fluconazole followed by a single dose of 7.5mg midazolam 60 minutes later\n\npopulation: 4 female and 5 male\n\nages: 19-25\n\nAUC_i/AUC (0-inf):421/113 = 3.726\n\nNOTE: The study shows a decrease in the ratio of 1-OH-MDZ to MDZ in the presence of fluconazole indicating that less of the parent is being converted to metabolite\n\n\ndescription: \nA double-dummy, randomized, cross-over study in three phases was performed in 9 healthy volunteers. The subjects were given orally fluconazole 400 mg and intravenously saline within 60 min; orally placebo and intravenously fluconazole 400 mg; and orally placebo and intravenously saline. An oral dose of 7.5 mg midazolam was ingested 60 min after oral intake of fluconazole/placebo, i.e. at the end of the corresponding infusion. Plasma concentrations of midazolam, alpha-hydroxymidazolam and fluconazole were determined and pharmacodynamic effects were measured up to 17 h. RESULTS: Both oral and intravenous fluconazole significantly increased the area under the midazolam plasma concentration-time curve (AUC0-3, AUC0-17) 2- to 3-fold, the elimination half-life of midazolam 2.5-fold and its peak concentration (Cmax) 2- to 2.5-fold compared with placebo. The AUC0-3 and the Cmax of midazolam were significantly higher after oral than after intravenous administration of fluconazole. Both oral and intravenous fluconazole increased the pharmacodynamic effects of midazolam but no differences were detected between the fluconazole phases.','boycer','12/10/2007 15:09:10\n','EV_PK_DDI_RCT','PKStudy',3.726,0.0075,0.4,9,'',NULL,NULL),(524,'evidence_1007','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(525,'evidence_1183','http://www.ncbi.nlm.nih.gov/pubmed/15258107','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: bufuralol\n\nreaction: bufuralol 1\'hydroxylation\n\nIC50 &gt; 200micM (see Table 3)\n\nQuote:\nCYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. ','boycer','09/23/2009 11:41:27\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,100),(526,'evidence_1911','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a preferred chemical 3a4 substrate (CYP3A4-->(testosterone -> 6beta-hydroxy-testosterone)) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','05/21/2007 10:32:12\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(527,'evidence_1750','http://www.ncbi.nlm.nih.gov/pubmed/18307373','NOTE: The AUC_i/AUC is from the combined male and female study results. The object dose was given intravenously as a 250 mg dose of aminophylline over 30 minutes.\r\n\r\nroute of administration: oral (duloxetine)/IV (theophylline)\r\n\r\nstudy duration: 5 days\r\n\r\npopulation: 28 healthy non-smokers (10 male, 18 female)\r\n\r\ntested for known CYP450 polymorphisms? No\r\n\r\nages: 18-55\r\n\r\ndescription:\r\n\r\nIn the nonsmoking men-only study, 10 of 11 subjects completed the study. One subject was withdrawn because of reports of several adverse events (cause not documented) before receiving the study drug. The mean (+/-SD) age of the subjects was 33 +/- 9 years, the mean height was 174.2 +/- 7.2 cm, the mean bodyweight was 73.9 +/- 9.3 kg and the mean BMI was 24.3 +/- 2.0 kg/m2. All subjects were Caucasian. In the nonsmoking women-only study, 18 of 20 subjects completed the study. Two subjects were withdrawn; one had mild to moderate adverse events related to duloxetine administration, and the other, who received only placebo, had poor venous access. The mean (+/-SD) age of the subjects was 38.2 +/- 9.8 years, the mean height was 166.5 +/- 7 cm, the mean bodyweight was 75.3 +/- 10 kg and the mean BMI was 27.1 +/- 2.8 kg/m2. Sixty percent of the subjects were Caucasian and the rest were African American.\r\n\r\nMETHODS:\r\nThe separate studies in women and men were designed identically as single-centre, subject-blind, randomized, two-way, two-period, balanced crossover studies. Duloxetine was administered in a subject-blind manner, but the infusion of aminophylline was open-label. In each period, duloxetine 60 mg and placebo were given orally twice daily on days 14 and once on the morning of day 5. On day 5, theophylline 197.5 mg was given as a 30-minute intravenous infusion of aminophylline 250 mg. Each aminophylline dose was separated by at least 17 days.\r\n\r\nRESULTS:\r\nIn men, the presence of duloxetine was associated with a small, statistically insignificant increase of 7% in the theophylline C_max and the AUC_inf (table IV). However, in women, there was a statistically significant increase in the theophylline C_max (9%) and the AUC_inf (20%). When the results from both men and women were combined, there was a statistically significant increase in the theophylline AUC_inf (13%) but not in the C_max (7%). Nonetheless, the change in the theophylline AUC_inf in the presence of duloxetine was small, and the 90% CI was within the 0.81.25 equivalence range for men, and for men and women combined, but narrowly missed the upper boundary of the equivalence range in women (0.81.27).','boycer','08/23/2010 14:30:03\r\n','EV_PK_DDI_RCT','PKStudy',1.13,0.1975,0.12,28,'',NULL,NULL),(528,'evidence_1376','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f','\nDrugs that affect drug metabolism via cytochrome P450:\nSome compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes has not been carefully evaluated.\n\nA randomized, double-blind, crossover interaction study in ten healthy volunteers between itraconazole (200 mg once daily for 4 days) and a single dose of zolpidem tartrate (10 mg) given 5 hours after the last dose of itraconazole resulted in a 34% increase in AUC0-inf of zolpidem tartrate. There were no significant pharmacodynamic effects of zolpidem on subjective drowsiness, postural sway, or psychomotor performance.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(529,'evidence_1883','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f','\nCo-administration of a single dose of zolpidem tartrate with 4 doses of ketoconazole, a potent CYP3A4 inhibitor increased Cmax of zolpidem (30%) and the total AUC of zolpidem (70%) compared to zolpidem alone and prolonged the elimination half-life (30%) along with an increase in the pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together. Patients should be advised that use of Edluar with ketoconazole may enhance the sedative effects.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(530,'evidence_1778','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: bufuralol 1\'hydroxylation\n\nK_i = 16micM\n\n16micM/1L x 1M/10^6micM x 426.484g/1M = 0.007g/1L','boycer','06/22/2009 12:14:13\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.007,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,101),(531,'evidence_1768','http://www.ncbi.nlm.nih.gov/pubmed/16120067','route of admininistration: oral\r\n\r\nstudy duration: 6 days\r\n\r\npopulation: 16 healthy subjects (8 male, 8 female) from the UK; 15 Caucasian, 1 of African ancestry\r\n\r\ntested for known CYP450 polymorphisms?\r\nYes -- CYP2D6 and CYP2C19 genotyping -- 1 CYP2D6 poor metabolizer\r\n\r\nages: 18-45\r\n\r\ndescription:\r\nSUBJECTS: 16 healthy subjects (18-45 years; eight male and eight female (15 Caucasian and one black subject) in the omeprazole study were recruited in the UK. CYP2D6 and CYP2C19 [genotyping] were determined according to standard methods. The results were only used to aid interpretation of the pharmacokinetic results. \r\nSTUDY DESIGN: Sixteen subjects were administered omeprazole (30 mg once daily) or placebo for 6 days. On the morning of day 5, a single dose of 20 mg escitalopram was administered. The wash-out period was 3 weeks between the treatments. \r\nRESULTS: Omeprazole (30 mg once daily) caused a significant increase (+51%) in the AUC(0-inf) for escitalopram given as a single 20 mg oral dose.\r\nA single CYP2D6 poor metabolizer was identified in each of the two studies. However, the results from these subjects were within the ranges of those from the other subjects.','boycer','09/15/2010 13:07:44\r\n','EV_PK_DDI_RCT','PKStudy',1.51,0.02,0.03,16,'',NULL,NULL),(532,'evidence_1106','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: dextromethorphan O-demethylation\n\nQuote: \n\nCYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors. ','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(533,'evidence_1693','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(534,'evidence_1907','http://www.ncbi.nlm.nih.gov/pubmed/8866916','\nEnzyme system: human liver microsomes:\n\nNADPH added: \n\nsubstrate used: tolbutamide\n\nreaction: tolbutamide 4-hydroxylation\n\nKi = 715 micM\n\nMW: 312.43366\n\n715micM/L X 1M/10^6micM X 312.43366g/M = 0.223g/L\n','boycer','02/13/2010 08:29:48\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.223,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,102),(535,'evidence_1983','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(536,'evidence_1713','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: dextromethorphan-o-demethylation\n\nk_i = 39micM\n\n39micM/L x 1M/10^6micM x 326.83g/1M = 0.013g/L ','boycer','05/06/2009 13:38:12\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.013,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,103),(537,'evidence_1505','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','04/29/2009 19:42:40\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(538,'evidence_1941','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','Renal: There is limited information on the pharmacokinetics of bupropion in patients with renal impairment. An inter-study comparison between normal subjects and patients with end-stage renal failure demonstrated that the parent drug Cmax and AUC values were comparable in the 2 groups, whereas the hydroxybupropion and threohydrobupropion metabolites had a 2.3- and 2.8-fold increase, respectively, in AUC for patients with end-stage renal failure. The elimination of the major metabolites of bupropion may be reduced by impaired renal function (see  PRECAUTIONS: Renal Impairment).','boycer','05/14/2009 16:37:18\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(539,'evidence_1676','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','Route of administration: oral\n\nstudy duration: not mentioned\n\npopulation: 24 (adults inferred)\n\nages: mean(std dev): not mentioned\n\n\nQuote:\nHaloperidol\n\nVenlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC. In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged. The mechanism explaining this finding is unknown. ','boycer','05/15/2009 10:17:11\n','Non_traceable_Drug_Label_Statement','PKStudy',1.7,0.002,0.15,24,'',NULL,NULL),(540,'evidence_1272','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(541,'evidence_1165','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA, in it most recent guidance document, recommends this as a chemical inhibitor of CYP2B6 for in vitro experiments at a K_i of 0.5micM. See Table 2, p. 28\n\n0.5micM/L X 1M/10^6micM X 321.822g/M = 0.0001609g/L','boycer','06/30/2009 13:30:47\n','Non_Tracable_Statement','In_vitro_inhibition_study',0.0001609,NULL,NULL,NULL,'none_assigned',NULL,NULL),(542,'evidence_1364','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','09/24/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(543,'evidence_1873','http://www.ncbi.nlm.nih.gov/pubmed/6861848','\nRoute of administration: oral\n\nstudy duration: single dose of diltiazem \n\npopulation: 12 subjects, unknown gender distribution\n\nages:20-26\n\nThe mean peak plasma concentration was found to be 54.3ng/ml','boycer','07/02/2007 16:59:47\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000543,NULL,NULL,NULL,'',0.06,NULL),(544,'evidence_1575','http://www.ncbi.nlm.nih.gov/pubmed/6684932','\n\nRoute of administration: oral\n\nstudy duration: single dose diltiazem 120mg PO \n\npopulation: 6 male \n\nages:22-31\n\nC_max ranged from 34 to 86ng/ml with a mean of 60.7ng/ml\n\n','boycer','07/02/2007 17:22:14\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00006067,NULL,NULL,NULL,'',0.12,NULL),(545,'evidence_1030','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: S-mepheytoin 4\'hydroxylation\n\nQuote:\n\nCYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI\nfluvoxamine (see Table 2). ','boycer','06/12/2009 11:34:51\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,104),(546,'evidence_1877','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(547,'evidence_1012','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(548,'evidence_1663','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 4-OH-midazolam using a recombinant CYP3A4 Supersome system (Km = 59microM).','boycer','07/02/2007 11:31:48\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(549,'evidence_1221','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/151ffcf4-e503-4954-af7c-93d0a4f9f80','\nDrug Interactions:\n\n...\nIn vitro studies of drug metabolism indicate that M1 inhibits CYP 450 2C9, which is responsible for the metabolism of phenytoin, tolbutamide, warfarin and many NSAIDs. ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(550,'evidence_1427','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=8876','Human metabolic studies show MOBAN to be rapidly absorbed and metabolized when given orally. Unmetabolized drug reached a peak blood level at 1.5 hours.\n\nPharmacological effect from a single oral dose persists for 24-36 hours. There are 36 recognized metabolites with less than 2-3% unmetabolized MOBAN being excreted in urine and feces.','boycer','04/29/2009 19:57:05\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(551,'evidence_1257','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: recombinant human enzymes (human lymphoblastoid)\n\nNADPH added: yes (a dehydrogenase generating system) \n\ninhibitor used: no\n\nThis study showed NO formation of didesmethylcitalopram (aka didemethylcitalopram) in a recombinant human lymphoblastoid cell system','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(552,'evidence_1713','http://www.ncbi.nlm.nih.gov/pubmed/14667956','\n\nRoute of administration: oral/IV\n\nstudy duration: on day 1 participants received either one dose of 10mgPO rosuvastatin or one IV infusion of 8mg rosuvastatin; a period of &gt;=7 days elapsed and the participants were given the drug form that they did not receive the first time they came in to the clinic. \n\npopulation: 10 male\n\nages:21-51\n\nDescription:\n\nTable 1, pg2558 shows, among other PK values, that the geometric mean of oral Cmax was 18.8ng/ml, bioavailabity (F) was calculated to be 20% of the oral dose, the hepatic extraction (E_H)ratio was .63 \n\nBased on these values the authors calculated absorbtion to be &quot;appreciably greater than 20% and estimate it to ~50% using F/(1-E_H). ','boycer','09/28/2007 12:38:26\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000188,NULL,NULL,NULL,'',0.01,NULL),(553,'evidence_1757','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','7.18 CYP3A4 and -2C19 Inhibitors\n\nIn vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.\n\n','boycer','05/15/2009 10:09:13\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(554,'evidence_1648','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','06/12/2009 19:03:08\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,105),(555,'evidence_1117','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/6c76e98d-b8c3-441f-bac5-a9de6dc8f14f','Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours. In a study in which normal volunteers (n=12) received perphenazine 4 mg q8h for 5 days, steady-state concentrations of perphenazine were reached within 72 hours. Mean (%CV) Cmax and Cmin values for perphenazine and 7-hydroxyperphenazine at steady-state are listed below:\n\nParameter	Perphenazine	7-Hydroxyperphenazine\nCmax (pg/mL)	984 (43)	509 (25)\nCmin (pg/mL)	442 (76)	350 (56)','boycer','05/06/2009 12:58:56\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000000984,NULL,NULL,NULL,'',0.004,NULL),(556,'evidence_1340','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','Absorption and Distribution\n\nFollowing a single oral dose (20 mg tablet or solution) of escitalopram, peak blood levels occur at about 5 hours. Absorption of escitalopram is not affected by food.\n\nThe absolute bioavailability of citalopram is about 80% relative to an intravenous dose, and the volume of distribution of citalopram is about 12 L/kg. Data specific on escitalopram are unavailable.\n\nThe binding of escitalopram to human plasma proteins is approximately 56%.\n\n','boycer','05/15/2009 09:52:39\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.8,NULL,NULL,NULL,'',NULL,NULL),(557,'evidence_1434','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA guidance considers (S)-mephenytoin 4-hydroxylation to be catalyzed selectively by CYP2C19 in vitro (see Table 3 of page 32) and lists it as a \'sensitive\' CYP2C19 substrate in vivo (see Table 4 page 21)','boycer','06/17/2009 13:15:05\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(558,'evidence_1038','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\n7.6 Combined Administration with Clarithromycin\n\nCombined administration consisting of rabeprazole, amoxicillin, and clarithromycin resulted in increases in plasma concentrations of rabeprazole and 14-hydroxyclarithromycin.{See CLINICAL PHARMACOLOGY, Combined Administration with Antimicrobials (12.3)}.\n\n','boycer','09/24/2009 13:56:23\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,106),(559,'evidence_1166','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\nMetabolism: \n...\nIn vitro studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole.','boycer','09/24/2009 13:58:07\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(560,'evidence_1115','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','CYP1A2: Venlafaxine did not inhibit CYP1A2 in vitro. This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.','boycer','05/14/2009 13:48:13\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(561,'evidence_1896','http://www.ncbi.nlm.nih.gov/pubmed/9205822','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nreaction: 7-O-deethylation of ethoxyresorufin to resorufin\n\nQuote: \nThe IC50 for venlafaxine\'s inhibition of the reaction was &gt; 1000micM \n\n\n','boycer','02/12/2010 14:12:02\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,107),(562,'evidence_1706','http://www.ncbi.nlm.nih.gov/pubmed/10073324','\n\nroute of administration: oral\n\nstudy duration: single doses of caffeine (200mg NoDoz) on days 1 and 8; venlafaxine 37.5 mg bid days 2-4 and 75 mg bid days 5-8.\n\npopulation:16 healthy volunteers (1 later dropped out); 9 male 7 female  \n\ntested for known CYP450 polymorphisms? no\n\nages: 21 - 41\n\ndescription:\nThe treatments did not differ significantly with respect to AUC, C_max, or clearance though there was a small but statistically significant decrease in caffeine half-life\n\n\n','boycer','02/12/2010 14:37:56\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,108),(563,'evidence_1739','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-desmethylcitalopram (aka demethylcitalopram) --&gt; R- and S- didemethylcitalopram\n\nQuote:\n\nQuinidine (5micM) reduced formation of DDCT from R- or S-DCT to only 70 to 80% of control (Fig. 7), whereas the same concentration of quinidine reduced formation of R- and S-DCT to less than 10% of control values in heterologously expressed CYP2D6.\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(564,'evidence_1708','http://www.ncbi.nlm.nih.gov/pubmed/9871431','\nroute of administration: oral\n\nstudy duration: two days\n\npopulation: 12 healthy volunteers (8 male, 4 female); non-smokers\n\ntested for known CYP450 polymorphisms?\nN/A\n\nages: 20 - 40\n\ndescription:\nTwelve healthy volunteers (8 men and 4 women), aged 20 to 40 years, participated after giving written informed consent. All were active ambulatory non-smoking adults, with no evidence of medical disease and taking no other medications. Female subjects were not taking oral contraceptives and did not have contraceptive implants.\n   The study had a double-blind, randomized, 5-way\ncrossover design, with at least 7 days elapsing between\ntreatments. Medications were separately and identically\npackaged in opaque capsules and administered orally. At 8 AM on study day 1, subjects entered the outpatient Clinical Psychopharmacology Research Unit where they received the initial dose of azole (or\nplacebo) and remained under observation for 30 minutes. Subjects took a second dose of azole (or placebo) at home at 4 PM on day 1. On the morning of day 2, after ingesting a standardized light breakfast with no caffeine-containing food or beverages and no grapefruit juice, they returned to the Research Unit at approximately 7:30 AM. They fasted until 12 noon, after which they resumed a normal diet (without grapefruit juice or caffeine-containing food or beverages). The third dose of azole (or placebo) was given at 8 AM, and the single dose of zolpidem or placebo was given at 9 AM. A final azole (or placebo) dose was given at 5 PM.\n    Coadministration of zolpidem with ketoconazole (treatment C) significantly prolonged zolpidem elimination half-life, increased total AUC, and decreased apparent oral clearance when compared to zolpidem plus placebo (treatment B; Figure 3 and Table II). Zolpidem AUC during treatment C was increased by a factor of 1.83 + 0.24 (mean +/- SE) compared to treatment B values, and clearance during treatment C was reduced to 64% +/- 7% of treatment B values.\n\n','boycer','08/10/2010 14:42:58\n','EV_PK_DDI_RCT','PKStudy',1.83,0.005,0.4,12,'',NULL,NULL),(565,'evidence_1665','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(566,'evidence_1493','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','Pharmacokinetics\n\nVenlafaxine is well absorbed and extensively metabolized in the liver. O-desmethylvenlafaxine (ODV) is the only major active metabolite. On the basis of mass balance studies, at least 92% of a single dose of venlafaxine is absorbed. ','boycer','05/15/2009 10:33:05\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.92,NULL,NULL,NULL,'',NULL,NULL),(567,'evidence_1594','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.025,NULL,NULL,NULL,'',NULL,NULL),(568,'evidence_1969','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(569,'evidence_1411','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(570,'evidence_1579','http://www.ncbi.nlm.nih.gov/pubmed/7690693','\nroute of administration: oral\n\nstudy duration: single dose\n\npopulation: 12 males, phenotyped using dextromethorphan (9 2D6 EMs, 2 PMs, 1 IM)\n\nages: 24 (SD:6) \n\nQuote:\nThe pharmacokinetics of a novel antipsychotic agent, risperidone, and the prolactin response were studied in 12 dextromethorphan-phenotyped healthy men after administration of 1 mg risperidone intravenously, intramuscularly, and orally. The formation of the equipotent major metabolite, 9-hydroxyrisperidone, exhibited CYP2D6-related polymorphism. The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers','boycer','06/17/2009 13:29:24\n','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,109),(571,'evidence_1931','http://www.ncbi.nlm.nih.gov/pubmed/10048600','\nEnzyme system: human liver microsomes:\n\nNADPH added: not mentioned but acceptable methods assumed\n\ninhibitor used: quinidine\n\nreaction: risperidone 9-hydroxylation\n\nNOTE: experiment used 100micM of risperidone which is likely well above C_max based on PMID 7690693\n\nQuote: \nrisperidone was incubated with human liver microsomes in the presence of different concentrations of   inhibitors of CYP enzymes. Both quinidine (inhibitor of CYP2D6) and ketoconazole (inhibitor of CYP3A) inhibited the formation of 9-hydroxyrisperidone in a concentration-dependent manner (Fig. 4).\n\n\n\n','boycer','02/13/2010 09:39:40\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,110),(572,'evidence_1323','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','04/29/2009 19:46:08\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(573,'evidence_1644','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.2,NULL,NULL,NULL,'',NULL,NULL),(574,'evidence_1640','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-desmethylcitalopram (aka demethylcitalopram) --&gt; R- and S- didemethylcitalopram\n\nQuote:\n\nQuinidine (5micM) reduced formation of DDCT from R- or S-DCT to only 70 to 80% of control (Fig. 7), whereas the same concentration of quinidine reduced formation of R- and S-DCT to less than 10% of control values in heterologously expressed CYP2D6.\n\n','boycer','06/12/2009 19:30:06\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,111),(575,'evidence_1939','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(576,'evidence_1355','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 13:40:40\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(577,'evidence_1943','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 13:39:31\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(578,'evidence_1176','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4. Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects (see CONTRAINDICATIONS and WARNINGS). Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01/11/2010 16:31:55\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(579,'evidence_1821','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Sildenafil:  The results of one published study in HIV-infected men (n=6) indicated that coadministration of indinavir (800 mg every 8 hours chronically) with a single 25-mg dose of sildenafil resulted in an 11% increase in average AUC0-8hr of indinavir and a 48% increase in average indinavir peak concentration (Cmax) compared to 800 mg every 8 hours alone. Average sildenafil AUC was increased by 340% following coadministration of sildenafil and indinavir compared to historical data following administration of sildenafil alone (see WARNINGS, Drug Interactions and PRECAUTIONS, Drug Interactions).','boycer','01/11/2010 16:59:43\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,112),(580,'evidence_1859','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','\nMetabolism and elimination \n...\nThe major oxidative metabolite formed, regardless of CYP2D6 status, is 4hydroxyatomoxetine, which is glucuronidated. 4Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes. NDesmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs).\n\n','boycer','09/24/2009 11:35:28\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(581,'evidence_1348','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(582,'evidence_1464','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(583,'evidence_1357','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(584,'evidence_1668','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: tolbutamide hydroxylation\n\nThe IC50 for ziprasidone inhibition of this reaction was greater than 100micM \n\n\n','boycer','06/19/2009 17:08:33\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,113),(585,'evidence_1620','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 4-OH-midazolam using a recombinant CYP3A5 Supersome system (Km = 116microM).','boycer','07/02/2007 11:32:52\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(586,'evidence_1448','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of both 1\'-OH-midazolam and 4-OH-midazolam in a recombinant cyp3a4 Supersome system','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(587,'evidence_1586','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','CYP3A4 Inhibitors: In vitro studies indicate that venlafaxine is likely metabolized to a minor, less active metabolite, N-desmethylvenlafaxine, by CYP3A4. Because CYP3A4 is typically a minor pathway relative to CYP2D6 in the metabolism of venlafaxine, the potential for a clinically significant drug interaction between drugs that inhibit CYP3A4-mediated metabolism and venlafaxine is small.','boycer','06/09/2009 19:52:03\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(588,'evidence_1695','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes \n\nHPLC with UV detection identified the formation of O-desmethyl- and N-desmethylvenlafaxine in HLMs\n','boycer','06/15/2009 16:20:45\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(589,'evidence_1210','http://www.ncbi.nlm.nih.gov/pubmed/10579479','\nNOTE: The AUC_i/AUC value given is for the r-propafenone enantiomer and calculated from Table I.\n\nroute of administration: oral\n\nstudy duration: 10 days\n\npopulation: 9 healthy Chinese volunteers (7 male, 2 female), all nonsmokers and non-drinkers\n\ntested for known CYP450 polymorphisms?\nYES -- CYP2D6 phenotyping - All classified as extensive metabolizers\n\nages: 24-46\n\ndescription:\nSUBJECTS: Nine healthy Chinese volunteers (seven men and two women) were included in the study. The ages ranged from 24 to 46 years and their weights ranged 50 to 75 kg. All subjects were healthy as assessed by a physical examination, an ECG, and blood biochemistry testing. None of the subjects smoked tobacco or drank alcohol. All subjects abstained from drugs for at least 2 weeks before and during the study. Subjects were excluded if they were receiving any medications known to induce or inhibit cytochrome P450. Pregnant women were excluded by a test for serum human chorionic gonadotropin. This study was approved by the Ethics Committee of Nanjing Medical University (Nanjing, China). Written informed consent was obtained from all subjects.\n\nCYP2D6 phenotype: The urinary molar metabolic ratio (MR) of the subjects was calculated by use of the equation: [MR = Dextromethorphan (mg/L)/dextrorphan (mg/L) x 0.948]. Phenotype was determined on the basis of an MR value according to the method of Schmid et al. Any subject with an MR &gt;0.3 was classified as a poor metabolizer; subjects with MR values &lt;=0.3 were classified as an extensive metabolizer.\n\nMETHODS: The study was divided into two phases. The first phase examined baseline dextromethorphan metabolic phenotyping and baseline pharmacokinetics of propafenone enantiomers. The second phase was a repeat of the first phase except that it was conducted after subjects took 20 mg/day fluoxetine for 10 days. There was at least a 2-week washout period between the two phases.\n\nRESULTS: All nine subjects had dextromethorphan MR values &lt;0.3 at baseline and were classified as having an extensive metabolizer phenotype for CYP2D6. The dextromethorphan MR for all subjects remained at less than 0.3 after pretreatment with fluoxetine (20 mg/day) for 10 days. However, there were significant differences of mean MR values before and after fluoxetine therapy (0.028 +/- 0.031 versus 0.080 +/- 0.058; P = .001), indicating a strong inhibition of the CYP2D6 activity by fluoxetine in Chinese subjects.\n\nMetabolism of propafenone enantiomers was also impaired significantly after fluoxetine. For S-propafenone, AUC_(0-[infinity]) increased from 2238.3 +/- 725.2 ug x h x L-1 at baseline to 3371.2 +/- 986.7 ug x h x L-1 (P = .001). For R-propafenone, AUC_(0-[infinity]) also increased from 1576.3 +/- 573.1 ug x h x L-1 before fluoxetinetherapy to 2370.7 +/- 704.5 ug x h x L-1 (P = .005).','boycer','09/16/2010 11:48:22\n','EV_PK_DDI_NR','PKStudy',1.5,0.4,0.02,9,'',NULL,NULL),(590,'evidence_1337','http://www.ncbi.nlm.nih.gov/pubmed/11452243','\n\nroute of administration: oral\n\nstudy duration: single dose of 100 mg sertraline \n\npopulation: 12 healthy Chinese male, non-smokers\n\ntested for known CYP450 polymorphisms? Patients were genotyped for CYP2C19 polymorphisms and also phenotyped using the omeprazole/5-hydroxy-omeprazole metabolic ratio. 6 extensive metabolizers (EM) and 6 poor metabolizers (PM) were chosen using stratified random selection from a pool of 66 EMs and 11 PMs.\n\nages: 19 - 22 years\n\ndescription:\nThe poor metabolizers had a 41% increase in sertraline AUC(0-inf) (983.6  199.3 micg  h/L versus 697.6  133.0 mcg  h/L; P &lt; .05) and a 51% increase in sertraline terminal elimination half-life (t_1/2) (35.5  5.6 hours 2 versus 23.5  4.4 hours; P &lt; .01) compared with extensive metabolizers. The oral clearance (CL_oral) of sertraline in poor metabolizers was significantly lower than that in extensive metabolizers (105.3  19.4 L/h versus 148.4  28.6 L/h; P &lt; .05). The AUC0-144 and Cmax of desmethylsertraline in poor metabolizers were significantly lower than the values in extensive metabolizers (627.6  203.8 g  h/L versus 972.1  270.3 g  h/L; P &lt; .05; 23.6  6.5 nmol/L versus 32.4  8.2 nmol/L; P &lt; .01; respectively). In addition, desmethylsertraline Tmax (time to reach Cmax) in poor metabolizers was markedly higher than that in extensive metabolizers (70.0  24.5 hours versus 26.4  5.4 hours; P &lt; .01). \n\n\n','boycer','09/28/2009 11:38:05\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,114),(591,'evidence_1560','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7e117c7e-02fc-4343-92a1-230061dfc5e0','\n&quot;Absorption\n\nRisperidone is well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution&quot;','boycer','06/15/2009 15:31:39\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.7,NULL,NULL,NULL,'',NULL,NULL),(592,'evidence_1472','http://www.ncbi.nlm.nih.gov/pubmed/7690693','\nroute of administration: oral\n\nstudy duration: single dose\n\npopulation: 12 males, phenotyped using dextromethorphan (9 2D6 EMs, 2 PMs, 1 IM)\n\nages: 24 (SD:6) \n\nTable III shows F_{abs}% = 65.9 +/- 27.7 for the participants who were found to be extensive metabolizers','boycer','06/17/2009 08:27:54\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.66,NULL,NULL,NULL,'',NULL,NULL),(593,'evidence_1043','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf','\nDrug Interactions\n...\nIn vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity.','boycer','09/24/2009 12:41:40\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(594,'evidence_1940','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a preferred CYP2D6 substrate for in vivo studies in it most recent guidance document. See Table 2, p. 19 \n\nCURATOR NOTE (04/29/2009): atomoxetine might have some relevant clearance by CYP2C19 and CYP1A2; evidence is currently being sought ','boycer','04/29/2009 20:16:41\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(595,'evidence_1486','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','\nMetabolism and elimination  Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway. People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs). For PMs, AUC of atomoxetine is approximately 10fold and Css,max is about 5fold greater than EMs. Laboratory tests are available to identify CYP2D6 PMs. Coadministration of STRATTERA with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)]. Atomoxetine did not inhibit or induce the CYP2D6 pathway.','boycer','09/24/2009 11:15:24\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(596,'evidence_1752','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(597,'evidence_1726','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(598,'evidence_1198','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(599,'evidence_1619','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','04/29/2009 19:41:31\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(600,'evidence_1469','http://www.ncbi.nlm.nih.gov/pubmed/9871431','NOTE: The AUC_i/AUC value is calculated from Table II and is not statistically significant\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 2 days\r\n\r\npopulation: 11 healthy volunteers, all nonsmokers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 20-40\r\n\r\ndescription:\r\nSUBJECTS: Twelve healthy volunteers (8 men and 4 women), aged 20 to 40 years, participated after giving written informed consent. All were active ambulatory nonsmoking adults, with no evidence of medical disease and taking no other medications. Female subjects were not taking oral contraceptives and did not have contraceptive implants. One of the subjects did not\r\ningest zolpidem as instructed during treatment; accordingly mean values for fluconazole treatment, n = 11.\r\n\r\nMETHODS: At 8 AM on study day 1, subjects entered the outpatient Clinical Psychopharmacology Research Unit where they received the initial dose of azole (fluconazole, 100 mg twice daily) (or placebo) and remained under observation for 30 minutes. Subjects took a second dose of azole (or placebo) at home at 4 PM on day 1. On the morning of day 2, after ingesting a standardized light breakfast with no caffeine-containing food or beverages and no grapefruit juice, they returned to the Research Unit at approximately 7:30 AM. They fasted until 12 noon, after which they resumed a normal diet (without grapefruit juice or caffeine-containing food or beverages). The third dose of azole (or placebo) was given at 8 AM, and the single dose of zolpidem or placebo was given at 9 AM. A final azole (or placebo) dose was given at 5 PM.\r\n\r\nRESULTS: Coadministration of zolpidem with itraconazole or fluconazole reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.\r\n\r\nSee Table II.','boycer','09/22/2010 14:15:36\r\n','EV_PK_DDI_RCT','PKStudy',1.31,0.005,0.2,11,'',NULL,NULL),(601,'evidence_1970','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(602,'evidence_1899','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',2,NULL,NULL,NULL,'',NULL,NULL),(603,'evidence_1609','http://www.ncbi.nlm.nih.gov/pubmed/9431831','\nEnzyme system: human liver microsomes\n NADPH added: yes\n inhibitor used: furafylline\n reaction: haloperidol --> 4-(4-chlorophenyl)-4-hydroxypiperidine\n Quote: Ketoconazole was a potent inhibitor of CPHP (4-(4-chlorophenyl)-4-hydroxypiperidine) formation with IC50 values of 0,10, 0,23 and 0,14 micM in microsomes HL-1, HL-6 and HL-9 respectively, wheras sulphaphenazole, furafylline and quinidine showed little inhibition (IC50 > 100micM)','boycer','06/11/2009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,115),(604,'evidence_1764','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(605,'evidence_1891','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2',' CYP3A4 Inhibitors: In vitro studies indicate that venlafaxine is likely metabolized to a minor, less active metabolite, N-desmethylvenlafaxine, by CYP3A4. Because CYP3A4 is typically a minor pathway relative to CYP2D6 in the metabolism of venlafaxine, the potential for a clinically significant drug interaction between drugs that inhibit CYP3A4-mediated metabolism and venlafaxine is small.','boycer','06/09/2009 19:50:43\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(606,'evidence_1663','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: venlafaxine --&gt; N-desmethylvenlafaxine\n\nNOTE: the concentration of venlafaxine used in this experiment is very high relative to that expected in clinical use of the drug\n\nQuote:\n&quot;Formation of NDV had a mean Vmax of 2.14 nmol min mg protein, and a mean Km of 2504 M (Table 2). Incubations of 750micM VF with SFZ and QUI led to 18% and 23% reduction in NDV production respectively, while increasing concentrations of ANA led to an 11% increase in NDV formation over baseline. KET [ketoconazole] had a more profound effect on NDV formation, leading to a 65% mean reduction in production of this metabolite (Figure 5).&quot;','boycer','06/20/2009 14:29:30\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,116),(607,'evidence_1998','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\n&quot;REMERONSolTab (mirtazapine) Orally Disintegrating Tablets are rapidly and completely absorbed following oral administration and have a half-life of about 2040 hours. Peak plasma concentrations are reached within about 2 hours following an oral dose. The presence of food in the stomach has a minimal effect on both the rate and extent of absorption and does not require a dosage adjustment. REMERONSolTab Orally Disintegrating Tablets are bioequivalent to REMERON (mirtazapine) Tablets.&quot;\n\nNOTE: various mirtazapine product labels indicate that there is no difference in fraction absorbed between the rapidly disintegrating and tablet formulations. \n\n','boycer','06/15/2009 15:11:07\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',1,NULL,NULL,NULL,'',NULL,NULL),(608,'evidence_1850','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','09/24/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(609,'evidence_1668','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.04,NULL,NULL,NULL,'',NULL,NULL),(610,'evidence_1240','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(611,'evidence_1688','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/cf26b007-df4f-4936-b2d3-183969761f69','&quot;In fasted normal volunteers, administration of a single oral 400 mg dose of fluconazole leads to a mean Cmax of 6.72 mcg/mL (range: 4.12 to 8.08 mcg/mL) and after single oral doses of 50 to 400 mg, fluconazole plasma concentrations and AUC (area under the plasma concentration-time curve) are dose proportional.&quot;','boycer','09/27/2007 10:41:16\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.007,NULL,NULL,NULL,'',0.4,NULL),(612,'evidence_1093','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','12.3 Pharmacokinetics\n\nDuloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state plasma concentrations are typically achieved after 3 days of dosing. Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP1A2 and CYP2D6.','boycer','05/05/2009 17:46:03\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(613,'evidence_1937','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(614,'evidence_1506','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: R-warfarin\n\nreaction: R-warfarin 6-hydroxylation\n\nQuote: \nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4.\n\n\n\n','boycer','09/22/2009 17:50:11\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,117),(615,'evidence_1232','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(616,'evidence_1116','http://www.ncbi.nlm.nih.gov/pubmed/3932079','\nroute of administration: oral (parent drug)\n\nstudy duration: Plasma profiles were obtained: 1) after a single 100 mg oral dose of [NON-XR] bupropion hydrochloride, 2) following administration of 100 mg 8-hourly for 14 days and 3) again after a single 100 mg dose 14 days later.\n\npopulation: 8 healthy, non-smoking, male subjects\n\ntested for known CYP450 polymorphisms? NO\n\nages: 22 - 42\n\nC_max of ERYTHROHYDROBUPROPION @ 300mg/day of NON-XR bupropion for 14 days: 0.6micM/L (OCCASION 2, Table 2, 17U)\n\n0.6micM/1L X 1M/10^6micM X 242.765g/1M = 0.0001457g/L ','boycer','06/22/2009 11:21:19\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0001457,NULL,NULL,NULL,'',0.3,NULL),(617,'evidence_1066','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','06/30/2009 13:53:44\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(618,'evidence_1491','http://www.ncbi.nlm.nih.gov/pubmed/10997935','Enzyme system: recombinant human enzymes in human lymphoblastoid cells\nNADPH added:yes\n\ninhibitor used: no\n\nTable 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. ','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(619,'evidence_1353','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP2C8 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','06/30/2009 15:15:52\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(620,'evidence_1584','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','the FDA lists this as a accepted in vitro inhibitor in it most recent guidance document. See Table 2, p. 28','boycer','10/19/2007 17:26:06\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(621,'evidence_1249','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(622,'evidence_1376','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(623,'evidence_1171','http://www.ncbi.nlm.nih.gov/pubmed/8748428','\nRoute of administration: oral\n\nstudy duration: read description below\n\npopulation: 48 male volunteers\n\nages: mean(std dev): 26(6.7)\n\nNOTE: no increase in the single dose or steady state nefazodone AUC or Cmax but a three-fold increase in the C_max and AUC of the nefazodone metabolite mCPP\n\nDescription:\nThis study was conducted to determine the potential for an interaction between nefazodone, a new antidepressant, and alprazolam after single- and multiple-dose administration in a randomized, double-blind, parallel-group, placebo-controlled study in 48 healthy male volunteers. A group of 12 subjects received either placebo twice daily, 1 mg of alprazolam twice daily, 200 mg of nefazodone twice daily, or the combination of 1 mg of alprazolam and 200 mg of nefazodone twice daily for 7 days. Serial blood samples were collected after dosing on day 1 and day 7 and before the morning dose on days 4, 5, and 6 for the determination of alprazolam and its metabolites alpha-hydroxyalprazolam (AOH) and 4-hydroxyalprazolam (4OH) and nefazodone and its metabolites hydroxynefazodone (HO-nefazodone), m-chlorophenylpiperazine (mCPP), and a triazole dione metabolite (dione) by validated high-performance liquid chromatography methods. Steady-state levels in plasma were reached by day 4 for alprazolam, 4OH, nefazodone, HO-nefazodone, mCPP, and dione. Noncompartmental pharmacokinetic analysis showed that at steady state, alprazolam Cmax and AUCtau values significantly increased approximately twofold and 4OH Cmax and AUCtau values significantly decreased by 40 and 26%, respectively, when nefazodone was coadministered with alprazolam. There was no effect of alprazolam on the single-dose or steady-state pharmacokinetics of nefazodone, HO-nefazodone, or dione after the coadministration of alprazolam and nefazodone. ','boycer','12/10/2007 15:49:02\n','EV_PK_DDI_RCT','PKStudy',NULL,0.001,0.2,48,'',NULL,NULL),(624,'evidence_1965','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(625,'evidence_1161','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: dextromethorphan O-demethylation\n\nQuote: \n\nCYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors. ','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(626,'evidence_1425','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/17209c32-56eb-4f84-954d-aed7b7a1b18d','Table 4 shows that paroxetine (20mg 1xd X 9) effected no increase (and in fact a slight decrease) of the AUC of asenapine in vivo','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(627,'evidence_1058','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','\nRoute of administration: oral\n\nstudy duration: single dose of bupropion XR with and w/out cimetidine\n\npopulation: 24 male\n\nages:young adult (inferred from statement)\n\nAUC_i/AUC: 16% increase stated --&gt; 1.16-fold increase\n\nQuote:\nThe effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers. Following oral administration of two 150-mg Bupropion Hydrochloride Extended-Release Tablets, USP (SR) with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and its hydroxy metabolite were unaffected. However, there were 16% and 32% increases, respectively, in the AUC and Cmax of the combined moieties of threohydro- and erythrohydro-bupropion.','boycer','05/14/2009 14:48:33\n','Non_traceable_Drug_Label_Statement','PKStudy',1.16,0.3,0.8,24,'',NULL,NULL),(628,'evidence_1877','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(629,'evidence_1762','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.\n\nKetoconazole and Other CYP3A4 Inhibitors\n\nCoadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.\n\nQuinidine and Other CYP2D6 Inhibitors\n\nCoadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with Major Depressive Disorder, ABILIFY should be administered without dosage adjustment as specified in DOSAGE AND ADMINISTRATION (2.3).\n\nCarbamazepine and Other CYP3A4 Inducers\n\nCoadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(630,'evidence_1114','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29-44, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2-3 fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. When fluoxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level. Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to the previous level.','boycer','01/11/2010 18:29:32\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,118),(631,'evidence_1521','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Paroxetine: Co-administration of paroxetine (20 mg/day for 5-8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18-65 resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6 fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. When paroxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level. Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to previous levels.','boycer','01/11/2010 18:32:05\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,119),(632,'evidence_1470','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6','\n\nMetabolism\n\nPantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. ','boycer','09/24/2009 13:18:40\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(633,'evidence_1455','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','04/29/2009 19:39:57\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(634,'evidence_1200','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\nsubstrate used: N/A\n\nreaction: \natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\n\ndescription:\nhuman liver microsomes incubated with both atorvastatin acid and atorvastatin lactone generated the ortho-hydroxy-atorvastatin metabolite','boycer','09/25/2007 07:33:52\n','EV_EX_Met_Enz_ID','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(635,'evidence_1265','http://www.ncbi.nlm.nih.gov/pubmed/16765141','\nRoute of administration: oral\n\nstudy duration: 7 days\n\nDose: 10mg atorvastatin\n\npopulation: 13 (7 male/6 female) in the exposure group; 15 (7 male and 8 female) in the control\n\nages:41-72 in the exposure and 30 - 60 in the control\n\nDescription:\northo-hydroxy-atorvastatin present in measurable quantities in both exposure and control populations','boycer','09/27/2007 09:24:23\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(636,'evidence_1444','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0','&quot;Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.&quot;','boycer','09/27/2007 10:30:02\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(637,'evidence_1074','http://www.ncbi.nlm.nih.gov/pubmed/12235455','Route of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: single 120mg oral dose of diltiazem with 24 hours of plasma level monitoring\n\npopulation: 15 individuals; 5 for each genetically based phenotype. Study does not state gender of participants\n\nages: 20-30\n\ndescription:\nThe aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS: Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence resonance energy transfer probes hybridized to polymerase chain reaction-amplified deoxyribonucleic acid. The first 5 individuals identified with genotypes corresponding to a homozygous extensive, heterozygous extensive, or homozygous poor CYP2D6-metabolizing phenotype, respectively, were voluntarily enrolled in the pharmacokinetic study. The participants received diltiazem, 120 mg, as a single oral dose, and plasma samples were collected up to 24 hours after administration. Plasma samples were purified by solid phase extraction. Diltiazem and 7 phase I metabolites were analyzed by liquid chromatography-mass spectrometry. RESULTS: The pharmacokinetics of diltiazem was not significantly different between the subgroups. However, the systemic exposure of the pharmacologically active metabolites desacetyl diltiazem and N-demethyldesacetyl diltiazem was &gt; or = 5 times higher in poor CYP2D6 metabolizers than in extensive CYP2D6 metabolizers (P &lt;.01). CONCLUSIONS: CYP2D6 activity does not have a major impact on the disposition of diltiazem. In contrast, desacetyl diltiazem and N-demethyldesacetyl diltiazem are markedly accumulated in individuals expressing a deficient CYP2D6 phenotype. Because these metabolites exhibit pharmacologic properties of possible importance, individual CYP2D6 activity might be an aspect to consider in the clinical use of diltiazem.','boycer','08/09/2007 07:19:28\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,120),(638,'evidence_1845','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(639,'evidence_1396','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(640,'evidence_1862','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nExcretion\n\nStudies in women receiving 20 mg of 14C tamoxifen have shown that approximately 65% of the administered dose was excreted from the body over a period of 2 weeks with fecal excretion as the primary route of elimination. The drug is excreted mainly as polar conjugates, with unchanged drug and unconjugated metabolites accounting for less than 30% of the total fecal radioactivity.','boycer','09/24/2009 14:20:42\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(641,'evidence_1840','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','\n12.3 Pharmacokinetics\n\nRanolazine is extensively metabolized in the gut and liver and its absorption is highly variable. For example, at a dose of 1000 mg twice daily, the mean steady-state Cmax was 2600 ng/mL with 95% confidence limits of 400 and 6100 ng/mL. The pharmacokinetics of the (+) R- and (-) S-enantiomers of ranolazine are similar in healthy volunteers. The apparent terminal half-life of ranolazine is 7 hours. Steady state is generally achieved within 3 days of twice-daily dosing with Ranexa. At steady state over the dose range of 500 to 1000 mg twice daily, Cmax and AUC0-&amp;#964; increase slightly more than proportionally to dose, 2.2- and 2.4-fold, respectively. With twice-daily dosing, the trough:peak ratio of the ranolazine plasma concentration is 0.3 to 0.6. The pharmacokinetics of ranolazine is unaffected by age, gender, or food. \n\n2600ng/mL X 1g/10^9ng X 1000ml/1L = 0.00026g/L ','boycer','09/24/2009 15:46:03\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.00026,NULL,NULL,NULL,'',2,NULL),(642,'evidence_1397','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA, in it most recent guidance document, recommends this as a chemical inhibitor of CYP2C8 for in vitro experiments at a K_i of 1.1micM. See Table 2, p. 28\n\n1.1micM/L X 1M/10^6micM X 586.183g/M = 0.0006448g/L','boycer','06/30/2009 13:49:04\n','Non_Tracable_Statement','In_vitro_inhibition_study',0.0006448,NULL,NULL,NULL,'none_assigned',NULL,NULL),(643,'evidence_1902','http://www.ncbi.nlm.nih.gov/pubmed/3771812','\nRoute of administration: oral\n\nstudy duration: 0.5mg oral triazolam was administered alone or after 3 days of pretreatment with .333 mg tid erythromycin\n\npopulation: 16 males (including 5 smokers)\nages: 19-42\n\nAUC_i/AUC: 41.4/20.1 = 2.06','boycer','10/29/2007 13:08:09\n','EV_PK_DDI_RCT','PKStudy',2.06,0.0005,0.333,16,'',NULL,NULL),(644,'evidence_1427','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative. In humans, unchanged citalopram is the predominant compound in plasma. At steady state, the concentrations of citalopram\'s metabolites, DCT and DDCT, in plasma are approximately one-half and one-tenth, respectively, that of the parent drug. In vitro studies show that citalopram is at least 8 times more potent than its metabolites in the inhibition of serotonin reuptake, suggesting that the metabolites evaluated do not likely contribute significantly to the antidepressant actions of citalopram.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(645,'evidence_1887','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','Drugs that Inhibit Cytochrome P450 Isoenzymes\n\nCYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants. Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism and venlafaxine. However, although imipramine partially inhibited the CYP2D6-mediated metabolism of venlafaxine, resulting in higher plasma concentrations of venlafaxine and lower plasma concentrations of ODV, the total concentration of active compounds (venlafaxine plus ODV) was not affected. Additionally, in a clinical study involving CYP2D6-poor and -extensive metabolizers, the total concentration of active compounds (venlafaxine plus ODV), was similar in the two metabolizer groups. Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.\n\n','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(646,'evidence_1047','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: paroxetine\n\nreaction: venlafaxine --&gt; O-desmethylvenlafaxine\n\nQuote: \n&quot;All six SSRIs inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;\n\nK_i for paroxetine vs O-desmethylvenlafaxine formation: 0.17micM','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(647,'evidence_1207','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\n\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: quinidine\n\nreaction: venlafaxine --&gt; O-desmethylvenlafaxine\n\nQuote: \n&quot;All six SSRIs [including quinidine] inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;\n\nK_i for quinidine vs O-desmethylvenlafaxine formation: 0.04micM','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(648,'evidence_1742','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','Drugs that Inhibit Cytochrome P450 Isoenzymes\n\nCYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants. Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism and venlafaxine. However, although imipramine partially inhibited the CYP2D6-mediated metabolism of venlafaxine, resulting in higher plasma concentrations of venlafaxine and lower plasma concentrations of ODV, the total concentration of active compounds (venlafaxine plus ODV) was not affected. Additionally, in a clinical study involving CYP2D6-poor and -extensive metabolizers, the total concentration of active compounds (venlafaxine plus ODV), was similar in the two metabolizer groups. Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.\n\n','boycer','05/15/2009 10:28:04\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(649,'evidence_1557','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: paroxetine\n\nreaction: venlafaxine --&gt; O-desmethylvenlafaxine\n\nQuote: \n&quot;All six SSRIs inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;\n\nK_i for paroxetine vs O-desmethylvenlafaxine formation: 0.17micM','boycer','06/20/2009 14:01:46\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,121),(650,'evidence_1078','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\n\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: quinidine\n\nreaction: venlafaxine --&gt; O-desmethylvenlafaxine\n\nQuote: \n&quot;All six SSRIs [including quinidine] inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;\n\nK_i for quinidine vs O-desmethylvenlafaxine formation: 0.04micM','boycer','06/20/2009 14:04:45\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,122),(651,'evidence_1224','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nMetabolism\n\nIn vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 ','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(652,'evidence_1601','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: dextromethorphan\n\nreaction: dextromethorphan O-demethylation\n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% at concentrations of 100micM (see Table 3).\n\n\n','boycer','02/12/2010 17:39:55\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,123),(653,'evidence_1858','http://www.ncbi.nlm.nih.gov/pubmed/2124217','\nroute of administration: oral\n\nstudy duration: single oral 200 mg dose of bupropion\n\npopulation: 8 healthy adult men and 8 non-depressed men with alcoholic liver disease. Note that this evidence item was from a urinary excretion sub-study involving four of the healthy men\n\nages: 42.1 (SD:8.7)\n\nDescription: \n(from p.331) The amount of unchanged drug excreted in the urine ranged from 0.22 - 2.14%\n\n','boycer','06/19/2009 12:20:06\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(654,'evidence_1563','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(655,'evidence_1800','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.\n\nKetoconazole and Other CYP3A4 Inhibitors\n\nCoadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.\n\nQuinidine and Other CYP2D6 Inhibitors\n\nCoadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with Major Depressive Disorder, ABILIFY should be administered without dosage adjustment as specified in DOSAGE AND ADMINISTRATION (2.3).\n\nCarbamazepine and Other CYP3A4 Inducers\n\nCoadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced.','boycer','04/29/2009 19:50:52\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(656,'evidence_1439','http://www.ncbi.nlm.nih.gov/pubmed/15770075','Route of administration: oral\n\nstudy duration: Two phases : Phase I - a single dose of aripiprazole; Phase II - 7 days pre-treatment with ITZ, single dose of aripiprazole with ITZ, then ITZ alone or 14 more days; a 35 day washout between Phase I and II\n\npopulation: 24 healthy adult Japanese males\n\nmeean age (SD): 23.2 (2.4)\n\nAUC_i/AUC (336hr): 1075/736 = 1.48\n\nDescription:\nThe objective of the present study was to investigate the influence of itraconazole (hereafter referred to as ITZ) co-administration (CYP3A4 inhibition) on the pharmacokinetics of ARIPIPRAZOLE administered to 24 healthy adult male volunteers in a fasting condition. The influence of CYP3A4 inhibition was also examined by CYP2D6 genotype. All subjects were administered a single oral dose of ARIPIPRAZOLE alone in Period I and a single oral dose of ARIPIPRAZOLE following administration of ITZ at 100 mg/day for 7 consecutive days in Period II. The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined. Co-administration of ITZ increased the Cmax, AUC336 hr, and t1/2,z of ARIPIPRAZOLE and OPC-14857 by 19.4%, 48.0%, and 18.6% and by 18.6%, 38.8%, and 53.4%, respectively. By co-administration of ITZ, the CL/F of ARIPIPRAZOLE in extensive metabolizers was decreased by 26.6%, with an even greater decrease (47.3%) in intermediate metabolizers. For the co-administration period, the CL/F of ARIPIPRAZOLE in intermediate metabolizers was about half of that in extensive metabolizers. For Cmax, there was no significant difference between extensive metabolizers and intermediate metabolizers, and the percent change by co-administration of ITZ was less than 20% in both extensive metabolizers and intermediate metabolizers. For OPC-14857, the t(max) in intermediate metabolizers was longer than that in extensive metabolizers, with the difference being amplified by co-administration of ITZ. The AUC336 hr showed similar increases by co-administration of ITZ in all genotypes. The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ. The influence of CYP3A4 inhibition on the pharmacokinetics of ARIPIPRAZOLE was not considered to be clinically significant. On the other hand, definite differences in pharmacokinetics were observed between CYP2D6 genotypes. ','boycer','05/06/2009 14:19:26\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,124),(657,'evidence_1080','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(658,'evidence_1226','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP2C8 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(659,'evidence_1396','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','the FDA lists this as a accepted in vitro inhibitor in it most recent guidance document. See Table 2, p. 28','boycer','10192007','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(660,'evidence_1322','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78','Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.','boycer','06/26/2007 06:45:13\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(661,'evidence_1858','http://www.ncbi.nlm.nih.gov/pubmed/2567646','In this narrative review the authors state that &quot;only about 20% of the administered dose [is] excreted as unchanged alprazolam&quot; citing Reineke et al 1978. However, I cannot get access to the cited reference.','boycer','07/02/2007 09:24:26\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(662,'evidence_1494','http://www.ncbi.nlm.nih.gov/pubmed/3323671','Table 1 of this paper states that, on average, 21.4% of an oral dose of alprazolam is excreted in urine. The table does not seem to be the product of the study described in this evidence item. Prior to referring to the table, the authors cite a paper produced by the drug\'s manufacturer (Upjohn) but I am unable to acquire this article.','boycer','08/09/2007 08:27:19\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(663,'evidence_1923','http://www.ncbi.nlm.nih.gov/pubmed/10952477','\nRoute of administration: oral\n\nstudy duration: 4 days pretreatment with oral fluconazole 400mg day 1 and 200mg days 2-4; on day 4 a single oral dose of 40mg fluvastatin\n\npopulation: 12\nmale: 5\nfemale: 7\n\nages: 19-26\n\nAUC_i/AUC 0 to infinity: 955 / 520 = 1.837','boycer','10/29/2007 11:59:09\n','EV_PK_DDI_RCT','PKStudy',1.837,0.04,0.2,12,'',NULL,NULL),(664,'evidence_1203','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 1\'-OH-midazolam using a recombinant CYP3A5 Supersome system (Km = 14microM).','boycer','07/02/2007 11:30:51\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(665,'evidence_1906','http://www.ncbi.nlm.nih.gov/pubmed/12404553','NOTE: AUC_0-24 is used for AUC_i/AUC.\n\nroute of administration: oral\n\nstudy duration: 27 days\n\npopulation: 20 healthy subjects (11 male, 9 female)\n\ntested for known CYP450 polymorphisms?\nYes -- CYP2D6 - all were extensive metabolizers\n\nages: 18-45\n\ndescription:\n\nSUBJECTS\nTwelve healthy male and twelve healthy female subjects aged between 18 and 45 years participated in this three-period crossover study. They were extensively screened within 3 weeks of study entry and had to be medically and mentally healthy, as evidenced by medical history, full physical examination, routine clinical laboratory investigations and ECG. Their body mass index had to be within the range 19-29 kg/m2 and they were not allowed to be smokers. Subjects were screened for being extensive metabolizers of CYP2D6 using dextromethorphan as a probe.\n\nOf the 12 males and 12 female subjects enrolled into the study, three subjects (1 male, 2 females) discontinued the study due to the emergence of adverse events on days 21, 23, and 27, respectively, of the 27 day treatment period.\n\nMETHODS\nSubjects meeting the inclusion criteria were enrolled into the study. They were randomly assigned to one of six treatment sequences in this three-period crossover study without washout intervals. They were admitted to the clinical pharmacology institute two days before the start of the study. In order to mimic clinical practice as much as possible, paroxetine was administered in the morning and mirtazapine in the evening, with a 12h interval between administrations. From day 1 up to and including day 26 paroxetine 20 or 40 mg or placebo was administered at 9 a.m. and mirtazapine 15 or 30 mg or placebo at 9 p.m. each day.\n\nThe treatments used were: (A) 20 mg paroxetine plus one placebo paroxetine capsule at 9 a.m. and two placebo mirtazapine tablets at 9 p.m. for the first three days followed by two 20 mg paroxetine capsules at 9 a.m. and two placebo mirtazapine tablets at 9 p.m. for the following 6 days; (B) two placebo paroxetine capsules at 9 a.m. and one 15 mg mirtazapine plus one placebo mirtazapine tablet at 9 p.m. for 3 days followed by two placebo paroxetine capsules at 9 a.m. and two 15 mg mirtazapine tablets at 9 p.m. for the following 6 days; (C) 20 mg paroxetine plus one placebo paroxetine capsule at 9 a.m. and 15 mg mirtazapine plus one placebo mirtazapine tablet at 9 p.m. for 3 days followed by two 20 mg paroxetine at 9 a.m. and two 15 mg mirtazapine at 9 p.m. for the following 6 days. Thus, six possible treatment sequences (TS1 - TS6) were used (Table 1). In those treatment sequences in which either paroxetine or mirtazapine had also been administered in the preceding treatment sequence, the drug was continued at the highest dose, i.e. two 20 mg capsules for paroxetine and two 15 mg tablets for mirtazapine. Two males and two females were randomized to each of the six treatment sequences.\n\nRESULTS\n\nAdding paroxetine to mirtazapine treatment increased the mirtazapine plasma concentrations. The AUC_0-24 increased by approximately 17% during concomitant administration of paxoetine. Statistically significant differences were observed in AUC_0-24 and C_max,av.','boycer','08/23/2010 15:39:12\n','EV_PK_DDI_RCT','PKStudy',1.17,0.03,0.04,20,'',NULL,NULL),(666,'evidence_1461','http://www.ncbi.nlm.nih.gov/pubmed/8889898','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam 1-hydroxylation\n\nMW:306.27103\n\n1.27micM/L X 1M/10^6micM X 306.27103g/M = 0.000389g/L','boycer','02/13/2010 10:09:42\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.000389,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,125),(667,'evidence_1503','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends coumarin to be an acceptable chemical CYP2A6 substrate (coumarin 7-hydroxylation) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','09/22/2009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(668,'evidence_1924','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nDrug-Drug Interactions\n\nIn vitro studies showed that erythromycin, cyclosporin, nifedipine and diltiazem competitively inhibited formation of N-desmethyl tamoxifen with apparent K1 of 20, 1, 45 and 30 M, respectively. The clinical significance of these in vitro studies is unknown.','boycer','09/24/2009 14:19:04\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,126),(669,'evidence_1948','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(670,'evidence_1936','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','Metabolism and Elimination:\n\n...\n\nQuetiapine is extensively metabolized by the liver. The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive. In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(671,'evidence_1277','http://www.ncbi.nlm.nih.gov/pubmed/15834460','\nRoute of administration: oral\n\nstudy duration: multiple doses of QTP with or without concomitant erythromycin\n\npopulation: 19; 10 female and 9 male NOTE:no participants were tested for known CYP phenotypes\n\nages:18-55 \n\nQuote:\nIn presence of erythromycin, activity of CYP3A4 decreased significantly; for QTP, C(max), AUC(0-24), and t(1/2) increased significantly, CL decreased significantly, and variations in AUC(0-24) and CL showed, respectively, significant negative and positive correlation to that of CYP3A4 activity;','boycer','12172009','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(672,'evidence_1230','http://www.ncbi.nlm.nih.gov/pubmed/16390352','\n\nroute of administration: oral\n\nstudy duration: An 8-day crossover trial -- in each branch participants were give 25 mg quetiapine before and after 4 days of treatment with ketoconazole 200 mg daily.\n\npopulation:12 healthy male volunteers\n\ntested for known CYP450 polymorphisms?\n\nages: mean 33 years\n\ndescription:\n...concomitant use of ketoconazole resulted in  substantial increases in plasma concentrations of quetiapine (Figure 3A). The mean Cmax and AUC of quetiapine were increased by 235% and 522%, respectively. Conversely, the geometric mean AUC and Cmax of the sulfoxide metabolite were decreased by 46% and 87%, respectively (Figure 3B). Mean CL/F of quetiapine was decreased by 84%, and mean t1/2 was increased from 2.61 to 6.76 h.\n\n\n','boycer','02132010','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(673,'evidence_1113','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a preferred chemical CYP3A4 substrate (CYP3A4-->(midazolam->1hydroxy-midazolam)) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','05/21/2007 10:10:51\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(674,'evidence_1068','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel\n\nk_i = 48.9micM\n\n48.9micM/1L x 1M/1e6 x 422.55g/1M = .021g/L\n\n(molecular weight from http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=64727) ','boycer','01/21/2008 15:51:51\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.021,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,127),(675,'evidence_1663','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','\nCYP3A Inhibitors \n\nDo not use Ranexa with strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir. Ketoconazole (200 mg twice daily) increases average steady-state plasma concentrations of ranolazine 3.2-fold','boycer','09/24/2009 15:51:39\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,128),(676,'evidence_1770','http://www.ncbi.nlm.nih.gov/pubmed/10771455','\nroute of administration: oral\n\nstudy duration:  single oral doses of ziprasidone 40 mg on three occasions at least 7 days apart. On one occasion ziprasidone was administered alone, on another occasion ziprasidone was co-administered with oral cimetidine 800 mg and on a third occasion  ziprasidone was co-administered with oral Maalox1.\n\n\npopulation: 11 healthy young subjects, 9 female, 3 male (only 10 completed the cimetidine - ziprasidone study)\n\ntested for known CYP450 polymorphisms?\n\nages: 18-45\n\ndescription:\nResults The administration of cimetidine increased the ziprasidone AUC(0,inf) by 6% but there were no statistically significant differences in Cmax, tmax or lambda_z between the ziprasidone + cimetidine group and the ziprasidone group. \n\n\n','boycer','09/22/2009 18:37:28\n','EV_PK_DDI_NR','PKStudy',1.069,0.04,0.8,10,'',NULL,NULL),(677,'evidence_1527','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: dextromethorphan-o-demethylation\n\nk_i = 0.8micM\n\n0.8micM/L x 1M/10^6micM x 403.97g/M = 0.00032g/L','boycer','04/25/2009 09:47:51\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.00032,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,129),(678,'evidence_1867','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative. In humans, unchanged citalopram is the predominant compound in plasma. At steady state, the concentrations of citalopram\'s metabolites, DCT and DDCT, in plasma are approximately one-half and one-tenth, respectively, that of the parent drug. In vitro studies show that citalopram is at least 8 times more potent than its metabolites in the inhibition of serotonin reuptake, suggesting that the metabolites evaluated do not likely contribute significantly to the antidepressant actions of citalopram.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(679,'evidence_1934','http://www.ncbi.nlm.nih.gov/pubmed/15963095','\nroute of administration: oral\n\nstudy duration: six days\n\npopulation: 18 healthy subjects (9 male, 9 female) All Japanese\n\ntested for known CYP450 polymorphisms?\nCYP2C19 -- 6 homozygous EMs, 6 heterozygous EMs, and 6 poor metabolizers\n\nages: 21-34\n\ndescription:\nNOTE: AUC_I/AUC in the DIKB knowledge-base is from the 6 participants classified as homozygous EMs and the value is for the R-enantiomer. The AUC increase for the S-enantiomer was greater; please see the full text. \n\nEighteen healthy subjects, of whom six each were homozygous extensive metabolizers (homEMs), heterozygous extensive metabolizers (hetEMs), or poor metabolizers (PMs) for CYP2C19, participated in the study. Each subject received either placebo or fluvoxamine, 25 mg twice daily for 6 days, then a single oral dose of 60 mg of racemic lansoprazole. The plasma concentrations of lansoprazole enantiomers and lansoprazole sulphone were subsequently measured for 24 h post lansoprazole administration using liquid chromatography.\n\nIn the homEMs and hetEMs, fluvoxamine significantly increased the AUC(0, inf) and C max and prolonged the elimination half-life of both (R)- and (S)-lansoprazole, whereas in the PMs, the only statistically significant effect of fluvoxamine was on\nthe AUC(0, inf) for (R)-lansoprazole. The mean fluvoxamine-mediated percent increase in the AUC(0, inf) of (R)-lansoprazole in the homEMs compared with the PMs was significant ( P = 0.0117); however, C max did not differ among the three CYP2C19 genotypes. On the other hand, fluvoxamine induced a significant percent increase in both the AUC(0, inf) and C max for (S)-lansoprazole in the homEMs compared with the hetEMs ( P = 0.0007 and P = 0.0125, respectively) as well as compared with the PMs ( P &lt; 0.0001 for each parameter).\n\n','boycer','08/10/2010 14:29:24\n','EV_PK_DDI_RCT','PKStudy',9.03,0.06,0.05,18,'',NULL,NULL),(680,'evidence_1902','http://www.ncbi.nlm.nih.gov/pubmed/16778714','\nNOTE: AUC_I/AUC in the DIKB knowledge-base is from the 6 participants classified as homozygous EMs.\n\nroute of administration: oral\n\nstudy duration: six days\n\npopulation: 18 healthy volunteers (9 male, 9 female); All Japanese\n\ntested for known CYP450 polymorphisms?\nYes -- CYP2C19 - 6 homozygous EMs, 6 heterozygous EMs, 6 homozygous PMs\n\nages: mean 25 years (+/- 3.8) \n\ndescription:\n\n      Eighteen healthy Japanese volunteers (9 men and 9\nwomen) who were H. pylori-negative were enrolled in this study. Their mean age was 25.1 +/- 3.8 years and mean body weight was 56.6 +/- 13.3 kg. The mutated alleles for CYP2C19, CYP2C19*3(*3), and CYP2C19*2(*2) had been identified using polymerase chain reaction-restriction fragment length polymorphism methods of De Morais et al, before this study. The CYP2C19 genotype analyses revealed 5 different patterns as follows: *1/*1 in 6, *1/*2 in 3, *1/*3 in 3, *2/*2 in 5, and *2/*3 in 1. These were divided into 3 groups, homozygous EMs (*1/*1, n = 6), heterozygous EMs (*1/*2 and *1/*3, n = 6), and PMs (*2/*2 and *2/*3, n = 6).\n      A randomized double-blind placebo-controlled\ncrossover study design in 3 phases was conducted at\nintervals of 2 weeks. Fluvoxamine (25 mg) as a capsule containing the equivalent of a tablet (Luvox, Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan), or matched placebo was given orally twice a day (9 AM, 9 PM) for 6 days. On day 6, they took a single oral 60-mg\ndose of lansoprazole (Takepron, Takeda Pharmaceutical\nCo, Ltd, Osaka, Japan) with 25 mg dose of fluvoxamine, or placebo after overnight fasting (9 AM).\nFluvoxamine pretreatment significantly increased AUC_0-24 of lansoprazole by 3.8-fold in homozygous EMs (P&lt;0.01) and 2.5-fold in heterozygous EMs (P&lt;0.05), and prolonged elimination half-life by 3.0-fold in homozygous EMs (P&lt;0.01) and by 1.7-fold in heterozygous EMs (P&lt;0.05), respectively. There were no differences in AUC_0-24 during fluvoxamine treatment among CYP2C19 genotypes.\n\n\n','boycer','08/10/2010 14:43:34\n','EV_PK_DDI_RCT','PKStudy',3.82,0.06,0.05,18,'',NULL,NULL),(681,'evidence_1877','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA lists this as a recommended in vivo inhibitor of CYP3A4 in it most recent guidance document. See Appendix A, Table 2, p. 19','boycer','05/21/2007 13:45:49\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(682,'evidence_1367','http://www.ncbi.nlm.nih.gov/pubmed/9152603','\nEnzyme system: human liver microsomes \n\nNADPH added: yes \n\ninhibitor used: ketoconazole \n\nreaction: \nclarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin \n\ndescription: clarithromycin oxidative metabolism was nearly completely wiped out by the addition of this selective inhibitor ','boycer','10/20/2007 08:21:46\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,130),(683,'evidence_1804','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of both 14-(R)-hydroxylase-clarithromycin and  14-N-demethylase-clarithromycin in a recombinant cyp3a4 Supersome system','boycer','10/20/2007 08:39:39\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(684,'evidence_1240','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nMetabolism and Excretion\n\nCinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(685,'evidence_1322','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nKetoconazole: Cinacalcet AUC(0-inf) and Cmax increased 2.3 and 2.2 times, respectively, when a single 90 mg cinacalcet dose on Day 5 was administered to subjects treated with 200 mg ketoconazole twice daily for 7 days compared to 90 mg cinacalcet given alone.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(686,'evidence_1942','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: tolbutamide --&gt; hydroxytolbutamide\n\nQuote:\n\nCYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7 (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM). ','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(687,'evidence_1998','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: perphenazine N-dealkylation\n\nQuote: \nTo identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.\n\n','boycer','06/15/2009 14:27:57\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,131),(688,'evidence_1898','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:31:59\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(689,'evidence_1358','http://www.ncbi.nlm.nih.gov/pubmed/9333110','\nroute of administration: oral\n\nstudy duration: single dose of perphenazine (0.11 mg/kg orally) or placebo following a randomized double-blind design. Perphenazine plasma concentrations and effects were assessed for a period of 8 hours. Subsequently, subjects were treated with a standard therapeutic dose of paroxetine (20 mg/day orally) for 10 days and test sessions with perphenazine and placebo were repeated.\n\npopulation: 8 adults (5 female, 3 male); all CYP2D6 EMs as determined by the dextromethorphan metabolite ration\n\nages: 21 - 49\n\nDescription: \nParoxetine treatment resulted in a twofold to 21-fold decrease in CYP2D6 activity (p &lt; 0.001). After pretreatment with paroxetine, perphenazine peak plasma concentrations increased twofold to 13-fold (p &lt; 0.01). This was associated with a significant increase in central nervous system side effects of perphenazine, including oversedation, extrapyramidal symptoms, and impairment of psychomotor performance and memory (p &lt; 0.05). \n','boycer','06/16/2009 18:11:05\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,132),(690,'evidence_1713','http://www.ncbi.nlm.nih.gov/pubmed/17429316','\n\nroute of administration: oral\n\nstudy duration: single-dose of perphenazine (0.1mg/kg)\n\npopulation: 22 healthy, non-smoking, adult males of chinese ancestry\n\ntested for known CYP450 polymorphisms? yes...&quot;DNA samples from all participants were genotyped for\nCYP2D6*10 and CYP2D6*5 using a nested and allele-\nspecific PCR-restriction fragment length polymorphism\nanalysis as described previously [34,35]. Alleles not being CYP2D6*5 or CYP2D6*10 were called CYP2D6*1. Geno-\ntyping for these three alleles has been shown in the past to be adequate for a reliable determination of CYP2D6 genotypes in Asians [8,15,34,35]. The invest igators did not have access to data on CYP2D6 genotype during ascertainment of the pharmacological phenotypes (i.e. perphenazine and prolactin concentration data); genotyping was also performed blind to the prolactin or plasma concentration data.&quot;\n\nages: 21 - 50\n\ndescription:\n&quot;In volunteers with CYP2D6*10/CYP2D6*10 genotype, the mean area under curve (AUC0-6) for perphenazine concentration was 2.9-fold higher than those who carry the CYP2D6*1 allele (P&lt;0.01).&quot;\n\n','boycer','06/20/2009 12:43:54\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,133),(691,'evidence_1080','http://www.ncbi.nlm.nih.gov/pubmed/8689810','\nroute of administration: oral\n\nstudy duration: During a 1-year period a blood sample was taken for genotyping together with blood for serum monitoring. Blood samples were taken from 151 patients\n\npopulation: patients undergoing therapeutic drug monitoring of orally-administered perphenazine. The analysis included 56 EMs and 3 PMs taking a drug that could potentially affect perphenazine metabolism, 32 EMs and 6 PMs taking a no drug known to affect perphenazine metabolism. All PMs were grouped for analysis since they did not carry a functional CYP2D6 allele.\n\ntested for known CYP450 polymorphisms? yes, genotyping found 142 CYP2D6 extensive metabolizers (EM) and 9 poor metabolizers (PM)\n\nages: 12 - 75; median of 38 years\n\ndescription:\nThe poor metabolizer group had the highest median steady-state serum concentration value (0.195 nmol/L per milligram), which was about twice the value of the extensive metablolizer group without potentially interacting medicine (0.098 nmol/L per milligram; p &lt; 0.01)\n\n','boycer','09/28/2009 12:08:09\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,134),(692,'evidence_1324','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: sulfinpyrazone\n\nreaction: venlafaxine --&gt; O-desmethylvenlafaxine\n\nQuote: \nIncubations of 50micM VF with varying concentra-\ntions of SFZ and ANA, inhibitors of CYP2C9 and CYP1A2, respectively, revealed no consistent inhibitory effect on ODV formation...biotransformation of a substrate. In the present study, ODV was produced by cDNA-expressed CYP2C9, CY2C19, and CYP2D6, although we were unable to identify the contribution of CYP2C9 or CYP2C19 in liver microsomes using either chemical inhibition by SFZ or anti-2C antibodies in human microsomes.\n\n\n\n','boycer','06/16/2009 14:21:24\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,135),(693,'evidence_1051','http://www.ncbi.nlm.nih.gov/pubmed/15961986','\nroute of administration: oral\n\nstudy duration: 4 days\n\npopulation: 12 healthy volunteers (all male); all nonsmokers\n\ntested for known CYP450 polymorphisms? No\n\nages: 22-27\n\ndescription:\nSUBJECTS: Twelve healthy, nonsmoking male volunteers aged 22 to 27 years (weight range, 67-95 kg; body mass index range, 21-26 kg/m2) participated in this study after having given written informed consent. The subjects were ascertained to be in good health by medical history, a full clinical examination, and standard hematologic and blood chemical laboratory tests before enrollment.\nMETHODS: This study was an open crossover study with 3 phases. Between phases 1 and 2, there was a 1-week-long washout period, and between phases 2 and 3, there was a washout period of 2 weeks. The first phase was a control period, in which all volunteers received a single oral dose of bupropion (Zyban sustained release, 150 mg; GlaxoSmithKline, Uxbridge, United Kingdom). In the second and third phases the volunteers received a 4-day-long oral antiplatelet agent pretreatment in randomized balanced order with either clopidogrel (Plavix, 75 mg once daily; Sanofi Synthelabo, Guildford, United Kingdom) or ticlopidine\n(Ticlid, 250 mg twice daily; Sanofi Synthelabo). On day 4, 1 hour after the last dose of the antiplatelet agent, a single 150-mg dose of bupropion was administered. Venous blood samples (10 mL each) for determination of bupropion and hydroxybupropion concentrations were taken just before and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, and 72 hours after administration of bupropion. In all phases the volunteers fasted for 8 hours before\nand 4 hours after administration of bupropion. Identical meals were provided on the 3 study days. Volunteers were also required to refrain from strenuous physical exercise, alcohol- or caffeine-containing drinks, smoking, grapefruit juice, and other medications for 2 days before and after study drug administration.\nRESULTS: Both of the thienopyridine\nderivatives had a significant effect on the AUC of\nbupropion: in the clopidogrel phase, the bupropion\nAUC increased by 60% (P = .02; 95% CI, 21% to\n98%).','boycer','09/15/2010 14:16:12\n','EV_PK_DDI_NR','PKStudy',1.6,0.15,0.075,12,'',NULL,NULL),(694,'evidence_1224','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(695,'evidence_1936','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','Bioavailability\n\nThe absolute bioavailability of fluvoxamine maleate is 53%. Oral bioavailability is not significantly affected by food.','boycer','05/14/2009 16:47:49\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.53,NULL,NULL,NULL,'',NULL,NULL),(696,'evidence_1040','http://www.ncbi.nlm.nih.gov/pubmed/15258107','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: bufuralol\n\nreaction: bufuralol 1\'hydroxylation\n\nIC50 &gt; 200micM (see Table 3)\n\nQuote: \nCYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM.\n\n\n\n','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(697,'evidence_1676','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(698,'evidence_1844','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1d149db-ad43-4f3f-aef1-fb0395ba4191','CYP3A4 IsozymeNefazodone has been shown in vitro to be an inhibitor of CYP3A4. This is consistent with the interactions observed between nefazodone and triazolam, alprazolam, buspirone, atorvastatin, and simvastatin, drugs metabolized by this isozyme. Consequently, caution is indicated in the combined use of nefazodone with any drugs known to be metabolized by CYP3A4. In particular, the combined use of nefazodone with triazolam should be avoided for most patients, including the elderly. The combined use of nefazodone with terfenadine, astemizole, cisapride, or pimozide is contraindicated (see CONTRAINDICATIONS and WARNINGS).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(699,'evidence_1627','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1d149db-ad43-4f3f-aef1-fb0395ba4191','Triazolam\n\nWhen a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. Nefazodone plasma concentrations were unaffected by triazolam. Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests. If triazolam is coadministered with nefazodone, a 75% reduction in the initial triazolam dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see CONTRAINDICATIONS and PRECAUTIONS).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(700,'evidence_1220','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','04/25/2009 10:21:12\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,136),(701,'evidence_1872','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233',' Metabolism: Bupropion is extensively metabolized in humans. Three metabolites have been shown to be active: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, which are formed via reduction of the carbonyl group. In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high or higher than those of bupropion.','boycer','01/19/2010 10:27:50\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(702,'evidence_1144','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(703,'evidence_1244','http://www.ncbi.nlm.nih.gov/pubmed/9010634','\nroute of administration: oral\n\nstudy duration: single dose\n\npopulation: 6 males\n\nages: 23 - 42\n\nNOTE: participants were not tested for known CYP phenotypes and this might have affected the results (e.g. see Section &quot;radiocarbon excretion&quot; on p. 83)\n\nQuote:\nDisposition and biotransformation of the new antipsychotic agent olanzapine (OLZ) were studied in six male healthy volunteers after a single oral dose of 12.5 mg containing 100 microCi of [14C]OLZ. Biological fluids were analyzed for total radioactivity, the parent compound (GC/MS), and metabolites (electrospray LC/MS and LC/MS/MS). Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.','boycer','06/16/2009 18:16:40\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(704,'evidence_1572','http://www.ncbi.nlm.nih.gov/pubmed/10997935','Enzyme system: recombinant human enzymes in human lymphoblastoid cells\nNADPH added:yes\n\ninhibitor used: no\n\nTable 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. ','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(705,'evidence_1083','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.2,NULL,NULL,NULL,'',NULL,NULL),(706,'evidence_1507','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','paroxetine is listed as a recommended inhibitor for AUC studies in Table 2 (p19)','boycer','04/29/2009 20:05:19\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(707,'evidence_1395','http://www.ncbi.nlm.nih.gov/pubmed/8513845','\n\nroute of administration: oral\n\nstudy duration: \n\npopulation: 17 males, 9 sparteine EMs and 8 sparteine PMs\n\nages: 20-24\n\nDescription: \nDuring paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively. The 5-fold decrease in clearance in EMs when desipramine was co-administered with paroxetine confirms that paroxetine is a potent inhibitor of CYP2D6. The lack of effect on clearance in PMs shows that paroxetine is a selective inhibitor of CYP2D6, which is absent from the livers of PMs. Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).','boycer','06/16/2009 18:02:53\n','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,137),(708,'evidence_1812','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f','\nDrugs that affect drug metabolism via cytochrome P450:\nSome compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes has not been carefully evaluated.','boycer','11/09/2009 12:48:23\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(709,'evidence_1782','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f','\nDrugs that affect drug metabolism via cytochrome P450:\nSome compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes has not been carefully evaluated.\n\nA randomized, double-blind, crossover interaction study in ten healthy volunteers between itraconazole (200 mg once daily for 4 days) and a single dose of zolpidem tartrate (10 mg) given 5 hours after the last dose of itraconazole resulted in a 34% increase in AUC0-inf of zolpidem tartrate. There were no significant pharmacodynamic effects of zolpidem on subjective drowsiness, postural sway, or psychomotor performance.','boycer','11/09/2009 12:45:49\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,138),(710,'evidence_1274','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f','\nCo-administration of a single dose of zolpidem tartrate with 4 doses of ketoconazole, a potent CYP3A4 inhibitor increased Cmax of zolpidem (30%) and the total AUC of zolpidem (70%) compared to zolpidem alone and prolonged the elimination half-life (30%) along with an increase in the pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together. Patients should be advised that use of Edluar with ketoconazole may enhance the sedative effects.','boycer','11/09/2009 12:51:14\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,139),(711,'evidence_1062','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(712,'evidence_1483','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/AB73778B-6794-441C-B127-610A6D0733EA','Concurrent use of mexiletine and theophylline may lead to increased plasma theophylline levels. One controlled study in eight normal subjects showed a 72% mean increase (range 35 to 136%) in plasma theophylline levels. This increase was observed at the first test point which was the second day after starting mexiletine. Theophylline plasma levels returned to pre-mexiletine values within 48 hours after discontinuing mexiletine. If mexiletine and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexiletine dose is changed. An appropriate adjustment in theophylline dose should be considered.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(713,'evidence_1606','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/AB73778B-6794-441C-B127-610A6D0733EA','Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of mexiletine.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(714,'evidence_1697','http://www.ncbi.nlm.nih.gov/pubmed/3428348','Route of administration: oral\n\nstudy duration: 2 days with patients who had been taking ketconazole for 1 to 6 months\n\npopulation: male:5 female:2\n\nages:20-68\n\nPeak plasma concentrations were found to be 3.2microM/L','boycer','06/05/2007 07:22:04\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.002,NULL,NULL,NULL,'',0.2,NULL),(715,'evidence_1156','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','09/24/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(716,'evidence_1001','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(717,'evidence_1790','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','04/29/2009 19:48:02\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(718,'evidence_1198','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Metabolism\n...\nIn vivo studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 1520% of Asian populations may be expected to be poor metabolizers. For Caucasians and Blacks, the prevalence of poor metabolizers is 35%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolizers have, on average, 4-fold higher voriconazole exposure (AUC&amp;#964;) than their homozygous extensive metabolizer counterparts. Subjects who are heterozygous extensive metabolizers have, on average, 2-fold higher voriconazole exposure than their homozygous extensive metabolizer counterparts.','boycer','09/24/2009 15:03:33\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(719,'evidence_1935','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.6,NULL,NULL,NULL,'',NULL,NULL),(720,'evidence_1046','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','NOTE: The object dose given and AUC are for EMs.\n\nroute of administration: not mentioned\n\nstudy duration: not mentioned\n\npopulation: 20 subjects\n\ntested for known CYP450 polymorphisms?\nYES - CYP2D6 -- 14 EMs, 6 PMs\n\nages:\n\nQuote:\nA pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n = 14) and 25 mg in poor metabolizers (PM; n = 6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.','boycer','02/16/2012 21:49:26\n','Non_traceable_Drug_Label_Statement','PKStudy',1.21,0.05,0.2,NULL,'',NULL,NULL),(721,'evidence_1180','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71be4cb7-a42f-43be-9b9b-f090edb2fd21','\nMetabolism\n\nAfter oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Zaleplon is primarily metabolized by aldehyde oxidase to form 5-oxo-zaleplon. Zaleplon is metabolized to a lesser extent by cytochrome P450 (CYP) 3A4 to form desethylzaleplon, which is quickly converted, presumably by aldehyde oxidase, to 5-oxo-desethylzaleplon. These oxidative metabolites are then converted to glucuronides and eliminated in urine. All of zaleplon\'s metabolites are pharmacologically inactive. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(722,'evidence_1856','http://www.ncbi.nlm.nih.gov/pubmed/8195463','Route of administration: oral (inferred because IV formulations do not appear to be available for fluoxetine and desipramine)\n\nstudy duration: see below\n\npopulation: 9 healthy males; all extensive metabolizers of dextromethorphan (o-demethylation)\n\nages: mean(std dev): &quot;adults&quot; but no mention of age. It can be inferred that these were healthy male adults and not exclusively elderly or children\n\nDescription: \nhe pharmacokinetic interactions of sertraline and fluoxetine with the tricyclic antidepressant desipramine were studied in 18 healthy male volunteers phenotyped as extensive metabolizers of dextromethorphan. Concentrations in plasma were determined after 7 days of desipramine (50 mg/day) dosing alone, during the 21 days of desipramine and selective serotonin reuptake inhibitor (SSRI) coadministration (fluoxetine, 20 mg/day; sertraline, 50 mg/day), and for 21 days of continued desipramine administration after SSRI discontinuation. Desipramine Cmax was increased 4.0-fold versus 31% and AUC0-24 was increased 4.8-fold versus 23% for fluoxetine versus sertraline, respectively, relative to baseline after 3 weeks of coadministration. Desipramine trough concentrations approached baseline within 1 week of sertraline discontinuation but remained elevated for the 3-week follow-up period after fluoxetine discontinuation. Concentrations of SSRIs and their metabolites correlated significantly with desipramine concentration changes (for fluoxetine/norfluoxetine, r = 0.94 to 0.96; p &lt; 0.001; for sertraline/desmethylsertraline, r = 0.63; p &lt; 0.01). Thus, sertraline had less pharmacokinetic interaction with desipramine than did fluoxetine at their respective, minimum, usually effective doses.','boycer','05/05/2009 15:27:35\n','EV_PK_DDI_NR','PKStudy',4.8,0.05,0.02,9,'',NULL,NULL),(723,'evidence_1660','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.10 Drugs Metabolized by CYP2C9\n\nDuloxetine does not inhibit the in vitro enzyme activity of CYP2C9. Inhibition of the metabolism of CYP2C9 substrates is therefore not anticipated, although clinical studies have not been performed.','boycer','05/05/2009 17:37:51\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(724,'evidence_1174','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(725,'evidence_1431','http://www.ncbi.nlm.nih.gov/pubmed/7690693','\nroute of administration: oral\n\nstudy duration: single dose\n\npopulation: 12 males, phenotyped using dextromethorphan (9 2D6 EMs, 2 PMs, 1 IM)\n\nages: 24 (SD:6)\n\nC_max: 7.9ng/mL (EMs)\n\n7.9ng/1L x 1g/10^9ng x 1000mL/1L = 0.0000079g/L\n\n','boycer','06/16/2009 15:47:15\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000079,NULL,NULL,NULL,'',0.001,NULL),(726,'evidence_1790','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3','Ritonavir also inhibits CYP2D6 to a lesser extent. Co-administration of substrates of CYP2D6 with ritonavir could result in increases (up to 2-fold) in the AUC of the other agent, possibly requiring a proportional dosage reduction. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(727,'evidence_1925','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3','Table 3 shows that the AUC of desipramine increased 145% in the presence of ritonavir','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(728,'evidence_1416','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends S-mepheytoin to be an acceptable chemical CYP2C19 substrate (S-mephenytoin 4\' hydroxylation) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','06/11/2009 16:04:51\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(729,'evidence_1537','http://www.ncbi.nlm.nih.gov/pubmed/7995001','Route of administration: oral\n\nstudy duration: four days pre-treatment with ketoconazole\n\npopulation: male: 3 female: 6\n\nages: 20-26\n\nKetoconazole increased the mean AUC of triazolam from 5.9ng/ml to 132ng/ml and the Cmax from 1.5 to 4.6ng/ml','boycer','06/05/2007 07:36:33\n','EV_PK_DDI_RCT','PKStudy',22.4,0.00025,0.4,9,'',NULL,NULL),(730,'evidence_1565','http://www.ncbi.nlm.nih.gov/pubmed/8632299','In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).\n\nNOTE: AUC increase values take from table 3','boycer','06/05/2007 07:46:02\n','EV_PK_DDI_RCT','PKStudy',9.16,0.000125,0.2,9,'',NULL,NULL),(731,'evidence_1761','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends caffeine as a preferred CYP1A2 substrate for in vivo studies in it most recent guidance document (See Table 2, p. 19) ','boycer','01/11/2010 17:13:34\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(732,'evidence_1787','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nMidazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(733,'evidence_1470','http://www.ncbi.nlm.nih.gov/pubmed/12235455','\nRoute of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: single 120mg oral dose of diltiazem with 24 hours of plasma level monitoring\n\npopulation: 15 individuals; 5 for each genetically based phenotype. Study does not state gender of participants\n\nages: 20-30\n\ndescription:\nThe aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS: Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence resonance energy transfer probes hybridized to polymerase chain reaction-amplified deoxyribonucleic acid. The first 5 individuals identified with genotypes corresponding to a homozygous extensive, heterozygous extensive, or homozygous poor CYP2D6-metabolizing phenotype, respectively, were voluntarily enrolled in the pharmacokinetic study. The participants received diltiazem, 120 mg, as a single oral dose, and plasma samples were collected up to 24 hours after administration. Plasma samples were purified by solid phase extraction. Diltiazem and 7 phase I metabolites were analyzed by liquid chromatography-mass spectrometry. RESULTS: The pharmacokinetics of diltiazem was not significantly different between the subgroups. However, the systemic exposure of the pharmacologically active metabolites desacetyl diltiazem and N-demethyldesacetyl diltiazem was &gt; or = 5 times higher in poor CYP2D6 metabolizers than in extensive CYP2D6 metabolizers (P &lt;.01). CONCLUSIONS: CYP2D6 activity does not have a major impact on the disposition of diltiazem. In contrast, desacetyl diltiazem and N-demethyldesacetyl diltiazem are markedly accumulated in individuals expressing a deficient CYP2D6 phenotype. Because these metabolites exhibit pharmacologic properties of possible importance, individual CYP2D6 activity might be an aspect to consider in the clinical use of diltiazem.','boycer','08/09/2007 07:10:32\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,140),(734,'evidence_1750','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(735,'evidence_1138','http://www.ncbi.nlm.nih.gov/pubmed/8889898','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam 1-hydroxylation\n\n\nKi = 1.44micM\nMW: 295.2995 (ChEBI)\n\n1.44micM/L X 1M/10^6micM X 295.2995g/M = 0.0004252g/L\n\n\n\n','boycer','02/13/2010 09:56:15\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.0004252,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,141),(736,'evidence_1755','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Metabolism and Elimination\n\nZiprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (&lt;1%) or feces (&lt;4%) as unchanged drug. Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methyl-dihydroziprasidone. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces. Unchanged ziprasidone represents about 44% of total drug-related material in serum. In vitro studies using human liver subcellular fractions indicate that S-methyl-dihydroziprasidone is generated in two steps. The data indicate that the reduction reaction is mediated by aldehyde oxidase and the subsequent methylation is mediated by thiol methyltransferase. In vitro studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone. CYP1A2 may contribute to a much lesser extent. Based on in vivo abundance of excretory metabolites, less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase.','boycer','05/14/2009 16:45:52\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(737,'evidence_1036','http://www.ncbi.nlm.nih.gov/pubmed/19585395','\n\nroute of administration: oral\n\nstudy duration: 13 days\n\npopulation: 50 healthy subjects (all male)\n\ntested for known CYP450 polymorphisms?\nYES -- CYP2D6 genotyping - all were extensive or ultrarapid metabolizers\n\nages: 18-54\n\ndescription:\nSUBJECTS: Sixty men aged 18-55 years were eligible to participate in the study if they had previously been genotyped as CYP2D6 extensive metabolizers or ultrarapid metabolizers of CYP2D6 substrates, on the basis of genetic testing. They were also required to have a body mass index of 18-30 kg/m2, supine blood pressure of 100-140 mmHg systolic/50-90 mmHg diastolic, and to smoke no more than 10 cigarettes, two cigars or two pipes per day. The subjects were considered to be healthy on the basis of physical examination, medical history, 12-lead electrocardiogram (ECG), serum chemistry, and hematology and urinalysis performed during the screening phase.\nExclusion criteria included: poor or intermediate CYP2D6 metabolizers, known allergy to study medications, recent history of substance abuse, history of any systemic disease or positive serology (including hepatitis B and C), bradycardia (heart rate &lt; 50 bpm) or consumption of &gt; 450 mg of caffeine per day. No medications (including non-prescription) were permitted during the course of the study, with the exception of acetaminophen (up to 1500 mg/day) for headache, anticholinergic agents for the treatment of emergent EPS and lorazepam for the management of muscle spasm at the investigators discretion.\nBoth treatment groups were balanced for demographic characteristics (Table 1). All subjects were male and aged 18-54 years, with the majority being white (75%). Ten subjects (all of whom were randomized to receive the combination of paroxetine and paliperidone ER followed by paliperidone ER alone) discontinued study medication and all in the first period (in which they received the combination regimen).\n\nMETHODS: This was a single-center, randomized, open-label, single-dose, two-treatment, two-period, crossover study (Fig. 1). The study consisted of three phases: screening, beginning within 21 days before first study drug administration; an open-label treatment phase consisting of two treatment periods; and end-of-study evaluations at study completion or upon withdrawal. Subjects were randomly assigned to one of two treatment-sequence groups (30 subjects per sequence group) according to a computer-generated randomization scheme. During the open-label treatment phase, all subjects received each of the following in order determined by randomization: one tablet of paliperidone ER 3 mg on Day 1 (Treatment A); or paroxetine 20 mg/day on Days 1-13, and one tablet of paliperidone ER 3 mg on Day 10 (Treatment B). Paliperidone ER was administered in the morning (between 07:30-10:00) while subjects were in the fasting state (overnight, for at least 10 h), and subjects continued to fast for 4 h after paliperidone ER administration prior to a standardized meal. On the day that both paroxetine and paliperidone ER were taken, paroxetine was administered in the fasted state 30 min before paliperidone ER; at all other time points, paroxetine was taken with food in the morning. There was a washout period of 14-28 days between paliperidone ER treatments.\n\nRESULTS: The 90% CI for the ratio of geometric treatment means was within the conventional no-effect boundaries (80-125%) for C_max, but not for AUC_0-last or AUC_inf (Table 3). However, the higher total exposure to paliperidone following administration of paliperidone ER and paroxetine compared with paliperidone ER alone was not considered clinically relevant, with a ratio of geometric treatment means of 116.48% for AUC_inf (90% CI: 104.49-129.84).','boycer','09/22/2010 12:19:19\n','EV_PK_DDI_RCT','PKStudy',1.16,0.003,0.02,50,'',NULL,NULL),(738,'evidence_1366','http://www.ncbi.nlm.nih.gov/pubmed/10073330','NOTE: The object_dose is the dose of risperidone given, the precip_dose is the venlafaxine dose given from days 8-14, and the AUC_i/AUC is calculated from Table II.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 15 days\r\n\r\npopulation: 24 healthy volunteers (18 male, 6 female)\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 19-45\r\n\r\ndescription:\r\nSUBJECTS: Thirty healthy male (22) and female (8) volunteers participated in the study. Informed consent was obtained for all subjects. Mean (range) age, weight, and height for the subjects were 29.6 years (19-45 years), 78.3 kg (46-102 kg), and 179 cm (158-198 cm), respectively.\r\n\r\nAll subjects were within +/- 15% of their ideal body weight and had acceptable physical examinations and laboratory tests for study entry. None had any known illness at baseline that might have interfered with the pharmacokinetics of the study drugs or the interpretation of the results. Twenty-eight of the 30 enrolled subjects completed the study. Two male subjects withdrew their consent, one on Day 8 during a morning clinic visit and the other on Day 12 before the morning dose of venlafaxine. Pharmacokinetic and pharmacodynamic data were evaluated for only 24 subjects. Four subjects were excluded from the analyses because of protocol violations. Two male subjects did not collect complete 96-hour urine samples, and 2 female subjects consumed xanthene-containing foods or beverages during the study.\r\n\r\n\r\nMETHODS: This was an open-label drug interaction study to evaluate the effects of steady-state venlafaxine on the pharmacokinetic disposition of single oral doses of risperidone. Single 1 mg doses of risperidone (1 mg Risperdal tablet, Janssen Pharmaceutica, Titusville, NJ) were administered on Days 1 and 11 with 180 mL of room-temperature water at approximately 10 a.m. following an overnight fast. Multiple doses of venlafaxine (37.5 mg and 75 mg Effexor tablets, Wyeth-Ayerst Laboratories, Radnor, PA) were administered as follows: 37.5 mg bid from Days 5 through 7 and then 75 mg twice daily from Days 8 through 14. Venlafaxine doses were administered with approximately 240 mL of room-temperature water at 8 a.m. and 8 p.m. with food (except during the designated fasting period on Day 11).\r\n\r\nSingle-dose pharmacokinetic profiles of risperidone and 9-hydroxyrisperidone and the total active moiety were evaluated on Days 1 through 5 (risperidone alone) and on Days 11 through 15 (risperidone plus venlafaxine).\r\n\r\nRESULTS: Peak plasma concentrations of 9-hydroxyrisperidone were significantly lower (4.03 +/- 2.08 ng/mL vs. 3.62 +/- 1.71 ng/mL) and significantly delayed (4.77 +/- 3.39 hours vs. 6.63 +/- 4.74 hours) following coadministration of risperidone and venlafaxine. Other pharmacokinetic parameters of 9-hydroxyrisperidone following risperidone administration were not significantly altered in the presence of steady-state venlafaxine. The mean apparent oral clearance and volume of distribution of 9-hydroxyrisperidone were not altered by venlafaxine coadministration, resulting in no significant change in its mean AUC_(0-inf). Bioequivalence criteria were met for both AUC_(0-inf) (90% CI = 95.2%-103%) and C_max (90% CI = 87.2%-99.8%) for 9-hydroxyrisperidone.\r\n\r\nCalculated from Table II, the AUC_i/AUC was 0.99.','boycer','09/22/2010 15:10:25\r\n','EV_PK_DDI_NR','PKStudy',0.99,0.001,0.15,24,'',NULL,NULL),(739,'evidence_1782','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Metabolism and Elimination\n\nZiprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methyl-dihydroziprasidone.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(740,'evidence_1385','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2D6 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent\n','boycer','09/25/2007 09:00:02\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(741,'evidence_1324','http://www.ncbi.nlm.nih.gov/pubmed/14551182','Route of administration: oral\n\nstudy duration: 40 participants were randomized to four groups of 10; one group of 10 received 10mg of MDZ on day followed by a washout of 2 days then participants were titrated to a dose of 200mg bid nefazodone and held at that dose until 12 days total of nefazodone treatment. On day 12 participants received a 10mg dose of MDZ. \n\npopulation: 17 male, 23 female\n\nages:18-50\n\nAUC_i/AUC (0-inf): 1171/257 = 4.56\n\n\n','boycer','11/13/2007 08:18:22\n','EV_PK_DDI_RCT','PKStudy',4.56,0.01,0.2,10,'',NULL,NULL),(742,'evidence_1892','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(743,'evidence_1613','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(744,'evidence_1806','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.02,NULL,NULL,NULL,'',NULL,NULL),(745,'evidence_1606','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 1\'-OH-alprazolam and recombinant cyp3a4 Supersome system; Km = 55','boycer','06/26/2007 07:50:38\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(746,'evidence_1203','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','(note that this value is for extended release but there appears to be no data in product labeling for non-XR formulations)\n\n136ng/1ml x 1g/10^9ng x 1000mL/1L = 0.000136g/L\n\nQuote:\nFollowing oral administration of Bupropion Hydrochloride Extended-Release Tablets, USP (SR) to healthy volunteers, peak plasma concentrations of bupropion are achieved within 3 hours. The mean peak concentration (Cmax) values were 91 and 143 ng/mL from 2 single-dose (150-mg) studies. At steady state, the mean Cmax following a 150-mg dose every 12 hours is 136 ng/mL.','boycer','05/15/2009 10:58:21\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000136,NULL,NULL,NULL,'',0.15,NULL),(747,'evidence_1367','http://www.ncbi.nlm.nih.gov/pubmed/9378846','\n\nroute of administration: oral\n\nstudy duration: &quot;On the morning of day I after an overnight fast, all of the volunteers ingested a single 150-mg bupropion sustained-release tablet with a glass of water.  Nineteen blood samples were collected from each volunteer, 1 immediately before and 18 during the 72 hours after administration (i.e., 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 24, 36, 48, 60, and 72 hours). On day 2, after the 24-hour postadministration assessment, all of the volunteers were released from the research unit, signifying the start of the outpatient period of the treatment phase.  During this period, volunteers returned to the research unit at scheduled times for blood draws.  Smokers were permitted to smoke cigarettes ad libitum during the study; in contrast, nonsmokers were required to refrain from smoking or using any tobacco products.&quot;\n\npopulation: 34 adults, 17 smokers (9 males/8 females) and 17 non-smokers (9 males/8 females)\n\ntested for known CYP450 polymorphisms? NO\n\nages: smokers - 26.7 SD:4.9; non-smokers - 25.7 SD:5.8\n\nNOTE: &quot;No clinically significant differences between smokers and nonsmokers or between male and female volunteers were observed for the pharmacokinetics of bupropion or its metabolites.&quot;\n\nC_max single-dose of 150mg EXTENDED RELEASE bupropion: 144ng/mL (the arithmetic average of C_max values for smokers and non-smokers)\n\n144ng/mL X 1g/10^9ng X 1000mL/1L = 0.000144g/L\n','boycer','06/20/2009 15:41:01\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000144,NULL,NULL,NULL,'',0.15,NULL),(748,'evidence_1244','http://www.ncbi.nlm.nih.gov/pubmed/3932079','\n\nroute of administration: oral\n\nstudy duration: Plasma profiles were obtained: 1) after a single 100 mg oral dose of [NON-XR] bupropion hydrochloride, 2) following administration of 100 mg 8-hourly for 14 days and 3) again after a single 100 mg dose 14 days later.\n\npopulation: 8 healthy, non-smoking, male subjects\n\ntested for known CYP450 polymorphisms? NO\n\nages: 22 - 42\n\nC_max @ 300mg/day of NON-XR bupropion for 14 days: 0.31micM/L (OCCASION 2, Table 1)\n\n0.31micM/1L X 1M/10^6micM X 272.2g/1M = 0.0000856g/L\n','boycer','06/22/2009 10:48:47\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000856,NULL,NULL,NULL,'',0.3,NULL),(749,'evidence_1959','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: dextromethorphan-o-demethylation\n\nk_i = 21.9micM\n\n21.9micM/L x 1M/10^6micM x 410.49g/1M = 0.009g/L ','boycer','05/06/2009 13:46:31\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.009,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,142),(750,'evidence_1817','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: bufuralol 1\'hydroxylation\n\nK_i = 6.9micM\n\n6.9micM/1L x 1M/10^6micM x 410.49g/1M = 0.003g/L','boycer','06/22/2009 12:09:50\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.003,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,143),(751,'evidence_1956','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(752,'evidence_1771','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','7.5  Effect of Atomoxetine on P450 Enzymes\n\nAtomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.','boycer','09/21/2009 14:55:32\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(753,'evidence_1771','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','\n&quot;The absolute oral bioavailability of paliperidone following INVEGA administration is 28%.&quot;','boycer','06/16/2009 16:12:22\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.28,NULL,NULL,NULL,'',NULL,NULL),(754,'evidence_1094','http://www.ncbi.nlm.nih.gov/pubmed/8988072','\nRoute of administration: oral\n\nstudy duration: 14 days\n\npopulation: 10 \n\nDose: 4 on 10mg q.d., 4 on 10mg b.i.d., and 2 on placebo\n\nages: within 19-55years\n\nC_max = 11.5ngEq/ml for the b.i.d. group and 7.41ngEq/ml for the q.d. group','boycer','09/27/2007 09:55:59\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000115,NULL,NULL,NULL,'',0.01,NULL),(755,'evidence_1912','http://www.ncbi.nlm.nih.gov/pubmed/8988072','\nRoute of administration: oral\n\nstudy duration: 14 days\n\npopulation: 10\n\nDose: 4 on 20mg q.d., 4 on 20mg b.i.d., and 2 on placebo\n\nages: within 19-55years\n\nC_max = 24.3ngEq/ml for the b.i.d. group and 14.9ngEq/ml for the q.d. group','boycer','09/27/2007 09:59:01\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000243,NULL,NULL,NULL,'',0.02,NULL),(756,'evidence_1966','http://www.ncbi.nlm.nih.gov/pubmed/8988072','\nRoute of administration: oral\n\nstudy duration: 14 days\n\npopulation: 10\n\nDose: 4 on 40mg q.d., 4 on 40mg b.i.d., and 2 on placebo\n\nages: within 19-55years\n\nC_max = 115ngEq/ml for the b.i.d. group and 66.8ngEq/ml for the q.d. group','boycer','09/27/2007 10:00:58\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000115,NULL,NULL,NULL,'',0.04,NULL),(757,'evidence_1591','http://www.ncbi.nlm.nih.gov/pubmed/8988072','\nRoute of administration: oral\n\nstudy duration: 14 days\n\npopulation: 10\n\nDose: 8 on 80mg q.d. and 2 on placebo\n\nages: within 19-55years\n\nC_max = 252ngEq/ml for the q.d. group','boycer','09/27/2007 10:02:30\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000252,NULL,NULL,NULL,'',0.08,NULL),(758,'evidence_1688','http://www.ncbi.nlm.nih.gov/pubmed/15114429','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 2 days ketoconazole pretreatment\n\npopulation: 8 male, 13 female\n\nages:23-55\n\ndescription: \nPlasma concentrations of midazolam, 1\'OH-midazolam and 4\'OH-midazolam were measured after the oral administration of 7.5 mg and 75 micro g midazolam in 13 healthy subjects without medication, in four subjects pretreated for 2 days with ketoconazole (200 mg b.i.d.), a CYP3A inhibitor, and in four subjects pretreated for 4 days with rifampicin (450 mg q.d.), a CYP3A inducer. RESULTS: After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1\'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively. No side effects were reported by the subjects taking this low dose of midazolam. Good correlations were observed between the 30-min total 1\'OH-midazolam/midazolam ratio and midazolam clearance in the group without co-medication (r(2)=0.64, P<0.001) and in the three groups taken together (r(2)=0.91, P<0.0001).','boycer','05/21/2007 15:16:35\n','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,144),(759,'evidence_1414','http://www.ncbi.nlm.nih.gov/pubmed/14551182','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 12 days\n\npopulation: 17 male, 23 female\n\nages:18-50\n\ndescription:\nForty healthy subjects were randomized to receive one of the four study drugs for 12 days in a parallel study design: fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days; fluvoxamine titrated to a daily dose of 200 mg; nefazodone titrated to a daily dose of 400 mg; or ketoconazole 200 mg per day. All 40 subjects received oral midazolam solution before and after the 12-day study drug regimen. Blood samples for determination of midazolam concentrations were drawn for 24 hours after each midazolam dose and used for the calculation of pharmacokinetic parameters. The effects of the study drugs on midazolam pharmacodynamics were assessed using the symbol digit modalities test (SDMT). The mean area under the curve (AUC) for midazolam was increased 771.9% by ketoconazole...','boycer','05/21/2007 15:27:20\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,145),(760,'evidence_1732','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1332','ketoconazole-janssen-2006-daily-med\n\nLabel date: 08/2006\nDate of DIKB entry: 05/21/2007\n\nAmbiguous statement? NO\n\ndescription:\nKetoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of NIZORAL Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. ','boycer','05/21/2007 16:08:37\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(761,'evidence_1369','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8ca815a8-bccb-4ee2-a042-922373329cae','Drug Interactions\n\nKetoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of ketoconazole tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. ','boycer','01/11/2010 17:05:33\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(762,'evidence_1758','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d15217da-4445-428f-9430-581bcb567c57','\nWhile this bioavailability value is from the label for the extended release formulation, the label states that it is comparable with the bioavailability of the non-extended release version (compare to Greenblatt 1993, Pmid: 8513649 - bioavailabilityu = 80-100%)\n\n','boycer','06/26/2007 06:41:02\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.9,NULL,NULL,NULL,'',NULL,NULL),(763,'evidence_1744','http://www.ncbi.nlm.nih.gov/pubmed/6152055','\nRoute of administration: oral/iv\n\nstudy duration: single dose of 1mg alprazolam given orally and by iv\n\npopulation: 6 male\n\nages:20-32\n\nQuote:\nSix fasting male subjects (20-32 years of age) received an oral tablet and an IV 1.0-mg dose of alprazolam in a crossover-design study. Alprazolam plasma concentration in multiple samples during 36 h after dosing was determined by electron-capture gas-liquid chromatography. Psychomotor performance tests, digit-symbol substitution (DSS), and perceptual speed (PS) were administered at 0, 1.25, 2.25, 5.0, and 12.5 h. Sedation was assessed by the subjects and by an observer using the Stanford Sleepiness Scale and a Nurse Rating Sedation Scale (NRSS), respectively. Mean kinetic parameters after IV and oral alprazolam were as follows: volume of distribution (Vd) 0.72 and 0.84 l/kg; elimination half-life (t1/2) 11.7 and 11.8 h; clearance (Cl) 0.74 and 0.89 ml/min/kg. There were no significant differences between IV and oral alprazolam in Vd, t1/2, or area under the curve. The mean fraction absorbed after oral administration was 0.92.','boycer','08/09/2007 08:34:07\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.92,NULL,NULL,NULL,'',NULL,NULL),(764,'evidence_1674','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.\n\nKetoconazole and Other CYP3A4 Inhibitors\n\nCoadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.\n\nQuinidine and Other CYP2D6 Inhibitors\n\nCoadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with Major Depressive Disorder, ABILIFY should be administered without dosage adjustment as specified in DOSAGE AND ADMINISTRATION (2.3).\n\nCarbamazepine and Other CYP3A4 Inducers\n\nCoadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced.','boycer','04/29/2009 19:51:34\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(765,'evidence_1871','http://www.ncbi.nlm.nih.gov/pubmed/10997944','\nEnzyme system: recombinant CYP450 enzymes in baculovirus-infected insect cells\n\nNADPH added: yes\n\nreaction: bupropion --&gt; hydroxybupropion\n\nQuote: \nEvaluation of BUP Hydroxylation by Individual cDNA-Ex- pressed Human P450s. Because the biphasic kinetic data observed with low activity HLMs (HLMs 20 and 24) indicated the contribution of more than one enzyme to BUP hydroxylation at higher substrate concentrations, a panel of eight cDNA-expressed enzymes (SUPER- SOMES) was screened for BUP hydroxylase activity at 12 mM to identify enzymes requiring further investigation (Fig. 7). This sub- strate concentration was selected to ensure saturation of any high Km isozyme capable of catalyzing BUP hydroxylation. cDNA-expressed CYP2B6 demonstrated the highest rate of HBUP formation (7.0 pmol/min/pmol of P450). cDNA-expressed CYP2E1 and CYP3A4 catalyzed BUP hydroxylation at the second and third highest rates, although at 3- and 30-fold lower rates than cDNA-expressed CYP2B6 (2.4 and 0.23 pmol/min/pmol of P450, respectively). Of note, CYP2E1 was the only cDNA-expressed enzyme in which cytochrome b5 was coexpressed. Rates of BUP hydroxylation by CYP1A2, CYP2A6, CYP2C9, CYP2C19, and CYP2D6 were greater than 30-fold lower than CYP2B6 (Fig. 7). HBUP formation in control microsomes was negligible. \n\n\n','boycer','06/19/2009 17:27:52\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(766,'evidence_1184','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','&quot;Fluvastatin is primarily (about 90%) eliminated in the feces as metabolites, with less than 2% present as unchanged drug. Urinary recovery is about 5%. After a radiolabeled dose of fluvastatin, the clearance was 0.8 L/h/kg. Following multiple oral doses of radiolabeled compound, there was no accumulation of fluvastatin; however, there was a 2.3- fold accumulation of total radioactivity.\n&quot;','boycer','10/20/2007 09:33:20\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(767,'evidence_1467','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/56b3f4c2-52af-4947-b225-6808ae9f26f5','\n&quot;Fluvoxamine\n\nThe effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady state concentration was evaluated in 10 male in-patients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased three-fold following co-administration of fluvoxamine. Fluvoxamine and thioridazine should not be co-administered&quot;','boycer','06/15/2009 15:46:29\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(768,'evidence_1012','http://www.ncbi.nlm.nih.gov/pubmed/2007317','\nroute of administration: oral\n\nstudy duration: single 25mg dose of thioridazine\n\npopulation: 19 healthy male subjects: 6 slow and 13 rapid hydroxylators of debrisoquin\n\nages: 19 - 41\n\nHPLC detected mesoridazine, thioridazine-5-sulfoxide (called thioridazine ring-sulphoxide in the study) and other metabolites\n\n','boycer','06/19/2009 19:19:46\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(769,'evidence_1274','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA, in it most recent guidance document, recommends this as a chemical inhibitor of CYP2C8 for in vitro experiments at a K_i of 1.7micM. See Table 2, p. 28\n\n1.7micM/L X 1M/10^6micM X 356.439g/M = 0.0006059g/L','boycer','06/30/2009 14:00:43\n','Non_Tracable_Statement','In_vitro_inhibition_study',0.0006059,NULL,NULL,NULL,'none_assigned',NULL,NULL),(770,'evidence_1572','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Absorption\n\nTablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%. ABILIFY can be administered with or without food. Administration of a 15 mg ABILIFY Tablet with a standard high-fat meal did not significantly affect the Cmax or AUC of aripiprazole or its active metabolite, dehydro-aripiprazole, but delayed Tmax by 3 hours for aripiprazole and 12 hours for dehydro-aripiprazole.\n\nOral Solution: Aripiprazole is well absorbed when administered orally as the solution. At equivalent doses, the plasma concentrations of aripiprazole from the solution were higher than that from the tablet formulation. In a relative bioavailability study comparing the pharmacokinetics of 30 mg aripiprazole as the oral solution to 30 mg aripiprazole tablets in healthy subjects, the solution to tablet ratios of geometric mean Cmax and AUC values were 122% and 114%, respectively [see DOSAGE AND ADMINISTRATION (2.6)]. The single-dose pharmacokinetics of aripiprazole were linear and dose-proportional between the doses of 5 mg to 30 mg.','boycer','04/29/2009 19:55:07\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.87,NULL,NULL,NULL,'',NULL,NULL),(771,'evidence_1902','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','06/30/2009 13:35:23\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(772,'evidence_1198','http://www.ncbi.nlm.nih.gov/pubmed/11038166','Enzyme system: recombinant human CYP3A4 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system catalyzed the above reactions with Km values od 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 25.6micM/L for the atorvastatin acid--&gt;para-hydroxy-atorvastatin\n','boycer','09/25/2007 08:46:11\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(773,'evidence_1062','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c','\nMetabolism\n\nZafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. ','boycer','09/24/2009 15:17:23\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(774,'evidence_1832','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/4259d9b1-de34-43a4-85a8-41dd214e9177','Ketoconazole - Combined administration of Celexa (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.','boycer','02/09/2012 10:08:53\n','Non_traceable_Drug_Label_Statement','PKStudy',0,0.04,0.2,NULL,'',NULL,NULL),(775,'evidence_1051','http://www.ncbi.nlm.nih.gov/pubmed/11213852','Route of administration: oral\n\nstudy duration: single dose\n\npopulation: 88 volunteers, 12 men, 6 women\n\nages: mean: 24.7\n\nDescription: \nPharmacokinetic parameters were determined after each treatment. The pharmacokinetic profile of citalopram administered alone was essentially identical to that when administered with ketoconazole. Similarly, the pharmacokinetics of the metabolite desmethylcitalopram were unaltered by ketoconazole.','boycer','02/09/2012 10:20:44\n','EV_PK_DDI_RCT','PKStudy',1.01,0.04,0.2,NULL,'',NULL,NULL),(776,'evidence_1691','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2','&quot;Following an oral dose of 14C-labeled lovastatin in man, 10% of the dose was excreted in urine and 83% in feces. The latter represents absorbed drug equivalents excreted in bile, as well as any unabsorbed drug. Plasma concentrations of total radioactivity (lovastatin plus 14C-metabolites) peaked at 2 hours and declined rapidly to about 10% of peak by 24 hours postdose. Absorption of lovastatin, estimated relative to an intravenous reference dose, in each of four animal species tested, averaged about 30% of an oral dose. In animal studies, after oral dosing, lovastatin had high selectivity for the liver, where it achieved substantially higher concentrations than in non-target tissues. Lovastatin undergoes extensive first-pass extraction in the liver, its primary site of action, with subsequent excretion of drug equivalents in the bile. As a consequence of extensive hepatic extraction of lovastatin, the availability of drug to the general circulation is low and variable. In a single dose study in four hypercholesterolemic patients, it was estimated that less than 5% of an oral dose of lovastatin reaches the general circulation as active inhibitors. Following administration of lovastatin tablets the coefficient of variation, based on between-subject variability, was approximately 40% for the area under the curve (AUC) of total inhibitory activity in the general circulation.&quot;\n','boycer','09/28/2007 13:54:17\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(777,'evidence_1811','http://www.ncbi.nlm.nih.gov/pubmed/16684709','Enzyme system: recombinant human enzymes in e.coli membranes\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam-->1\'-hydroxy-midazolam\n\nQuote:\nestimated k_i from Table 3: 8.82microM/L','boycer','06/25/2007 14:07:24\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Recom','In_vitro_inhibition_study',0.006,NULL,NULL,NULL,'Human_Recombinant_Enzymes',NULL,146),(778,'evidence_1208','http://www.ncbi.nlm.nih.gov/pubmed/15743977','\nEnzyme system: human enzymes liver microsomes\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam-->1\'-hydroxy-midazolam\n\nQuote:\nestimated k_i from Table 2: 15.2 microM/L','boycer','06/25/2007 14:30:42\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.011,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,147),(779,'evidence_1654','http://www.ncbi.nlm.nih.gov/pubmed/16679385','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: \nmidazolam --&gt; 1\'-OH-MDZ\n\nK_i = 11micM/L\n\nTable 2 on p1298 lists many k_i values from various studies. This evidence is from the last erythromycin study referenced as occuring by &quot;this laboratory&quot;.','boycer','10/16/2007 09:25:29\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.008,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,148),(780,'evidence_1647','http://www.ncbi.nlm.nih.gov/pubmed/9549635','Route of administration: oral\n\nstudy duration: 14days\n\ndose: 10mg atorvastatin 1xday for 14 days\n\npopulation: 19\n\nages:19-69\n\nDescription:\nNineteen subjects with calculated creatinine clearances ranging from 13 mL/min to 143 mL/min were administered 10 mg atorvastatin daily for 2 weeks. Pharmacokinetic parameters and lipid responses were analyzed by regression on calculated creatinine clearance. Correlations between steady-state atorvastatin pharmacokinetic or pharmacodynamic parameters and creatinine clearance were weak and, in general, did not achieve statistical significance.\n\n','boycer','09/24/2007 10:24:04\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(781,'evidence_1214','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0','&quot;Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.&quot;','boycer','09/27/2007 10:22:25\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(782,'evidence_1101','http://www.ncbi.nlm.nih.gov/pubmed/1680649','Route of administration: oral and IV\n\nstudy duration: 1 day, single dose cross-over with a 7-day washout period between administrations. IV: 9.9mg; PO: 19.2mg\n\npopulation: 8 male, 0 female\n\nages:21-39yrs\n\ndescription: \nIV: ~68% of parent compound (pravastatin) retrieved from urine and feces\n\nPO: ~29% of parent compound (pravastatin) retrieved from urine and ~48% retrieved from feces','boycer','08/10/2007 10:48:11\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(783,'evidence_1193','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP1A1 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent\n','boycer','09/25/2007 08:56:58\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(784,'evidence_1289','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',1.05,NULL,NULL,NULL,'',NULL,NULL),(785,'evidence_1246','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(786,'evidence_1728','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2D6 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent ','boycer','01/14/2008 12:55:21\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(787,'evidence_1135','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(788,'evidence_1959','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(789,'evidence_1553','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3249','&quot;Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of rosuvastatin. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by rosuvastatin.&quot;','boycer','09/28/2007 08:03:06\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(790,'evidence_1657','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=4844','Drug Interactions\n\nIn vitro drug metabolism studies suggest that there is a potential for drug interactions when trazodone is given with CYP3A4 inhibitors. Ritonavir, a potent CYP3A4 inhibitor, increased the Cmax, AUC, and elimination half-life, and decreased clearance of trazodone after administration of ritonavir twice daily for 2 days. Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were co-administered. It is likely that ketoconazole, indinavir, and other CYP3A4 inhibitors such as itraconazole or nefazodone may lead to substantial increases in trazodone plasma concentrations, with the potential for adverse effects. If trazodone is used with a potent CYP3A4 inhibitor, a lower dose of trazodone should be considered.\n\nCarbamazepine reduced plasma concentrations of trazodone when co-administered. Patients should be closely monitored to see if there is a need for an increased dose of trazodone when taking both drugs.','boycer','05/14/2009 14:33:26\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(791,'evidence_1678','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdfa991c-0ba9-4d12-ba4c-8909504c27d6','\nCLINICAL PHARMACOLOGY\n...\nFollowing oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. Plasma concentrations of metronidazole are proportional to the administered dose. Oral administration of 250 mg, 500 mg, or 2,000 mg produced peak plasma concentrations of 6 mcg/mL, 12 mcg/mL, and 40 mcg/mL, respectively. Studies reveal no significant bioavailability differences between males and females; however, because of weight differences, the resulting plasma levels in males are generally lower.\n\n6mcg/mL X 1g/10^6mcg X 1000mL/L = 0.0006g/L','boycer','09/24/2009 10:29:32\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.0006,NULL,NULL,NULL,'',0.25,NULL),(792,'evidence_1325','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdfa991c-0ba9-4d12-ba4c-8909504c27d6','\nCLINICAL PHARMACOLOGY\n...\nFollowing oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. Plasma concentrations of metronidazole are proportional to the administered dose. Oral administration of 250 mg, 500 mg, or 2,000 mg produced peak plasma concentrations of 6 mcg/mL, 12 mcg/mL, and 40 mcg/mL, respectively. Studies reveal no significant bioavailability differences between males and females; however, because of weight differences, the resulting plasma levels in males are generally lower.\n\n12mcg/mL X 1g/10^6mcg X 1000mL/L = 0.001g/L','boycer','09/24/2009 10:31:17\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.001,NULL,NULL,NULL,'',0.5,NULL),(793,'evidence_1417','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdfa991c-0ba9-4d12-ba4c-8909504c27d6','\nCLINICAL PHARMACOLOGY\n...\nFollowing oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. Plasma concentrations of metronidazole are proportional to the administered dose. Oral administration of 250 mg, 500 mg, or 2,000 mg produced peak plasma concentrations of 6 mcg/mL, 12 mcg/mL, and 40 mcg/mL, respectively. Studies reveal no significant bioavailability differences between males and females; however, because of weight differences, the resulting plasma levels in males are generally lower.\n\n40mcg/mL X 1g/10^6mcg X 1000mL/L = 0.004g/L','boycer','09/24/2009 11:56:43\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.004,NULL,NULL,NULL,'',2,NULL),(794,'evidence_1150','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(795,'evidence_1026','http://www.ncbi.nlm.nih.gov/pubmed/16390352','Enzyme system: recombinant human enzymes in human lymphoblastoid\nNADPH added: not explicitly mentioned but assumed\n\ninhibitor used: no\n\nQuetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4.','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(796,'evidence_1626','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Dextromethorphan: A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in Cmax of dextromethorphan.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(797,'evidence_1829','http://www.ncbi.nlm.nih.gov/pubmed/9431831','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: haloperidol --&gt; 4-(4-chlorophenyl)-4-\nhydroxypiperidine\n\nQuote: \nKetoconazole was a potent inhibitor of CPHP (4-(4-chlorophenyl)-4-hydroxypiperidine) formation with IC50 values of 0,10, 0,23 and 0,14 micM in microsomes HL-1, HL-6 and HL-9 respectively, wheras sulphaphenazole, furafylline and quinidine showed little inhibition (IC50 &gt; 100micM)','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(798,'evidence_1826','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(799,'evidence_1817','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nAn in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(800,'evidence_1438','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(801,'evidence_1944','http://www.ncbi.nlm.nih.gov/pubmed/1387301','\nRoute of administration: oral/iv\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days simvastatin only, 8 days simva and clarithromycin\n\ndose: single dose of .250g clarithromycin oral vs .250g i.v. infusion at three seperate times 1 week apart\n\npopulation: 20 men\n\nages:18-40\n\ndescription:\nThe absolute bioavailability of clarithromycin, a new macrolide antimicrobial agent, was assessed in a three-way, randomized, single-dose, crossover study conducted with 22 healthy volunteers, 19 of whom provided analyzable study data. The bioavailability parameters of two 250-mg oral tablet formulations were calculated with reference to an identical dose administered by intravenous infusion of the lactobionate salt. After adjustment for formulation potency, the mean absolute bioavailabilities of the two oral formulations were 52 and 55%, on the basis of the appearance of parent compound in the systemic circulation.','boycer','06/05/2007 11:46:56\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.55,NULL,NULL,NULL,'',NULL,NULL),(802,'evidence_1052','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(803,'evidence_1861','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3249','&quot;In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5 hours following oral dosing. Both peak concentration (Cmax) and area under the plasma concentration-time curve (AUC) increased in approximate proportion to rosuvastatin dose. The absolute bioavailability of rosuvastatin is approximately 20%&quot;','boycer','09/28/2007 07:57:12\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.2,NULL,NULL,NULL,'',NULL,NULL),(804,'evidence_1507','http://www.ncbi.nlm.nih.gov/pubmed/14667956','\nRoute of administration: oral/IV\n\nstudy duration: on day 1 participants received either one dose of 10mgPO rosuvastatin or one IV infusion of 8mg rosuvastatin; a period of &gt;=7 days elapsed and the participants were given the drug form that they did not receive the first time they came in to the clinic. \n\npopulation: 10 male\n\nages:21-51\n\nDescription:\n\nTable 1, pg2558 shows, among other PK values, that the geometric mean of oral Cmax was 18.8ng/ml, bioavailabity (F) was calculated to be 20% of the oral dose, the hepatic extraction (E_H)ratio was .63 \n\nBased on these values the authors calculated absorbtion to be &quot;appreciably greater than 20% and estimate it to ~50% using F/(1-E_H). ','boycer','09/28/2007 12:33:13\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.2,NULL,NULL,NULL,'',NULL,NULL),(805,'evidence_1525','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(806,'evidence_1509','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Dextromethorphan\n\nConsistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.','boycer','05/14/2009 13:42:42\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,149),(807,'evidence_1612','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(808,'evidence_1373','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(809,'evidence_1563','http://www.ncbi.nlm.nih.gov/pubmed/19142106','\nRoute of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: 100 mg desvenlafaxine on day 1 followed by 120 hours of PK data sampling; repeated on day 11\n\npopulation: healthy adults, non-smokers (&gt; 1yr), genotyped (7 CYP2D6 extensive metabolizers and 7 poor metabolizers)\n\nages: 18-55\n\ndescription: \nResults: After administration of venlafaxine ER, mean Cmax and AUC of venlafaxine were significantly greater in PMs compared with EMs, whereas mean Cmax and AUC of its metabolite, desvenlafaxine, were significantly lower for PMs than for EMs (P = 0.001, all comparisons). In contrast, mean Cmax and AUC of desvenlafaxine after administration of desvenlafaxine were comparable between EMs and PMs.\n','boycer','12172009','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(810,'evidence_1198','http://www.ncbi.nlm.nih.gov/pubmed/10048600','\nEnzyme system: human liver microsomes:\n\nNADPH added: note explicitly mentioned but acceptable methods assumed\n\ninhibitor used: ketoconazole\n\nreaction: risperidone 9-hydroxylation\n\nNOTE: experiment used 100micM of risperidone which is likely well above C_max based on PMID 7690693 \n\nQuote:\nrisperidone was incubated with human liver microsomes in the presence of different concentrations of inhibitors of CYP enzymes. Both quinidine (inhibitor of CYP2D6) and ketoconazole (inhibitor of CYP3A) inhibited the formation of 9-hydroxyrisperidone in a concentration-dependent manner (Fig. 4). \n\n','boycer','02/13/2010 09:43:11\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,150),(811,'evidence_1923','http://www.ncbi.nlm.nih.gov/pubmed/1438031','\nroute of administration: oral\n\nstudy duration: a three way cross-over study, 1) single dose of 100mg trazodone after overnight fasting, 2) single dose of 100mg trazodone after a standardized breakfast, 3) single IV infusion of  100mg trazodone after a standardized meal. two weeks in between drug adminstration events\n\npopulation: 8 adults, 4 males and 4 females\n\nages: 25 - 34 \n\nDescription: \nUrinary excretion of unchanged trazodone during 26 hr was less than 0.13 per cent of the administered dose, suggesting a high degree of trazodone metabolism.\n','boycer','06/16/2009 13:49:18\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(812,'evidence_1916','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(813,'evidence_1888','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote: \n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.\n\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(814,'evidence_1032','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','NOTE: XR and immediate release formulations have slightly different bioavailabilities. The higer of the two was chosen (XR = 29%).\n\nQuote:\n&quot;Following administration of a 10 mg dose, the absolute bioavailability is 24% (range 9%-50%). Administration with food reduces the rate but not the extent of absorption...Fluvastatin administered as Lescol XL 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low-fat meal, or 2.5 hours after a low-fat meal. The mean relative bioavailability of the XL tablet is approximately 29% (range: 9%-66%) compared to that of the Lescol immediate-release capsule administered under fasting conditions. Administration of a high-fat meal delayed the absorption (Tmax: 6H) and increased the bioavailability of the XL tablet by approximately 50%. &quot;','boycer','10/20/2007 09:31:37\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.29,NULL,NULL,NULL,'',NULL,NULL),(815,'evidence_1029','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','7.2 Effects of Ranolazine on Other Drugs\n\nIn vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(816,'evidence_1603','http://www.ncbi.nlm.nih.gov/pubmed/10460810','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: dextromethorphan-o-demethylation\n\nk_i = 7.2micM\n\n7.2micM/L x 1M/10^6micM x 375.9g/1M = 0.003g/L ','boycer','05/06/2009 13:43:26\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.003,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,151),(817,'evidence_1310','http://www.ncbi.nlm.nih.gov/pubmed/8866916','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: S-mephenytoin\n\nreaction: S-mephenytoin 4-hydroxylation\n\nKi = 69 micM\n\nMW: 326.83\n\n69micM/L X 1M/10^6micM X 326.83g/M = 0.023g/L\n\n\n','boycer','02/13/2010 08:51:07\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.023,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,152),(818,'evidence_1718','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/57c11bb8-d133-43e2-a74f-838c31296eb5','CLINICAL PHARMACOLOGY\n...\nFollowing single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours. Orally administered indomethacin capsules are virtually 100% bioavailable, with 90% of the dose absorbed within 4 hours.','boycer','09/24/2009 12:19:31\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',1,NULL,NULL,NULL,'',NULL,NULL),(819,'evidence_1293','http://www.ncbi.nlm.nih.gov/pubmed/9152603','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: sulphaphenazole\n\nreaction:\nclarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin\nclarithromycin --&gt; 14-N-demethylase-clarithromycin\n\ndescription:\nclarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor','boycer','01/14/2008 13:12:06\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,153),(820,'evidence_1819','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','06/30/2009 14:29:36\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(821,'evidence_1633','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/0a238e82-20d5-45ec-8c13-4725d1065230','Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose. Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (<5%).','boycer','05/29/2007 15:33:36\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(822,'evidence_1963','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2','&quot;Potent inhibitors of CYP3A4: Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a potent inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin.&quot;\n','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(823,'evidence_1298','http://www.ncbi.nlm.nih.gov/pubmed/8689812','\nRoute of administration: oral\n\nstudy duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4\n\npopulation: 12\nmale: 5\nfemale: 7 (2 on contraceptive steroids)\n\nages: 20-29\n\nAUC_i/AUC: 546/15 = &gt;36.4\nNOTE: AUC of lovastatin w/ placebo could not be measured but was known to be &lt; 15ng/ml*h','boycer','12172009','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(824,'evidence_1243','http://www.ncbi.nlm.nih.gov/pubmed/9152603','\nEnzyme system: human liver microsomes\nNADPH added: yes\n\ninhibitor used: quinidine\nreaction:\nclarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin\n\ndescription: clarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor','boycer','01/14/2008 13:20:24\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,154),(825,'evidence_1202','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(826,'evidence_1222','http://www.ncbi.nlm.nih.gov/pubmed/11910267','\nNOTE: The object dose given is the dose starting the 9th day of the study. The AUC_i/AUC is the comparison between study days 19 and 15.\n\nroute of administration: oral\n\nstudy duration: 19 days\n\npopulation: 7 subjects with selected psychotic disorders (all male)\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 21-59\n\ndescription:\nSUBJECTS: Thirteen men entered the study (eight were white, four black, and one mixed ethnicity). The mean (range) age, weight, and height of the patients were 37.5 (2159) years, 86.7 (49140) kg, and 177.8 (160193) cm, respectively. Nine men (69.2%) had schizoaffective disorder, three (23.1%) had bipolar disorder, and one (7.7%) had paranoid schizophrenia. Six patients were withdrawn because of lack of efficacy (N = 2), adverse events (N = 2), and refusal to continue (N = 2). All 13 patients were included in the safety analysis, but only the seven patients who completed the entire study were entered into the pharmacokinetic analysis.\n\nMETHODS:   Thirteen men (aged 1860 years) with selected psychotic disorders were entered into this open-label, non-randomized, escalating-dose, pharmacokinetic trial conducted at a single center.  Psychotropic medications were withdrawn on day, 1 and patients underwent a 2-day washout period. On days 3 to 8, patients received quetiapine in escalating doses from 25 to 150 mg three times daily, at approximately 7 a.m., 3 p.m., and 11 p.m. Quetiapine 150 mg three times daily was then administered on days 9 to 18. The final dose was given on the morning of day 19. Cimetidine 400 mg was initiated on the afternoon of day 15 and was administered three times daily with each dose of quetiapine thereafter.\n\nRESULTS: The mean plasma concentration versus time profiles for quetiapine determined on days 11, 15, and 19 were similar with a slight increase in the mean plasma concentration during coadministration with cimetidine. Using day 15 as baseline, geometric mean steady-state AUC_08h and C_max increased by 24% and 19%, respectively, after coadministration with cimetidine (day 19). Using day 11 as baseline, however, increases of only 10% and 4% were detected. In addition, differences between the 2 baseline days (11 and 15) in mean steady-state AUC_08h and C_max were 13% and 14%, respectively (intrasubject variability).\n\nThe geometric mean quetiapine AUC_08h,ss was significantly higher with cimetidine than without compared with day 15 (p=0.002) but not on day 11 (p=0.09). However, variability between the days without cimetidine coadministration (i.e., days 11 and 15) was also significant (p=0.04), with a change of 13% (p=0.04).','boycer','09/16/2010 12:29:46\n','EV_PK_DDI_NR','PKStudy',1.24,0.45,1.2,7,'',NULL,NULL),(827,'evidence_1890','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(828,'evidence_1871','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: 7-ethoxyresoruvin O-deethylation\n\nThe IC50 for ziprasidone inhibition of this reaction was greater than 100micM \n\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(829,'evidence_1283','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf','\nDrug Interactions\n...\nIn vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity.','boycer','09/24/2009 12:43:32\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(830,'evidence_1866','http://www.ncbi.nlm.nih.gov/pubmed/10741630','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 14 days diltiazem pretreatment\n\npopulation: 5 male, 5 women\n\nages:19-35\n\n(mean AUC_i)/(mean AUC) = 55.4/11.5\n\ndescription: \nA fixed-order study was conducted in 10 healthy volunteers with a 2-week washout period between the phases. In one arm of the study, a single 20-mg dose of simvastatin was administered orally; the second arm entailed administration of a single 20-mg dose of simvastatin orally after 2 weeks of treatment with 120 mg diltiazem twice a day. RESULTS: Diltiazem significantly increased the mean peak serum concentration of simvastatin by 3.6-fold (P < .05) and simvastatin acid by 3.7-fold (P < .05). Diltiazem also significantly increased the area under the serum concentration-time curve of simvastatin 5-fold (P < .05) and the elimination half-life 2.3-fold (P < .05).','boycer','05/29/2007 10:27:50\n','EV_PK_DDI_NR','PKStudy',4.817,0.02,0.12,10,'',NULL,NULL),(831,'evidence_1711','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: S-mephenytoin\n\nreaction: S-mephenytoin hydroxylation\n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).\n\n\n','boycer','02132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(832,'evidence_1696','http://www.ncbi.nlm.nih.gov/pubmed/9431831','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: haloperidol --&gt; 4-(4-chlorophenyl)-4-\nhydroxypiperidine\n\nQuote: \nKetoconazole was a potent inhibitor of CPHP (4-(4-chlorophenyl)-4-hydroxypiperidine) formation with IC50 values of 0,10, 0,23 and 0,14 micM in microsomes HL-1, HL-6 and HL-9 respectively, wheras sulphaphenazole, furafylline and quinidine showed little inhibition (IC50 &gt; 100micM)','boycer','06/17/2009 07:57:02\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,155),(833,'evidence_1884','http://www.ncbi.nlm.nih.gov/pubmed/7923194','\nEnzyme system: recombinant human enzyme in Hep G2 cells\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel\n\nOnly CYP2C8 formed detectable 6alpha-OH-paclitaxel in experiments using recombinant CYPs 1A2, 3A4, 3A5, 2B6, 2C8, 2C9, 2C9R144C \n\n\n\n\n','boycer','10/29/2007 09:47:10\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(834,'evidence_1907','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(835,'evidence_1513','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71be4cb7-a42f-43be-9b9b-f090edb2fd21','\nAbsorption\n\nZaleplon is rapidly and almost completely absorbed following oral administration. Peak plasma concentrations are attained within approximately 1 hour after oral administration. Although zaleplon is well absorbed, its absolute bioavailability is approximately 30% because it undergoes significant presystemic metabolism. ','boycer','09/23/2009 16:11:30\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.3,NULL,NULL,NULL,'',NULL,NULL),(836,'evidence_1447','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645','Drug Interactions\n...\nAmiodarone is also known to be an inhibitor of CYP3A4. Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4. While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, the potential for other interactions should be anticipated. This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics. If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured. In view of the long and variable half-life of amiodarone, potential for drug interactions exists, not only with concomitant medication, but also with drugs administered after discontinuation of amiodarone.','boycer','01/11/2010 16:35:31\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(837,'evidence_1216','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(838,'evidence_1315','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(839,'evidence_1952','http://www.ncbi.nlm.nih.gov/pubmed/10771448','\nroute of administration: oral\n\nstudy duration: &quot;Methods Single and multiple doses of ziprasidone were given orally (as two divided daily doses), at fixed dosages of 10 and 40 mg/day, and using titrated regimens of 40 +/- 80 and 40 +/-120 mg/day, for 14 days. All dosages were taken immediately after food.\n\npopulation: 39 healthy, non-smoking, males. None were tested for known CYP450 phenotypes. &quot;In this double-blind, parallel-group study, subjects were randomised to receive placebo or one of four doses of ziprasidone&quot;\n\nages: 18 - 49\n\nC_max @ 10mg/day: 14.8ng/mL\n\n14.8ng/mL x 1g/10^9ng x 1000mL/1L = 0.0000148g/L \n\n\n','boycer','06/19/2009 18:35:16\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000148,NULL,NULL,NULL,'',0.01,NULL),(840,'evidence_1547','http://www.ncbi.nlm.nih.gov/pubmed/10771448','\n\nroute of administration: oral\n\nstudy duration: &quot;Methods Single and multiple doses of ziprasidone were given orally (as two divided daily doses), at fixed dosages of 10 and 40 mg/day, and using titrated regimens of 40 +/- 80 and 40 +/-120 mg/day, for 14 days. All dosages were taken immediately after food.\n\npopulation: 39 healthy, non-smoking, males. None were tested for known CYP450 phenotypes. &quot;In this double-blind, parallel-group study, subjects were randomised to receive placebo or one of four doses of ziprasidone&quot;\n\nages: 18 - 49\n\nC_max @ 40mg/day: 44.6ng/mL\n\n44.6ng/mL x 1g/10^9ng x 1000mL/1L = 0.0000446g/L \n\n\n','boycer','06/19/2009 18:37:46\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000446,NULL,NULL,NULL,'',0.04,NULL),(841,'evidence_1570','http://www.ncbi.nlm.nih.gov/pubmed/10771448','\nroute of administration: oral\n\nstudy duration: &quot;Methods Single and multiple doses of ziprasidone were given orally (as two divided daily doses), at fixed dosages of 10 and 40 mg/day, and using titrated regimens of 40 +/- 80 and 40 +/-120 mg/day, for 14 days. All dosages were taken immediately after food.\n\npopulation: 39 healthy, non-smoking, males. None were tested for known CYP450 phenotypes. &quot;In this double-blind, parallel-group study, subjects were randomised to receive placebo or one of four doses of ziprasidone&quot;\n\nages: 18 - 49\n\nC_max @ 80mg/day: 118.6ng/mL\n\n118.6ng/mL x 1g/10^9ng x 1000mL/1L = 0.0001186g/L \n\n\n','boycer','06/19/2009 18:41:36\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0001186,NULL,NULL,NULL,'',0.08,NULL),(842,'evidence_1035','http://www.ncbi.nlm.nih.gov/pubmed/10771448','\nroute of administration: oral\n\nstudy duration: &quot;Methods Single and multiple doses of ziprasidone were given orally (as two divided daily doses), at fixed dosages of 10 and 40 mg/day, and using titrated regimens of 40 +/- 80 and 40 +/-120 mg/day, for 14 days. All dosages were taken immediately after food.\n\npopulation: 39 healthy, non-smoking, males. None were tested for known CYP450 phenotypes. &quot;In this double-blind, parallel-group study, subjects were randomised to receive placebo or one of four doses of ziprasidone&quot;\n\nages: 18 - 49\n\nC_max @ 120mg/day: 139.4ng/mL\n\n139.4ng/mL x 1g/10^9ng x 1000mL/1L = 0.0001394g/L \n\n\n','boycer','06/19/2009 18:44:50\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0001394,NULL,NULL,NULL,'',0.12,NULL),(843,'evidence_1099','http://www.ncbi.nlm.nih.gov/pubmed/10771449','\n\nroute of administration: oral\n\nstudy duration: &quot;oral ziprasidone 40 mg/day, in two evenly divided daily doses, for 7 days, followed by a single 20 mg dose on day 8.&quot; \n\npopulation: 35 participants including Eight young men, 11 young women (NOTE: three withdrew early on in the study), 8 elderly men and 8 elderly women where young is defined as 18-45 years of age and elderly is defined as (&gt; or = 65 years). All participants were considered healthy and the majority were white.\n\ntested for known CYP450 polymorphisms? NO\n\nages: see above\n\nC_max @ 40mg/day ziprasidone for 7 days (average of combined young and old C_max from Table 3): (69 + 85) / 2 = 77ng/mL\n\n77ng/mL X 1g/10^9ng X 1000mL/1L = 0.000077g/L\n \n\n\n','boycer','06/22/2009 10:22:16\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000077,NULL,NULL,NULL,'',0.04,NULL),(844,'evidence_1235','http://www.ncbi.nlm.nih.gov/pubmed/10771449','\nroute of administration: oral\n\nstudy duration: &quot;oral ziprasidone 40 mg/day, in two evenly divided daily doses, for 7 days, followed by a single 20 mg dose on day 8.&quot;\n\npopulation: 35 participants including Eight young men, 11 young women (NOTE: three withdrew early on in the study), 8 elderly men and 8 elderly women where young is defined as 18-45 years of age and elderly is defined as (&gt; or = 65 years). All participants were considered healthy and the majority were white.\n\ntested for known CYP450 polymorphisms? NO\n\nages: see above\n\nC_max @ 20mg single dose ziprasidone (average of combined young and old C_max from Table 2): (56 + 60) / 2 = 58ng/mL \n\n58ng/mL X 1g/10^9ng X 1000mL/1L = 0.000058g/L','boycer','06/22/2009 10:27:28\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000058,NULL,NULL,NULL,'',0.02,NULL),(845,'evidence_1531','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote:\n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.\n','boycer','06/12/2009 11:00:24\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,156),(846,'evidence_1562','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','12.3 Pharmacokinetics\n\nDuloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state plasma concentrations are typically achieved after 3 days of dosing. Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP1A2 and CYP2D6.','boycer','05/05/2009 17:51:26\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(847,'evidence_1765','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','duloxetine is listed as a moderate inhibitor in Table 6 (p23) but does not show up in Table 2 (a table listing several selective in viVo inhibitors)','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(848,'evidence_1592','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.9 Drugs Metabolized by CYP2D6\n\nDuloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold [see Warnings and Precautions (5.10)].\n\n','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(849,'evidence_1066','http://www.ncbi.nlm.nih.gov/pubmed/12621382','\nroute of administration: oral\n\nstudy duration: &quot;Study 1 was conducted in 2 distinct periods separated by a 7-day washout. In period 1, a single 50-mg dose of desipramine was administered, and blood samples were obtained for the measurement of desipramine plasma concentrations immediately before the dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 hours after dosing. In period 2, duloxetine was administered at an initial dose of 40 mg twice daily. Subjects who did not tolerate this dose were allowed to have the dose lowered to 20 mg twice daily for up to 5 doses, after which dosing at 40 mg twice daily was resumed. On the seventh day of duloxetine dosing (day 14 of the overall protocol), the dose was increased to 60 mg twice daily and was continued at that level for an additional 14 days. On day 21 of the overall protocol (day 8 of duloxetine 60 mg twice daily dosing), a 50-mg dose of desipramine was administered. Blood samples were drawn to determine desipramine plasma concentrations as described for period 1, with additional samples at 168 and 192 hours after the desipramine dose. On the day before and the day of the period 2 desipramine dose (protocol days 20 and 21), blood samples for the measurement of duloxetine plasma concentrations were drawn immediately before duloxetine administration and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after administration.&quot;\n\npopulation: 14 healthy, non-smoking, adults; 7 male, 7 female; nearly all were of apparent European decent (&quot;white&quot;)\n\ntested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.\n\nages: 21 - 63\n\ndescription:\n&quot;Duloxetine increased the maximum plasma concentration of desipramine 1.7-fold and the area under the concentration-time curve 2.9-fold.&quot;\n\n','boycer','01132010','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(850,'evidence_1577','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(851,'evidence_1565','http://www.ncbi.nlm.nih.gov/pubmed/11009047','NOTE: The AUC_i/AUC value given is the AUC_0-24.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 14 days\r\n\r\npopulation: 12 healthy volunteers (all male), not heavy smokers (&lt;10 cigarettes/day).\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 18-45\r\n\r\ndescription:\r\nSUBJECTS: Twelve healthy male volunteers aged 18-45 years participated in this study. They were extensively screened within 3 weeks of study entry and had to be medically and mentally healthy, as evidenced by medical history, full physical examination, routine clinical laboratory investigations and electrocardiograms (ECGs). Their body-mass index had to be within the range 19 +/- 29 kg/m2, and they were not allowed to be heavy smokers (less than ten cigarettes or equivalent per day). On admission to the unit, they were screened for alcohol or drug use. No concomitant medication was allowed, with the exception of paracetamol for severe (head)aches.\r\n\r\nMETHODS: Twelve male subjects meeting the inclusion and exclusion criteria were randomly assigned to one of two groups in this two-period crossover study, with a medication-free washout interval of at least 2 weeks. For each study period, they were admitted to the clinical pharmacology institute 1 day before the start of the study. After admission, subjects were re-screened for alcohol and drugs. During one treatment period, subjects were given cimetidine (800 mg b.i.d. orally) for 14 days, with mirtazapine (30 mg nocte orally) added from the 6th to the 12th day of this period. During the alternate treatment period, cimetidine tablets were replaced by placebo tablets. Medication was taken together with water. Standard meals and snacks were served at fixed times of day. The use of alcohol was forbidden for 48 h prior to the start of the study and up to 48 h after the last study day. There were restrictions with regard to the use of coffee, tea and chocolate. The daily dosages of mirtazapine (30 mg nocte) and cimetidine (800 mg b.i.d.) were in agreement with the manufacturers\' recommendations and coincided with current therapeutic practice.\r\n\r\nRESULTS: The combined administration of mirtazapine and cimetidine resulted in a statistically significant increase in AUC_0-24 of mirtazapine compared with the administration of mirtazapine as a single drug (AUC_0-24: 979 versus 635 ng x h/ml).','boycer','09/16/2010 12:05:16\r\n','EV_PK_DDI_RCT','PKStudy',1.54,0.03,1.6,12,'',NULL,NULL),(852,'evidence_1819','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(853,'evidence_1433','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/6c76e98d-b8c3-441f-bac5-a9de6dc8f14f','Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours. In a study in which normal volunteers (n=12) received perphenazine 4 mg q8h for 5 days, steady-state concentrations of perphenazine were reached within 72 hours. Mean (%CV) Cmax and Cmin values for perphenazine and 7-hydroxyperphenazine at steady-state are listed below:\n\nParameter	Perphenazine	7-Hydroxyperphenazine\nCmax (pg/mL)	984 (43)	509 (25)\nCmin (pg/mL)	442 (76)	350 (56)\n\nPeak 7-hydroxyperphenazine concentrations were observed between 2 to 4 hours with a terminal phase half-life ranging between 9.9 to 18.8 hours. ','boycer','05/06/2009 13:05:37\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(854,'evidence_1746','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/0a238e82-20d5-45ec-8c13-4725d1065230','The major active metabolites of simvastatin present in human plasma are the &#946;-hydroxyacid of simvastatin and its 6&#8242;-hydroxy, 6&#8242;-hydroxymethyl, and 6&#8242;-exomethylene derivatives.','boycer','05/29/2007 14:41:49\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(855,'evidence_1334','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 4-OH-alprazolam in a recombinant cyp3a4 Supersome system Km = 81','boycer','06/26/2007 07:48:37\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(856,'evidence_1265','http://www.ncbi.nlm.nih.gov/pubmed/18307373','\nNOTE: The AUC_i/AUC value is the AUC_0-inf of the oral dose of duloxetine. The object drug\'s dose given is the oral dose.\n\nroute of administration: oral (both duloxetine and fluvoxamine), and IV (duloxetine)\n\nstudy duration: 24 days\n\npopulation: 14 healthy smokers (all male)\n\ntested for known CYP450 polymorphisms? No\n\nages: 18-65\n\ndescription: Healthy subjects were selected by the investigators based on their medical history, physical examination, ECGs and routine clinical laboratory test results. Up to 18 male smokers (aged 1865 years) were to be enrolled in the fluvoxamine study. Sixteen men who were smokers were enrolled, and 14 completed the study. Two subjects were withdrawn by the investigator before receiving the study drug. The mean (+/- SD) age of the subjects was 37 +/- 11 years, the mean height was 174 +/- 6 cm, the mean bodyweight was 76.9 +/- 10.6 kg and the mean body mass index (BMI) was 25.4 +/- 2.9 kg/m2. The majority of subjects were Caucasian (81%) and the rest were African American.\n\nMETHODS: This was an open-label, four-period, sequential crossover study. The dosing sequence started with duloxetine administration only (intravenous or oral; dosing periods 1 and 2), followed by duloxetine (intravenous or oral) in the presence of steady-state fluvoxamine (dosing periods 3 and 4). Duloxetine administration was planned on days 1, 5, 14 and 20 and fluvoxamine was administered from days 8 to 24. The sequence of intravenous and oral duloxetine dosing was randomized. The oral dose of duloxetine was a single 60-mg dose and the intravenous dose of duloxetine was a 10-mg infusion over 30 minutes. Fluvoxamine was initiated at a single dose of 50 mg for 1 day followed by 100 mg once daily for at least 16 additional days. Subjects unable to tolerate fluvoxamine 100 mg once daily were discontinued from the study. The washout period between each dose of duloxetine was a minimum of 4 days and a maximum of 14 days.\n\nRESULTS: The oral duloxetine C_max and AUC_inf were increased by 141% (90% CI 93, 200) and 460% (90% CI 359, 584), respectively, whereas the intravenous duloxetine AUC_inf increased by 170% (90% CI 121, 230).','boycer','09/01/2010 15:15:26\n','EV_PK_DDI_NR','PKStudy',4.6,0.06,0.1,14,'',NULL,NULL),(857,'evidence_1954','http://www.ncbi.nlm.nih.gov/pubmed/9331518','route of administration: oral\n\nstudy duration: 2 weeks\n\npopulation: 18 nonsmoking white men\n\ntested for known CYP450 polymorphisms? NO\n\nages: 19-27\n\ndescription:\nSUBJECTS: Eighteen nonsmoking white men participated in the study. The subjects were healthy as determined by medical history, physical examination, electrocardiography (ECG), and standard clinical chemistry and hematology tests. The subjects were not allowed to take any other medication for 2 weeks before or during the study.\n\nMETHODS: The study was conducted in two parts. In part 1, the 18 subjects were randomized into two parallel groups to receive in a double-blind fashion either 20 mg of citalopram (group A, n = 12; Cipramil, Lundbeck, Copenhagen, Denmark) or placebo (group B, n = 6) orally once daily for 14 days. Selegiline 10 mg (Eldepryl, Orion) once daily was added to both medications from day 11 to day 14. The groups were comparable with respect to demographic characteristics and baseline blood pressure and heart rate (Table 1). After a 5-week wash-out period, the 12 subjects that had received citalopram in part 1 of the study (group A) continued to part 2 to receive 10 mg of selegiline once daily for 4 days in an open cross-over mannger, in order to study the pharmacokinetics of selegiline without citalopram.\n\nRESULTS: The mean AUC (0-5 h) of selegiline was 29% (p = 0.008; Table 3 and Fig. 4) lower in group A subjects when selegiline was administered concomitantly with citalopram compared with selegiline alone.','boycer','02/09/2012 11:36:43\n','EV_PK_DDI_RCT','PKStudy',0.7,0.01,0.02,NULL,'',NULL,NULL),(858,'evidence_1382','http://www.ncbi.nlm.nih.gov/pubmed/10997944','\nEnzyme system: recombinant CYP450 enzymes in baculovirus-infected insect cells\n\nNADPH added: yes\n\nreaction: bupropion --&gt; hydroxybupropion\n\nQuote: \nEvaluation of BUP Hydroxylation by Individual cDNA-Ex- pressed Human P450s. Because the biphasic kinetic data observed with low activity HLMs (HLMs 20 and 24) indicated the contribution of more than one enzyme to BUP hydroxylation at higher substrate concentrations, a panel of eight cDNA-expressed enzymes (SUPER- SOMES) was screened for BUP hydroxylase activity at 12 mM to identify enzymes requiring further investigation (Fig. 7). This sub- strate concentration was selected to ensure saturation of any high Km isozyme capable of catalyzing BUP hydroxylation. cDNA-expressed CYP2B6 demonstrated the highest rate of HBUP formation (7.0 pmol/min/pmol of P450). cDNA-expressed CYP2E1 and CYP3A4 catalyzed BUP hydroxylation at the second and third highest rates, although at 3- and 30-fold lower rates than cDNA-expressed CYP2B6 (2.4 and 0.23 pmol/min/pmol of P450, respectively). Of note, CYP2E1 was the only cDNA-expressed enzyme in which cytochrome b5 was coexpressed. Rates of BUP hydroxylation by CYP1A2, CYP2A6, CYP2C9, CYP2C19, and CYP2D6 were greater than 30-fold lower than CYP2B6 (Fig. 7). HBUP formation in control microsomes was negligible. \n\n\n','boycer','06/19/2009 17:28:21\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(859,'evidence_1460','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA recommends this as a CYPC19 substrate for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','09/24/2009 10:38:30\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(860,'evidence_1533','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','&quot;\nFluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.\n\n      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;','boycer','10/20/2007 09:39:51\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(861,'evidence_1649','http://www.ncbi.nlm.nih.gov/pubmed/8880291','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 5 day petreatment with clarithromycin \n\npopulation: 4 male, 8 female\n\nages:24-53\n\nIn an open randomized crossover study of 3 phases 12 healthy volunteers received either clarithromycin (250 mg twice a day for 5 days), azithromycin (500 mg once a day for 3 days) or no pretreatment. On the last day of antibiotic treatment they ingested 15 mg midazolam. Plasma samples were collected for midazolam analysis up to 24 h and pharmacodynamic performance measured by a series of tests up to 12 h. Pretreatment with clarithromycin caused large and statistically significant changes in both the pharmacokinetic and pharmacodynamic parameters of midazolam compared to control. For example, the AUC was increased from 248.84-888.75 hng/ml (factor of 3.57, p < 0.0001) and the mean duration of sleep increased from 135.4 min to 281.3 min (p < 0.05).','boycer','06/05/2007 14:12:44\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,157),(862,'evidence_1479','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 13:05:51\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(863,'evidence_1466','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/aa44552c-3cfe-4111-8aa5-4251aeed9be9','Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.\n\nClarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.','boycer','01/11/2010 16:45:51\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(864,'evidence_1697','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 13:07:14\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(865,'evidence_1347','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/aa44552c-3cfe-4111-8aa5-4251aeed9be9','Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.\n\nClarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.','boycer','01/11/2010 16:47:28\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(866,'evidence_1841','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(867,'evidence_1962','http://www.ncbi.nlm.nih.gov/pubmed/15114429','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 2 days ketoconazole pretreatment\n\npopulation: 8 male, 13 female\n\nages:23-55\n\ndescription: \nPlasma concentrations of midazolam, 1\'OH-midazolam and 4\'OH-midazolam were measured after the oral administration of 7.5 mg and 75 micro g midazolam in 13 healthy subjects without medication, in four subjects pretreated for 2 days with ketoconazole (200 mg b.i.d.), a CYP3A inhibitor, and in four subjects pretreated for 4 days with rifampicin (450 mg q.d.), a CYP3A inducer. RESULTS: After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1\'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively. No side effects were reported by the subjects taking this low dose of midazolam. Good correlations were observed between the 30-min total 1\'OH-midazolam/midazolam ratio and midazolam clearance in the group without co-medication (r(2)=0.64, P<0.001) and in the three groups taken together (r(2)=0.91, P<0.0001).','boycer','12172009','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(868,'evidence_1484','http://www.ncbi.nlm.nih.gov/pubmed/14551182','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 12 days\n\npopulation: 17 male, 23 female\n\nages:18-50\n\ndescription:\nForty healthy subjects were randomized to receive one of the four study drugs for 12 days in a parallel study design: fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days; fluvoxamine titrated to a daily dose of 200 mg; nefazodone titrated to a daily dose of 400 mg; or ketoconazole 200 mg per day. All 40 subjects received oral midazolam solution before and after the 12-day study drug regimen. Blood samples for determination of midazolam concentrations were drawn for 24 hours after each midazolam dose and used for the calculation of pharmacokinetic parameters. The effects of the study drugs on midazolam pharmacodynamics were assessed using the symbol digit modalities test (SDMT). The mean area under the curve (AUC) for midazolam was increased 771.9% by ketoconazole...','boycer','12172009','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(869,'evidence_1221','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/090660C1-6E6D-457F-ADB5-046DDFCD1465','ketoconazole-janssen-2006-daily-med\n\nLabel date: 08/2006\nDate of DIKB entry: 05/21/2007\n\nAmbiguous statement? NO\n\ndescription:\nKetoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of NIZORAL Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(870,'evidence_1807','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8ca815a8-bccb-4ee2-a042-922373329cae','Drug Interactions\n\nKetoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of ketoconazole tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(871,'evidence_1641','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(872,'evidence_1038','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71be4cb7-a42f-43be-9b9b-f090edb2fd21','\nMetabolism\n\nAfter oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Zaleplon is primarily metabolized by aldehyde oxidase to form 5-oxo-zaleplon. Zaleplon is metabolized to a lesser extent by cytochrome P450 (CYP) 3A4 to form desethylzaleplon, which is quickly converted, presumably by aldehyde oxidase, to 5-oxo-desethylzaleplon. These oxidative metabolites are then converted to glucuronides and eliminated in urine. All of zaleplon\'s metabolites are pharmacologically inactive. ','boycer','11/09/2009 12:41:35\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(873,'evidence_1477','http://www.ncbi.nlm.nih.gov/pubmed/17687273','NOTE: The AUC_i/AUC is from the AUC_0-inf of all the subjects taken together, not separated by genotype.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 4 days\r\n\r\npopulation: 12 healthy volunteers (all male), all nonsmokers\r\n\r\ntested for known CYP450 polymorphisms? Yes -- CYP2D6 genotypes - 8 EMs, 1 PM, 3 UMs \r\n\r\nages: 20-29\r\n\r\ndescription: 12 male volunteers (age range: 2029 years; weight range: 6589 kg) were recruited. The subjects were ascertained to be in good health by medical history, physical examination, and standard hematological and clinical chemistry tests. All subjects were non-smokers and used no concomitant medications.\r\n\r\nAll 12 subjects completed the study according to the protocol. Genotyping of CYP2D6 revealed that eight subjects could be classified as EMs: six of them were homozygous for CYP2D6*1 allele, and two of them had the genotype CYP2D6*1/*4. One subject was classified as PM having the CYP2D6*3/*4 genotype, and three subjects without *3 or *4 were classified as UMs having a CYP2D6*1/*1x2 genotype. This high frequency of UM (25%) was much more than expected, but the subjects were not selected for the study by genotype.\r\n\r\nMETHODS: The study was an open-label, randomized, three-phase crossover study with a washout period of 4 weeks between the phases. The volunteers were given either no pretreatment (control phase) or oral terbinafine (terbinafine phase) for 4 days in a randomized order. The dose of terbinafine (Lamisil 250mg tablet; Novartis Pharma, Huningue, France) was 250mg once a day at 0800 hours for 4 days. Terbinafine were self-administered by subjects except for the last doses, which were administered by the study personnel.\r\n\r\nOne hour after the last dose of terbinafine was ingested, all volunteers received 75 mg oral dose of venlafaxine (Efexor 75 mg tablet; Wyeth Pharmaceuticals, New Lane, Havant, Hants, England) at 0900 hours with 150 ml of water. During all phases, the subjects fasted overnight before administration of venlafaxine and continued fasting until a standardized lunch was served 4 h after venlafaxine ingestion. The subjects were forbidden to use any other medication for 14 days before and during the study and any drug known to cause enzyme induction or inhibition for a period of 30 days before the study. Caffeine, grapefruit juice, and alcohol-containing beverages were not allowed during the study.\r\n\r\nRESULTS: When all the subjects were examined together, without subdivision into groups according to the genotype, terbinafine pretreatment increased the area under the plasma concentrationtime curve (AUC_0inf) of venlafaxine 4.9-fold (range: 1.5- to 8.2-fold; P&lt;0.001).\r\n\r\n\r\n','boycer','09/01/2010 15:40:49\n','EV_PK_DDI_RCT','PKStudy',4.9,0.075,0.25,12,'',NULL,NULL),(874,'evidence_1891','http://www.ncbi.nlm.nih.gov/pubmed/9825830','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor: troleandomycin\n\nreaction: reduced-haloperidol --&gt; 4-(4-chlorophenyl)-4-hydroxypiperidine \n\nDescription:\nTroleandomycin was a potent inhibitor of both HAL and 4-(4-chlorophenyl)-4-hydroxypiperidine formation, see p.387\n\n','boycer','06/22/2009 12:33:59\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,158),(875,'evidence_1777','http://www.ncbi.nlm.nih.gov/pubmed/9825830','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor: ketoconazole\n\nreaction: reduced-haloperidol --&gt; 4-(4-chlorophenyl)-4-hydroxypiperidine\n\nDescription:\nketoconazole was a potent inhibitor of both HAL and 4-(4-chlorophenyl)-4-hydroxypiperidine formation, see p.387 ','boycer','06/22/2009 12:36:26\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,159),(876,'evidence_1819','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/3829d74e-b3ab-46df-a08b-f0327b63304e','\nMetabolism Following oral dosing, theophylline does not undergo any measurable first-pass elimination. In adults and children beyond one year of age, approximately 90%of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6%of a theophylline dose is N-methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.\n\nCaffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity. 3-methylxanthine has approximately one tenth the pharmacologic activity of theophylline and serum concentrations in adults with normal renal function are <1 mcg/mL. In patients with end-stage renal disease, 3-methylxanthine may accumulate to concentrations that approximate the unmetabolized theophylline concentration. Caffeine concentrations are usually undetectable in adults regardless of renal function. In neonates, caffeine may accumulate to concentrations that approximate the unmetabolized theophylline concentration and thus, exert a pharmacologic effect.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(877,'evidence_1935','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(878,'evidence_1174','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(879,'evidence_1295','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(880,'evidence_1576','http://www.ncbi.nlm.nih.gov/pubmed/11872324','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: quinidine\n\nreaction: nefazodone --&gt; OH-NEF ; nefazodone --&gt; mCPP\n\nQuote: \nIncubations of human liver microsomes with NEF and the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3). Incubations of human liver microsomes with NEF and the CYP2D6 inhibitor quinidine did not affect the production of OH-NEF and mCPP. Incubations of OH-NEF with the CYP3A4 inhibitor ketoconazole resulted in the inhibition of metabolite formation, and incubations with the CYP2D6 inhibitor quinidine did not, similar to what was found with NEF metabolism (data not presented).\n\n\n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(881,'evidence_1344','http://www.ncbi.nlm.nih.gov/pubmed/8889898','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam 1-hydroxylation\n\nKi = 11.5 micM\nMW: 309.32617\n\n11.5micM/L X 1M/10^6micM X 309.32617g/M = 0.004g/L','boycer','02/13/2010 10:01:31\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.004,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,160),(882,'evidence_1102','http://www.ncbi.nlm.nih.gov/pubmed/10997935','Enzyme system: recombinant human enzymes in human lymphoblastoid cells\nNADPH added:yes\n\ninhibitor used: no\n\nTable 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. ','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(883,'evidence_1623','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','CYP1A2: Venlafaxine did not inhibit CYP1A2 in vitro. This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(884,'evidence_1124','http://www.ncbi.nlm.nih.gov/pubmed/9205822','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nreaction: 7-O-deethylation of ethoxyresorufin to resorufin\n\nQuote: \nThe IC50 for venlafaxine\'s inhibition of the reaction was &gt; 1000micM \n\n\n','boycer','02132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(885,'evidence_1381','http://www.ncbi.nlm.nih.gov/pubmed/10073324','\n\nroute of administration: oral\n\nstudy duration: single doses of caffeine (200mg NoDoz) on days 1 and 8; venlafaxine 37.5 mg bid days 2-4 and 75 mg bid days 5-8.\n\npopulation:16 healthy volunteers (1 later dropped out); 9 male 7 female  \n\ntested for known CYP450 polymorphisms? no\n\nages: 21 - 41\n\ndescription:\nThe treatments did not differ significantly with respect to AUC, C_max, or clearance though there was a small but statistically significant decrease in caffeine half-life\n\n\n','boycer','02132010','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(886,'evidence_1720','http://www.ncbi.nlm.nih.gov/pubmed/17124578','\nNOTE: The AUC_i/AUC value given is the AUC_0-inf taken from Table 1.\n\nroute of administration: oral\n\nstudy duration: 6 days\n\npopulation: 12 healthy Japanese volunteers (9 male, 3 female)\n\ntested for known CYP450 polymorphisms?\nYes -- CYP2D6 genotypes - 4 with no mutated allele, 6 with one mutated allele, 2 with 2 mutated alleles\n\nages: 20-35\n\ndescription:\nSUBJECTS: Twelve healthy Japanese volunteers (nine males, three females) were enrolled in this study. Their mean +/- SD of age (range) was 24.8 +/- 2.5 (2035) years and mean body weight was 58.3 +/- 8.5 (4675) kg. The subjects had the following CYP2D6 genotypes: wt/wt (4 subjects), *10/wt (6), *10/*10 (1) and *5/*10 (1), respectively. No subjects regarded as poor metabolizers were included. These patients were divided into three groups according to the number of mutated alleles: no mutated allele in 4, one mutated allele in 6 and two mutated alleles in 2 subjects.\n\nMETHODS: A randomized crossover study design was conducted at intervals of 4 weeks. One capsule containing either 125 mg of terbinafine or a matched placebo with 240 ml of tap water was given once daily at 0800 hours for 6 days. Compliance of the test drug was confirmed by pill-count.\n\nRESULTS: The AUC (048) of paroxetine during trebinafine treatment was higher than placebo by 2.53-fold (1.85, 4.58-fold). The total AUC of paroxetine during trebinafine treatment was higher than placebo by 2.88-fold (1.99, 5.41-fold).\n\n','boycer','09/15/2010 15:26:19\n','EV_PK_DDI_RCT','PKStudy',3.03,0.02,0.125,12,'',NULL,NULL),(887,'evidence_1978','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978','Clozapine is almost completely metabolized prior to excretion and only trace amounts of unchanged drug are detected in the urine and feces. Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. The demethylated, hydroxylated and N-oxide derivatives are components in both urine and feces. Pharmacological testing has shown the desmethyl metabolite to have only limited activity, while the hydroxylated and N-oxide derivatives were inactive.','boycer','05/15/2009 11:03:54\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(888,'evidence_1403','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(889,'evidence_1000','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Metabolism and Elimination\n\nZiprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methyl-dihydroziprasidone.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(890,'evidence_1966','http://www.ncbi.nlm.nih.gov/pubmed/12397887','NOTE: The object dose given is for days 6-11 of the study. The AUC_i/AUC was calculated from Table 1.\n\nroute of administration: oral (indinavir)\n\nstudy duration: 11 days\n\npopulation: 8 healthy subjects (5 male, 3 female)\n\ntested for known CYP450 polymorphisms?\nYES - CYP2D6 phenotyping -- one poor metabolizer\n\nages: over 18\n\ndescription:\nSUBJECTS: Nine subjects entered the study and were phenotyped and 8 of the 9 subjects completed the study (5 males, 3 females). One CYP2D6 poor metabolizer (PM) was identified and inclusion of her data had no effect on the outcome of the analyses.\n\nMETHODS: The protocol was conducted in three phases: indinavir administered alone (I), venlafaxine administered alone (II), and indinavir administered after achieving expected steady-state plasma concentrations of venlafaxine (III). During phase I, subjects received one 800 mg dose of indinavir on an empty subject. Phase II of the study began the following day with subjects taking venlafaxine according to the following titration schedule: 25 mg every 8 hours for 4 days increased to 50 mg every 8 hours for an additional 4 days. Phase III began on day 11 with each subject simultaneously receiving the morning dose of venlafaxine 50mg and indinavir 800 mg.\n\nRESULTS: The mean AUC of venlafaxine after the addition of a single dose of indinavir demonstrated a nonsignificant increase. Half of the subjects experienced an increased AUC (mean of 55 [27%]) and the other half a decreased AUC (mean of 19 [6%]).','boycer','02/09/2012 12:01:55\n','EV_PK_DDI_NR','PKStudy',1.16,0.15,0.8,NULL,'',NULL,NULL),(891,'evidence_1096','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','route of administration: oral (indinavir)\n\nstudy duration: not mentioned (venlafaxine steady-state)\n\npopulation: 9 healthy volunteers\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: not mentioned\n\nQuote:\nIn a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown.','boycer','02/16/2012 21:19:58\n','Non_traceable_Drug_Label_Statement','PKStudy',0,0.15,0.8,NULL,'',NULL,NULL),(892,'evidence_1438','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: venlafaxine --&gt; N-desmethylvenlafaxine\n\nNOTE: the concentration of venlafaxine used in this experiment is very high relative to that expected in clinical use of the drug\n\nQuote: \n&quot;Formation of NDV had a mean Vmax of 2.14 nmol min mg protein, and a mean Km of 2504 M (Table 2). Incubations of 750micM VF with SFZ and QUI led to 18% and 23% reduction in NDV production respectively, while increasing concentrations of ANA led to an 11% increase in NDV formation over baseline. KET [ketoconazole] had a more profound effect on NDV formation, leading to a 65% mean reduction in production of this metabolite (Figure 5).&quot;','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(893,'evidence_1581','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(894,'evidence_1327','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2',' Venlafaxine is well absorbed and extensively metabolized in the liver. O-desmethylvenlafaxine (ODV) is the only major active metabolite. On the basis of mass balance studies, at least 92% of a single dose of venlafaxine is absorbed. Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%). Renal elimination of venlafaxine and its metabolites is the primary route of excretion. The relative bioavailability of venlafaxine from a tablet was 100% when compared to an oral solution. Food has no significant effect on the absorption of venlafaxine or on the formation of ODV.','boycer','06/09/2009 19:56:35\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(895,'evidence_1909','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes \n\nHPLC with UV detection identified the formation of O-desmethyl- and N-desmethylvenlafaxine in HLMs\n','boycer','06/15/2009 16:19:38\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(896,'evidence_1510','http://www.ncbi.nlm.nih.gov/pubmed/1487561','\nroute of administration: oral\n\nstudy duration: &quot;The study was a randomized three-period cross-over design using a pair of Latin squares. Each sub-ject participated for three 5-day venlafaxine treatment periods separated by a 9-day drug-free interval. Each treatment period consisted of 25, 75, or 150mg of venlafaxine given as a single dose on day 1, followed by the same dose given every 8 hours (q8h) on days 2 to 4, and ending with a single dose given on day 5, for a total of 2 doses. All doses were administered after food as multiple tablets of 25 mg venlafaxine base. The single doses on days 1 and 5 were administered 30 minutes after the subject had eaten a medium-fat breakfast and were followed by a 4-hour fast.&quot;\n\npopulation: 18, non-smoking, healthy men, NOTE: none were tested for known CYP450 phenotypes\n\nages: 20 - 34 \n\nHPLC with UV detection identified O-desmethylvenlafaxine in the plasma of study participants administered venlafaxine as described above\n\n','boycer','06/22/2009 10:02:28\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(897,'evidence_1790','http://www.ncbi.nlm.nih.gov/pubmed/8195463','Route of administration: oral (inferred because IV formulations do not appear to be available for sertraline and desipramine)\n\nstudy duration: see below\n\npopulation: 9 healthy males; all extensive metabolizers of dextromethorphan (o-demethylation)\n\nages: mean(std dev): &quot;adults&quot; but no mention of age. It can be inferred that these were healthy male adults and not exclusively elderly or children\n\nDescription:\nThe pharmacokinetic interactions of sertraline and fluoxetine with the tricyclic antidepressant desipramine were studied in 18 healthy male volunteers phenotyped as extensive metabolizers of dextromethorphan. Concentrations in plasma were determined after 7 days of desipramine (50 mg/day) dosing alone, during the 21 days of desipramine and selective serotonin reuptake inhibitor (SSRI) coadministration (fluoxetine, 20 mg/day; sertraline, 50 mg/day), and for 21 days of continued desipramine administration after SSRI discontinuation. Desipramine Cmax was increased 4.0-fold versus 31% and AUC0-24 was increased 4.8-fold versus 23% for fluoxetine versus sertraline, respectively, relative to baseline after 3 weeks of coadministration. Desipramine trough concentrations approached baseline within 1 week of sertraline discontinuation but remained elevated for the 3-week follow-up period after fluoxetine discontinuation. Concentrations of SSRIs and their metabolites correlated significantly with desipramine concentration changes (for fluoxetine/norfluoxetine, r = 0.94 to 0.96; p &lt; 0.001; for sertraline/desmethylsertraline, r = 0.63; p &lt; 0.01). Thus, sertraline had less pharmacokinetic interaction with desipramine than did fluoxetine at their respective, minimum, usually effective doses.','boycer','05/05/2009 15:37:50\n','EV_PK_DDI_NR','PKStudy',1.2,0.05,0.05,9,'',NULL,NULL),(898,'evidence_1451','http://www.ncbi.nlm.nih.gov/pubmed/9241008',' Route of administration: oral (inferred because IV formulations do not appear to be available for sertraline and desipramine)\n\nstudy duration: see below\n\npopulation: 17 volunteers (design called for 24 but several dropped out or were excluded due to non-compliance); all participants were extensive metabolizers of dextromethorphan (o-demethylation)\n\nages: mean(std dev): 30.4 (+/-5.2)\n\nAUC_i/AUC (24 hour): 838 / 611 = 1.37\n\nNOTE: AUC increase mentioned is for the phase of the study using 50mg of paroxetine.\n\nDescription:\nThe pharmacokinetics of desipramine when coadministered with the selective serotonin reuptake inhibitors (SSRIs) paroxetine and sertraline were studied in 24 healthy male volunteers (CYP2D6 extensive metabolizers). Desipramine (50 mg/day) was administered for 23 days in each phase of the crossover study with a 7-day drug-free period between phases. In addition, subjects were randomly assigned to receive concomitant paroxetine (20 mg/day on days 8 through 17 followed by 30 mg/day on days 18 through 20) or sertraline (50 mg/day on days 8 through 17 and 100 mg/day on days 18 through 20). SSRI treatments were switched between phases. After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p &lt; 0.001). An approximately 10-fold increase in the Cmax and AUC(24) of paroxetine and an approximately 2-fold increase in these parameters for sertraline occurred simultaneously with the desipramine concentration changes. Thus, when coadministered with 50 mg/day desipramine, sertraline had significantly less pharmacokinetic interaction than paroxetine with desipramine at the recommended starting dosages of 50 mg/day and 20 mg/day, respectively.','boycer','05/05/2009 16:11:50\n','EV_PK_DDI_NR','PKStudy',1.37,0.05,0.05,17,'',NULL,NULL),(899,'evidence_1938','http://www.ncbi.nlm.nih.gov/pubmed/9284850','\nRoute of administration: oral\n\nstudy duration: PK values of a single dose of desipramine was compared with the same values after eight days of treatment with desipramine + sertraline\n\npopulation: 6 healthy males, all participants were extensive metabolizers of dextromethorphan (o-demethylation) (c.f. page 154, paragraph 3). \n\nages: mean(std dev):42 (9)\n\nAUC_i/AUC (24 hour): 796/516 = 1.54\n\nDescription: \nParticipants received a 50 mg single dose of either desipramine or imipramine under three conditions: alone, after a single 150 mg dose of sertraline, and after the eighth daily 150 mg dose of sertraline. Plasma samples were analyzed for desipramine or imipramine concentration by HPLC with electrochemical detection, and pharmacokinetics were determined with use of noncompartmental analysis of individual data. RESULTS: Multiple-dose, but not single-dose, treatment with sertraline significantly reduced apparent plasma clearance (CL/F) and prolonged the half-life of desipramine relative to baseline. These changes resulted in higher plasma desipramine concentrations, as indicated by a significant increase in maximum plasma concentration (Cmax) and area under the plasma concentration-time curve extrapolated to infinity [AUC(0-infinity)] (22% and 54%, respectively). Both single- and multiple-dose treatment with sertraline significantly reduced the CL/F of imipramine. This effect was stronger after multiple predoses of sertraline, when imipramine Cmax and AUC(0-infinity) were increased by 39% and 68%, respectively. These treatment effects were consistent between individuals.','boycer','05/05/2009 16:37:01\n','EV_PK_DDI_NR','PKStudy',1.54,0.05,0.15,6,'',NULL,NULL),(900,'evidence_1746','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71be4cb7-a42f-43be-9b9b-f090edb2fd21','\nParoxetine\n\nCoadministration of a single dose of zaleplon 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance. Additionally, paroxetine did not alter the pharmacokinetics of zaleplon, reflecting the absence of a role of CYP2D6 in zaleplon\'s metabolism. \n\n','boycer','11/09/2009 12:39:21\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,161),(901,'evidence_1950','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.24,NULL,NULL,NULL,'',NULL,NULL),(902,'evidence_1026','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants. Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism and venlafaxine. However, although imipramine partially inhibited the CYP2D6-mediated metabolism of venlafaxine, resulting in higher plasma concentrations of venlafaxine and lower plasma concentrations of ODV, the total concentration of active compounds (venlafaxine plus ODV) was not affected. Additionally, in a clinical study involving CYP2D6-poor and -extensive metabolizers, the total concentration of active compounds (venlafaxine plus ODV), was similar in the two metabolizer groups. Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor. ','boycer','06/09/2009 19:53:13\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(903,'evidence_1982','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: quinidine\n\nreaction: venlafaxine --&gt; O-desmethylvenlafaxine\n\nQuote:\n&quot;All six SSRIs [including quinidine] inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;\n\nK_i for quinidine vs O-desmethylvenlafaxine formation: 0.04micM','boycer','06/20/2009 14:31:52\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,162),(904,'evidence_1006','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: paroxetine\n\nreaction: venlafaxine --&gt; O-desmethylvenlafaxine\n\nQuote:\n&quot;All six SSRIs inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;\n\nK_i for paroxetine vs O-desmethylvenlafaxine formation: 0.17micM','boycer','06/20/2009 14:33:21\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,163),(905,'evidence_1909','http://www.ncbi.nlm.nih.gov/pubmed/11240973','\nNOTE: The AUC_i/AUC value given is the AUC_0-inf calculated from Table 1.\n\nroute of administration: oral\n\nstudy duration: 8 days\n\npopulation: 6 healthy Japanese volunteers (all male); 3 smokers, 3 nonsmokers\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 26-36\n\ndescription:\nSUBJECTS: Six healthy male Japanese volunteers who had given informed consent participated in this study. Their mean age and body weight were 31 +/- 4 years (range, 26-36 years) and 66.3 +/- 5.1 kg (range, 57-72 kg), respectively. Three subjects were nonsmokers and three were smokers (20-40 cigarettes per day). All subjects were in good health as assessed by medical history, physical examination, routine hematology, blood chemistry, urinary tests, and cardiac function (electrocardiography).\n\nSTUDY DESIGN: A randomized crossover design with two phases was used. A 7-day washout period separated the two treatment conditions. Each subject received an oral dose of mexiletine (200 mg) at 7:00 AM with 100 mL of water. In the one phase, they received mexiletine alone (study 1); in the other phase, they received fluvoxamine (50 mg twice a day) for 7 days, and on the eighth day they received mexiletine and fluvoxamine concomitantly at 7:00 AM (study 2). Each subject fasted overnight for at least 10 hours before the administration of mexiletine at 7:00 AM and continued to fast for an additional 6 hours after administration. The subjects were instructed not to take any medications or drink anything that included caffeine or alcoholic beverages for 1 week before the study and throughout the study.\n\nRESULTS: The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 g x h/mL, P = .006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 g/mL, P = .008, respectively).\n\n\n\n\n','boycer','09/16/2010 11:13:14\n','EV_PK_DDI_RCT','PKStudy',1.55,0.2,0.1,6,'',NULL,NULL),(906,'evidence_1663','http://www.ncbi.nlm.nih.gov/pubmed/9366029','Route of administration: oral\n\nstudy duration: rac-citalopram given @ 40mg qd X 21days\n\npopulation: 10 adults (6 female and 4 male) all extensive metabolizers according to 2d6 and 2c19 specific assays (sparteine and mephenytoin respectively)\n\nages: 23-32\n\n\nDescription: \nC_max for R-demethylcitalopram : 62.7nMol/L\n\n62.7nMol/L X 1M/10^9nMol X 324.39g/1M = 0.00001946g/L','boycer','06/12/2009 20:00:32\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00001946,NULL,NULL,NULL,'',0.04,NULL),(907,'evidence_1551','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','Fluvoxamine is listed as a recommended inhibitor of CYP1A2 for in vivo studies in Table 2 (p. 19). Typically, this would qualify it as a in vivo selective inhibitor however, Table 2 also shows fluvoxamine as a recommended inhibitor of 2C19.','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(908,'evidence_1942','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','Theophylline\n\nThe effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy nonsmoking, male volunteers. The clearance of theophylline was decreased approximately 3-fold. Therefore, if theophylline is coadministered with fluvoxamine maleate, its dose should be reduced to one-third of the usual daily maintenance dose and plasma concentrations of theophylline should be monitored. No dosage adjustment is required for fluvoxamine maleate tablets.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(909,'evidence_1668','http://www.ncbi.nlm.nih.gov/pubmed/11719727','\nroute of administration: oral\n\nstudy duration: single-dose theophylline (250 mg) after  taking fluvoxamine for 9 days at 3 doses (0, 25, or 75 mg/day) in a randomized crossover design\n\npopulation: 9 healthy non-smoking volunteers (5 male, 4 female)\n\nparticipants tested known CYP450 phenotypes? No\n\nages: 23 - 40\n\nDescription: \nTable II shows AUC_i/AUC (0-48) for theophylline as follows:\n\nfluvoxamine @ 25mg/day for 9 days: 504/349 = 1.44\nfluvoxamine @ 75mg/day for 9 days: 710/349 = 2.03\n \n\n','boycer','01132010','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(910,'evidence_1237','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(911,'evidence_1698','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends bufuralol to be an acceptable chemical CYP2D6 substrate (bufuralol 1\'-hydroxylation) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','06/22/2009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(912,'evidence_1375','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel\n\n&quot;No IC50 values could be determined for rosuvastatin and pravastatin with concentrations up to 100micM&quot;\n\nConcentration of pravastatin in vivo based on the largest C_max in label in table 1 of http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1652:\n\n3650ng/1ml x 1g/1e9ng x 1e3ml/1L = .004g/L\n\n.004g/L x 1M/853.9g = 4.68micM/L','boycer','11/13/2007 13:39:32\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,164),(913,'evidence_1963','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','ABILIFY activity is presumably primarily due to the parent drug, aripiprazole, and to a lesser extent, to its major metabolite, dehydro-aripiprazole, which has been shown to have affinities for D2 receptors similar to the parent drug and represents 40% of the parent drug exposure in plasma. The mean elimination half-lives are about 75 hours and 94 hours for aripiprazole and dehydro-aripiprazole, respectively. Steady-state concentrations are attained within 14 days of dosing for both active moieties.','boycer','04/29/2009 19:25:40\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(914,'evidence_1019','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(915,'evidence_1393','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA recommends this as a CYPC19 substrate for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','09/24/2009 10:39:11\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(916,'evidence_1114','http://www.ncbi.nlm.nih.gov/pubmed/8866916','\nEnzyme system: human liver microsomes:\n\nNADPH added: not explicitly mentioned but accepted methods assumed\n\nsubstrate used: midazolam\n\nreaction: midazolam 1-hydroxylation\n\nKi = 491 micM\n\n491micM/L X 1M/10^6micM X 312.43366g/M = 0.153g/L\n\n\n','boycer','02/13/2010 08:14:44\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.153,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,165),(917,'evidence_1533','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(918,'evidence_1652','http://www.ncbi.nlm.nih.gov/pubmed/11907488','NOTE; The precipitant drug dose is the Period 3 dose of the EMs. The AUC_i/AUC is the combined (both EMs and PMs) AUC_0-8h of Period 3.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: Period 1 - 3 days, Periods 2 and 3 - 7 days\r\n\r\npopulation: 10 healthy volunteers, all Caucasian, all nonsmokers\r\n\r\ntested for known CYP450 polymorphisms?\r\nYes -- CYP2D6 phenotyping - 5 extensive metabolizers, 5 poor metabolizers\r\n\r\nages: 22-45\r\n\r\ndescription:\r\nSUBJECTS: Twelve healthy white subjects, 6 men and 6 women, aged 22 to 45 years (mean, 30 years) and weighing 56 to 94 kg (mean, 81 kg for the men and 69 kg for the women), participated in this study, which included 7 EMs and 5 PMs of debrisoquin. The debrisoquin metabolic ratio (MR) ranged from 0.57 to 2.2 in EMs and from 35 to 260 in PMs. Genotyping of CYP2D6 and CYP2C19 was performed in 1 subject (subject No. 12) by the methods of Heim and Meyer (CYP2D6*3 and *4) and de Morais et al (CYP2C19*2). All subjects were healthy as assessed by medical history, physical examination, urine drug screen, standard 12-lead electrocardiogram, virologic testing, and routine laboratory analyses. All were nonsmokers and had been drug-free for at least 1 week before the study.\r\nTwo EM subjects (subjects No. 1 and No. 4) were not able to participate in period 3 because of travel abroad and, therefore, were replaced by 2 new EMs (subjects No. 12 and No. 13). They also followed the protocol in period 1 before entering period 3.\r\n\r\nMETHODS: Single oral doses of 100 mg caffeine and 20 mg omeprazole were given separately to 5 EMs and 5 PMs of debrisoquin to assess the activity of CYP1A2 and CYP2C19, respectively. Initially, a single oral dose of fluvoxamine (25 mg to PMs and 50 mg to EMs) was given [Period 1], followed by 1 week of daily administration of 25 mg  2 to EMs and 25 mg  1 to PMs [Period 2]. Caffeine (day 6) and omeprazole (day 7) were again administered at the steady state of fluvoxamine. Later the study protocol was repeated with a lower dose of fluvoxamine, 10 mg  2 to EMs and 10 mg  1 to PMs for 1 week [Period 3]. Concentrations of fluvoxamine, caffeine, omeprazole, and their metabolites were analyzed by HPLC methods in plasma and urine.\r\nBecause fluvoxamine kinetics is partly dependent on the polymorphic enzyme CYP2D6, we gave double the dose of fluvoxamine to EMs of debrisoquin compared with PMs of debrisoquin to obtain similar plasma concentrations of fluvoxamine.\r\n\r\nRESULTS: The geometric means of omeprazole AUC(0-8 h) increased with 174% (P &lt; .001) with 10 mg x 1 or x 2 [Period 3] and 330% (P &lt; .001) with 25 mg x 1 or  2 of fluvoxamine [Periods 1-2].','boycer','09/15/2010 15:02:35\r\n','EV_PK_DDI_NR','PKStudy',1.74,0.02,0.02,10,'',NULL,NULL),(919,'evidence_1572','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Both CYP3A4 and CYP2D6 are responsible for iloperidone metabolism. Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., fluoxetine, paroxetine) can inhibit iloperidone elimination and cause increased blood levels.\n\nKetoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18-45, increased the AUC of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.','boycer','01/11/2010 18:27:15\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,166),(920,'evidence_1823','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.06,NULL,NULL,NULL,'',NULL,NULL),(921,'evidence_1444','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(922,'evidence_1698','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6','\nMetabolism\n\nPantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(923,'evidence_1475','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(924,'evidence_1852','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(925,'evidence_1802','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: S-mepheytoin 4\'hydroxylation\n\nQuote: \n\nCYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI\nfluvoxamine (see Table 2).\n\n\n','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(926,'evidence_1725','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(927,'evidence_1065','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3249','&quot;Metabolism:\n\nRosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of rosuvastatin. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by rosuvastatin.\n\nExcretion:\n\nFollowing oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). The elimination half-life (t1/2) of rosuvastatin is approximately 19 hours.\n\nAfter an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route.\n\n&quot;','boycer','09/28/2007 07:59:41\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(928,'evidence_1291','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:30:47\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(929,'evidence_1616','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84','\n12.3 Pharmacokinetics\n...\nAbsorption: The absorption of lansoprazole is rapid, with the mean Cmax occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%. In healthy subjects, the mean (SD) plasma half-life was 1.5 (1.0) hours. Both the Cmax and AUC are diminished by about 50% to 70% if lansoprazole is given 30 minutes after food, compared to the fasting condition. There is no significant food effect if lansoprazole is given before meals.\n','boycer','09/24/2009 10:21:30\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.8,NULL,NULL,NULL,'',NULL,NULL),(930,'evidence_1467','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\nMirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(931,'evidence_1134','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: mirtazapine N-demethylation (25 and 250 micM) and mirtazapine N-oxidation (250micM) \n\nQuote: \nIncubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-\noxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. \n\nNOTE: lowest MIR concentration tested was 25 micM\n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(932,'evidence_1109','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','duloxetine is listed as a moderate inhibitor in Table 6 (p23) but does not show up in Table 2 (a table listing several selective in viVo inhibitors)','boycer','04/29/2009 20:02:14\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(933,'evidence_1903','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','7.9 Drugs Metabolized by CYP2D6\n\nDuloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold [see Warnings and Precautions (5.10)].\n\n','boycer','05/05/2009 17:52:52\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,167),(934,'evidence_1712','http://www.ncbi.nlm.nih.gov/pubmed/12621382','\nroute of administration: oral\n\nstudy duration: &quot;Study 1 was conducted in 2 distinct periods separated by a 7-day washout. In period 1, a single 50-mg dose of desipramine was administered, and blood samples were obtained for the measurement of desipramine plasma concentrations immediately before the dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 hours after dosing. In period 2, duloxetine was administered at an initial dose of 40 mg twice daily. Subjects who did not tolerate this dose were allowed to have the dose lowered to 20 mg twice daily for up to 5 doses, after which dosing at 40 mg twice daily was resumed. On the seventh day of duloxetine dosing (day 14 of the overall protocol), the dose was increased to 60 mg twice daily and was continued at that level for an additional 14 days. On day 21 of the overall protocol (day 8 of duloxetine 60 mg twice daily dosing), a 50-mg dose of desipramine was administered. Blood samples were drawn to determine desipramine plasma concentrations as described for period 1, with additional samples at 168 and 192 hours after the desipramine dose. On the day before and the day of the period 2 desipramine dose (protocol days 20 and 21), blood samples for the measurement of duloxetine plasma concentrations were drawn immediately before duloxetine administration and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after administration.&quot;\n\npopulation: 14 healthy, non-smoking, adults; 7 male, 7 female; nearly all were of apparent European decent (&quot;white&quot;)\n\ntested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.\n\nages: 21 - 63\n\ndescription:\n&quot;Duloxetine increased the maximum plasma concentration of desipramine 1.7-fold and the area under the concentration-time curve 2.9-fold.&quot;\n\n','boycer','06/20/2009 13:44:41\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,168),(935,'evidence_1620','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(936,'evidence_1760','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7e117c7e-02fc-4343-92a1-230061dfc5e0','\n&quot;Risperidone is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug (e.g., the active moiety) results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.&quot;','boycer','06/16/2009 16:32:34\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(937,'evidence_1234','http://www.ncbi.nlm.nih.gov/pubmed/7690693','\nroute of administration: oral\n\nstudy duration: single dose\n\npopulation: 12 males, phenotyped using dextromethorphan (9 2D6 EMs, 2 PMs, 1 IM)\n\nages: 24 (SD:6) \n\na direct radioimmunoassay detected 9-hydroxyrisperidone in the plasma of  participants after they were given risperidone','boycer','06/17/2009 08:31:04\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(938,'evidence_1385','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA, in it most recent guidance document, recommends this as a chemical inhibitor of CYP2C8 for in vitro experiments at a K_i of 5.6micM. See Table 2, p. 28\n\n5.6micM/L X 1M/10^6micM X 357.427g/M = 0.002g/L','boycer','06/30/2009 14:12:32\n','Non_Tracable_Statement','In_vitro_inhibition_study',0.002,NULL,NULL,NULL,'none_assigned',NULL,NULL),(939,'evidence_1140','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','06102009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(940,'evidence_1103','http://www.ncbi.nlm.nih.gov/pubmed/8453848','\nRoute of administration: oral\n\nstudy duration: 5 days pretreatment with erythromycin, midazolam on the 6th day\n\nDosing: 500mg erythromycin t.i.d, 15mg midazolam\n\npopulation: 12\nmale: 3\nfemale: 9\n\nages:18-29\n\nAUC_i/AUC = 53/12 micG*min/ml = 4.417\n\nQuote: \n&quot;\nInteraction between erythromycin and midazolam was investigated in two double-blind, randomized, crossover studies. In the first study, 12 healthy volunteers were given 500 mg erythromycin three times a day or placebo for 1 week. On the sixth day, the subjects ingested 15 mg midazolam. In the second study, midazolam (0.05 mg/kg) was given intravenously to six of the same subjects, after similar pretreatments. Plasma samples were collected, and psychomotor performance was measured. Erythromycin increased the area under the midazolam concentration-time curve after oral intake more than four times (p &lt; 0.001) and reduced clearance of intravenously administered midazolam by 54% (p &lt; 0.05). In psychomotor tests (e.g., saccadic eye movements), the interaction between erythromycin and orally administered midazolam was statistically significant (p &lt; 0.05) from 15 minutes to 6 hours. Metabolism of both erythromycin and midazolam by the same cytochrome P450IIIA isozyme may explain the observed pharmacokinetic interaction. Prescription of midazolam for patients receiving erythromycin should be avoided or the dose of midazolam should be reduced by 50% to 75%.&quot;','boycer','10/16/2007 09:57:09\n','EV_PK_DDI_RCT','PKStudy',4.417,0.015,0.5,12,'',NULL,NULL),(941,'evidence_1911','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel \n\nk_i = 15.9micM\n\n15.9micM/1L x 1M/1e6micM x 1209.42g/1M = .019g/1L','boycer','10/29/2007 10:42:21\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.019,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,169),(942,'evidence_1919','http://www.ncbi.nlm.nih.gov/pubmed/12235455','Route of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: single 120mg oral dose of diltiazem with 24 hours of plasma level monitoring\n\npopulation: 15 individuals; 5 for each genetically based phenotype. Study does not state gender of participants\n\nages: 20-30\n\ndescription: \nThe aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS: Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence resonance energy transfer probes hybridized to polymerase chain reaction-amplified deoxyribonucleic acid. The first 5 individuals identified with genotypes corresponding to a homozygous extensive, heterozygous extensive, or homozygous poor CYP2D6-metabolizing phenotype, respectively, were voluntarily enrolled in the pharmacokinetic study. The participants received diltiazem, 120 mg, as a single oral dose, and plasma samples were collected up to 24 hours after administration. Plasma samples were purified by solid phase extraction. Diltiazem and 7 phase I metabolites were analyzed by liquid chromatography-mass spectrometry. RESULTS: The pharmacokinetics of diltiazem was not significantly different between the subgroups. However, the systemic exposure of the pharmacologically active metabolites desacetyl diltiazem and N-demethyldesacetyl diltiazem was &gt; or = 5 times higher in poor CYP2D6 metabolizers than in extensive CYP2D6 metabolizers (P &lt;.01). CONCLUSIONS: CYP2D6 activity does not have a major impact on the disposition of diltiazem. In contrast, desacetyl diltiazem and N-demethyldesacetyl diltiazem are markedly accumulated in individuals expressing a deficient CYP2D6 phenotype. Because these metabolites exhibit pharmacologic properties of possible importance, individual CYP2D6 activity might be an aspect to consider in the clinical use of diltiazem.','boycer','12172009','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(943,'evidence_1377','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(944,'evidence_1415','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978','Pharmacokinetic-related Interactions\n\nClozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(945,'evidence_1535','http://www.ncbi.nlm.nih.gov/pubmed/9384460','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: fluvoxamine\n\nreaction: clozapine demethylation and N-oxidation\n\nQuote: \nFluvoxamine inhibited the demethylation [of clozapine] by 34+/-27% at 1 micM and 53+/-28% at 10 micM...Fluvoxamine caused an inhibition by 12+/-21% and 22+/-18% at 1 and 10 micM respectively. \n\n\n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(946,'evidence_1125','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote:\n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM. ','boycer','06/12/2009 11:51:26\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,170),(947,'evidence_1498','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a4d555fa-787c-40fb-bb7d-b0d4f7318fd0','Drug Interactions:\n\nConcomitant administration of SPORANOX (itraconazole) Capsules, Injection, or Oral Solution and certain drugs metabolized by the cytochrome P450 3A4 isoenzyme system (CYP3A4) may result in increased plasma concentrations of those drugs, leading to potentially serious and/or life-threatening adverse events. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(948,'evidence_1066','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:33:32\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(949,'evidence_1886','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: perphenazine N-dealkylation\n\nQuote:\nTo identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.\n','boycer','06/15/2009 16:42:36\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,171),(950,'evidence_1559','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(951,'evidence_1002','http://www.ncbi.nlm.nih.gov/pubmed/10997935','Enzyme system: recombinant human enzymes in human lymphoblastoid cells\nNADPH added:yes\n\ninhibitor used: no\n\nTable 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. ','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(952,'evidence_1611','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','Approximately 7% of the normal population has a genetic defect that leads to reduced levels of activity of cytochrome P450IID6 isozyme. Such individuals have been referred to as &quot;poor metabolizers&quot; (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in thirteen PM subjects demonstrated altered pharmacokinetic properties compared to sixteen &quot;extensive metabolizers&quot; (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by IID6 isozyme. Caution is indicated in patients known to have reduced levels of P450IID6 activity and those receiving concomitant drugs known to inhibit this isozyme (e.g., quinidine).','boycer','05/15/2009 08:46:10\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(953,'evidence_1806','http://www.ncbi.nlm.nih.gov/pubmed/8823236','\nroute of administration: oral\n\nstudy duration: single 50mg dose fluvoxamine \n\npopulation: 7 male and 7 female; 10 CYP2D6 EMs and four PMs according to debrisoquine metabolism. 5 EMs smoked during the study as did 3 PMs\n\nages: 25 - 49\n\nDescription: \nCompared with nonsmoking extensive metabolizers, nonsmoking poor metabolizers had a statistically significant (p = 0.02, Mann-Whitney U test) about twofold higher maximum plasma concentration, longer half-life, and fivefold lower oral clearance of fluvoxamine.\n','boycer','06/16/2009 18:52:14\n','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,172),(954,'evidence_1792','http://www.ncbi.nlm.nih.gov/pubmed/8866916','\nEnzyme system: human liver microsomes:\n\nNADPH added: not explicitly mentioned but accepted methods assumed\n\nsubstrate used: midazolam\n\nreaction: midazolam 1-hydroxylation\n\nKi = 326.83\n\nMW: 326.83 \n\n99micM/L X 1M/10^6micM X 326.83g/1M = 0.032g/L\n\n\n','boycer','02/13/2010 08:22:48\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.032,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,173),(955,'evidence_1489','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3249','&quot;Cytochrome P450 3A4: In vitro and in vivo data indicate that rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent. This has been confirmed in studies with known cytochrome P450 3A4 inhibitors (ketoconazole, erythromycin, itraconazole).\n\nKetoconazole: Coadministration of ketoconazole (200 mg twice daily for 7 days) with rosuvastatin (80 mg) resulted in no change in plasma concentrations of rosuvastatin.\n\nErythromycin: Coadministration of erythromycin (500 mg four times daily for 7 days) with rosuvastatin (80 mg) decreased AUC and Cmax of rosuvastatin by 20% and 31%, respectively. These reductions are not considered clinically significant.&quot;','boycer','09/28/2007 12:06:44\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(956,'evidence_1333','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(957,'evidence_1647','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: S-mephenytoin 4\'-hydroxylatoin\n\nThe IC50 for ziprasidone inhibition of this reaction was greater than 100micM \n\n\n','boycer','06/19/2009 17:10:35\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,174),(958,'evidence_1895','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(959,'evidence_1828','http://www.ncbi.nlm.nih.gov/pubmed/8866916','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: tolbutamide\n\nreaction:tolbutamide 4-hydroxylation\n\nKi = 32 micM\nMW: 326.83\n\n32micM/L X 1M/10^6micM X 326.83g/1M = 0.01g/L\n\n\n','boycer','02/13/2010 08:36:16\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.01,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,175),(960,'evidence_1022','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(961,'evidence_1775','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(962,'evidence_1963','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','\nAbsorption: Peak plasma levels of celecoxib occur approximately 3 hrs after an oral dose. Under fasting conditions, both peak plasma levels (Cmax) and area under the curve (AUC) are roughly dose-proportional up to 200 mg BID; at higher doses there are less than proportional increases in Cmax and AUC [see Food Effects]. Absolute bioavailability studies have not been conducted. With multiple dosing, steady-state conditions are reached on or before Day 5. The pharmacokinetic parameters of celecoxib in a group of healthy subjects are shown in Table 3.\n\nTable 3 Summary of Single Dose (200 mg) Disposition Kinetics of\nCelecoxib in Healthy Subjects* Mean (%CV) PK Parameter Values\n\nCmax, ng/mL|Tmax, hr|Effective t1/2, hr|Vss/F, L   |CL/F, L/hr\n  705 (38) |2.8 (37)|11.2 (31)         | 429 (34)  | 27.7 (28)\n\n*Subjects under fasting conditions (n=36, 1952 yrs.)\n\n\n\n705ng/mL X 1g/10^9ng X 1000mL/1L = 0.0000705g/L\n','boycer','09/24/2009 11:06:27\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.0000705,NULL,NULL,NULL,'',0.2,NULL),(963,'evidence_1269','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(964,'evidence_1982','http://www.ncbi.nlm.nih.gov/pubmed/9366029','\n\nRoute of administration: oral\n\nstudy duration: rac-citalopram given @ 40mg qd X 21days\n\npopulation: 10 adults (6 female and 4 male) all extensive metabolizers according to 2d6 and 2c19 specific assays (sparteine and mephenytoin respectively)\n\nages: 23-32\n\n\nDescription: \n\n(p 688) &quot;The total amount of administered dose recovered in urine was 36%&quot;\n\n(p 689) &quot;Non-renal clearances (87 +/- 5% and 76 +/- 4% of CL/F for (+)-(S)- and (-)-(R)-citalopram, respectively) demonstrated a significant biotransformation of both citalopram enantiomers&quot;','boycer','06/12/2009 12:58:52\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(965,'evidence_1211','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(966,'evidence_1066','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(967,'evidence_1017','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(968,'evidence_1147','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.84,NULL,NULL,NULL,'',NULL,NULL),(969,'evidence_1151','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=4844','Drug Interactions\n\nIn vitro drug metabolism studies suggest that there is a potential for drug interactions when trazodone is given with CYP3A4 inhibitors. Ritonavir, a potent CYP3A4 inhibitor, increased the Cmax, AUC, and elimination half-life, and decreased clearance of trazodone after administration of ritonavir twice daily for 2 days. Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were co-administered. It is likely that ketoconazole, indinavir, and other CYP3A4 inhibitors such as itraconazole or nefazodone may lead to substantial increases in trazodone plasma concentrations, with the potential for adverse effects. If trazodone is used with a potent CYP3A4 inhibitor, a lower dose of trazodone should be considered.\n\nCarbamazepine reduced plasma concentrations of trazodone when co-administered. Patients should be closely monitored to see if there is a need for an increased dose of trazodone when taking both drugs.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(970,'evidence_1605','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(971,'evidence_1553','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=4844','Metabolism\n\nIn vitro studies in human liver microsomes show that trazodone is metabolized to an active metabolite, m-chlorophenylpiperazine (mCPP) by cytochrome P450 3A4 (CYP3A4). Other metabolic pathways that may be involved in metabolism of trazodone have not been well characterized.','boycer','05/14/2009 14:31:20\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(972,'evidence_1049','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','7.19 Drugs Metabolized by Cytochrome P4502D6\n\nIn vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(973,'evidence_1036','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: dextromethorphan O-demethylation\n\nQuote: \n\nCYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors.\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(974,'evidence_1420','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','7.19 Drugs Metabolized by Cytochrome P4502D6\n\nIn vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(975,'evidence_1499','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: tolbutamide --&gt; hydroxytolbutamide\n\nQuote:\n\nCYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7 (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM). ','boycer','06/12/2009 11:22:50\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,176),(976,'evidence_1760','http://www.ncbi.nlm.nih.gov/pubmed/10234598','\nRoute of administration: oral\n\nstudy duration: a single 10mg reference dose of atorvastatin, 2 wk washout, then 12 days erythromycin (500mg qid) with a single 10mg dose on day 7 of atorvastatin \n\npopulation: 12 healthy adults (on withdrew before study completion_\nmale: 8\nfemale: 4\nages: 22-57 years\n\nAUC_i/AUC: 167/126 ng*hr/ml = 1.325 (CI: 5.9 to 65.4)\n\nNOTE: The 0-infinity AUC values were used\n\nQuote: \n&quot;\nThe effect of erythromycin on the pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase, was investigated in 12 healthy volunteers. Each subject received a single 10 mg dose of atorvastatin on two separate occasions, separated by 2 weeks. Erythromycin (500 mg qid) was given from 7 days before through 4 days after the second atorvastatin dose. Atorvastatin concentrations were determined by an enzyme inhibition assay, which measured both atorvastatin and active metabolites. When erythromycin was coadministered with atorvastatin, mean Cmax and AUC(0-infinity) increased by 37.7% and 32.5%, respectively. Mean terminal half-life was similar following each atorvastatin dose. Possible mechanisms for this interaction include erythromycin inhibition of first-pass conversion of atorvastatin to inactive metabolites and erythromycin inhibition of P-glycoprotein-mediated intestinal or biliary secretion.&quot;','boycer','10/16/2007 09:50:31\n','EV_PK_DDI_NR','PKStudy',1.325,0.01,0.5,11,'',NULL,NULL),(977,'evidence_1409','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1','Variability in metabolism  A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6). Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the TCAs. In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized Sfluoxetine at a slower rate and thus achieved higher concentrations of Sfluoxetine. Consequently, concentrations of Snorfluoxetine at steady state were lower. The metabolism of Rfluoxetine in these poor metabolizers appears normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4 active enantiomers was not significantly greater among poor metabolizers. Thus, the net pharmacodynamic activities were essentially the same. Alternative, nonsaturable pathways (non2D6) also contribute to the metabolism of fluoxetine. This explains how fluoxetine achieves a steadystate concentration rather than increasing without limit.','boycer','05/14/2009 14:29:52\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(978,'evidence_1804','http://www.ncbi.nlm.nih.gov/pubmed/8941024','\n\nroute of administration: oral\n\nstudy duration: \n\npopulation: 20 healthy, non-smoking, males\n\ntested for known CYP450 polymorphisms? Yes, using debrisoquin / 4-hydroxydebrisoquin metabolite ratio; 10 were CYP2D6 EMs and 10 PMs\n\nages: 18 - 32\n\ndescription:\n\n&quot;Poor metabolizers had significantly greater fluoxetine peak plasma concentrations (Cmax; increases 57%), area under the concentration versus time curve (AUCzero--&gt;infinity; increases 290%), and terminal elimination half-life (increases 216%) compared with extensive metabolizers. The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p &lt; 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p &lt; 0.05). Norfluoxetine Cmax and AUCzero--&gt;t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p &lt; 0.05).&quot;\n\n','boycer','06/22/2009 15:33:44\n','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,177),(979,'evidence_1472','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(980,'evidence_1530','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of both 1\'-OH-midazolam and 4-OH-midazolam in a recombinant cyp3a4 Supersome system','boycer','07/02/2007 11:06:38\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(981,'evidence_1959','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','\nRoute of administration: oral\n\nstudy duration: multi-dose of fluvastatin\n\npopulation: 17\n\nages:?\n\nC_max = 200ng/ml\n\ndata taken from table 1','boycer','10/20/2007 09:18:15\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.0002,NULL,NULL,NULL,'',0.02,NULL),(982,'evidence_1074','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','Route of administration: oral\n\nstudy duration: multi-dose of fluvastatin\n\npopulation: 16\n\nages:?\n\nC_max = 432ng.ml\n\nTable 1 shows single-dose and steady-state pharmacokinetic parameters for fluvastatin. This value was take for 40 mg 2x/day.','boycer','10/20/2007 09:21:49\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.00043,NULL,NULL,NULL,'',0.04,NULL),(983,'evidence_1997','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','\nRoute of administration: oral\n\nstudy duration: single dose of fluvastatin\n\npopulation: 24\n\nages:?\n\nC_max = 183ng.ml\n\ndata taken from table 1, this is a single dose study with participants that had eaten a high fat meal','boycer','10/20/2007 09:26:33\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000183,NULL,NULL,NULL,'',0.08,NULL),(984,'evidence_1674','http://www.ncbi.nlm.nih.gov/pubmed/9825830','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor: troleandomycin\n\nreaction: reduced-haloperidol --&gt; 4-(4-chlorophenyl)-4-hydroxypiperidine \n\nDescription:\nTroleandomycin was a potent inhibitor of both HAL and 4-(4-chlorophenyl)-4-hydroxypiperidine formation, see p.387\n\n','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(985,'evidence_1867','http://www.ncbi.nlm.nih.gov/pubmed/9825830','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor: ketoconazole\n\nreaction: reduced-haloperidol --&gt; 4-(4-chlorophenyl)-4-hydroxypiperidine\n\nDescription:\nketoconazole was a potent inhibitor of both HAL and 4-(4-chlorophenyl)-4-hydroxypiperidine formation, see p.387 ','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(986,'evidence_1512','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nAn in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(987,'evidence_1771','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(988,'evidence_1381','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(989,'evidence_1788','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','Fluvoxamine is listed as a recommended inhibitor of CYP2C19 for in vivo studies in Table 2 (p. 19). Typically, this would qualify it as a in vivo selective inhibitor however, Table 2 also shows fluvoxamine as a recommended inhibitor of CYP1A2.','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(990,'evidence_1126','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','(table from section &quot;Drug Interactions&quot;)\n\nBased on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also  WARNINGS for details) and limited in vitro data for the IIIA4 isozyme, it appears that fluvoxamine inhibits the following isozymes that are known to be involved in the metabolism of the listed drugs:\nIA2             IIC9	        IIIA4         IIC19\nWarfarin	Warfarin	Alprazolam   Omeprazole\nTheophylline			\nPropranolol			\nTizanidine			','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(991,'evidence_1754','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f','\nFollowing administration of single 10 mg Edluar, in 18 (18-65 years of age) healthy adult subjects, the mean peak concentration (Cmax) of zolpidem was 106 ng/mL (range: 52 to 205 ng/ml) occurring at a median time (Tmax) of 82 minutes (range: 30-180 min).\n\n106ng/mL X 1g/10^9ng X 1000ml/1L = 0.000106g/L','boycer','11/09/2009 12:59:51\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000106,NULL,NULL,NULL,'',0.01,NULL),(992,'evidence_1302','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: S-mepheytoin 4\'hydroxylation\n\nQuote:\n\nCYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI\nfluvoxamine (see Table 2). ','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(993,'evidence_1304','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends tolbutamide to be an acceptable chemical CYP2C9 substrate (tolbutamide methyl-hydroxylation)) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','06/11/2009 15:08:24\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(994,'evidence_1222','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3249','&quot;Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of rosuvastatin. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by rosuvastatin.&quot;','boycer','09/28/2007 08:06:28\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(995,'evidence_1490','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(996,'evidence_1542','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(997,'evidence_1722','http://www.ncbi.nlm.nih.gov/pubmed/11910262','Route of administration: oral\n\nstudy duration: read description below\n\npopulation: (paroxetine group) 13 healthy volunteers (8 male and 5 female), all extensive metabolizers of dextromethorphan\n\nages: mean(std dev): 28 (unknown)\n\nDescription: \nIn an open label, parallel group study of 45 healthy volunteers, the time course of CYP2D6 inhibition of the above SSRIs was evaluated. Subjects were randomized to receive paroxetine at 20 mg/day for 10 days; sertraline at 50 mg/day for 3 days, followed by sertraline at 100 mg/day for 10 days; or fluoxetine at 20 mg/day for 28 days. CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine. Following SSRI discontinuation, calculation of a CYP2D6 inhibition half-life (t(1/2)inh) revealed the time course of fluoxetine inhibition (t(1/2)inh = 7.0 +/- 1.5 days) to be significantly longer than either paroxetine (t(1/2)inh = 2.9 +/- 1.9) or sertraline (t(1/2)inh = 3.0 +/- 3.0) (p &lt; 0.01), but the latter were not significantly different from each other (p &gt; 0.05). Time for the extrapolated DMR versus time log-linear plots to return to baseline was significantly different between fluoxetine (63.2 +/- 5.6 days) and both paroxetine (20.3 +/- 6.4 days) and sertraline (25.0 +/- 11.0 days) (p &lt; 0.01), making the rank order (from longest to shortest) of time for CYP2D6 inhibition to dissipate: fluoxetine &gt; sertraline &gt;or= paroxetine. Differences between mean baseline DMR values and measured values obtained after drug discontinuation for each drug group became nonsignificant on discontinuation day 5 for both paroxetine and sertraline and on discontinuation day 42 for fluoxetine. ','boycer','12172009','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(998,'evidence_1803','http://www.ncbi.nlm.nih.gov/pubmed/12173784','\n\nroute of administration: oral\n\nstudy duration: paroxetine 20mg qd for eight days\n\npopulation: 32 healthy adults, all extensive CYP2D6 metabolizers based on DM:DX\n\nages: unmentioned\n\nDescription: \nThe urinary concentration ratio of dextromethorphan:dextrorphan (interpreted as an in vivo index of CYP2D6 activity) was determined for each subject before and after the 8 days of receiving SSRIs. Plasma SSRI trough concentrations were measured on days 6-9. The CYP2D6 genotype was determined in a subject with an undetectable paroxetine concentration. Inhibition of CYP2D6 correlated significantly with plasma concentrations of paroxetine and fluoxetine. In contrast, no significant correlations emerged between CYP2D6 inhibition and plasma concentrations of sertraline or fluvoxamine. The subject with an undetectable paroxetine concentration was found to carry at least three functional CYP2D6 genes.','boycer','12172009','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(999,'evidence_1272','http://www.ncbi.nlm.nih.gov/pubmed/12584155','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nQuote:\nTo determine whether preincubation affects the inhibition of human liver microsomal dextromethorphan demethylation activity by paroxetine, we used a two-step incubation scheme in which all of the enzyme assay components, minus substrate, are preincubated with paroxetine...Time-dependent inhibition was demonstrated with an apparent K(I) of 4.85 microM and an apparent k(INACT) value of 0.17 min(-1). Spectral scanning of CYP2D6 with paroxetine yielded an increase in absorbance at 456 nm suggesting paroxetine inactivation of CYP2D6 via the formation of a metabolite intermediate complex.\n...In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation-dependent increase in inhibitory potency. These data are consistent with mechanism-based inhibition of CYP2D6 by paroxetine but not by quinidine or fluoxetine.','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1000,'evidence_1243','http://www.ncbi.nlm.nih.gov/pubmed/8513845','\nroute of administration: oral\n\nstudy duration: \n\npopulation: 17 males, 9 sparteine EMs and 8 sparteine PMs\n\nages: 20-24\n\nDescription: \nDuring paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively. The 5-fold decrease in clearance in EMs when desipramine was co-administered with paroxetine confirms that paroxetine is a potent inhibitor of CYP2D6. The lack of effect on clearance in PMs shows that paroxetine is a selective inhibitor of CYP2D6, which is absent from the livers of PMs. Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).','boycer','12172009','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1001,'evidence_1212','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/89dd7e24-85fc-4152-89ea-47ec2b48a1ed','Drug-Drug Interactions\n\nIn vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions). ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1002,'evidence_1281','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','7.5  Effect of Atomoxetine on P450 Enzymes\n\nAtomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1003,'evidence_1072','http://www.ncbi.nlm.nih.gov/pubmed/16778714','NOTE: The AUC_i/AUC is from the heterozygous EMs and calculated from Table 1.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 6 days\r\n\r\npopulation: 18 healthy volunteers (9 male, 9 female), all Japanese\r\n\r\ntested for known CYP450 polymorphisms?\r\nYes -- CYP2C19 genotypes - 6 homozygous EMs, 6 heterozygous EMs, 6 homozygous PMs\r\n\r\nages: mean 25.1 years (+/- 3.8)\r\n\r\ndescription:\r\nEighteen healthy Japanese volunteers (9 men and 9 women) who were H. pylori-negative were enrolled in this study. Their mean age was 25.1 +/- 3.8 years and mean body weight was 56.6 +/- 13.3 kg. Most subjects in this study had participated in our previous studies. The mutated alleles for CYP2C19, CYP2C19*3(*3), and CYP2C19*2(*2) had been identified using polymerase chain reaction-restriction fragment length polymorphism methods of De Morais et al, before this study. The CYP2C19 genotype analyses revealed 5 different patterns as follows: *1/*1 in 6, *1/*2 in 3, *1/*3 in 3, *2/*2 in 5, and *2/*3 in 1. These were divided into 3 groups, homozygous EMs (*1/*1, n=6), heterozygous EMs (*1/*2 and *1/*3, n=6), and PMs (*2/*2 and *2/*3, n=6).\r\nMETHODS: A randomized double-blind placebo-controlled crossover study design in 3 phases was conducted at intervals of 2 weeks. Clarithromycin (400 mg) as a capsule containing the equivalent of 2 tablets, fluvoxamine (25 mg) as a capsule containing the equivalent of a tablet, or matched placebo was given orally twice a day (9 AM, 9 PM) for 6 days. Six volunteers within each group were allocated to each of the 3 different drug sequences: placebo-clarithromycin-fluvoxamine, fluvoxamine-placebo-clarithromycin, or clarithromycin-fluvoxamine-placebo. On day 6, they took a single oral 60-mg dose of lansoprazole with 400 mg dose of clarithromycin, 25mg dose of fluvoxamine, or placebo after overnight fasting (9 AM). No other medications were taken during the study periods. No meal was allowed until 4 hours after the dosing (1 PM). The use of alcohol, tea, coffee, and cola was forbidden during the test days.\r\nRESULTS: Clarithromycin treatment significantly increased Cmax and AUC_0-24 of lansoprazole in heterozygous EMs (P&lt;0.05) and in PMs (P&lt;0.01), and prolonged elimination half-life by 1.6-fold (P&lt;0.05) in PMs. Calculated from Table 1, the AUC_i/AUC were: 1.62 (homozygous EMs), 1.71 (heterozygous EMs [p&lt;0.05]), and 1.89 (PMs [p&lt;0.01]).','boycer','08/23/2010 13:04:42\r\n','EV_PK_DDI_RCT','PKStudy',1.71,0.06,0.8,18,'',NULL,NULL),(1004,'evidence_1281','http://www.ncbi.nlm.nih.gov/pubmed/10445377','\nroute of administration: oral\n\nstudy duration: 16 days\n\npopulation: 9 nonsmoking, stable schizophrenic patients, physically healthy (all male)\n\ntested for known CYP450 polymorphisms?\nYES -- CYP2D6 phenotyping - all extensive metabolizers\n\nages: mean age 38.0 +/- 12.4\n\ndescription:\nSUBJECTS:Nine non-smoking stable schizophrenic patients (mean age 38.0 +/- 12.4 years and weight 59.1 +/- 12.3 kg) gave informed consent to participated in this study. Each patient met the DSM-IV criteria for schizophrenia, had not previously received CLZ or FLV and had not consumed beverages containing caffeine, alcohol or grapefruit juice for at least 1 month prior to the study. Patients were also not taking any known CYP1A2 inducers or inhibitors or other routinely prescribed medications. Only lorazepam as needed 2 mg every 46 h was allowed during the study. All patients were evaluated to be physically healthy by physical examination, medical history, and routine hematological, biochemical and urinalysis tests. These patients were not classified as refractory schizophrenics by the criteria proposed by Kane et al. (1988). Prior to the study, these patients were phenotyped with dextromethorphan and all subjects were extensive metabolizers of CYP2D6 (Lane et al. 1996). Also, prior to the study, these patients were also administered a test dose of caffeine 200 mg and CYP1A2 status was evaluated. Caffeine and metabolite ratios were within values previously reported by other investigators, indicating the absence of any unusual metabolizers of CYP1A2 in this group of patients (Bertilsson et al. 1994).\n\nMETHODS: On the first study day at 8:00 a.m., each patient received a single CLZ 50 mg dose (two 25 mg tablets). Venous blood samples (5 ml) were collected in heparinized tubes and obtained prior to the dosage administration and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36 and 48 h post-drug. The blood samples were centrifuged at 3000 rpm for 15 min and the separated plasma frozen at 920C until assay. FLV 50 mg was administered twice a day to each patient from day 3 to day 16. On day 15, CLZ 50 mg was given as a single dose. Blood samples were obtained at the same times during the first study period.\n\nRESULTS: The total AUC of CLZ increased by a factor of 2.84 upon FLV addition (t = 5.364, P = 0.0007).\n','boycer','09/16/2010 14:13:21\n','EV_PK_DDI_NR','PKStudy',2.84,0.05,0.1,9,'',NULL,NULL),(1005,'evidence_1643','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 1\'-OH-alprazolam in a recombinant cyp3a5 Supersome system; Km = 178','boycer','06/26/2007 07:53:46\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1006,'evidence_1237','http://www.ncbi.nlm.nih.gov/pubmed/8866916','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: S-mephenytoin\n\nreaction: S-mephenytoin 4-hydroxylation\n\nKi = 920 micM\n\nMW: 312.43366 (ChEBI)\n\n920micM/L X 1M/10^6micM X 312.43366g/1M = 0.287\n\n\n','boycer','02/13/2010 08:45:11\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.287,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,178),(1007,'evidence_1940','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7e117c7e-02fc-4343-92a1-230061dfc5e0','&quot;There were no significant interactions between risperidone (1 mg QD) and erythromycin (500 mg QID)&quot;','boycer','06/16/2009 12:53:40\n','Non_traceable_Drug_Label_Statement','PKStudy',0,0.5,0.001,NULL,'',NULL,NULL),(1008,'evidence_1323','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nMetabolism and Excretion\n\nCinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2. After administration of a 75 mg radiolabeled dose to healthy volunteers, cinacalcet was rapidly and extensively metabolized via: 1) oxidative N-dealkylation to hydrocinnamic acid and hydroxy-hydrocinnamic acid, which are further metabolized via &amp;#946;-oxidation and glycine conjugation; the oxidative N-dealkylation process also generates metabolites that contain the naphthalene ring; and 2) oxidation of the naphthalene ring on the parent drug to form dihydrodiols, which are further conjugated with glucuronic acid. The plasma concentrations of the major circulating metabolites including the cinnamic acid derivatives and glucuronidated dihydrodiols markedly exceed parent drug concentrations. The hydrocinnamic acid metabolite was shown to be inactive at concentrations up to 10 M in a cell-based assay measuring calcium-receptor activation. The glucuronide conjugates formed after cinacalcet oxidation were shown to have a potency approximately 0.003 times that of cinacalcet in a cell-based assay measuring a calcimimetic response.','boycer','09/24/2009 12:31:33\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1009,'evidence_1878','http://www.ncbi.nlm.nih.gov/pubmed/9146848','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 3 day pretreatment with diltiazem\n\npopulation: 7 male\n\nages: 20-22\n\ndescription: \nWe investigated the interaction between triazolam and diltiazem in a randomized, three-phase crossover study. Seven healthy male volunteers received orally either a single 0.25 mg dose of triazolam, a 0.25 mg dose of triazolam after a 3-day treatment of diltiazem (180 mg day-1), or a placebo. Plasma samples were collected to determine triazolam concentration over a 24 h period. The pharmacodynamic effects of triazolam were investigated using the peak saccadic velocity of eye movements (PSV), electroencephalogram (EEG), and visual analogue scale (VAS) through 8 h. RESULTS: Diltiazem pretreatment significantly increased the area under the triazolam concentration-time curve (8.0 +/- 2.4 to 18.2 +/- 3.1 ng ml-1 h; P < 0.001; mean +/- s.d.). Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01). The PSV, EEG, and VAS of the triazolam plus diltiazem group revealed significant differences from the triazolam alone group or the control placebo group.','boycer','12172009','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1010,'evidence_1562','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1011,'evidence_1897','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: triazolam hydroxylation\n\nQuote: \n\nCYP3A. CT and metabolites all were very weak or negligible inhibitors of CYP3A, as indicated by triazolam hydroxylation. None of the compounds (at 100micM) produced more than 50% inhibition. Fluvoxamine and nefazodone were moderately strong inhibitors (von\nMoltke et al., 1996b, 1999c).','boycer','06/11/2009 16:32:24\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,179),(1012,'evidence_1845','http://www.ncbi.nlm.nih.gov/pubmed/10907965','\n\nroute of administration: oral\n\nstudy duration: Subjects received triazolam 0.25 mg alone and another 0.25-mg dose after 4 weeks of citalopram 20 mg/day for 1 week, followed by 3 weeks of citalopram 40 mg/day\n\npopulation: 17 (7 men and 10 women) completed the study)\n\ntested for known CYP450 polymorphisms?\n\nages: 18 - 31\n\ndescription:\nThe pharmacokinetics of triazolam and its metabolite alpha-hydroxytriazolam were unchanged by citalopram coadministration.\n\n','boycer','02/12/2010 14:46:20\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,180),(1013,'evidence_1219','http://www.ncbi.nlm.nih.gov/pubmed/9152603','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: furafylline\nreaction:\nclarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin\n\ndescription: clarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor','boycer','01/14/2008 13:18:20\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,181),(1014,'evidence_1394','http://www.ncbi.nlm.nih.gov/pubmed/11563412','\n\nroute of administration: oral\n\nstudy duration: five consecutive nightly doses of of 10 mg zolpidem administered alone or in the presence of 19 days of 50 mg sertraline once per day\n\npopulation: 27 healthy females non-smoking (&gt;=6months)\n\ntested for known CYP450 polymorphisms?\n\nages: mean 30, range 20 - 44\n\ndescription:\nFollowing one or five consecutive doses of zolpidem 10 mg, there were no significant differences in the AUC of zolpidem, irrespective of whether it had been administered alone or in the presence of sertraline.\n\n\n','boycer','09/23/2009 12:06:54\n','EV_PK_DDI_RCT','PKStudy',1,0.01,0.05,27,'',NULL,NULL),(1015,'evidence_1683','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA lists this as a recommended in viVo inhibitor in it most recent guidance document. See Table 2, p. 19.','boycer','04/24/2009 15:52:16\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1016,'evidence_1772','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1017,'evidence_1517','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: tolbutamide hydroxylation\n\nThe IC50 for ziprasidone inhibition of this reaction was greater than 100micM \n\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1018,'evidence_1215','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','\nMetabolism and elimination \n...\nThe major oxidative metabolite formed, regardless of CYP2D6 status, is 4hydroxyatomoxetine, which is glucuronidated. 4Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes. NDesmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs).','boycer','09/24/2009 11:28:40\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1019,'evidence_1865','http://www.ncbi.nlm.nih.gov/pubmed/15258107','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam 1\'hydroxylation\n\nIC50 &gt; 200micM (see Table 3)\n\nQuote:\nPantoprazole showed a stronger inhibitory effect (Ki 22mM) on midazolam 1\'-hydroxylation than omeprazole (Ki 42micM), esomeprazole (Ki 47micM), and rabeprazole (Ki 51micM). The IC50 of lansoprazole was over 200 M. \n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1020,'evidence_1394','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','7.19 Drugs Metabolized by Cytochrome P4502D6\n\nIn vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6.','boycer','05/15/2009 10:11:58\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,182),(1021,'evidence_1654','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','7.19 Drugs Metabolized by Cytochrome P4502D6\n\nIn vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6.','boycer','05/14/2009 13:37:41\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1022,'evidence_1647','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: dextromethorphan O-demethylation\n\nQuote: \n\nCYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors.\n\n','boycer','06/11/2009 16:23:37\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,183),(1023,'evidence_1356','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1024,'evidence_1865','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4. Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects (see CONTRAINDICATIONS and WARNINGS). Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1025,'evidence_1916','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Sildenafil:  The results of one published study in HIV-infected men (n=6) indicated that coadministration of indinavir (800 mg every 8 hours chronically) with a single 25-mg dose of sildenafil resulted in an 11% increase in average AUC0-8hr of indinavir and a 48% increase in average indinavir peak concentration (Cmax) compared to 800 mg every 8 hours alone. Average sildenafil AUC was increased by 340% following coadministration of sildenafil and indinavir compared to historical data following administration of sildenafil alone (see WARNINGS, Drug Interactions and PRECAUTIONS, Drug Interactions).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1026,'evidence_1155','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1027,'evidence_1708','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84','\n12.5 Drug-Drug Interactions\n...\nPREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. ','boycer','09/24/2009 10:17:24\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1028,'evidence_1336','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1029,'evidence_1199','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 1\'-OH-midazolam using a recombinant CYP3A4 Supersome system.','boycer','07/02/2007 11:13:20\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1030,'evidence_1664','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: tolbutamide --&gt; hydroxytolbutamide\n\nQuote:\n\nCYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7 (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM). ','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1031,'evidence_1185','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as an acceptable chemical CYP2D6 substrate (CYP2D6--&gt;(debrisoquin-&gt;4-hydroxydebrisoquin)) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','05/06/2009 11:02:57\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1032,'evidence_1224','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1033,'evidence_1118','http://www.ncbi.nlm.nih.gov/pubmed/8911886','\nroute of administration: oral\n\nstudy duration: &quot;All volunteers received two single oral doses of 12 mg fluphenazine-HCl: Lyorodin (4 mg fluphenazine-HCl tablet, batch No. 120291), Lyogen retard (3 mg fluphenazine-HCl tablet, batch No. 390061); and an intravenous dose of 2.5 mg: Lyogen 5 solution (5 mg fluphenazine-HCl/ampoule, batch No. 488011) after at least 12 h of fasting on three different days. The washout period was between 7 and 14 days. The three doses were administered according to a randomisation table. All volunteers received standard meals 4 and 10 h after administration of the study medication. The total intake of water within the first 10 h post-dose was 1.5L.&quot;\n\npopulation: 14 healthy volunteers (8 male, 6 female); no participants were tested for known CYP450 phenotypes. NOTE: only twelve participants completed the trial\n\nages: 30.5 (SD:7.2)\n\nC_max @ 12mg fluphenazine IMMEDIATE RELEASE: 2.3ng/mL\n\n2.3ng/mL X 1g/10^9ng X 1000mL/1L = 0.0000023g/L','boycer','06/20/2009 11:28:24\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000023,NULL,NULL,NULL,'',0.012,NULL),(1034,'evidence_1239','http://www.ncbi.nlm.nih.gov/pubmed/8911886','\nroute of administration: oral\n\nstudy duration: &quot;All volunteers received two single oral doses of 12 mg fluphenazine-HCl: Lyorodin (4 mg fluphenazine-HCl tablet, batch No. 120291), Lyogen retard (3 mg fluphenazine-HCl tablet, batch No. 390061); and an intravenous dose of 2.5 mg: Lyogen 5 solution (5 mg fluphenazine-HCl/ampoule, batch No. 488011) after at least 12 h of fasting on three different days. The washout period was between 7 and 14 days. The three doses were administered according to a randomisation table. All volunteers received standard meals 4 and 10 h after administration of the study medication. The total intake of water within the first 10 h post-dose was 1.5L.&quot;\n\npopulation: 14 healthy volunteers (8 male, 6 female); no participants were tested for known CYP450 phenotypes. NOTE: only twelve participants completed the trial\n\nages: 30.5 (SD:7.2)\n\nC_max @ 12mg fluphenazine EXTENDED RELEASE: 1.2ng/mL\n\n1.2ng/mL X 1g/10^9ng X 1000mL/1L = 0.0000012g/L','boycer','06/20/2009 11:39:17\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000012,NULL,NULL,NULL,'',0.012,NULL),(1035,'evidence_1173','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1036,'evidence_1393','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9550','\nPharmacokinetics\n\nMidodrine hydrochloride is a prodrug, i.e., the therapeutic effect of orally administered midodrine is due to the major metabolite desglymidodrine, formed by deglycination of midodrine. After oral administration, midodrine hydrochloride is rapidly absorbed...The absolute bioavailability of midodrine (measured as desglymidodrine) is 93%. The bioavailability of desglymidodrine is not affected by food. Approximately the same amount of desglymidodrine is formed after intravenous and oral administration of midodrine. Neither midodrine nor desglymidodrine is bound to plasma proteins to any significant extent.','boycer','09/24/2009 12:56:20\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.93,NULL,NULL,NULL,'',NULL,NULL),(1037,'evidence_1822','http://www.ncbi.nlm.nih.gov/pubmed/8243504','Route of administration: oral\n\nstudy duration: single dose with 24 hours of blood sampling\n\ndose: single dose of 90mg diltiazem\n\npopulation: 10 male, 10 female\n\nages:19-50\n\ndescription:\nPlasma concentrations and urinary excretion of DTZ and its metabolites were determined in 20 healthy volunteers (10 males and 10 females) after they had each been given a single oral 90 mg dose of DTZ. DTZ and six of its metabolites which included N-monodesmethyl DTZ (MA), deacetyl DTZ (M1), deacetyl N-monodesmethyl DTZ (M2), deacetyl O-desmethyl DTZ (M4) and deacetyl DTZ N-oxide (M1NO) and deacetyl N,O-didesmethyl DTZ (M6), were determined by a sensitive and specific HPLC assay. The major metabolites measurable in the plasma of all the volunteers were MA, M1, and M2. The terminal half-lives (t1/2) of M1 and M2 were considerably longer than those of DTZ and MA. ','boycer','09/24/2007 09:38:25\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1038,'evidence_1647','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1039,'evidence_1620','http://www.ncbi.nlm.nih.gov/pubmed/15834460','\nRoute of administration: oral\n\nstudy duration: multiple doses of QTP with or without concomitant erythromycin\n\npopulation: 19; 10 female and 9 male\n\nages:18-55\n\nHPLC-MS detected 7-hydroxy-N-desalkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine','boycer','06/15/2009 15:57:29\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1040,'evidence_1182','http://www.ncbi.nlm.nih.gov/pubmed/9757151','\nRoute of administration: oral\n\nstudy duration: 1 day pre-treatment with erythromycin 500mg 2x/day\n\npopulation: 12 healthy adults \nmale: 6\nfemale: 6\nages: 21-39 years\n\nAUC_i/AUC: 20.9/5.5\n\nQuote:\nIn a randomized, double-blind, 5-trial clinical pharmacokinetic-pharmacodynamic study, 12 volunteers received 0.125 mg triazolam orally, together with placebo, azithromycin, erythromycin, or clarithromycin. In a fifth trial they received placebo plus placebo...Apparent oral clearance was significantly reduced (P < .05) during erythromycin and clarithromycin trials (146 and 95 mL/min). Peak plasma concentration was correspondingly increased, and elimination half-life was prolonged. The effects of triazolam on dynamic measures were nearly identical when triazolam was given with placebo or azithromycin, but benzodiazepine agonist effects were enhanced during erythromycin and clarithromycin trials.','boycer','12172009','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1041,'evidence_1381','http://www.ncbi.nlm.nih.gov/pubmed/8720318','\nRoute of administration: oral\n\nstudy duration: 4 days pre-treatment with erythromycin 500mg 3x/day; 5th day patients in the treatment arm received a single 15mg oral dose of MDZ\n\npopulation: 12 healthy adults\nmale: 4\nfemale: 8\nages: 24-53 years\n\nAUC_i/AUC: 662.71/173.77 ng*hr/ml = 3.814\n\nNOTE: AUC values  appear to be 0-24 hour \n\nQuote:\n&quot;The pharmacokinetic and pharmacodynamic interaction between azithromycin (CAS 83905-01-5), an azalide antibiotic, and midazolam (CAS 59467-70-8), a short-acting hypnotic agent, was investigated in an open, three-way cross-over study, including erythromycin (CAS 114-07-8) as a positive control. Twelve healthy male and female subjects had standard doses of azithromycin (500 mg o.d. over 3 days), or erythromycin (500 mg t.i.d. over 5 days), or no pretreatment. On the day of the last dose, they ingested 15 mg midazolam. Blood samples were collected and psychometric tests performed. Erythromycin pretreatment (E) significantly changed the pharmacokinetics of midazolam compared to control (C), whereas azithromycin (A) had no such effect. The parameters are summarized as follows: area under the concentration-time curve, AUC (C) 173.8 h.ng.ml-1 vs. (E) 662.7 h.ng.ml-1*+ and (A) 220.0 h.ng.ml-1; concentration maxima (C) 67.2 ng.ml-1 vs. (E) 182.3 ng.ml-1*+ and (A) 86.7 ng.ml-1; elimination half-life (C) 2.21 h vs. (E) 4.85 h* and (A) 2.41 h (* p &lt; 0.05 vs. (C), +p &lt; 0.05 vs. (A)). Pharmacodynamic tests (digit symbol substitution test; critical flicker fusion test; subjective analog scale for rating of alertness; duration of sleep) consistently showed significant differences after erythromycin pretreatment compared to control, but not after azithromycin. Erythromycin, but not azithromycin, causes clinically significant changes in the pharmacokinetics and pharmacodynamics of midazolam.&quot;','boycer','12172009','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1042,'evidence_1906','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','04/25/2009 10:16:03\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,184),(1043,'evidence_1732','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','\nMetabolism and Excretion\n\nTopiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose). ','boycer','09/24/2009 15:54:08\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1044,'evidence_1570','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme. Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro. In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150mg twice daily followed by a single dose of 50mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively. The effect was present for at least 7 days after the last dose of bupropion. Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.','boycer','05/15/2009 10:51:26\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,185),(1045,'evidence_1384','http://www.ncbi.nlm.nih.gov/pubmed/15876900','\n\nroute of administration: oral\n\nstudy duration: &quot;dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching placebo. Subjects quit smoking 3 days before the second dextromethorphan administration.&quot;\n\npopulation: 21 smoking, 9 female, 11 male\n\ntested for known CYP450 polymorphisms? yes ... all participants were considered CYP2D6 extensive metabolizers according to dextromethorphan:dextrorphan metabolite ratio\n\nages: 21 - 40\n\nNOTE: &quot;24-hour period preceding each laboratory visit. Two subjects reported taking medications that could potentially affect CYP2D6 metabolism and therefore alter bupropion concentrations (one reported use of hormone replacement therapy and another oral contraceptives).&quot;\n\ndescription:\n&quot;Among those taking bupropion, DM/DX ratio in-\ncreased significantly at the second assessment relative to the first (0.012  0.012 vs. 0.418  0.302; P &lt; 0.0004) (Fig. 1). No such change was observed in those randomized to placebo (0.009  0.010 vs. 0.017  0.015; P = NS). Of those receiving bupropion, 46% (6/13) were phenotypically poor metabolizers after treatment.&quot;\n\n\n','boycer','06/20/2009 14:58:06\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,186),(1046,'evidence_1870','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','Drug interactions:\n\nIn vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1047,'evidence_1812','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nMetabolism and Excretion\n\nCinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1048,'evidence_1926','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nKetoconazole: Cinacalcet AUC(0-inf) and Cmax increased 2.3 and 2.2 times, respectively, when a single 90 mg cinacalcet dose on Day 5 was administered to subjects treated with 200 mg ketoconazole twice daily for 7 days compared to 90 mg cinacalcet given alone.','boycer','09/24/2009 10:51:26\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,187),(1049,'evidence_1447','http://www.ncbi.nlm.nih.gov/pubmed/16390352','Enzyme system: recombinant human enzymes in human lymphoblastoid\nNADPH added: not explicitly mentioned but assumed\n\ninhibitor used: no\n\nQuetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4.','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1050,'evidence_1980','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1051,'evidence_1171','http://www.ncbi.nlm.nih.gov/pubmed/8889898','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam 1-hydroxylation\n\nKi = 0.0037 micM\nMW: 531.44\n\n0.0037micM/L X 1M/10^6micM X 531.44g/M = 1.966 X 10e-6g/L','boycer','02/13/2010 10:28:19\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.000001966,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,188),(1052,'evidence_1168','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','11/09/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1053,'evidence_1815','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nAn in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1054,'evidence_1573','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: S-mepheytoin 4\'hydroxylation\n\nQuote: \n\nCYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI\nfluvoxamine (see Table 2).\n\n\n','boycer','06/11/2009 16:08:54\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,189),(1055,'evidence_1606','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1056,'evidence_1855','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','06/12/2009 19:22:19\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,190),(1057,'evidence_1839','http://www.ncbi.nlm.nih.gov/pubmed/14747427','\nroute of administration: oral\n\nstudy duration: &quot;Two 14-day, placebo-controlled, double-blind studies...In Study 1, 37 subjects were randomized to aripiprazole 5 mg, 10 mg, 15 mg, 20 mg, or placebo once daily. In Study 2, 11 subjects were randomized to aripiprazole, titrated from 10 to 30 mg/day, or placebo.&quot;\n\npopulation: adult males\n\nages: 34.3 (SD:5.1)\n\nC_max @ 5mg/day: 98.2ng/mL\n\n98.2ng/mL X 1g/10^9ng X 1000mL/1L = 0.0000982g/L\n\n','boycer','06/19/2009 18:59:46\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000982,NULL,NULL,NULL,'',0.005,NULL),(1058,'evidence_1647','http://www.ncbi.nlm.nih.gov/pubmed/14747427','\nroute of administration: oral\n\nstudy duration: &quot;Two 14-day, placebo-controlled, double-blind studies...In Study 1, 37 subjects were randomized to aripiprazole 5 mg, 10 mg, 15 mg, 20 mg, or placebo once daily. In Study 2, 11 subjects were randomized to aripiprazole, titrated from 10 to 30 mg/day, or placebo.&quot;\n\npopulation: adult males\n\nages: 28.6 (SD:4.1)\n\nC_max @ 10mg/day: 163ng/mL\n\n163ng/mL X 1g/10^9ng X 1000mL/1L = 0.000163g/L ','boycer','06/19/2009 19:02:45\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000163,NULL,NULL,NULL,'',0.01,NULL),(1059,'evidence_1760','http://www.ncbi.nlm.nih.gov/pubmed/14747427','\nroute of administration: oral\n\nstudy duration: &quot;Two 14-day, placebo-controlled, double-blind studies...In Study 1, 37 subjects were randomized to aripiprazole 5 mg, 10 mg, 15 mg, 20 mg, or placebo once daily. In Study 2, 11 subjects were randomized to aripiprazole, titrated from 10 to 30 mg/day, or placebo.&quot;\n\npopulation: adult males\n\nages: 29.8  (SD:8.2)\n\nC_max @ 15mg/day: 242ng/mL\n\n242ng/mL X 1g/10^9ng X 1000mL/1L = 0.000242g/L ','boycer','06/19/2009 19:05:11\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000242,NULL,NULL,NULL,'',0.015,NULL),(1060,'evidence_1070','http://www.ncbi.nlm.nih.gov/pubmed/14747427','\nroute of administration: oral\n\nstudy duration: &quot;Two 14-day, placebo-controlled, double-blind studies...In Study 1, 37 subjects were randomized to aripiprazole 5 mg, 10 mg, 15 mg, 20 mg, or placebo once daily. In Study 2, 11 subjects were randomized to aripiprazole, titrated from 10 to 30 mg/day, or placebo.&quot;\n\npopulation: adult males\n\nages: 26 (SD:8.2)\n\nC_max @ 20mg/day: 393ng/mL\n\n393ng/mL X 1g/10^9ng X 1000mL/1L = 0.000393g/L ','boycer','06/19/2009 19:07:53\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000393,NULL,NULL,NULL,'',0.02,NULL),(1061,'evidence_1889','http://www.ncbi.nlm.nih.gov/pubmed/14747427','\nroute of administration: oral\n\nstudy duration: &quot;Two 14-day, placebo-controlled, double-blind studies...In Study 1, 37 subjects were randomized to aripiprazole 5 mg, 10 mg, 15 mg, 20 mg, or placebo once daily. In Study 2, 11 subjects were randomized to aripiprazole, titrated from 10 to 30 mg/day, or placebo.&quot;\n\npopulation: adult males\n\nages: 29.3 (SD:6.3)\n\nC_max @ 30mg/day: 452ng/mL\n\n452ng/mL X 1g/10^9ng X 1000mL/1L = 0.000452g/L ','boycer','06/19/2009 19:10:22\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000452,NULL,NULL,NULL,'',0.03,NULL),(1062,'evidence_1660','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1063,'evidence_1961','http://www.ncbi.nlm.nih.gov/pubmed/1487561','\nroute of administration: oral\n\nstudy duration: &quot;The study was a randomized three-period cross-over design using a pair of Latin squares.  Each sub-ject participated for three 5-day venlafaxine treatment periods separated by a 9-day drug-free interval.  Each treatment period consisted of 25, 75, or 150mg of venlafaxine given as a single dose on day 1, followed by the same dose given every 8 hours (q8h) on days 2 to 4, and ending with a single dose given on day 5, for a total of 2 doses. All doses were administered after food as multiple tablets of 25 mg venlafaxine base. The single doses on days 1 and 5 were administered 30 minutes after the subject had eaten a medium-fat breakfast and were followed by a 4-hour fast.&quot;\n\npopulation: 18, non-smoking, healthy men, NOTE: none were tested for known CYP450 phenotypes \n\nages: 20 - 34\n\nC_max (day 4) @ 75mg/day venlafaxine: 53ng/mL\n\n53ng/mL X 1g/10^9ng X 1000mL/1L = 0.000053g/L\n','boycer','06/19/2009 20:19:10\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000053,NULL,NULL,NULL,'',0.075,NULL),(1064,'evidence_1355','http://www.ncbi.nlm.nih.gov/pubmed/1487561','\n\nroute of administration: oral\n\nstudy duration: &quot;The study was a randomized three-period cross-over design using a pair of Latin squares.  Each sub-ject participated for three 5-day venlafaxine treatment periods separated by a 9-day drug-free interval.  Each treatment period consisted of 25, 75, or 150mg of venlafaxine given as a single dose on day 1, followed by the same dose given every 8 hours (q8h) on days 2 to 4, and ending with a single dose given on day 5, for a total of 2 doses. All doses were administered after food as multiple tablets of 25 mg venlafaxine base. The single doses on days 1 and 5 were administered 30 minutes after the subject had eaten a medium-fat breakfast and were followed by a 4-hour fast.&quot;\n\npopulation: 18, non-smoking, healthy men, NOTE: none were tested for known CYP450 phenotypes \n\nages: 20 - 34\n\nC_max (day 4) @ 225mg/day venlafaxine: 167ng/mL\n\n167ng/mL X 1g/10^9ng X 1000mL/1L = 0.000167g/L\n','boycer','06/19/2009 20:22:02\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000167,NULL,NULL,NULL,'',0.225,NULL),(1065,'evidence_1965','http://www.ncbi.nlm.nih.gov/pubmed/1487561','\n\nroute of administration: oral\n\nstudy duration: &quot;The study was a randomized three-period cross-over design using a pair of Latin squares.  Each sub-ject participated for three 5-day venlafaxine treatment periods separated by a 9-day drug-free interval.  Each treatment period consisted of 25, 75, or 150mg of venlafaxine given as a single dose on day 1, followed by the same dose given every 8 hours (q8h) on days 2 to 4, and ending with a single dose given on day 5, for a total of 2 doses. All doses were administered after food as multiple tablets of 25 mg venlafaxine base. The single doses on days 1 and 5 were administered 30 minutes after the subject had eaten a medium-fat breakfast and were followed by a 4-hour fast.&quot;\n\npopulation: 18, non-smoking, healthy men, NOTE: none were tested for known CYP450 phenotypes \n\nages: 20 - 34\n\nC_max (day 4) @ 450mg/day venlafaxine: 393ng/mL\n\n393ng/mL X 1g/10^9ng X 1000mL/1L = 0.000393g/L\n','boycer','06/19/2009 20:46:08\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000393,NULL,NULL,NULL,'',0.45,NULL),(1066,'evidence_1564','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1067,'evidence_1967','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes \n\nNADPH added: yes \n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel \n\nk_i = 41.1micM \n\n41.1micM/1L x 1M/1e6micM x 436.58g/1M = .018g/L\n\n(molecular weight from simvastatin acid entry in pubchem; http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=64718)\n\n','boycer','10/29/2007 10:37:47\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.018,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,191),(1068,'evidence_1633','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nAn in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1069,'evidence_1124','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','Metabolism and Elimination\n\nFollowing oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance.\n\nEscitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT). In humans, unchanged escitalopram is the predominant compound in plasma. At steady state, the concentration of the escitalopram metabolite S-DCT in plasma is approximately one-third that of escitalopram. The level of S-DDCT was not detectable in most subjects. In vitro studies show that escitalopram is at least 7 and 27 times more potent than S-DCT and S-DDCT, respectively, in the inhibition of serotonin reuptake, suggesting that the metabolites of escitalopram do not contribute significantly to the antidepressant actions of escitalopram. S-DCT and S-DDCT also have no or very low affinity for serotonergic (5-HT1-7) or other receptors including alpha- and beta-adrenergic, dopamine (D1-5), histamine (H1-3), muscarinic (M1-5), and benzodiazepine receptors. S-DCT and S-DDCT also do not bind to various ion channels including Na+, K+, Cl-, and Ca++ channels.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1070,'evidence_1221','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1071,'evidence_1561','http://www.ncbi.nlm.nih.gov/pubmed/10997944','\nEnzyme system: recombinant CYP450 enzymes in baculovirus-infected insect cells\n\nNADPH added: yes\n\nreaction: bupropion --&gt; hydroxybupropion\n\nNOTE: the experiment provides no clear minimum Km CYP2B6 catalysis of the mentioned reaction\n\nQuote:\n&quot;Evaluation of BUP Hydroxylation by Individual cDNA-Expressed Human P450s. Because the biphasic kinetic data observed with low activity HLMs (HLMs 20 and 24) indicated the contribution of more than one enzyme to BUP hydroxylation at higher substrate concentrations, a panel of eight cDNA-expressed enzymes (SUPER- SOMES) was screened for BUP hydroxylase activity at 12 mM to identify enzymes requiring further investigation (Fig. 7). This sub- strate concentration was selected to ensure saturation of any high Km isozyme capable of catalyzing BUP hydroxylation. cDNA-expressed CYP2B6 demonstrated the highest rate of HBUP formation (7.0 pmol/min/pmol of P450). cDNA-expressed CYP2E1 and CYP3A4 catalyzed BUP hydroxylation at the second and third highest rates, although at 3- and 30-fold lower rates than cDNA-expressed CYP2B6 (2.4 and 0.23 pmol/min/pmol of P450, respectively). Of note, CYP2E1 was the only cDNA-expressed enzyme in which cytochrome b5 was coexpressed. Rates of BUP hydroxylation by CYP1A2, CYP2A6, CYP2C9, CYP2C19, and CYP2D6 were greater than 30-fold lower than CYP2B6 (Fig. 7). HBUP formation in control microsomes was negligible.&quot;','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1072,'evidence_1564','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/08320ea3-8f93-6f04-5d1c-f69af3eb5a81','\n&quot;Paroxetine is extensively metabolized and the metabolites are considered to be inactive. Nonlinearity in pharmacokinetics is observed with increasing doses. Paroxetine metabolism is mediated in part by CYP2D6, and the metabolites are primarily excreted in the urine and to some extent in the feces.&quot;','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1073,'evidence_1539','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1074,'evidence_1780','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP2C8 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 13:37:42\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1075,'evidence_1485','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1076,'evidence_1835','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1077,'evidence_1890','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1078,'evidence_1385','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/6c76e98d-b8c3-441f-bac5-a9de6dc8f14f','Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours. In a study in which normal volunteers (n=12) received perphenazine 4 mg q8h for 5 days, steady-state concentrations of perphenazine were reached within 72 hours. Mean (%CV) Cmax and Cmin values for perphenazine and 7-hydroxyperphenazine at steady-state are listed below:\n\nParameter	Perphenazine	7-Hydroxyperphenazine\nCmax (pg/mL)	984 (43)	509 (25)\nCmin (pg/mL)	442 (76)	350 (56)\n\nPeak 7-hydroxyperphenazine concentrations were observed between 2 to 4 hours with a terminal phase half-life ranging between 9.9 to 18.8 hours. ','boycer','05/06/2009 13:10:22\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000000509,NULL,NULL,NULL,'',0.004,NULL),(1079,'evidence_1690','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','09/24/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1080,'evidence_1441','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1081,'evidence_1420','http://www.ncbi.nlm.nih.gov/pubmed/12584155','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nQuote:\nTo determine whether preincubation affects the inhibition of human liver microsomal dextromethorphan demethylation activity by paroxetine, we used a two-step incubation scheme in which all of the enzyme assay components, minus substrate, are preincubated with paroxetine...Time-dependent inhibition was demonstrated with an apparent K(I) of 4.85 microM and an apparent k(INACT) value of 0.17 min(-1). Spectral scanning of CYP2D6 with paroxetine yielded an increase in absorbance at 456 nm suggesting paroxetine inactivation of CYP2D6 via the formation of a metabolite intermediate complex.\n...In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation-dependent increase in inhibitory potency. These data are consistent with mechanism-based inhibition of CYP2D6 by paroxetine but not by quinidine or fluoxetine.','boycer','06/16/2009 13:07:54\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,192),(1082,'evidence_1607','http://www.ncbi.nlm.nih.gov/pubmed/1438031','\nroute of administration: oral\n\nstudy duration: a three way cross-over study, 1) single dose of 100mg trazodone after overnight fasting, 2) single dose of 100mg trazodone after a standardized breakfast, 3) single IV infusion of 100mg trazodone after a standardized meal. two weeks in between drug adminstration events\n\npopulation: 8 adults, 4 males and 4 females\n\nparticipants tested for known CYP450 phenotypes? no\n\nages: 25 - 34\n\nC_max @ 100mg (fasting): 1.88micg/mL\n\n1.88micg/mL X 1g/10^6micg X 1000mL/1L = 0.002g/L','boycer','06/20/2009 13:02:58\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.002,NULL,NULL,NULL,'',0.1,NULL),(1083,'evidence_1114','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1084,'evidence_1172','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1085,'evidence_1288','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1086,'evidence_1014','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: coumarin\n\nreaction: coumarin 7-hydroxylation\n\nQuote:\nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. ','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1087,'evidence_1227','http://www.ncbi.nlm.nih.gov/pubmed/11147928','\nRoute of administration: oral\n\nstudy duration: three weeks\n\npopulation: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks\n\nages: 29 - 55\n\n\nQuote:\n\nThe effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline.','boycer','06/16/2009 14:26:57\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,193),(1088,'evidence_1081','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.5,NULL,NULL,NULL,'',NULL,NULL),(1089,'evidence_1278','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84','\n12.5 Drug-Drug Interactions\n...\nPREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. ','boycer','09/24/2009 10:16:14\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1090,'evidence_1648','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','\n&quot;One week following administration of a single oral dose of 1 mg immediate-release 14C-paliperidone to 5 healthy volunteers, 59% (range 51%  67%) of the dose was excreted unchanged into urine, 32% (26%  41%) of the dose was recovered as metabolites, and 6%  12% of the dose was not recovered. Approximately 80% of the administered radioactivity was recovered in urine and 11% in the feces. Four primary metabolic pathways have been identified in vivo, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.&quot;','boycer','06/16/2009 16:10:19\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1091,'evidence_1262','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/56b3f4c2-52af-4947-b225-6808ae9f26f5','\n&quot;The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady state concentration was evaluated in 10 male in-patients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased three-fold following co-administration of fluvoxamine. Fluvoxamine and thioridazine should not be co-administered.&quot;','boycer','06/16/2009 16:50:58\n','Non_traceable_Drug_Label_Statement','PKStudy',3,NULL,0.025,NULL,'',NULL,NULL),(1092,'evidence_1736','http://www.ncbi.nlm.nih.gov/pubmed/19242403','NOTE: The AUCi/AUC value is calculated from Table 1.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 2 days\r\n\r\npopulation: 10 healthy, nonsmoking volunteers (6 male, 4 female); 7 Caucasian, 2 African-American, 1 Hispanic\r\n\r\ntested for known CYP450 polymorphisms? No.\r\n\r\nages: 21-47\r\n\r\ndescription: Ten healthy, nonsmoking volunteers (6 male and 4 female), aged 2147 years, initiated participation after giving written informed consent. All were active, ambulatory adults, with no evidence of medical disease and taking no other medication. The ethnic distribution was: 7 Caucasian, 2 African-American, 1 Hispanic.\r\n\r\nMETHODS: The study was a randomized, double blind, 5-way crossover study with at least 7 days elapsing between trials. Medications were: trazodone hydrochloride, 50 mg (Desyrel; Bristol-Myers Squibb, Princeton, NJ); zolpidem tartrate, 5 mg (Ambien; Sanofi-Aventis, Bridgewater, NJ); and clarithromycin, 500 mg (Biaxin; Abbott, North Chicago, IL). The five treatment conditions were: (i) placebo + placebo, (ii) zolpidem + placebo, (iii) zolpidem + clarithromycin, (iv) trazodone + placebo, and (v) trazodone + clarithromycin. All medications were identically packaged in opaque capsules (void space filled with sucrose) and administered orally. Subjects were given 500 mg doses of clarithromycin (or matching placebo) at approximately 24 h, 8 h, and 1 h prior to, and again at 8 h after, administration of zolpidem, trazodone, or placebo.\r\n\r\nAt 7 am on the study day, subjects were admitted to the Clinical Psychopharmacology Research Unit at Tufts University School of Medicine. They ingested a light breakfast with no caffeine containing beverages or food, and no grapefruit juice. The 500 mg dose of clarithromycin (or matching placebo) was administered with 200 ml of tap water. One hour later, subjects took a challenge dose of 5 mg zolpidem, 50 mg of trazodone, or placebo with 200 ml tap water. Volunteers resumed a normal diet at noon (without caffeine).\r\n\r\nVenous blood samples were drawn into heparinized tubes prior to challenge dosing and at postdosage times of 1/2, 1, 1 1/2, 2, 2 1/2, 3, 4, 5, 6, and 8 h. Another 500 mg of clarithromycin or placebo was given following the 8-h blood sample. The subjects were then discharged from the study unit. They returned the next morning for a 24-h blood sample. All blood samples were centrifuged, and the plasma was separated and frozen until the time of the assay.\r\n\r\nRESULTS: Coadministration of trazodone with clarithromycin compared to placebo significantly increased peak plasma concentration (C_max) (681 ng/ml vs. 922 ng/ml), prolonged t_1/2 (7.1 h vs. 13.9 h), increased AUC (4,668 ng/ml x h vs. 9,275 ng/ml x h), and reduced oral clearance (166 ml/min vs. 89 ml/min).','boycer','09/01/2010 14:29:10\r\n','EV_PK_DDI_RCT','PKStudy',1.99,0.05,0.5,10,'',NULL,NULL),(1093,'evidence_1145','http://www.ncbi.nlm.nih.gov/pubmed/8911886','\nroute of administration: oral\n\nstudy duration: &quot;All volunteers received two single oral doses of 12 mg fluphenazine-HCl: Lyorodin (4 mg fluphenazine-HCl tablet, batch No. 120291), Lyogen retard (3 mg fluphenazine-HCl tablet, batch No. 390061); and an intravenous dose of 2.5 mg: Lyogen 5 solution (5 mg fluphenazine-HCl/ampoule, batch No. 488011) after at least 12 h of fasting on three different days. The washout period was between 7 and 14 days. The three doses were administered according to a randomisation table. All volunteers received standard meals 4 and 10 h after administration of the study medication. The total intake of water within the first 10 h post-dose was 1.5L.&quot;\n\npopulation: 14 healthy volunteers (8 male, 6 female) NOTE: only twelve participants completed the trial\n\nages: 30.5 (SD:7.2)\n\nDescription: \n&quot;The geometric means for the absolute bioavailability of fluphenazine were 2.7% for the immediate release formulation and 3.4% for the slow release formulation. The absolute bioavailability of fluphenazine is thus much lower than previously generally accepted.&quot;\n\nNOTE: these two values of bioavailability have been combined and rounded to get a value of 3%\n','boycer','06/20/2009 11:20:30\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.03,NULL,NULL,NULL,'',NULL,NULL),(1094,'evidence_1682','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','thioridizine is listed in table 4 (p21) as a CYP2D6 substrate with a narrow therapeutic range','boycer','04/29/2009 20:08:03\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1095,'evidence_1345','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/56b3f4c2-52af-4947-b225-6808ae9f26f5','\n&quot;Drugs That Inhibit Cytochrome P450 2D6\n\nIn a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared to rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of cytochrome P450 2D6 isozyme activity. Thus, this study suggests that drugs that inhibit P450 2D6 or the presence of reduced activity levels of this isozyme will produce elevated plasma levels of thioridazine. Therefore, the co-administration of drugs that inhibit P450 2D6 with thioridazine and the use of thioridazine in patients known to have reduced activity of P450 2D6 are contraindicated.&quot;','boycer','06/15/2009 15:36:15\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1096,'evidence_1816','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1097,'evidence_1566','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1098,'evidence_1297','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: tolbutamide --&gt; hydroxytolbutamide\n\nQuote: \n\nCYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7  (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM).\n\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1099,'evidence_1413','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:35:28\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1100,'evidence_1827','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: quinidine\n\nreaction: perphenazine N-dealkylation\n\nQuote:\nTo identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.\n','boycer','06/15/2009 16:47:08\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,194),(1101,'evidence_1757','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel\n\n&quot;No IC50 values could be determined for rosuvastatin and pravastatin with concentrations up to 100micM&quot;\n\nConcentration of rosuvastatin in vivo based on the C_max from PMID:14667956 of a 10mg dose (small): .188nM/L; according to labeling both peak concentration (Cmax) and area under the plasma concentration-time curve (AUC) increased in approximate proportion to rosuvastatin dose.','boycer','11/13/2007 13:35:40\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,195),(1102,'evidence_1775','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71be4cb7-a42f-43be-9b9b-f090edb2fd21','\nMetabolism\n\nAfter oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Zaleplon is primarily metabolized by aldehyde oxidase to form 5-oxo-zaleplon. Zaleplon is metabolized to a lesser extent by cytochrome P450 (CYP) 3A4 to form desethylzaleplon, which is quickly converted, presumably by aldehyde oxidase, to 5-oxo-desethylzaleplon. These oxidative metabolites are then converted to glucuronides and eliminated in urine. All of zaleplon\'s metabolites are pharmacologically inactive. ','boycer','09/23/2009 16:13:26\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1103,'evidence_1091','http://www.ncbi.nlm.nih.gov/pubmed/7891353','\nEnzyme system: human liver microsomes\n\nNADPH added: yes \n\nQuote:\nMetabolism of clozapine to stable and protein-reactive metabolites by human liver.     \n\nChromatographic analysis of the microsomal       incubation supernatants showed that clozapine was metabolized to five metabolites: desmethylclozapine,     clozapine N-oxide, 7-hydroxyclozapine and two un-\nidentified metabolites (fig 1). The CYP2D6            genotype did not affect the formation of these metabolites (table 2).','boycer','06/15/2009 16:14:19\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1104,'evidence_1141','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','7.2 Effects of Ranolazine on Other Drugs\n\nIn vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1105,'evidence_1611','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','Drug Interactions\n...\nAn in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1106,'evidence_1062','http://www.ncbi.nlm.nih.gov/pubmed/8801057','\nRoute of administration: fluconazole oral; warfarin - IV\n\nstudy duration: phase 1 - 8 days of .75mg/kg warfarin alone; phase 2 (21 days later) 14 days of .75mg/kg q.d. AND 400mg q.d. of fluconazole\n\npopulation: 6 male\n\nages: 23-29\n\ndescription: \nformation of 6- and 7-OH-(s)-warfarin decreased by 70%; this reaction is considered primarily catalyzed by CYP2C9. There was also a notable increase in AUC of (S)-warfarin (mean AUC_i/AUC=7.633)','boycer','12172009','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1107,'evidence_1437','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP2C9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1108,'evidence_1785','fda2006','The FDA recommends this as an acceptable chemical CYP3A4 substrate (CYP3A4-->(triazolam->4-hydroxytriazolam)) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','05/21/2007 10:37:30\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1109,'evidence_1937','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: chlorzoxazone\n\nreaction: chlorzoxazone hydroxylation\n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).\n\n\n','boycer','02/12/2010 17:54:38\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,196),(1110,'evidence_1460','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1111,'evidence_1995','http://www.ncbi.nlm.nih.gov/pubmed/12682802','\nRoute of administration: oral\n\nstudy duration: 7 days pre-treatment with erythromycin 500mg 4x/day\n\npopulation: 11 healthy adults (14 started the study but only 11 had data from both dosing periods)\nmale: 14\nfemale: 0\nages: 22-44 years\n\nAUC_i/AUC: 202/253\n\nNOTE: The 0-48 hout AUC values were used rather than the 0-infinity values\n\nQuote:\nIn this randomised, double-blind, two-way cross-over, placebo-controlled trial 14 healthy volunteers were given 500 mg erythromycin or placebo four times daily for 7 days. A single dose of 80 mg rosuvastatin was co-administered on day 4 of dosing. Plasma concentrations of rosuvastatin and active and total HMG-CoA reductase inhibitors were measured up to 96 h after dosing. RESULTS: Eleven volunteers had data available from both dosing periods. There was no increase in rosuvastatin plasma exposure following co-administration with erythromycin compared to placebo. In fact, following co-administration with erythromycin, rosuvastatin geometric least square mean AUC((0-t)) and C(max) were 20% and 31%, respectively, lower than with placebo. Individual treatment ratios for AUC((0-t)) ranged from 0.48 to 1.17, and for C(max) ranged from 0.33 to 2.19. Essentially all of the circulating active HMG-CoA reductase inhibitors and most (>94%) of the total inhibitors were accounted for by rosuvastatin. Erythromycin did not affect the proportion of circulating active or total inhibitors accounted for by circulating rosuvastatin. CONCLUSIONS: Erythromycin did not produce any increase in rosuvastatin plasma exposure.','boycer','06/25/2007 13:16:20\n','EV_PK_DDI_RCT','PKStudy',0.8,0.08,0.5,11,'',NULL,NULL),(1112,'evidence_1142','http://www.ncbi.nlm.nih.gov/pubmed/12709722','\nRoute of administration: oral\n\nstudy duration: 14 healthy male volunteers received itraconazole, 200 mg, or placebo once daily for 5 days; on day 4,  80 mg  of rosuvastatin was coadministered. \n\npopulation: 14 male\nages: 18-65\n\nAUC_i/AUC (geometric least-square mean, 0 to the time of last quantifiable concentration): 1.28','boycer','11/13/2007 09:18:02\n','EV_PK_DDI_RCT','PKStudy',1.28,0.08,0.2,14,'',NULL,NULL),(1113,'evidence_1562','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1114,'evidence_1582','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nDrug Interactions\n...\nDesipramine: The effect of cinacalcet (90 mg) on the pharmacokinetics of desipramine (50 mg) has been studied in healthy subjects who were CYP2D6 extensive metabolizers. The AUC and Cmax of desipramine increased by 3.6 (296.5-446.7%) and 1.75 (157.5-194.9%) fold, respectively, in the presence of cinacalcet. This indicates that cinacalcet is a strong in vivo inhibitor of CYP2D6 and can increase the blood concentrations of drugs metabolized by CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1115,'evidence_1356','http://www.ncbi.nlm.nih.gov/pubmed/16680561','\n\nroute of administration: oral\n\nstudy duration: controls: a single dose of 50 mg of desipramine alone; exposed: a single dose of 50 mg of desipramine after seven days of 90 mg cinacalcet. The groups were randomized and then alternated after a 10-day washout period.\n\npopulation: 14 healthy subjects; non-smokers; 8 female, 7 male\n\ntested for known CYP450 polymorphisms? subjects were required to be CYP2D6 extensive metabolizers based on genotyping\n\nages: 18 - 55\n\ndescription:\nRelative to when desipramine was administered alone, a\n3.6-fold increase in AUC(0-inf) and 1.8-fold increase in Cmax of desipramine was observed when cinacalcet was\nadministered for 5 days before and 2 days after dosing\nwith desipramine (Table 1, Fig. 1). Administration with\ncinacalcet resulted in an increase in the AUC(0-inf) and Cmax of desipramine for all subjects (Fig. 2). Coadministration of desipramine and cinacalcet also resulted in a notable reduction in desipramine oral clearance. The terminal half-life of desipramine was also increased by approximately twofold when desipramine was coadministered with cinacalcet. The median tmax was 6 h following administration of desipramine alone and following administration\nwith cinacalcet.\n\n\n\n','boycer','01132010','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1116,'evidence_1226','http://www.ncbi.nlm.nih.gov/pubmed/17652181','\n\nroute of administration: oral\n\nstudy duration: Each subject received 50 mg of cinacalcet (25-mg [as free base] film tablets,\nKirin Brewery Co, Ltd, Tokyo, Japan) or a matched\nplacebo orally once daily for 8 days. On day 8, each\nsubject also received a single oral dose of 30 mg DEX\n(Medicon, 15-mg film tablets, Shionogi &amp; Co, Ltd,\nOsaka, Japan). \n\npopulation: 23 male volunteers \n\ntested for known CYP450 polymorphisms? all participants included in the PK analaysis wer classified as a CYP2D6 extensive metabolizers based on the dextromethorphan/dextorpham metabolic ratio\n\nages: 20 - 33\n\ndescription:\nThe Cmax, AUC(0-t), and AUC(0-inf) of DEX were significantly higher during the cinacalcet treatment than with placebo, with a ratio of 7.481, 14.373, and 11.475, respectively. The Cmax of DOR was decreased, and the AUC(0-t) and AUC(0-inf) of DOR were slightly increased during cinacalcet treatment.\n\n\n','boycer','01132010','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1117,'evidence_1020','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nAbsorption\n\nThe pharmacokinetic properties of voriconazole are similar following administration by the intravenous and oral routes. Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%). Bioequivalence was established between the 200 mg tablet and the 40 mg/mL oral suspension when administered as a 400 mg Q12h loading dose followed by a 200 mg Q12h maintenance dose.','boycer','09/24/2009 15:01:25\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.96,NULL,NULL,NULL,'',NULL,NULL),(1118,'evidence_1828','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','thioridizine is listed in table 4 (p21) as a CYP2D6 substrate with a narrow therapeutic range','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1119,'evidence_1177','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/56b3f4c2-52af-4947-b225-6808ae9f26f5','\n&quot;Drugs That Inhibit Cytochrome P450 2D6\n\nIn a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared to rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of cytochrome P450 2D6 isozyme activity. Thus, this study suggests that drugs that inhibit P450 2D6 or the presence of reduced activity levels of this isozyme will produce elevated plasma levels of thioridazine. Therefore, the co-administration of drugs that inhibit P450 2D6 with thioridazine and the use of thioridazine in patients known to have reduced activity of P450 2D6 are contraindicated.&quot;','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1120,'evidence_1400','http://www.ncbi.nlm.nih.gov/pubmed/9784084','\nRoute of administration: oral\n\npolymorphic enzyme: no\n\nstudy duration: three days pre-treatment with itraconazola @ 200mg with a single oral dose of alprazolam on day 4 @ 0.8mg and two days continued dosing with itraconazole\n\npopulation: 10 male\n\nages: 25-38\n\ndescription: \n\nFrom Table 1, the AUC_i/AUC increase from 0-time of measurement: 357/221 = 1.615;  AUC_i/AUC increase from 0-inf: 671/252 = 2.66','boycer','07/02/2007 16:46:00\n','EV_PK_DDI_RCT','PKStudy',1.615,0.0008,0.2,10,'',NULL,NULL),(1121,'evidence_1053','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA lists this as a recommended in vivo substrate of CYP2C9 in it most recent guidance document. See Appendix A, Table 2, p. 19','boycer','09/27/2007 10:57:03\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1122,'evidence_1472','http://www.ncbi.nlm.nih.gov/pubmed/9825830','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nreaction: reduced-haloperidol --&gt; 4-(4-chlorophenyl)-4-hydroxypiperidine \n\nHPLC identified 4-(4-chlorophenyl)-4-hydroxypiperidine formation in HLMs incubated with reduced-haloperidol \n\n\n','boycer','06/22/2009 12:28:40\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1123,'evidence_1135','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP2D6 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1124,'evidence_1343','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7c6c1494-fb92-4442-bcff-764b77397495','Drug Interactions\n\nIn vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of LAMISIL should be done with careful monitoring and may require a reduction in dose of the 2D6-metabolized drug. In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in Cmax and a 5-fold increase in AUC. In this study, these effects were shown to persist at the last observation at 4 weeks after discontinuation of LAMISIL. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1125,'evidence_1756','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','04/29/2009 19:40:38\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1126,'evidence_1015','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4.','boycer','04/29/2009 19:53:02\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1127,'evidence_1964','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\nMirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1128,'evidence_1244','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978','(NOTE: the dose used to establish C_max appears to be more than two-fold under the usual dose)\n\nIn man, clozapine tablets (25 mg and 100 mg) are equally bioavailable relative to a clozapine solution. Following a dosage of 100 mg b.i.d., the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing. The average minimum concentration at steady-state was 122 ng/mL (range: 41 to 343 ng/mL), after 100 mg b.i.d. dosing. Food does not appear to affect the systemic bioavailability of clozapine. Thus, clozapine may be administered with or without food.','boycer','05/15/2009 11:07:44\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000319,NULL,NULL,NULL,'',0.1,NULL),(1129,'evidence_1616','http://www.ncbi.nlm.nih.gov/pubmed/3508549','\nRoute of administration: oral\n\nstudy duration: multiple dose (see quote below)\n\npopulation: 12 male\n\nages:18-55\n\nC_max = 138ng/mL\n\n138ng/mL x 1000/1L x 1g/10^9ng = 0.000138\n\nQuote:\nAfter a 2-day buildup, patients were dosed continuously with clozapine solution at three ascending dose levels (37.5, 75, and 150 mg bid for 7 days at each dose level). Following the morning administration on the twenty-third day of dosing a drug holiday was instituted which lasted for a minimum of 48 hr. Serial plasma samples were obtained during each of the periods and during the drug holiday for the calculation of the steady-state parameters AUCSS, CSSmax, and CSSmin at each dose level as well as for the assessment of the terminal elimination rate. Mean parameter values for AUCSS, CSSmax, and CSSmin showed a linearly increasing response with the dose, well described by a straight line passing through the origin.\n','boycer','06/15/2009 15:03:01\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000138,NULL,NULL,NULL,'',0.0375,NULL),(1130,'evidence_1111','http://www.ncbi.nlm.nih.gov/pubmed/3508549','\nRoute of administration: oral\n\nstudy duration: multiple dose (see quote below)\n\npopulation: 12 male\n\nages:18-55\n\nC_max = 314ng/mL\n\n314ng/mL x 1000/1L x 1g/10^9ng = 0.000314g/L\n\nQuote:\nAfter a 2-day buildup, patients were dosed continuously with clozapine solution at three ascending dose levels (37.5, 75, and 150 mg bid for 7 days at each dose level). Following the morning administration on the twenty-third day of dosing a drug holiday was instituted which lasted for a minimum of 48 hr. Serial plasma samples were obtained during each of the periods and during the drug holiday for the calculation of the steady-state parameters AUCSS, CSSmax, and CSSmin at each dose level as well as for the assessment of the terminal elimination rate. Mean parameter values for AUCSS, CSSmax, and CSSmin showed a linearly increasing response with the dose, well described by a straight line passing through the origin.\n','boycer','06/15/2009 15:05:30\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000314,NULL,NULL,NULL,'',0.075,NULL),(1131,'evidence_1253','http://www.ncbi.nlm.nih.gov/pubmed/3508549','\nRoute of administration: oral\n\nstudy duration: multiple dose (see quote below)\n\npopulation: 12 male\n\nages:18-55\n\nC_max = 564ng/mL\n\n564ng/mL x 1000/1L x 1g/10^9ng = 0.000564g/L\n\nQuote:\nAfter a 2-day buildup, patients were dosed continuously with clozapine solution at three ascending dose levels (37.5, 75, and 150 mg bid for 7 days at each dose level). Following the morning administration on the twenty-third day of dosing a drug holiday was instituted which lasted for a minimum of 48 hr. Serial plasma samples were obtained during each of the periods and during the drug holiday for the calculation of the steady-state parameters AUCSS, CSSmax, and CSSmin at each dose level as well as for the assessment of the terminal elimination rate. Mean parameter values for AUCSS, CSSmax, and CSSmin showed a linearly increasing response with the dose, well described by a straight line passing through the origin.\n','boycer','06/15/2009 15:07:27\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000564,NULL,NULL,NULL,'',0.15,NULL),(1132,'evidence_1068','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978','Pharmacokinetic-related Interactions\n\nClozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes.','boycer','05/15/2009 11:00:35\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1133,'evidence_1502','http://www.ncbi.nlm.nih.gov/pubmed/9384460','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: fluvoxamine\n\nreaction: clozapine demethylation and N-oxidation\n\nQuote: \nFluvoxamine inhibited the demethylation [of clozapine] by 34+/-27% at 1 micM and 53+/-28% at 10 micM...Fluvoxamine caused an inhibition by 12+/-21% and 22+/-18% at 1 and 10 micM respectively. \n\n\n\n','boycer','02/12/2010 18:15:23\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,197),(1134,'evidence_1634','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1135,'evidence_1395','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.2,NULL,NULL,NULL,'',NULL,NULL),(1136,'evidence_1510','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1137,'evidence_1983','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1138,'evidence_1052','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1139,'evidence_1057','http://www.ncbi.nlm.nih.gov/pubmed/15518608','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days pravastatin only, 8 days pravastatin and clarithromycin\n\ndose: .040g pravastatin 1xday\n.5g clarithromycin 2xday\n\npopulation: 45 men and women (only 15 received pravastatin)\n\nages:18-60\n\n(mean AUC_i)/(mean AUC) = 114/54\n\ndescription: \nClarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC) and simvastatin acid (12-fold), followed by atorvastatin (greater than fourfold) and then pravastatin (almost twofold).','boycer','06/05/2007 08:33:16\n','EV_PK_DDI_RCT','PKStudy',2.1,0.04,0.5,15,'',NULL,NULL),(1140,'evidence_1704','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','Warfarin\n\nWhen fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for 2 weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged. Thus patients receiving oral anticoagulants and fluvoxamine maleate tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. No dosage adjustment is required for fluvoxamine maleate tablets.','boycer','05/15/2009 09:08:19\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,198),(1141,'evidence_1951','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1142,'evidence_1376','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71be4cb7-a42f-43be-9b9b-f090edb2fd21','\nParoxetine\n\nCoadministration of a single dose of zaleplon 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance. Additionally, paroxetine did not alter the pharmacokinetics of zaleplon, reflecting the absence of a role of CYP2D6 in zaleplon\'s metabolism. \n\n','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1143,'evidence_1611','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1144,'evidence_1787','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1145,'evidence_1214','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','route of administration: not mentioned\n\nstudy duration: not mentioned (both drugs at steady-state)\n\npopulation: 18 healthy subjects\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: not mentioned\n\nQuote:\nConcomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.','boycer','02/16/2012 21:43:46\n','Non_traceable_Drug_Label_Statement','PKStudy',1.6,0,0,NULL,'',NULL,NULL),(1146,'evidence_1871','http://www.ncbi.nlm.nih.gov/pubmed/9602962','\nNOTE: The AUC_i/AUC value given is the AUC_0-24 and calculated from Table II.\n\nroute of administration: oral\n\nstudy duration: 10 days\n\npopulation: 18 healthy volunteers (9 male, 9 female)\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 18-41\n\ndescription:\nSUBJECTS: Twenty-four healthy volunteers were enrolled and 18 (9 men and 9 women) completed the study. The subjects ranged in age from 18 to 41 years (mean 26 years). Weight ranged from 43 to 71 kg (mean 56 kg) for the women and 60 to 83 kg (mean 71 kg) for the\nmen (Table I). Health status was established on the\nbasis of medical history, physical examination, and\nbiochemical laboratory test findings. Subjects         were excluded from entry into the study if these test results were outside the normal ranges and if there was\na history of drug or alcohol abuse. Additional exclusion criteria included: sensitivity to antidepressants or cimetidine; ingestion within the prior 3 months of agents that might alter hepatic enzyme activity; ingestion of any prescription or investigational drug within one month and any nonprescription drug within 2 weeks before the study; excessive tobacco smoking (more than 10 cigarettes/day) or caffeine ingestion (more than 5 cups of coffee/day).\n Of the original 24 volunteers, six did not complete the study. One withdrew from the study for personal reasons unrelated to the drug, and one other participant was dropped from the study because of an infection noticed on day 5, also unrelated to the study drug. Four volunteers withdrew because of apparent drug-related events on days 1 to 3. The symptoms leading to discontinuation included one or more of the following: nausea, vomiting, dizziness, blurred vision, mydriasis, nervousness, tremor, abdominal pain, and headache. The remaining 18 volunteers completed the study.\n\nMETHODS: The study was conducted according to an open-label, nonrandomized, cross-over design and lasted 11 days.\nThe study was divided into two 5-day periods during which the participants resided in a clinical unit, with the exception of a single night in between the two 5-day periods that was spent outside the clinic. The subjects began their stay on the night before the first experimental day. At 8:00 AM of the following morning (day 1), each participant ate a standard, medium fat breakfast consisting of cereal, low-fat milk, one egg, one piece of bacon, one piece of toast with butter, and one glass of orange juice. Thirty minutes later, the participants ingested a single 25-mg tablet of venlafaxine. A multiple oral dose regimen began after this first dose; each participant ingested a single 50-mg tablet of venlafaxine with 8 ounces of water every 8 hours for the next 10 days.\nThe control period (i.e., no cimetidine) lasted from day 1 through day 5. Subjects fasted overnight before the morning dose on days 5 and 10. The experimental drug interaction phase of the study began on the evening of day 6, when each subject ingested a single 800-mg tablet of cimetidine at 10:00 PM with 8 ounces of water. Venlafaxine dose administration continued during this phase of the study as described above. Once daily cimetidine administration (800 mg/day) continued through day 10, and participants were discharged from the clinical unit on day 11.\n\nRESULTS: Consistent with the above findings, cimetidine produced a significant increase in the C_max, C_min, and AUC of venlafaxine (P &lt; 0.001) but no significant changes in these three parameters for 0-des-methylvenlafaxine.','boycer','09/16/2010 13:02:43\n','EV_PK_DDI_NR','PKStudy',1.62,0.15,0.8,18,'',NULL,NULL),(1147,'evidence_1500','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.02,NULL,NULL,NULL,'',NULL,NULL),(1148,'evidence_1585','http://www.ncbi.nlm.nih.gov/pubmed/15258107','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: bufuralol\n\nreaction: bufuralol 1\'hydroxylation\n\nIC50 &gt; 200micM (see Table 3)\n\nQuote:\nCYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. ','boycer','09/23/2009 11:43:26\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,199),(1149,'evidence_1011','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d5051fbc-846b-4946-82df-341fb1216341','\n&quot;Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended. When using ZYPREXA and fluoxetine in combination, also refer to the Drug Interactions section of the package insert for Symbyax.&quot;','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1150,'evidence_1283','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: triazolam hydroxylation\n\nQuote:\n\nCYP3A. CT and metabolites all were very weak or negligible inhibitors of CYP3A, as indicated by triazolam hydroxylation. None of the compounds (at 100micM) produced more than 50% inhibition. Fluvoxamine and nefazodone were moderately strong inhibitors (von\nMoltke et al., 1996b, 1999c).','boycer','06/12/2009 11:36:28\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,200),(1151,'evidence_1906','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1152,'evidence_1961','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1153,'evidence_1836','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: triazolam hydroxylation\n\nQuote: \n\nCYP3A. CT and metabolites all were very weak or negligible inhibitors of CYP3A, as indicated by triazolam hydroxylation. None of the compounds (at 100micM) produced more than 50% inhibition. Fluvoxamine and nefazodone were moderately strong inhibitors (von\nMoltke et al., 1996b, 1999c).','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1154,'evidence_1292','http://www.ncbi.nlm.nih.gov/pubmed/10907965','\n\nroute of administration: oral\n\nstudy duration: Subjects received triazolam 0.25 mg alone and another 0.25-mg dose after 4 weeks of citalopram 20 mg/day for 1 week, followed by 3 weeks of citalopram 40 mg/day\n\npopulation: 17 (7 men and 10 women) completed the study)\n\ntested for known CYP450 polymorphisms?\n\nages: 18 - 31\n\ndescription:\nThe pharmacokinetics of triazolam and its metabolite alpha-hydroxytriazolam were unchanged by citalopram coadministration.\n\n','boycer','02132010','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1155,'evidence_1691','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:34:16\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1156,'evidence_1785','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: furafylline\n\nreaction: perphenazine N-dealkylation\n\nQuote:\nTo identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.\n','boycer','06/15/2009 16:44:31\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,201),(1157,'evidence_1847','http://www.ncbi.nlm.nih.gov/pubmed/9366029','\nRoute of administration: oral\n\nstudy duration: rac-citalopram given @ 40mg qd X 21days\n\npopulation: 10 adults (6 female and 4 male) all extensive metabolizers according to 2d6 and 2c19 specific assays (sparteine and mephenytoin respectively)\n\nages: 23-32\n\n\nDescription: \nC_max for S-didemethylcitalopram : 6.4nMol/L\n\n6.4nMol/L X 1M/10^9nMol X 324.39g/1M = 0.000001897g/L','boycer','06/12/2009 20:15:00\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000001897,NULL,NULL,NULL,'',0.04,NULL),(1158,'evidence_1490','http://www.ncbi.nlm.nih.gov/pubmed/8889898','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam 1-hydroxylation\n\nKi =  0.275 micM\nMW: 705.63314\n\n0.275micM/L X 1M/10^6micM X 705.63314g/M = 0.000194g/L','boycer','02/13/2010 10:22:30\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.000194,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,202),(1159,'evidence_1655','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1160,'evidence_1016','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/3829d74e-b3ab-46df-a08b-f0327b63304e','\nMetabolism Following oral dosing, theophylline does not undergo any measurable first-pass elimination. In adults and children beyond one year of age, approximately 90%of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6%of a theophylline dose is N-methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.\n','boycer','09/24/2009 14:43:07\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1161,'evidence_1697','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1162,'evidence_1804','http://www.ncbi.nlm.nih.gov/pubmed/9278211','\n\nroute of administration: oral\n\nstudy duration: a single 25 mg dose of racemic warfarin either alone or on Day 15 of a 21-day oral dosing regimen of 40 mg citalopram daily. Blood samples for pharmacokinetic analysis were obtained over a 168 h period after warfarin dosing.\n\npopulation: 12 healthy males \n\ntested for known CYP450 polymorphisms? no\n\nages: 21 - 32\n\ndescription:\nCitalopram produced no change in the pharmacokinetics of (R)- and (S)-warfarin, indicating that citalopram does not alter the metabolism of warfarin mediated via CYP1A2, CYP3A4 and CYP2C9.\n\n\n','boycer','02132010','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1163,'evidence_1115','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Metabolism and Elimination\n\nZiprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methyl-dihydroziprasidone.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1164,'evidence_1688','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide/sulphone\n2) ziprasidone --&gt; oxindole acetic acid \n\nHPLC w/ radioactive monitoring identified ziprasidone-sulphoxide and other metabolites in HLMs','boycer','06/19/2009 18:06:17\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1165,'evidence_1719','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends p-nitrophenol to be an acceptable chemical CYP2E1 substrate (p-nitrophenol 3-hydroxylation) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','09/22/2009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1166,'evidence_1010','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','Following oral administration of 200 mg of 14C-bupropion in humans, 87% and 10% of the radioactive dose were recovered in the urine and feces, respectively. The fraction of the oral dose of bupropion excreted unchanged was only 0.5%.','boycer','05/15/2009 11:09:24\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1167,'evidence_1233','http://www.ncbi.nlm.nih.gov/pubmed/18832427','\nNOTE: This is entered as &quot;for&quot; but the evidence board suggests that the AUC value might not be significant.\n\nroute of administration: oral\n\nstudy duration: 21 days\n\npopulation: 17 healthy subjects (96% male), 64% white\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 19-44 \n\ndescription:\nStudies 1 and 2 enrolled healthy male and female subjects aged 18-45 years with a body mass index (BMI) of 18-33 kg/m2 between August and September 2006 (Study 1) or August and November 2006 (Study 2). Excluded were women who were pregnant, breastfeeding or of childbearing potential without an acceptable contraceptive method; subjects with any significant acute or chronic medical or psychiatric illness or history of neuroleptic malignant syndrome, serotonin syndrome or acute dystonic reactions and subjects with a history of allergy to the study treatments or related compounds, or exposure to monoamine oxidase inhibitors, or CYP2D6 or CYP3A4 inhibitors or inducers in the 4 weeks before the study.\n\nThe majority of subjects in Study 2 were male (96%), and 64% were white. The mean +/- SD age was 29 +/- 8 years (range 19-44 years), the mean +/- SD weight was 79.5 +/- 8.7 kg (range 60.2-98.6 kg) and the mean +/- SD BMI was 25.3 +/- 2.6 kg/m2 (range 21.6-32.0 kg/m2). Of the subjects who received concomitant medications while taking aripiprazole and venlafaxine, eight received lorazepam for akathisia and five received benztropine for EPS-related AEs.\n\nOf the 25 subjects who received treatment (safety sample), 23 completed treatment with escitalopram monotherapy and received adjunctive aripiprazole. Two subjects discontinued escitalopram monotherapy (investigators decision, n = 1; consent withdrawn, n = 1). Six subjects discontinued during adjunctive aripiprazole treatment (AEs, n = 3; consent withdrawn, n = 3) and 17 subjects completed the study (pharmacokinetic sample).\n\nThe design of Study 2 was similar, except that subjects received escitalopram 10 mg/day for 7 days (Day -7 to Day -1) before the addition of once-daily aripiprazole 10 mg/day on Study Day 1 for a further 14 days (Day +1 to Day +14).\n\nMean steady-state plasma concentrationtime profiles for escitalopram administered alone or in combination with aripiprazole were similar (Figure 1C) with a small effect of aripiprazole 10 mg/day on AUC_TAU (7% increase; Table 2). Based on the escitalopram C_min on Day 14 (at t = 0 h and t = 24 h), escitalopram plasma concentration appeared to be at steady state (Table 2).','boycer','09/23/2010 14:03:24\n','EV_PK_DDI_NR','PKStudy',1.07,0.01,0.01,17,'',NULL,NULL),(1168,'evidence_1255','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme. Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro. In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150mg twice daily followed by a single dose of 50mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively. The effect was present for at least 7 days after the last dose of bupropion. Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1169,'evidence_1037','http://www.ncbi.nlm.nih.gov/pubmed/15876900','\n\nroute of administration: oral\n\nstudy duration: &quot;dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching placebo. Subjects quit smoking 3 days before the second dextromethorphan administration.&quot;\n\npopulation: 21 smoking, 9 female, 11 male\n\ntested for known CYP450 polymorphisms? yes ... all participants were considered CYP2D6 extensive metabolizers according to dextromethorphan:dextrorphan metabolite ratio\n\nages: 21 - 40\n\nNOTE: &quot;24-hour period preceding each laboratory visit. Two subjects reported taking medications that could potentially affect CYP2D6 metabolism and therefore alter bupropion concentrations (one reported use of hormone replacement therapy and another oral contraceptives).&quot;\n\ndescription:\n&quot;Among those taking bupropion, DM/DX ratio in-\ncreased significantly at the second assessment relative to the first (0.012  0.012 vs. 0.418  0.302; P &lt; 0.0004) (Fig. 1). No such change was observed in those randomized to placebo (0.009  0.010 vs. 0.017  0.015; P = NS). Of those receiving bupropion, 46% (6/13) were phenotypically poor metabolizers after treatment.&quot;\n\n\n','boycer','12172009','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1170,'evidence_1897','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','&quot;\nFluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.\n\n      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1171,'evidence_1063','http://www.ncbi.nlm.nih.gov/pubmed/11910256','\nroute of administration: oral\n\nstudy duration: quetiapine 300 mg bid and risperidone 3 mg bid for 7 consecutive days after titration periods of at least 17 days for quetiapine and two days for risperidone (see Figure 1). Risperidone was given after participant\'s quetiapine levels were considered to have reached steady state\n\npopulation: 11 adults with schizophrenic, schizoaffective, or bipolar disorder (see NOTE below)\n\ntested for known CYP450 polymorphisms? No\n\nages: 18 - 60\n\ndescription:\nCoadministration of risperidone resulted in only small\nand statistically insigni&amp;#64257;cant mean changes in quetiapine AUCtSS, CmaxSS, CminSS, and CL/f (Figure 2B, Table 3). Among individual patients, 6 of 11 patients had AUCtSS values that increased between days 17B and 5B, 3 had values that decreased, and 2 had values that changed very little.\n\nNOTE: for some unknown reason, the authors calculated AUC and CL/f with data from 11 participants rather than all 12 participants who completed the study.\n\n','boycer','09/22/2009 19:01:50\n','EV_PK_DDI_NR','PKStudy',1,0.3,0.003,11,'',NULL,NULL),(1172,'evidence_1580','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1173,'evidence_1255','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84','\n12.5 Drug-Drug Interactions\n...\nPREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1174,'evidence_1590','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','04/25/2009 10:20:16\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,203),(1175,'evidence_1339','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1176,'evidence_1112','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1177,'evidence_1492','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote: \n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.\n\n\n','boycer','06/11/2009 15:00:17\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,204),(1178,'evidence_1845','http://www.ncbi.nlm.nih.gov/pubmed/11452243','\nroute of administration: oral\n\nstudy duration: single dose of 100 mg sertraline\n\npopulation: 12 healthy Chinese male, non-smokers\n\ntested for known CYP450 polymorphisms? Patients were genotyped for CYP2C19 polymorphisms and also phenotyped using the omeprazole/5-hydroxy-omeprazole metabolic ratio. 6 extensive metabolizers (EM) and 6 poor metabolizers (PM) were chosen using stratified random selection from a pool of 66 EMs and 11 PMs.\n\nages: 19 - 22 years\n\ndescription:\nThe poor metabolizers had a 41% increase in sertraline AUC(0-inf) (983.6  199.3 micg  h/L versus 697.6  133.0 mcg  h/L; P &lt; .05) and a 51% increase in sertraline terminal elimination half-life (t_1/2) (35.5  5.6 hours 2 versus 23.5  4.4 hours; P &lt; .01) compared with extensive metabolizers. The oral clearance (CL_oral) of sertraline in poor metabolizers was significantly lower than that in extensive metabolizers (105.3  19.4 L/h versus 148.4  28.6 L/h; P &lt; .05). The AUC0-144 and Cmax of desmethylsertraline in poor metabolizers were significantly lower than the values in extensive metabolizers (627.6  203.8 g  h/L versus 972.1  270.3 g  h/L; P &lt; .05; 23.6  6.5 nmol/L versus 32.4  8.2 nmol/L; P &lt; .01; respectively). In addition, desmethylsertraline Tmax (time to reach Cmax) in poor metabolizers was markedly higher than that in extensive metabolizers (70.0  24.5 hours versus 26.4  5.4 hours; P &lt; .01).\n','boycer','09/28/2009 12:17:52\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1179,'evidence_1427','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 13:52:12\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1180,'evidence_1081','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','\n&quot;One week following administration of a single oral dose of 1 mg immediate-release 14C-paliperidone to 5 healthy volunteers, 59% (range 51%  67%) of the dose was excreted unchanged into urine, 32% (26%  41%) of the dose was recovered as metabolites, and 6%  12% of the dose was not recovered. Approximately 80% of the administered radioactivity was recovered in urine and 11% in the feces. Four primary metabolic pathways have been identified in vivo, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.&quot;','boycer','06/16/2009 16:30:32\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1181,'evidence_1729','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','CYP3A4: Venlafaxine did not inhibit CYP3A4 in vitro. This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.','boycer','05/14/2009 13:07:10\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1182,'evidence_1318','http://www.ncbi.nlm.nih.gov/pubmed/9205822','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nreaction: testosterone 6beta hydroxylation\n\nQuote: \nThe IC50 for venlafaxine\'s inhibition of the reaction was &gt; 1000micM ','boycer','02/12/2010 14:20:00\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,205),(1183,'evidence_1361','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1184,'evidence_1804','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1185,'evidence_1909','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1186,'evidence_1832','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.','boycer','05/15/2009 10:38:46\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1187,'evidence_1833','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.8,NULL,NULL,NULL,'',NULL,NULL),(1188,'evidence_1673','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel\n\n&quot;No IC50 values could be  determined for rosuvastatin and pravastatin with concentrations up to 100micM&quot;\n\nConcentration of pravastatin in vivo based on the largest C_max in label in table 1 of http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1652:\n\n3650ng/1ml x 1g/1e9ng x 1e3ml/1L = .004g/L\n\n.004g/L x 1M/853.9g = 4.68micM/L','boycer','10/29/2007 10:11:10\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,206),(1189,'evidence_1440','http://www.ncbi.nlm.nih.gov/pubmed/7690693','\nroute of administration: oral\n\nstudy duration: single dose\n\npopulation: 12 males, phenotyped using dextromethorphan (9 2D6 EMs, 2 PMs, 1 IM)\n\nages: 24 (SD:6) \n\nQuote:\nThe pharmacokinetics of a novel antipsychotic agent, risperidone, and the prolactin response were studied in 12 dextromethorphan-phenotyped healthy men after administration of 1 mg risperidone intravenously, intramuscularly, and orally. The formation of the equipotent major metabolite, 9-hydroxyrisperidone, exhibited CYP2D6-related polymorphism. The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers','boycer','12172009','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1190,'evidence_1443','http://www.ncbi.nlm.nih.gov/pubmed/10048600','\nEnzyme system: human liver microsomes:\n\nNADPH added: not mentioned but acceptable methods assumed\n\ninhibitor used: quinidine\n\nreaction: risperidone 9-hydroxylation\n\nNOTE: experiment used 100micM of risperidone which is likely well above C_max based on PMID 7690693\n\nQuote: \nrisperidone was incubated with human liver microsomes in the presence of different concentrations of   inhibitors of CYP enzymes. Both quinidine (inhibitor of CYP2D6) and ketoconazole (inhibitor of CYP3A) inhibited the formation of 9-hydroxyrisperidone in a concentration-dependent manner (Fig. 4).\n\n\n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1191,'evidence_1510','http://www.ncbi.nlm.nih.gov/pubmed/7891353','\nEnzyme system: human liver microsomes\n\nNADPH added: yes \n\nQuote:\nMetabolism of clozapine to stable and protein-reactive metabolites by human liver.     \n\nChromatographic analysis of the microsomal       incubation supernatants showed that clozapine was metabolized to five metabolites: desmethylclozapine,     clozapine N-oxide, 7-hydroxyclozapine and two un-\nidentified metabolites (fig 1). The CYP2D6            genotype did not affect the formation of these metabolites (table 2).','boycer','06/15/2009 16:12:54\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1192,'evidence_1420','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nMetabolism and Excretion\n...\nRenal excretion of metabolites was the primary route of elimination of radioactivity. Approximately 80% of the dose was recovered in the urine and 15% in the feces.','boycer','09/24/2009 12:25:07\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1193,'evidence_1078','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdfa991c-0ba9-4d12-ba4c-8909504c27d6','CLINICAL PHARMACOLOGY\n\n...\n\nThe major route of elimination of metronidazole and its metabolites is via the urine (60 to 80% of the dose), with fecal excretion accounting for 6 to 15% of the dose. The metabolites that appear in the urine result primarily from side chain oxidation [1-(Beta-hydroxyethyl)-2- hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide conjugation, with unchanged metronidazole accounting for approximately 20% of the total. Renal clearance of metronidazole is approximately 10 mL/min/1.73 m2.','boycer','09/21/2009 15:06:58\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1194,'evidence_1510','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2C9 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent\n','boycer','09/25/2007 09:02:14\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1195,'evidence_1104','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: tolbutamide --&gt; hydroxytolbutamide\n\nQuote: \n\nCYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7  (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM).\n\n\n','boycer','06/11/2009 15:12:49\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,207),(1196,'evidence_1957','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram\n\nQuote:\n\nChemical Inhibition of CT and DCT Biotransformation in\nMicrosomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by\nketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1197,'evidence_1529','http://www.ncbi.nlm.nih.gov/pubmed/8243504','\nRoute of administration: oral\n\nstudy duration: single dose with 24 hours of blood sampling\n\ndose: single dose of 90mg diltiazem\n\npopulation: 10 male, 10 female\n\nages:19-50\n\ndescription:\nPlasma concentrations and urinary excretion of DTZ and its metabolites were determined in 20 healthy volunteers (10 males and 10 females) after they had each been given a single oral 90 mg dose of DTZ. DTZ and six of its metabolites which included N-monodesmethyl DTZ (MA), deacetyl DTZ (M1), deacetyl N-monodesmethyl DTZ (M2), deacetyl O-desmethyl DTZ (M4) and deacetyl DTZ N-oxide (M1NO) and deacetyl N,O-didesmethyl DTZ (M6), were determined by a sensitive and specific HPLC assay. The major metabolites measurable in the plasma of all the volunteers were MA, M1, and M2. The terminal half-lives (t1/2) of M1 and M2 were considerably longer than those of DTZ and MA. ','boycer','09/24/2007 09:37:31\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1198,'evidence_1809','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 14-OH-clarithromycin using a recombinant CYP3A4 Supersome system','boycer','10/20/2007 08:41:37\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1199,'evidence_1419','http://www.ncbi.nlm.nih.gov/pubmed/9152603','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction:\nclarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin\n\ndescription: clarithromycin oxidative metabolism was nearly completely wiped out by the addition of this selective inhibitor','boycer','10/20/2007 08:43:35\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,208),(1200,'evidence_1880','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Smoking\n\nBased on in vitro studies utilizing human liver enzymes, ziprasidone is not a substrate for CYP1A2; smoking should therefore not have an effect on the pharmacokinetics of ziprasidone. Consistent with these in vitro results, population pharmacokinetic evaluation has not revealed any significant pharmacokinetic differences between smokers and nonsmokers.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1201,'evidence_1884','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1202,'evidence_1548','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: furafylline\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide/sulphone\n2) ziprasidone --&gt; oxindole acetic acid\n\nQuote:\nInhibition of metabolite formation by each inhibitor is\nsummarized in Table 2. Ketoconazole (10micM) inhibited\nthe formation of ziprasidone sulphoxide (sulphoxide and\nsulphone) by 79% and oxindole acetic acid N-dealkylated\nproduct) completely. Sulphaphenazole an furafylline did\nnot inhibit the formation of ziprasidone sulphoxide. The formation of oxindole acetic acid was inhibited (~50%) by furafylline. The formation of ziprasidone metabolites was not inhibited by quinidine but rather increased. ','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1203,'evidence_1886','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','fluoxetine is listed as a recommended inhibitor for AUC studies in Table 2 (p19)','boycer','04/29/2009 20:04:21\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1204,'evidence_1698','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nExcretion\n\nVoriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine. After administration of a single radiolabelled dose of either oral or IV voriconazole, preceded by multiple oral or IV dosing, approximately 80% to 83% of the radioactivity is recovered in the urine. The majority (&gt;94%) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing.','boycer','09/24/2009 15:05:17\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1205,'evidence_1914','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.25,NULL,NULL,NULL,'',NULL,NULL),(1206,'evidence_1653','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1207,'evidence_1434','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1208,'evidence_1198','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','he FDA recommends this as a acceptable chemical CYP1A2 inhibitor for in vitro experiments in it most recent guidance document. See Table 2, p. 28','boycer','08/10/2007 09:11:36\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1209,'evidence_1248','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nMetabolism\n\nIn vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1210,'evidence_1503','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1211,'evidence_1913','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 14:14:05\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1212,'evidence_1465','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/4471223e-9023-457e-be2e-8e4e0c2d94d1','Midazolam\n\nConcomitant administration of telithromycin with intravenous or oral midazolam resulted in 2- and 6-fold increases, respectively, in the AUC of midazolam due to inhibition of CYP 3A4-dependent metabolism of midazolam. ','boycer','01/11/2010 15:43:44\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,209),(1213,'evidence_1164','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/4471223e-9023-457e-be2e-8e4e0c2d94d1','Drug interactions\n\nTelithromycin is a strong inhibitor of the cytochrome P450 3A4 system. Co-administration of KETEK tablets and a drug primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentration of the drug co-administered with telithromycin that could increase or prolong both the therapeutic and adverse effects. Therefore, appropriate dosage adjustments may be necessary for the drug co-administered with telithromycin.','boycer','01/11/2010 15:46:06\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1214,'evidence_1909','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\nElimination: Following a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites. The remainder of the dose was recovered in the feces. Total recovery of radioactivity was 99.8%. No unchanged rabeprazole was recovered in the urine or feces.','boycer','09/24/2009 14:01:21\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1215,'evidence_1995','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','\nMetabolism\n\nIn vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1216,'evidence_1715','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2','&quot;lovastatin is a lactone which is readily hydrolyzed in vivo to the corresponding beta-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the beta-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of lovastatin.\n\n&quot;','boycer','09/28/2007 13:21:21\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1217,'evidence_1840','http://www.ncbi.nlm.nih.gov/pubmed/19142106','\n\nroute of administration: oral\n\nstudy duration: On day 1, subjects received a single 100-mg dose of desvenlafaxine or 75-mg dose of venlafaxine ER, followed by 120 hours of pharmacokinetic sampling. Subjects fasted over night for at least 10 hours before the required blood sample collection and administration of test article. Study treatment washout occurred between study days 7 and 9. On day 11, the alternate treatment was administered (ie, either a single 100-mg dose of desvenlafaxine or 75-mg dose of venlafaxine ER), followed by 120 hours of pharmacokinetic sampling, under the same conditions described for day 1. On study day 16, subjects completed the study. \n\npopulation: non-smokers (&gt; 1 year)\n\ntested for known CYP450 polymorphisms? seven participants were found to be CYP2D6 extensive metabolizers and seven were found be be CYP2D6 poor metabolizers based on genotyping. They excluded intermediate and ultra metabolizers.\n\nages: 18 - 55\n\ndescription:\nThe mean Cmax and AUC for venlafaxine after administration of venlafaxine ER were significantly higher, by approximately 149% and 331%, respectively, in PM subjects compared with EM subjects (P = 0.001)\n\n','boycer','09/25/2009 11:00:03\n','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,210),(1218,'evidence_1291','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','\nCYP2D6 Inhibitors\n\nThe potent CYP2D6 inhibitor, paroxetine (20 mg once daily), increases ranolazine concentrations 1.2-fold. No dose adjustment of Ranexa is required in patients treated with CYP2D6 inhibitors.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1219,'evidence_1928','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: triazolam hydroxylation\n\nQuote:\n\nCYP3A. CT and metabolites all were very weak or negligible inhibitors of CYP3A, as indicated by triazolam hydroxylation. None of the compounds (at 100micM) produced more than 50% inhibition. Fluvoxamine and nefazodone were moderately strong inhibitors (von\nMoltke et al., 1996b, 1999c).','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1220,'evidence_1958','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7e117c7e-02fc-4343-92a1-230061dfc5e0','\n&quot;Risperidone is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug (e.g., the active moiety) results from the combined concentrations of risperidone plus 9-hydroxyrisperidone...CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs. CYP 2D6 is subject to genetic polymorphism (about 6%8% of Caucasians, and a very low percentage of Asians, have little or no activity and are &quot;poor metabolizers&quot;) and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of the active moiety, after single and multiple doses, are similar in extensive and poor metabolizers&quot;','boycer','06/16/2009 16:37:55\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1221,'evidence_1089','http://www.ncbi.nlm.nih.gov/pubmed/9152603','\nEnzyme system: human liver microsomes \nNADPH added: yes \n\ninhibitor used: quinidine \nreaction: \nclarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin \n\ndescription: clarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor ','boycer','10/20/2007 08:16:32\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,211),(1222,'evidence_1540','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.0125,NULL,NULL,NULL,'',NULL,NULL),(1223,'evidence_1536','http://www.ncbi.nlm.nih.gov/pubmed/10997935','Enzyme system: recombinant human enzymes in human lymphoblastoid cells\nNADPH added:yes\n\ninhibitor used: no\n\nTable 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. ','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1224,'evidence_1090','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','\nMetabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. ','boycer','09/23/2009 16:05:45\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1225,'evidence_1771','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1226,'evidence_1623','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/08320ea3-8f93-6f04-5d1c-f69af3eb5a81','\n&quot;Paroxetine is extensively metabolized and the metabolites are considered to be inactive. Nonlinearity in pharmacokinetics is observed with increasing doses. Paroxetine metabolism is mediated in part by CYP2D6, and the metabolites are primarily excreted in the urine and to some extent in the feces.&quot;','boycer','06/16/2009 16:42:46\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1227,'evidence_1512','http://www.ncbi.nlm.nih.gov/pubmed/10492058','NOTE: The AUC_i/AUC value is calculated from Table 1 using the formula CL = dose / AUC\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 5 days\r\n\r\npopulation: 6 young healthy volunteers (all male)\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- CYP2D6 and CYP2C19 phenotyping - All extensive metabolizers\r\n\r\nages: none given\r\n\r\ndescription:\r\nSUBJECTS: This was an open study of six young healthy male volunteers, all phenotyped as extensive metabolisers of sparteine (CYP2D6) (metabolic ratio &lt; 20) and mephenytoin (CYP2C19) (S/R ratio &lt; 0.5). All volunteers gave written informed consent. The study was approved by the regional ethics committee and the Danish National Board of Health. Before inclusion, all volunteers were screened by physical examination, laboratory tests and electrocardiogram.\r\n\r\nMETHODS: On study day 1, the volunteers took a single oral dose of 250 mg tolbutamide (CYP2C9) (Tolbutamid \'\'Dak\'\', Nycomed DAK, Denmark) at 0800 hours. On study day 2, the volunteers took 100 mg sparteine (CYP2D6) (Depasan, Giulini Pharma, Germany), 100 mg mephenytoin (CYP2C19) (Mesantoin, Sandoz Pharmaceuticals, USA) and 200 mg caffeine (CYP1A2) (Koffein \'\'Dak\'\', Nycomed DAK) orally at 0800 hours.\r\nOn study day 3, following an overnight fast from 2400 hours, the volunteers took a single oral dose of 200 mg quinidine sulfate (Kinidin \'\'Dak\'\', Nycomed DAK), equivalent to 511 umol quinidine. The volunteers were allowed normal meals after the blood sample at t = 1 h was drawn. Following a washout period of 6-8 weeks, the volunteers took 100 mg of fluvoxamine (Fevarin, Solvay Duphar, Netherlands) daily at 0800 hours on study days -1, 0, 1, 2, 3 and 4. The study procedures on days 1-4, above, were repeated. During the study, the volunteers refrained from intake of any other medications, alcohol or grapefruit juice. Consumption of coffee or xanthine-containing foods was not allowed for a period of 48 h before and the 12 h during caffeine testing. The quinidine and the quinidine and fluvoxamine sessions were performed without randomisation of the sequence, justified by only using hard end-points, i.e. drug- and metabolite-concentrations in plasma and urine, in the study.\r\n\r\nRESULTS: The total apparent oral clearance of quinidine was calculated as: CLq = Dose / AUCq (0 -&gt; inf). The quinidine total apparent oral clearance, clearance by N-oxidation and by 3-hydroxylation were statistically significantly reduced during fluvoxamine treatment by medians of 29%, 33% and 44%, respectively.\r\n\r\nSee Table 1 and formula.','boycer','09/22/2010 11:27:10\r\n','EV_PK_DDI_NR','PKStudy',1.42,0.2,0.1,6,'',NULL,NULL),(1228,'evidence_1037','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2C19 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent ','boycer','01/14/2008 13:31:56\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1229,'evidence_1942','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a preferred CYP3A4 substrate for in vivo studies  in it most recent guidance document. See Table 2, p. 19','boycer','08/09/2007 09:35:05\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1230,'evidence_1341','http://www.ncbi.nlm.nih.gov/pubmed/15834460','\n\nRoute of administration: oral\n\nstudy duration: multiple doses of QTP with or without concomitant erythromycin\n\npopulation: 19; 10 female and 9 male\n\nages:18-55\n\nHPLC-MS detected 7-hydroxy-N-desalkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine','boycer','06/15/2009 15:54:38\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1231,'evidence_1990','http://www.ncbi.nlm.nih.gov/pubmed/10634135','\nRoute of administration: oral\n\nstudy duration: two days pre-treatment with 200mg bid ketoconazole and a single treatment of 1mg alprazolam\n\npopulation: 17\nmale: 16\nfemale: 1\n\nages: 22-55\n\nNOTE: All participants were treated with alprazolam alone by only 4 participants received ketoconazole pre-treatment. \n\nAUC_i/AUC (0 to inf): 426.2/242.2 = 1.76','boycer','10/30/2007 08:24:58\n','EV_PK_DDI_NR','PKStudy',1.76,0.001,0.2,17,'',NULL,NULL),(1232,'evidence_1534','http://www.ncbi.nlm.nih.gov/pubmed/9757147','\nRoute of administration: oral\n\nstudy duration: three days pre-treatment with ketoconazole oral 200mg bid; on day three a single 1mg dose of oral alprazolam; control group took placebo.\n\npopulation: 7 male, 0 female\n\nages:21-44yrs\n\nAUC_I/AUC : 944/237 = 3.983\n','boycer','10/30/2007 11:32:55\n','EV_PK_DDI_RCT','PKStudy',3.983,0.001,0.2,7,'',NULL,NULL),(1233,'evidence_1122','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.18,NULL,NULL,NULL,'',NULL,NULL),(1234,'evidence_1692','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c','Metabolism\n\nZafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1235,'evidence_1641','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c','\nDrug-Drug Interactions:\n...\nCoadministration of multiple doses of zafirlukast (160 mg/day) to steady-state with a single 25 mg dose of warfarin (a substrate of CYP2C9) resulted in a significant increase in the mean AUC (+63%) and half-life (+36%) of S-warfarin. The mean prothrombin time increased by approximately 35%. The pharmacokinetics of zafirlukast were unaffected by coadministration with warfarin.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1236,'evidence_1278','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote:\n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1237,'evidence_1914','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf',' The FDA recommends this as a preferred CYP2D6 substrate for in vivo studies in it most recent guidance document. See Table 2, p. 19\n\nCURATOR NOTE (04/29/2009): desipramine might have some relevant clearance by CYP2C19 and CYP1A2; evidence is currently being sought','boycer','04/29/2009 20:15:14\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1238,'evidence_1974','http://www.ncbi.nlm.nih.gov/pubmed/12920410','\nroute of administration: oral\n\nstudy duration: a single dose of 1 mg alprazolam followed by a minimum three-day washout and then  administration of 20 mg citalopram for a minimum of 21 days\'\n\npopulation: 10 female subjects; health state no mentioned though the study provides explicit exclusion criteria\n\ntested for known CYP450 polymorphisms?\n\nages: inferred to be adults\n\ndescription:\nAfter administration with citalopram, the Tmax of alprazolam increased significantly from 0.9 +/- 0.8 to 1.4 +/-0.8 hours ( P &lt; 0.05). There were no other significant changes in alprazolam pharmacokinetics postcitalopram as compared with precitalopram (Table 3 and Fig. 2). There was no correlation between citalopram steady-state concentration and change in  alprazolam AUC.\n\n\n','boycer','09/23/2009 12:26:47\n','EV_PK_DDI_NR','PKStudy',1,0.001,0.02,10,'',NULL,NULL),(1239,'evidence_1272','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7e117c7e-02fc-4343-92a1-230061dfc5e0','\n&quot;Risperidone is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug (e.g., the active moiety) results from the combined concentrations of risperidone plus 9-hydroxyrisperidone...CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs. CYP 2D6 is subject to genetic polymorphism (about 6%8% of Caucasians, and a very low percentage of Asians, have little or no activity and are &quot;poor metabolizers&quot;) and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of the active moiety, after single and multiple doses, are similar in extensive and poor metabolizers&quot;','boycer','06/16/2009 16:34:31\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1240,'evidence_1420','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84','\n12.5 Drug-Drug Interactions\n...\nPREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1241,'evidence_1034','http://www.ncbi.nlm.nih.gov/pubmed/12911366','\nRoute of administration: oral\n\npolymorphic enzyme: no\n\nstudy duration: this was a matched pair study; 7 patients already take atorvastatin were matched with patients who were not taking atorvastatin or any other known CYP3A4 inhibitor. Of the patients taking atorvastatin, 5 were on 10mg/day, 1 on 20mg/day, and one on 40mg/day. All patient\'s received a .25mg/kg bolus of IV midazolam.\n\npopulation: 14 individuals; 10 male, 4 female\n\nages: generally older ~61 (unfortunately ages given in mean/std dev)\n\nAUC_i/AUC of midazolam: 889.4/629.1=1.41\n\n\n','boycer','09/24/2007 10:42:50\n','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,212),(1242,'evidence_1818','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2E1 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent ','boycer','01/14/2008 13:44:53\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1243,'evidence_1253','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01','\nNOTE: This value is for the extended release formulation. Table 1 of the drug label lists PK parameters for lovastatin and &quot;lovastatin acid&quot; (6\'beta-hydroxy-lovastatin) for both the immediate and extended release forms. \n\nLovastatin (immediate release):5.5ng/ml\nLovastatin (extended release):7.8ng/ml\nLovastatin acid (immediate release):5.8ng/ml\nLovastatin acid (extended release):11.9ng/ml\n\n','boycer','09/28/2007 13:05:21\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.0000078,NULL,NULL,NULL,'',0.04,NULL),(1244,'evidence_1714','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1245,'evidence_1689','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nMetabolism and Excretion\n\nCinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1246,'evidence_1369','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA, in it most recent guidance document, recommends this as a chemical inhibitor of CYP2C19 for in vitro experiments at a K_i of 1.2micM. See Table 2, p. 28\n\n1.2micM/L X 1M/10^6micM X 263.786g/M = 0.0003165g/L','boycer','06/30/2009 14:25:03\n','Non_Tracable_Statement','In_vitro_inhibition_study',0.0003165,NULL,NULL,NULL,'none_assigned',NULL,NULL),(1247,'evidence_1937','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1248,'evidence_1062','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1249,'evidence_1193','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: R-warfarin\n\nreaction: R-warfarin 10-hydroxylation\n\nQuote:\nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. ','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1250,'evidence_1041','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1','(NOTE: the maximum C_max value chosen from the range provided to bias the system towards making more sensitive DDI predictions) \n\nSystemic bioavailability  In man, following a single oral 40mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.','boycer','05/15/2009 11:13:19\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.000055,NULL,NULL,NULL,'',0.04,NULL),(1251,'evidence_1657','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1252,'evidence_1725','http://www.ncbi.nlm.nih.gov/pubmed/1438031','\nroute of administration: oral\n\nstudy duration: a three way cross-over study, 1) single dose of 100mg trazodone after overnight fasting, 2) single dose of 100mg trazodone after a standardized breakfast, 3) single IV infusion of 100mg trazodone after a standardized meal. two weeks in between drug adminstration events\n\npopulation: 8 adults, 4 males and 4 females\n\nparticipants tested for known CYP450 phenotypes? no\n\nages: 25 - 34\n\nF% (bioavailability) from Table I (fasting): 63%','boycer','06/20/2009 13:06:25\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.63,NULL,NULL,NULL,'',NULL,NULL),(1253,'evidence_1403','http://www.ncbi.nlm.nih.gov/pubmed/3608351','\n\nroute of administration: oral\n\nstudy duration: single dose of 50mg trazodone\n\npopulation: 43 healthy participants divided into young (18 to 40 years of age; n=25)  and elderly (60 - 78 years of age; n = 18_\n\ntested for known CYP450 polymorphisms? NO\n\nages: 18 - 78\n\nBioavailability for 23 non-obese participants (Table II): 81%\n\n\n','boycer','06/22/2009 15:53:50\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.81,NULL,NULL,NULL,'',NULL,NULL),(1254,'evidence_1592','http://www.ncbi.nlm.nih.gov/pubmed/11038166','Enzyme system: recombinant human CYP3A5 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nAccording to the authors, this enzyme system catalyzed the above reactions similar to that of the CYP3A4 recombinant enzyme system whose Km values ranged from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin\n','boycer','09/25/2007 08:44:00\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1255,'evidence_1386','http://www.ncbi.nlm.nih.gov/pubmed/10997935','Enzyme system: recombinant human enzymes in human lymphoblastoid cells\nNADPH added:yes\n\ninhibitor used: no\n\nTable 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. ','boycer','02/12/2010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1256,'evidence_1336','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/151ffcf4-e503-4954-af7c-93d0a4f9f80','\nDrug Interactions:\n\n...\nIn vitro studies of drug metabolism indicate that M1 inhibits CYP 450 2C9, which is responsible for the metabolism of phenytoin, tolbutamide, warfarin and many NSAIDs. ','boycer','09/24/2009 12:12:08\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1257,'evidence_1412','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\nMirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.','boycer','06/15/2009 15:24:41\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1258,'evidence_1222','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: mirtazapine N-demethylation (25 and 250 micM) and mirtazapine N-oxidation (250micM) \n\nQuote: \nIncubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-\noxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. \n\nNOTE: lowest MIR concentration tested was 25 micM\n\n','boycer','02/13/2010 07:52:43\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,213),(1259,'evidence_1778','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\nMirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.','boycer','06/15/2009 15:25:44\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1260,'evidence_1714','http://www.ncbi.nlm.nih.gov/pubmed/11147928','\nRoute of administration: oral\n\nstudy duration: three weeks\n\npopulation: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks\n\nages: 29 - 55\n\n\nQuote:\n\nThe effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline.','boycer','06/16/2009 12:01:53\n','EV_PK_DDI_NR','PKStudy',0,0.05,0.2,17,'',NULL,NULL),(1261,'evidence_1746','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/19a30c59-15da-4324-bc08-d09495dc1074','Quinidine is not metabolized by cytochrome P450IID6, but therapeutic serum levels of quinidine inhibit the action of cytochrome P450IID6, effectively converting extensive metabolizers into poor metabolizers. Caution must be exercised whenever quinidine is prescribed together with drugs metabolized by cytochrome P450IID6.','boycer','01/11/2010 17:38:30\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1262,'evidence_1329','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.065,NULL,NULL,NULL,'',NULL,NULL),(1263,'evidence_1467','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: S-mephenytoin\n\nreaction: S-mephenytoin hydroxylation\n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).\n\n\n','boycer','02/12/2010 17:35:55\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,214),(1264,'evidence_1551','http://www.ncbi.nlm.nih.gov/pubmed/8904618','\nRoute of administration: oral\n\nstudy duration: four phase crossover study; each phase consisted of four days pre-treatment with placebo or fluconazole (50,100, or 200mg), on day four 0.25mg of triazolam was administered\n\npopulation: 8 healthy adults \nmale:3\nfemale:5\n\nages: 20-32\n\nAUC_i/AUC (0-inf): \n50mg fluconazole = 1.63\n100mg fluconazole = 2.05\n200mg fluconazole = 4.42\n\ndescription: \n','boycer','01132010','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1265,'evidence_1487','http://www.ncbi.nlm.nih.gov/pubmed/16172184','\nRoute of administration: oral\n\nstudy duration: 4-way crossover; subjects received oral fluconazole (100, 200, or 400mg) or placebo;  2 hours later a single dose of MDZ (1mg IV or oral depending on the study arm) was given followed 30 minutes later by 4mg IV of ondansetron, followed by 15ug/kg of IV alfentanil (one arm) or 40mcg oral alfentanil.\n\npopulation: 6 male, 6 female\n\nages: 19-36\n\nAUC_i/AUC (0-inf; oral dosing; 100mg fluconazole): 46.1/21.3 \n\nAUC_i/AUC (0-inf; oral dosing; 200mg fluconazole): 70.7/21.3 \n\nAUC_i/AUC (0-inf; oral dosing; 400mg fluconazole): 105/21.3 \n','boycer','01132010','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1266,'evidence_1623','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1267,'evidence_1201','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','\nExcretion: Celecoxib is eliminated predominantly by hepatic metabolism with little (&lt;3%) unchanged drug recovered in the urine and feces. Following a single oral dose of radiolabeled drug, approximately 57% of the dose was excreted in the feces and 27% was excreted into the urine. The primary metabolite in both urine and feces was the carboxylic acid metabolite (73% of dose) with low amounts of the glucuronide also appearing in the urine. It appears that the low solubility of the drug prolongs the absorption process making terminal half-life (t1/2) determinations more variable.','boycer','09/24/2009 10:58:43\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1268,'evidence_1921','http://www.ncbi.nlm.nih.gov/pubmed/10952477','\nRoute of administration: oral\n\nstudy duration: 4 days pretreatment with oral fluconazole 400mg day 1 and 200mg days 2-4; on day 4 a single oral dose of 40mg pravastatin\n\npopulation: 12\nmale: 5\nfemale: 7\n\nages: 19-26\n\nNo statistically significant (p &lt; .05) increase in pravastatin AUC occured when co-administered with patients pretreated with fluconazole','boycer','10/29/2007 12:04:09\n','EV_PK_DDI_RCT','PKStudy',0,0.04,0.2,12,'',NULL,NULL),(1269,'evidence_1125','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/cf26b007-df4f-4936-b2d3-183969761f69','&quot;In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug. About 11% of the dose is excreted in the urine as metabolites.&quot;','boycer','09/27/2007 10:44:18\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1270,'evidence_1613','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Metabolism and Elimination\n\n... In vitro studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone. CYP1A2 may contribute to a much lesser extent. Based on in vivo abundance of excretory metabolites, less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase.','boycer','05/15/2009 11:20:22\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1271,'evidence_1764','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19,2D6, and 3A4 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','06/19/2009 12:45:00\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1272,'evidence_1245','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide/sulphone\n2) ziprasidone --&gt; oxindole acetic acid\n\nQuote: \nInhibition of metabolite formation by each inhibitor is\nsummarized in Table 2. Ketoconazole (10micM) inhibited\nthe formation of ziprasidone sulphoxide (sulphoxide and\nsulphone) by 79% and oxindole acetic acid N-dealkylated\nproduct) completely. Sulphaphenazole an furafylline did\nnot inhibit the formation of ziprasidone sulphoxide. The formation of oxindole acetic acid was inhibited (~50%) by furafylline. The formation of ziprasidone metabolites was not inhibited by quinidine but rather increased.\n\n\n','boycer','06/19/2009 17:43:12\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,215),(1273,'evidence_1064','http://www.ncbi.nlm.nih.gov/pubmed/10771458','\n\nroute of administration: oral\n\nstudy duration: \n\npopulation: 14 healthy, non-smoking, adults (6 male, 8 female); only 13 completed the study\n\ntested for known CYP450 polymorphisms? \n\nages: 18 - 45\n\ndescription:\n&quot;Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole. Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively. The treatment effect on both of these parameters was statistically significant (P&lt;0.02).&quot;\n','boycer','06/20/2009 13:13:40\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,216),(1274,'evidence_1971','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/445a4720-bb65-4146-90c7-a49fb14a2c74','After oral administration, diltiazem undergoes extensive metabolism in man by deacetylation, N-demethylation, and O-demethylation via cytochrome P-450 (oxidative metabolism) in addition to conjugation. ','boycer','05/29/2007 10:33:52\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1275,'evidence_1245','http://www.ncbi.nlm.nih.gov/pubmed/9010634','\nroute of administration: oral\n\nstudy duration: single dose\n\npopulation: 6 males\n\nages: 23 - 42\n\nNMR/MS detection of metabolites\n\nQuote:\nWith the help of NMR and MS data, a major metabolite of OLZ in humans was characterized as a novel tertiary N-glucuronide in which the glucuronic acid moiety is attached to the nitrogen at position 10 of the benzodiazepine ring. Another N-glucuronide was detected in urine and identified as the quaternary N-linked 4\'-N-glucuronide. Oxidative metabolism on the allylic methyl group resulted in 2-hydroxymethyl and 2-carboxylic acid derivatives of OLZ. The methyl piperazine moiety was also subject to oxidative attack, giving rise to the N-oxide and N-deemethyl metabolites. Other metabolites, including the N-deemethyl-2-carboxy derivative, resulted from metabolic reactions at both the 4\' nitrogen and 2-methyl groups. The 10-N-glucuronide and OLZ were the two most abundant urinary components, accounting for approximately 13% and 7% of the dose, respectively. In fecal extracts, the only significant radioactive HPLC peaks were due to 10-N-glucuronide and OLZ representing, respectively, approximately 8% and 2% of the administered dose.','boycer','06/16/2009 18:19:35\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1276,'evidence_1698','http://www.ncbi.nlm.nih.gov/pubmed/11061579','\nRoute of administration: oral\n\nstudy duration: 13 days\n\npopulation: 18 participants; 5 male, 5 female\n\nages:18-45\n\ndose: 40mg of pravastatin on day one, three days no drug, days 6-10 participants were given 200mg itraconazole 1xday for 5 days, on day 10 a portion of the participants were given a single dose of 40 mg pravastatin. PK parameters were measured followed for another three days\n\n(mean AUC_i)/(mean AUC) = 75.2/50.6 (AUC is 0-infinity)\n\n\ndescription:\nn this single-site, randomized, three-way crossover, open-labeled study, healthy subjects (n = 18) received single doses of cerivastatin 0.8 mg, atorvastatin 20 mg, or pravastatin 40 mg without and with itraconazole 200 mg. Pharmacokinetic parameters [AUC(0-infinity), AUC(0-tn), peak concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2)] were determined for parent statins and major metabolites. RESULTS: Concomitant cerivastatin/itraconazole treatment produced small elevations in the cerivastatin AUC(0-infinity), Cmax, and t1/2 (27%, 25%, and 19%, respectively; P &lt; .05 versus cerivastatin alone). Itraconazole coadministration produced similar changes in pravastatin pharmacokinetics [AUC elevated 51% (P &lt; .05 versus pravastatin alone), 24% (Cmax), and 23% (t1/2), respectively]. However, itraconazole dramatically increased atorvastatin AUC (150%), Cmax (38%), and t1/2 (30%) (P &lt; .05).','boycer','09/28/2007 07:25:01\n','EV_PK_DDI_RCT','PKStudy',1.486,0.04,0.2,18,'',NULL,NULL),(1277,'evidence_1485','http://www.ncbi.nlm.nih.gov/pubmed/15518608','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: both drugs were given once daily for 30 days; pharmacokinetic measures were taken on days 1 and 30\n\ndose: 40mg pravastatin; 200mg itraconazole\n\npopulation: 104\n\nages:18-60\n\n(mean AUC_i)/(mean AUC) = 210/188ng/ml/h\n\ndescription: \nThere was no significant increase in the AUC of pravastatin\n\n','boycer','06/05/2007 14:32:49\n','EV_PK_DDI_RCT','PKStudy',1.117,0.04,0.2,104,'',NULL,NULL),(1278,'evidence_1103','http://www.ncbi.nlm.nih.gov/pubmed/9542477','\nRoute of administration: oral\n\nstudy duration: volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of  pravastatin (study II).\n\npopulation: 10 : 7 male, 3 female\n\nages:19-29\n\nRESULTS: \nIn study II, itraconazole slightly increased the AUC(0-infinity) and Cmax of pravastatin, but the changes were statistically nonsignificant (p = 0.052 and 0.172, respectively). The t1/2 was not altered. The AUC(0-infinity) and Cmax of HMG-CoA reductase inhibitors were increased less than twofold (p &lt; 0.05 and p = 0.063, respectively) by itraconazole.\n\nNOTE: a statistically significant increase in HMG-CoA inhibitors occured  but we cannot distinguish which metabolites of pravastatin were increased from the study','boycer','10/29/2007 12:36:05\n','EV_PK_DDI_RCT','PKStudy',0,0.04,0.2,10,'',NULL,NULL),(1279,'evidence_1066','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d5051fbc-846b-4946-82df-341fb1216341','\n&quot;Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended. When using ZYPREXA and fluoxetine in combination, also refer to the Drug Interactions section of the package insert for Symbyax.&quot;','boycer','06/16/2009 16:55:20\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,217),(1280,'evidence_1966','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1281,'evidence_1031','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: R-warfarin\n\nreaction: R-warfarin 10-hydroxylation\n\nQuote:\nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. ','boycer','09/22/2009 18:02:20\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,218),(1282,'evidence_1610','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1283,'evidence_1734','http://www.ncbi.nlm.nih.gov/pubmed/14667956','\n\nRoute of administration: oral/IV\n\nstudy duration: on day 1 participants received either one dose of 10mgPO rosuvastatin or one IV infusion of 8mg rosuvastatin; a period of &gt;=7 days elapsed and the participants were given the drug form that they did not receive the first time they came in to the clinic. \n\npopulation: 10 male\n\nages:21-51\n\nDescription:\n\nTable 1, pg2558 shows, among other PK values, that the geometric mean of oral Cmax was 18.8ng/ml, bioavailabity (F) was calculated to be 20% of the oral dose, the hepatic extraction (E_H)ratio was .63 \n\nBased on these values the authors calculated absorbtion to be &quot;appreciably greater than 20% and estimate it to ~50% using F/(1-E_H). ','boycer','09/28/2007 12:36:15\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.4999,NULL,NULL,NULL,'',NULL,NULL),(1284,'evidence_1487','http://www.ncbi.nlm.nih.gov/pubmed/9152603','Enzyme system: human liver microsomes \n\nNADPH added: yes \n\ninhibitor used: furafylline \nreaction: \nclarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin \n\ndescription: clarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor ','boycer','10/20/2007 08:15:16\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,219),(1285,'evidence_1920','http://www.ncbi.nlm.nih.gov/pubmed/12235455','\nRoute of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: single 120mg oral dose of diltiazem with 24 hours of plasma level monitoring\n\npopulation: 15 individuals; 5 for each genetically based phenotype. Study does not state gender of participants\n\nages: 20-30\n\ndescription:\nThe aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS: Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence resonance energy transfer probes hybridized to polymerase chain reaction-amplified deoxyribonucleic acid. The first 5 individuals identified with genotypes corresponding to a homozygous extensive, heterozygous extensive, or homozygous poor CYP2D6-metabolizing phenotype, respectively, were voluntarily enrolled in the pharmacokinetic study. The participants received diltiazem, 120 mg, as a single oral dose, and plasma samples were collected up to 24 hours after administration. Plasma samples were purified by solid phase extraction. Diltiazem and 7 phase I metabolites were analyzed by liquid chromatography-mass spectrometry. RESULTS: The pharmacokinetics of diltiazem was not significantly different between the subgroups. However, the systemic exposure of the pharmacologically active metabolites desacetyl diltiazem and N-demethyldesacetyl diltiazem was &gt; or = 5 times higher in poor CYP2D6 metabolizers than in extensive CYP2D6 metabolizers (P &lt;.01). CONCLUSIONS: CYP2D6 activity does not have a major impact on the disposition of diltiazem. In contrast, desacetyl diltiazem and N-demethyldesacetyl diltiazem are markedly accumulated in individuals expressing a deficient CYP2D6 phenotype. Because these metabolites exhibit pharmacologic properties of possible importance, individual CYP2D6 activity might be an aspect to consider in the clinical use of diltiazem.','boycer','12172009','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1286,'evidence_1013','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: tolbutamide --&gt; hydroxytolbutamide\n\nQuote: \n\nCYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7  (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM).\n\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1287,'evidence_1802','http://www.ncbi.nlm.nih.gov/pubmed/10494454','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: citalopram --&gt; desmethylcitalopram\n\nQuote: \nKetoconazole produced concentration-dependent inhibition of DCT formation (Figure 4). The mean (+/-SE) IC50 values for ketoconazole were 0.81 (+/-.24) micM/L at\nCT = 10 micM/L, and 1.54 (+/-.35) micM/L CT = 100 micM/L; these values were not significantly different.\n\n\n\n','boycer','02/12/2010 18:32:55\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,220),(1288,'evidence_1424','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','\nKetoconazole\n\nCombined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.','boycer','06/12/2009 13:16:14\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,221),(1289,'evidence_1362','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends this as a CYPC9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1290,'evidence_1359','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645','Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1291,'evidence_1091','http://www.ncbi.nlm.nih.gov/pubmed/9728898','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 2 day pretreatment with erythromycin @ 500mg 3x/day\n\nNOTE: study states two day pretreatment but there were only four doses given before object drug was administered\n\npopulation: 12 \nmale: 8\nfemale: four\nages:20-29\n\ndescription:\nTable 2 shows AUC_i/AUC: 100/25.5 ng/ml*hr\nNOTE: > 20-fold inter-individual variation for this parameter','boycer','06/25/2007 14:53:54\n','EV_PK_DDI_RCT','PKStudy',3.9,0.04,0.5,12,'',NULL,NULL),(1292,'evidence_1183','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','11/09/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1293,'evidence_1773','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','Fluvoxamine is listed as a recommended inhibitor of CYP1A2 for in vivo studies in Table 2 (p. 19). Typically, this would qualify it as a in vivo selective inhibitor however, Table 2 also shows fluvoxamine as a recommended inhibitor of 2C19.','boycer','05/05/2009 17:26:22\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1294,'evidence_1852','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','Theophylline\n\nThe effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy nonsmoking, male volunteers. The clearance of theophylline was decreased approximately 3-fold. Therefore, if theophylline is coadministered with fluvoxamine maleate, its dose should be reduced to one-third of the usual daily maintenance dose and plasma concentrations of theophylline should be monitored. No dosage adjustment is required for fluvoxamine maleate tablets.','boycer','05/15/2009 09:03:48\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,222),(1295,'evidence_1486','http://www.ncbi.nlm.nih.gov/pubmed/11719727','\nroute of administration: oral\n\nstudy duration: single-dose theophylline (250 mg) after  taking fluvoxamine for 9 days at 3 doses (0, 25, or 75 mg/day) in a randomized crossover design\n\npopulation: 9 healthy non-smoking volunteers (5 male, 4 female)\n\nparticipants tested known CYP450 phenotypes? No\n\nages: 23 - 40\n\nDescription: \nTable II shows AUC_i/AUC (0-48) for theophylline as follows:\n\nfluvoxamine @ 25mg/day for 9 days: 504/349 = 1.44\nfluvoxamine @ 75mg/day for 9 days: 710/349 = 2.03\n \n\n','boycer','06/20/2009 11:54:59\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,223),(1296,'evidence_1685','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel\n\n&quot;No IC50 values could be determined for rosuvastatin and pravastatin with concentrations up to 100micM&quot;\n\nConcentration of rosuvastatin in vivo based on the C_max from PMID:14667956 of a 10mg dose (small): .188nM/L; according to labeling both peak concentration (Cmax) and area under the plasma concentration-time curve (AUC) increased in approximate proportion to rosuvastatin dose. \n\n','boycer','10/29/2007 10:23:54\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,224),(1297,'evidence_1210','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nDrug Interactions\n...\nDesipramine: The effect of cinacalcet (90 mg) on the pharmacokinetics of desipramine (50 mg) has been studied in healthy subjects who were CYP2D6 extensive metabolizers. The AUC and Cmax of desipramine increased by 3.6 (296.5-446.7%) and 1.75 (157.5-194.9%) fold, respectively, in the presence of cinacalcet. This indicates that cinacalcet is a strong in vivo inhibitor of CYP2D6 and can increase the blood concentrations of drugs metabolized by CYP2D6.','boycer','09/24/2009 12:22:35\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,225),(1298,'evidence_1974','http://www.ncbi.nlm.nih.gov/pubmed/16680561','\n\nroute of administration: oral\n\nstudy duration: controls: a single dose of 50 mg of desipramine alone; exposed: a single dose of 50 mg of desipramine after seven days of 90 mg cinacalcet. The groups were randomized and then alternated after a 10-day washout period.\n\npopulation: 14 healthy subjects; non-smokers; 8 female, 7 male\n\ntested for known CYP450 polymorphisms? subjects were required to be CYP2D6 extensive metabolizers based on genotyping\n\nages: 18 - 55\n\ndescription:\nRelative to when desipramine was administered alone, a\n3.6-fold increase in AUC(0-inf) and 1.8-fold increase in Cmax of desipramine was observed when cinacalcet was\nadministered for 5 days before and 2 days after dosing\nwith desipramine (Table 1, Fig. 1). Administration with\ncinacalcet resulted in an increase in the AUC(0-inf) and Cmax of desipramine for all subjects (Fig. 2). Coadministration of desipramine and cinacalcet also resulted in a notable reduction in desipramine oral clearance. The terminal half-life of desipramine was also increased by approximately twofold when desipramine was coadministered with cinacalcet. The median tmax was 6 h following administration of desipramine alone and following administration\nwith cinacalcet.\n\n\n\n','boycer','09/25/2009 10:03:28\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,226),(1299,'evidence_1548','http://www.ncbi.nlm.nih.gov/pubmed/17652181','\n\nroute of administration: oral\n\nstudy duration: Each subject received 50 mg of cinacalcet (25-mg [as free base] film tablets,\nKirin Brewery Co, Ltd, Tokyo, Japan) or a matched\nplacebo orally once daily for 8 days. On day 8, each\nsubject also received a single oral dose of 30 mg DEX\n(Medicon, 15-mg film tablets, Shionogi &amp; Co, Ltd,\nOsaka, Japan). \n\npopulation: 23 male volunteers \n\ntested for known CYP450 polymorphisms? all participants included in the PK analaysis wer classified as a CYP2D6 extensive metabolizers based on the dextromethorphan/dextorpham metabolic ratio\n\nages: 20 - 33\n\ndescription:\nThe Cmax, AUC(0-t), and AUC(0-inf) of DEX were significantly higher during the cinacalcet treatment than with placebo, with a ratio of 7.481, 14.373, and 11.475, respectively. The Cmax of DOR was decreased, and the AUC(0-t) and AUC(0-inf) of DOR were slightly increased during cinacalcet treatment.\n\n\n','boycer','09/25/2009 10:47:42\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,227),(1300,'evidence_1070','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','\nMetabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1301,'evidence_1045','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','\nDrugs That Inhibit CYP3A4 (Ketoconazole)\n\nCYP3A4 is a major metabolic pathway for elimination of eszopiclone. The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days. Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1302,'evidence_1162','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf','\nMetabolism and Elimination\n\nThe major route of elimination is metabolism (~90%), primarily by the liver, with subsequent renal elimination of the metabolites. Urine alkalinization has no effect on the elimination of modafinil.\n\nMetabolism occurs through hydrolytic deamidation, S-oxidation, aromatic ring hydroxylation, and glucuronide conjugation. Less than 10% of an administered dose is excreted as the parent compound. In a clinical study using radiolabeled modafinil, a total of 81% of the administered radioactivity was recovered in 11 days post-dose, predominantly in the urine (80% vs. 1.0% in the feces). The largest fraction of the drug in urine was modafinil acid, but at least six other metabolites were present in lower concentrations. Only two metabolites reach appreciable concentrations in plasma, i.e., modafinil acid and modafinil sulfone. In preclinical models, modafinil acid, modafinil sulfone, 2-[(diphenylmethyl)sulfonyl]acetic acid and 4-hydroxy modafinil, were inactive or did not appear to mediate the arousal effects of modafinil. ','boycer','09/24/2009 12:33:54\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1303,'evidence_1293','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.015,NULL,NULL,NULL,'',NULL,NULL),(1304,'evidence_1362','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/6c76e98d-b8c3-441f-bac5-a9de6dc8f14f','Perphenazine is extensively metabolized in the liver to a number of metabolites by sulfoxidation, hydroxylation, dealkylation, and glucuronidation.','boycer','05/06/2009 12:53:11\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1305,'evidence_1160','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1306,'evidence_1825','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','\nAbsorption and distribution  Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Maximal plasma concentrations (Cmax) are reached approximately 1 to 2 hours after dosing.','boycer','09/24/2009 11:11:08\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.63,NULL,NULL,NULL,'',NULL,NULL),(1307,'evidence_1503','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','\nMetabolism and Excretion\n\nRanolazine is metabolized mainly by CYP3A and, to a lesser extent, by CYP2D6. Following a single oral dose of ranolazine solution, approximately 75% of the dose is excreted in urine and 25% in feces. Ranolazine is metabolized rapidly and extensively in the liver and intestine; less than 5% is excreted unchanged in urine and feces. The pharmacologic activity of the metabolites has not been well characterized. ','boycer','09/24/2009 15:47:51\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1308,'evidence_1465','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','the FDA lists this as a accepted in vitro inhibitor in it most recent guidance document. See Table 2, p. 28\n	','boycer','07/02/2007 09:53:03\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1309,'evidence_1182','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends debrisoquine to be an acceptable chemical CYP2D6 substrate (CYP2D6--&gt;(debrisoquine-&gt;4-OH-debrisoquine)) for in vitro experiments in it most recent guidance document. See Table 3, p. 32','boycer','05/06/2009 12:50:59\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1310,'evidence_1543','http://www.ncbi.nlm.nih.gov/pubmed/15601809','\nNOTE: The AUC_i/AUC value is calculated from Table I and the precip_dose is the starting dose.\n\nroute of administration: oral\n\nstudy duration: 36 days\n\npopulation: 6 subjects with a DSM-IV diagnosis of schizophrenia or schizoaffective disorders (all male), 4 black, 1 white, 1 Hispanic\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 20-44\n\ndescription:\nSUBJECTS: The valproate study enrolled 10 male subjects, with 6 completers whose results are reported here. The average age was 33 years (range, 22-40), with 4 of black ethnicity, 1 white, and 1 Hispanic. Mean weight was 85.0 kg (range, 79.2-92.3), mean height was 174.8 cm (range, 170.2-177.8), and mean body mass index was 27.8 (range, 25.0-30.5). All achieved steady-state valproate concentrations above 50 mg/L by day 36 of the study.\n\nMETHODS:    After a medication washout period, subjects on day 1 were administered aripiprazole 30 mg once daily (2 tablets of 15 mg) for the duration of the study. On day 14, serial blood samples were collected for the determination of aripiprazole pharmacokinetics. Beginning on day 15 and lasting for the next 21 days (days 15-36), valproate (divalproex sodium) was coadministered with aripiprazole. For patients in the valproate study, the dose was titrated upward from a starting dose of 250 mg twice a day until a serum concentration of 50 to 125 mg/L was achieved or until dose-limiting adverse events were observed. After day 21, the dose of valproate was held constant for the following 2 weeks (days 22-36). On the final day of valproate and aripiprazole coadministration, serial blood samples were collected for the determination of aripiprazole pharmacokinetics in the presence of therapeutic concentrations of valproate.\n\nRESULTS: Coadministration of divalproex had minor effects on the pharmacokinetics of aripiprazole (Table I and Figure 2). It decreased the geometric mean AUC_t and C_max of aripiprazole by 24% and 26%, respectively; it increased median t_max of aripiprazole by 2 hours and the CLT/F of aripiprazole by 33%.\n','boycer','09/22/2010 13:45:12\n','EV_PK_DDI_NR','PKStudy',0.76,0.03,0.5,6,'',NULL,NULL),(1311,'evidence_1171','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: phenacetin\n\nreaction: phenacetin O-deethylation\n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).\n\n\n','boycer','02132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1312,'evidence_1060','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/3829d74e-b3ab-46df-a08b-f0327b63304e','\nExcretion In neonates, approximately 50% of the theophylline dose is excreted unchanged in the urine. Beyond the first three months of life, approximately 10% of the theophylline dose is excreted unchanged in the urine. The remainder is excreted in the urine mainly as 1,3-dimethyluric acid (35-40%), 1-methyluric acid (20-25%) and 3-methylxanthine (15-20%). Since little theophylline is excreted unchanged in the urine and since active metabolites of theophylline (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage renal disease, no dosage adjustment for renal insufficiency is necessary in adults and children &gt;3 months of age. In contrast, the large fraction of the theophylline dose excreted in the urine as unchanged theophylline and caffeine in neonates requires careful attention to dose reduction and frequent monitoring of serum theophylline concentrations in neonates with reduced renal function','boycer','09/24/2009 14:28:51\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1313,'evidence_1541','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nMetabolism and Excretion\n\nCinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1314,'evidence_1836','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','06/30/2009 12:57:08\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1315,'evidence_1497','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','7.5  Effect of Atomoxetine on P450 Enzymes\n\nAtomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.','boycer','09/21/2009 14:57:14\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1316,'evidence_1913','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','7.5  Effect of Atomoxetine on P450 Enzymes\n...\n\nCYP2D6 Substrate (e.g., Desipramine)  Coadministration of STRATTERA (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended for drugs metabolized by CYP2D6.','boycer','09/21/2009 15:02:28\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,228),(1317,'evidence_1249','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\n&quot;Mirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.&quot;','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1318,'evidence_1256','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: quinidine\n\nreaction: mirtazapine 8-hydroxylation (25 and 250 micM) \n\nQuote: \nIncubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-\noxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. \n\nNOTE: lowest MIR concentration tested was 25 micM\n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1319,'evidence_1552','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1320,'evidence_1574','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1321,'evidence_1734','http://www.ncbi.nlm.nih.gov/pubmed/9929499','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: lovastatin-->beta-OH-lovastatin-->6\'beta-hydroxy-lovastatin\n\nQuote:\n\nLovastatin was metabolized by human liver microsomes to two major metabolites: 6\'beta-hydroxy [Michaelis-Menten constant (Km): 7.8 +/- 2.7 microM] and 6\'-exomethylene lovastatin (Km,10.3 +/- 2.6 microM). 6\'beta-Hydroxylovastatin formation in the liver was inhibited by the specific CYP3A inhibitors cyclosporine (Ki, 7.6 +/- 2.3 microM), ketoconazole (Ki, 0.25 +/- 0.2 microM), and troleandomycin (Ki, 26.6 +/- 18.5 microM).\n\nNOTE: though not clearly stated in the paper, the authors mention that lovastatin itself it fully converted by esterases to its open ring acid form which we in the DIKB infer to be beta-OH-lovastatin','boycer','06/25/2007 12:18:52\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,229),(1322,'evidence_1202','http://www.ncbi.nlm.nih.gov/pubmed/8646822','Route of administration: oral\n\nstudy duration: 10 days pre-treatment with erythromycin 400mg 3x/day\n\npopulation: 12 healthy adults\nmale:  12\nfemale: 0\nages: 25-41 years\n\nAUC_i/AUC: 322/200 ng*hr/ml\n\nNOTE: The 0-48 hout AUC values were used rather than the 0-infinity values\n\nQuote:\n\nTwelve healthy male volunteers were randomly allocated to one of the two different treatment sequences, placebo-erythromycin or erythromycin-placebo, with an at least 6-week washout period between the two trial phases. Each volunteer received 400 mg erythromycin or matched placebo given orally three times a day for 10 days and an oral dose (0.8 mg) of alprazolam on the posttreatment day 8. Plasma concentration of alprazolam was measured up to 48 hours after the administration, and psychomotor function was assessed at each time of blood samplings with use of the Digit Symbol Substitution Test, visual analog scale, and Udvalg for kliniske underser side effect rating scale. RESULTS: Erythromycin significantly (p < 0.001) increased the area under the plasma concentration-time curves (200 +/- 43 versus 322 +/- 49 ng . hr/ml from 0 to 48 hours and 229 +/- 52 versus 566 +/- 161 ng . hr/ml from 0 hour to infinity), decreased the apparent oral clearance (1.02 +/- 0.31 versus 0.41 +/- 0.12 ml/min/kg), and prolonged the elimination half-life (16.0 +/- 4.5 versus 40.3 +/- 14.4 hours) of alprazolam. However, any psychomotor function variables did not differ significantly between the erythromycin and placebo trial phases.','boycer','06/25/2007 13:07:07\n','EV_PK_DDI_RCT','PKStudy',1.61,0.0008,0.4,12,'',NULL,NULL),(1323,'evidence_1895','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1324,'evidence_1941','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: S-mephenytoin 4\'-hydroxylatoin\n\nThe IC50 for ziprasidone inhibition of this reaction was greater than 100micM \n\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1325,'evidence_1591','http://www.ncbi.nlm.nih.gov/pubmed/11910256','\nroute of administration: oral\n\nstudy duration: quetiapine 300 mg bid and haloperidol 7.5 mg bid for 7 consecutive days after titration periods of at least 17 days for quetiapine and two days for haloperidol (see Figure 1). Haloperidol was given after participant\'s quetiapine levels were considered to have reached steady state (see NOTE below)\n\npopulation: 12 adults with schizophrenic, schizoaffective, or bipolar disorder; 11 male, 1 female\n\ntested for known CYP450 polymorphisms? No\n\nages: 18 - 60\n\ndescription:\nAlthough co-administration of haloperidol led to an\nincrease in mean plasma quetiapine concentration (Figure 2A) and a decrease in Cl/f (10%), the changes\nwere small and not clinically significant (Table 2). The same was true for increases in geometric means for AUCtSS, CmaxSS, and CminSS (11%, 23%, and 17%, respectively). The trend toward increased AUCtSS  etween days 17B and 5B was seen for 9 of 12 patients. The increases in CmaxSS and CminSS were considered to be of no clinical concern.\n\nNOTE: during co-administration of haloperidol six patients recieved benztropine mesylate\n','boycer','09/22/2009 19:11:15\n','EV_PK_DDI_NR','PKStudy',1,0.3,0.0075,11,'',NULL,NULL),(1326,'evidence_1608','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1327,'evidence_1815','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','Warfarin\n\nWhen fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for 2 weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged. Thus patients receiving oral anticoagulants and fluvoxamine maleate tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. No dosage adjustment is required for fluvoxamine maleate tablets.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1328,'evidence_1156','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1329,'evidence_1037','http://www.ncbi.nlm.nih.gov/pubmed/15770075','Route of administration: oral\n\nstudy duration: Two phases : Phase I - a single dose of aripiprazole; Phase II - 7 days pre-treatment with ITZ, single dose of aripiprazole with ITZ, then ITZ alone or 14 more days; a 35 day washout between Phase I and II\n\npopulation: 24 healthy adult Japanese males\n\nmean age (SD): 23.2 (2.4)\n\nAUC_i/AUC (336hr): 365/269 = 1.36\n\nDescription:\nThe objective of the present study was to investigate the influence of itraconazole (hereafter referred to as ITZ) co-administration (CYP3A4 inhibition) on the pharmacokinetics of ARIPIPRAZOLE administered to 24 healthy adult male volunteers in a fasting condition. The influence of CYP3A4 inhibition was also examined by CYP2D6 genotype. All subjects were administered a single oral dose of ARIPIPRAZOLE alone in Period I and a single oral dose of ARIPIPRAZOLE following administration of ITZ at 100 mg/day for 7 consecutive days in Period II. The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined. Co-administration of ITZ increased the Cmax, AUC336 hr, and t1/2,z of ARIPIPRAZOLE and OPC-14857 by 19.4%, 48.0%, and 18.6% and by 18.6%, 38.8%, and 53.4%, respectively. By co-administration of ITZ, the CL/F of ARIPIPRAZOLE in extensive metabolizers was decreased by 26.6%, with an even greater decrease (47.3%) in intermediate metabolizers. For the co-administration period, the CL/F of ARIPIPRAZOLE in intermediate metabolizers was about half of that in extensive metabolizers. For Cmax, there was no significant difference between extensive metabolizers and intermediate metabolizers, and the percent change by co-administration of ITZ was less than 20% in both extensive metabolizers and intermediate metabolizers. For OPC-14857, the t(max) in intermediate metabolizers was longer than that in extensive metabolizers, with the difference being amplified by co-administration of ITZ. The AUC336 hr showed similar increases by co-administration of ITZ in all genotypes. The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ. The influence of CYP3A4 inhibition on the pharmacokinetics of ARIPIPRAZOLE was not considered to be clinically significant. On the other hand, definite differences in pharmacokinetics were observed between CYP2D6 genotypes. ','boycer','12172009','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1330,'evidence_1044','http://www.ncbi.nlm.nih.gov/pubmed/9366029','Route of administration: oral\n\nstudy duration: rac-citalopram given @ 40mg qd X 21days\n\npopulation: 10 adults (6 female and 4 male) all extensive metabolizers according to 2d6 and 2c19 specific assays (sparteine and mephenytoin respectively)\n\nages: 23-32\n\n\nDescription: \nC_max for S-citalopram : 154.2nMol/L\n\n154.2nMol/L X 1M/10^9nMol X 324.39g/1M = 0.00005002g/L','boycer','06/12/2009 19:50:46\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00005002,NULL,NULL,NULL,'',0.04,NULL),(1331,'evidence_1126','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','7.5  Effect of Atomoxetine on P450 Enzymes\n\nAtomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1332,'evidence_1616','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','7.5  Effect of Atomoxetine on P450 Enzymes\n...\n\nCYP2D6 Substrate (e.g., Desipramine)  Coadministration of STRATTERA (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended for drugs metabolized by CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1333,'evidence_1502','http://www.ncbi.nlm.nih.gov/pubmed/12404553','NOTE: The AUC_i/AUC value given is calculate from Table 7 and is the value for both genders taken together.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 27 days (each treatment was 9 days)\r\n\r\npopulation: 20 healthy subjects (11 male, 9 female)\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 18-45\r\n\r\ndescription:\r\nSUBJECTS: Subjects meeting the inclusion criteria were enrolled into the study. They were randomly assigned to one of six treatment sequences in this three-period crossover study without washout intervals. They were admitted to the clinical pharmacology institute two days before the start of the study. After admission, subjects were re-screened for alcohol and drugs, and 20% female subjects were given a pregnancy test.\r\n\r\nOf the 12 males and 12 female subjects enrolled into the study, three subjects (1 male, 2 females) discontinued the study due to the emergence of adverse events on days 21, 23 and 27, respectively, of the 27 day treatment period. Data from these subjects were not used in the pharmacokinetic and psychometric data analyses. One subject missed the mirtazapine medication on day 26. Data from this subject were not used in the pharmacokinetic analyses.\r\n\r\nMETHODS:   In order to mimic clinical practice as much as possible, paroxetine was administered in the morning and mirtazapine in the evening, with a 12 h interval between administrations. From day 1 up to and including day 26 paroxetine 20 or 40 mg or placebo was administered at 9 a.m. and mirtazapine 15 or 30 mg or placebo at 9 p.m. each day.\r\nThe treatments used were: (A) 20 mg paroxetine plus one placebo paroxetine capsule at 9 a.m. and two placebo mirtazapine tablets at 9 p.m. for the first 3 days followed by two 20 mg paroxetine capsules at 9 a.m. and two placebo mirtazapine tablets at 9 p.m. for the following 6 days; (B) two placebo paroxetine capsules at 9 a.m. and one 15 mg mirtazapine plus one placebo mirtazapine tablet at 9 p.m. for 3 days followed by two placebo paroxetine capsules at 9 a.m. and two 15 mg mirtazapine tablets at 9 p.m. for the following 6 days; (C) 20 mg paroxetine plus one placebo paroxetine capsule at 9 a.m. and 15 mg mirtazapine plus one placebo mirtazapine tablet at 9 p.m. for 3 days followed by two 20 mg paroxetine at 9 a.m. and two 15 mg mirtazapine at 9 p.m. for the following 6 days. Thus, six possible treatment sequences (TS1-TS6) were used (Table 1). In those treatment sequences in which either paroxetine or mirtazapine had also been administered in the preceding treatment sequence, the drug was continued at the highest dose, i.e. two 20 mg capsules for paroxetine and two 15 mg tablets for mirtazapine. Two males and two females were randomized to each of the six treatment sequences.\r\n\r\nRESULTS: Pharmacokinetic parameters of paroxetine were not altered by adding mirtazapine.\r\n\r\nSee Tables 7-8. Calculated from Table 7, the AUC_0-24 for males alone was 1.03, for females alone was 0.94, and combined was 0.99.','boycer','09/22/2010 13:23:08\r\n','EV_PK_DDI_RCT','PKStudy',0.99,0.04,0.03,20,'',NULL,NULL),(1334,'evidence_1076','http://www.ncbi.nlm.nih.gov/pubmed/2007317','\nroute of administration: oral\n\nstudy duration: single 25mg dose of thioridazine\n\npopulation: 19 healthy male subjects: 6 slow and 13 rapid hydroxylators of debrisoquin\n\nages: 19 - 41 \n\nQuote:\n&quot;Slow hydroxylators of debrisoquin obtained higher serum levels of thioridazine with a 2.4-fold higher Cmax and a 4.5-fold larger AUC(0-infinity) associated with a twofold longer half-life compared with that of rapid hydroxylators.&quot;','boycer','06/20/2009 15:52:09\n','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,230),(1335,'evidence_1832','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.08,NULL,NULL,NULL,'',NULL,NULL),(1336,'evidence_1277','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1337,'evidence_1600','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\nAbsorption: Absolute bioavailability for a 20 mg oral tablet of rabeprazole (compared to intravenous administration) is approximately 52%. When rabeprazole is administered with a high fat meal, its Tmax is variable and may delay its absorption up to 4 hours or longer, however, the Cmax and the extent of rabeprazole absorption (AUC) are not significantly altered. Thus rabeprazole may be taken without regard to timing of meals.','boycer','09/24/2009 14:02:44\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.52,NULL,NULL,NULL,'',NULL,NULL),(1338,'evidence_1002','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1339,'evidence_1308','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2','Drugs Metabolized by Cytochrome P450 Isoenzymes\n\nCYP2D6: In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6. These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine to that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan. ','boycer','05/15/2009 10:30:24\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1340,'evidence_1142','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1341,'evidence_1708','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: S-warfarin\n\nreaction: S-warfarin 7-hydroxylation\n\nQuote:\nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. ','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1342,'evidence_1020','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','Quetiapine is extensively metabolized by the liver. The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive. In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite and in the metabolism of its active metabolite N-desalkyl quetiapine .','boycer','05/14/2009 14:20:53\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1343,'evidence_1307','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb','7.5  Effect of Atomoxetine on P450 Enzymes\n\nAtomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.','boycer','09/21/2009 14:59:07\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1344,'evidence_1386','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','Sertraline is listed as a moderate inhibitor in Table 6 (p23) but does not show up in Table 2 (a table listing several selective in viVo inhibitors)','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1345,'evidence_1133','http://www.ncbi.nlm.nih.gov/pubmed/11910262','Route of administration: oral\n\nstudy duration: read description below\n\npopulation: (sertraline group) 12 healthy volunteers (8 male and 4 female), all extensive metabolizers of dextromethorphan\n\nages: mean(std dev): 27 (unknown)\n\nDescription: \nIn an open label, parallel group study of 45 healthy volunteers, the time course of CYP2D6 inhibition of the above SSRIs was evaluated. Subjects were randomized to receive paroxetine at 20 mg/day for 10 days; sertraline at 50 mg/day for 3 days, followed by sertraline at 100 mg/day for 10 days; or fluoxetine at 20 mg/day for 28 days. CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine. Following SSRI discontinuation, calculation of a CYP2D6 inhibition half-life (t(1/2)inh) revealed the time course of fluoxetine inhibition (t(1/2)inh = 7.0 +/- 1.5 days) to be significantly longer than either paroxetine (t(1/2)inh = 2.9 +/- 1.9) or sertraline (t(1/2)inh = 3.0 +/- 3.0) (p &lt; 0.01), but the latter were not significantly different from each other (p &gt; 0.05). Time for the extrapolated DMR versus time log-linear plots to return to baseline was significantly different between fluoxetine (63.2 +/- 5.6 days) and both paroxetine (20.3 +/- 6.4 days) and sertraline (25.0 +/- 11.0 days) (p &lt; 0.01), making the rank order (from longest to shortest) of time for CYP2D6 inhibition to dissipate: fluoxetine &gt; sertraline &gt;or= paroxetine. Differences between mean baseline DMR values and measured values obtained after drug discontinuation for each drug group became nonsignificant on discontinuation day 5 for both paroxetine and sertraline and on discontinuation day 42 for fluoxetine. ','boycer','12172009','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1346,'evidence_1705','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1de3ed9-1cb8-e419-3f25-5b0aeed5779a','Drugs Metabolized by P450 2D6\n\nMany drugs effective in the treatment of major depressive disorder, e.g., the SSRIs, including sertraline, and most tricyclic antidepressant drugs effective in the treatment of major depressive disorder inhibit the biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase), and, thus, may increase the plasma concentrations of coadministered drugs that are metabolized by P450 2D6. The drugs for which this potential interaction is of greatest concern are those metabolized primarily by 2D6 and which have a narrow therapeutic index, e.g., the tricyclic antidepressant drugs effective in the treatment of major depressive disorder and the Type 1C antiarrhythmics propafenone and flecainide. The extent to which this interaction is an important clinical problem depends on the extent of the inhibition of P450 2D6 by the antidepressant and the therapeutic index of the coadministered drug. There is variability among the drugs effective in the treatment of major depressive disorder in the extent of clinically important 2D6 inhibition, and in fact sertraline at lower doses has a less prominent inhibitory effect on 2D6 than some others in the class. Nevertheless, even sertraline has the potential for clinically important 2D6 inhibition. Consequently, concomitant use of a drug metabolized by P450 2D6 with sertraline may require lower doses than usually prescribed for the other drug. Furthermore, whenever sertraline is withdrawn from cotherapy, an increased dose of the coadministered drug may be required (see PRECAUTIONS: Drug Interactions: Tricyclic Antidepressant Drugs Effective in the Treatment of Major Depressive Disorder). ','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1347,'evidence_1674','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1348,'evidence_1028','http://www.ncbi.nlm.nih.gov/pubmed/1412613','\nroute of administration: oral\n\nstudy duration: single dose of haloperidol (2 or 4mg)\n\npopulation: 12 healthy volunteers \n\ntested for known CYP450 polymorphisms? yes, six participants were phenotyped as debrisoquine extensive metabolizers and six as debrisoquine poor metabolizers\n\nages: not mentioned; assumed to be adults\n\nHPLC identified reduced-haloperidol in participants after taking haloperidol\n\n\n','boycer','06/20/2009 14:46:49\n','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,231),(1349,'evidence_1633','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','06/30/2009 12:55:42\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1350,'evidence_1029','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;weak&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','06/30/2009 12:54:27\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1351,'evidence_1532','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1352,'evidence_1540','http://www.ncbi.nlm.nih.gov/pubmed/15998357','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel \n\nK_i = 18.9micM\n\n18.9micM/1L x 1M/1e6micM x 433.46g/1M = .008g/L\n','boycer','10/29/2007 10:49:47\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.008,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,232),(1353,'evidence_1202','http://www.ncbi.nlm.nih.gov/pubmed/9728898','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 2 day pretreatment with erythromycin @ 500mg 3x/day\n\nNOTE: study states two day pretreatment but there were only four doses given before object drug was administered\n\npopulation: 12 \nmale: 8\nfemale: four\nages:20-29\n\ndescription:\nTable 2 shows AUC_i/AUC: 110/17.7 ng/ml*hr','boycer','06/25/2007 14:46:07\n','EV_PK_DDI_RCT','PKStudy',6.3,0.04,0.5,12,'',NULL,NULL),(1354,'evidence_1443','http://www.ncbi.nlm.nih.gov/pubmed/12102620','\nNOTE: The AUC_i/AUC value is from Table 1.\n\nroute of administration: oral\n\nstudy duration: 8 days\n\npopulation: 15 healthy subjects (11 male, 4 female), all nonsmokers; 13 Caucasian, 1 Hispanic, 1 Asian\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 23-40\n\ndescription:\nSUBJECTS: Subjects were nonsmokers who were of normal build and had no clinically significant abnormalities. Fifteen subjects (4 females and 11 males) completed the study. Thirteen subjects were Caucasian, 3 were Hispanic, and one was Asian. Ages ranged from 23 to 40 years (mean = 32 +/- 5 years). At admission, mean height was 173 +/- 10 cm and mean weight was 71 +/- 13 kg.\n\nMETHODS: The pharmacokinetics of 3 identical single therapeutic doses of olanzapine (5 mg) were determined in 15 healthy nonsmoking volunteers. The first dose of olanzapine was taken alone, the second given after a single oral dose of fluoxetine (60 mg), and the third given after 8 days of treatment with fluoxetine 60 mg, qd. There was an interval of 10 days between olanzapine doses of periods 1 and 2, and at least 15 days between olanzapine doses of periods 2 and 3. During each period, the volunteers remained in the clinical pharmacology unit for 24 hours following the administration of olanzapine.\n\nRESULTS: After single coadministration of fluoxetine, the C_max and AUC_0-inf of olanzapine increased by 18%, whereas the total apparent clearance decreased by 15%.\n','boycer','09/16/2010 15:29:01\n','EV_PK_DDI_NR','PKStudy',1.18,0.005,0.06,15,'',NULL,NULL),(1355,'evidence_1828','http://www.ncbi.nlm.nih.gov/pubmed/15258107','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: midazolam\n\nreaction: midazolam 1\'hydroxylation\n\nIC50 &gt; 200micM (see Table 3)\n\nQuote:\nPantoprazole showed a stronger inhibitory effect (Ki 22mM) on midazolam 1\'-hydroxylation than omeprazole (Ki 42micM), esomeprazole (Ki 47micM), and rabeprazole (Ki 51micM). The IC50 of lansoprazole was over 200 M. \n','boycer','09/23/2009 11:47:32\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,233),(1356,'evidence_1383','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','Metabolism: Bupropion is extensively metabolized in humans. Three metabolites have been shown to be active: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, which are formed via reduction of the carbonyl group. In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high or higher than those of bupropion.','boycer','01/19/2010 10:43:29\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1357,'evidence_1822','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/0a238e82-20d5-45ec-8c13-4725d1065230','The major active metabolites of simvastatin present in human plasma are the &#946;-hydroxyacid of simvastatin and its 6&#8242;-hydroxy, 6&#8242;-hydroxymethyl, and 6&#8242;-exomethylene derivatives.','boycer','05/29/2007 14:40:26\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1358,'evidence_1505','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1359,'evidence_1019','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4','Metabolism and Elimination:\n\n...\n\nQuetiapine is extensively metabolized by the liver. The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive. In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite.','boycer','05/15/2009 09:50:28\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1360,'evidence_1706','http://www.ncbi.nlm.nih.gov/pubmed/15834460','\nRoute of administration: oral\n\nstudy duration: multiple doses of QTP with or without concomitant erythromycin\n\npopulation: 19; 10 female and 9 male NOTE:no participants were tested for known CYP phenotypes\n\nages:18-55 \n\nQuote:\nIn presence of erythromycin, activity of CYP3A4 decreased significantly; for QTP, C(max), AUC(0-24), and t(1/2) increased significantly, CL decreased significantly, and variations in AUC(0-24) and CL showed, respectively, significant negative and positive correlation to that of CYP3A4 activity;','boycer','06/16/2009 17:22:10\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,234),(1361,'evidence_1897','http://www.ncbi.nlm.nih.gov/pubmed/16390352','\n\nroute of administration: oral\n\nstudy duration: An 8-day crossover trial -- in each branch participants were give 25 mg quetiapine before and after 4 days of treatment with ketoconazole 200 mg daily.\n\npopulation:12 healthy male volunteers\n\ntested for known CYP450 polymorphisms?\n\nages: mean 33 years\n\ndescription:\n...concomitant use of ketoconazole resulted in  substantial increases in plasma concentrations of quetiapine (Figure 3A). The mean Cmax and AUC of quetiapine were increased by 235% and 522%, respectively. Conversely, the geometric mean AUC and Cmax of the sulfoxide metabolite were decreased by 46% and 87%, respectively (Figure 3B). Mean CL/F of quetiapine was decreased by 84%, and mean t1/2 was increased from 2.61 to 6.76 h.\n\n\n','boycer','02/13/2010 09:22:55\n','EV_PK_DDI_NR','Evidence',NULL,NULL,NULL,NULL,'',NULL,235),(1362,'evidence_1396','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1363,'evidence_1872','http://www.ncbi.nlm.nih.gov/pubmed/10048600','\nEnzyme system: human liver microsomes:\n\nNADPH added: note explicitly mentioned but acceptable methods assumed\n\ninhibitor used: ketoconazole\n\nreaction: risperidone 9-hydroxylation\n\nNOTE: experiment used 100micM of risperidone which is likely well above C_max based on PMID 7690693 \n\nQuote:\nrisperidone was incubated with human liver microsomes in the presence of different concentrations of inhibitors of CYP enzymes. Both quinidine (inhibitor of CYP2D6) and ketoconazole (inhibitor of CYP3A) inhibited the formation of 9-hydroxyrisperidone in a concentration-dependent manner (Fig. 4). \n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL);
INSERT INTO `Evidence` VALUES (1364,'evidence_1837','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f','\nDrugs that affect drug metabolism via cytochrome P450:\nSome compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes has not been carefully evaluated.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1365,'evidence_1045','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Metabolism and Elimination\n\nZiprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methyl-dihydroziprasidone.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1366,'evidence_1526','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1367,'evidence_1259','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1368,'evidence_1129','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1369,'evidence_1912','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1370,'evidence_1053','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/4471223e-9023-457e-be2e-8e4e0c2d94d1','Midazolam\n\nConcomitant administration of telithromycin with intravenous or oral midazolam resulted in 2- and 6-fold increases, respectively, in the AUC of midazolam due to inhibition of CYP 3A4-dependent metabolism of midazolam. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1371,'evidence_1157','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/4471223e-9023-457e-be2e-8e4e0c2d94d1','Drug interactions\n\nTelithromycin is a strong inhibitor of the cytochrome P450 3A4 system. Co-administration of KETEK tablets and a drug primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentration of the drug co-administered with telithromycin that could increase or prolong both the therapeutic and adverse effects. Therefore, appropriate dosage adjustments may be necessary for the drug co-administered with telithromycin.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1372,'evidence_1372','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','09212009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1373,'evidence_1104','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: coumarin\n\nreaction: coumarin 7-hydroxylation\n\nQuote:\nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. ','boycer','09/22/2009 17:55:50\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,236),(1374,'evidence_1679','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78','Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.','boycer','06/26/2007 06:50:04\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1375,'evidence_1830','http://www.ncbi.nlm.nih.gov/pubmed/7946933','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: alprazolam --&gt; 4-OH-alprazolam\nalprazolam --&gt; 1\'-OH-alprazolam\n\n\nketoconazole effectively and significantly reduced the production of 4-OH-alprazolam (Ki = .046microM) and 1\'-OH-alprazolam (Ki = .076microM)','boycer','07/02/2007 16:32:13\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,237),(1376,'evidence_1696','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYPC19 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1377,'evidence_1036','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1378,'evidence_1202','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.','boycer','01/11/2010 19:14:00\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,238),(1379,'evidence_1106','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1380,'evidence_1009','http://www.ncbi.nlm.nih.gov/pubmed/1531484','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: single dose of clarithromycin \n\npopulation: 26 male\n\nages:28-42\n\nC_max = .88mg/L  for subjects given breakfast two hours after drug administration and .97mg/L for subjects given breakfast 1/2 hour before drug administration. The difference was was not statistically significan so lowest value will be entered into the system','boycer','07/02/2007 12:57:03\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00088,NULL,NULL,NULL,'',0.5,NULL),(1381,'evidence_1633','http://www.ncbi.nlm.nih.gov/pubmed/1474166','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: single dose of clarithromycin\n\npopulation: 12 male\n\nages:18-30 \n\nC_max = .66mg/L','boycer','07/02/2007 13:18:59\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00066,NULL,NULL,NULL,'',0.5,NULL),(1382,'evidence_1768','http://www.ncbi.nlm.nih.gov/pubmed/8331208','\n\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 250mg  clarithromycin 2x/day for 5 doses \n\npopulation: 6 \'healthy volunteers\'\n\nages:45-64\n\nC_max = .83','boycer','07/02/2007 13:30:00\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00083,NULL,NULL,NULL,'',0.25,NULL),(1383,'evidence_1478','http://www.ncbi.nlm.nih.gov/pubmed/8408732','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 250mg  clarithromycin single dose \n\npopulation: 17 male\n\nages:18-40\n\nC_max = .65mg/L','boycer','07/02/2007 13:43:24\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00065,NULL,NULL,NULL,'',0.25,NULL),(1384,'evidence_1368','http://www.ncbi.nlm.nih.gov/pubmed/7923194','\nEnzyme system: recombinant human enzyme in Hep G2 cells\n\nNADPH added: yes\n\nreaction: paclitaxel --&gt; 6alpha-OH-paclitaxel\n\nOnly CYP2C8 formed detectable 6alpha-OH-paclitaxel ','boycer','10/29/2007 09:41:33\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1385,'evidence_1769','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7e117c7e-02fc-4343-92a1-230061dfc5e0','\n&quot;Metabolism and Drug Interactions\n\nRisperidone is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug (e.g., the active moiety) results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.&quot;','boycer','06/15/2009 15:33:10\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1386,'evidence_1685','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\n\nMetabolism: \n...\nIn vitro studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole.','boycer','09/24/2009 13:59:22\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1387,'evidence_1958','http://www.ncbi.nlm.nih.gov/pubmed/11038166','\nEnzyme system: recombinant human CYP2B6 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\natorvastatin acid--&gt;para-hydroxy-atorvastatin\natorvastatin lactone--&gt;para-hydroxy-atorvastatin\n\ndescription:\nThis enzyme system FAILED TO catalyze the above reactions to any measurable extent ','boycer','01/14/2008 13:16:13\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1388,'evidence_1396','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.4,NULL,NULL,NULL,'',NULL,NULL),(1389,'evidence_1237','http://www.ncbi.nlm.nih.gov/pubmed/11147928','\nRoute of administration: oral\n\nstudy duration: three weeks\n\npopulation: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks \n\nages: 29 - 55\n\n\nQuote: \n\nThe effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline.','boycer','06/11/2009 11:57:05\n','EV_PK_DDI_NR','PKStudy',0,0.05,0.2,17,'',NULL,NULL),(1390,'evidence_1374','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA guidance considers omeprazole-5-hydroxylation to be catalyzed selectively by CYP2C19; see Table 3 of page 32','boycer','04/24/2009 16:23:23\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1391,'evidence_1261','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1392,'evidence_1989','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37','Dextromethorphan\n\nConsistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1393,'evidence_1164','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','11/09/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1394,'evidence_1695','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of N-Desmethyl diltiazem using a recombinant CYP3A5 Supersome system.','boycer','05/29/2007 09:02:40\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1395,'evidence_1760','http://www.ncbi.nlm.nih.gov/pubmed/12124305','Enzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of N-Desmethyl diltiazem   using a recombinant CYP3A4 Supersome system. ','boycer','05/29/2007 08:49:06\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1396,'evidence_1461','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','09/24/2009 14:09:55\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1397,'evidence_1769','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db','Effects of Voriconazole on Other Drugs\n\nIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.','boycer','09/24/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1398,'evidence_1599','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9550','Metabolism and Excretion\n...\nThorough metabolic studies have not been conducted, but it appears that deglycination of midodrine to desglymidodrine takes place in many tissues, and both compounds are metabolized in part by the liver. Neither midodrine nor desglymidodrine is a substrate for monoamine oxidase. Renal elimination of midodrine is insignificant. The renal clearance of desglymidodrine is of the order of 385 mL/minute, most, about 80%, by active renal secretion. The actual mechanism of active secretion has not been studied, but it is possible that it occurs by the base-secreting pathway responsible for the secretion of several other drugs that are bases (see also Potential for Drug Interactions).','boycer','09/21/2009 15:09:25\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1399,'evidence_1982','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\n&quot;Mirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.&quot;','boycer','06/15/2009 15:22:05\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1400,'evidence_1770','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: quinidine\n\nreaction: mirtazapine 8-hydroxylation (25 and 250 micM) \n\nQuote: \nIncubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-\noxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. \n\nNOTE: lowest MIR concentration tested was 25 micM\n\n','boycer','02/13/2010 07:56:10\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,239),(1401,'evidence_1155','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1402,'evidence_1353','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','04/29/2009 19:39:11\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1403,'evidence_1230','http://www.ncbi.nlm.nih.gov/pubmed/9695720','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 5 days\n\npopulation: 5 male, 5 female \n\nages:21-35\n\ndose: 200mg itraconazole 1xday for 5 days, a single dose of 40 mg atorvastatin on day 4. \n\n(mean AUC_i)/(mean AUC) = 179.7/24.2 (AUC is 0-infinity)\n\nNOTE: three females were on contraceptive steroids\n\ndescription:\nIn a randomized, double-blind, two-phase crossover study, 10 healthy volunteers took 200 mg itraconazole or matched placebo orally once daily for 4 days. On day 4, 40 mg atorvastatin was administered orally, and a further dose of 200 mg itraconazole or placebo was taken 24 hours after atorvastatin intake. Serum concentrations of atorvastatin acid, atorvastatin lactone, 2-hydroxyatorvastatin acid and lactone, 4-hydroxyatorvastatin acid and lactone, active and total HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were measured up to 72 hours. RESULTS: Itraconazole increased the area under the concentration--time curve from time zero to 72 hours [AUC(0-72)] and the elimination half-life of atorvastatin acid about threefold (p &lt; 0.001), whereas the peak serum concentration was not significantly changed. The AUC(0-72) of atorvastatin lactone was increased about fourfold (p &lt; 0.001), and the peak serum concentration and half-life were increased more than twofold (p &lt; 0.01).\n','boycer','09/24/2007 09:59:20\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,240),(1404,'evidence_1539','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35','\nMirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1405,'evidence_1976','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: alpha-napthoflavone\n\nreaction: mirtazapine 8-hydroxylation (25 and 250 micM) \n\nQuote: \nIncubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-\noxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. \n\nNOTE: lowest MIR concentration tested was 25 micM\n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1406,'evidence_1961','http://www.ncbi.nlm.nih.gov/pubmed/9366029','\nRoute of administration: oral\n\nstudy duration: rac-citalopram given @ 40mg qd X 21days\n\npopulation: 10 adults (6 female and 4 male) all extensive metabolizers according to 2d6 and 2c19 specific assays (sparteine and mephenytoin respectively)\n\nages: 23-32\n\n\nDescription: \nC_max for R-didemethylcitalopram : 13.4nMol/L\n\n13.4nMol/L X 1M/10^9nMol X 324.39g/1M = 0.000003971g/L','boycer','06/12/2009 20:17:25\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.000003971,NULL,NULL,NULL,'',0.04,NULL),(1407,'evidence_1827','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 14:15:06\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1408,'evidence_1653','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.15,NULL,NULL,NULL,'',NULL,NULL),(1409,'evidence_1436','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','7.2 Effects of Ranolazine on Other Drugs\n\nIn vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. ','boycer','09/25/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1410,'evidence_1930','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','7.2 Effects of Ranolazine on Other Drugs\n\nIn vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. ','boycer','09/25/2009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1411,'evidence_1389','http://www.ncbi.nlm.nih.gov/pubmed/7995001','\nRoute of administration: oral\n\nstudy duration: four days pre-treatment with itraconazole (200mg 1x/day) and a single .25mg dose of oral triazolam on day 4\n\npopulation: 9 :  male: 3 female: 6\n\nages: 20-26\n\nAUC_i/AUC (0 to infinity): 160/5.9 = 27','boycer','10/29/2007 12:44:32\n','EV_PK_DDI_RCT','PKStudy',27,0.00025,0.2,9,'',NULL,NULL),(1412,'evidence_1002','http://www.ncbi.nlm.nih.gov/pubmed/8841155','\nRoute of administration: oral\n\nstudy duration: 5-phase randomized cross-over study with participants receiving a single oral dose of .25mg triazolam either simultaneously or 3,12, or 24 hours before triazolam\n\npopulation: 10\nmale: 6\nfemale: 4\n\nages: 19-27\n\nAUC_i/AUC 0 to infinity (itra simultaneous w/ TRZ): 38.2/12.3 = 3.1\n\nAUC_i/AUC 0 to infinity (itra 3 hours prior to TRZ): 55.1/12.3 = 4.48\n\nAUC_i/AUC 0 to infinity (itra 12 hours prior to TRZ): 53.2/12.3 = 4.33\n\nAUC_i/AUC 0 to infinity (itra 24 hours prior to TRZ): 43.9/12.3 = 3.57\n\nAverage: 3.87\n\n','boycer','10/29/2007 12:59:15\n','EV_PK_DDI_RCT','PKStudy',3.87,0.00025,0.2,10,'',NULL,NULL),(1413,'evidence_1196','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: furafylline\n\nreaction: perphenazine N-dealkylation\n\nQuote: \nTo identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.\n\n','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1414,'evidence_1425','http://www.ncbi.nlm.nih.gov/pubmed/11136295','Enzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1415,'evidence_1649','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','06/30/2009 13:42:29\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1416,'evidence_1773','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/AB73778B-6794-441C-B127-610A6D0733EA','Concurrent use of mexiletine and theophylline may lead to increased plasma theophylline levels. One controlled study in eight normal subjects showed a 72% mean increase (range 35 to 136%) in plasma theophylline levels. This increase was observed at the first test point which was the second day after starting mexiletine. Theophylline plasma levels returned to pre-mexiletine values within 48 hours after discontinuing mexiletine. If mexiletine and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexiletine dose is changed. An appropriate adjustment in theophylline dose should be considered.','boycer','01/11/2010 17:09:51\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,241),(1417,'evidence_1357','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/AB73778B-6794-441C-B127-610A6D0733EA','Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of mexiletine.','boycer','01/11/2010 17:15:31\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,242),(1418,'evidence_1447','http://www.ncbi.nlm.nih.gov/pubmed/14709940','\nroute of administration: oral\n\nstudy duration: Sertraline was dosed at 100 mg/day for 8 days. On the morning of the ninth day participants received a final dose of antidepressant followed by a 3-mCi dose of radio-labled erythromycin by IV then, 20 minutes later, a 2 mg dose of alprazolam orally. (See NOTE below)\n\npopulation: 16 healthy males, non-smokers, \n\ntested for known CYP450 polymorphisms? Yes; &quot;subjects were phenotyped with dextromethorphan prior to entering the study to exclude CYP2D6-poor metabolizers&quot;\n\nages:18 - 25\n\ndescription:\nCompared to baseline, venlafaxine, sertraline, and fluoxetine caused no apparent inhibition or induction of erythromycin metabolism ( P &gt; 0.05). For nefazodone, a statistically significant inhibition was observed ( P &lt; 0.0005). Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration  versus  time curve (AUC; P &lt; 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P &lt; 0.05) compared with values at  aseline. No significant differences were found in the pharmacokinetics of ALPZ with any of the other antidepressants tested. \n\n\nNOTE: Although erythromycin is known to inhibit CYP3A4 activity, it isi the opinion of DIKB reviewer\'s, the dose of erythromycin given in this study was too low to have any relevant inhibitory effect on CYP3A4','boycer','09/22/2009 19:32:54\n','EV_PK_DDI_NR','PKStudy',1,0.002,0.1,16,'',NULL,NULL),(1419,'evidence_1803','http://www.ncbi.nlm.nih.gov/pubmed/9029748','\nNOTE: The AUC_i/AUC value is calculated from Table 1 using equation 1.\n\nroute of administration: oral\n\nstudy duration: 7 days\n\npopulation: 12 nonsmoking volunteers (all male)\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 22-30\n\ndescription:\nSUBJECTS: The study was carried out as an open, randomized, crossover study of 12 volunteers, all men with a median age of 23 years (range, 22-30 years). All were nonsmokers and had no known heart, liver, or kidney diseases according to clinical investigation, clinical chemical/hematological screening, and ECG test. They were not consuming alcohol or drugs on a regular basis at the time of the study. The volunteers consented to participate in the study on the basis of written and verbal information, and the study was approved by the regional ethics committee of the counties of Vejle and Funen and by the Danish National Board of Health.\n\nMETHODS: The volunteers were randomized into three groups. All three groups went through three testing periods, which were separated by 2 weeks of washout. In all three periods, the volunteers abstained from ingesting methylxanthine-containing beverages, foods, and medication for 3 days before study and until the last blood sample was drawn. In period A, a blood sample was drawn before intake of a tablet of 300 mg theophylline ethylenediamine (Teofylamin; Nycomed DAK, Copenhagen, Denmark), containing 257 mg theophylline. In period B, the volunteers received a tablet of 50 mg fluvoxamine (Solvay Duphar BV, Weesp, the Netherlands) for 1 day, and during the following 6 days they received 100 mg fluvoxamine each day. On day 4, a blood sample was drawn before the intake of 300 mg theophylline ethylenediamine; thereafter, blood samples were drawn at 1, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, and 96 h.\n\nRESULTS: The total theophylline clearance was calculated as EQUATION 1 [Cl_13DMX = Dose / AUC_13DMX(total)] where Cl is clearance and AUC_13DMX(total) is the area under the plasma concentration time curve calculated by the trapezoidal rule with extrapolation from the last measurable concentration to infinity. Complete absorption of theophylline from the intestine was assumed.\n\nSee Table 1 and equation 1.','boycer','09/22/2010 11:47:06\n','EV_PK_DDI_RCT','PKStudy',3.33,0.3,0.1,12,'',NULL,NULL),(1420,'evidence_1554','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a4d555fa-787c-40fb-bb7d-b0d4f7318fd0','Drug Interactions:\n\nConcomitant administration of SPORANOX (itraconazole) Capsules, Injection, or Oral Solution and certain drugs metabolized by the cytochrome P450 3A4 isoenzyme system (CYP3A4) may result in increased plasma concentrations of those drugs, leading to potentially serious and/or life-threatening adverse events. ','boycer','01/11/2010 17:03:24\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1421,'evidence_1054','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8','Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1422,'evidence_1720','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\n\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nreaction: R- and S-desmethylcitalopram (aka demethylcitalopram) --&gt; R- and S- didemethylcitalopram\n\nQuote:\n\nQuinidine (5micM) reduced formation of DDCT from R- or S-DCT to only 70 to 80% of control (Fig. 7), whereas the same concentration of quinidine reduced formation of R- and S-DCT to less than 10% of control values in heterologously expressed CYP2D6.\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1423,'evidence_1572','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab','Absorption and Distribution\n\nFollowing a single oral dose (40 mg tablet) of citalopram, peak blood levels occur at about 4 hours. The absolute bioavailability of citalopram was about 80% relative to an intravenous dose, and absorption is not affected by food. The volume of distribution of citalopram is about 12 L/kg and the binding of citalopram (CT), demethylcitalopram (DCT), and didemethylcitalopram (DDCT) to human plasma proteins is about 80%.','boycer','05/15/2009 10:39:59\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.8,NULL,NULL,NULL,'',NULL,NULL),(1424,'evidence_1839','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA recommends sildenafil as a preferred CYP3A4/3A5 substrate for in vivo studies in it most recent guidance document (See Table 2, p. 19) ','boycer','01/11/2010 16:56:42\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1425,'evidence_1222','http://www.ncbi.nlm.nih.gov/pubmed/9241008','Route of administration: oral (inferred because IV formulations do not appear to be available for paroxetine and desipramine)\n\nstudy duration: see below\n\npopulation: 17 volunteers (design called for 24 but several dropped out or were excluded due to non-compliance); all participants were extensive metabolizers of dextromethorphan (o-demethylation)\n\nages: mean(std dev): 30.4 (+/-5.2)\n\nAUC_i/AUC (24 hour): 3305 / 634 = 5.2\n\nNOTE: AUC increase mentioned is for the phase of the study using 20mg of paroxetine.\n\nDescription: \nThe pharmacokinetics of desipramine when coadministered with the selective serotonin reuptake inhibitors (SSRIs) paroxetine and sertraline were studied in 24 healthy male volunteers (CYP2D6 extensive metabolizers). Desipramine (50 mg/day) was administered for 23 days in each phase of the crossover study with a 7-day drug-free period between phases. In addition, subjects were randomly assigned to receive concomitant paroxetine (20 mg/day on days 8 through 17 followed by 30 mg/day on days 18 through 20) or sertraline (50 mg/day on days 8 through 17 and 100 mg/day on days 18 through 20). SSRI treatments were switched between phases. After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p &lt; 0.001). An approximately 10-fold increase in the Cmax and AUC(24) of paroxetine and an approximately 2-fold increase in these parameters for sertraline occurred simultaneously with the desipramine concentration changes. Thus, when coadministered with 50 mg/day desipramine, sertraline had significantly less pharmacokinetic interaction than paroxetine with desipramine at the recommended starting dosages of 50 mg/day and 20 mg/day, respectively.','boycer','05/05/2009 16:05:09\n','EV_PK_DDI_NR','PKStudy',5.2,0.05,0.02,17,'',NULL,NULL),(1426,'evidence_1145','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226','Drug interactions:\n\nIn vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1427,'evidence_1052','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','Statement in the \'Drug Interactions\' section:\n\n&quot;\nErythromycin:\n\nErythromycin (500 mg, single dose) did not affect steady-state plasma levels of fluvastatin (40 mg daily).\n&quot;\n','boycer','10/22/2007 12:17:17\n','Non_traceable_Drug_Label_Statement','PKStudy',0,0.04,0.5,NULL,'',NULL,NULL),(1428,'evidence_1050','http://www.ncbi.nlm.nih.gov/pubmed/16765147','\nRoute of administration: oral\n\npolymorphic enzyme: yes\n\nstudy duration: single dose with 72 hours of plasma level monitoring\n\npopulation: study does not state gender of participants\n\nages: 22-30\n\ndescription: \nOur objective was to evaluate the effect of the CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. METHODS: Nineteen healthy male volunteers were divided into 3 groups on the basis of the genetic polymorphism of CYP3A5. The groups comprised subjects with CYP3A5*1/*1 (n=5), CYP3A5*1/*3 (n=7), or CYP3A5*3/*3 (n=7). After a single oral 1-mg dose of alprazolam, plasma concentrations of alprazolam were measured up to 72 hours, together with assessment of psychomotor function by use of the Digit Symbol Substitution Test, according to CYP3A5 genotype. RESULTS: The area under the plasma concentration-time curve for alprazolam was significantly greater in subjects with CYP3A5*3/*3 (830.5+/-160.4 ng . h/mL [mean+/-SD]) than in those with CYP3A5*1/*1 (599.9+/-141.0 ng . h/mL) (P=.030). The oral clearance of alprazolam was also significantly different between the CYP3A5*1/*1 group (3.5+/-0.8 L/h) and CYP3A5*3/*3 group (2.5+/-0.5 L/h) (P=.036). Although a trend was noted for the area under the Digit Symbol Substitution Test score change-time curve (area under the effect curve) to be greater in subjects with CYP3A5*3/*3 (177.2+/-84.6) than in those with CYP3A5*1/*1 (107.5+/-44), the difference did not reach statistical significance (P=.148). CONCLUSIONS: The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam.','boycer','01132010','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1429,'evidence_1621','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of both 1\'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a5 Supersome system','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1430,'evidence_1095','http://www.ncbi.nlm.nih.gov/pubmed/11872324','Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19\nNADPH added:yes\n\ninhibitor used: no\n\nWhen NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4).','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1431,'evidence_1537','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336','\nMetabolism\n\nTamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1432,'evidence_1440','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote: \n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.\n\n\n','boycer','12172009','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1433,'evidence_1866','http://www.ncbi.nlm.nih.gov/pubmed/11270914','NOTE: The AUC_i/AUC given is for EMs and calculated from Table 2 using the formula AUC = dose/Cl\n\nroute of administration: oral\n\nstudy duration: 2 days\n\npopulation: 15 healthy men, all nonsmokers\n\ntested for known CYP450 polymorphisms?\nYES - CYP2D6 phenotyping -- 9 EMs (7 CYP2D6*1/*1, 2 CYP2D6*1/*4), 6 PMs (1 CYP2D6*3/*4, 4 CYP2D6*4/*4, 1 CYP2D6*7/*7)\n\nages: average age 27 +/- 5\n\ndescription:\nSUBJECTS: Fifteen healthy men (nine EMs and six PMs) participated in the study. Their mean (+/-SD) age was 27 +/- 4 years and 27 +/- 5 years, and their mean body weight was 71 +/- 8 kg and 84 +/- 11 kg for EMs and PMs, respectively (Table 1). All volunteers were nonsmokers and healthy as determined by routine physical examination, electrocardiogram, and laboratory tests.\n\nMETHODS: Subjects received oral doses (N = 5) of 18.75 mg venlafaxine hydrochloride (Effexor, Wyeth-Ayerst Canada, Inc., Montreal, Canada) every 12 hours for 48 hours on two occasions: once alone and once during the concomitant administration of 50 mg of diphenhydramine hydrochloride (Benadryl, Warner Wellcome, Scarborough, Canada) every 12 hours. Diphenhydramine was also administered alone and during concomitant administration of venlafaxine. The three study arms were performed 1 week apart. Venlafaxine tablets were prepared by the Department of Pharmacy, Laval Hospital, by cutting 37.5-mg venlafaxine hydrochloride tablets in half. No other drugs, caffeine-containing foods or beverages, chocolate, or alcohol were allowed 48 hours before and during the study.\n\nRESULTS: When venlafaxine was administered alone, mean\nAUC012 values for all subjects studied were 3.1 +/- 2.2 umol.hr-1.L-1 in PMs and 0.8 +/- 0.6 umol.hr-1.L-1 in EMs, respectively ( p &amp;lt; 0.05). The right panels of Figure 2 illustrate plasma concentrations of venlafaxine measured after the oral administration of venlafaxine during concomitant administration of diphenhydramine in the same PM and EM. Coadministration of diphenhydramine did not alter the plasma concentrations of venlafaxine in the PM. In contrast, diphenhydramine increased the AUC012 of venlafaxine more than 4-fold in the EM, leading to values toward those measured in the PM subject. On average, diphenhydramine increased venlafaxine AUC012 by more than 2-fold in EMs ( p &amp;lt; 0.05).\n\nFigure 3 and Table 2 report the pharmacokinetic parameters observed in EMs and PMs on venlafaxine alone and during concomitant administration of diphenhydramine. The mean oral clearance of venlafaxine was more than 4-fold greater in EMs compared with PMs when venlafaxine was administered alone. In EMs, coadministration of diphenhydramine decreased oral clearance of venlafaxine by more than 2-fold ( p &amp;lt; 0.05), leading to values close to those measured in PMs. In contrast, coadministration of diphenhydramine did not affect the oral clearance of venlafaxine in PMs.','boycer','02/16/2012 21:55:54\n','EV_PK_DDI_NR','PKStudy',2.42,0.0375,0.1,NULL,'',NULL,NULL),(1434,'evidence_1597','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338','In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1435,'evidence_1340','http://www.ncbi.nlm.nih.gov/pubmed/12102670','\nEnzyme system: human liver microsomes\n\nNADPH added: assumed based on the date of the article and authors\n\nsubstrate used: R-warfarin\n\nreaction: R-warfarin 6-hydroxylation\n\nQuote: \nNo inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4.\n\n\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1436,'evidence_1874','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','12172009','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1437,'evidence_1621','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81','\nMetabolism and Excretion\n\nCinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1438,'evidence_1206','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78','Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.','boycer','06/26/2007 06:56:58\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1439,'evidence_1093','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of 1\'-OH-alprazolam in a recombinant cyp3a4 Supersome system; Km = 55\n\n','boycer','11/17/2007 12:26:28\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1440,'evidence_1113','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2','\n&quot;\nLovastatin undergoes extensive first-pass extraction in the liver, its primary site of action, with subsequent excretion of drug equivalents in the bile. As a consequence of extensive hepatic extraction of lovastatin, the availability of drug to the general circulation is low and variable. In a single dose study in four hypercholesterolemic patients, it was estimated that less than 5% of an oral dose of lovastatin reaches the general circulation as active inhibitors. Following administration of lovastatin tablets the coefficient of variation, based on between-subject variability, was approximately 40% for the area under the curve (AUC) of total inhibitory activity in the general circulation.&quot;\n\nNOTE: the label only states that first pass is extensive and that bioavailability is &lt;5% so we enter .9 because this is mapped to qualitatively \'high\' level.\n','boycer','09/28/2007 13:50:27\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.9,NULL,NULL,NULL,'',NULL,NULL),(1441,'evidence_1880','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: perphenazine N-dealkylation\n\nQuote: \nTo identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.\n\n','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1442,'evidence_1306','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1443,'evidence_1573','http://www.ncbi.nlm.nih.gov/pubmed/9333110','\nroute of administration: oral\n\nstudy duration: single dose of perphenazine (0.11 mg/kg orally) or placebo following a randomized double-blind design. Perphenazine plasma concentrations and effects were assessed for a period of 8 hours. Subsequently, subjects were treated with a standard therapeutic dose of paroxetine (20 mg/day orally) for 10 days and test sessions with perphenazine and placebo were repeated.\n\npopulation: 8 adults (5 female, 3 male); all CYP2D6 EMs as determined by the dextromethorphan metabolite ration\n\nages: 21 - 49\n\nDescription: \nParoxetine treatment resulted in a twofold to 21-fold decrease in CYP2D6 activity (p &lt; 0.001). After pretreatment with paroxetine, perphenazine peak plasma concentrations increased twofold to 13-fold (p &lt; 0.01). This was associated with a significant increase in central nervous system side effects of perphenazine, including oversedation, extrapyramidal symptoms, and impairment of psychomotor performance and memory (p &lt; 0.05). \n','boycer','01132010','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1444,'evidence_1322','http://www.ncbi.nlm.nih.gov/pubmed/17429316','\n\nroute of administration: oral\n\nstudy duration: single-dose of perphenazine (0.1mg/kg)\n\npopulation: 22 healthy, non-smoking, adult males of chinese ancestry\n\ntested for known CYP450 polymorphisms? yes...&quot;DNA samples from all participants were genotyped for\nCYP2D6*10 and CYP2D6*5 using a nested and allele-\nspecific PCR-restriction fragment length polymorphism\nanalysis as described previously [34,35]. Alleles not being CYP2D6*5 or CYP2D6*10 were called CYP2D6*1. Geno-\ntyping for these three alleles has been shown in the past to be adequate for a reliable determination of CYP2D6 genotypes in Asians [8,15,34,35]. The invest igators did not have access to data on CYP2D6 genotype during ascertainment of the pharmacological phenotypes (i.e. perphenazine and prolactin concentration data); genotyping was also performed blind to the prolactin or plasma concentration data.&quot;\n\nages: 21 - 50\n\ndescription:\n&quot;In volunteers with CYP2D6*10/CYP2D6*10 genotype, the mean area under curve (AUC0-6) for perphenazine concentration was 2.9-fold higher than those who carry the CYP2D6*1 allele (P&lt;0.01).&quot;\n\n','boycer','01132010','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1445,'evidence_1906','http://www.ncbi.nlm.nih.gov/pubmed/8689810','\nroute of administration: oral\n\nstudy duration: During a 1-year period a blood sample was taken for genotyping together with blood for serum monitoring. Blood samples were taken from 151 patients\n\npopulation: patients undergoing therapeutic drug monitoring of orally-administered perphenazine. The analysis included 56 EMs and 3 PMs taking a drug that could potentially affect perphenazine metabolism, 32 EMs and 6 PMs taking a no drug known to affect perphenazine metabolism. All PMs were grouped for analysis since they did not carry a functional CYP2D6 allele.\n\ntested for known CYP450 polymorphisms? yes, genotyping found 142 CYP2D6 extensive metabolizers (EM) and 9 poor metabolizers (PM)\n\nages: 12 - 75; median of 38 years\n\ndescription:\nThe poor metabolizer group had the highest median steady-state serum concentration value (0.195 nmol/L per milligram), which was about twice the value of the extensive metablolizer group without potentially interacting medicine (0.098 nmol/L per milligram; p &lt; 0.01)\n\n','boycer','01132010','EV_CT_PK_Genotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1446,'evidence_1873','http://www.ncbi.nlm.nih.gov/pubmed/9378846','\nroute of administration: oral\n\nstudy duration: &quot;On the morning of day I after an overnight fast, all of the volunteers ingested a single 150-mg bupropion sustained-release tablet with a glass of water. Nineteen blood samples were collected from each volunteer, 1 immediately before and 18 during the 72 hours after administration (i.e., 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 24, 36, 48, 60, and 72 hours). On day 2, after the 24-hour postadministration assessment, all of the volunteers were released from the research unit, signifying the start of the outpatient period of the treatment phase. During this period, volunteers returned to the research unit at scheduled times for blood draws. Smokers were permitted to smoke cigarettes ad libitum during the study; in contrast, nonsmokers were required to refrain from smoking or using any tobacco products.&quot;\n\npopulation: 34 adults, 17 smokers (9 males/8 females) and 17 non-smokers (9 males/8 females)\n\ntested for known CYP450 polymorphisms? NO\n\nages: smokers - 26.7 SD:4.9; non-smokers - 25.7 SD:5.8\n\nNOTE: &quot;No clinically significant differences between smokers and nonsmokers or between male and female volunteers were observed for the pharmacokinetics of bupropion or its metabolites.&quot;\n\nC_max of HYDROXYBUPROPION based on a single-dose of 150mg EXTENDED RELEASE bupropion: 430ng/mL (the arithmetic average of C_max values for smokers and non-smokers)\n\n430ng/mL X 1g/10^9ng X 1000mL/1L = 0.00043g/L ','boycer','06/20/2009 15:45:45\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.00043,NULL,NULL,NULL,'',0.15,NULL),(1447,'evidence_1958','http://www.ncbi.nlm.nih.gov/pubmed/3932079','\nroute of administration: oral (parent drug)\n\nstudy duration: Plasma profiles were obtained: 1) after a single 100 mg oral dose of [NON-XR] bupropion hydrochloride, 2) following administration of 100 mg 8-hourly for 14 days and 3) again after a single 100 mg dose 14 days later.\n\npopulation: 8 healthy, non-smoking, male subjects\n\ntested for known CYP450 polymorphisms? NO\n\nages: 22 - 42\n\nC_max of HYDROXYBUPROPION @ 300mg/day of NON-XR bupropion for 14 days: 4.2micM/L (OCCASION 2, Table 2, 306U)\n\n4.2micM/1L X 1M/10^6micM X 256.749g/1M = 0.001g/L\n','boycer','06/22/2009 10:55:54\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.001,NULL,NULL,NULL,'',0.3,NULL),(1448,'evidence_1823','http://www.ncbi.nlm.nih.gov/pubmed/9929499','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: n/a\n\nreaction: beta-OH-lovastatin--&gt;6\'beta-Hydroxylovastatin\n\nQuote:\n\nLovastatin was metabolized by human liver microsomes to two major metabolites: 6\'beta-hydroxy [Michaelis-Menten constant (Km): 7.8 +/- 2.7 microM] and 6\'-exomethylene lovastatin (Km,10.3 +/- 2.6 microM). 6\'beta-Hydroxylovastatin formation in the liver was inhibited by the specific CYP3A inhibitors cyclosporine (Ki, 7.6 +/- 2.3 microM), ketoconazole (Ki, 0.25 +/- 0.2 microM), and troleandomycin (Ki, 26.6 +/- 18.5 microM).\n	\nNOTE: though not clearly stated in the paper, the authors mention that lovastatin itself it fully converted by esterases to its open ring acid form which we in the DIKB infer to be beta-OH-lovastatin ','boycer','09/28/2007 13:25:31\n','EV_EX_Met_Enz_ID','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1449,'evidence_1730','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1450,'evidence_1302','http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237','&quot;\nFluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.\n\n      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;','boycer','10/20/2007 09:35:47\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1451,'evidence_1671','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c','Approximately 7% of the normal population has a genetic defect that leads to reduced levels of activity of cytochrome P450IID6 isozyme. Such individuals have been referred to as &quot;poor metabolizers&quot; (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in thirteen PM subjects demonstrated altered pharmacokinetic properties compared to sixteen &quot;extensive metabolizers&quot; (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by IID6 isozyme. Caution is indicated in patients known to have reduced levels of P450IID6 activity and those receiving concomitant drugs known to inhibit this isozyme (e.g., quinidine).','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1452,'evidence_1633','http://www.ncbi.nlm.nih.gov/pubmed/8823236','\nroute of administration: oral\n\nstudy duration: single 50mg dose fluvoxamine \n\npopulation: 7 male and 7 female; 10 CYP2D6 EMs and four PMs according to debrisoquine metabolism. 5 EMs smoked during the study as did 3 PMs\n\nages: 25 - 49\n\nDescription: \nCompared with nonsmoking extensive metabolizers, nonsmoking poor metabolizers had a statistically significant (p = 0.02, Mann-Whitney U test) about twofold higher maximum plasma concentration, longer half-life, and fivefold lower oral clearance of fluvoxamine.\n','boycer','12172009','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1453,'evidence_1612','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1454,'evidence_1729','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba','12.3 Pharmacokinetics\n\nDuloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state plasma concentrations are typically achieved after 3 days of dosing. Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP1A2 and CYP2D6.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1455,'evidence_1206','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','Metabolism: Bupropion is extensively metabolized in humans. Three metabolites have been shown to be active: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, which are formed via reduction of the carbonyl group. In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05/14/2009 16:34:06\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1456,'evidence_1089','http://www.ncbi.nlm.nih.gov/pubmed/10997944','\nEnzyme system: recombinant CYP450 enzymes in baculovirus-infected insect cells\n\nNADPH added: yes\n\nreaction: bupropion --&gt; hydroxybupropion\n\nNOTE: the experiment provides no clear minimum Km CYP2B6 catalysis of the mentioned reaction\n\nQuote:\n&quot;Evaluation of BUP Hydroxylation by Individual cDNA-Expressed Human P450s. Because the biphasic kinetic data observed with low activity HLMs (HLMs 20 and 24) indicated the contribution of more than one enzyme to BUP hydroxylation at higher substrate concentrations, a panel of eight cDNA-expressed enzymes (SUPER- SOMES) was screened for BUP hydroxylase activity at 12 mM to identify enzymes requiring further investigation (Fig. 7). This sub- strate concentration was selected to ensure saturation of any high Km isozyme capable of catalyzing BUP hydroxylation. cDNA-expressed CYP2B6 demonstrated the highest rate of HBUP formation (7.0 pmol/min/pmol of P450). cDNA-expressed CYP2E1 and CYP3A4 catalyzed BUP hydroxylation at the second and third highest rates, although at 3- and 30-fold lower rates than cDNA-expressed CYP2B6 (2.4 and 0.23 pmol/min/pmol of P450, respectively). Of note, CYP2E1 was the only cDNA-expressed enzyme in which cytochrome b5 was coexpressed. Rates of BUP hydroxylation by CYP1A2, CYP2A6, CYP2C9, CYP2C19, and CYP2D6 were greater than 30-fold lower than CYP2B6 (Fig. 7). HBUP formation in control microsomes was negligible.&quot;','boycer','06/20/2009 15:25:17\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1457,'evidence_1992','http://www.ncbi.nlm.nih.gov/pubmed/11872324','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: nefazodone --&gt; OH-NEF and nefazodone --&gt; mCPP\n\nQuote: \nIncubations of human liver microsomes with NEF and\nthe CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3).\n\n\n\n','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1458,'evidence_1405','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab','\nCYP2D6 Inhibitors\n\nThe potent CYP2D6 inhibitor, paroxetine (20 mg once daily), increases ranolazine concentrations 1.2-fold. No dose adjustment of Ranexa is required in patients treated with CYP2D6 inhibitors.','boycer','09/24/2009 15:49:33\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,243),(1459,'evidence_1189','http://www.ncbi.nlm.nih.gov/pubmed/8880291','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 5 day petreatment with clarithromycin \n\npopulation: 4 male, 8 female\n\nages:24-53\n\nIn an open randomized crossover study of 3 phases 12 healthy volunteers received either clarithromycin (250 mg twice a day for 5 days), azithromycin (500 mg once a day for 3 days) or no pretreatment. On the last day of antibiotic treatment they ingested 15 mg midazolam. Plasma samples were collected for midazolam analysis up to 24 h and pharmacodynamic performance measured by a series of tests up to 12 h. Pretreatment with clarithromycin caused large and statistically significant changes in both the pharmacokinetic and pharmacodynamic parameters of midazolam compared to control. For example, the AUC was increased from 248.84-888.75 hng/ml (factor of 3.57, p < 0.0001) and the mean duration of sleep increased from 135.4 min to 281.3 min (p < 0.05).','boycer','12172009','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1460,'evidence_1076','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','12172009','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1461,'evidence_1862','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/aa44552c-3cfe-4111-8aa5-4251aeed9be9','Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.\n\nClarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1462,'evidence_1560','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','the FDA lists this as a preferred in vitro inhibitor in it most recent guidance document. See Table 2, p. 28','boycer','10/19/2007 17:24:33\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1463,'evidence_1478','http://www.ncbi.nlm.nih.gov/pubmed/9366029','\nRoute of administration: oral\n\nstudy duration: rac-citalopram given @ 40mg qd X 21days\n\npopulation: 10 adults (6 female and 4 male) all extensive metabolizers according to 2d6 and 2c19 specific assays (sparteine and mephenytoin respectively)\n\nages: 23-32\n\n\nDescription: \n\n(p 688) &quot;The total amount of administered dose recovered in urine was 36%&quot;\n\n(p 689) &quot;Non-renal clearances (87 +/- 5% and 76 +/- 4% of CL/F for (+)-(S)- and (-)-(R)-citalopram, respectively) demonstrated a significant biotransformation of both citalopram enantiomers&quot;','boycer','06/12/2009 12:53:00\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1464,'evidence_1828','http://www.ncbi.nlm.nih.gov/pubmed/15518608','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days simvastatin only, 8 days simva and clarithromycin\n\ndose: .040g simvastatin 1xday\n.5g clarithromycin 2xday\n\npopulation: 45 men and women\n\nages:18-60\n\n(mean AUC_i)/(mean AUC) = 73/6\n\ndescription: Clarithromycin significantly increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC) and simvastatin acid (12-fold)','boycer','12172009','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1465,'evidence_1985','http://www.ncbi.nlm.nih.gov/pubmed/9542477','Route of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 4 days\n\npopulation: 7 male, 3 female\n\nages:19-29\n\ndescription:\nTwo randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001).','boycer','12172009','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1466,'evidence_1968','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYPC19 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 13:55:41\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1467,'evidence_1573','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','04/29/2009 19:48:35\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1468,'evidence_1134','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','06/30/2009 13:51:06\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1469,'evidence_1659','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1d149db-ad43-4f3f-aef1-fb0395ba4191','CYP3A4 IsozymeNefazodone has been shown in vitro to be an inhibitor of CYP3A4. This is consistent with the interactions observed between nefazodone and triazolam, alprazolam, buspirone, atorvastatin, and simvastatin, drugs metabolized by this isozyme. Consequently, caution is indicated in the combined use of nefazodone with any drugs known to be metabolized by CYP3A4. In particular, the combined use of nefazodone with triazolam should be avoided for most patients, including the elderly. The combined use of nefazodone with terfenadine, astemizole, cisapride, or pimozide is contraindicated (see CONTRAINDICATIONS and WARNINGS).','boycer','01/11/2010 17:20:39\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1470,'evidence_1510','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1d149db-ad43-4f3f-aef1-fb0395ba4191','Triazolam\n\nWhen a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. Nefazodone plasma concentrations were unaffected by triazolam. Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests. If triazolam is coadministered with nefazodone, a 75% reduction in the initial triazolam dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see CONTRAINDICATIONS and PRECAUTIONS).','boycer','01/11/2010 17:23:29\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,244),(1471,'evidence_1825','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf','\nDrug-Drug Interactions:\n\nBased on in vitro data, modafinil is metabolized partially by the 3A isoform subfamily of hepatic cytochrome P450 (CYP3A4). I','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1472,'evidence_1437','http://www.ncbi.nlm.nih.gov/pubmed/15599502','\nNOTE: The AUC_i/AUC value is calculated from Table 1.\n\nroute of administration: oral\n\nstudy duration: 12 days\n\npopulation: 19 Chinese patients diagnosed with schizophrenia or schizophreniform disorder (9 male, 10 female)\n\ntested for known CYP450 polymorphisms?\nNO\n\nages: 18-45\n\ndescription:\nSUBJECTS: Only the patients who were first-episode, had not obtained significant therapeutic effects or could not tolerate the side effects using clozapine, risperidone or any other antipsychotic drugs were enrolled in the study. In the study, 21 Chinese in-patients were involved; 2 subjects discontinued the study due to side effects of erythromycin on the digestive tract. Of the subjects who completed the study, 19 (10 females, 9 males; age 1845 years, weight 4160 kg) were diagnosed with schizophrenia or schizophreniform disorder (criteria of CCMD-III). They refrained from cigarettes and alcohol.\n\nMETHODS: During the first period (days 18), multiple and rising doses of quetiapine were given to the subjects twice daily (b.i.d). The dosage started at 25 mg b.i.d, reached 200 mg b.i.d by day 4 and remained at 200 mg b.i.d on days 57. Only a morning dose of quetiapine (200 mg) was given on days 8. During the second period (days 912), fixed doses of quetiapine (200 mg, b.i.d) and erythromycin (500 mg, three times daily) were co-administered to the subjects. A final combination dose of quetiapine (200 mg) and erythromycin (500 mg) was given in the morning of days 12.\n\nRESULTS: For quetiapine, co-administration of quetiapine and erythromycin led to 68, 129 and 92% increases in mean C_max (P=0.001), AUC_0inf (P=0.000) and t_1/2 (P=0.000), respectively,','boycer','09/16/2010 14:49:44\n','EV_PK_DDI_NR','PKStudy',2.29,0.4,1.5,19,'',NULL,NULL),(1473,'evidence_1901','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a','In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1474,'evidence_1038','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:38:08\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1475,'evidence_1167','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','\nElimination\n\nAfter oral administration, eszopiclone is eliminated with a mean t1/2 of approximately 6 hours. Up to 75% of an oral dose of racemic zopiclone is excreted in the urine, primarily as metabolites. A similar excretion profile would be expected for eszopiclone, the S-isomer of racemic zopiclone. Less than 10% of the orally administered eszopiclone dose is excreted in the urine as parent drug.','boycer','11/09/2009 12:18:41\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1476,'evidence_1832','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: perphenazine N-dealkylation\n\nQuote: \nTo identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.\n\n','boycer','06/15/2009 14:25:13\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,245),(1477,'evidence_1446','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant CYP enzymes in baculovirus infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:27:12\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1478,'evidence_1893','http://www.ncbi.nlm.nih.gov/pubmed/11136295','\nEnzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells\n\nNADPH added: yes \n\nQuote:\ncDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.','boycer','06/15/2009 16:34:48\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1479,'evidence_1876','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/3829d74e-b3ab-46df-a08b-f0327b63304e','\nMetabolism Following oral dosing, theophylline does not undergo any measurable first-pass elimination. In adults and children beyond one year of age, approximately 90%of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6%of a theophylline dose is N-methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.\n\nCaffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity. 3-methylxanthine has approximately one tenth the pharmacologic activity of theophylline and serum concentrations in adults with normal renal function are <1 mcg/mL. In patients with end-stage renal disease, 3-methylxanthine may accumulate to concentrations that approximate the unmetabolized theophylline concentration. Caffeine concentrations are usually undetectable in adults regardless of renal function. In neonates, caffeine may accumulate to concentrations that approximate the unmetabolized theophylline concentration and thus, exert a pharmacologic effect.','boycer','009242009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1480,'evidence_1300','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/1ec7ef4d-8ea8-4189-b1ac-b8ac57d7ebe2','\n&quot;Biotransformation pathways elucidated for pravastatin include: (a) isomerization to 6-epi pravastatin and the 3alpha-hydroxyisomer of pravastatin (SQ 31,906), (b) enzymatic ring hydroxylation to SQ 31,945, (c) omega-1 oxidation of the ester side chain, (d) beta-oxidation of the carboxy side chain, (e) ring oxidation followed by aromatization, (f) oxidation of a hydroxyl group to a keto group, and (g) conjugation. The major degradation product is the 3alpha-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound.&quot;','boycer','10/29/2007 11:50:24\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1481,'evidence_1471','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a &quot;moderate&quot; CYP2D6 inhibitor in vivo in it most recent guidance document. See Table 6, p23','boycer','06/30/2009 14:16:34\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1482,'evidence_1372','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7c6c1494-fb92-4442-bcff-764b77397495','Drug Interactions\n\nIn vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of LAMISIL should be done with careful monitoring and may require a reduction in dose of the 2D6-metabolized drug. In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in Cmax and a 5-fold increase in AUC. In this study, these effects were shown to persist at the last observation at 4 weeks after discontinuation of LAMISIL. ','boycer','01/11/2010 17:40:55\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1483,'evidence_1462','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84','\n12.5 Drug-Drug Interactions\n...\nPREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. ','boycer','09/24/2009 10:14:47\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1484,'evidence_1912','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac','Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1485,'evidence_1955','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.01,NULL,NULL,NULL,'',NULL,NULL),(1486,'evidence_1603','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1487,'evidence_1907','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7','In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.','boycer','01/11/2010 19:12:06\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,246),(1488,'evidence_1433','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1de3ed9-1cb8-e419-3f25-5b0aeed5779a','Metabolism\n\nSertraline undergoes extensive first-pass metabolism. The principal initial pathway of metabolism for sertraline is N-demethylation. N-desmethylsertraline has a plasma terminal elimination half-life of 62 to 104 hours. Both in vitro biochemical and in vivo pharmacological testing have shown N-desmethylsertraline to be substantially less active than sertraline. Both sertraline and N-desmethylsertraline undergo oxidative deamination and subsequent reduction, hydroxylation, and glucuronide conjugation. In a study of radiolabeled sertraline involving two healthy male subjects, sertraline accounted for less than 5% of the plasma radioactivity. About 40% to 45% of the administered radioactivity was recovered in urine in 9 days. Unchanged sertraline was not detectable in the urine. For the same period, about 40% to 45% of the administered radioactivity was accounted for in feces, including 12% to 14% unchanged sertraline. ','boycer','05/14/2009 14:25:16\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1489,'evidence_1651','http://www.ncbi.nlm.nih.gov/pubmed/18832427','\nRoute of administration: oral\n\nstudy duration: venlafaxine for 4 days followed  by 14 days of venlafaxine and aripiprazole\n\npopulation: 27 (55% male) \n\nmean age (SD):35 (7)\n\nNOTE: aripiprazole dose was titrated over the 14 day period from 10mg/day to 20mg/day\n\nAUC_i/AUC: 657/777 = 1.183 (geometric means)\n\nDescription:\nHealthy subjects received venlafaxine 75 mg/day (Study 1; N = 38) or escitalopram 10 mg/day (Study 2; N = 25) with the addition of aripiprazole 10-20 mg/day (10 mg/day fixed dose in Study 2) for 14 days. ... In healthy subjects, point estimates [90% CI] for the ratios of geometric means of Cmax (venlafaxine 1.148 [1.083-1.217]; escitalopram 1.04 [0.99-1.09]) and AUCTAU (venlafaxine 1.183 [1.130-1.238]; escitalopram 1.07 [1.04-1.11]) indicated no meaningful increase in ADT exposure in the presence of aripiprazole. ','boycer','05/06/2009 14:34:29\n','EV_PK_DDI_NR','PKStudy',1.183,0.075,0.02,27,'',NULL,NULL),(1490,'evidence_1767','http://www.ncbi.nlm.nih.gov/pubmed/12124305','\nEnzyme system: recombinant human enzymes in Supersomes\n\nNADPH added: yes\n\ninhibitor used: no\n\nThis study showed the formation of both 1\'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a4 Supersome system','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1491,'evidence_1096','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78','\n&quot;Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.&quot;','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1492,'evidence_1583','http://www.ncbi.nlm.nih.gov/pubmed/10548453','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (p. 394 `chemical inhibition`\n\ninhibitor used: \n\nreaction: alprazolam --&gt; 4-OH-alprazolam\n          alprazolam --&gt; 1\'-OH-alprazolam\n\nQuote: \n\n&quot;Co-incubation of human liver microsomes with the prototypic 3A4 inhibitor, troleandomycin, ( &gt; 50microM) resulted in no detectable formation of 1\'-OH-alprazolam and 4-OH-alprazolam&quot;','boycer','01132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1493,'evidence_1877','http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9550','\nPotential for Drug Interactions\n\n It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. Thus there may be a potential for drug-drug interaction with these drugs.','boycer','09/24/2009 13:00:08\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1494,'evidence_1723','http://www.ncbi.nlm.nih.gov/pubmed/8198928','\noute of administration: oral\n\nstudy duration: one day pretreatment w/ diltiazem 60mg 3x PO; on day two subjects continued diltiazem and received  1 dose of midazolam @ 15mg PO\n\npopulation: 9 female\n\nages: 19-31 \n\nAUC_i/AUC 0 to infinity: 45 / 12 = 3.75','boycer','07/02/2007 17:46:41\n','EV_PK_DDI_RCT','PKStudy',3.75,0.00015,0.06,9,'',NULL,NULL),(1495,'evidence_1773','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a','in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1496,'evidence_1792','http://www.ncbi.nlm.nih.gov/pubmed/9626922','\n\nroute of administration: oral\n\nstudy duration: 4 days\n\npopulation: 10 healthy volunteers; 4 men, 6 women\n\nages: 20-22\n\ndescription:\nThe mean AUC(0-inf) of zolpidem was 34% larger\n(P = 0.09) during the itraconazole phase than during\nthe placebo phase (Fig. 1, Table 1). The 95% CI for the\nmean ratio of zolpidem AUC(0-inf) after itraconazole and\nplacebo was from 103% to 162%, indicating a statisti-\ncally signifcant effect of itraconazole.\n\n\n','boycer','07/29/2010 11:47:52\n','EV_PK_DDI_RCT','PKStudy',1.34,0.01,0.2,10,'',NULL,NULL),(1497,'evidence_1138','http://www.ncbi.nlm.nih.gov/pubmed/9871431','NOTE: The AUC_i/AUC value is calculated from Table II and is not statistically significant\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 2 days\r\n\r\npopulation: 11 healthy volunteers, all nonsmokers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 20-40\r\n\r\ndescription:\r\nSUBJECTS: Twelve healthy volunteers (8 men and 4 women), aged 20 to 40 years, participated after giving written informed consent. All were active ambulatory nonsmoking adults, with no evidence of medical disease and taking no other medications. Female subjects were not taking oral contraceptives and did not have contraceptive implants. One of the subjects did not ingest zolpidem as instructed during treatment; accordingly mean values for itraconazole treatment, n=11.\r\n\r\nMETHODS: At 8 AM on study day 1, subjects entered the outpatient Clinical Psychopharmacology Research Unit where they received the initial dose of azole (or placebo) and remained under observation for 30 minutes. Subjects took a second dose of azole (or placebo) at home at 4 PM on day 1. On the morning of day 2, after ingesting a standardized light breakfast with no caffeine-containing food or beverages and no grapefruit juice, they returned to the Research Unit at approximately 7:30 AM. They fasted until 12 noon, after which they resumed a normal diet (without grapefruit juice or caffeine-containing food or beverages). The third dose of azole (or placebo) was given at 8 AM, and the single dose of zolpidem or placebo was given at 9 AM. A final azole (or placebo) dose was given at 5 PM.\r\n\r\nRESULTS: Coadministration of zolpidem with itraconazole reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.\r\n\r\nSee Table II.','boycer','09/22/2010 13:58:46\r\n','EV_PK_DDI_RCT','PKStudy',1.32,0.005,0.2,11,'',NULL,NULL),(1498,'evidence_1947','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: dextromethorphan\n\nreaction: dextromethorphan O-demethylation\n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% at concentrations of 100micM (see Table 3).\n\n\n','boycer','02132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1499,'evidence_1525','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6','\nAbsorption\n\nThe absorption of pantoprazole is rapid, with a Cmax of 2.5 mcg/mL that occurs approximately 2.5 hours after administration of a single or multiple oral 40-mg doses of pantoprazole sodium delayed-release tablets. Pantoprazole is well absorbed; it undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%. Pantoprazole absorption is not affected by concomitant administration of antacids. \n\n\n2.5mcg/mL X 1g/10^6mcg X 1000mL/1L = 0.00025g/L','boycer','09/24/2009 13:13:36\n','Non_traceable_Drug_Label_Statement','Maximum_concentration_study',0.00025,NULL,NULL,NULL,'',0.04,NULL),(1500,'evidence_1020','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/69ca7cae-fdf3-413a-900b-95cf6e9e7b63','Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.','boycer','05/29/2007 11:32:02\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.4,NULL,NULL,NULL,'',NULL,NULL),(1501,'evidence_1169','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/cce1108d-5b73-429d-a091-8b990dfd576b','The absolute bioavailability of diltiazem from a single dose of Dilacor XR (compared to intravenous administration) is 41% ( 14). The value was shown to be similar to the 40% systemic availability reported following administration of an immediate release diltiazem HCl formulation.\n\n','boycer','05/29/2007 11:34:00\n','Non_traceable_Drug_Label_Statement','EvidenceContinousVal',0.41,NULL,NULL,NULL,'',NULL,NULL),(1502,'evidence_1120','http://www.ncbi.nlm.nih.gov/pubmed/6861848','\nRoute of administration: oral\n\nstudy duration: single dose of diltiazem\n\npopulation: 12 subjects, unknown gender distribution\n\nages:20-26 \n\nThere was wide variation amongst subjects; Bioavailability ranged from 24 - 74% with a mean of 42%\n\n','boycer','07/02/2007 17:07:37\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.42,NULL,NULL,NULL,'',NULL,NULL),(1503,'evidence_1151','http://www.ncbi.nlm.nih.gov/pubmed/6684932','\nRoute of administration: oral\n\nstudy duration: single dose of diltiazem, 20mg i.v and 120mg PO\n\npopulation: 6 male \n\nages:22-31\n\nBioavailability ranged from 34 to 59% for the 6 subjects with an average of 44%','boycer','07/02/2007 17:16:44\n','EV_CT_Pharmacokinetic','EvidenceContinousVal',0.44,NULL,NULL,NULL,'',NULL,NULL),(1504,'evidence_1318','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA recommends this as a CYPC9 substrate for in vivo studies in it most recent guidance document. See Table 2, p. 19','boycer','09/24/2009 11:52:51\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1505,'evidence_1448','http://www.ncbi.nlm.nih.gov/pubmed/11075313','oute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days\n\npopulation: 12 male\n\nages:21-41\n\ndescription:\nPotential for inhibition of CYP3A activity by simvastatin, an HMG-CoA reductase inhibitor, was evaluated in 12 healthy male subjects who received placebo or 80 mg of simvastatin, the maximal recommended dose, once daily for 7 consecutive days. On day 7, an intravenous injection of 3 microCi [14C N-methyl]erythromycin for the erythromycin breath test (EBT) was coadministered with a 2 mg oral solution of midazolam. The values for percent 14C exhaled during the first hour (for EBT) and the pharmacokinetic parameters of midazolam (AUC, Cmax, t1/2) were not affected following multiple once-daily oral doses of simvastatin 80 mg. The 95% confidence interval was 0.97 to 1.18 for EBT and 0.99 to 1.23 for midazolam AUC. In addition, the total urinary recoveries of midazolam and its 1\'-hydroxy metabolites (free plus conjugate) obtained from both treatments were not statistically different (p > 0.200). These data demonstrate that multiple dosing of simvastatin, at the highest recommended clinical dose, does not significantly alter the in vivo hepatic or intestinal CYP3A4/5 activity as measured by the commonly used EBT and oral midazolam probes.','boycer','05/21/2007 10:48:30\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,247),(1506,'evidence_1120','http://www.ncbi.nlm.nih.gov/pubmed/11910262','Route of administration: oral\n\nstudy duration: read description below\n\npopulation: (paroxetine group) 13 healthy volunteers (8 male and 5 female), all extensive metabolizers of dextromethorphan\n\nages: mean(std dev): 28 (unknown)\n\nDescription: \nIn an open label, parallel group study of 45 healthy volunteers, the time course of CYP2D6 inhibition of the above SSRIs was evaluated. Subjects were randomized to receive paroxetine at 20 mg/day for 10 days; sertraline at 50 mg/day for 3 days, followed by sertraline at 100 mg/day for 10 days; or fluoxetine at 20 mg/day for 28 days. CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine. Following SSRI discontinuation, calculation of a CYP2D6 inhibition half-life (t(1/2)inh) revealed the time course of fluoxetine inhibition (t(1/2)inh = 7.0 +/- 1.5 days) to be significantly longer than either paroxetine (t(1/2)inh = 2.9 +/- 1.9) or sertraline (t(1/2)inh = 3.0 +/- 3.0) (p &lt; 0.01), but the latter were not significantly different from each other (p &gt; 0.05). Time for the extrapolated DMR versus time log-linear plots to return to baseline was significantly different between fluoxetine (63.2 +/- 5.6 days) and both paroxetine (20.3 +/- 6.4 days) and sertraline (25.0 +/- 11.0 days) (p &lt; 0.01), making the rank order (from longest to shortest) of time for CYP2D6 inhibition to dissipate: fluoxetine &gt; sertraline &gt;or= paroxetine. Differences between mean baseline DMR values and measured values obtained after drug discontinuation for each drug group became nonsignificant on discontinuation day 5 for both paroxetine and sertraline and on discontinuation day 42 for fluoxetine. ','boycer','05/05/2009 17:09:29\n','EV_PK_DDI_Par_Grps','Evidence',NULL,NULL,NULL,NULL,'',NULL,248),(1507,'evidence_1005','http://www.ncbi.nlm.nih.gov/pubmed/12173784','\n\nroute of administration: oral\n\nstudy duration: paroxetine 20mg qd for eight days\n\npopulation: 32 healthy adults, all extensive CYP2D6 metabolizers based on DM:DX\n\nages: unmentioned\n\nDescription: \nThe urinary concentration ratio of dextromethorphan:dextrorphan (interpreted as an in vivo index of CYP2D6 activity) was determined for each subject before and after the 8 days of receiving SSRIs. Plasma SSRI trough concentrations were measured on days 6-9. The CYP2D6 genotype was determined in a subject with an undetectable paroxetine concentration. Inhibition of CYP2D6 correlated significantly with plasma concentrations of paroxetine and fluoxetine. In contrast, no significant correlations emerged between CYP2D6 inhibition and plasma concentrations of sertraline or fluvoxamine. The subject with an undetectable paroxetine concentration was found to carry at least three functional CYP2D6 genes.','boycer','06/16/2009 17:10:18\n','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,249),(1508,'evidence_1787','http://www.ncbi.nlm.nih.gov/pubmed/12584155','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\nQuote:\nTo determine whether preincubation affects the inhibition of human liver microsomal dextromethorphan demethylation activity by paroxetine, we used a two-step incubation scheme in which all of the enzyme assay components, minus substrate, are preincubated with paroxetine...Time-dependent inhibition was demonstrated with an apparent K(I) of 4.85 microM and an apparent k(INACT) value of 0.17 min(-1). Spectral scanning of CYP2D6 with paroxetine yielded an increase in absorbance at 456 nm suggesting paroxetine inactivation of CYP2D6 via the formation of a metabolite intermediate complex.\n...In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation-dependent increase in inhibitory potency. These data are consistent with mechanism-based inhibition of CYP2D6 by paroxetine but not by quinidine or fluoxetine.','boycer','06/16/2009 17:12:46\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,250),(1509,'evidence_1462','http://www.ncbi.nlm.nih.gov/pubmed/8513845','\nroute of administration: oral\n\nstudy duration: \n\npopulation: 17 males, 9 sparteine EMs and 8 sparteine PMs\n\nages: 20-24\n\nDescription: \nDuring paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively. The 5-fold decrease in clearance in EMs when desipramine was co-administered with paroxetine confirms that paroxetine is a potent inhibitor of CYP2D6. The lack of effect on clearance in PMs shows that paroxetine is a selective inhibitor of CYP2D6, which is absent from the livers of PMs. Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).','boycer','06/16/2009 18:00:03\n','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,251),(1510,'evidence_1389','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/89dd7e24-85fc-4152-89ea-47ec2b48a1ed','Drug-Drug Interactions\n\nIn vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions). ','boycer','01/11/2010 17:35:08\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1511,'evidence_1424','http://www.ncbi.nlm.nih.gov/pubmed/10997935','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\nsubstrate used: phenacetin\n\nreaction: phenacetin O-deethylation\n\nQuote: \nMirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).\n\n\n','boycer','02/12/2010 15:01:51\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,252),(1512,'evidence_1853','http://www.ncbi.nlm.nih.gov/pubmed/10192828','\nEnzyme system: human liver microsomes:\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: venlafaxine --&gt; N-desmethylvenlafaxine\n\nNOTE: the concentration of venlafaxine used in this experiment is very high relative to that expected in clinical use of the drug\n\nQuote: \n&quot;Formation of NDV had a mean Vmax of 2.14 nmol min mg protein, and a mean Km of 2504 M (Table 2). Incubations of 750micM VF with SFZ and QUI led to 18% and 23% reduction in NDV production respectively, while increasing concentrations of ANA led to an 11% increase in NDV formation over baseline. KET [ketoconazole] had a more profound effect on NDV formation, leading to a 65% mean reduction in production of this metabolite (Figure 5).&quot;','boycer','06/20/2009 14:13:20\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,253),(1513,'evidence_1247','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1514,'evidence_1582','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916','Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1515,'evidence_1707','http://www.ncbi.nlm.nih.gov/pubmed/9929499','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: ketoconazole\n\nreaction: beta-OH-lovastatin--&gt;6\'beta-hydroxy-lovastatin\n\nQuote:\n\nLovastatin was metabolized by human liver microsomes to two major metabolites: 6\'beta-hydroxy [Michaelis-Menten constant (Km): 7.8 +/- 2.7 microM] and 6\'-exomethylene lovastatin (Km,10.3 +/- 2.6 microM). 6\'beta-Hydroxylovastatin formation in the liver was inhibited by the specific CYP3A inhibitors cyclosporine (Ki, 7.6 +/- 2.3 microM), ketoconazole (Ki, 0.25 +/- 0.2 microM), and troleandomycin (Ki, 26.6 +/- 18.5 microM).\n\nNOTE: the authors mention that lovastatin is a lactone that is completely converted to its &quot;open acid&quot; form in vivo - we in the DIKB infer this form to be beta-OH-lovastatin','boycer','09/28/2007 13:32:46\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem','Evidence',NULL,NULL,NULL,NULL,'',NULL,254),(1516,'evidence_1422','http://www.ncbi.nlm.nih.gov/pubmed/8689812','\nRoute of administration: oral\n\nstudy duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4\n\npopulation: 12\nmale: 5\nfemale: 7 (2 on contraceptive steroids)\n\nages: 20-29\n\nAUC_i/AUC: 1212/54.8 = 22.117\n\n','boycer','10/29/2007 13:20:44\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,255),(1517,'evidence_1126','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\n7.5 Drugs metabolized by CYP2C19\n\nIn a clinical study in Japan evaluating rabeprazole in patients categorized by CYP2C19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. This could be due to higher rabeprazole plasma levels in poor metabolizers. Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.','boycer','09/24/2009 13:53:17\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1518,'evidence_1541','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19\'','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1519,'evidence_1065','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/aa44552c-3cfe-4111-8aa5-4251aeed9be9','Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.\n\nClarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1520,'evidence_1047','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: dextromethorphan-o-demethylation\n\nk_i = 1.4micM\n\n1.4micM/L x 1M/10^6micM x 407.05g/1M = 0.0005699g/L ','boycer','05/06/2009 13:54:41\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','In_vitro_inhibition_study',0.0005699,NULL,NULL,NULL,'Human_Liver_Microsomes',NULL,256),(1521,'evidence_1578','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','04/25/2009 10:23:23\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,257),(1522,'evidence_1050','http://www.ncbi.nlm.nih.gov/pubmed/9010634','\nroute of administration: oral\n\nstudy duration: single dose \n\npopulation: 6 males \n\nages: 23 - 42\n\nC_max: 10.5ng/mL\n\n10.5ng/mL x 1000mL/1L x 1g/10^9ng = 0.0000105g/L\n\n\n','boycer','06/16/2009 15:53:21\n','EV_CT_Pharmacokinetic','Maximum_concentration_study',0.0000105,NULL,NULL,NULL,'',0.0125,NULL),(1523,'evidence_1573','Effective-dose-collection-spreadsheet-FINAL-08072009.xls','GERIATRIC AND ADULT DOSE RANGE','boycer','10/08/2009','Non_Tracable_Statement','EvidenceContinousVal',0.04,NULL,NULL,NULL,'',NULL,NULL),(1524,'evidence_1615','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/0a238e82-20d5-45ec-8c13-4725d1065230','The major active metabolites of simvastatin present in human plasma are the &#946;-hydroxyacid of simvastatin and its 6&#8242;-hydroxy, 6&#8242;-hydroxymethyl, and 6&#8242;-exomethylene derivatives. ','boycer','05/29/2007 14:42:38\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1525,'evidence_1666','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1','Variability in metabolism  A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6). Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the TCAs. In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized Sfluoxetine at a slower rate and thus achieved higher concentrations of Sfluoxetine. Consequently, concentrations of Snorfluoxetine at steady state were lower. The metabolism of Rfluoxetine in these poor metabolizers appears normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4 active enantiomers was not significantly greater among poor metabolizers. Thus, the net pharmacodynamic activities were essentially the same. Alternative, nonsaturable pathways (non2D6) also contribute to the metabolism of fluoxetine. This explains how fluoxetine achieves a steadystate concentration rather than increasing without limit.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1526,'evidence_1698','http://www.ncbi.nlm.nih.gov/pubmed/8941024','\n\nroute of administration: oral\n\nstudy duration: \n\npopulation: 20 healthy, non-smoking, males\n\ntested for known CYP450 polymorphisms? Yes, using debrisoquin / 4-hydroxydebrisoquin metabolite ratio; 10 were CYP2D6 EMs and 10 PMs\n\nages: 18 - 32\n\ndescription:\n\n&quot;Poor metabolizers had significantly greater fluoxetine peak plasma concentrations (Cmax; increases 57%), area under the concentration versus time curve (AUCzero--&gt;infinity; increases 290%), and terminal elimination half-life (increases 216%) compared with extensive metabolizers. The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p &lt; 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p &lt; 0.05). Norfluoxetine Cmax and AUCzero--&gt;t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p &lt; 0.05).&quot;\n\n','boycer','12172009','EV_CT_PK_Phenotype','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1527,'evidence_1106','http://www.ncbi.nlm.nih.gov/pubmed/11038166','Enzyme system: recombinant human CYP3A5 enzymes in insect microsomes\n\nNADPH added: yes\nsubstrate used: atorvastatin acid and lactone\n\nreaction:\natorvastatin acid--&gt;ortho-hydroxy-atorvastatin\natorvastatin lactone--&gt;ortho-hydroxy-atorvastatin\n\ndescription:\nAccording to the authors, this enzyme system catalyzed the above reactions similar to that of the CYP3A4 recombinant enzyme system whose Km was 3.9micM/L for atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin and 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin\n','boycer','09/25/2007 08:49:18\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1528,'evidence_1155','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1529,'evidence_1215','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1530,'evidence_1201','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA lists this as a accepted in vivo probe substrate for CY2C8 PK clinical trials in this guidance document. See Table 2, p. 22','boycer','10/29/2007 11:08:59\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1531,'evidence_1310','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','\nThe FDA lists this as a weak inhibitor of cyp2c9 in Table 6 of its most recent guidance','boycer','06/16/2009 14:11:27\n','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1532,'evidence_1878','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f','Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1533,'evidence_1430','http://www.ncbi.nlm.nih.gov/pubmed/16003291','\nNOTE: AUC_i/AUC is AUC_0-24.\n\nroute of administration: oral\n\nstudy duration: 6 days\n\npopulation: 12 healthy volunteers (all male), all Japanese\n\ntested for known CYP450 polymorphisms? No\n\nages: 20-28\n\ndescription: Twelve healthy Japanese male volunteers were enrolled in this study. Their mean age (+/- SD) was 24.0 +/- 2.0 years (range, 20-28 years), and their mean body weight was 64.8 +/- 6.2 kg (range, 53-86 kg).\n\nMETHODS: A randomized crossover study design was conducted at intervals of 4 weeks. Two 40-mg tablets of verapamil (Vasolan; Eisai Pharmaceutical, Tokyo, Japan) 3 times daily (at 8 AM, 1 PM, and 6 PM) or matched placebo with 240 mL of tap water was given for 6 days. The volunteers took a single oral 1-mg dose of risperidone at 9 AM on day 6 with 240 mL of tap water.\n\nRESULTS: The total AUC of risperidone during verapamil treatment was higher than during placebo by 1.82-fold (95% CI, 1.24- to 2.82-fold).\n\n','boycer','09/01/2010 14:06:24\n','EV_PK_DDI_RCT','PKStudy',1.82,0.001,0.24,12,'',NULL,NULL),(1534,'evidence_1162','http://www.ncbi.nlm.nih.gov/pubmed/10460810','Enzyme system: human liver microsomes\n\nNADPH added: yes\n\nreaction: omeprazole-5-hydroxylation\n\nNo k_i observed','boycer','04/25/2009 10:13:19\n','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,258),(1535,'evidence_1381','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f','Metabolism\n\nFollowing oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1536,'evidence_1529','http://www.ncbi.nlm.nih.gov/pubmed/16390352','Enzyme system: recombinant human enzymes in human lymphoblastoid\nNADPH added: not explicitly mentioned but assumed\n\ninhibitor used: no\n\nQuetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4.','boycer','02132010','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1537,'evidence_1041','http://www.ncbi.nlm.nih.gov/pubmed/8689812','\nRoute of administration: oral\n\nstudy duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4\n\npopulation: 12\nmale: 5\nfemale: 7 (2 on contraceptive steroids)\n\nages: 20-29\n\nAUC_i/AUC: 546/15 = &gt;36.4\nNOTE: AUC of lovastatin w/ placebo could not be measured but was known to be &lt; 15ng/ml*h','boycer','12/07/2007 12:34:34\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,259),(1538,'evidence_1128','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233','In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.','boycer','05142009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1539,'evidence_1768','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: recombinant human enzymes (human lymphoblastoid)\n\nNADPH added: yes (a dehydrogenase generating system) \n\ninhibitor used: no\n\nThis study showed NO formation of didesmethylcitalopram (aka didemethylcitalopram) in a recombinant human lymphoblastoid cell system','boycer','06/12/2009 12:36:17\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1540,'evidence_1242','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645','Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. ','boycer','01/11/2010 16:37:52\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1541,'evidence_1983','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: phenacetin O-deethylation\n\nQuote:\n\nIn all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors\nof phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1542,'evidence_1352','http://www.ncbi.nlm.nih.gov/pubmed/15834460','\nRoute of administration: oral\n\nstudy duration: multiple doses of QTP with or without concomitant erythromycin\n\npopulation: 19; 10 female and 9 male\n\nages:18-55\n\nHPLC-MS detected 7-hydroxy-N-desalkyl-quetiapine, quetiapine sulfoxide, and 7-hydroxy-quetiapine','boycer','06/15/2009 15:58:31\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1543,'evidence_1317','http://www.ncbi.nlm.nih.gov/pubmed/11454728','\nEnzyme system: human liver microsomes\n\nNADPH added: yes (a dehydrogenase generating system)\n\nprobe reaction: dextromethorphan O-demethylation\n\nQuote: \n\nCYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors.\n\n','boycer','01132010','EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1544,'evidence_1253','http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf','The FDA notes that this is a weak CYP2D6 inhibitor for in vivo studies in it most recent guidance document. See Table 6, p. 23','boycer','01132010','Non_Tracable_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1545,'evidence_1660','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645','Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. ','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1546,'evidence_1614','http://www.ncbi.nlm.nih.gov/pubmed/10771452','\n\nEnzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells\n\nNADPH added: yes\n\nreaction: 1) ziprasidone --&gt; ziprasidone sulphoxide \n          2) ziprasidone --&gt; ziprasidone sulphone \n\nQuote: \n&quot;The ability of specific CYP isoforms to metabolize\nziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;\n\n','boycer','06/19/2009 12:41:48\n','EV_EX_Met_Enz_ID_Cyp450_Hum_Recom','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1547,'evidence_1513','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b','Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.','boycer','01/11/2010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1548,'evidence_1065','http://www.ncbi.nlm.nih.gov/pubmed/9929499','\nEnzyme system: human liver microsomes\n\nNADPH added: yes\n\ninhibitor used: n/a\n\nreaction: beta-OH-lovastatin--&gt;6\'-exomethylene-lovastatin\n\nQuote:\n\nLovastatin was metabolized by human liver microsomes to two major metabolites: 6\'beta-hydroxy [Michaelis-Menten constant (Km): 7.8 +/- 2.7 microM] and 6\'-exomethylene lovastatin (Km,10.3 +/- 2.6 microM). 6\'beta-Hydroxylovastatin formation in the liver was inhibited by the specific CYP3A inhibitors cyclosporine (Ki, 7.6 +/- 2.3 microM), ketoconazole (Ki, 0.25 +/- 0.2 microM), and troleandomycin (Ki, 26.6 +/- 18.5 microM).\n\nNOTE: though the authors do note clearly state it, they do mention that lovastatin is completely converted to its &quot;open acid&quot; form which we in the DIKB infer to be beta-OH-lovastatin','boycer','09/28/2007 13:28:09\n','EV_EX_Met_Enz_ID','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1549,'evidence_1396','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\n\nMetabolism: \n...\nIn vitro studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole.','boycer','01132010','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1550,'evidence_1760','http://www.ncbi.nlm.nih.gov/pubmed/8243504','\nRoute of administration: oral\n\nstudy duration: single dose with 24 hours of blood sampling\n\ndose: single dose of 90mg diltiazem\n\npopulation: 10 male, 10 female\n\nages:19-50\n\ndescription: \nPlasma concentrations and urinary excretion of DTZ and its metabolites were determined in 20 healthy volunteers (10 males and 10 females) after they had each been given a single oral 90 mg dose of DTZ. DTZ and six of its metabolites which included N-monodesmethyl DTZ (MA), deacetyl DTZ (M1), deacetyl N-monodesmethyl DTZ (M2), deacetyl O-desmethyl DTZ (M4) and deacetyl DTZ N-oxide (M1NO) and deacetyl N,O-didesmethyl DTZ (M6), were determined by a sensitive and specific HPLC assay. The major metabolites measurable in the plasma of all the volunteers were MA, M1, and M2. The terminal half-lives (t1/2) of M1 and M2 were considerably longer than those of DTZ and MA.\n\n','boycer','09/24/2007 09:35:47\n','EV_CT_Pharmacokinetic','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1551,'evidence_1136','http://www.ncbi.nlm.nih.gov/pubmed/11075313','\nRoute of administration: oral\n\npolymorphic enzyme: NO\n\nstudy duration: 7 days\n\npopulation: 12 male\n\nages:21-41\n\ndescription:\nPotential for inhibition of CYP3A activity by simvastatin, an HMG-CoA reductase inhibitor, was evaluated in 12 healthy male subjects who received placebo or 80 mg of simvastatin, the maximal recommended dose, once daily for 7 consecutive days. On day 7, an intravenous injection of 3 microCi [14C N-methyl]erythromycin for the erythromycin breath test (EBT) was coadministered with a 2 mg oral solution of midazolam. The values for percent 14C exhaled during the first hour (for EBT) and the pharmacokinetic parameters of midazolam (AUC, Cmax, t1/2) were not affected following multiple once-daily oral doses of simvastatin 80 mg. The 95% confidence interval was 0.97 to 1.18 for EBT and 0.99 to 1.23 for midazolam AUC. In addition, the total urinary recoveries of midazolam and its 1\'-hydroxy metabolites (free plus conjugate) obtained from both treatments were not statistically different (p &gt; 0.200). These data demonstrate that multiple dosing of simvastatin, at the highest recommended clinical dose, does not significantly alter the in vivo hepatic or intestinal CYP3A4/5 activity as measured by the commonly used EBT and oral midazolam probes.','boycer','11/13/2007 13:26:37\n','EV_PK_DDI_RCT','Evidence',NULL,NULL,NULL,NULL,'',NULL,260),(1552,'evidence_1869','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6','\nElimination\n\nAfter a single oral or intravenous dose of 14C-labeled pantoprazole to healthy, normal metabolizer volunteers, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion. There was no renal excretion of unchanged pantoprazole. ','boycer','09/24/2009 13:07:38\n','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1553,'evidence_1560','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\n7.6 Combined Administration with Clarithromycin\n\nCombined administration consisting of rabeprazole, amoxicillin, and clarithromycin resulted in increases in plasma concentrations of rabeprazole and 14-hydroxyclarithromycin.{See CLINICAL PHARMACOLOGY, Combined Administration with Antimicrobials (12.3)}.\n\n','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1554,'evidence_1372','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068','\nMetabolism: \n...\nIn vitro studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole.','boycer','12172009','Non_traceable_Drug_Label_Statement','Evidence',NULL,NULL,NULL,NULL,'',NULL,NULL),(1555,'evidence_1097','http://www.ncbi.nlm.nih.gov/pubmed/17244765','NOTE: The AUC_i/AUC is from Table IV. The object_dose is the average dose.\r\n\r\nroute of administration: oral (alprazolam)/transdermal patch (selegiline)\r\n\r\nstudy duration: 7 days\r\n\r\npopulation: 12 healthy male and female volunteers.\r\n\r\nages: 18-45','boycer','04/25/2012 13:09:11\n','EV_PK_DDI_RCT','PKStudy',0.86,0.006,0.0015,NULL,NULL,NULL,NULL),(1556,'evidence_1516','http://www.ncbi.nlm.nih.gov/pubmed/11372588','NOTE: AUC_i/AUC calculated from Table 1\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 4 days\r\n\r\npopulation: 12 healthy, nonsmoking volunteers (9 male, 3 female)\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 20-32','boycer','04/25/2012 13:16:17\r\n','EV_PK_DDI_RCT','PKStudy',0.87,0.01,0.2,NULL,NULL,NULL,NULL),(1557,'evidence_1524','http://www.ncbi.nlm.nih.gov/pubmed/17244765','NOTE: AUC_i/AUC is from Table IV. The object_dose listed is the average dose.\r\n\r\nroute of administration: oral (olanzapine)/transdermal patch (selegiline)\r\n\r\nstudy duration: 10 days\r\n\r\npopulation: 12 healthy male and female volunteers, 5 male and 7 female (2 white, 6 black, 3 Hispanic, 1 other race)\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 18-45','boycer','04/25/2012 13:27:05\n','EV_PK_DDI_RCT','PKStudy',0.94,0.006,0.005,NULL,NULL,NULL,NULL),(1558,'evidence_1681','http://www.ncbi.nlm.nih.gov/pubmed/18094219','NOTE: The AUC_i/AUC is the AUC_0-inf given in the Results section. The precip_dose is the initial dose given (0.01 is the daily maintenance dose).\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 10 days\r\n\r\npopulation: 30 healthy men (24 Caucasian, 2 African descent, 4 mixed race)\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 18-53','boycer','04/25/2012 13:46:16\n','EV_PK_DDI_NR','PKStudy',1.18,0.15,0.06,NULL,NULL,NULL,NULL),(1559,'evidence_1435','http://www.ncbi.nlm.nih.gov/pubmed/15961986','NOTE: The AUC_i/AUC comes from the Results section and Table I.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 4 days\r\n\r\npopulation: 12 healthy, nonsmoking male volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 22-27','boycer','04/25/2012 13:53:08\n','EV_PK_DDI_NR','PKStudy',1.85,0.15,0.5,NULL,NULL,NULL,NULL),(1560,'evidence_1310','http://www.ncbi.nlm.nih.gov/pubmed/20484617','NOTE: The AUC_i/AUC is from Table III and the Results section. All data here is for the low-dose protocol.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 30 days\r\n\r\npopulation: 19 healthy male volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 18-55','boycer','04/25/2012 14:28:23\n','EV_PK_DDI_NR','PKStudy',0.78,0.15,0.2,NULL,NULL,NULL,NULL),(1561,'evidence_1410','http://www.ncbi.nlm.nih.gov/pubmed/10890312','NOTE: The AUC_i/AUC is calculated from Table 3.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 10 days\r\n\r\npopulation: 12 healthy male volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 18-45','boycer','04/25/2012 14:40:01\n','EV_PK_DDI_RCT','PKStudy',1.02,0.03,0.6,NULL,NULL,NULL,NULL),(1562,'evidence_1259','http://www.ncbi.nlm.nih.gov/pubmed/8562300','NOTE: The AUC_i/AUC is from Table 1.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 7 days\r\n\r\npopulation: 18 healthy male volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 19-40','boycer','04/25/2012 14:52:54\n','EV_PK_DDI_RCT','PKStudy',1.07,0.4,1.2,NULL,NULL,NULL,NULL),(1563,'evidence_1729','http://www.ncbi.nlm.nih.gov/pubmed/17571477','NOTE: The AUC_i/AUC value is from Table 2. The object_dose and precip_dose are from days 13-19 of the study. All values listed here are for Group B (Effect of Desipramine on Nefazodone Pharmacokinetics).\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 19 days\r\n\r\npopulation: 9 healthy volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- All were phenotyped as EMs for CYP2D6\r\n\r\nages: 18-40 (average age was 27.0 +/- 1.5)','boycer','04/25/2012 15:10:57\n','EV_PK_DDI_Par_Grps','PKStudy',0.78,0.3,0.075,NULL,NULL,NULL,NULL),(1564,'evidence_1636','http://www.ncbi.nlm.nih.gov/pubmed/10192752','NOTE: The AUC_i/AUC value comes from Table 3.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 3 weeks\r\n\r\npopulation: 12 healthy volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- 1 Poor metabolizer of CYP2D6\r\n\r\nages: 18-41','boycer','04/25/2012 15:22:32\n','EV_PK_DDI_NR','PKStudy',1.09,0.4,1,NULL,NULL,NULL,NULL),(1565,'evidence_1841','http://www.ncbi.nlm.nih.gov/pubmed/12621382','NOTE: The AUC_i/AUC value given is the AUC_0-24 from Table II.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 20 days\r\n\r\npopulation: 9 healthy men (nearly all of Chinese or Malay descent)\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- all were genotyped as EMs of CYP2D6\r\n\r\nages: 21-27','boycer','04/26/2012 11:11:17\n','EV_PK_DDI_NR','PKStudy',1.59,0.04,0.02,NULL,NULL,NULL,NULL),(1566,'evidence_1568','http://www.ncbi.nlm.nih.gov/pubmed/15496643','NOTE: The AUC_i/AUC is from the Results section.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 35 days\r\n\r\npopulation: 54 healthy volunteers, 38 men and 16 women (49 white, 4 black, 1 Native American)\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- all EMs of CYP2D6\r\n\r\nages: 18-50','boycer','04/26/2012 11:21:21\n','EV_PK_DDI_RCT','PKStudy',0.89,0.02,0.005,NULL,NULL,NULL,NULL),(1567,'evidence_1145','http://www.ncbi.nlm.nih.gov/pubmed/11304903','NOTE: The AUC_i/AUC value given is calculated from Table I. It is for both the R-fluoxetine and S-fluoxetine enantiomers, as the value is the same for both.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 15 days\r\n\r\npopulation: 12 healthy nonsmoking volunteers, 8 female and 4 male (11 white, 1 black)\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- all genotyped as EMs of CYP2D6\r\n\r\nages: 21-50','boycer','04/26/2012 11:33:34\n','EV_PK_DDI_NR','PKStudy',1.1,0.02,0.002,NULL,NULL,NULL,NULL),(1568,'evidence_1235','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba ','NOTE: From Section 7.2\r\n\r\n\"Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.\"','boycer','04/26/2012 12:07:08\n','Drug_Label','PKStudy',1.6,0.04,0.02,NULL,NULL,NULL,NULL),(1569,'evidence_1148','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba ','When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n = 14) duloxetine AUC was increased approximately 6-fold, the Cmax was increased about 2.5-fold, and duloxetine t_1/2 was increased approximately 3-fold.','boycer','04/26/2012 12:12:24\n','Drug_Label','PKStudy',6,0.06,0.1,NULL,NULL,NULL,NULL),(1570,'evidence_1786','http://www.ncbi.nlm.nih.gov/pubmed/17244765','NOTE: AUC_i/AUC value comes from Table IV. The object_dose is the average dose.\r\n\r\nroute of administration: oral (risperidone)/transdermal patch (selegiline)\r\n\r\nstudy duration: 7 days\r\n\r\npopulation: 12 healthy volunteers, 6 male and 6 female (8 white, 4 black)\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- One genotyped as slow metabolizer of CYP2D6\r\n\r\nages: 18-45','boycer','04/26/2012 13:43:43\n','EV_PK_DDI_RCT','PKStudy',0.93,0.006,0.002,NULL,NULL,NULL,NULL),(1571,'evidence_1745','http://www.ncbi.nlm.nih.gov/pubmed/12723462','NOTE: The AUC_i/AUC value is calculated from Table 1 using Total AUC.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 2 days\r\n\r\npopulation: 10 healthy, HIV-seronegative, nonsmokers (9 male, 1 female)\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 20-46','boycer','04/26/2012 15:05:51\n','EV_PK_DDI_RCT','PKStudy',2.37,0.05,0.4,NULL,NULL,NULL,NULL),(1572,'evidence_1685','http://www.ncbi.nlm.nih.gov/pubmed/2530759','NOTE: The AUC_i/AUC value is calculated from Table 3.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 28 days\r\n\r\npopulation: 11 healthy male volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: none given','boycer','04/26/2012 15:25:09\n','EV_PK_DDI_NR','PKStudy',1.51,0.03,0.9,NULL,NULL,NULL,NULL),(1573,'evidence_1056','http://www.ncbi.nlm.nih.gov/pubmed/11583471','NOTE: The AUC_i/AUC value given was calculated from Table IV using the AUC_0-inf values from the table.\r\n\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 1 day\r\n\r\npopulation: 8 healthy volunteers (7 male, 1 female)\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- 1 poor metabolizer of CYP2C19 and 1 poor metabolizer of CYP2D6; all others extensive metabolizers\r\n\r\nages: 24-45','boycer','05/02/2012 11:53:29\n','EV_PK_DDI_RCT','PKStudy',1.67,0.05,0.6,NULL,NULL,NULL,NULL),(1574,'evidence_1216','http://www.ncbi.nlm.nih.gov/pubmed/16638740','NOTE: The AUC_i/AUC value is from Table I and is not statistically significant.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 2 days\r\n\r\npopulation: 7 healthy male volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 18-45','boycer','05/02/2012 12:17:23\n','EV_PK_DDI_RCT','PKStudy',1.2,0.075,0.4,NULL,NULL,NULL,NULL),(1575,'evidence_1409','http://www.ncbi.nlm.nih.gov/pubmed/19444001','NOTE: The AUC_i/AUC value is calculated from Table 2.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: Unsure; Figure 1 shows at least 4 weeks\r\n\r\npopulation: 7 Caucasian inpatients diagnosed with major depression (HAM-D greater than or equal to 18); 5 females and 2 males\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 44.2 +/- 11.3 average age','boycer','05/03/2012 13:35:55\n','EV_PK_DDI_RCT','PKStudy',1.05,0.075,0.1,NULL,NULL,NULL,NULL),(1576,'evidence_1833','http://www.ncbi.nlm.nih.gov/pubmed/3912187','NOTE: The AUC_i/AUC value is calculated from the AUC numbers given in the Results section.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 3 days\r\n\r\npopulation: 10 healthy men\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 21-40','boycer','05/03/2012 13:59:29\n','EV_PK_DDI_RCT','PKStudy',1.8,0.1,0.3,NULL,NULL,NULL,NULL),(1577,'evidence_1128','http://www.ncbi.nlm.nih.gov/pubmed/14610241','NOTE: The AUC_i/AUC value is calculated from the AUC_0-inf values given in Table 4. The precip_dose is the dose for the majority of study participants, but the first six subjects received 0.08 g per day instead (all subjects\' data combined for PK data).\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 13 days\r\n\r\npopulation: 21 healthy men and women\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- all genotyped as EMs of CYP2D6\r\n\r\nages: 26-55','boycer','05/03/2012 14:18:21\n','EV_PK_DDI_NR','PKStudy',1.06,0.05,0.12,NULL,NULL,NULL,NULL),(1578,'evidence_1454','http://www.ncbi.nlm.nih.gov/pubmed/1544284','NOTE: THE AUC_i/AUC value is calculated from Table II.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: at least 8 days\r\n\r\npopulation: 5 normal white male volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 35-53','boycer','05/09/2012 12:02:07\n','EV_PK_DDI_NR','PKStudy',7.43,0.05,0.06,NULL,NULL,NULL,NULL),(1579,'evidence_1487','http://www.ncbi.nlm.nih.gov/pubmed/9088587','NOTE: The AUC_i/AUC value was calculated from the data given in the Results section of the study.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 14 days\r\n\r\npopulation: 6 nonsmoking male subjects\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 24-39','boycer','05/09/2012 13:00:16\n','EV_PK_DDI_RCT','PKStudy',1.02,0.1,0.2,NULL,NULL,NULL,NULL),(1580,'evidence_1638','http://www.ncbi.nlm.nih.gov/pubmed/8930024','NOTE: The AUC_i/AUC was calculated from Table 2. The object_dose is the dose of imipramine given.\r\n\r\nroute of administration: not sure, but likely oral\r\n\r\nstudy duration: 15 days\r\n\r\npopulation: 9 male inpatient veterans\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 31-60','boycer','05/09/2012 13:31:59\n','EV_PK_DDI_NR','PKStudy',4.28,0.05,0.03,NULL,NULL,NULL,NULL),(1581,'evidence_1329','http://www.ncbi.nlm.nih.gov/pubmed/8513845','NOTE: The AUC_i/AUC value is calculated from Table 3 using the equation CL=dose/AUC, where CL is the total clearance, and is for all EMs. For PMs, the AUC_i/AUC is 0.83.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 11 days\r\n\r\npopulation: 17 male Dutch volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- CYP2D6 phenotyping via sparteine - 9 EMs and 8 PMs\r\n\r\nages: 20-24','boycer','05/09/2012 14:08:12\n','EV_PK_DDI_NR','PKStudy',4.64,0.1,0.02,NULL,NULL,NULL,NULL),(1582,'evidence_1784','http://www.ncbi.nlm.nih.gov/pubmed/3950073','NOTE: The AUC_i/AUC is calculated from the total AUC values given in Table 1.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 5 days\r\n\r\npopulation: 10 healthy volunteers, 5 male and 5 female\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 22-45','boycer','05/16/2012 11:14:46\n','EV_PK_DDI_RCT','PKStudy',1.31,0.1,1.2,NULL,NULL,NULL,NULL),(1583,'evidence_1308','http://www.ncbi.nlm.nih.gov/pubmed/3792426','NOTE: The AUC_i/AUC value given is calculated from AUC values in Table 1.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 6 days\r\n\r\npopulation: 12 healthy nonsmoking men\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 22-34','boycer,ajgp2012','05/30/2012 14:07:58\n','EV_PK_DDI_RCT','PKStudy',2.72,0.1,1.2,NULL,NULL,NULL,NULL),(1584,'evidence_1765','http://www.ncbi.nlm.nih.gov/pubmed/6692646','NOTE: AUC_i/AUC value given is calculated from AUC-72 values in Table 1.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 3 days\r\n\r\npopulation: 6 healthy men\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 20-33','boycer,ajgp2012','05/30/2012 14:11:14\n','EV_PK_DDI_RCT','PKStudy',1.4,0.1,1.2,NULL,NULL,NULL,NULL),(1585,'evidence_1742','http://www.ncbi.nlm.nih.gov/pubmed/6726654','NOTE: The object_dose given is the oral dose of imipramine. 0.0125g imipramine was given in an iv dose in another part of the study. The AUC_i/AUC value given is for the oral imipramine/cimetidine phase and is calculated from the total AUC values in Table 1.\r\n\r\nroute of administration: oral (both), iv (imipramine)\r\n\r\nstudy duration: 4 days\r\n\r\npopulation: 6 healthy volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 24-35','boycer,ajgp2012','05/30/2012 14:18:21\n','EV_PK_DDI_RCT','PKStudy',1.86,0.05,1.2,NULL,NULL,NULL,NULL),(1586,'evidence_1456','http://www.ncbi.nlm.nih.gov/pubmed/1544284','NOTE: The AUC_i/AUC value given is calculated from Table IV from the values given from a single dose of each drug. The AUC_i/AUC was 3.33 when fluoxetine was given in eight daily doses.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: at least 8 days\r\n\r\npopulation: 5 normal male volunteers, 4 Caucasian and 1 Hispanic\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 38-51','boycer','05/30/2012 14:33:47\n','EV_PK_DDI_NR','PKStudy',1.89,0.05,0.06,NULL,NULL,NULL,NULL),(1587,'evidence_1841','http://www.ncbi.nlm.nih.gov/pubmed/9088587','NOTE: The AUC_i/AUC value is calculated from numbers given in the Results section of the paper.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 14 days\r\n\r\npopulation: 6 non-smoking male subjects\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 24-39','boycer,ajgp2012','05/30/2012 14:41:51\n','EV_PK_DDI_RCT','PKStudy',1.2,0.1,0.2,NULL,NULL,NULL,NULL),(1588,'evidence_1993','http://www.ncbi.nlm.nih.gov/pubmed/8930024','NOTE: The AUC_i/AUC value is calculated from Table 1.\r\n\r\nroute of administration: don\'t know; likely oral\r\n\r\nstudy duration: 15 days\r\n\r\npopulation: 9 male inpatient veterans, some smokers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 31-60','boycer','05/30/2012 14:51:23\n','EV_PK_DDI_NR','PKStudy',1.74,0.05,0.03,NULL,NULL,NULL,NULL),(1589,'evidence_1061','http://www.ncbi.nlm.nih.gov/pubmed/1613128','NOTE: The AUC_i/AUC value is calculated from Table 1 and also in the Abstract. 10 of the 12 subjects saw a significant increase (mean increase 15%).\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 4 days\r\n\r\npopulation: 12 healthy nonsmoking men\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 20-36','boycer','05/30/2012 15:01:48\n','EV_PK_DDI_RCT','PKStudy',1.15,0.1,0.36,NULL,NULL,NULL,NULL),(1590,'evidence_1129','http://www.ncbi.nlm.nih.gov/pubmed/1613128','NOTE: The AUC_i/AUC value given is calculated from Table 1 and is in the Abstract. 11 of 13 subjects saw a significant increase (mean increase of 35%).\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 4 days\r\n\r\npopulation: 13 healthy nonsmoking men\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 20-36','boycer,ajgp2012','05/30/2012 15:07:12\n','EV_PK_DDI_RCT','PKStudy',1.3,0.1,0.27,NULL,NULL,NULL,NULL),(1591,'evidence_1935','http://www.ncbi.nlm.nih.gov/pubmed/6692646','NOTE: The AUC_i/AUC is calculated from Table I and is not statistically significant.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 3 days\r\n\r\npopulation: 6 healthy men\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 20-33','boycer','05/30/2012 15:13:30\n','EV_PK_DDI_RCT','PKStudy',1.2,0.1,1.2,NULL,NULL,NULL,NULL),(1592,'evidence_1658','http://www.ncbi.nlm.nih.gov/pubmed/11673748','NOTE: The precip_dose given is for weeks 3-4. The AUC_i/AUC value given is calculated from Table II and is for the 0.04g period (weeks 3-4).\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 4 weeks\r\n\r\npopulation: 4 healthy volunteers, 2 male and 2 female, 3 white and 1 white/American Indian\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES - CYP2D6 genotyping - all ultrametabolizers (3 *1/2x2, 1 *1/2x3)\r\n\r\nages: 23-46','boycer,ajgp2012','05/31/2012 12:27:49\n','EV_PK_DDI_NR','PKStudy',4.88,0.05,0.04,NULL,NULL,NULL,NULL),(1593,'evidence_1710','http://www.ncbi.nlm.nih.gov/pubmed/3788228','NOTE: The AUC_i/AUC value is calculated from Tab. 2 and is the AUC_t-inf.\r\n\r\nroute of administration: don\'t know\r\n\r\nstudy duration: 1 week\r\n\r\npopulation: 6 male volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 20-37','boycer','05/31/2012 12:31:07\n','EV_PK_DDI_RCT','PKStudy',2.26,0.05,1,NULL,NULL,NULL,NULL),(1594,'evidence_1553','http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1de3ed9-1cb8-e419-3f25-5b0aeed5779a','NOTE: Found under the Drug Interactions heading.\r\n\r\n&quot;In a study assessing disposition of sertraline hydrochloride (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), Cmax (24%) and half-life (26%) compared to the placebo group. The clinical significance of these changes is unknown.&quot;','boycer','05/31/2012 12:48:29\n','Non_traceable_Drug_Label_Statement','PKStudy',1.5,0.1,0.8,NULL,NULL,NULL,NULL),(1595,'evidence_1508','http://www.ncbi.nlm.nih.gov/pubmed/18809731','NOTE: AUC_i/AUC calculated from Table 2\n          \nroute of administration: oral (implied)\n\nstudy duration: 15 days\n\npopulation:17 healthy volunteers (80% male, 45% black, 30% white)\n\ntested for known CYP450 polymorphisms?\nYes for CYP2D6, 90% predicted to be EMs\n\nages: 18-55\n\ndescription:\n This single-center, randomized, open-label, four-period, crossover study was undertaken to evaluate the effect of multiple doses of desvenlafaxine (100 mg/day, twice the recommended therapeutic dose for major depressive disorder in the United States) and duloxetine (30 mg b.i.d.) on the pharmacokinetics (PK) of a single dose of desipramine (50 mg). A single dose of desipramine was given first to assess its PK. Desvenlafaxine or duloxetine was then administered, in a crossover design, so that steady-state levels were achieved; a single dose of desipramine was then coadministered. The geometric least-square mean ratios (coadministration versus desipramine alone) for area under the plasma concentration versus time curve (AUC) and peak plasma concentrations (C(max)) of desipramine and 2-hydroxydesipramine were compared using analysis of variance. Relative to desipramine alone, increases in AUC and C(max) of desipramine associated with duloxetine administration (122 and 63%, respectively) were significantly greater than those associated with desvenlafaxine (22 and 19%, respectively; P < 0.001). Duloxetine coadministered with desipramine was also associated with a decrease in 2-hydroxydesipramine C(max) that was significant compared with the small increase seen with desvenlafaxine and desipramine (-24 versus 9%; P < 0.001); the difference between changes in 2-hydroxydesipramine AUC did not reach statistical significance (P = 0.054). Overall, desvenlafaxine had a minimal impact on the PK of desipramine compared with duloxetine, suggesting a lower risk for CYP2D6-mediated drug interactions.','boycer,ajgp2012','11/27/2012 11:22:28\n','EV_PK_DDI_RCT','PKStudy',1.23,0.05,0.1,NULL,NULL,NULL,NULL),(1596,'evidence_1950','http://www.ncbi.nlm.nih.gov/pubmed/8451775','NOTE: The object dose is for a dose of imipramine. The AUC_i/AUC value is the AUC_0-24 value calculated from Table 2.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 10 days\r\n\r\npopulation: 8 healthy male Caucasian volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nall EMs of sparteine and mephenytoin\r\n\r\nages: 20-31','boycer,ajgp2012','12/11/2012 13:02:37\n','EV_PK_DDI_NR','PKStudy',1.47,0.1,0.04,NULL,NULL,NULL,NULL),(1597,'evidence_1827','http://www.ncbi.nlm.nih.gov/pubmed/11084219','NOTE: AUC_i/AUC value comes from the Results section\r\n\r\nroute of administration: don\'t know\r\n\r\nstudy duration: 14 days\r\n\r\npopulation: 6 male veterans; 5 Caucasian and 1 African-American (3 subjects used 0.5-1.0 mg lorazepam for sleep during study)\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 23-64','boycer,ajgp2012','12/11/2012 13:20:13\n','EV_PK_DDI_NR','PKStudy',1.28,0.1,0.15,NULL,NULL,NULL,NULL),(1598,'evidence_1262','http://www.ncbi.nlm.nih.gov/pubmed/11084219','NOTE: The object_dose is the dose of imipramine; also the AUC_i/AUC value comes from the Results section\r\n\r\nroute of administration: don\'t know\r\n\r\nstudy duration: 14 days\r\n\r\npopulation: 6 male veterans; 5 Caucasian and 1 African-American (3 subjects used 0.5-1.0 mg lorazepam for sleep during study)\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 23-64','boycer,ajgp2012','12/11/2012 13:30:06\n','EV_PK_DDI_NR','PKStudy',1.4,0.1,0.15,NULL,NULL,NULL,NULL),(1599,'evidence_1694','http://www.ncbi.nlm.nih.gov/pubmed/19001559','NOTE: AUC_i/AUC value comes from the Results section\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 9 days\r\n\r\npopulation: 20 healthy men and women (17 male, 3 female); 1 Asian, 7 white, 11 black, 1 other\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- CYP2D6 genotyping: 16 EMs, 3 IMs, 1 PM\r\n\r\nages: 21-50 (mean 35.0 +/- 7.7)','boycer,ajgp2012','12/11/2012 13:38:30\n','EV_PK_DDI_NR','PKStudy',1.36,0.05,0.1,NULL,NULL,NULL,NULL),(1600,'evidence_1638','http://www.ncbi.nlm.nih.gov/pubmed/12544511','NOTE: The AUC_i/AUC value is the value for the AUC_0-12 of the S-venlafaxine enantiomer for EMs and is calculated from Table 2. For the R-venlafaxine enantiomer for EMs, the AUC_i/AUC value is 12.18 and is calculated from Table 3. The values for PMs are not significant.\r\n\r\nroute of administration: oral\r\n\r\nstudy duration: 2 days (twice, a week apart)\r\n\r\npopulation: 12 volunteers\r\n\r\ntested for known CYP450 polymorphisms?\r\nYES -- CYP2D6 phenotyping and genotyping -- 7 EMs (3 *1/*4, 4 *1/*1), 5 PMs (1 *3/*4, 4 *4/*4)\r\n\r\nages: 22-37','boycer,ajgp2012','12/11/2012 14:08:15\n','EV_PK_DDI_NR','PKStudy',3.85,0.0375,0.2,NULL,NULL,NULL,NULL),(1601,'evidence_1411','http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=753ef4af-e31b-40f0-b757-b088e5bbf1b6','route of administration: don\'t know\r\n\r\nstudy duration: not mentioned\r\n\r\npopulation: 15 male subjects\r\n\r\ntested for known CYP450 polymorphisms?\r\nNO\r\n\r\nages: 19-35\r\n\r\nDESCRIPTION:\r\nIn a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2, 5 and 2 fold, respectively. The effect was present for at least 7 days after the last dose of bupropion.','boycer,ajgp2012','12/11/2012 14:18:58\n','Non_traceable_Drug_Label_Statement','PKStudy',5,0.05,0.3,NULL,NULL,NULL,NULL);
/*!40000 ALTER TABLE `Evidence` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `Evidence_map`
--

DROP TABLE IF EXISTS `Evidence_map`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `Evidence_map` (
  `id` int(11) NOT NULL,
  `assert_ev_id` int(11) DEFAULT NULL,
  `assert_id` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `Evidence_map`
--

LOCK TABLES `Evidence_map` WRITE;
/*!40000 ALTER TABLE `Evidence_map` DISABLE KEYS */;
INSERT INTO `Evidence_map` VALUES (1,1,1),(2,2,2),(3,3,3),(4,4,4),(5,5,5),(6,6,6),(7,6,6),(8,7,7),(9,8,8),(10,9,9),(11,10,10),(12,10,10),(13,11,11),(14,12,12),(15,13,13),(16,14,14),(17,15,15),(18,16,16),(19,16,16),(20,17,17),(21,18,17),(22,19,18),(23,20,19),(24,20,19),(25,21,20),(26,21,20),(27,21,20),(28,22,21),(29,23,22),(30,24,23),(31,25,24),(32,25,24),(33,26,25),(34,27,26),(35,28,27),(36,29,28),(37,30,29),(38,30,29),(39,31,30),(40,32,31),(41,33,32),(42,34,33),(43,35,34),(44,36,35),(45,37,36),(46,37,36),(47,37,36),(48,38,37),(49,39,38),(50,40,39),(51,40,39),(52,41,40),(53,42,41),(54,42,41),(55,42,41),(56,43,42),(57,44,43),(58,45,44),(59,45,44),(60,46,45),(61,47,46),(62,47,46),(63,47,46),(64,48,47),(65,48,47),(66,49,48),(67,49,48),(68,49,48),(69,50,49),(70,50,49),(71,50,49),(72,51,50),(73,52,51),(74,53,52),(75,54,53),(76,55,54),(77,56,55),(78,57,56),(79,58,57),(80,58,57),(81,59,58),(82,60,59),(83,61,61),(84,62,62),(85,63,63),(86,64,64),(87,65,65),(88,65,65),(89,65,65),(90,66,66),(91,67,67),(92,68,69),(93,69,70),(94,70,71),(95,71,72),(96,72,73),(97,73,74),(98,74,75),(99,75,76),(100,76,77),(101,77,78),(102,78,79),(103,79,80),(104,80,81),(105,81,82),(106,82,83),(107,83,84),(108,84,85),(109,85,86),(110,86,87),(111,87,88),(112,88,89),(113,89,90),(114,90,91),(115,91,92),(116,92,93),(117,93,93),(118,93,93),(119,94,94),(120,95,95),(121,96,96),(122,97,97),(123,97,97),(124,97,97),(125,98,98),(126,98,98),(127,99,100),(128,100,101),(129,101,103),(130,101,103),(131,102,104),(132,103,105),(133,104,106),(134,105,107),(135,106,108),(136,107,109),(137,108,110),(138,108,110),(139,108,110),(140,109,111),(141,109,111),(142,110,112),(143,111,113),(144,111,113),(145,112,114),(146,112,114),(147,113,115),(148,114,116),(149,115,117),(150,115,117),(151,116,118),(152,117,119),(153,118,120),(154,119,121),(155,120,123),(156,121,124),(157,122,125),(158,123,126),(159,124,127),(160,124,127),(161,125,128),(162,126,129),(163,127,130),(164,128,131),(165,128,131),(166,128,131),(167,128,131),(168,129,132),(169,129,132),(170,130,133),(171,131,135),(172,132,136),(173,133,137),(174,134,138),(175,135,139),(176,136,140),(177,137,141),(178,138,142),(179,139,143),(180,140,144),(181,141,145),(182,142,146),(183,143,147),(184,144,148),(185,145,149),(186,146,151),(187,147,152),(188,148,153),(189,148,153),(190,148,153),(191,149,154),(192,150,155),(193,150,155),(194,151,156),(195,152,158),(196,153,159),(197,154,160),(198,155,161),(199,156,162),(200,156,162),(201,157,163),(202,158,164),(203,159,165),(204,159,165),(205,159,165),(206,160,166),(207,161,167),(208,162,168),(209,163,169),(210,164,170),(211,164,170),(212,165,171),(213,165,171),(214,166,172),(215,167,173),(216,168,174),(217,169,175),(218,170,176),(219,171,177),(220,171,177),(221,171,177),(222,172,178),(223,173,179),(224,174,180),(225,175,181),(226,175,181),(227,176,182),(228,177,183),(229,178,184),(230,178,184),(231,179,185),(232,180,186),(233,181,187),(234,182,188),(235,183,189),(236,184,190),(237,185,191),(238,186,192),(239,187,193),(240,188,194),(241,189,195),(242,189,195),(243,190,196),(244,191,197),(245,192,198),(246,193,199),(247,194,200),(248,194,200),(249,194,200),(250,194,200),(251,195,201),(252,195,201),(253,195,201),(254,196,202),(255,197,203),(256,198,204),(257,199,205),(258,200,206),(259,201,207),(260,202,208),(261,203,209),(262,204,210),(263,205,211),(264,205,211),(265,206,212),(266,207,213),(267,208,214),(268,209,215),(269,210,216),(270,211,217),(271,212,219),(272,213,220),(273,214,221),(274,214,221),(275,215,222),(276,216,224),(277,217,225),(278,218,226),(279,219,227),(280,220,228),(281,221,229),(282,222,230),(283,223,231),(284,224,232),(285,225,233),(286,225,233),(287,226,234),(288,227,235),(289,227,235),(290,228,236),(291,229,237),(292,230,238),(293,231,239),(294,232,240),(295,232,240),(296,233,241),(297,233,241),(298,234,242),(299,234,242),(300,235,243),(301,236,244),(302,237,245),(303,238,246),(304,239,247),(305,240,248),(306,241,249),(307,242,251),(308,243,252),(309,244,253),(310,245,254),(311,246,255),(312,247,256),(313,248,257),(314,248,257),(315,248,257),(316,249,259),(317,250,260),(318,251,261),(319,252,262),(320,252,262),(321,253,263),(322,254,264),(323,255,265),(324,255,265),(325,256,266),(326,257,267),(327,258,268),(328,259,269),(329,260,270),(330,261,271),(331,261,271),(332,262,272),(333,263,273),(334,263,273),(335,264,274),(336,265,275),(337,265,275),(338,266,276),(339,267,277),(340,268,278),(341,269,279),(342,270,280),(343,271,281),(344,272,282),(345,273,283),(346,274,284),(347,275,285),(348,276,286),(349,277,287),(350,278,288),(351,279,289),(352,280,290),(353,281,291),(354,282,292),(355,283,293),(356,284,294),(357,285,295),(358,286,296),(359,287,297),(360,287,297),(361,288,298),(362,289,299),(363,290,300),(364,291,301),(365,292,302),(366,292,302),(367,293,303),(368,294,303),(369,295,304),(370,296,305),(371,297,306),(372,297,306),(373,298,307),(374,299,308),(375,300,309),(376,301,311),(377,302,312),(378,302,312),(379,303,313),(380,303,313),(381,304,314),(382,305,315),(383,306,316),(384,306,316),(385,307,317),(386,308,318),(387,309,320),(388,309,320),(389,310,321),(390,311,322),(391,312,324),(392,313,325),(393,314,326),(394,315,327),(395,316,328),(396,317,329),(397,318,330),(398,319,331),(399,320,332),(400,321,333),(401,322,334),(402,323,335),(403,323,335),(404,324,336),(405,325,337),(406,326,338),(407,327,339),(408,328,340),(409,329,341),(410,330,343),(411,331,344),(412,332,345),(413,333,346),(414,334,347),(415,335,348),(416,336,349),(417,336,349),(418,337,350),(419,337,350),(420,338,351),(421,338,351),(422,339,352),(423,340,353),(424,341,354),(425,341,354),(426,342,355),(427,343,356),(428,344,357),(429,344,357),(430,345,358),(431,346,360),(432,347,361),(433,348,362),(434,349,363),(435,350,364),(436,350,364),(437,350,364),(438,351,365),(439,351,365),(440,351,365),(441,352,366),(442,353,367),(443,353,367),(444,354,368),(445,355,369),(446,356,370),(447,357,371),(448,358,372),(449,359,373),(450,360,374),(451,360,374),(452,361,375),(453,362,376),(454,363,377),(455,364,378),(456,364,378),(457,365,379),(458,365,379),(459,366,380),(460,367,381),(461,368,383),(462,369,384),(463,370,385),(464,371,386),(465,372,387),(466,373,388),(467,373,388),(468,374,389),(469,375,390),(470,376,392),(471,377,393),(472,378,394),(473,379,395),(474,380,396),(475,381,397),(476,382,398),(477,383,399),(478,384,400),(479,385,401),(480,385,401),(481,386,402),(482,387,403),(483,387,403),(484,388,404),(485,388,404),(486,389,405),(487,390,406),(488,391,407),(489,392,408),(490,393,409),(491,394,410),(492,395,411),(493,396,412),(494,397,413),(495,398,414),(496,399,415),(497,400,416),(498,400,416),(499,400,416),(500,401,417),(501,401,417),(502,402,418),(503,403,419),(504,404,420),(505,405,421),(506,406,422),(507,406,422),(508,407,423),(509,408,425),(510,409,426),(511,410,427),(512,411,428),(513,412,429),(514,413,430),(515,413,430),(516,413,430),(517,414,431),(518,414,431),(519,415,432),(520,415,432),(521,416,434),(522,416,434),(523,416,434),(524,417,435),(525,418,436),(526,419,437),(527,420,440),(528,421,441),(529,421,441),(530,422,442),(531,423,443),(532,424,444),(533,425,445),(534,426,446),(535,427,447),(536,428,448),(537,429,449),(538,430,450),(539,431,451),(540,432,452),(541,433,453),(542,434,454),(543,435,455),(544,435,455),(545,436,457),(546,437,458),(547,438,459),(548,439,460),(549,440,461),(550,441,462),(551,442,463),(552,443,464),(553,444,465),(554,444,465),(555,445,466),(556,446,467),(557,447,468),(558,448,469),(559,448,469),(560,449,470),(561,449,470),(562,449,470),(563,450,471),(564,451,472),(565,452,473),(566,453,475),(567,454,477),(568,455,478),(569,456,479),(570,457,480),(571,457,480),(572,458,481),(573,459,482),(574,460,483),(575,461,484),(576,462,485),(577,463,486),(578,463,486),(579,463,486),(580,464,487),(581,465,488),(582,465,488),(583,466,489),(584,466,489),(585,467,490),(586,468,491),(587,469,492),(588,469,492),(589,470,493),(590,471,494),(591,472,495),(592,472,495),(593,473,497),(594,474,499),(595,474,499),(596,475,500),(597,476,501),(598,476,501),(599,477,502),(600,478,503),(601,479,504),(602,480,505),(603,481,506),(604,482,507),(605,483,508),(606,483,508),(607,484,509),(608,485,511),(609,486,512),(610,487,513),(611,488,514),(612,489,515),(613,490,516),(614,490,516),(615,491,517),(616,492,518),(617,493,519),(618,494,520),(619,495,521),(620,496,522),(621,497,523),(622,498,524),(623,499,525),(624,500,526),(625,501,527),(626,502,528),(627,503,529),(628,504,530),(629,505,531),(630,506,532),(631,506,532),(632,507,533),(633,508,534),(634,509,535),(635,509,535),(636,509,535),(637,510,536),(638,511,537),(639,512,538),(640,513,539),(641,514,541),(642,515,542),(643,516,543),(644,517,544),(645,518,545),(646,518,545),(647,518,545),(648,519,546),(649,519,546),(650,519,546),(651,520,547),(652,521,549),(653,522,550),(654,523,551),(655,524,552),(656,524,552),(657,525,553),(658,526,554),(659,527,555),(660,528,556),(661,528,556),(662,528,556),(663,529,557),(664,530,558),(665,531,559),(666,532,560),(667,533,561),(668,534,562),(669,535,563),(670,536,564),(671,536,564),(672,536,564),(673,537,565),(674,538,566),(675,539,567),(676,540,568),(677,541,569),(678,542,570),(679,543,571),(680,543,571),(681,544,572),(682,545,573),(683,545,573),(684,546,574),(685,546,574),(686,547,576),(687,548,577),(688,548,577),(689,548,577),(690,548,577),(691,548,577),(692,549,578),(693,550,579),(694,551,580),(695,552,581),(696,553,582),(697,554,583),(698,554,583),(699,554,583),(700,555,584),(701,556,585),(702,557,586),(703,558,587),(704,559,588),(705,560,589),(706,561,590),(707,561,590),(708,562,591),(709,563,592),(710,563,592),(711,564,593),(712,564,593),(713,564,593),(714,565,594),(715,566,595),(716,567,596),(717,568,597),(718,569,598),(719,570,599),(720,571,600),(721,572,601),(722,573,602),(723,574,603),(724,575,604),(725,576,605),(726,577,606),(727,577,606),(728,578,607),(729,579,608),(730,579,608),(731,580,609),(732,581,610),(733,582,611),(734,583,612),(735,584,613),(736,585,614),(737,586,615),(738,587,616),(739,588,617),(740,589,618),(741,590,619),(742,591,620),(743,592,621),(744,593,622),(745,594,623),(746,595,624),(747,595,624),(748,595,624),(749,596,625),(750,596,625),(751,597,626),(752,598,627),(753,599,628),(754,600,629),(755,600,629),(756,600,629),(757,600,629),(758,601,630),(759,601,630),(760,601,630),(761,601,630),(762,602,631),(763,602,631),(764,603,632),(765,604,633),(766,605,634),(767,606,635),(768,606,635),(769,607,636),(770,608,637),(771,609,638),(772,610,639),(773,611,640),(774,612,641),(775,612,641),(776,613,642),(777,614,643),(778,614,643),(779,614,643),(780,615,644),(781,615,644),(782,616,645),(783,617,646),(784,618,647),(785,619,648),(786,620,649),(787,621,650),(788,622,651),(789,623,652),(790,624,654),(791,625,655),(792,625,655),(793,625,655),(794,626,656),(795,627,657),(796,628,659),(797,629,660),(798,630,661),(799,631,662),(800,632,663),(801,633,664),(802,634,665),(803,635,666),(804,635,666),(805,636,667),(806,636,667),(807,637,668),(808,637,668),(809,638,669),(810,639,670),(811,640,671),(812,641,672),(813,642,673),(814,643,674),(815,644,675),(816,645,676),(817,646,677),(818,647,678),(819,648,679),(820,649,680),(821,650,681),(822,651,683),(823,651,683),(824,652,684),(825,653,685),(826,654,686),(827,655,687),(828,655,687),(829,656,688),(830,657,689),(831,658,690),(832,659,691),(833,660,692),(834,661,693),(835,662,694),(836,663,695),(837,664,696),(838,665,697),(839,666,698),(840,666,698),(841,666,698),(842,666,698),(843,666,698),(844,666,698),(845,667,699),(846,668,700),(847,669,701),(848,669,701),(849,669,701),(850,670,702),(851,671,703),(852,672,704),(853,673,705),(854,674,706),(855,675,707),(856,676,708),(857,677,709),(858,678,710),(859,679,711),(860,680,712),(861,681,713),(862,681,713),(863,681,713),(864,682,714),(865,682,714),(866,683,715),(867,684,716),(868,684,716),(869,684,716),(870,684,716),(871,685,718),(872,686,719),(873,687,720),(874,688,721),(875,688,721),(876,689,722),(877,690,723),(878,690,723),(879,691,724),(880,691,724),(881,692,725),(882,693,726),(883,694,727),(884,694,727),(885,694,727),(886,695,728),(887,696,729),(888,697,730),(889,698,731),(890,699,732),(891,699,732),(892,700,733),(893,701,734),(894,702,735),(895,702,735),(896,702,735),(897,703,736),(898,703,736),(899,703,736),(900,704,737),(901,705,738),(902,706,739),(903,706,739),(904,706,739),(905,707,740),(906,708,741),(907,709,742),(908,709,742),(909,709,742),(910,710,743),(911,711,744),(912,712,745),(913,713,746),(914,714,747),(915,715,748),(916,716,749),(917,717,751),(918,718,752),(919,719,753),(920,720,754),(921,721,755),(922,722,756),(923,723,757),(924,724,758),(925,724,758),(926,725,759),(927,726,760),(928,727,761),(929,728,762),(930,729,763),(931,729,763),(932,730,764),(933,730,764),(934,730,764),(935,731,765),(936,732,766),(937,732,766),(938,733,767),(939,734,768),(940,735,769),(941,736,770),(942,737,771),(943,738,772),(944,739,773),(945,739,773),(946,740,774),(947,741,775),(948,742,776),(949,742,776),(950,743,777),(951,744,779),(952,745,780),(953,745,780),(954,746,781),(955,747,782),(956,748,783),(957,748,783),(958,749,784),(959,750,785),(960,751,786),(961,752,787),(962,753,788),(963,754,789),(964,755,790),(965,756,791),(966,757,792),(967,758,793),(968,759,794),(969,760,795),(970,761,796),(971,762,797),(972,763,798),(973,763,798),(974,764,798),(975,765,799),(976,766,800),(977,767,802),(978,767,802),(979,768,803),(980,769,805),(981,770,806),(982,770,806),(983,770,806),(984,771,807),(985,771,807),(986,772,808),(987,773,809),(988,774,810),(989,775,811),(990,775,811),(991,776,813),(992,777,814),(993,778,815),(994,779,816),(995,780,817),(996,781,818),(997,782,819),(998,782,819),(999,782,819),(1000,782,819),(1001,782,819),(1002,783,820),(1003,784,821),(1004,785,822),(1005,786,823),(1006,787,824),(1007,788,825),(1008,789,826),(1009,790,827),(1010,791,828),(1011,791,828),(1012,791,828),(1013,792,829),(1014,793,830),(1015,794,831),(1016,795,832),(1017,795,832),(1018,796,833),(1019,797,834),(1020,798,835),(1021,799,835),(1022,799,835),(1023,800,836),(1024,800,836),(1025,800,836),(1026,801,837),(1027,802,838),(1028,803,839),(1029,804,840),(1030,805,841),(1031,806,842),(1032,807,843),(1033,808,844),(1034,808,844),(1035,809,845),(1036,810,846),(1037,811,848),(1038,812,849),(1039,813,850),(1040,814,851),(1041,814,851),(1042,815,852),(1043,816,853),(1044,817,854),(1045,817,854),(1046,818,855),(1047,819,856),(1048,819,856),(1049,820,857),(1050,821,858),(1051,822,859),(1052,823,860),(1053,824,861),(1054,825,862),(1055,826,863),(1056,827,864),(1057,828,865),(1058,828,865),(1059,828,865),(1060,828,865),(1061,828,865),(1062,829,866),(1063,830,867),(1064,830,867),(1065,830,867),(1066,831,868),(1067,832,869),(1068,833,870),(1069,834,871),(1070,835,872),(1071,836,873),(1072,837,874),(1073,838,875),(1074,839,876),(1075,840,877),(1076,841,878),(1077,842,879),(1078,843,880),(1079,844,881),(1080,845,882),(1081,846,883),(1082,847,884),(1083,848,885),(1084,849,886),(1085,850,887),(1086,850,887),(1087,851,888),(1088,852,889),(1089,853,890),(1090,854,891),(1091,855,892),(1092,856,893),(1093,857,894),(1094,858,895),(1095,858,895),(1096,859,896),(1097,860,897),(1098,860,897),(1099,861,898),(1100,861,898),(1101,862,899),(1102,863,900),(1103,864,901),(1104,865,902),(1105,866,903),(1106,867,904),(1107,867,904),(1108,868,905),(1109,869,906),(1110,870,907),(1111,871,908),(1112,872,909),(1113,873,910),(1114,874,911),(1115,874,911),(1116,874,911),(1117,875,912),(1118,876,913),(1119,876,913),(1120,877,914),(1121,878,915),(1122,879,916),(1123,880,917),(1124,880,917),(1125,881,918),(1126,882,919),(1127,883,920),(1128,884,921),(1129,884,921),(1130,884,921),(1131,884,921),(1132,885,922),(1133,885,922),(1134,886,923),(1135,887,924),(1136,888,925),(1137,889,926),(1138,890,927),(1139,891,928),(1140,892,929),(1141,893,930),(1142,894,931),(1143,895,932),(1144,896,933),(1145,897,934),(1146,897,934),(1147,898,935),(1148,899,936),(1149,900,937),(1150,901,938),(1151,902,939),(1152,903,940),(1153,903,940),(1154,903,940),(1155,904,941),(1156,904,941),(1157,905,942),(1158,906,943),(1159,907,944),(1160,908,945),(1161,909,946),(1162,909,946),(1163,910,947),(1164,910,947),(1165,911,948),(1166,912,949),(1167,913,950),(1168,914,951),(1169,914,951),(1170,915,952),(1171,916,953),(1172,917,954),(1173,918,955),(1174,919,956),(1175,920,957),(1176,921,958),(1177,922,959),(1178,923,960),(1179,924,961),(1180,925,962),(1181,926,963),(1182,926,963),(1183,927,964),(1184,927,964),(1185,928,965),(1186,929,966),(1187,930,967),(1188,931,969),(1189,932,970),(1190,932,970),(1191,933,971),(1192,934,972),(1193,935,973),(1194,936,974),(1195,937,975),(1196,938,977),(1197,939,978),(1198,940,979),(1199,940,979),(1200,941,980),(1201,941,980),(1202,942,980),(1203,943,981),(1204,944,982),(1205,945,983),(1206,946,984),(1207,947,985),(1208,948,986),(1209,949,987),(1210,950,988),(1211,951,989),(1212,951,989),(1213,951,989),(1214,952,990),(1215,953,991),(1216,954,992),(1217,955,993),(1218,956,994),(1219,957,995),(1220,958,996),(1221,959,997),(1222,960,998),(1223,961,999),(1224,962,1000),(1225,963,1001),(1226,964,1002),(1227,965,1003),(1228,966,1004),(1229,967,1005),(1230,968,1006),(1231,969,1007),(1232,969,1007),(1233,970,1008),(1234,971,1009),(1235,971,1009),(1236,972,1010),(1237,973,1011),(1238,974,1012),(1239,975,1013),(1240,976,1014),(1241,977,1015),(1242,978,1016),(1243,979,1017),(1244,980,1018),(1245,981,1019),(1246,982,1020),(1247,983,1021),(1248,984,1022),(1249,984,1022),(1250,985,1023),(1251,986,1024),(1252,987,1025),(1253,987,1025),(1254,988,1026),(1255,989,1027),(1256,990,1028),(1257,991,1029),(1258,991,1029),(1259,992,1030),(1260,993,1031),(1261,994,1032),(1262,995,1033),(1263,996,1035),(1264,997,1036),(1265,997,1036),(1266,997,1036),(1267,998,1037),(1268,999,1038),(1269,1000,1039),(1270,1001,1040),(1271,1001,1040),(1272,1001,1040),(1273,1001,1040),(1274,1002,1041),(1275,1003,1042),(1276,1004,1043),(1277,1005,1043),(1278,1005,1043),(1279,1006,1044),(1280,1007,1045),(1281,1007,1045),(1282,1008,1046),(1283,1009,1047),(1284,1010,1048),(1285,1011,1049),(1286,1012,1050),(1287,1013,1051),(1288,1014,1051),(1289,1015,1052),(1290,1015,1052),(1291,1016,1053),(1292,1017,1054),(1293,1018,1055),(1294,1018,1055),(1295,1018,1055),(1296,1019,1056),(1297,1020,1057),(1298,1020,1057),(1299,1020,1057),(1300,1021,1058),(1301,1021,1058),(1302,1022,1059),(1303,1023,1060),(1304,1024,1061),(1305,1025,1062),(1306,1026,1063),(1307,1027,1064),(1308,1028,1065),(1309,1029,1066),(1310,1030,1067),(1311,1031,1068),(1312,1032,1069),(1313,1033,1070),(1314,1034,1071),(1315,1035,1072),(1316,1035,1072),(1317,1036,1073),(1318,1036,1073),(1319,1037,1075),(1320,1038,1076),(1321,1039,1077),(1322,1040,1078),(1323,1041,1080),(1324,1041,1080),(1325,1042,1081),(1326,1043,1082),(1327,1044,1083),(1328,1045,1084),(1329,1045,1084),(1330,1046,1085),(1331,1047,1086),(1332,1047,1086),(1333,1048,1087),(1334,1049,1088),(1335,1050,1089),(1336,1051,1090),(1337,1052,1091),(1338,1053,1092),(1339,1054,1093),(1340,1055,1094),(1341,1055,1094),(1342,1056,1095),(1343,1057,1096),(1344,1058,1097),(1345,1058,1097),(1346,1058,1097),(1347,1059,1098),(1348,1060,1100),(1349,1061,1102),(1350,1062,1103),(1351,1063,1104),(1352,1064,1105),(1353,1065,1106),(1354,1066,1107),(1355,1067,1108),(1356,1068,1109),(1357,1069,1110),(1358,1070,1111),(1359,1071,1112),(1360,1071,1112),(1361,1071,1112),(1362,1072,1113),(1363,1073,1114),(1364,1074,1115),(1365,1075,1116),(1366,1076,1117),(1367,1077,1118),(1368,1078,1119),(1369,1079,1120),(1370,1079,1120),(1371,1079,1120),(1372,1080,1121),(1373,1080,1121),(1374,1081,1122),(1375,1081,1122),(1376,1082,1123),(1377,1083,1124),(1378,1083,1124),(1379,1084,1125),(1380,1085,1126),(1381,1085,1126),(1382,1085,1126),(1383,1085,1126),(1384,1086,1127),(1385,1087,1128),(1386,1088,1129),(1387,1089,1130),(1388,1090,1131),(1389,1091,1133),(1390,1092,1134),(1391,1093,1136),(1392,1093,1136),(1393,1094,1137),(1394,1095,1138),(1395,1096,1139),(1396,1097,1140),(1397,1098,1141),(1398,1099,1142),(1399,1100,1143),(1400,1100,1143),(1401,1101,1144),(1402,1102,1145),(1403,1103,1146),(1404,1104,1147),(1405,1104,1147),(1406,1105,1148),(1407,1106,1149),(1408,1107,1150),(1409,1108,1151),(1410,1109,1152),(1411,1110,1153),(1412,1110,1153),(1413,1111,1154),(1414,1111,1154),(1415,1112,1155),(1416,1112,1155),(1417,1112,1155),(1418,1113,1156),(1419,1114,1157),(1420,1115,1158),(1421,1116,1159),(1422,1117,1161),(1423,1118,1162),(1424,1119,1163),(1425,1120,1164),(1426,1121,1165),(1427,1122,1166),(1428,1123,1167),(1429,1123,1167),(1430,1124,1168),(1431,1125,1169),(1432,1126,1170),(1433,1127,1171),(1434,1128,1172),(1435,1128,1172),(1436,1129,1173),(1437,1130,1174),(1438,1131,1176),(1439,1131,1176),(1440,1132,1177),(1441,1133,1178),(1442,1133,1178),(1443,1133,1178),(1444,1133,1178),(1445,1133,1178),(1446,1134,1179),(1447,1134,1179),(1448,1135,1180),(1449,1136,1181),(1450,1137,1182),(1451,1138,1183),(1452,1138,1183),(1453,1139,1184),(1454,1140,1185),(1455,1141,1186),(1456,1141,1186),(1457,1142,1187),(1458,1143,1188),(1459,1144,1189),(1460,1144,1189),(1461,1144,1189),(1462,1145,1190),(1463,1146,1191),(1464,1147,1192),(1465,1147,1192),(1466,1148,1193),(1467,1149,1194),(1468,1150,1195),(1469,1150,1195),(1470,1150,1195),(1471,1151,1196),(1472,1152,1197),(1473,1153,1198),(1474,1154,1199),(1475,1155,1200),(1476,1156,1201),(1477,1156,1201),(1478,1157,1202),(1479,1158,1203),(1480,1159,1204),(1481,1160,1205),(1482,1160,1205),(1483,1161,1206),(1484,1162,1207),(1485,1163,1208),(1486,1164,1209),(1487,1164,1209),(1488,1165,1210),(1489,1166,1212),(1490,1167,1213),(1491,1167,1213),(1492,1167,1213),(1493,1168,1214),(1494,1169,1215),(1495,1170,1216),(1496,1171,1217),(1497,1172,1217),(1498,1173,1218),(1499,1174,1219),(1500,1175,1220),(1501,1175,1220),(1502,1175,1220),(1503,1175,1220),(1504,1176,1221),(1505,1177,1222),(1506,1178,1223),(1507,1178,1223),(1508,1178,1223),(1509,1178,1223),(1510,1178,1223),(1511,1179,1224),(1512,1180,1225),(1513,1181,1226),(1514,1181,1226),(1515,1182,1227),(1516,1182,1227),(1517,1183,1228),(1518,1184,1229),(1519,1184,1229),(1520,1185,1230),(1521,1186,1231),(1522,1187,1232),(1523,1188,1233),(1524,1189,1234),(1525,1190,1235),(1526,1190,1235),(1527,1191,1236),(1528,1192,1237),(1529,1193,1238),(1530,1194,1239),(1531,1195,1241),(1532,1196,1242),(1533,1197,1243),(1534,1198,1244),(1535,1199,1245),(1536,1200,1246),(1537,1201,1247),(1538,1202,1248),(1539,1203,1249),(1540,1204,1250),(1541,1205,1251),(1542,1206,1252),(1543,1207,1253),(1544,1208,1254),(1545,1208,1254),(1546,1209,1255),(1547,1210,1256),(1548,1211,1257),(1549,1212,1258),(1550,1213,1259),(1551,1214,1260),(1552,1215,1261),(1553,1216,1262),(1554,1216,1262),(1555,1217,1263),(1556,1218,1264),(1557,1219,1265),(1558,1220,1266),(1559,1221,1267),(1560,1222,1268),(1561,1223,1269),(1562,1224,1270),(1563,1225,1271),(1564,1226,1272),(1565,1227,1273),(1566,1228,1274),(1567,1229,1275),(1568,1227,1273),(1569,676,708),(1570,1230,1276),(1571,1231,1277),(1572,1232,1278),(1573,1233,1279),(1574,1222,1268),(1575,1234,1280),(1576,1235,1281),(1577,1236,1282),(1578,573,602),(1579,1237,1283),(1580,1120,1164),(1581,1120,1164),(1582,1238,1284),(1583,1239,1285),(1584,1239,1285),(1585,1239,1285),(1586,1240,1286),(1587,1241,1287),(1588,1242,1288),(1589,1243,1289),(1590,1244,1290),(1591,1245,1291),(1592,1246,1292),(1593,1235,1281),(1594,1247,1293),(1595,1248,1294),(1596,1249,1295),(1597,1250,1296),(1598,1251,1297),(1599,1248,1294),(1600,1252,1298),(1601,1253,1299);
/*!40000 ALTER TABLE `Evidence_map` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `Evidence_slot_map`
--

DROP TABLE IF EXISTS `Evidence_slot_map`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `Evidence_slot_map` (
  `id` int(11) NOT NULL,
  `assert_id` int(11) DEFAULT NULL,
  `d_slot_id` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `Evidence_slot_map`
--

LOCK TABLES `Evidence_slot_map` WRITE;
/*!40000 ALTER TABLE `Evidence_slot_map` DISABLE KEYS */;
INSERT INTO `Evidence_slot_map` VALUES (1,204,1),(2,790,1),(3,1085,9),(4,187,10),(5,407,10),(6,465,10),(7,233,11),(8,693,11),(9,765,11),(10,162,12),(11,335,12),(12,835,12),(13,959,12),(14,1160,12),(15,1216,12),(16,207,13),(17,673,13),(18,758,13),(19,798,13),(20,897,13),(21,85,14),(22,871,14),(23,467,15),(24,494,24),(25,272,25),(26,430,26),(27,1097,27),(28,1210,28),(29,237,29),(30,736,29),(31,830,29),(32,1031,29),(33,1133,29),(34,1156,29),(35,539,30),(36,580,38),(37,796,38),(38,957,38),(39,1169,38),(40,419,39),(41,604,39),(42,661,39),(43,1082,39),(44,414,40),(45,1140,40),(46,688,49),(47,168,50),(48,1065,72),(49,575,79),(50,1059,83),(51,152,91),(52,1196,92),(53,287,93),(54,230,94),(55,497,95),(56,399,99),(57,1214,112),(58,106,128),(59,267,136),(60,556,137),(61,1122,138),(62,312,145),(63,97,146),(64,98,146),(65,266,146),(66,137,147),(67,1167,147),(68,1213,147),(69,113,148),(70,1176,148),(71,525,149),(72,631,150),(73,900,159),(74,719,167),(75,737,167),(76,931,168),(77,601,168),(78,931,168),(79,694,169),(80,197,178),(81,214,179),(82,521,180),(83,159,181),(84,1005,184),(85,565,185),(86,805,190),(87,491,191),(88,143,192),(89,840,192),(90,392,209),(91,1261,209),(92,711,211),(93,1219,217),(94,622,218),(95,738,219),(96,254,220),(97,533,220),(98,125,221),(99,756,221),(100,936,222),(101,227,223),(102,151,224),(103,309,227),(104,234,228),(105,760,241),(106,816,242),(107,464,249),(108,782,250),(109,411,251),(110,1056,252),(111,899,253),(112,652,254),(113,666,255),(114,1047,256),(115,32,289),(116,981,295),(117,1023,297),(118,802,298),(119,1235,299),(120,177,300),(121,365,301),(122,38,302),(123,222,303),(124,725,304),(125,303,305),(126,493,305),(127,602,305),(128,1107,305),(129,1171,322),(130,285,331),(131,174,339),(132,331,339),(133,657,339),(134,857,339),(135,1112,339),(136,109,340),(137,326,340),(138,390,340),(139,564,340),(140,1246,340),(141,54,341),(142,517,341),(143,563,341),(144,651,341),(145,965,341),(146,67,342),(147,75,342),(148,672,342),(149,839,342),(150,877,342),(151,850,343),(152,1006,343),(153,1095,343),(154,1252,343),(155,126,352),(156,1233,353),(157,512,354),(158,640,355),(159,375,356),(160,63,357),(161,211,357),(162,81,358),(163,1009,358),(164,468,363),(165,49,375),(166,536,378),(167,611,384),(168,1049,385),(169,721,410),(170,807,411),(171,916,412),(172,519,429),(173,743,430),(174,692,434),(175,87,439),(176,158,440),(177,499,442),(178,627,448),(179,1072,448),(180,1096,448),(181,182,449),(182,820,449),(183,1086,449),(184,260,450),(185,833,450),(186,1063,451),(187,982,476),(188,598,478),(189,275,484),(190,482,485),(191,599,486),(192,298,487),(193,383,487),(194,547,487),(195,84,488),(196,987,488),(197,991,488),(198,454,489),(199,595,489),(200,1141,489),(201,339,490),(202,478,490),(203,793,490),(204,191,491),(205,912,492),(206,555,498),(207,744,504),(208,346,512),(209,157,514),(210,976,515),(211,111,517),(212,851,518),(213,496,519),(214,643,520),(215,216,521),(216,543,521),(217,769,521),(218,800,521),(219,908,521),(220,1053,521),(221,1078,521),(222,1106,521),(223,1166,521),(224,1197,521),(225,1142,522),(226,23,530),(227,186,531),(228,12,532),(229,846,533),(230,915,544),(231,319,558),(232,1101,566),(233,1,567),(234,148,567),(235,864,567),(236,243,568),(237,759,568),(238,977,568),(239,68,569),(240,280,569),(241,393,569),(242,862,569),(243,968,569),(244,975,569),(245,121,570),(246,1050,570),(247,1170,570),(248,1253,570),(249,27,589),(250,61,590),(251,294,591),(252,741,603),(253,99,604),(254,483,604),(255,682,604),(256,548,605),(257,1161,605),(258,160,606),(259,218,606),(260,699,606),(261,799,606),(262,814,607),(263,841,607),(264,1010,607),(265,1163,610),(266,607,619),(267,77,626),(268,422,632),(269,1192,633),(270,276,634),(271,133,635),(272,706,636),(273,1110,636),(274,1234,636),(275,122,637),(276,869,638),(277,1088,666),(278,895,672),(279,913,673),(280,1244,674),(281,163,675),(282,305,676),(283,395,676),(284,635,676),(285,1230,677),(286,891,686),(287,86,694),(288,184,694),(289,235,694),(290,236,694),(291,428,694),(292,452,694),(293,526,694),(294,723,694),(295,768,694),(296,37,695),(297,108,695),(298,213,695),(299,488,695),(300,501,695),(301,507,695),(302,933,695),(303,1024,695),(304,1226,695),(305,442,696),(306,628,697),(307,729,698),(308,921,706),(309,262,707),(310,367,707),(311,922,707),(312,6,708),(313,117,708),(314,773,708),(315,397,709),(316,702,710),(317,289,711),(318,901,711),(319,971,711),(320,448,712),(321,677,712),(322,781,712),(323,785,712),(324,352,721),(325,1020,721),(326,336,740),(327,905,741),(328,379,746),(329,645,747),(330,969,755),(331,745,756),(332,1204,757),(333,609,760),(334,89,774),(335,288,775),(336,167,776),(337,255,776),(338,777,776),(339,791,776),(340,925,776),(341,387,777),(342,697,777),(343,784,777),(344,872,777),(345,1092,777),(346,238,778),(347,224,786),(348,300,787),(349,528,788),(350,986,794),(351,217,799),(352,1134,800),(353,284,802),(354,123,805),(355,1193,805),(356,582,806),(357,1123,806),(358,443,807),(359,1208,816),(360,924,817),(361,263,818),(362,281,824),(363,282,824),(364,572,825),(365,1158,827),(366,775,828),(367,943,829),(368,57,830),(369,116,830),(370,176,830),(371,252,830),(372,295,830),(373,344,830),(374,909,830),(375,914,830),(376,1043,830),(377,1153,830),(378,1217,830),(379,134,831),(380,250,831),(381,438,831),(382,1034,831),(383,1074,831),(384,671,832),(385,884,840),(386,654,841),(387,795,842),(388,797,843),(389,1025,844),(390,1148,853),(391,5,854),(392,329,854),(393,778,854),(394,347,855),(395,444,855),(396,1200,864),(397,181,872),(398,750,872),(399,1058,873),(400,2,874),(401,169,874),(402,249,874),(403,345,874),(404,860,874),(405,1054,874),(406,1137,874),(407,115,875),(408,203,875),(409,321,875),(410,459,875),(411,1018,875),(412,1184,875),(413,1245,875),(414,196,876),(415,1000,876),(416,1041,893),(417,360,894),(418,455,901),(419,1138,902),(420,1139,902),(421,385,903),(422,386,903),(423,371,904),(424,827,905),(425,848,906),(426,978,906),(427,1259,906),(428,259,907),(429,416,908),(430,30,909),(431,206,909),(432,380,909),(433,689,909),(434,1215,909),(435,1220,910),(436,342,922),(437,1240,922),(438,1205,943),(439,917,944),(440,720,945),(441,728,945),(442,853,954),(443,477,962),(444,1131,963),(445,13,964),(446,24,964),(447,357,964),(448,516,964),(449,524,964),(450,843,964),(451,1045,964),(452,1046,964),(453,1121,964),(454,349,965),(455,718,965),(456,887,965),(457,910,965),(458,1001,965),(459,1022,965),(460,1094,965),(461,1125,965),(462,1172,965),(463,205,974),(464,993,976),(465,867,982),(466,546,983),(467,1225,983),(468,545,984),(469,733,984),(470,306,985),(471,470,985),(472,963,985),(473,1093,985),(474,44,986),(475,351,986),(476,400,986),(477,727,986),(478,492,987),(479,735,987),(480,314,988),(481,332,988),(482,451,988),(483,616,988),(484,475,989),(485,1033,1022),(486,307,1023),(487,427,1024),(488,437,1036),(489,989,1049),(490,1149,1049),(491,1119,1050),(492,1120,1050),(493,614,1051),(494,698,1059),(495,7,1060),(496,93,1060),(497,413,1060),(498,1040,1060),(499,1255,1060),(500,1173,1061),(501,200,1061),(502,445,1061),(503,553,1061),(504,980,1061),(505,1173,1061),(506,170,1062),(507,489,1062),(508,667,1062),(509,783,1062),(510,792,1062),(511,248,1063),(512,687,1063),(513,832,1063),(514,1080,1063),(515,1136,1063),(516,617,1064),(517,731,1064),(518,947,1064),(519,1116,1064),(520,154,1065),(521,439,1082),(522,510,1082),(523,804,1082),(524,251,1107),(525,511,1107),(526,881,1107),(527,62,1108),(528,372,1108),(529,626,1108),(530,101,1117),(531,223,1118),(532,258,1118),(533,376,1118),(534,471,1119),(535,498,1119),(536,56,1120),(537,145,1120),(538,457,1120),(539,1132,1120),(540,226,1121),(541,576,1121),(542,1251,1121),(543,515,1122),(544,127,1130),(545,700,1130),(546,273,1131),(547,1185,1131),(548,83,1132),(549,188,1132),(550,189,1132),(551,603,1132),(552,764,1132),(553,51,1133),(554,52,1133),(555,173,1133),(556,231,1133),(557,701,1133),(558,440,1134),(559,956,1143),(560,341,1144),(561,293,1145),(562,888,1154),(563,128,1155),(564,128,1155),(565,105,1164),(566,241,1164),(567,242,1164),(568,253,1164),(569,504,1164),(570,596,1164),(571,787,1164),(572,1104,1164),(573,1159,1164),(574,55,1165),(575,208,1165),(576,274,1165),(577,398,1165),(578,431,1165),(579,432,1165),(580,734,1165),(581,757,1165),(582,896,1165),(583,522,1179),(584,831,1180),(585,1032,1182),(586,418,1183),(587,883,1184),(588,1241,1190),(589,112,1201),(590,394,1201),(591,730,1201),(592,747,1201),(593,1021,1201),(594,1124,1201),(595,1209,1201),(596,192,1202),(597,199,1202),(598,261,1202),(599,473,1202),(600,668,1202),(601,803,1202),(602,964,1202),(603,542,1203),(604,754,1212),(605,135,1213),(606,290,1214),(607,278,1234),(608,1239,1241),(609,79,1247),(610,80,1247),(611,479,1247),(612,551,1247),(613,621,1247),(614,818,1247),(615,845,1247),(616,849,1247),(617,932,1247),(618,985,1247),(619,1198,1247),(620,183,1248),(621,500,1248),(622,537,1248),(623,538,1248),(624,685,1248),(625,715,1248),(626,868,1248),(627,930,1248),(628,984,1248),(629,1090,1248),(630,1117,1248),(631,767,1249),(632,990,1274),(633,469,1282),(634,1129,1282),(635,1228,1282),(636,229,1283),(637,1258,1283),(638,1262,1283),(639,1091,1284),(640,313,1301),(641,401,1302),(642,269,1311),(643,382,1316),(644,780,1319),(645,1183,1320),(646,221,1321),(647,929,1321),(648,1055,1321),(649,742,1322),(650,811,1322),(651,1083,1322),(652,316,1323),(653,91,1324),(654,571,1324),(655,708,1324),(656,740,1324),(657,752,1324),(658,822,1324),(659,892,1324),(660,1003,1324),(661,1157,1324),(662,581,1325),(663,644,1334),(664,1146,1336),(665,629,1342),(666,368,1343),(667,1089,1344),(668,47,1345),(669,48,1345),(670,82,1345),(671,94,1345),(672,408,1345),(673,618,1345),(674,646,1345),(675,974,1345),(676,19,1346),(677,20,1346),(678,315,1346),(679,377,1346),(680,649,1346),(681,1004,1346),(682,1016,1346),(683,1130,1346),(684,1015,1347),(685,100,1348),(686,46,1349),(687,535,1349),(688,653,1350),(689,770,1351),(690,8,1352),(691,1190,1358),(692,813,1385),(693,591,1386),(694,592,1386),(695,441,1387),(696,1115,1387),(697,10,1388),(698,72,1393),(699,406,1394),(700,594,1396),(701,630,1397),(702,716,1398),(703,859,1399),(704,33,1400),(705,70,1400),(706,96,1400),(707,212,1400),(708,472,1400),(709,600,1400),(710,608,1400),(711,641,1400),(712,1007,1400),(713,876,1417),(714,554,1418),(715,1155,1427),(716,593,1428),(717,153,1461),(718,1231,1462),(719,172,1463),(720,402,1464),(721,1128,1481),(722,1013,1482),(723,605,1489),(724,480,1490),(725,670,1490),(726,970,1491),(727,1114,1491),(728,246,1492),(729,340,1493),(730,766,1494),(731,625,1495),(732,825,1496),(733,953,1496),(734,495,1497),(735,973,1514),(736,655,1522),(737,429,1523),(738,164,1524),(739,1011,1527),(740,228,1535),(741,423,1541),(742,1227,1542),(743,132,1543),(744,1180,1544),(745,1257,1544),(746,1099,1545),(747,566,1546),(748,485,1571),(749,486,1571),(750,696,1571),(751,704,1571),(752,1075,1571),(753,1242,1571),(754,124,1572),(755,130,1572),(756,751,1572),(757,836,1572),(758,837,1572),(759,1181,1572),(760,732,1573),(761,880,1590),(762,613,1607),(763,844,1616),(764,852,1617),(765,789,1618),(766,322,1619),(767,421,1619),(768,894,1620),(769,1064,1621),(770,567,1623),(771,541,1629),(772,185,1630),(773,505,1631),(774,1188,1632),(775,994,1633),(776,369,1634),(777,1151,1634),(778,1152,1634),(779,95,1635),(780,675,1635),(781,902,1635),(782,962,1660),(783,142,1668),(784,561,1680),(785,919,1709),(786,865,1717),(787,73,1718),(788,74,1718),(789,209,1718),(790,291,1718),(791,370,1718),(792,481,1718),(793,552,1718),(794,597,1718),(795,632,1718),(796,1194,1718),(797,958,1719),(798,14,1719),(799,195,1719),(800,358,1719),(801,531,1719),(802,665,1719),(803,878,1719),(804,907,1719),(805,944,1719),(806,958,1719),(807,1076,1719),(808,78,1720),(809,502,1720),(810,534,1720),(811,918,1720),(812,1145,1720),(813,31,1721),(814,484,1721),(815,523,1721),(816,612,1721),(817,755,1721),(818,746,1722),(819,950,1723),(820,1212,1723),(821,637,1724),(822,426,1736),(823,945,1749),(824,302,1758),(825,588,1758),(826,779,1758),(827,999,1758),(828,1027,1758),(829,1029,1758),(830,1030,1758),(831,1143,1758),(832,338,1759),(833,381,1759),(834,520,1759),(835,726,1759),(836,763,1759),(837,920,1759),(838,1073,1759),(839,1147,1759),(840,22,1760),(841,549,1760),(842,906,1760),(843,1035,1760),(844,1224,1760),(845,119,1761),(846,120,1761),(847,690,1761),(848,1068,1761),(849,1218,1761),(850,1087,1762),(851,66,1763),(852,509,1764),(853,141,1765),(854,717,1770),(855,590,1771),(856,1002,1773),(857,874,1774),(858,1223,1775),(859,819,1776),(860,363,1777),(861,147,1778),(862,559,1778),(863,615,1778),(864,1164,1778),(865,691,1787),(866,660,1788),(867,584,1789),(868,435,1790),(869,35,1791),(870,1100,1791),(871,676,1792),(872,1081,1793),(873,842,1797),(874,658,1798),(875,1069,1802),(876,283,1804),(877,311,1805),(878,794,1810),(879,647,1811),(880,220,1812),(881,308,1812),(882,722,1812),(883,1203,1812),(884,1039,1813),(885,514,1821),(886,29,1822),(887,201,1822),(888,638,1822),(889,904,1823),(890,1036,1823),(891,1113,1823),(892,560,1824),(893,129,1825),(894,193,1825),(895,434,1825),(896,503,1825),(897,557,1825),(898,1038,1825),(899,420,1826),(900,1028,1835),(901,461,1836),(902,998,1853),(903,1150,1854),(904,1126,1863),(905,1071,1880),(906,1102,1880),(907,1103,1880),(908,50,1881),(909,286,1881),(910,292,1881),(911,43,1882),(912,353,1882),(913,409,1882),(914,425,1882),(915,529,1882),(916,568,1882),(917,686,1882),(918,703,1882),(919,934,1882),(920,265,1891),(921,1084,1892),(922,449,1893),(923,1207,1894),(924,972,1895),(925,194,1903),(926,856,1903),(927,1019,1903),(928,574,1904),(929,1070,1904),(930,1174,1904),(931,156,1905),(932,270,1905),(933,271,1905),(934,808,1905),(935,903,1905),(936,1057,1905),(937,16,1906),(938,610,1906),(939,662,1906),(940,861,1906),(941,870,1906),(942,911,1906),(943,179,1907),(944,826,1907),(945,328,1914),(946,39,1916),(947,139,1916),(948,458,1916),(949,513,1916),(950,923,1916),(951,939,1916),(952,724,1917),(953,817,1917),(954,926,1917),(955,927,1917),(956,1168,1917),(957,1187,1917),(958,11,1918),(959,961,1918),(960,1195,1918),(961,334,1919),(962,583,1919),(963,586,1919),(964,110,1920),(965,354,1920),(966,619,1920),(967,636,1937),(968,462,1946),(969,140,1954),(970,748,1956),(971,104,1962),(972,1060,1963),(973,1008,1964),(974,838,1965),(975,890,1965),(976,1206,1965),(977,232,1966),(978,955,1966),(979,1014,1966),(980,436,1967),(981,1108,1967),(982,180,1968),(983,834,1968),(984,138,1969),(985,762,1970),(986,450,1971),(987,1179,1979),(988,15,1988),(989,1191,1988),(990,966,1996),(991,1051,1996),(992,1175,1996),(993,17,1997),(994,17,1997),(995,299,1997),(996,171,1998),(997,323,1998),(998,359,1998),(999,391,1998),(1000,530,1998),(1001,828,1998),(1002,940,1999),(1003,946,1999),(1004,1118,1999),(1005,544,2000),(1006,570,2000),(1007,709,2001),(1008,1012,2001),(1009,1162,2002),(1010,518,2011),(1011,681,2036),(1012,21,2038),(1013,36,2044),(1014,257,2045),(1015,1260,2046),(1016,1222,2047),(1017,18,2048),(1018,476,2049),(1019,256,2050),(1020,64,2083),(1021,65,2083),(1022,320,2083),(1023,165,2084),(1024,166,2084),(1025,606,2084),(1026,634,2085),(1027,1182,2087),(1028,806,2093),(1029,935,2094),(1030,25,2095),(1031,58,2096),(1032,59,2096),(1033,712,2096),(1034,161,2097),(1035,366,2097),(1036,952,2097),(1037,801,2098),(1038,1105,2099),(1039,674,2100),(1040,90,2125),(1041,92,2125),(1042,680,2125),(1043,202,2126),(1044,361,2126),(1045,663,2126),(1046,1243,2127),(1047,1221,2130),(1048,815,2131),(1049,983,2136),(1050,4,2137),(1051,69,2146),(1052,889,2154),(1053,317,2155),(1054,107,2156),(1055,396,2156),(1056,1067,2156),(1057,403,2165),(1058,404,2165),(1059,695,2165),(1060,1250,2165),(1061,356,2166),(1062,415,2166),(1063,1052,2166),(1064,1254,2166),(1065,942,2175),(1066,150,2176),(1067,337,2176),(1068,774,2176),(1069,198,2177),(1070,527,2177),(1071,245,2194),(1072,1135,2194),(1073,1249,2194),(1074,136,2195),(1075,136,2195),(1076,463,2195),(1077,310,2196),(1078,456,2196),(1079,474,2196),(1080,938,2196),(1081,995,2197),(1082,532,2222),(1083,648,2222),(1084,753,2222),(1085,863,2222),(1086,866,2222),(1087,885,2222),(1088,886,2222),(1089,988,2222),(1090,1144,2222),(1091,1256,2222),(1092,40,2223),(1093,114,2223),(1094,268,2223),(1095,330,2223),(1096,650,2223),(1097,786,2223),(1098,809,2223),(1099,810,2223),(1100,879,2223),(1101,882,2223),(1102,296,2224),(1103,659,2225),(1104,318,2242),(1105,215,2243),(1106,146,2244),(1107,587,2244),(1108,1232,2252),(1109,1044,2253),(1110,937,2254),(1111,1042,2255),(1112,446,2256),(1113,749,2256),(1114,824,2256),(1115,642,2257),(1116,1247,2259),(1117,1017,2265),(1118,155,2266),(1119,683,2267),(1120,992,2268),(1121,540,2269),(1122,118,2270),(1123,348,2271),(1124,333,2294),(1125,131,2296),(1126,34,2297),(1127,573,2297),(1128,997,2297),(1129,1048,2297),(1130,378,2298),(1131,679,2298),(1132,684,2298),(1133,829,2298),(1134,713,2299),(1135,714,2299),(1136,1189,2300),(1137,1229,2300),(1138,417,2301),(1139,847,2302),(1140,41,2303),(1141,45,2304),(1142,103,2304),(1143,240,2304),(1144,821,2304),(1145,893,2304),(1146,928,2304),(1147,664,2305),(1148,219,2306),(1149,373,2309),(1150,9,2315),(1151,771,2316),(1152,948,2320),(1153,42,2333),(1154,669,2334),(1155,669,2334),(1156,1061,2343),(1157,466,2351),(1158,297,2352),(1159,577,2352),(1160,761,2352),(1161,1201,2352),(1162,350,2353),(1163,858,2353),(1164,1154,2353),(1165,1178,2353),(1166,247,2354),(1167,88,2355),(1168,705,2356),(1169,144,2357),(1170,569,2357),(1171,550,2358),(1172,949,2358),(1173,624,2366),(1174,190,2367),(1175,873,2368),(1176,854,2369),(1177,951,2370),(1178,3,2371),(1179,585,2371),(1180,1109,2371),(1181,279,2372),(1182,678,2380),(1183,453,2389),(1184,579,2390),(1185,1037,2391),(1186,788,2399),(1187,589,2400),(1188,967,2401),(1189,239,2402),(1190,53,2403),(1191,178,2404),(1192,324,2404),(1193,388,2404),(1194,412,2404),(1195,71,2405),(1196,374,2405),(1197,855,2405),(1198,1165,2405);
/*!40000 ALTER TABLE `Evidence_slot_map` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `Metabolite`
--

DROP TABLE IF EXISTS `Metabolite`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `Metabolite` (
  `id` int(11) NOT NULL,
  `_name` varchar(100) DEFAULT NULL,
  `metabolite` tinyint(1) DEFAULT NULL,
  `primary_total_clearance_mechanism` int(11) DEFAULT NULL,
  `primary_metabolic_clearance_enzyme` int(11) DEFAULT NULL,
  `primary_total_clearance_enzyme` int(11) DEFAULT NULL,
  `in_vitro_probe_substrate_of_enzyme` int(11) DEFAULT NULL,
  `in_viVo_probe_substrate_of_enzyme` int(11) DEFAULT NULL,
  `in_vitro_selective_inhibitor_of_enzyme` int(11) DEFAULT NULL,
  `in_viVo_selective_inhibitor_of_enzyme` int(11) DEFAULT NULL,
  `pceut_entity_of_concern` int(11) DEFAULT NULL,
  `maximum_concentration` int(11) DEFAULT NULL,
  `minimum_therapeutic_dose` int(11) DEFAULT NULL,
  `maximum_therapeutic_dose` int(11) DEFAULT NULL,
  `assumed_effective_dose` int(11) DEFAULT NULL,
  `substrate_of` int(11) DEFAULT NULL,
  `is_not_substrate_of` int(11) DEFAULT NULL,
  `inhibits` int(11) DEFAULT NULL,
  `does_not_inhibit` int(11) DEFAULT NULL,
  `has_metabolite` int(11) DEFAULT NULL,
  `permanently_deactivates_catalytic_function` int(11) DEFAULT NULL,
  `does_not_permanently_deactivate_catalytic_function` int(11) DEFAULT NULL,
  `inhibition_constant` int(11) DEFAULT NULL,
  `induces` int(11) DEFAULT NULL,
  `increases_auc` int(11) DEFAULT NULL,
  `sole_PK_effect_alter_metabolic_clearance` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `Metabolite`
--

LOCK TABLES `Metabolite` WRITE;
/*!40000 ALTER TABLE `Metabolite` DISABLE KEYS */;
INSERT INTO `Metabolite` VALUES (1,'modafinil-sulfone',1,41,42,43,44,45,46,47,48,NULL,NULL,NULL,NULL,NULL,NULL,49,50,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(2,'6\'-hydroxy-simvastatin',1,104,105,106,107,108,109,110,111,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(3,'desglymidodrine',1,112,113,114,115,116,117,118,119,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(4,'N-desmethylsertraline',1,120,121,122,123,124,125,126,127,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(5,'threohydrobupropion',1,128,129,130,131,132,133,134,135,136,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(6,'6\'-exomethylene-simvastatin',1,193,194,195,196,197,198,199,200,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(7,'S-N-desmethylzopiclone',1,201,202,203,204,205,206,207,208,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(8,'6\'-exomethylene-lovastatin',1,233,234,235,236,237,238,239,240,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(9,'4-(4-chlorophenyl)-4-hydroxypiperidine',1,273,274,275,276,277,278,279,280,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(10,'6beta-Hydroxytestosterone',1,306,307,308,309,310,311,312,313,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(11,'O-desmethylvenlafaxine',1,367,368,369,370,371,372,373,374,375,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(12,'N-demethyldesacetyl-diltiazem',1,376,377,378,379,380,381,382,383,NULL,NULL,NULL,NULL,384,385,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(13,'10-N-glucuronide',1,394,395,396,397,398,399,400,401,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(14,'reduced-haloperidol',1,402,403,404,405,406,407,408,409,NULL,NULL,NULL,NULL,410,411,NULL,NULL,412,NULL,NULL,NULL,NULL,NULL,NULL),(15,'S-zopiclone-N-oxide',1,460,461,462,463,464,465,466,467,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(16,'4-hydroxyatomoxetine',1,534,535,536,537,538,539,540,541,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(17,'norpropoxyphene',1,571,572,573,574,575,576,577,578,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(18,'N-demethyldiltiazem',1,579,580,581,582,583,584,585,586,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(19,'R-demethylcitalopram',1,595,596,597,598,599,600,601,602,603,NULL,NULL,NULL,604,605,606,607,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(20,'S-mephenytoin',1,616,617,618,619,620,621,622,623,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(21,'beta-hydroxy-simvastatin',1,624,625,626,627,628,629,630,631,NULL,NULL,NULL,NULL,632,633,634,635,636,NULL,637,638,NULL,NULL,NULL),(22,'6\'beta-hydroxy-lovastatin',1,647,648,649,650,651,652,653,654,655,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(23,'S-methyl-dihydroziprasidone',1,722,723,724,725,726,727,728,729,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(24,'N-desalkylquetiapine',1,766,767,768,769,770,771,772,773,NULL,NULL,NULL,NULL,774,775,776,777,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(25,'alpha-naphthoflavone',1,789,790,791,792,793,794,795,796,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(26,'R-didemethylcitalopram',1,845,846,847,848,849,850,851,852,853,NULL,NULL,NULL,NULL,NULL,854,855,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(27,'7-hydroxy-N-desalkyl-quetiapine',1,856,857,858,859,860,861,862,863,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(28,'3-methylxanthine',1,877,878,879,880,881,882,883,884,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(29,'1-methyluric-acid',1,885,886,887,888,889,890,891,892,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(30,'N-desmethylvenlafaxine',1,911,912,913,914,915,916,917,918,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(31,'M-chlorophenylpiperazine',1,1025,1026,1027,1028,1029,1030,1031,1032,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(32,'didemethylcitalopram',1,1074,1075,1076,1077,1078,1079,1080,1081,NULL,NULL,NULL,NULL,NULL,NULL,1082,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(33,'hydroxy-hydrocinnamic-acid',1,1091,1092,1093,1094,1095,1096,1097,1098,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(34,'voriconazole-N-oxide',1,1099,1100,1101,1102,1103,1104,1105,1106,NULL,NULL,NULL,NULL,NULL,NULL,1107,1108,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(35,'S-demethylcitalopram',1,1109,1110,1111,1112,1113,1114,1115,1116,1117,NULL,NULL,NULL,1118,1119,1120,1121,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(36,'clozapine-N-oxide',1,1146,1147,1148,1149,1150,1151,1152,1153,NULL,NULL,NULL,NULL,1154,1155,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(37,'4-hydroxytriazolam',1,1266,1267,1268,1269,1270,1271,1272,1273,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(38,'N-desmethyltamoxifen',1,1303,1304,1305,1306,1307,1308,1309,1310,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(39,'4-hydroxymidazolam',1,1326,1327,1328,1329,1330,1331,1332,1333,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(40,'alpha-hydroxyalprazolam',1,1429,1430,1431,1432,1433,1434,1435,1436,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(41,'4-hydroxydebrisoquine',1,1473,1474,1475,1476,1477,1478,1479,1480,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(42,'4-hydroxyalprazolam',1,1498,1499,1500,1501,1502,1503,1504,1505,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(43,'beta-hydroxy-lovastatin',1,1533,1534,1535,1536,1537,1538,1539,1540,1541,NULL,NULL,NULL,1542,1543,NULL,NULL,1544,NULL,1545,1546,NULL,NULL,NULL),(44,'1,3-dimethyluric-acid',1,1547,1548,1549,1550,1551,1552,1553,1554,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(45,'6\'-hydroxymethyl-simvastatin',1,1555,1556,1557,1558,1559,1560,1561,1562,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(46,'7-hydroxyperphenazine',1,1582,1583,1584,1585,1586,1587,1588,1589,1590,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(47,'norfluoxetine',1,1599,1600,1601,1602,1603,1604,1605,1606,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1607,NULL,NULL,NULL),(48,'3alpha-hydroxypravastatin',1,1636,1637,1638,1639,1640,1641,1642,1643,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(49,'7-hydroxyclozapine',1,1652,1653,1654,1655,1656,1657,1658,1659,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(50,'9-hydroxyrisperidone',1,1660,1661,1662,1663,1664,1665,1666,1667,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1668,NULL,NULL,NULL),(51,'benzisothiazole-sulphone',1,1669,1670,1671,1672,1673,1674,1675,1676,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(52,'N-desmethylatomoxetine',1,1701,1702,1703,1704,1705,1706,1707,1708,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(53,'quetiapine-sulfoxide',1,1725,1726,1727,1728,1729,1730,1731,1732,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(54,'1-methylxanthine',1,1741,1742,1743,1744,1745,1746,1747,1748,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1749,NULL,NULL,NULL,NULL,NULL,NULL),(55,'teriflunomide',1,1827,1828,1829,1830,1831,1832,1833,1834,NULL,NULL,NULL,NULL,NULL,NULL,1835,1836,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(56,'14-hydroxyclarithromycin',1,1855,1856,1857,1858,1859,1860,1861,1862,1863,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(57,'N-Demethyl_erythromycin',1,1864,1865,1866,1867,1868,1869,1870,1871,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(58,'dehydro-aripiprazole',1,1883,1884,1885,1886,1887,1888,1889,1890,NULL,NULL,NULL,NULL,1891,1892,1893,1894,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(59,'hydroxybupropion',1,1971,1972,1973,1974,1975,1976,1977,1978,1979,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(60,'erythrohydrobupropion',1,2003,2004,2005,2006,2007,2008,2009,2010,2011,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(61,'benzisothiazole-sulphoxide',1,2012,2013,2014,2015,2016,2017,2018,2019,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(62,'thioridazine-5-sulfoxide',1,2020,2021,2022,2023,2024,2025,2026,2027,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(63,'4-hydroxytamoxifin',1,2028,2029,2030,2031,2032,2033,2034,2035,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(64,'ziprasidone-sulphoxide',1,2101,2102,2103,2104,2105,2106,2107,2108,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(65,'7-hydroxy-quetiapine',1,2138,2139,2140,2141,2142,2143,2144,2145,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(66,'S-didemethylcitalopram',1,2167,2168,2169,2170,2171,2172,2173,2174,2175,NULL,NULL,NULL,NULL,NULL,2176,2177,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(67,'hydrocinnamic-acid',1,2178,2179,2180,2181,2182,2183,2184,2185,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(68,'demethylcitalopram',1,2186,2187,2188,2189,2190,2191,2192,2193,NULL,NULL,NULL,NULL,2194,2195,2196,2197,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(69,'desmethylclozapine',1,2206,2207,2208,2209,2210,2211,2212,2213,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(70,'1\'-hydroxymidazolam',1,2272,2273,2274,2275,2276,2277,2278,2279,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(71,'desacetyldiltiazem',1,2307,2308,2309,2310,2311,2312,2313,2314,NULL,NULL,NULL,NULL,2315,2316,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL);
/*!40000 ALTER TABLE `Metabolite` ENABLE KEYS */;
UNLOCK TABLES;

--
-- Table structure for table `Value`
--

DROP TABLE IF EXISTS `Value`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `Value` (
  `id` int(11) NOT NULL,
  `value_id` int(11) DEFAULT NULL,
  `value_string` varchar(100) DEFAULT NULL,
  `value_numeric` int(11) DEFAULT NULL,
  `value_boolean` tinyint(1) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=latin1;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `Value`
--

LOCK TABLES `Value` WRITE;
/*!40000 ALTER TABLE `Value` DISABLE KEYS */;
INSERT INTO `Value` VALUES (1,1,'continuous_value',1085,NULL),(2,2,'cyp3a4',NULL,NULL),(3,2,'cyp2d6',NULL,NULL),(4,2,'cyp2c19',NULL,NULL),(5,5,'cyp2e1',NULL,NULL),(6,5,'cyp1a2',NULL,NULL),(7,5,'cyp2c19',NULL,NULL),(8,5,'cyp2c9',NULL,NULL),(9,6,'S-demethylcitalopram',NULL,NULL),(10,6,'S-didemethylcitalopram',NULL,NULL),(11,7,'continuous_value',467,NULL),(12,8,'cyp2c19',NULL,NULL),(13,10,'cyp2d6',NULL,NULL),(14,12,'N-desmethylsertraline',NULL,NULL),(15,13,'desipramine',736,NULL),(16,14,'cyp2d6',NULL,NULL),(17,14,'cyp3a5',NULL,NULL),(18,14,'cyp3a4',NULL,NULL),(19,14,'cyp2c9',NULL,NULL),(20,16,'4-hydroxytamoxifin',NULL,NULL),(21,16,'N-desmethyltamoxifen',NULL,NULL),(22,17,'cyp2c19',NULL,NULL),(23,19,'cyp3a4',NULL,NULL),(24,21,'cyp2c19',NULL,NULL),(25,23,'modafinil-sulfone',NULL,NULL),(26,24,'continuous_value',267,NULL),(27,25,'continuous_value',312,NULL),(28,26,'cyp3a4',NULL,NULL),(29,26,'cyp3a5',NULL,NULL),(30,27,'cyp1a2',NULL,NULL),(31,28,'4-hydroxyalprazolam',NULL,NULL),(32,28,'alpha-hydroxyalprazolam',NULL,NULL),(33,30,'continuous_value',631,NULL),(34,31,'cyp3a4',NULL,NULL),(35,32,'cyp2d6',NULL,NULL),(36,32,'cyp2d6',NULL,NULL),(37,33,'continuous_value',694,NULL),(38,34,'continuous_value',197,NULL),(39,35,'continuous_value',214,NULL),(40,36,'cyp2c8',NULL,NULL),(41,41,'continuous_value',1219,NULL),(42,42,'continuous_value',622,NULL),(43,43,'continuous_value',738,NULL),(44,44,'cyp2c19',NULL,NULL),(45,44,'cyp3a4',NULL,NULL),(46,47,'cyp2d6',NULL,NULL),(47,48,'continuous_value',151,NULL),(48,49,'continuous_value',464,NULL),(49,51,'cyp3a4',NULL,NULL),(50,53,'cyp2c8',NULL,NULL),(51,54,'N-desmethylrosuvastatin',NULL,NULL),(52,55,'continuous_value',666,NULL),(53,56,'continuous_value',1047,NULL),(54,57,'continuous_value',1023,NULL),(55,58,'cyp2d6',NULL,NULL),(56,60,'cyp2d6',NULL,NULL),(57,62,'norfluoxetine',NULL,NULL),(58,64,'cyp3a4',725,NULL),(59,65,'propafenone',493,NULL),(60,65,'desipramine',602,NULL),(61,65,'olanzapine',1107,NULL),(62,66,'venlafaxine',1171,NULL),(63,67,'cyp3a4',NULL,NULL),(64,70,'cyp3a4',NULL,NULL),(65,70,'cyp2c19',NULL,NULL),(66,70,'cyp2c9',NULL,NULL),(67,70,'cyp1a2',NULL,NULL),(68,70,'cyp2d6',NULL,NULL),(69,71,'quetiapine-sulfoxide',NULL,NULL),(70,71,'7-hydroxy-N-desalkyl-quetiapine',NULL,NULL),(71,71,'N-desalkylquetiapine',NULL,NULL),(72,71,'7-hydroxy-quetiapine',NULL,NULL),(73,72,'continuous_value',126,NULL),(74,73,'continuous_value',1233,NULL),(75,74,'continuous_value',512,NULL),(76,75,'cyp2c9',NULL,NULL),(77,77,'cyp3a4',NULL,NULL),(78,77,'cyp2c9',NULL,NULL),(79,79,'continuous_value',49,NULL),(80,80,'cyp2d6',NULL,NULL),(81,82,'cyp3a4',NULL,NULL),(82,85,'cyp1a2',NULL,NULL),(83,89,'cyp1a2',NULL,NULL),(84,89,'cyp2c9',NULL,NULL),(85,89,'cyp2d6',NULL,NULL),(86,90,'N-desmethylatomoxetine',NULL,NULL),(87,90,'4-hydroxyatomoxetine',NULL,NULL),(88,91,'continuous_value',1063,NULL),(89,92,'continuous_value',275,NULL),(90,93,'continuous_value',482,NULL),(91,94,'continuous_value',599,NULL),(92,95,'cyp3a4',NULL,NULL),(93,95,'cyp2c19',NULL,NULL),(94,95,'cyp2c9',NULL,NULL),(95,97,'cyp2c9',NULL,NULL),(96,97,'cyp3a4',NULL,NULL),(97,97,'cyp2c19',NULL,NULL),(98,99,'voriconazole-N-oxide',NULL,NULL),(99,100,'continuous_value',912,NULL),(100,101,'cyp3a4',NULL,NULL),(101,103,'cyp3a4',NULL,NULL),(102,104,'cyp3a4',643,NULL),(103,105,'triazolam',543,NULL),(104,105,'midazolam',769,NULL),(105,105,'atorvastatin',800,NULL),(106,105,'beta-hydroxy-simvastatin',1053,NULL),(107,105,'alprazolam',1078,NULL),(108,105,'simvastatin',1106,NULL),(109,105,'quetiapine',1197,NULL),(110,106,'continuous_value',23,NULL),(111,107,'continuous_value',186,NULL),(112,108,'desglymidodrine',NULL,NULL),(113,109,'continuous_value',846,NULL),(114,111,'cyp2d6',NULL,NULL),(115,111,'cyp2c19',NULL,NULL),(116,111,'cyp3a4',NULL,NULL),(117,114,'cyp2c19',NULL,NULL),(118,114,'cyp2c9',NULL,NULL),(119,114,'cyp1a2',NULL,NULL),(120,114,'cyp2d6',NULL,NULL),(121,115,'continuous_value',741,NULL),(122,116,'cyp2d6',NULL,NULL),(123,119,'cyp2c19',NULL,NULL),(124,119,'cyp2c9',NULL,NULL),(125,119,'cyp1a2',NULL,NULL),(126,120,'cyp3a4',NULL,NULL),(127,123,'cyp3a4',NULL,NULL),(128,124,'6\'-hydroxymethyl-simvastatin',NULL,NULL),(129,124,'6\'-hydroxy-simvastatin',NULL,NULL),(130,124,'6\'-exomethylene-simvastatin',NULL,NULL),(131,125,'cyp2c8',NULL,NULL),(132,126,'cyp2c8',869,NULL),(133,128,'cyp2d6',NULL,NULL),(134,131,'cyp2c19',NULL,NULL),(135,132,'thioridazine-5-sulfoxide',NULL,NULL),(136,132,'sulforidazine',NULL,NULL),(137,132,'mesoridazine',NULL,NULL),(138,133,'cyp2d6',1230,NULL),(139,135,'cyp3a5',NULL,NULL),(140,135,'cyp2e1',NULL,NULL),(141,135,'cyp3a4',NULL,NULL),(142,135,'cyp1a2',NULL,NULL),(143,135,'cyp2c9',NULL,NULL),(144,135,'cyp2c8',NULL,NULL),(145,135,'cyp2d6',NULL,NULL),(146,135,'cyp2c19',NULL,NULL),(147,135,'cyp2a6',NULL,NULL),(148,136,'cyp2d6',442,NULL),(149,137,'continuous_value',628,NULL),(150,138,'continuous_value',921,NULL),(151,139,'cyp2d6',NULL,NULL),(152,139,'cyp3a4',NULL,NULL),(153,139,'cyp1a2',NULL,NULL),(154,142,'cyp2c19',NULL,NULL),(155,143,'clozapine-N-oxide',NULL,NULL),(156,143,'7-hydroxyclozapine',NULL,NULL),(157,143,'desmethylclozapine',NULL,NULL),(158,144,'cyp2d6',448,NULL),(159,144,'cyp2c19',677,NULL),(160,144,'cyp3a4',781,NULL),(161,144,'cyp2c9',785,NULL),(162,145,'cyp2b6',352,NULL),(163,145,'cyp2c19',1020,NULL),(164,148,'cyp2c8',NULL,NULL),(165,149,'3alpha-hydroxypravastatin',NULL,NULL),(166,150,'cyp3a4',NULL,NULL),(167,153,'cyp1a2',NULL,NULL),(168,153,'cyp2c9',NULL,NULL),(169,153,'cyp2c19',NULL,NULL),(170,153,'cyp2d6',NULL,NULL),(171,153,'cyp3a4',NULL,NULL),(172,154,'continuous_value',224,NULL),(173,156,'cyp2d6',NULL,NULL),(174,157,'cyp2c19',NULL,NULL),(175,158,'cyp2d6',NULL,NULL),(176,159,'escitalopram',443,NULL),(177,160,'continuous_value',1208,NULL),(178,161,'continuous_value',924,NULL),(179,162,'teriflunomide',NULL,NULL),(180,163,'cyp3a4',NULL,NULL),(181,165,'cyp3a4',943,NULL),(182,166,'3alpha-hydroxypravastatin',116,NULL),(183,166,'beta-hydroxy-lovastatin',176,NULL),(184,166,'midazolam',252,NULL),(185,166,'lovastatin',295,NULL),(186,166,'atorvastatin',344,NULL),(187,166,'rosuvastatin',909,NULL),(188,166,'alprazolam',914,NULL),(189,166,'triazolam',1153,NULL),(190,166,'zolpidem',1217,NULL),(191,167,'atorvastatin',NULL,NULL),(192,167,'simvastatin',NULL,NULL),(193,167,'beta-hydroxy-lovastatin',NULL,NULL),(194,167,'beta-hydroxy-simvastatin',NULL,NULL),(195,167,'lovastatin',NULL,NULL),(196,168,'continuous_value',884,NULL),(197,169,'cyp3a4',NULL,NULL),(198,171,'M-chlorophenylpiperazine',NULL,NULL),(199,172,'continuous_value',1025,NULL),(200,173,'continuous_value',1148,NULL),(201,175,'cyp1a2',NULL,NULL),(202,175,'cyp2d6',NULL,NULL),(203,176,'cyp3a4',NULL,NULL),(204,179,'CYP1A2',NULL,NULL),(205,179,'CYP3A4',NULL,NULL),(206,179,'CYP2C19',NULL,NULL),(207,179,'CYP2A6',NULL,NULL),(208,179,'CYP2E1',NULL,NULL),(209,179,'CYP2C9',NULL,NULL),(210,179,'CYP2D6',NULL,NULL),(211,180,'S-N-desmethylzopiclone',NULL,NULL),(212,180,'S-zopiclone-N-oxide',NULL,NULL),(213,181,'continuous_value',455,NULL),(214,184,'cyp3a4',NULL,NULL),(215,186,'N-demethyldiltiazem',NULL,NULL),(216,186,'N-demethyldesacetyl-diltiazem',NULL,NULL),(217,186,'desacetyldiltiazem',NULL,NULL),(218,187,'cyp3a4',NULL,NULL),(219,188,'cyp3a4',416,NULL),(220,189,'triazolam',30,NULL),(221,189,'beta-hydroxy-lovastatin',206,NULL),(222,189,'simvastatin',689,NULL),(223,189,'midazolam',1215,NULL),(224,190,'continuous_value',1220,NULL),(225,191,'cyp2d6',NULL,NULL),(226,193,'venlafaxine',720,NULL),(227,193,'paroxetine',728,NULL),(228,194,'continuous_value',477,NULL),(229,195,'continuous_value',1131,NULL),(230,197,'cyp2e1',NULL,NULL),(231,197,'cyp2d6',NULL,NULL),(232,197,'cyp2a6',NULL,NULL),(233,197,'cyp2c19',NULL,NULL),(234,197,'cyp3a5',NULL,NULL),(235,197,'cyp3a4',NULL,NULL),(236,197,'cyp2c9',NULL,NULL),(237,197,'cyp2b6',NULL,NULL),(238,197,'cyp1a2',NULL,NULL),(239,198,'continuous_value',867,NULL),(240,199,'cyp2d6',NULL,NULL),(241,199,'cyp3a4',NULL,NULL),(242,201,'cyp2d6',NULL,NULL),(243,202,'cyp3a4',NULL,NULL),(244,202,'cyp2c9',NULL,NULL),(245,202,'cyp1a2',NULL,NULL),(246,203,'N-desmethylvenlafaxine',NULL,NULL),(247,203,'O-desmethylvenlafaxine',NULL,NULL),(248,204,'risperidone',314,NULL),(249,206,'continuous_value',1033,NULL),(250,207,'continuous_value',307,NULL),(251,208,'norpropoxyphene',NULL,NULL),(252,209,'cyp3a4',NULL,NULL),(253,209,'cyp3a5',NULL,NULL),(254,211,'continuous_value',698,NULL),(255,212,'cyp3a4',NULL,NULL),(256,215,'cyp3a4',NULL,NULL),(257,215,'cyp1a2',NULL,NULL),(258,215,'cyp2c9',NULL,NULL),(259,215,'cyp2c19',NULL,NULL),(260,215,'cyp2d6',NULL,NULL),(261,216,'benzisothiazole-sulphoxide',NULL,NULL),(262,216,'S-methyl-dihydroziprasidone',NULL,NULL),(263,216,'ziprasidone-sulphoxide',NULL,NULL),(264,216,'benzisothiazole-sulphone',NULL,NULL),(265,217,'cyp2d6',154,NULL),(266,219,'cyp3a4',NULL,NULL),(267,219,'cyp2c19',NULL,NULL),(268,219,'cyp2c9',NULL,NULL),(269,221,'continuous_value',101,NULL),(270,222,'cyp2d6',NULL,NULL),(271,225,'cyp2c19',NULL,NULL),(272,225,'cyp2c9',NULL,NULL),(273,225,'cyp1a2',NULL,NULL),(274,226,'cyp2d6',NULL,NULL),(275,226,'cyp1a2',NULL,NULL),(276,228,'cyp2d6',NULL,NULL),(277,229,'cyp3a4',NULL,NULL),(278,229,'cyp3a5',NULL,NULL),(279,229,'cyp2c9',NULL,NULL),(280,229,'cyp2c19',NULL,NULL),(281,230,'theophylline',440,NULL),(282,232,'cyp2c19',NULL,NULL),(283,233,'cyp2d6',293,NULL),(284,235,'cyp2d6',NULL,NULL),(285,235,'cyp2d6',NULL,NULL),(286,236,'cyp3a5',NULL,NULL),(287,236,'cyp3a4',NULL,NULL),(288,237,'cyp2a6',NULL,NULL),(289,237,'cyp2e1',NULL,NULL),(290,237,'cyp2d6',NULL,NULL),(291,237,'cyp2b6',NULL,NULL),(292,237,'cyp2c9',NULL,NULL),(293,237,'cyp2c19',NULL,NULL),(294,237,'cyp1a2',NULL,NULL),(295,238,'cyp2d6',NULL,NULL),(296,242,'cyp3a4',NULL,NULL),(297,242,'cyp2c19',NULL,NULL),(298,242,'cyp2a6',NULL,NULL),(299,242,'cyp2d6',NULL,NULL),(300,242,'cyp1a2',NULL,NULL),(301,242,'cyp2c8',NULL,NULL),(302,242,'cyp2c9',NULL,NULL),(303,243,'cyp2c8',542,NULL),(304,244,'continuous_value',754,NULL),(305,245,'continuous_value',135,NULL),(306,246,'continuous_value',290,NULL),(307,248,'cyp2c9',NULL,NULL),(308,248,'cyp3a4',NULL,NULL),(309,248,'cyp3a5',NULL,NULL),(310,248,'cyp2b6',NULL,NULL),(311,248,'cyp2c19',NULL,NULL),(312,248,'cyp2e1',NULL,NULL),(313,248,'cyp2a6',NULL,NULL),(314,248,'cyp1a1',NULL,NULL),(315,248,'cyp1a2',NULL,NULL),(316,248,'cyp2d6',NULL,NULL),(317,248,'cyp2c8',NULL,NULL),(318,249,'cyp2c8',767,NULL),(319,250,'cyp3a4',NULL,NULL),(320,250,'cyp3a5',NULL,NULL),(321,250,'cyp2c19',NULL,NULL),(322,252,'continuous_value',1091,NULL),(323,253,'cyp1a2',NULL,NULL),(324,255,'cyp2d6',NULL,NULL),(325,257,'cyp2c19',NULL,NULL),(326,257,'cyp2c9',NULL,NULL),(327,257,'cyp1a2',NULL,NULL),(328,259,'cyp1a2',316,NULL),(329,260,'tolbutamide',91,NULL),(330,260,'lansoprazole',571,NULL),(331,260,'duloxetine',708,NULL),(332,260,'mexiletine',740,NULL),(333,260,'omeprazole',752,NULL),(334,260,'clozapine',822,NULL),(335,260,'quinidine',1003,NULL),(336,260,'theophylline',1157,NULL),(337,261,'continuous_value',581,NULL),(338,262,'continuous_value',629,NULL),(339,263,'continuous_value',368,NULL),(340,264,'continuous_value',1089,NULL),(341,265,'cyp3a5',NULL,NULL),(342,265,'cyp3a4',NULL,NULL),(343,267,'cyp3a4',NULL,NULL),(344,269,'para-hydroxy-atorvastatin',NULL,NULL),(345,269,'ortho-hydroxy-atorvastatin',NULL,NULL),(346,270,'cyp2c8',NULL,NULL),(347,271,'cyp2c8',770,NULL),(348,272,'continuous_value',8,NULL),(349,273,'continuous_value',813,NULL),(350,274,'cyp3a5',NULL,NULL),(351,274,'cyp3a4',NULL,NULL),(352,276,'continuous_value',594,NULL),(353,277,'cyp3a4',NULL,NULL),(354,279,'cyp3a4',859,NULL),(355,280,'simvastatin',33,NULL),(356,280,'midazolam',70,NULL),(357,280,'zolpidem',472,NULL),(358,280,'triazolam',608,NULL),(359,280,'alprazolam',1007,NULL),(360,281,'cyp2c8',NULL,NULL),(361,283,'cyp1a2',NULL,NULL),(362,285,'continuous_value',153,NULL),(363,287,'cyp2c19',NULL,NULL),(364,288,'continuous_value',402,NULL),(365,289,'continuous_value',605,NULL),(366,290,'cyp2d6',NULL,NULL),(367,290,'cyp3a4',NULL,NULL),(368,293,'cyp2c19',NULL,NULL),(369,294,'9-hydroxyrisperidone',NULL,NULL),(370,295,'cyp2d6',625,NULL),(371,297,'continuous_value',495,NULL),(372,298,'continuous_value',655,NULL),(373,299,'continuous_value',429,NULL),(374,300,'continuous_value',164,NULL),(375,301,'continuous_value',423,NULL),(376,302,'cyp3a4',NULL,NULL),(377,305,'cyp2c8',NULL,NULL),(378,306,'cyp2c8',566,NULL),(379,307,'cyp3a5',NULL,NULL),(380,307,'cyp3a4',NULL,NULL),(381,308,'cyp2b6',NULL,NULL),(382,308,'cyp2e1',NULL,NULL),(383,308,'cyp2c9',NULL,NULL),(384,308,'cyp1a2',NULL,NULL),(385,310,'continuous_value',880,NULL),(386,311,'cyp3a4',613,NULL),(387,312,'continuous_value',844,NULL),(388,314,'cyp2c19',NULL,NULL),(389,315,'cyp1a2',322,NULL),(390,315,'cyp2d6',421,NULL),(391,316,'continuous_value',894,NULL),(392,317,'continuous_value',541,NULL),(393,318,'continuous_value',185,NULL),(394,319,'continuous_value',505,NULL),(395,320,'cyp2d6',NULL,NULL),(396,322,'cyp2d6',NULL,NULL),(397,322,'cyp3a5',NULL,NULL),(398,322,'cyp3a4',NULL,NULL),(399,324,'cyp2d6',142,NULL),(400,325,'continuous_value',865,NULL),(401,326,'cyp3a4',NULL,NULL),(402,326,'cyp2d6',NULL,NULL),(403,327,'cyp1a2',NULL,NULL),(404,327,'cyp2b6',NULL,NULL),(405,327,'cyp2c9',NULL,NULL),(406,327,'cyp1a1',NULL,NULL),(407,327,'cyp2c19',NULL,NULL),(408,327,'cyp2e1',NULL,NULL),(409,327,'cyp2c8',NULL,NULL),(410,327,'cyp1a2',NULL,NULL),(411,327,'cyp2a6',NULL,NULL),(412,329,'cyp2c19',NULL,NULL),(413,329,'cyp2d6',NULL,NULL),(414,329,'cyp1a2',NULL,NULL),(415,329,'cyp3a4',NULL,NULL),(416,329,'cyp2c9',NULL,NULL),(417,330,'dehydro-aripiprazole',NULL,NULL),(418,331,'escitalopram',950,NULL),(419,331,'venlafaxine',1212,NULL),(420,332,'continuous_value',637,NULL),(421,333,'1-methyluric-acid',NULL,NULL),(422,334,'cyp1a2',NULL,NULL),(423,334,'cyp3a4',NULL,NULL),(424,334,'cyp3a5',NULL,NULL),(425,334,'cyp2d6',NULL,NULL),(426,337,'cyp2c9',NULL,NULL),(427,337,'cyp2e1',NULL,NULL),(428,337,'cyp2c19',NULL,NULL),(429,337,'cyp1a2',NULL,NULL),(430,337,'cyp2d6',NULL,NULL),(431,339,'continuous_value',66,NULL),(432,341,'cyp2d6',NULL,NULL),(433,343,'cyp2d6',NULL,NULL),(434,346,'mirtazapine',559,NULL),(435,346,'paliperidone',615,NULL),(436,346,'desipramine',1164,NULL),(437,347,'cyp3a4',NULL,NULL),(438,350,'cyp2c19',NULL,NULL),(439,351,'reduced-haloperidol',NULL,NULL),(440,352,'cyp2d6',676,NULL),(441,354,'continuous_value',794,NULL),(442,355,'continuous_value',647,NULL),(443,356,'1-methylxanthine',NULL,NULL),(444,356,'1,3-dimethyluric-acid',NULL,NULL),(445,356,'3-methylxanthine',NULL,NULL),(446,356,'caffeine',NULL,NULL),(447,357,'continuous_value',514,NULL),(448,358,'cyp2c9',NULL,NULL),(449,358,'cyp3a4',NULL,NULL),(450,358,'cyp3a5',NULL,NULL),(451,360,'cyp3a4',560,NULL),(452,361,'triazolam',129,NULL),(453,361,'midazolam',434,NULL),(454,361,'fluvastatin',557,NULL),(455,362,'continuous_value',420,NULL),(456,363,'cyp2c9',NULL,NULL),(457,365,'continuous_value',998,NULL),(458,366,'continuous_value',1150,NULL),(459,367,'continuous_value',1126,NULL),(460,368,'cyp1a2',NULL,NULL),(461,368,'cyp3a5',NULL,NULL),(462,368,'cyp3a4',NULL,NULL),(463,370,'escitalopram',409,NULL),(464,370,'theophylline',425,NULL),(465,370,'ziprasidone',568,NULL),(466,370,'quetiapine',686,NULL),(467,370,'mirtazapine',703,NULL),(468,370,'venlafaxine',934,NULL),(469,371,'cyp3a4',NULL,NULL),(470,374,'cyp1a2',NULL,NULL),(471,375,'cyp1a2',NULL,NULL),(472,375,'cyp3a4',NULL,NULL),(473,375,'cyp2d6',NULL,NULL),(474,377,'cyp2d6',NULL,NULL),(475,378,'cyp3a4',NULL,NULL),(476,378,'cyp3a5',NULL,NULL),(477,378,'cyp2c9',NULL,NULL),(478,378,'cyp1a2',NULL,NULL),(479,378,'cyp2c19',NULL,NULL),(480,379,'hydrocinnamic-acid',NULL,NULL),(481,379,'hydroxy-hydrocinnamic-acid',NULL,NULL),(482,380,'cyp3a4',NULL,NULL),(483,381,'cyp2d6',NULL,NULL),(484,382,'cyp3a5',NULL,NULL),(485,382,'cyp3a4',NULL,NULL),(486,383,'cyp1a2',NULL,NULL),(487,384,'alprazolam',110,NULL),(488,384,'triazolam',354,NULL),(489,384,'midazolam',619,NULL),(490,385,'cyp2c8',636,NULL),(491,386,'continuous_value',104,NULL),(492,387,'continuous_value',1060,NULL),(493,388,'continuous_value',1008,NULL),(494,389,'cyp2c19',NULL,NULL),(495,389,'cyp3a5',NULL,NULL),(496,389,'cyp3a4',NULL,NULL),(497,392,'cyp2d6',NULL,NULL),(498,392,'cyp3a4',NULL,NULL),(499,393,'lansoprazole',138,NULL),(500,394,'continuous_value',762,NULL),(501,395,'continuous_value',1179,NULL),(502,396,'cyp2c19',NULL,NULL),(503,399,'cyp3a4',NULL,NULL),(504,399,'cyp2c9',NULL,NULL),(505,399,'cyp2e1',NULL,NULL),(506,400,'didemethylcitalopram',NULL,NULL),(507,400,'demethylcitalopram',NULL,NULL),(508,402,'continuous_value',1162,NULL),(509,403,'continuous_value',518,NULL),(510,404,'cyp3a4',NULL,NULL),(511,407,'cyp3a4',NULL,NULL),(512,408,'beta-hydroxy-simvastatin',NULL,NULL),(513,409,'cyp2c8',NULL,NULL),(514,410,'cyp2c8',256,NULL),(515,411,'cyp3a5',NULL,NULL),(516,411,'cyp3a4',NULL,NULL),(517,411,'cyp2d6',NULL,NULL),(518,413,'continuous_value',806,NULL),(519,414,'continuous_value',935,NULL),(520,415,'continuous_value',25,NULL),(521,416,'cyp2c8',NULL,NULL),(522,416,'cyp2c9',NULL,NULL),(523,416,'cyp3a4',NULL,NULL),(524,418,'cyp2c8',NULL,NULL),(525,419,'cyp2c8',1105,NULL),(526,420,'continuous_value',674,NULL),(527,421,'cyp3a4',NULL,NULL),(528,421,'cyp3a5',NULL,NULL),(529,421,'cyp1a2',NULL,NULL),(530,423,'risperidone',1243,NULL),(531,424,'continuous_value',983,NULL),(532,425,'continuous_value',4,NULL),(533,426,'continuous_value',889,NULL),(534,427,'continuous_value',317,NULL),(535,428,'hydroxybupropion',396,NULL),(536,429,'cyp2c9',NULL,NULL),(537,429,'cyp2d6',NULL,NULL),(538,429,'cyp3a4',NULL,NULL),(539,429,'cyp1a2',NULL,NULL),(540,431,'continuous_value',942,NULL),(541,433,'cyp1a2',NULL,NULL),(542,433,'cyp2d6',NULL,NULL),(543,437,'cyp3a4',NULL,NULL),(544,438,'cyp2d6',NULL,NULL),(545,438,'cyp3a4',NULL,NULL),(546,439,'cyp2c19',NULL,NULL),(547,439,'cyp2e1',NULL,NULL),(548,439,'cyp2b6',NULL,NULL),(549,439,'cyp2a6',NULL,NULL),(550,439,'cyp2c9',NULL,NULL),(551,439,'cyp2c8',NULL,NULL),(552,439,'cyp1a2',NULL,NULL),(553,439,'cyp1a1',NULL,NULL),(554,440,'cyp2d6',NULL,NULL),(555,442,'cyp1a2',NULL,NULL),(556,444,'continuous_value',1232,NULL),(557,445,'cyp2d6',NULL,NULL),(558,447,'10-N-glucuronide',NULL,NULL),(559,448,'cyp2c9',446,NULL),(560,448,'cyp3a4',749,NULL),(561,448,'cyp2c19',824,NULL),(562,449,'continuous_value',1017,NULL),(563,450,'cyp3a4',NULL,NULL),(564,452,'beta-hydroxy-lovastatin',NULL,NULL),(565,453,'cyp2c8',NULL,NULL),(566,454,'cyp2c8',118,NULL),(567,455,'continuous_value',348,NULL),(568,456,'continuous_value',131,NULL),(569,457,'cyp3a4',NULL,NULL),(570,458,'cyp2c9',NULL,NULL),(571,458,'cyp2d6',NULL,NULL),(572,458,'cyp1a2',NULL,NULL),(573,459,'cyp3a4',NULL,NULL),(574,459,'cyp3a5',NULL,NULL),(575,461,'14-hydroxyclarithromycin',NULL,NULL),(576,462,'cyp3a4',NULL,NULL),(577,463,'cyp3a4',41,NULL),(578,464,'triazolam',45,NULL),(579,464,'atorvastatin',103,NULL),(580,464,'midazolam',240,NULL),(581,464,'lansoprazole',821,NULL),(582,464,'trazodone',893,NULL),(583,464,'pravastatin',928,NULL),(584,465,'continuous_value',664,NULL),(585,466,'continuous_value',219,NULL),(586,467,'cyp2d6',NULL,NULL),(587,470,'cyp2d6',NULL,NULL),(588,470,'cyp2d6',NULL,NULL),(589,471,'continuous_value',466,NULL),(590,472,'cyp1a2',NULL,NULL),(591,472,'cyp2d6',NULL,NULL),(592,472,'cyp3a4',NULL,NULL),(593,475,'cyp2c19',NULL,NULL),(594,476,'7-hydroxyperphenazine',NULL,NULL),(595,477,'cyp1a2',144,NULL),(596,477,'cyp2d6',569,NULL),(597,478,'continuous_value',624,NULL),(598,481,'cyp2d6',NULL,NULL),(599,483,'erythrohydrobupropion',NULL,NULL),(600,483,'hydroxybupropion',NULL,NULL),(601,483,'threohydrobupropion',NULL,NULL),(602,484,'continuous_value',678,NULL),(603,485,'cyp2b6',453,NULL),(604,486,'bupropion',579,NULL),(605,487,'continuous_value',788,NULL),(606,488,'continuous_value',589,NULL),(607,489,'continuous_value',967,NULL),(608,490,'cyp2c9',NULL,NULL),(609,492,'cyp2d6',NULL,NULL),(610,493,'cyp3a4',NULL,NULL),(611,493,'cyp2c19',NULL,NULL),(612,493,'cyp2c9',NULL,NULL);
/*!40000 ALTER TABLE `Value` ENABLE KEYS */;
UNLOCK TABLES;
/*!40103 SET TIME_ZONE=@OLD_TIME_ZONE */;

/*!40101 SET SQL_MODE=@OLD_SQL_MODE */;
/*!40014 SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS */;
/*!40014 SET UNIQUE_CHECKS=@OLD_UNIQUE_CHECKS */;
/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
/*!40111 SET SQL_NOTES=@OLD_SQL_NOTES */;

-- Dump completed on 2013-11-04  8:00:02
